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Gastric cancer is one of the most common tumors worldwide. It has a heterogeneous 
milieu, where the genetic background, tumor immunology, oxidative stress, and 
microbial infections are key players in the multiple stages of tumorigenesis. These 
diverse factors are linked to the prognosis of the gastric cancer and the survival of 
gastric cancer patients. This book is appropriate for scientists and students in the 
field of oncology, gastroenterology, molecular biology, immunology, cell biology, 
biology, biochemistry, and pathology. This authoritative text carefully explains the 
fundamentals, providing a general overview of the principles followed by more 
detailed explanations of these recent topics efficiently. The topics presented herein 
contain the most recent knowledge in gastric cancer concerning the oncogenic 
signaling, genetic instability, the epigenetic aspect, molecular features and their 
clinical implications, miRNAs, integrin and E-cadherin, carbohydrate-associated-
transferases, free radicals, immune cell responses, mucins, Helicobacter-pylori,  
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of  science, medicine  and modern  technology,  the  trend  of  gastric  cancer  in  the  last 
decades is directed toward the stability for many areas and decreasing in some other 
parts  of  world.  The  thankful  enterprise  to  open  more  novel  windows  for  the 
development  of  innovative  therapeutic  strategies  against  gastric  cancer  is  greatly 
appreciated for scientists all over the world. This book is appropriate for scientists and 
students  in  the  field of oncology, gastroenterology, molecular biology,  immunology, 
cell  biology,  biology,  biochemistry,  pathology,  and  many  other  fields  ‐    this 
authoritative  text carefully explains  the  fundamentals, providing a general overview 
of  the  principles  followed  by  more  detailed  explanations  of  these  recent  topics 
efficiently. With its easy‐to‐read writing style, this book introduces in‐depth coverage 
on  such  hot  topics  as  signaling  pathways,  H.  pylori,  epigenetic  and  oncogenic 





transferases,  free  radicals,  immune  cell  responses,  mucins,    Helicobacter‐pylori, 
neoadjuvant  and  adjuvant  therapy,  prophylactic  strategy  for  peritoneal  recurrence, 
and hepatic metastasis. 
Our  authentic  gratitude  is  due  to  our  brilliant  authors,  co‐authors,  reviewers, 
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Oncogenic Signaling in Gastric Cancer 
Natália R. Costa, Andreia Sousa, Cristina Teixeira, Joana Castro,  
Nuno Guimarães and Filipe Santos–Silva 
IPATIMUP and Faculdade de Medicina da Universidade do Porto 
Portugal 
1. Introduction 
Gastric cancer is one of the most common and life-threatening cancers worldwide (for 
review see Power et al., 2010). The late diagnosis and high mortality of this disease reflects 
the reduced understanding of its etiological factors and pathogenesis model and the lack of 
effective treatments. This disease results from the complex interplay between genetic and 
environmental factors at the gastric mucosa level that deregulates cell potentially oncogenic 
signaling pathways, leading to gastric cancer development. It is known that more than 80% 
of gastric cancer cases can be attributed to deregulation of signaling pathways caused by 
Helicobacter pylori infection (Houghton & Wang, 2005). Some of these signaling pathways are 
important during gastric embryogenesis and during the normal lifetime of a gastric cell, but 
can be tumorigenic if deregulated and therefore their better understanding is crucial for the 
development of new therapeutic drugs. In this review we will summarize the most 
important intracellular signaling pathways that have been found to be deregulated in gastric 
carcinoma and we will include new data recently obtained in our laboratory, focused on 
MUC1 mucin-mediated signaling pathways.This new information is a relevant contribution 
for the understanding of the gastric oncogenic signaling scenario and opens new 
perspectives for the development of innovative therapeutic strategies against the disease.  
2. Signaling pathways involved in gastric carcinogenesis 
2.1 EGFR and the extracellular signal-regulated MAPK pathway 
The mitogen-activated protein kinases (MAPKs) pathway is activated either by extracellular 
ligand binding or intracellular stimuli, and regulates a series of cell activities such as 
proliferation, differentiation and cell death. The extracellular signal-regulated kinase (ERK) 
MAPK pathway has been often found to be deregulated in cancers and consists of several 
kinases (Ras, Raf, MEK) that are activated by phosphorylation upon ligand binding to a 
membrane receptor, ending up in the activation of several proteins involved in processes of 
cell invasion, apoptosis, transcription, survival and drug resistance (for review see Kim EK 
& Choi E, 2010). Members of this cascade have been found to be deregulated in gastric 
cancers, such as RAS family members (Adjei, 2001; Velho et al., 2010). Ras/MAPK activation 
was found  to be associated with cell proliferation in gastric carcinomas (Regalo et al., 2010). 
ERK1/2, the final effectors of this pathway, were also found to be  activated in gastric 
cancers (Liang et al., 2005) and in Helicobacter pylori related gastric cancers (Hatakeyama , 
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2006; Chen et al., 2006). In contrast, ERK2 activity was found to be reduced by nonsteroidal 
anti-inflammatory drugs NSAIDS, therefore inhibiting the proliferation of gastric carcinoma 
cells (Husain et al., 2001). All of these events were found in cell lines, but when examining 
human gastric carcinoma specimens, a decrease in the activation of ERK1/2  was found (Wu 
et al., 2008). One possible explanation for this fact is that gastric cells start expressing 
molecules that attenuate ERK-mediated signaling upon its activation, or on the other hand, 
the cells act by activating negative feedback mechanisms. 
The epidermal growth factor receptor (EGFR) is a member of the growth factor family HER 
and works as a cell surface receptor of extracellular ligands. Ligand binding to EGFR 
extracellular domain leads to its activation, with subsequent homodimerization, leading to 
the phosphorylation of its intracellular tyrosine kinase domain. This will initiate a series of 
intracellular signals, including activation of the central Ras/Raf/mitogen activated protein 
kinase (MAPK) signaling pathway (Figure 1). This molecule modulates processes of cell , 
migration, adhesion and proliferation and it is known to provide tumor cells with growth 
and survival advantages (for review see Nicholson et al., 2001). EGFR expression was found 
to be deregulated in several types of cancers, including gastric cancer. High EGFR levels in 
gastric carcinoma have been associated with the disease prognosis (Kim et al., 2008) and 
presence of lymph node metastasis (Choi et al., 2009). Therapies against EGFR have been 
developed and are active in gastric cancer treatments (Pinto et al., 2007; Liu et al., 2011), 
although not completely effective. The EGFR/MAPK pathway has also been  shown to be 
activated in gastric carcinomas with microsatellite instability (Corso et al., 2011). 
 
 
Fig. 1. EGFR/MAPK signaling pathway. 
2.2 E-cadherin and Wnt/beta-catenin pathway 
E-cadherin is a calcium-dependent cell-cell adhesion molecule that is essential for the 
maintenance of the normal epithelium architecture (for review see Van Roy & Berx , 2008). 
Loss of expression of this molecule has been found in gastric cancers, relating with tumor 
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dedifferentiation, invasiveness, metastasis and prognosis (Shino et al.,1995; Gabbert et al., 
1996). Mutations of this molecule have been often found in familial gastric cancers (for 
review see Oliveira et al., 2006). The cytoplasmic domain of this molecule interacts with the 
molecule beta-catenin, forming strong cohesive nets between the actin cytoskeleton 
(Leckband & Sivasankar, 2000), essential for processes of cell-cell adhesion and cell shape, 
polarity, migration and invasion.  
EGFR and E-cadherin were found to interact through the respectives extracellular domains 
and signaling mediated by EGFR was found to be inhibited by E-cadherin (Qian et al., 2004). 
EGFR was found to be hyper-activated in cells where the extracellular domain of E-cadherin 
is not present (Bremm et al., 2008). Therefore, it may be of therapeutic value to use EGFR 
inhibitors in the treatment of gastric cancers in which there is a deregulation of E-cadherin. 
Beta-catenin is important in mediating the E-cadherin related cell adhesion and also by 
participating in Wnt signaling pathways. The Wnt signaling pathway regulates several 
processes during development, such as determination of cell fate, morphology, polarity, 
adhesion and growth. Wnt signaling can be divided into canonical and non-canonical 
pathways. In the canonical one, wnt signals (extracellular ligands, such as wnt-1) stabilize 
beta catenin, therefore activating gene transcription by interaction of beta-catenin with 
transcriptional factors (Figure 2). 
 
 
Fig. 2. Wnt signaling pathway (canonical). 
This pathway was found to be deregulated in several cancers (for review see Polakis, 2007), 
including gastric carcinoma (Katoh et al., 2001; Clements et al., 2002; Nabais et al., 2003). The 
non canonical pathway is not related to beta-catenin and is involved in embryonic 
development and cell polarity and has also been linked to the development of gastric 
cancers (Kurayoshi et al., 2006;  Gencer et al., 2010).  This pathway seems to be repressed by 
Notch1 receptor in keratinocytes (Nicolas et al., 2003). Beta catenin was found to be 
activated by the bacterium Helicobacter pylori in gastric cancers (Franco et al., 2005). 
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In gastric cancer tissues, the expression of Wnt-1, beta-catenin and E-cadherin was found to 
be increased when compared to normal gastric tissue, as well as tumor size, tumor invasive 
depth, lymph node metastasis, pTNM stage, differentiation and five-year survival rate 
(Zhang & Xue , 2008). Therefore, these molecules are promising therapeutic targets for 
gastric carcinoma. 
2.3 Hedgehog pathway 
Hedgehog (Hh) signaling plays an important role during embryonic development and 
differentiation, proliferation and maintenance of adult tissues through the maintenance of 
stem cells population. Until now, three different members of the Hh family have been 
identified: Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh). All 
of them are secreted-type glycoproteins with a N-terminal signal peptide, a Hedgehog 
signaling domain and a Hint domain that signals through ligation to the hedgehog receptor 
Patched (Ptch), which usually acts by inhibiting the seven-span transmembrane receptor 
Smoothened (Smo) (Katoh and Katoh, 2005).  
Of all Hh members, Shh is the most studied signaling pathway in vertebrates and plays a 
crucial role in stomach development. Shh protein expression is increased in parietal cells of 
the normal adult, gastric corpus and antrum (Saqui-Salces and Merchant, 2010). It is 
believed that Shh is important for regulation of gastric epithelial differentiation and its 
silencing causes gastric atrophy and subsequent disruption of glandular differentiation (Van 
den Brink, 2007). Recently, with the development of a mouse model expressing a parietal 
cell-specific Shh deletion, the function of this protein in adult stomach has been better 
clarified (Xiao et al., 2010). 
  
 
Fig. 3. Human Hedgehog signaling pathway. 
Shh ligand is expressed as a 45-kDa precursor that is cleaved autocatalytically to yield a 
19kDa amino terminal fragment, that contains all the signaling functions and a 26-kDa 
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carboxy-terminal fragment (ShhC), that acts as a cholesterol transferase (Goetz et al., 2006; 
Zavros et al., 2007). This activation process depends on the acid-activated protease pepsin A. 
Gastrin increases acid secretion in parietal cells leading to conversion of pepsinogen A to 
pepsin A, mediating Shh processing (Zavros et al., 2007). In the stomach, Shh binds directly 
to Ptch receptor but not to Smo being the activity of Smo controlled indirectly by Ptch 
(Figure 3). In Shh absence Ptch supresses Smo activity. The binding of Shh to Ptch results in 
loss of Ptc activity and consequently Smo activation. Smo activation triggers Hh signal into 
the cytoplasm by triggering activation of Glioblastoma family transcription factors (Gli1, 
Gli2 and Gli3) that induce transcription of signaling targets like Wnt and the zinc finger 
transcription factor, Snail (Martin et al., 2010). Gli 1 induces the transcription of Snail that 
inhibits E-cadherin transcription. The inhibition of E-cadherin, a protein that plays an 
important role in cell adhesion, is associated with an increase in nuclear beta-catenin, 
triggering the activation of Wnt pathway targets like CD44, c-Myc and cyclin D1 (Li et al., 
2006; Medici et al., 2008; Tanaka et al., 2002).  
Alterations in Hh signaling pathway activation are related to different types of cancer such 
as gastric cancer, breast cancer, small-cell lung cancer, skin and pancreatic cancer (Kubo et 
al., 2004; Thayer et al., 2003; Watkins et al., 2003; Yang et al., 2010). The expression of Hh 
ligands, Ptch1, Smo and the three Gli transcription factors (Gli1, Gli2 and Gli3) has been 
related with more than two-thirds of primary gastric cancers and correlated with poorly 
differentiated and more aggressive tumors (Fukaya et al., 2006; Lee et al., 2007). Hh 
signaling activation is triggered by expression of hedgehog ligands like Shh and Ihh or an 
increased Ptch receptor expression (Wu et al., 2010; Zavros, 2008). Inhibition of Shh 
signaling pathway using Smo or antagonists like cyclopamine or Hedgehog neutralizing 
antibody 5E1 causes growth inhibition and regression of xenograft tumors in vivo (Berman 
et al., 2003). However, in the presence of precancerous lesions such as gastric atrophy (loss 
of parietal cells) or intestinal metaplasia, Shh protein expression is reduced or totally lost 
(Shiotani et al., 2005; Suzuki et al., 2005; van den Brink et al., 2001). This observation is 
associated with Helicobacter pylori infection, which is directly linked to the development of 
gastric cancer (Correa et al., 1975; Uemura et al., 2001). Taken together, these evidences may 
indicate that the inactivation of Hh signaling mediates in part the precancerous tissue 
alterations induced by Helicobacter pylori infection while its re-activation confers survival 
advantages in later stages of gastric carcinogenesis.  
2.4 Notch pathway 
Notch signaling pathway is evolutionary conserved and plays a role in many important and 
fundamental processes in cell and tissues such as proliferation, differentiation, apoptosis, 
cell fate determination, and maintenance of stem cells (Koch and Radtke, 2007; Leong and 
Karsan, 2006; Radtke and Raj, 2003). Notch signaling is activated during cell-to-cell contact 
through four receptors (Notch1-4) that can interact with ligands of the Delta (Dll-1, Dll-3, 
Dll-4) and Jagged (Jagged-1 and Jagged-2) family (Bray, 2006). Notch-ligand binding 
induces the cleavage of Notch receptor through a cascade of proteolytic cleavages by the 
metalloprotease tumor necrosis factor-α-converting enzyme (TACE) and γ-secretase, 
releasing the intracellular domain of Notch (NICD) (Katoh, 2007a; Wang et al., 2009). The 
NICD is translocated into the nucleus to associate with CSL transcription factor triggering 
the activation of Notch target genes (Androutsellis-Theotokis et al., 2006; Miele, 2006). Until 
now, few Notch target genes have been identified in different cellular and developmental 
contexts (Borggrefe and Oswald, 2009), such as Hes-1 (Hairy enhance of split-1), Cyclin D1, 
Nuclear factor-κB (NF-κB) and c-myc (Miele, 2006) (Figure 4). 
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Fig. 3. Human Hedgehog signaling pathway. 
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Oncogenic Signaling in Gastric Cancer 
 
7 
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Fig. 4. Notch signaling pathway. 
Recently, it has been described an association between Notch signaling and progression of 
gastric cancer. Three Notch receptors (Notch1-Notch3) and Notch ligand Jagged1 are 
expressed in human gastric cancer (Katoh, 2006; Sander and Powell, 2004; Sekine et al., 2006) 
and Notch signaling pathway is activated after infection with Helicobacter pylori in gastric 
cancer (Katoh, 2007b). Gastric cancer patients with Jagged1 expression in tumor tissues have 
more aggressive tumors and poor survival, suggesting an important role of this pathway in 
gastric cancer progression (Yeh et al., 2009).  This aggressiveness seems to be correlated with 
the interaction between Notch signaling pathway and COX-2, an independent prognostic 
factor of gastric cancer (Shi et al., 2003). Notch signaling induces Cox-2 expression by 
directly binding to it through the intracellular domain of Notch1 receptor producing a 
stimulatory effect on cancer growth and invasion (Yeh et al., 2009). Nuclear factor-κB is also 
involved in Notch signaling and mediates COX-2 expression to regulate cell proliferation of 
human gastric cancer cells (Espinosa et al., 2003). Therefore, COX-2 inhibitors may be a new 
strategy to be used for treatment of gastric cancer in the future. 
Twist, another transcription factor regulated by Notch signaling, was also shown to regulate 
cell motility and invasion in gastric cancer cell lines, probably through N-cadherin and 
fibronectin (Yang et al., 2007). Possibly, these EMT mediators induced by NICD could lead 
to an increased expression of COX-2. Whether N1ICD induces expression of COX-2 to 
modulate metastasis in gastric cancer through EMT mediators remains unknown.  
Furthermore, activation of Notch signal pathway is involved in epithelial-mesenchymal 
transition (EMT), during development and tumorigenesis. Notch signaling increases Snail-1 
expression and elevates EMT in cardiac development, kidney tubular cell differentiation, 
and hypoxia (Sahlgren et al., 2008; Timmerman et al., 2004; Zavadil et al., 2004). The 
Jagged1-activated Notch signaling also promotes EMT through E-cadherin repression by 
Slug (Leong et al., 2007). Jagged1 and Hey1, a target gene of Notch signal pathway, are also 
involved in mediating transforming growth factor-β–induced EMT (Zavadil et al., 2004). All 
these findings together indicate that Notch signaling plays a multitude of important roles in 
gastric carcinogenesis. 
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2.5 COX-2/PGE2 pathway 
The regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a 
reduced risk of cancer development in the gastrointestinal tract (Thun et al., 1993; Farrow et 
al., 1998; Oshima et al., 2009). The major target of NSAIDs is cyclooxygenases (COXs), such 
as COX-2, which is a rate-limiting enzyme responsible for the conversion of arachidonic acid 
to prostaglandins (PGs) (Chan et al., 2007; Williams et al., 1999). The anticancer effect of 
these agents is thought to be caused by the inhibition of COX-2 and, consequently the 
reduction of PG synthesis (Wu et al., 2010). Regular use of NSAIDs is associated with a 
decreased incidence of gastric cancer (Oshima et al., 2009, as cited in Thun et al, 1993; 
Zaridze et al., 1999). 
The over-expression of COX-2 was reported in several common human malignancies, such 
as in lung, colon, pancreas, bladder, head and neck cancers, being its main expression in 
gastrointestinal tract (Pereira et al., 2009, as cited by Fujimura et al., 2006 and van Rees & 
Ristimaki, 2001; Schuller et al., 2006). Several studies have shown that the treatment with 
NSAIDs or COX-2 selective inhibitors (COXIBs)  suppressed chemically induced tumor 
formation and xenografted tumor growth, so these results show that the COX-2 pathway 
plays an essential role in cancer development (Oshima & Taketo, 2002; Oshima et al., 2009). 
The inducible enzyme, COX-2 is responsible for catalyzing the biosynthesis of prostaglandin 
(PG) H2, which is further converted to PGE2 by microsomal PGE synthase-1 (mPGES-1), a 
PGE2 converting enzyme that is functionally coupled with COX-2 (Murakami et al., 2000; 
Seno et al, 2002). Cox-2-derived PGE2, a stable prostanoid synthesized by prostaglandin E 
synthase (PGES) can modulate inflammation (Huang & Chen, 2011, as cited in Harizi et al., 
2000), relax vascular smooth muscles (Huang & Chen, 2011, as cited in Smyth et al., 2009) 
and act as a promoter of cancer progression (Huang & Chen, 2011, as cited in Iniguez, 2008). 
This molecule also has the ability to stimulate tumor-associated angiogenesis (formation of 
new blood vessels that supply oxygen and nutrients), promote cellular proliferation, inhibit 
apoptosis and enhance cellular invasiveness, facilitating the progression of cancers (Gross et 
al, 2005). Among the COX-2 downstream prostanoids, PGE2 is the one that is better studied, 
concerning its potential role in tumor progression (Huang & Chen, 2011) and mediates most, 
if not all, of the oncogenic effect of COX-2 in gastric cancer (Muller-Decker & Furstenberger, 
2007). Such as for COX-2, an up-regulation of PGE2 in most of the gastrointestinal cancers 
also occurs (Huang & Chen, 2011).  Therefore, it is crucial for gastric carcinogenesis an 
increased level of PGE2 through the induction of COX-2 and mPGES-1. Simultaneous 
induction of COX-2 and mPGES-1 is observed in gastric cancer tissues, which suggests the 
induction of PGE2 pathway in gastric tumors (Oshima et al., 2006).  Several studies using 
mouse models have elucidated the roles of the PGE2 pathway in gastric tumorigenesis in the 
Wnt-activated and BMP-suppressed gastric mucosa (Oshima et al., 2009).  
It is known that Helicobacter pylori infection causes chronic gastritis, as well as an over-
expression of COX-2 and mPGES-1(Oshima et al., 2009). Concordantly, after eradication of 
H. pylori, COX-2 expression is suppressed (McCarthy et al., 1999), with correlation with 
decreased levels of mPGES-1, indicating that H. pylori infection induces the PGE2 pathway 
through induction of both COX-2 and mPGES-1. Several studies have found over-expression 
of COX-2 in gastric precancerous lesions and in gastric cancer (Tatsuguchi et al., 2000; 
Wambura et al., 2002). The molecular mechanism for COX-2 induction in tumors has not 
been totally elucidated, however there is a possibility that H. pylori can stimulate Toll-like 
receptors (TLRs) leading to the activation of the nuclear factor-κB (NF-κB) pathway that in 
turn induces the expression of COX-2. Another possibility is that the cytokine network can 
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be activated by infection and, as a result, an induction of COX-2 expression occurs (Chang et 
al., 2004; Smith et al., 2003). Transgenic mice over-expressing COX-2 and mPGES-1 
simultaneously develop intestinal metaplasia and hyperplastic tumors in the glandular 
stomach, which is associated with macrophage infiltration, so these results suggest that 
increased levels of PGE2 enhance infiltration of macrophages, whose activation by H. pylori 
may enhance gastric carcinogenesis (Oshima et al., 2004; Wu et al., 2010). 
2.6 NF-KB pathway 
NF-κB (Nuclear Factor kappa B) is a critical regulator of genes involved in cell survival and 
proliferation, cellular stress response, innate immunity and inflammation (Baeuerle & 
Baltimore, 1996; Barnes & Karin, 1997). The NF-κB family is composed by five closely 
related DNA binding proteins: RelA (p65), RelB, c-Rel, NF-κB1/p50 and NF-κB2/p52, which 
function as various homodimers and heterodimers. All share a highly conserved domain 
called the Rel homology domain (RHD), responsible for their dimerization, nuclear 
translocation, DNA binding and also interaction with the inhibitors of NF-κB (IκBs) 
(Gilmore, 2006). This family can be subdivided according to differences in synthesis and C-
terminal sequences. While members of the “Rel subfamily” (RelA, RelB and c-Rel) have a 
transactivation domain (TAD) at their C-termini and are synthesized directly as mature 
forms, p50 and p52 from “NF-κB subfamily” are generated from large precursor proteins, 
p105 and p100, respectively, by limited proteolysis or arrested translation. Although lacking 
a TAD, the precursors of the second subfamily contain a C-terminal with multiple copies of 
ankyrin repeats - ankyrin repeat domain (ARD) - the typical domain of IκBs. Characteristic 
NF-κB dimmers usually involve one member from each subfamily, although all NF-κB 
members may form various homo- or heterodimers. p50 or p52 homodimers inhibit NF-κB 
target gene expression due to lack of a TAD, therefore, members of the NF-κB subfamily are 
generally not activators of transcription but function as IκB-like inhibitors of NF-κB, except 
when they form heterodimers with members of the Rel subfamily, participating in target 
gene transactivation (Li & Verma, 2002). 
NF-κB is essencial in cellular response regulation being an example of transcription factors 
that are present in cells in an inactive state and do not require new protein synthesis to be 
activated. The activation of NF-κB requires phosphorylation of IκBs, resulting in their 
ubiquitin-dependent degradation. Therefore, NF-κB can enter the nucleus and activate the 
genes in response to certain stimuli, including reactive oxygen species (ROS), tumor necrosis 
factor alpha (TNFα), interleukin 1-beta (IL-1β) and bacterial lipopolysaccharides (LPS) - a 
component of the outer membrane of Gram-negative bacteria including H. pylori (Thanos & 
Maniatis, 1995). In unstimulated cells, the NF-κB dimers are sequestered in the cytoplasm by 
IκBs. There are two pathways leading to NF-κB activation: the canonical/classical and non-
canonical/alternative. The canonical pathway can be activated by several stimuli including 
inflammation cytokines and antigens that induce the phosphorylation and activation of an 
IκB kinase (IKK) complex, consisting of catalytic kinase subunits (IKKα and/or IKKβ) and a 
scaffold, sensing protein termed NF-κB essential modulator (NEMO). The activated IKK 
promotes phosphorylation of IκBα and its ubiquitin-dependent degradation by the 
proteasome. The released NF-κB is able to enter the nucleus and regulate the expression of a 
wide range of genes including activation of its own repressor, IκBα (Nelson et al., 2004) 
(Figure 5).  
 




Fig. 5. NF-kB signaling pathway (canonical activation). 
The non-canonical pathway is induced by certain receptor signals like B-cell activating 
factor (BAFF), Lymphotoxin β (LTβ), CD40 ligand, TNF-like weak inducer of apoptosis 
(TWEAK) and receptor activator of NF-κB ligand (RANKL) (Xiao et al., 2006). It is a slow 
process that depends on NF-κB-inducing kinase (NIK) protein synthesis. Despite the fact 
that its mRNA expression is abundant, protein levels are usually low due to its constitutive 
degradation by a TRAF3-dependent mechanism (Qing et al., 2005). When non-canonical NF-
κB stimuli occur, the key components of this mechanism are degraded by the proteasome 
and NIK is activated and then able to activate an IKKα complex (an homodimer lacking 
NEMO), that consequentially phosphorylates p100, leading to its partial proteolysis (in the 
proteasome) and formation of p52. The p52/RelB complex then translocates into the nucleus 
to modulate gene expression (Zarnegar et al., 2008) (Figure 6). 
There is evidence that NF-κB is constitutively activated in gastric cancer tissues, with 
higher levels in gastric carcinoma cells in comparison to normal adjacent epithelial cells 
(Sasaki et al., 2001) although it is RelA and not NF-κB that is used as a prognostic 
indicator of gastric carcinoma. It has also been reported that patients with highly 
activated NF-κB levels in cancer cells would have a lower survival potential when 
compared to those with low NF-κB activation (Yamanaka et al., 2004). In gastric cancer, 
abnormal NF-κB activation has been shown to lead to enhanced proliferation, evasion of 
apoptosis, genomic instability, increased rate of glycolysis and drug resistance (Cho et al., 
2008; Kang et al., 2008; X. Liu et al., 2010). 
Regarding drug resistance, a study has been performed in order to evaluate the effect of 5-
Fluorouracil (5-FU) and irinotecan (CPT-11) in NF-κB activation. It led to the conclusion that 
these components are inducing two different pathways: apoptosis through direct effect on 
nucleic acids, and inhibition of apoptosis through activation of NF-κB. Moreover, the same 
authors used an inhibitor of NF-κB and predicted that its combination with 5-FU and CPT-
11 may be a more effective treatment option instead of chemotherapy alone for gastric 
cancer (Camp et al., 2004). 
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Since the discovery that blocking NF-κB can cause tumor cells to stop proliferating, to die, or 
enhance their sensitivity to the action of anti-tumor agents NF-κB has been widely used as a 
target for anti-cancer therapy (Escarcega et al., 2007). HIF-1α, one of the components of 
hypoxia-inducible factor 1 (HIF-1), has been directly implicated in tumorigenesis including 
angiogenesis, tumor cell proliferation, metastasis, as well as chemo- and radiotherapy 
response, particularly in gastric cancer ( Liu et al., 2008; Weidemann & Johnson, 2008). 
Interestingly, a recent study showed that NF-κB inhibition in gastric cancer suppressed 
hypoxia-induced HIF-1α protein expression (but not at the mRNA level), suggesting that 
this protein is a downstream molecule of NF-κB in the angiogenesis pathway in gastric 
cancer. Also, NF-κB seems to be activated by hypoxia leading to HIF-1α protein 
accumulation at the translational level, but not at the transcriptional or post-translational 
levels. Thus, NF-κB/HIF-1α pathway may be a fitter candidate target for inhibition in 
gastric carcinoma therapy (Nam et al., 2011).  
Using a different approach, other investigators described a new mechanism in gastric tumor 
cells associated with NF-κB inhibition responsible for impairment of cell proliferation and 
induction of apoptosis of cancer cells. By blocking NF-κB (with a RelA inhibitor, SN50) they 
achieved an increase in p53 expression, which led to the induction of pro-apoptotic and 
autophagic proteins. Thus, p53 contributes to NF-κB inhibitor-induced apoptosis of cancer 
cells by activation of autophagic mechanisms (Zhu et al., 2011). 
2.7 Transforming growth factor- β, bone morphogenic protein pathway 
Transforming growth factor (TGF)-β is a multifunctional cytokine that controls 
differentiation, apoptosis, cell growth and immune reactions (Roberts, 2002; Shi & 
Massagué, 2003). TGF-β1, -β2, and -β3 are three isoforms of TGF-β that are present in 
mammals. In most types of cells, TGF-β is a potent growth inhibitor, so alterations on TGF-β 
signaling lead to tumor progression by the induction of angiogenesis, extracellular matrix 
accumulation and immunosuppression (Blobe et al., 2000; Derynck et al., 2001; Wakefield & 
Roberts, 2002). 
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This pathway is considered to be a tumor suppressor pathway that negatively regulates cell 
growth and promotes apoptosis of epithelial cells (Siegel & Massagué, 2003). In early stages 
of cancer, TGF- β signaling acts as a tumor-suppressor and in later stages promotes invasion 
and metastasis (Wu et al., 2010). TGF-β signaling pathway is composed of two distinct 
receptors with intrinsic serine/threonine kinase activity, TGF-β type I and type II receptors 
(TbRI and TbRII) and Smad proteins. The binding of TGF-β to TbRII leads to recruitment 
and transphosphorylation of TbRI (heteromeric complex). Cytoplasmatic Smad2 and Smad3 
are then phosphorylated by activated TbRI kinase, allowing them to form a heteromeric 
complex with Smad4, that is translocated into the nucleus acting as transcription factors.  
(Massagué, 1998; Miyazono et al., 2000; Miyazono et al., 2003) (Figure 7).  
 
 
Fig. 7. Wnt signaling pathway (canonical). 
Several studies demonstrated that the over-expression of TGF-β, in gastric cancer, is 
correlated with lymph node metastasis and poor prognosis (Maehara et al., 1999; Saito et al., 
2000), as well as promotion of invasion and metastasis (via Smad3-, ERK- and JNK-
dependent signal pathways) (Fu et al., 2009; Wang et al., 2006; Yoo et al., 2008). TGF-β 
induces RUNX3, a transcription factor that is involved in the formation of a variety of 
cancers (Ito, 2004). RUNX3 is expressed in glandular stomach epithelial cells, however, the 
loss of expression of this gene is associated with the progression, differentiation, metastasis 
and poor prognosis of gastric cancer (Li et al., 2002; Sugiura et al., 2008; Wei et al., 2005). 
Vogiatzi and colleagues (2006) demonstrated that RUNX3 interacts with FoxO3a /FKHRL1 
to activate Bim and induce apoptosis in gastric cancer cells. H. pylori causes methylation of 
RUNX3 gene and its loss of expression in gastric epithelial cells (Katayama et al., 2009). 
Moreover, RUNX3, Smad4 inactivation has been documented in gastric cancer (Wu et al., 
2010 as cited in Powell et al., 1997). Another study carried out by Shinto and colleagues 
(2011) demonstrated that the expression of p-Smad2 is associated with malignant phenotype 
and poor prognosis in patients with advanced gastric carcinoma.  
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Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily (von Bubnoff 
& Cho, 2001). They were originally identified as osteoinductive cytokines that regulate bone 
and cartilage formation  (Balemans & Van Hul, 2002; Chen et al., 2004; Hogan, 1996). The 
BMPs mediate their effects by binding to type I and II serine–threonine kinase receptors 
(BMPR), leading to the phosphorylation of Smad1, Smad5 and Smad8. These 
phosphorylated Smads heterodimerize with Smad4 and this complex is translocated to the 
nucleus to activate the transcription of downstreams targets  (Derynck et al., 1998; 
Kretzschmar et al., 1997; Heldin et al., 1997). Several studies have demonstrated that BMPs 
play important roles in the regulation of cell motility, proliferation, apoptosis, 
differentiation, self-renewal of embryonic stem cells and remodeling of the extracellular 
matrix (Hardwick et al., 2004; Hogan, 1996; Li et al., 1996; Massagué, 1996; Nissinen et al., 
1997; Von Bubnoff, 2001). BMP proteins are expressed in adult stomach (Peek & Blaser, 2002; 
van den Brink et al., 2001).  
BMP signaling in the stomach is down-regulated in cancer and upregulated during 
inflammation (Wu et al., 2010). H. pylori infection leads to an increase in BMP expression, 
mainly caused by an influx of BMP2-producing cells. The influx correlates with an increase 
in the activity of the BMP pathway (Bleumeing et al., 2006). A study carried out by Wen and 
colleagues (2004) demonstrated that BMP-2, a BMPR ligand, caused cell cycle arrest in the 
G1-phase in MKN74 and OUMS37 cells, and that this growth inhibitory action may be 
mediated by p21Waf1/Cip1 (BMP-2 suppresses gastric cancer cells proliferation). Moreover, 
this BMP is suppressed by tumor methylation in gastric cancer cells (Wen et al., 2006). Taken 
together, these results suggest that the inhibition of BMP signaling contributes to gastric 
tumorigenesis through the suppression of differentiation. (Oshima et al., 2009). However, 
recent studies have discovered that BMP-2 can accelerate the migration and invasiveness of 
gastric cancer cells and may correlate with disease progression (Kang et al., 2010; Park et al., 
2010).  
3. MUC1 mucin-mediated signaling pathways in gastric cancer  
The stomach is continuously subjected to a harsh acidic environment and several external 
aggressions. The mucus layer produced by the gastric epithelium has a crucial protective 
role against these adverse conditions. Three major heavily glycosylated proteins (mucins) 
line the stomach epithelium under normal conditions: one membrane associated mucin, 
MUC1, and two secreted mucins, MUC5AC and MUC6. They all contribute to the formation 
and maintenance of a cohesive “mucin net” that covers the entire epithelium, working as an 
efficient barrier. Abnormal expression and glycosylation have been described for these 
highly polymorphic mucins in gastric carcinoma and pre-neoplastic lesions (Reis et al., 1999; 
Teixeira et al., 2002). MUC1 polymorphism defines different susceptibility backgrounds 
associated with the development of conditions that precede gastric carcinoma: chronic 
atrophic gastritis and intestinal metaplasia (Silva et al., 2001). 
MUC1 and MUC4 have been recently identified as participating in intracellular signaling 
pathways, by their cytoplasmic domains (Carraway et al., 2003; Hollingsworth and 
Swanson, 2004). The phosphorylation of MUC1 cytoplasmic domain (MUC1-CD) has been 
found to modulate its interaction with several molecules, such as EGFR, β-catenin, p53, ER- 
α, ICAM-1, among other molecules (for review see Singh & Hollingsworth , 2006). These 
interactions have been mainly found for breast, pancreatic and lung cancer cells and so far 
the data about MUC1-mediated signaling pathways or MUC1 signaling partners in gastric 
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carcinoma cells is limited. MUC1-CD is known to interact with beta-catenin and upregulate 
the Wnt signaling pathway in CagA Helicobacter pylori-infected gastric carcinoma 
(Udhayakumar et al., 2007). 
Our group has been studying the MUC1-dependent signaling pathways in gastric cancer 
cells. We have stably down-regulated MUC1 expression in MKN45 gastric carcinoma cell 
line by shRNA and we evaluated MUC1 down-regulation impact in potential MUC1-
mediated signaling pathways. We observed that MUC1-downregulation leads to abnormal 
expression levels of ERK1/2 proteins and an increased phosphorylation of these kinases. We 
further characterized the association between MUC1 and ERK1/2 and we showed by 
proximity ligation assays that MUC1-CD directly interacts with ERK1/2 kinases in these 
cells. The impact of MUC1 in the transcription and stability of these kinases and the 
interaction with other signaling partners (e.g. EGFR) are being currently evaluated, 
nonethless this clearly suggests that MUC1-CD is involved at different levels in the 
regulation of the MAPK signaling pathway in gastric carcinoma cells (Figure 8). 
 
 
Fig. 8. MUC1 and EGFR/MAPK signaling pathway. 
The kinases of EGFR/MAPK signaling pathway are crucial effectors responsible for cell 
proliferation and oncogenic transformation. Recent data from other tumor models further 
reinforce the relevance of MUC1 as a key player in cell-cell (microenvironment) signaling 
contexts (Behrens et al., 2010). Therefore, it assumes critical relevance an extensive 
characterization of MUC1-mediated signaling events in this pathway and their impact in 
gastric carcinoma phenotype. These results suggest MUC1 as a new and promising 
candidate to be targeted by therapies against gastric cancer.  
4. Conclusions 
Gastric cancer is a leading cause of cancer-related death worldwide. Given the limited 
options currently available for gastric cancer therapy and prevention, it becomes urgent to 
better understand the oncogenic signaling pathways beyond the emergence of the disease. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
14
Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily (von Bubnoff 
& Cho, 2001). They were originally identified as osteoinductive cytokines that regulate bone 
and cartilage formation  (Balemans & Van Hul, 2002; Chen et al., 2004; Hogan, 1996). The 
BMPs mediate their effects by binding to type I and II serine–threonine kinase receptors 
(BMPR), leading to the phosphorylation of Smad1, Smad5 and Smad8. These 
phosphorylated Smads heterodimerize with Smad4 and this complex is translocated to the 
nucleus to activate the transcription of downstreams targets  (Derynck et al., 1998; 
Kretzschmar et al., 1997; Heldin et al., 1997). Several studies have demonstrated that BMPs 
play important roles in the regulation of cell motility, proliferation, apoptosis, 
differentiation, self-renewal of embryonic stem cells and remodeling of the extracellular 
matrix (Hardwick et al., 2004; Hogan, 1996; Li et al., 1996; Massagué, 1996; Nissinen et al., 
1997; Von Bubnoff, 2001). BMP proteins are expressed in adult stomach (Peek & Blaser, 2002; 
van den Brink et al., 2001).  
BMP signaling in the stomach is down-regulated in cancer and upregulated during 
inflammation (Wu et al., 2010). H. pylori infection leads to an increase in BMP expression, 
mainly caused by an influx of BMP2-producing cells. The influx correlates with an increase 
in the activity of the BMP pathway (Bleumeing et al., 2006). A study carried out by Wen and 
colleagues (2004) demonstrated that BMP-2, a BMPR ligand, caused cell cycle arrest in the 
G1-phase in MKN74 and OUMS37 cells, and that this growth inhibitory action may be 
mediated by p21Waf1/Cip1 (BMP-2 suppresses gastric cancer cells proliferation). Moreover, 
this BMP is suppressed by tumor methylation in gastric cancer cells (Wen et al., 2006). Taken 
together, these results suggest that the inhibition of BMP signaling contributes to gastric 
tumorigenesis through the suppression of differentiation. (Oshima et al., 2009). However, 
recent studies have discovered that BMP-2 can accelerate the migration and invasiveness of 
gastric cancer cells and may correlate with disease progression (Kang et al., 2010; Park et al., 
2010).  
3. MUC1 mucin-mediated signaling pathways in gastric cancer  
The stomach is continuously subjected to a harsh acidic environment and several external 
aggressions. The mucus layer produced by the gastric epithelium has a crucial protective 
role against these adverse conditions. Three major heavily glycosylated proteins (mucins) 
line the stomach epithelium under normal conditions: one membrane associated mucin, 
MUC1, and two secreted mucins, MUC5AC and MUC6. They all contribute to the formation 
and maintenance of a cohesive “mucin net” that covers the entire epithelium, working as an 
efficient barrier. Abnormal expression and glycosylation have been described for these 
highly polymorphic mucins in gastric carcinoma and pre-neoplastic lesions (Reis et al., 1999; 
Teixeira et al., 2002). MUC1 polymorphism defines different susceptibility backgrounds 
associated with the development of conditions that precede gastric carcinoma: chronic 
atrophic gastritis and intestinal metaplasia (Silva et al., 2001). 
MUC1 and MUC4 have been recently identified as participating in intracellular signaling 
pathways, by their cytoplasmic domains (Carraway et al., 2003; Hollingsworth and 
Swanson, 2004). The phosphorylation of MUC1 cytoplasmic domain (MUC1-CD) has been 
found to modulate its interaction with several molecules, such as EGFR, β-catenin, p53, ER- 
α, ICAM-1, among other molecules (for review see Singh & Hollingsworth , 2006). These 
interactions have been mainly found for breast, pancreatic and lung cancer cells and so far 
the data about MUC1-mediated signaling pathways or MUC1 signaling partners in gastric 
 
Oncogenic Signaling in Gastric Cancer 
 
15 
carcinoma cells is limited. MUC1-CD is known to interact with beta-catenin and upregulate 
the Wnt signaling pathway in CagA Helicobacter pylori-infected gastric carcinoma 
(Udhayakumar et al., 2007). 
Our group has been studying the MUC1-dependent signaling pathways in gastric cancer 
cells. We have stably down-regulated MUC1 expression in MKN45 gastric carcinoma cell 
line by shRNA and we evaluated MUC1 down-regulation impact in potential MUC1-
mediated signaling pathways. We observed that MUC1-downregulation leads to abnormal 
expression levels of ERK1/2 proteins and an increased phosphorylation of these kinases. We 
further characterized the association between MUC1 and ERK1/2 and we showed by 
proximity ligation assays that MUC1-CD directly interacts with ERK1/2 kinases in these 
cells. The impact of MUC1 in the transcription and stability of these kinases and the 
interaction with other signaling partners (e.g. EGFR) are being currently evaluated, 
nonethless this clearly suggests that MUC1-CD is involved at different levels in the 
regulation of the MAPK signaling pathway in gastric carcinoma cells (Figure 8). 
 
 
Fig. 8. MUC1 and EGFR/MAPK signaling pathway. 
The kinases of EGFR/MAPK signaling pathway are crucial effectors responsible for cell 
proliferation and oncogenic transformation. Recent data from other tumor models further 
reinforce the relevance of MUC1 as a key player in cell-cell (microenvironment) signaling 
contexts (Behrens et al., 2010). Therefore, it assumes critical relevance an extensive 
characterization of MUC1-mediated signaling events in this pathway and their impact in 
gastric carcinoma phenotype. These results suggest MUC1 as a new and promising 
candidate to be targeted by therapies against gastric cancer.  
4. Conclusions 
Gastric cancer is a leading cause of cancer-related death worldwide. Given the limited 
options currently available for gastric cancer therapy and prevention, it becomes urgent to 
better understand the oncogenic signaling pathways beyond the emergence of the disease. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
16
There is an increased knowledge about the alterations occurring in multiple signaling 
pathways and the acquisition of gastric cancer phenotype. The complex interplay between 
environmental factors and oncogenic signaling pathways involving cell proliferation, 
differentiation, apoptosis and invasion, remains however elusive. Emerging evidence in 
other models has brought new evidences on the complex interaction among different 
oncogenic signaling pathways. Whether such phenomena occur in gastric cancer, remains 
unclear.  
The elucidation of individual interactions is thus required to develop a more consistent 
understanding of the gastric oncogenic signaling networks and will help to identify novel 
targets for anticancer drug development. The reviewed signaling pathways are relevant 
contributors for gastric carcinogenesis and encompass a multitude of potential therapeutic 
targets. In addition to these signaling-related targets we included new data on MUC1 
mucin, previously described as being involved in gastric cancer susceptibility phenotype. 
The characterization of the complete spectrum of MUC1-dependent oncogenic signaling 
interactions in gastric cancer cells, will offer the molecular basis for the development of 
innovative therapies using MUC1 as an elective target. Furthermore an integrative 
perspective, of these MUC1-mediated signaling pathways, will be critical to design 
therapeutic strategies that inhibit multiple signaling pathways enhancing the efficacy of 
gastric cancer therapies and probably prevent the development of drug resistance 
phenotype. 
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1. Introduction 
Gastric cancer remains a worldwide burden as a second leading cause of cancer death in 
both sexes (Globocan, 2011; Nobili et al., 2011). Although its incidence is in decline in 
developed countries, it is still the fourth most common malignancy in the world, behind 
cancers of the lung, breast, colon, and rectum (Globocan, 2011). The fall in its incidence is 
attributed mainly to the decline of the intestinal type of stomach cancer, whereas the 
incidence of the diffuse type has remained constant over time (Yamashita et al., 2011). On 
the other hand, there has been a progressive increase in the cardia and gastroesophageal 
junction adenocarcinoma (Milne et al., 2009; Yamashita et al., 2011). The exact cause of this 
shift in location is not known. The general decrease of gastric cancer frequency in developed 
countries is attributed to the changes in dietary habits and food preservation methods (Crew 
& Neugut, 2006; Kufe et al., 2003). The prevalence of gastric cancer varies throughout the 
world, with the highest rates reported in Korea, Japan, Central and South America, and 
Eastern Europe, whereas Western Europe, North America, Africa, Australia, and New 
Zealand are low incidence areas (Crew & Neugut, 2006; Tahara, 2008; Yamashita et al., 
2011). Despite the decrease in its incidence and improvements in diagnosis, curative 
surgery, and treatment, gastric cancer remains major health burden due to its poor 
prognosis (Smith et al., 2006; Yamashita et al., 2011).   
Adenocarcinoma is the major histological type of gastric cancer; accounting for 90% to 95% 
of all gastric malignancies, and this chapter will focus only on this type of gastric tumours 
(Hamilton & Meltzer, 2006). Adenocarcinoma develops from the glandular cells of stomach 
mucosa, while other rare stomach cancers develop in lymph tissue (lymphoma), hormone – 
producing cells (carcinoid tumours), muscle cells (soft tissue sarcomas) or certain nerve cells 
(gastrointestinal  stromal tumours or GIST) (Smith et al., 2006). Based on the widely used 
Lauren classification, adenocarcinomas are divided into two distinct pathological entities, 
intestinal and diffuse types, which have different clinicopathological and prognostic 
features (Yamashita et al., 2011). Intestinal type is associated with Helicobacter pylori 
infection, obesity and certain dietary factors, such as high intake of salt, smoked meats and 
food preserved with nitrites or nitrates, and is believed to arise through a long-term 
multistep progression from chronic gastritis to chronic atrophy to intestinal metaplasia to 
dysplasia (Crew & Neugut, 2006; Hamilton & Meltzer, 2006; Yamashita et al., 2011). 
Histologically it is well differentiated and occurs more commonly in older patients, males 
and blacks (Crew & Neugut, 2006). Diffuse type is poorly differentiated with infiltrating, 
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1. Introduction 
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both sexes (Globocan, 2011; Nobili et al., 2011). Although its incidence is in decline in 
developed countries, it is still the fourth most common malignancy in the world, behind 
cancers of the lung, breast, colon, and rectum (Globocan, 2011). The fall in its incidence is 
attributed mainly to the decline of the intestinal type of stomach cancer, whereas the 
incidence of the diffuse type has remained constant over time (Yamashita et al., 2011). On 
the other hand, there has been a progressive increase in the cardia and gastroesophageal 
junction adenocarcinoma (Milne et al., 2009; Yamashita et al., 2011). The exact cause of this 
shift in location is not known. The general decrease of gastric cancer frequency in developed 
countries is attributed to the changes in dietary habits and food preservation methods (Crew 
& Neugut, 2006; Kufe et al., 2003). The prevalence of gastric cancer varies throughout the 
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Zealand are low incidence areas (Crew & Neugut, 2006; Tahara, 2008; Yamashita et al., 
2011). Despite the decrease in its incidence and improvements in diagnosis, curative 
surgery, and treatment, gastric cancer remains major health burden due to its poor 
prognosis (Smith et al., 2006; Yamashita et al., 2011).   
Adenocarcinoma is the major histological type of gastric cancer; accounting for 90% to 95% 
of all gastric malignancies, and this chapter will focus only on this type of gastric tumours 
(Hamilton & Meltzer, 2006). Adenocarcinoma develops from the glandular cells of stomach 
mucosa, while other rare stomach cancers develop in lymph tissue (lymphoma), hormone – 
producing cells (carcinoid tumours), muscle cells (soft tissue sarcomas) or certain nerve cells 
(gastrointestinal  stromal tumours or GIST) (Smith et al., 2006). Based on the widely used 
Lauren classification, adenocarcinomas are divided into two distinct pathological entities, 
intestinal and diffuse types, which have different clinicopathological and prognostic 
features (Yamashita et al., 2011). Intestinal type is associated with Helicobacter pylori 
infection, obesity and certain dietary factors, such as high intake of salt, smoked meats and 
food preserved with nitrites or nitrates, and is believed to arise through a long-term 
multistep progression from chronic gastritis to chronic atrophy to intestinal metaplasia to 
dysplasia (Crew & Neugut, 2006; Hamilton & Meltzer, 2006; Yamashita et al., 2011). 
Histologically it is well differentiated and occurs more commonly in older patients, males 
and blacks (Crew & Neugut, 2006). Diffuse type is poorly differentiated with infiltrating, 
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non-cohesive cells and is more frequent in younger patients (Crew & Neugut, 2006; Panani, 
2008). Studies showed that Helicobacter pylori infection also plays a role in the development 
of diffuse gastric cancer, through chronic inflammation, but without occurrence of 
intermediate steps, such as gastric atrophy and intestinal metaplasia (Milne et al., 2009).    
It is believed that the pathogenesis of gastric cancer represents a classic example of gene-
environment interactions (Panani, 2008). Epidemiologic studies have shown a reduction of 
its incidence in migrant populations, when they move from high-risk areas to low-incidence 
ones. Subsequent populations acquire risk levels similar to those in the host country, 
indicating the importance of environmental influences on its development (Crew & Neugut, 
2006; Matysiak-Budnik & Megraud, 2006). Therefore, it is generally acknowledged that both, 
environmental and genetic factors are implicated in the pathogenesis of gastric cancer 
development (Milne et al., 2009). Furthermore, several researchers believe that 
environmental factors have a greater influence on the development of intestinal type, 
whereas diffuse type might have a stronger genetic background (Matysiak-Budnik & 
Megraud, 2006; Milne et al., 2009). Nevertheless, despite tremendous efforts in the past few 
decades, there is still no clear agreement on the genetic and epigenetic changes underlying 
the initiation and progression of both types of gastric adenocarcinoma (Milne et al., 2009; 
Panani, 2008).  
This review is intended to focus on different molecular hypotheses of gastric carcinogenesis. 
New advances in the fields of high-throughput methodologies, functional genomics and 
molecular profiling will be discussed.   
2. Molecular mechanisms of gastric carcinogenesis 
Numerous cytogenetic and molecular genetic studies tested common cancer hypotheses, 
such as oncogene overexpression, suppressor, mutator, and methylator pathway 
hypotheses, but exact molecular mechanisms of gastric cancer development remain elusive. 
In nearly two decades of research a vast amount of articles referring to overexpression and 
silencing of genes was published (Resende et al., 2010). Several studies reported 
amplification and overexpression of growth factors, growth factor receptors, tyrosine 
kinases, nuclear factors, matrix metalloproteinases, cell cycle regulators cytokines and other 
genes (Panani, 2008; Tahara, 2008; Wu et al., 2010). Furthermore, other studies have shown 
that loss of heterozigosity (LOH) and inactivation of tumour suppressor genes seem to be 
involved in the development of gastric adenocarcinomas (Gazvoda et al., 2007; Juvan et al., 
2007; Panani, 2008; Resende et al., 2010). The presence of spontaneous DNA replication 
errors in simple repetitive microsatellite sequences indicated a novel pathway of 
carcinogenesis, microsatellite instability (MSI) (Loeb, 2001; Panani, 2008; Simpson et al., 
2001). It was found that it could be the consequence of defective DNA mismatch repair 
mechanism (MMR), caused by genetic alterations in MLH1, MSH2, PMS1, and PMS2 genes 
(Hudler et al., 2004; Loeb, 2001; Panani, 2008; Simpson et al., 2001). In recent years, 
epigenetic changes, such as promoter methylation, hypomethylation and histone acetylation 
have been also recognized in gastric carcinogenesis (Hudler et al., 2004; Mitani et al., 2005; 
Schneider et al., 2010; Suzuki et al., 2006; Yamamoto et al., 2011).  
In the 90‘s a model, describing genetic events of colorectal carcinogenesis, was suggested by 
Fearon and Vogelstein, which has shaped our understanding of the evolution of most types 
of malignancies today (Fearon & Vogelstein, 1990). The so-called 'Vogelgram' predicts that 
alterations in at least four to five cancer-related genes (oncogenes and tumour suppressor 
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genes) are needed for malignancy to occur, and that the total accumulation of changes rather 
than the order of their appearance is responsible for progression of the cancer (Fearon & 
Vogelstein, 1990).  
Although molecular mechanisms and alterations contributing to initiation and progression 
of gastric tumorigenesis are still not completely understood, it is now widely accepted that it 
is initiated by several genetic and epigenetic alterations that result in overexpression of 
oncogenes and growth factors, as well as impaired expression of tumour suppressor genes. 
It has also become evident that alterations in genome stability genes can initiate and 
accelerate these neoplastic processes (Nobili et al., 2011; Oda et al., 2005; Zheng et al., 2004). 
It is also important to note that the prevalence of these abnormalities varies between 
intestinal and diffuse types of gastric cancer (Hamilton & Meltzer, 2006). 
Recently, another type of genetic instability has been recognized as the most common 
feature of gastric cancers, namely chromosomal instability (CIN), leading to aneuploidy 
(Buffart et al., 2011; Nobili et al., 2011). New advances in high-throughput methodologies 
have shown that majority of solid tumours are characterized by gross chromosomal 
abnormalities, such as gain and/or loss of whole chromosomes or chromosomal segments 
(Duesberg & Rasnick, 2000; Gollin, 2005).  
2.1 Oncogenes  
Cell proliferation is tightly regulated through signal transduction pathways, which are 
regulated by growth factors and their receptors. Alterations in growth factors and other 
oncogenes result in constantly active genes or active under conditions in which the wild-
type genes are not. Oncogenes are mainly activated due to gene amplifications, intragenic 
mutations that regulate the activity of gene product or chromosomal translocations, all 
leading to overexpression of the oncoproteins. The occurrence and development of gastric 
cancer was found closely related to a variety of oncogenes, few of which are briefly 
discussed below.  
Ras family oncogenes play an important role in the pathogenesis of colon and pancreatic 
cancers and were reported, though less frequently, in gastric carcinomas (Pellegata et al., 
1992; Soh et al., 1993). The prevalence of alterations in HRAS (K-ras), which encodes a 
protein involved in cellular signal transduction pathways, appeared to be dependent of 
geographic and ethnic origins of gastric cancer cases. While HRAS mutations were rare in 
Western Europe and Japan, the prevalence in China was up to 30% (Deng et al., 1994; 
Hiyama et al., 2002; van Rees et al., 1999). Genetic changes in HRAS have been observed in 
gastric intestinal metaplasia and gastric adenomas, and could be an early event in the 
development of gastric cancer (Hirohashi & Sugimura, 1991; Osaki et al., 1996). Despite 
many studies focused on HRAS mutations, there is still some controversial data on the 
functional role of these mutations that needs to be elucidated. 
Overexpression or activation, due to either amplification or mutation of genes of some 
tyrosine kinases (hepatocyte growth factor receptor (MET or c-met), fibroblast growth factor 
receptor 2 (FGFR2 or K-sam), human epithelial growth factor receptor 2 (HER2), and 
epithelial growth factor receptor (EGFR)) could be associated with human gastric cancer. 
Both, HER2 and EGFR, were found overexpressed in gastric cancer, with prevalence in the 
intestinal type cancers (Garcia et al., 2003). Receptors have an intracellular domain with 
tyrosine kinase activity and EGFR can bind ligands with its extracellular domain, which 
induces homodimerization of the receptor and generates autophosphorylation, initiating 
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silencing of genes was published (Resende et al., 2010). Several studies reported 
amplification and overexpression of growth factors, growth factor receptors, tyrosine 
kinases, nuclear factors, matrix metalloproteinases, cell cycle regulators cytokines and other 
genes (Panani, 2008; Tahara, 2008; Wu et al., 2010). Furthermore, other studies have shown 
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mechanism (MMR), caused by genetic alterations in MLH1, MSH2, PMS1, and PMS2 genes 
(Hudler et al., 2004; Loeb, 2001; Panani, 2008; Simpson et al., 2001). In recent years, 
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Fearon and Vogelstein, which has shaped our understanding of the evolution of most types 
of malignancies today (Fearon & Vogelstein, 1990). The so-called 'Vogelgram' predicts that 
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genes) are needed for malignancy to occur, and that the total accumulation of changes rather 
than the order of their appearance is responsible for progression of the cancer (Fearon & 
Vogelstein, 1990).  
Although molecular mechanisms and alterations contributing to initiation and progression 
of gastric tumorigenesis are still not completely understood, it is now widely accepted that it 
is initiated by several genetic and epigenetic alterations that result in overexpression of 
oncogenes and growth factors, as well as impaired expression of tumour suppressor genes. 
It has also become evident that alterations in genome stability genes can initiate and 
accelerate these neoplastic processes (Nobili et al., 2011; Oda et al., 2005; Zheng et al., 2004). 
It is also important to note that the prevalence of these abnormalities varies between 
intestinal and diffuse types of gastric cancer (Hamilton & Meltzer, 2006). 
Recently, another type of genetic instability has been recognized as the most common 
feature of gastric cancers, namely chromosomal instability (CIN), leading to aneuploidy 
(Buffart et al., 2011; Nobili et al., 2011). New advances in high-throughput methodologies 
have shown that majority of solid tumours are characterized by gross chromosomal 
abnormalities, such as gain and/or loss of whole chromosomes or chromosomal segments 
(Duesberg & Rasnick, 2000; Gollin, 2005).  
2.1 Oncogenes  
Cell proliferation is tightly regulated through signal transduction pathways, which are 
regulated by growth factors and their receptors. Alterations in growth factors and other 
oncogenes result in constantly active genes or active under conditions in which the wild-
type genes are not. Oncogenes are mainly activated due to gene amplifications, intragenic 
mutations that regulate the activity of gene product or chromosomal translocations, all 
leading to overexpression of the oncoproteins. The occurrence and development of gastric 
cancer was found closely related to a variety of oncogenes, few of which are briefly 
discussed below.  
Ras family oncogenes play an important role in the pathogenesis of colon and pancreatic 
cancers and were reported, though less frequently, in gastric carcinomas (Pellegata et al., 
1992; Soh et al., 1993). The prevalence of alterations in HRAS (K-ras), which encodes a 
protein involved in cellular signal transduction pathways, appeared to be dependent of 
geographic and ethnic origins of gastric cancer cases. While HRAS mutations were rare in 
Western Europe and Japan, the prevalence in China was up to 30% (Deng et al., 1994; 
Hiyama et al., 2002; van Rees et al., 1999). Genetic changes in HRAS have been observed in 
gastric intestinal metaplasia and gastric adenomas, and could be an early event in the 
development of gastric cancer (Hirohashi & Sugimura, 1991; Osaki et al., 1996). Despite 
many studies focused on HRAS mutations, there is still some controversial data on the 
functional role of these mutations that needs to be elucidated. 
Overexpression or activation, due to either amplification or mutation of genes of some 
tyrosine kinases (hepatocyte growth factor receptor (MET or c-met), fibroblast growth factor 
receptor 2 (FGFR2 or K-sam), human epithelial growth factor receptor 2 (HER2), and 
epithelial growth factor receptor (EGFR)) could be associated with human gastric cancer. 
Both, HER2 and EGFR, were found overexpressed in gastric cancer, with prevalence in the 
intestinal type cancers (Garcia et al., 2003). Receptors have an intracellular domain with 
tyrosine kinase activity and EGFR can bind ligands with its extracellular domain, which 
induces homodimerization of the receptor and generates autophosphorylation, initiating 
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several signalling cascades that lead to DNA synthesis and cell proliferation. 
Overexpression of EGFR promotes cell migration, angiogenesis and inhibits apoptosis and 
has been observed in up to 47% of gastric cancers. Moreover, it was found to correlate with 
disease progression and poor clinical outcome (Malden et al., 1989; Yonemura et al., 1992; 
Yoshida et al., 1990). HER2 does not bind to any known ligand, but it is known to 
heterodimerize with other members of the family, especially when it is overexpressed. The 
protein has been reported to be overexpressed or activated in 19% of gastric cancer cases. 
Studies suggest that overexpression of HER2 might be prognostic factor for intestinal-type 
gastric cancer associated with shorter relapse-free survival and overall survival (Vizoso et 
al., 2004; Zhang et al., 2009).  
Abnormalities in genes, such as FGFR2 (K-sam), belonging to fibroblast growth factor 
receptor family, are associated with diffuse-type gastric cancer. Activation of FGFR2 has 
been found in approximately 50% of diffuse type gastric cancers, and was associated with 
neoplastic progression and metastasis (Hara et al., 1998; Hattori et al., 1996; Werner et al., 
2001). 
The oncogene MET (c-met) encodes a receptor with tyrosine-kinase activity that binds 
hepatocyte growth factor. Aberrantly active receptor was preferentially found in intestinal-
type gastric cancer tumours and was correlated with poor prognosis (Nakajima et al., 1999; 
Tsugawa et al., 1998). Employing a simple method of fluorescent multiplex RT-PCR assay 
and capillary electrophoresis separation we found overexpression of MET in 56% of 
Slovenian patients with gastric cancer (Rajcevic et al., 2007; Rajcevic et al., 2001). MET 
amplification could constitute an important biomarker for selecting patients for a targeted 
therapy, because it has been observed that a fraction of gastric cancer cell lines appeared to 
be exquisitely sensitive to a specific MET inhibitor (Smolen et al., 2006). 
Vascular endothelial growth factor (VEGF), a pro-angiogenic molecule, was found 
frequently overexpressed in poorly differentiated gastric cancer (Brown et al., 1993; 
Scartozzi et al., 2004; Tian et al., 2001; Yamamoto et al., 1998). Recently, a VEGF +1612G/A 
gene polymorphism was found to be associated with gastric cancer in Chinese Han patients 
and was previously shown to affect VEGF plasma levels (Zhou et al., 2011). Several other 
oncogenes have been found overexpressed in gastric carcinomas (Nobili et al., 2011; Rajcevic 
et al., 2007; Tahara, 2004). Nevertheless, years of research have shown that overexpression of 
oncogenes is not the sole mechanism implicated in gastric cancer pathogenesis.  
2.2 Suppressor phenotype 
Tumour suppressor genes are targeted in the opposite way than oncogenes. Molecular 
abnormalities that result in a truncation of the proteins, deletions or insertions or epigenetic 
silencing, reduce the activity of the gene product. Generally, alterations in both alleles are 
required to confer impairment of the gene product, except in the case of haplo-insufficient 
genes (Dang et al., 2008; Vogelstein & Kinzler, 2004). Inactivation of the wild-type allele 
arises due to allelic loss, termed also loss of heterozygosity (LOH) or mutations (Knudson, 
1993). The suppressor phenotype in gastric cancer is characterized by inactivation of 
suppressor genes, such as TP53 (p53), APC, MCC, DCC, CDH1, Rb1, FHIT, and other 
(Hamilton & Meltzer, 2006; Nobili et al., 2011). 
In our study we evaluated LOH on loci associated with the following tumour suppressors: 
TPp53, APC, nm23, and RB) and found that 52% of all cases exhibited LOH in at least one 
locus (Gazvoda et al., 2007). The highest frequency of LOH was at APC locus (36%), 
 
Genetic Instability in Gastric Cancer 
 
31 
followed by TP53-1 (33%), nm23 (33%), TP53-2 (24%) and RB (24%). Interestingly, 5% of the 
samples exhibited MSI on all the evaluated loci (in LOH as well as in MSI evaluation). These 
samples were associated with clinicopathological features that differed from the rest. All 
tumours belonged to intestinal type, displayed expansive growth and were mostly tubular. 
Furthermore, we found that LOH on loci TP53-1 and TP53-2 was associated with more 
expansive growth and LOH on TP53-1 locus tended to be associated with intestinal type 
tumours. In contrast, tumours without LOH on TP53-1 locus were associated with 
ulcerating, infiltrating type of gastric adenocarcinoma (Gazvoda et al., 2007). 
The TP53 gene encodes a main regulator of cell growth and division, and its function in 
intestinal type of gastric cancer is mainly altered due to LOH and mutations. When protein 
p53 is impaired, the cells may not be able to induce apoptosis and control tumour growth 
(Vousden & Prives, 2005). Studies showed that mutations in TP53 are present in a range of 
40%-70% of early and advanced gastric cancers, and inactivation of TP53 resulting from 
LOH is found in 60%-70% of intestinal-type gastric cancers, thus making this gene among 
the most frequently mutated genes in cancers (Hamilton & Meltzer, 2006; Werner et al., 
2001). It was suggested that accumulation of mutations in TP53 is involved in initiating 
carcinogenic processes, though not all studies are in agreement with this hypothesis (Liu et 
al., 2001; Zwick et al., 1997). The expression of p53 protein can be easily detected by 
immunohistochemical staining, because mutations in TP53 gene increase the half-life of its 
product, and it was postulated that it could be used as a biomarker in a clinical setting 
(Zheng et al., 2004). However, there are conflicting results regarding the prevalence and of 
TP53 mutations and its expression and their relationship to clinicopathological features of 
gastric cancer (Panani, 2008). We and some other researchers found that the TP53 mutational 
status was not in association with p53 expression (Bataille et al., 2003; Juvan et al., 2007; 
Panani, 2008). Furthermore, we found that positive TP53 expression was associated with 
poorer survival, which was accordance with some other studies (Bani-Hani et al., 2005; 
Lazar et al., 2010). On the other hand, other studies did not reveal this association, therefore, 
the prognostic value of TP53 remains controversial (Panani, 2008).    
Loss of APC gene function was first identified in 60%-80% of patients with familial 
adenomatous polyposis-associated colorectal cancers (Kinzler et al., 1991; Lynch & Lynch, 
1998). Mutations and LOH of the gene were also reported in more than 50% of gastric 
cancers of intestinal type (Tahara, 1995; Wright & Williams, 1993). Functional product of 
APC gene targets β-catenin for ubiquitination, and thus prevents β-catenin associated 
induction of genes involved in growth control (Caca et al., 1999; Park et al., 1999). 
E-cadherin, encoded by CDH1 gene, is an adhesion molecule expressed from epithelial cells, 
which plays a crucial role in epithelial structural integrity and was found to be implicated in 
carcinogenesis. Germline mutations in CDH1 were first described in patients with 
hereditary diffuse type gastric cancer, however the rate of CDH1 mutations in sporadic 
gastric cancer was found to be as high as 50%, and reduced expression of E-cadherin protein 
was found in 51% of diffuse type gastric cancers (Becker et al., 1994; Guilford et al., 1998; 
Xiangming et al., 1999). Susceptible individuals with a germline mutation in tumour 
suppressor gene CDH1 require the inactivation of the second allele due to somatic mutation 
or DNA methylation, rendering E-cadherin completely inactive (Becker et al., 2000). 
Abnormal expression of E-cadherin is thought to promote metastatic ability of gastric cancer 
cells (Kanai & Hirohashi, 1997).  
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Xiangming et al., 1999). Susceptible individuals with a germline mutation in tumour 
suppressor gene CDH1 require the inactivation of the second allele due to somatic mutation 
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2.3 Alterations in other genes 
Genetic and epigenetic abnormalities have been found in numerous other genes that 
participate in proliferation, invasion and metastasis, such as cell cycle regulators, cell-
adhesion molecules, growth factors, cytokines, nuclear factors, matrix metalloproteinases, 
DNA repair genes, and apoptosis regulators (Nobili et al., 2011; Tahara, 2004; Yokozaki et 
al., 2001). For example, cyclin E1 together with cyclin-dependent kinase, CDK2, promotes 
the entry into the S-phase of the cell cycle, and it was found overexpressed in one third of 
gastric cancer cases. Amplification of this gene was found to correlate with tumour 
aggressiveness (Jiaqing et al., 1998; Nobili et al., 2011; Xiangming et al., 2000). In our study 
we observed overexpression of cyclin E1 in 42% of patients with gastric cancer and in 57% of 
patients with precancerous lesions, indicating that abnormalities in this gene could be early 
event in gastric carcinogenesis (Rajcevic et al., 2007). Moreover, we also found 
overexpression of epidermal growth factor family members, such as TDGF1 and EGF, and 
NRG1, signalling protein, that mediates cell-cell interactions and plays critical roles in the 
growth and development of multiple organ systems (Rajcevic et al., 2007). Several other 
genes have been reviewed extensively elsewhere (Nobili et al., 2011; Resende et al., 2010; 
Tahara, 2004; Wu et al., 2010; Yokozaki et al., 2001).  
2.4 MSI and mutator phenotype 
Molecular abnormalities in oncogenes and tumour suppressor genes drive the neoplastic 
process by increasing tumour growth. The increase is achieved by activating of genes that 
drive the cell cycle or by inhibiting normal apoptotic pathways (Vogelstein & Kinzler, 2004). 
The third class of genes that contribute to cancer development are the stability genes, which, 
when mutated, promote tumorigenesis in a completely different way. They keep genetic 
alterations to a minimum, and thus, when they are inactivated, mutations in oncogenes and 
tumour suppressor genes occur at a higher rate (Freiberg, 2003). As with tumour suppressor 
genes, both alleles must be inactivated for physiologic effect to result.  
Mismatch repair (MMR) genes are an example of genome stability genes and molecular 
inactivation of these genes is a hallmark of so-called mutator pathway, which results in 
microsatellite instability (MSI) or mutator phenotype. Microsatellites are short tandem 
repeats abundant throughout the genome. They are polymorphic among individuals, but 
their length is stable in every noncancerous tissue within a given individual. Patients with 
MSI phenotype exhibit a high frequency of changes in length of microsatellites within a 
tumour tissue compared to normal tissue, due to slippage of DNA polymerase during DNA 
replication on repetitive sequences, which leads to insertion or deletion of nucleotides. In 
short, MSI phenotype is characterized by appearance of new alleles not present in the 
normal genotype. These postreplicational DNA errors are detected and repaired by a 
complex of MMR proteins, rather than proofreading activity of the polymerase. Inactivation 
or deficiency of one or more MMR genes, particularly MLH1 or MSH2, leads to 
manifestation of MSI phenotype in gastric cancer. As shown in Figure 1, MSI often leads to 
additional genetic changes and allelic losses, due to frameshift mutations in coding 
repetitive sequences of genes involved in cell growth regulation, apoptosis and DNA repair 
(Buermeyer et al., 1999; Ottini et al., 2004). Remarkably, every human MMR gene except 
MLH1 includes a mononucleotide repeats, suggesting that the MMR process becomes 
increasingly defective with subsequent losses of involved proteins (Perucho, 1996). 
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Impairment of MMR, eventually leading to cancer development, can occur: 1) by mutational 
inactivation of one or two MMR genes, or 2) by epigenetic inactivation of MMR genes. In 
gastric cancer, functional inactivation of MMR is mainly caused by latter. Epigenetic 
hypermethylation of MLH1promoter has been found to be responsible for the development 
of the majority, more than 50%, of MSI-H positive gastric cancers, whereas mutations in 
MLH1 and MSH2 are being reported in 12-15% of gastric cancer exhibiting MSI-H 
phenotype (Bacani et al., 2005; Wu et al., 2000; Yamamoto et al., 1999) (Figure 1). Silencing of 
multiple genes, including known tumour-related genes such as CDKN2A (p16), hMLH1, 
THBS1, and CDH1, due to promoter hypermethylation, is an important epigenetic event in 
stomach carcinogenesis and was shown to occur in early stages of gastric cancer 
development. This pathway of methylation of CpG islands characterizes alternative 
molecular phenotype of gastric cancer, referred to as the CpG island methylator phenotype 
(CIMP) (Nobili et al., 2011; Oue et al., 2001; Resende et al., 2010). 
2.4.1 MSI analysis 
MSI can be detected with polymerase chain reaction (PCR), where each microsatellite under 
investigation is amplified using specific primers. Lengths of PCR obtained products are 
usually assessed and compared between normal and tumour tissues from each individual 
using a simple and cost effective fluorescent multiplex PCR, followed by capillary 
electrophoresis separation (Gazvoda et al., 2007; Suraweera et al., 2002). Because of a  huge 
number and diversity of microsatellite regions in the human genome, it is difficult to 
determine the prevalence of MSI in human cancers and its incidence varies depending on 
which loci are investigated (Lawes et al., 2003). To overcome this confusion, a standard 
panel of microsatellite markers, including mononucleotide repeats (BAT25 and BAT26) and 
dinucleotide repeats (D2S123, D5S346 and D17S250) has been recommended to identify MSI 
phenotype (Nobili et al., 2011). Cancers were subdivided in three groups based on the 
number of markers displaying instability: those demonstrating instability in > 30-40% of the 
loci investigated were classified as high-level MSI (MSI-H); those demonstrating instability 
in <30-40% of the loci investigated were classified as low level MSI (MSI-L); and stable 
cancers (MSS) showing no instability (Boland et al., 1998). Although these criteria were 
initially aimed at identifying MSI positive colorectal cancer, they were also successfully used 
for detecting MSI-H gastric cancers. Incidence of MSI-H has been observed in range 2-18% 
of gastric cancer cases, depending on the ethnic background.  In Japan the incidence of MSI-
H phenotype in patients with gastric cancer was reported in 5% of cases, whereas in 
Western populations it was ranging from 2 to 15% (Gu et al., 2009; Hudler et al., 2004; Leung 
et al., 1999; Pedrazzani et al., 2009; Schneider et al., 2000; Zhou et al., 1998). Moreover, 
studies reported 3-fold higher prevalence of MSI-H status in intestinal rather than diffuse-
type gastric cancers (Leite et al., 2011). As reviewed by Lawes et al., patients with gastric 
cancer that exhibit MSI-H phenotype were associated with a better survival (64-88%) when 
compared to MSS counterparts (39-53%) (Lawes et al., 2003). Furthermore, we and other 
researchers have found that MSI-H phenotype was not associated with LOH-H phenotype, 
which is in agreement with other studies proposing that the mutator and suppressor 
pathways are independent of each other at least in the early stages of gastric carcinogenesis 
(Gazvoda et al., 2007; Kim et al., 2001). Likewise, patients with LOH-H were associated with 
MSI-L or did not show MSI (microsatellite stable, MSS) on evaluated loci. In our study we 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
32
2.3 Alterations in other genes 
Genetic and epigenetic abnormalities have been found in numerous other genes that 
participate in proliferation, invasion and metastasis, such as cell cycle regulators, cell-
adhesion molecules, growth factors, cytokines, nuclear factors, matrix metalloproteinases, 
DNA repair genes, and apoptosis regulators (Nobili et al., 2011; Tahara, 2004; Yokozaki et 
al., 2001). For example, cyclin E1 together with cyclin-dependent kinase, CDK2, promotes 
the entry into the S-phase of the cell cycle, and it was found overexpressed in one third of 
gastric cancer cases. Amplification of this gene was found to correlate with tumour 
aggressiveness (Jiaqing et al., 1998; Nobili et al., 2011; Xiangming et al., 2000). In our study 
we observed overexpression of cyclin E1 in 42% of patients with gastric cancer and in 57% of 
patients with precancerous lesions, indicating that abnormalities in this gene could be early 
event in gastric carcinogenesis (Rajcevic et al., 2007). Moreover, we also found 
overexpression of epidermal growth factor family members, such as TDGF1 and EGF, and 
NRG1, signalling protein, that mediates cell-cell interactions and plays critical roles in the 
growth and development of multiple organ systems (Rajcevic et al., 2007). Several other 
genes have been reviewed extensively elsewhere (Nobili et al., 2011; Resende et al., 2010; 
Tahara, 2004; Wu et al., 2010; Yokozaki et al., 2001).  
2.4 MSI and mutator phenotype 
Molecular abnormalities in oncogenes and tumour suppressor genes drive the neoplastic 
process by increasing tumour growth. The increase is achieved by activating of genes that 
drive the cell cycle or by inhibiting normal apoptotic pathways (Vogelstein & Kinzler, 2004). 
The third class of genes that contribute to cancer development are the stability genes, which, 
when mutated, promote tumorigenesis in a completely different way. They keep genetic 
alterations to a minimum, and thus, when they are inactivated, mutations in oncogenes and 
tumour suppressor genes occur at a higher rate (Freiberg, 2003). As with tumour suppressor 
genes, both alleles must be inactivated for physiologic effect to result.  
Mismatch repair (MMR) genes are an example of genome stability genes and molecular 
inactivation of these genes is a hallmark of so-called mutator pathway, which results in 
microsatellite instability (MSI) or mutator phenotype. Microsatellites are short tandem 
repeats abundant throughout the genome. They are polymorphic among individuals, but 
their length is stable in every noncancerous tissue within a given individual. Patients with 
MSI phenotype exhibit a high frequency of changes in length of microsatellites within a 
tumour tissue compared to normal tissue, due to slippage of DNA polymerase during DNA 
replication on repetitive sequences, which leads to insertion or deletion of nucleotides. In 
short, MSI phenotype is characterized by appearance of new alleles not present in the 
normal genotype. These postreplicational DNA errors are detected and repaired by a 
complex of MMR proteins, rather than proofreading activity of the polymerase. Inactivation 
or deficiency of one or more MMR genes, particularly MLH1 or MSH2, leads to 
manifestation of MSI phenotype in gastric cancer. As shown in Figure 1, MSI often leads to 
additional genetic changes and allelic losses, due to frameshift mutations in coding 
repetitive sequences of genes involved in cell growth regulation, apoptosis and DNA repair 
(Buermeyer et al., 1999; Ottini et al., 2004). Remarkably, every human MMR gene except 
MLH1 includes a mononucleotide repeats, suggesting that the MMR process becomes 
increasingly defective with subsequent losses of involved proteins (Perucho, 1996). 
 
Genetic Instability in Gastric Cancer 
 
33 
Impairment of MMR, eventually leading to cancer development, can occur: 1) by mutational 
inactivation of one or two MMR genes, or 2) by epigenetic inactivation of MMR genes. In 
gastric cancer, functional inactivation of MMR is mainly caused by latter. Epigenetic 
hypermethylation of MLH1promoter has been found to be responsible for the development 
of the majority, more than 50%, of MSI-H positive gastric cancers, whereas mutations in 
MLH1 and MSH2 are being reported in 12-15% of gastric cancer exhibiting MSI-H 
phenotype (Bacani et al., 2005; Wu et al., 2000; Yamamoto et al., 1999) (Figure 1). Silencing of 
multiple genes, including known tumour-related genes such as CDKN2A (p16), hMLH1, 
THBS1, and CDH1, due to promoter hypermethylation, is an important epigenetic event in 
stomach carcinogenesis and was shown to occur in early stages of gastric cancer 
development. This pathway of methylation of CpG islands characterizes alternative 
molecular phenotype of gastric cancer, referred to as the CpG island methylator phenotype 
(CIMP) (Nobili et al., 2011; Oue et al., 2001; Resende et al., 2010). 
2.4.1 MSI analysis 
MSI can be detected with polymerase chain reaction (PCR), where each microsatellite under 
investigation is amplified using specific primers. Lengths of PCR obtained products are 
usually assessed and compared between normal and tumour tissues from each individual 
using a simple and cost effective fluorescent multiplex PCR, followed by capillary 
electrophoresis separation (Gazvoda et al., 2007; Suraweera et al., 2002). Because of a  huge 
number and diversity of microsatellite regions in the human genome, it is difficult to 
determine the prevalence of MSI in human cancers and its incidence varies depending on 
which loci are investigated (Lawes et al., 2003). To overcome this confusion, a standard 
panel of microsatellite markers, including mononucleotide repeats (BAT25 and BAT26) and 
dinucleotide repeats (D2S123, D5S346 and D17S250) has been recommended to identify MSI 
phenotype (Nobili et al., 2011). Cancers were subdivided in three groups based on the 
number of markers displaying instability: those demonstrating instability in > 30-40% of the 
loci investigated were classified as high-level MSI (MSI-H); those demonstrating instability 
in <30-40% of the loci investigated were classified as low level MSI (MSI-L); and stable 
cancers (MSS) showing no instability (Boland et al., 1998). Although these criteria were 
initially aimed at identifying MSI positive colorectal cancer, they were also successfully used 
for detecting MSI-H gastric cancers. Incidence of MSI-H has been observed in range 2-18% 
of gastric cancer cases, depending on the ethnic background.  In Japan the incidence of MSI-
H phenotype in patients with gastric cancer was reported in 5% of cases, whereas in 
Western populations it was ranging from 2 to 15% (Gu et al., 2009; Hudler et al., 2004; Leung 
et al., 1999; Pedrazzani et al., 2009; Schneider et al., 2000; Zhou et al., 1998). Moreover, 
studies reported 3-fold higher prevalence of MSI-H status in intestinal rather than diffuse-
type gastric cancers (Leite et al., 2011). As reviewed by Lawes et al., patients with gastric 
cancer that exhibit MSI-H phenotype were associated with a better survival (64-88%) when 
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evaluated MSI on loci BAT25, BAT26, BAT40, D2S123, D3S1277, and D10S107, and as 
mentioned before, LOH on loci, associated with tumour suppressors. Interestingly, the 
highest frequency of MSI was found at RB locus (21%), which was initially tested for LOH, 
followed by BAT25 (15%), D3S1277 (14%), D2S123 (13%), D10S107 (13%), BAT40 (12%) and 
BAT26 (10%) (Gazvoda et al., 2007). We observed that in our study BAT26 was the most 
informative locus. We also correlated MSI with clinicopathological features and found that 




Fig. 1. Mutator pathway overlapping with suppressor and methylator pathways in gastric 
tumorigenesis. These changes should not be considered a specific sequence of alterations, 
but rather an overall collection of abnormalities that contribute to the pathogenesis of gastric 
cancer (Adopted from Boland & Goel, 2010). 
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It has recently become evident that dinucleotide repeats are less sensitive than 
mononucleotide repeats for detection of MSI-H, therefore revised criteria proposes the use 
of a mononucleotide markers in order to define MSI-H instability (Umar et al., 2004). A 
panel of five mononucleotide repeats (BAT25, BAT26, NR-21, NR-22 and NR-24) that may 
be more  instrumental for detecting MSI-H status in humans has been suggested (Buhard et 
al., 2004). It has been further demonstrated that these markers are quasimonomorphic in 
1206 studied individuals from 55 different populations worldwide, and can therefore be 
used for MSI-H determination without the requirement for matching normal DNA (Buhard 
et al., 2006). By adopting the panel, MSI-H phenotype was reported in a range from 5% to 
50% of all gastric carcinomas with significant differences in various population groups 
(Leite et al., 2011; Ottini et al., 2004; Simpson et al., 2001). 
2.4.2 Mutational impairment of MMR activity and pathogenic significance of observed 
alterations 
The most common inherited condition that gives rise to MSI positive cancers is Lynch 
syndrome, an autosomal dominant disease, also referred to as Hereditary Non-polyposis 
Colorectal Cancer (HNPCC), where gastric cancer is a common neoplasia, occurring in 6% of 
Lynch syndrome cases (Percesepe et al., 2001; Samowitz et al., 2001). Predisposed 
individuals carry a recessive, first-hit germline mutation in the MMR genes, including large 
genomic rearrangement, which account for 5-20% of all mutations. In reference of 
Knudson's hypothesis, the MSI-H phenotype requires the "second hit" inactivation of the 
responsible MMR gene for development of malignant phenotype.  
In Lynch syndromes, somatic inactivation of the remaining wild-type allele can occur due to 
different mechanisms: loss of heterozygosity (LOH), somatic mutation and promoter 
methylation (Imai & Yamamoto, 2008). The relative risk of gastric cancer development in 
Lynch syndrome individuals has been reported to be 4-19-fold higher, compared to general 
population, suggesting that screening for MMR mutations in predisposed carriers could be 
of importance for the detection of predisposed individuals (Gylling et al., 2007). Particularly, 
patients with MSI-positive gastric carcinomas, but lacking MLH1 promoter 
hypermethylation are regarded as potential germline MMR-related mutation carriers.  
Majority of MMR alterations, found in patients with Lynch syndrome are known to be 
pathogenic as they result in premature termination of protein synthesis and thus loss of 
MMR activity. However, hundreds of MMR variants that do not lead to truncation of the 
respective MMR protein have been identified in Lynch cancer cases and their pathogenic 
significance is often difficult to establish on clinical samples alone. 
Information on functional nature of MMR alterations is essential for accurate early diagnosis 
and prognosis as well as for proper genetic counselling for members from affected families. 
Therefore in the past decade, many functional assays have been developed to ease the 
interpretation of pathogenicity of unclassified variants (UVs). Recent and some of the most 
recognized in vivo and in vitro assays together with available in silico algorithms are 
summarised in Table 1.  
While many in vitro assays characterize specific biological functions of MMR proteins, in 
vivo tests strive to assess the MMR repair capacity as a complex cellular process (Ou et al., 
2007). Since efficiency of MMR repair relies on several successfully completed biochemical 
events of involved proteins (e.g. protein expression levels and stability, localization of MMR 
protein to the nucleus, heterodimerization ability and effective recognition and repair of the 
DNA lesions, etc.), in vivo approaches are preferable and are either cell line- or yeast-based. 
However, all assays have their limitations and problems, mostly concerning toxic episomal 
overexpression of MMR proteins and lack of evolutionary conserved regions between yeast 
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used for MSI-H determination without the requirement for matching normal DNA (Buhard 
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2.4.2 Mutational impairment of MMR activity and pathogenic significance of observed 
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Lynch syndrome cases (Percesepe et al., 2001; Samowitz et al., 2001). Predisposed 
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Knudson's hypothesis, the MSI-H phenotype requires the "second hit" inactivation of the 
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patients with MSI-positive gastric carcinomas, but lacking MLH1 promoter 
hypermethylation are regarded as potential germline MMR-related mutation carriers.  
Majority of MMR alterations, found in patients with Lynch syndrome are known to be 
pathogenic as they result in premature termination of protein synthesis and thus loss of 
MMR activity. However, hundreds of MMR variants that do not lead to truncation of the 
respective MMR protein have been identified in Lynch cancer cases and their pathogenic 
significance is often difficult to establish on clinical samples alone. 
Information on functional nature of MMR alterations is essential for accurate early diagnosis 
and prognosis as well as for proper genetic counselling for members from affected families. 
Therefore in the past decade, many functional assays have been developed to ease the 
interpretation of pathogenicity of unclassified variants (UVs). Recent and some of the most 
recognized in vivo and in vitro assays together with available in silico algorithms are 
summarised in Table 1.  
While many in vitro assays characterize specific biological functions of MMR proteins, in 
vivo tests strive to assess the MMR repair capacity as a complex cellular process (Ou et al., 
2007). Since efficiency of MMR repair relies on several successfully completed biochemical 
events of involved proteins (e.g. protein expression levels and stability, localization of MMR 
protein to the nucleus, heterodimerization ability and effective recognition and repair of the 
DNA lesions, etc.), in vivo approaches are preferable and are either cell line- or yeast-based. 
However, all assays have their limitations and problems, mostly concerning toxic episomal 
overexpression of MMR proteins and lack of evolutionary conserved regions between yeast 
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and human MMR proteins at the regions of interest. Moreover, since variety of strategies 
have been used, it is difficult to establish and compare clinical significance of analysed 
variants. Finally, it is also not easy to determine sensitivity and specificity of these tests, 
therefore results should still be utilized with caution and interpreted alongside clinical data 
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GST pull-down  Raevaara, 2005; Guerette, 
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2008 
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Western blotting Takahashi, 2007 
mRNA splicing pCAS minigene Tournier, 2008 
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Takahashi, 2007; Raevaara, 
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Intracellular 
localization 
Fluorescence microscopy Raevaara, 2005 
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integrated hMMR gene 
Vogelsang, 2009;  
Vogelsang, 2010 
Dominant mutator effect Raevara, 2005;Takahashi, 
2007; Shimodaira, 1998 
Functional assay using yeast Ellison, 2001;Wanat, 2007 
Utility of MLH1-deficient cells Blasi, 2006 





SIFT  Kumar, 2009; Ng, 2003 
PolyPhen Ramensky, 2002 
MAPP-MMR Chao, 2008 
Align GVDV Tavgtigian, 2006; Mathe, 
2006 
mRNA splicing NNSPLICE Sharp, 2004 
Table 1. Compilation of functional assays used in characterizing pathogenic significance of 
MMR variants found in Lynch syndrome patients. 
We have recently described an in vivo yeast-based functional approach, expressing human 
MMR genes in yeast, enabling all variants found within the coding region of the MMR gene 
to be analysed. With chromosomal integration of relevant human MMR genes we obtained 
their stable expression throughout the experiment (Vogelsang et al., 2009). With our 
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approach we have functionally characterized four missense MLH1 variants, which we 
previously identified in MSI-H positive gastric cancers with limited MLH1 
hypermethylation. We also assessed two of the variants, which were described for the first 
time in our study (Hudler et al., 2004). We have shown that identified  missense mutations 
were not causally associated with MSI-H phenotype in analysed gastric cancer tissues 
(Vogelsang & Komel, 2010).  
2.5 Chromosomal instability (CIN) and aneuploidy 
In contrast to MSI, CIN is characterized by gross chromosomal abnormalities, such as gain 
or loss of whole chromosomes and/or fractions of chromosomes (LOH, amplifications, 
translocations) (Martin et al., 2010). Aneuploidy is the state of altered chromosome number 
in malignant cells (Pino & Chung, 2010). Studies showed that MSI phenotype is 
characteristic for hereditary type of gastric cancer, developed in the context of Lynch 
syndrome, and a smaller subset of sporadic cancers ranging from 15% to 35% (Panani, 2008). 
CIN, however, has been recently recognized as the most common feature of sporadic gastric 
cancers, and has been reported in up to 84% of gastrointestinal tumours (Grabsch et al., 
2004; Ottini et al., 2006). 
Several techniques, such as karyotyping, cytometry, detection of LOH, and fluorescent in 
situ hybridization (FISH) have been developed to measure CIN and some of them have 
already been successfully transferred to clinical practice. New methods, such as CGH arrays 
and copy number variation analysis (CNV), have advanced the field, due to their ability to 
detect chromosomal abnormalities with higher resolution and accuracy (Pino & Chung, 
2010).     
CIN has been recognized as valuable prognostic factor and tumour stage indicator in gastric 
cancers, although in the study of Birkbak et al. it has been found that intermediate CIN had 
more impact on poor prognosis than extreme CIN phenotype  (Birkbak et al., 2011; Suzuki et 
al., 2003). Furthermore, it has been found that DNA copy number changes are not uniform 
in gastric cancers and subgroups with different patterns of DNA copy number alterations 
have been recognized, which have been associated with prognosis, lymph node status and 
metastasis (Buffart et al., 2007b; Kang et al., 2006; Morohara et al., 2005; Panani, 2008; Weiss 
et al., 2004; Wu et al., 2002).  
Buffart et al. explored the differences in DNA copy number by CGH arrays and reported 
that the mean number of chromosomal events was lower in adenomas compared to gastric 
carcinomas, suggesting that distinct losses and gains on chromosomes likely represent early 
events in carcinogenesis (Buffart et al., 2007b). In another study they compared CGH 
profiles of gastric cancers in young and old patients (Buffart et al., 2007a). They found out 
that chromosome regions 11q23.3 and 19p13.3 contributed most to age-related differences in 
tumour profiles and that tumours of younger patients showed gains in chromosomal 
regions 6p21, 9p34, 11p15, 11q23, 17p13, 19p13, and 22q13, whereas in the majority of older 
patients normal copy status was observed. They concluded that these differences in genomic 
profiles likely reflect different pathogenic mechanisms of the disease.  
Varis et al., similarly observed that the most frequent cytogenetic aberrations were gains 
seen at 17q, 19q, and 20q in younger patients (Varis et al., 2003). They also found  
that DNA copy number changes were mostly detected in intestinal or mixed types of 
tumours.  
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and human MMR proteins at the regions of interest. Moreover, since variety of strategies 
have been used, it is difficult to establish and compare clinical significance of analysed 
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MAPP-MMR Chao, 2008 
Align GVDV Tavgtigian, 2006; Mathe, 
2006 
mRNA splicing NNSPLICE Sharp, 2004 
Table 1. Compilation of functional assays used in characterizing pathogenic significance of 
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MMR genes in yeast, enabling all variants found within the coding region of the MMR gene 
to be analysed. With chromosomal integration of relevant human MMR genes we obtained 
their stable expression throughout the experiment (Vogelsang et al., 2009). With our 
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approach we have functionally characterized four missense MLH1 variants, which we 
previously identified in MSI-H positive gastric cancers with limited MLH1 
hypermethylation. We also assessed two of the variants, which were described for the first 
time in our study (Hudler et al., 2004). We have shown that identified  missense mutations 
were not causally associated with MSI-H phenotype in analysed gastric cancer tissues 
(Vogelsang & Komel, 2010).  
2.5 Chromosomal instability (CIN) and aneuploidy 
In contrast to MSI, CIN is characterized by gross chromosomal abnormalities, such as gain 
or loss of whole chromosomes and/or fractions of chromosomes (LOH, amplifications, 
translocations) (Martin et al., 2010). Aneuploidy is the state of altered chromosome number 
in malignant cells (Pino & Chung, 2010). Studies showed that MSI phenotype is 
characteristic for hereditary type of gastric cancer, developed in the context of Lynch 
syndrome, and a smaller subset of sporadic cancers ranging from 15% to 35% (Panani, 2008). 
CIN, however, has been recently recognized as the most common feature of sporadic gastric 
cancers, and has been reported in up to 84% of gastrointestinal tumours (Grabsch et al., 
2004; Ottini et al., 2006). 
Several techniques, such as karyotyping, cytometry, detection of LOH, and fluorescent in 
situ hybridization (FISH) have been developed to measure CIN and some of them have 
already been successfully transferred to clinical practice. New methods, such as CGH arrays 
and copy number variation analysis (CNV), have advanced the field, due to their ability to 
detect chromosomal abnormalities with higher resolution and accuracy (Pino & Chung, 
2010).     
CIN has been recognized as valuable prognostic factor and tumour stage indicator in gastric 
cancers, although in the study of Birkbak et al. it has been found that intermediate CIN had 
more impact on poor prognosis than extreme CIN phenotype  (Birkbak et al., 2011; Suzuki et 
al., 2003). Furthermore, it has been found that DNA copy number changes are not uniform 
in gastric cancers and subgroups with different patterns of DNA copy number alterations 
have been recognized, which have been associated with prognosis, lymph node status and 
metastasis (Buffart et al., 2007b; Kang et al., 2006; Morohara et al., 2005; Panani, 2008; Weiss 
et al., 2004; Wu et al., 2002).  
Buffart et al. explored the differences in DNA copy number by CGH arrays and reported 
that the mean number of chromosomal events was lower in adenomas compared to gastric 
carcinomas, suggesting that distinct losses and gains on chromosomes likely represent early 
events in carcinogenesis (Buffart et al., 2007b). In another study they compared CGH 
profiles of gastric cancers in young and old patients (Buffart et al., 2007a). They found out 
that chromosome regions 11q23.3 and 19p13.3 contributed most to age-related differences in 
tumour profiles and that tumours of younger patients showed gains in chromosomal 
regions 6p21, 9p34, 11p15, 11q23, 17p13, 19p13, and 22q13, whereas in the majority of older 
patients normal copy status was observed. They concluded that these differences in genomic 
profiles likely reflect different pathogenic mechanisms of the disease.  
Varis et al., similarly observed that the most frequent cytogenetic aberrations were gains 
seen at 17q, 19q, and 20q in younger patients (Varis et al., 2003). They also found  
that DNA copy number changes were mostly detected in intestinal or mixed types of 
tumours.  
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Tsukamoto et al. observed higher frequencies of DNA copy number aberrations, especially 
in the case of 20q13 chromosome gain, which was detected in 97% of cases, compared to 
other studies (Tsukamoto et al., 2008). They used laser microdissection method to isolate 
tumour cells, therefore their samples contained fewer cells from tumour microenvironment. 
They also identified 114 upregulated candidate genes located in regions of amplification and 
11 down-regulated genes located in regions of deletion.  
Several other studies reported different DNA copy number changes in patients with gastric 
cancer (Buffart et al., 2007b; Hou et al., 2008; Junnila et al., 2010; Kimura et al., 2004). Hou et 
al., for example, used an integrated approach using CGH and 100K SNP arrays, FISH, 
reverse transcription PCR, Western immunoblotting, and siRNA-mediated gene knockdown 
to determine and identify potential overexpressed genes in region 6p11p12, which they 
found to be amplified in their study (Hou et al., 2008). They identified RAB23, which could 
be implicated in invasion.  
Despite the remarkable effort made by researchers to identify significant chromosomal 
aberrations in gastric cancers and to correlate them with clinicopathological features, the 
results are still inconclusive and not consistent with each other (reviewed in Nobili et al., 
2011; Panani, 2008).  
2.5.1 LOH 
As stated before, LOH studies have already revealed several chromosomal loci with 
significant allelic losses, facilitating the identification of tumour suppressor genes, which 
could be important in gastric tumorigenesis (Gazvoda et al., 2007; Juvan et al., 2007; Kim et 
al., 1991; Kondo et al., 2005; Panani, 2008; Tamura, 2006). LOH is also a marker of 
chromosomal instability and might indicate a second inactivational hit of a cancer 
suppressor gene. Allelic losses are typically detected by using highly polymorphic 
microsatellite sequences that are dispersed throughout the human genome. Several LOH 
studies demonstrated that the extent of chromosomal loss appeared to be of prognostic 
significance (French et al., 2004; Gazvoda et al., 2007; Koo et al., 2004). It was established that 
there was a trend of two distinct subtypes, high-level LOH (named LOH-H) and low-level 
LOH (named LOH-L), being correlated with intestinal or mixed and diffuse growth 
patterns, respectively (Hong et al., 2010). In our study we also found out that LOH-H was 
associated with intestinal type of gastric cancer (Gazvoda et al., 2007). LOH has been shown 
to relate to cancer progression, where a transition from LOH-L to LOH-H is thought to 
reflect an increase in chromosomal instability during tumour advancement. These findings 
on LOH events suggest that the degrees of allelic loss may have an influence on the clinical 
course of gastric cancer.   
2.5.2 Aneuploidy 
Although some opinions still diverge regarding the clinical impact of aneuploidy alone 
(mostly measured by FISH, flow cytometry or image cytometry), recently there are reports 
pointing out that it could be of importance as a predictive marker in gastric cancer, and its 
potential clinical practicability in pre-malignant disease to stratify patients by their cancer 
risk. It is important to note recent evidence supporting the hypothesis of stepwise ploidy 
progression: from diploid or minor aneuploid in most early cancers to aneuploid in most 
advanced cancers (Duesberg et al., 2005). As a progressive increase in the severity of 
aneuploidy with neoplastic progression has been observed, it has thus been shown to be a 
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useful prognostic indicator for patient classification as low or high-risk cases for cancer 
development (Russo et al., 2000; Yasa et al., 2005).  
Interestingly, aneuploidy was found in human tumours more than 100 years ago by von 
Hansenmann and Boveri (Duesberg & Rasnick, 2000; Ricke et al., 2008). However, in the last 
decades, the research was oriented towards oncogenes and tumour suppressors’ hunt, and 
in identifying mutator and methylator pathways of gastric carcinogenesis. Yet to date, not 
one subtype of gastric adenocarcinomas has been completely described and no cancer-
causing genes or combination of genes have been found to be specific for gastric cancers, 
although a number of mutations and other genetic changes have been described (Duesberg 
& Rasnick, 2000; Nobili et al., 2011; Panani, 2008; Weber, 2002).  
Recently, it has been found that aneuploidy, either in the form of LOH or gross 
chromosomal copy number changes, stands out as the most consistent marker of neoplastic 
cells in solid tumours (Duesberg & Li, 2003; Ottini et al., 2006). Indeed, several studies 
confirmed a high frequency of aneuploidy in sporadic gastric cancers, even up to 84% 
(Belien et al., 2009; Buffart et al., 2007b; Buffart et al., 2011; Grabsch et al., 2004; Russo et al., 
2000).   
2.5.3 Mechanisms leading to chromosomal instability 
The mechanisms leading to abnormal chromosome content and other chromosomal 
abnormalities are poorly understood, although it is now believed that CIN might, through 
stepwise clonal progression, lead to oncogene activation, tumour suppressor inactivation 
and alterations in other crucial genes, implicated in establishing the malignant phenotype of 
cells. Several different mechanisms have been proposed by researchers, such as telomere 
dysfunction, defective DNA damage response, impaired chromosomal segregation, and 
aberrations in cell cycle regulators (Castro et al., 2007; Gollin, 2005; Grabsch et al., 2004; 
Yasui et al., 1999).  
Lately, the attention of researchers in the field of epithelial tumours, including gastric 
adenocarcinomas, has focused on genetic changes in mitotic genes, with emphasis on 
chromosome segregation. Segregation is one of the fundamental processes in cells, which 
are rapidly dividing, such as gastric epithelial cells. Therefore, if regulation mechanisms, 
governing this process are damaged, the cells might proceed through cytokinesis with DNA 
or spindle errors and thus could inherit unrepaired mutations or gain an abnormal number 
of chromosomes (aneuploidy) (Schmit & Ahmad, 2007). However, the molecular defects 
underlying CIN and aneuploidy and weather it is a cause or consequence of tumour 
phenotype are not completely clear. At least two possible mechanisms for CIN development 
have been suggested: mutations and/or polymorphisms in mitotic genes, implicated in 
chromosome segregation, or the activity of carcinogens on susceptible genetic background 
of individuals. (Duesberg et al., 2005; Iovino et al., 2006).  
Studies on several animal species and humans showed that certain genetic mutations and 
polymorphisms in genes involved in segregation of chromosomes might cause an increased 
incidence of a particular tumour type (Shepard et al., 2007; Tomonaga & Nomura, 2007). 
Kim et al. analysed expression of MAD2L1, a component of the mitotic spindle assembly 
checkpoint, and kinase gene BUB1, involved in activating the spindle checkpoint. They 
found mutations in MAD2L, whereas they did not detect any mutations in BUB1.  
Grabsch et al., on other hand, observed overexpression of BUB1 protein in gastric cancers, 
which was significantly higher in tissues of patients with diffuse type adenocarcinomas 
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to relate to cancer progression, where a transition from LOH-L to LOH-H is thought to 
reflect an increase in chromosomal instability during tumour advancement. These findings 
on LOH events suggest that the degrees of allelic loss may have an influence on the clinical 
course of gastric cancer.   
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Although some opinions still diverge regarding the clinical impact of aneuploidy alone 
(mostly measured by FISH, flow cytometry or image cytometry), recently there are reports 
pointing out that it could be of importance as a predictive marker in gastric cancer, and its 
potential clinical practicability in pre-malignant disease to stratify patients by their cancer 
risk. It is important to note recent evidence supporting the hypothesis of stepwise ploidy 
progression: from diploid or minor aneuploid in most early cancers to aneuploid in most 
advanced cancers (Duesberg et al., 2005). As a progressive increase in the severity of 
aneuploidy with neoplastic progression has been observed, it has thus been shown to be a 
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useful prognostic indicator for patient classification as low or high-risk cases for cancer 
development (Russo et al., 2000; Yasa et al., 2005).  
Interestingly, aneuploidy was found in human tumours more than 100 years ago by von 
Hansenmann and Boveri (Duesberg & Rasnick, 2000; Ricke et al., 2008). However, in the last 
decades, the research was oriented towards oncogenes and tumour suppressors’ hunt, and 
in identifying mutator and methylator pathways of gastric carcinogenesis. Yet to date, not 
one subtype of gastric adenocarcinomas has been completely described and no cancer-
causing genes or combination of genes have been found to be specific for gastric cancers, 
although a number of mutations and other genetic changes have been described (Duesberg 
& Rasnick, 2000; Nobili et al., 2011; Panani, 2008; Weber, 2002).  
Recently, it has been found that aneuploidy, either in the form of LOH or gross 
chromosomal copy number changes, stands out as the most consistent marker of neoplastic 
cells in solid tumours (Duesberg & Li, 2003; Ottini et al., 2006). Indeed, several studies 
confirmed a high frequency of aneuploidy in sporadic gastric cancers, even up to 84% 
(Belien et al., 2009; Buffart et al., 2007b; Buffart et al., 2011; Grabsch et al., 2004; Russo et al., 
2000).   
2.5.3 Mechanisms leading to chromosomal instability 
The mechanisms leading to abnormal chromosome content and other chromosomal 
abnormalities are poorly understood, although it is now believed that CIN might, through 
stepwise clonal progression, lead to oncogene activation, tumour suppressor inactivation 
and alterations in other crucial genes, implicated in establishing the malignant phenotype of 
cells. Several different mechanisms have been proposed by researchers, such as telomere 
dysfunction, defective DNA damage response, impaired chromosomal segregation, and 
aberrations in cell cycle regulators (Castro et al., 2007; Gollin, 2005; Grabsch et al., 2004; 
Yasui et al., 1999).  
Lately, the attention of researchers in the field of epithelial tumours, including gastric 
adenocarcinomas, has focused on genetic changes in mitotic genes, with emphasis on 
chromosome segregation. Segregation is one of the fundamental processes in cells, which 
are rapidly dividing, such as gastric epithelial cells. Therefore, if regulation mechanisms, 
governing this process are damaged, the cells might proceed through cytokinesis with DNA 
or spindle errors and thus could inherit unrepaired mutations or gain an abnormal number 
of chromosomes (aneuploidy) (Schmit & Ahmad, 2007). However, the molecular defects 
underlying CIN and aneuploidy and weather it is a cause or consequence of tumour 
phenotype are not completely clear. At least two possible mechanisms for CIN development 
have been suggested: mutations and/or polymorphisms in mitotic genes, implicated in 
chromosome segregation, or the activity of carcinogens on susceptible genetic background 
of individuals. (Duesberg et al., 2005; Iovino et al., 2006).  
Studies on several animal species and humans showed that certain genetic mutations and 
polymorphisms in genes involved in segregation of chromosomes might cause an increased 
incidence of a particular tumour type (Shepard et al., 2007; Tomonaga & Nomura, 2007). 
Kim et al. analysed expression of MAD2L1, a component of the mitotic spindle assembly 
checkpoint, and kinase gene BUB1, involved in activating the spindle checkpoint. They 
found mutations in MAD2L, whereas they did not detect any mutations in BUB1.  
Grabsch et al., on other hand, observed overexpression of BUB1 protein in gastric cancers, 
which was significantly higher in tissues of patients with diffuse type adenocarcinomas 
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(Grabsch et al., 2004). However, their study did not reveal any association between BUB1 
protein expression level and DNA ploidy status of examined tumour types.  
Aurora kinase A (AURKA or STK15) located at 20q13, a region that is frequently amplified 
in gastric cancer, has been found overexpressed in stomach adenocarcinomas (Dar et al., 
2008). Functional analysis of upregulated AURKA gene, done by the same researchers, 
revealed a possible novel oncogenic pathway, involved in gastric carcinogenesis. AURKA 
overexpression led to a significant increase in mRNA levels of several direct targets of the β-
catenin/TCF transcription complex (cyclin D1, MYC, MYC-binding protein, CLDN1, FGF18, 
and VEGF).  
However, these and several other studies, explored overexpression and/or mutations of 
these genes, which could already be the consequence of CIN. Therefore, it has been 
proposed that minor alterations in mitotic genes could contribute to the onset of cancer 
(Frank, 2004). The mounting evidence is suggesting that subtle variations, such as single-
nucleotide polymorphisms (SNPs) or non-lethal mutations, might induce CIN and 
aneuploidy. This hypothesis of low-penetrance allelic variants or risk alleles is further 
supported by the fact that non-heritable cancers usually develop in elderly, whereas 
dominant mutations in oncogenes and tumour suppressors usually induce the disease early 
in life (Duesberg & Rasnick, 2000; Frank, 2004). Minor genetic variants in mitotic genes 
could in combination with environmental factors modulate mitotic pathways, and could 
thus exert minor changes in the DNA of replicating epithelial cells. The search for these 
changes has begun only recently, and further investigations are needed to clarify these 
aberrations and their involvement in carcinogenesis.  
In our study, we genotyped two polymorphic sites, T91A (F31I) and G169A (V57I) in serine-
threonine-kinase STK15 (AURKA), which is involved in the regulation of several cell cycle 
events (Hudler et al., 2009). It is responsible for the functioning of centrosome, for 
microtubule formation and stabilization at the spindle pole throughout all phases of 
segregation, and for chromosome segregation during anaphase. We found a putative 
protective role of the genotype A/T (F31I) in examined population of gastric cancer patients. 
We also found a weak protective association between homozygotes A/A, heterozygotes 
A/G (V57I) and A/T (F31I) genotype and reduced risk for perineural invasion. In another 
study we performed the case-control study of selected polymorphisms rs151658 and 
rs239559, rs1031963 and rs1801376 in mitotic segregation genes, TTK and BUB1B, 
respectively (Hudler et al., 2010). We found a significant interaction between patients and 
control cases for genotype A/G in rs151658 polymorphism. We also observed a statistically 
important difference in genotype frequencies between female patients and control cases for 
polymorphism rs1801376. Our results showed that this difference was significant only for 
female population of patients. Polymorphisms rs151658, rs1031963 and rs1801376 showed 
significant associations with certain clinicopathological factors, such as differentiation of 
tumours, infiltration, and intestinal type of gastric cancers. This study provides new support 
for the role of mitotic genes in gastric cancer development, suggesting that smaller changes 
could be associated with genetically unstable gastric tumours. However, the biological basis 
for the role of risk alleles of mitotic genes in cancers of the upper gastrointestinal tract needs 
to be established to understand its consequences and role during carcinogenesis. 
Carcinogens are a second probable cause of CIN and particular agents, such as Helicobacter 
pylori infection, tobacco, nitrates, and nitrites have an important impact on gastric 
tumorigenesis in genetically susceptible individuals (Matysiak-Budnik & Megraud, 2006). In 
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addition, a combination of SNPs within pro-inflammatory genes IL-1β, IL-1RA, TNFα, and 
IL-10 conferred even greater risk for gastric cancer development in combination with CIN 
causing Helicobacter pylori infection (El-Omar et al., 2003).  
3. Future directions 
Recent advances in high-throughput methods revealed the lack of consistency regarding the 
number and species of genes mutated in all subtypes of gastric adenocarcinomas, or even 
from one cell to another within the same tumour, which points to amazing genetic diversity 
of cancer cells. The idea that mutations in a few specific genes are necessary and sufficient to 
cause the disease in any of the most common human cancer forms was opposed by 
observation that random mutations accumulate much faster inside genetically unstable 
malignant cells and that genome instability might be a critical early event that leads to the 
mutation of oncogenes and suppressor genes. Furthermore, in contrast to gene mutation 
hypotheses neoplastic transformation of normal epithelial cells is a slow process, which 
explains the fact that majority of cancers appear at an advanced age. All these facts make 
relevant molecular cancer diagnosis and treatment extremely complex and difficult to fulfil. 
Therefore, in the future we suggest performing combined analyses of gene expression 
profiles, genetic polymorphisms in mitotic genes, and functional analyses of these 
polymorphisms. Studies should be expanded on candidate genes by employing genome-
wide association studies in order to identify novel genetic variants associated with gastric 
cancer.   
4. Conclusion 
It is apparent that majority of gastric cancers are characterized by genetic instability, either 
MSI or CIN. Whereas MSI is characterized by changes in short repeat sequences, the 
hallmark of CIN are gross chromosomal rearrangements, such as the gain or loss of whole 
chromosomes (Martin et al., 2010). Accumulating evidence shows that CIN and aneuploidy 
are the most common characteristics of sporadic gastric adenocarcinomas, accounting for 
more than 60% of cases, whereas MSI is characteristic for hereditary type of gastric cancer, 
developed in the context of Lynch syndrome, and a smaller subset of sporadic cancers, 
ranging from 15% to 35% (Panani, 2008). The newly formed chromosomal/aneuploidy 
hypothesis (aneuploidy could be the consequence of carcinogens or genetic changes in 
certain mitotic genes) could answer several questions remaining from the currently 
established classic oncogene overexpression model, mutator and suppressor theories, which 
postulate that cancer is caused by clonal expansion of one single cell, which has 
accumulated 4-7 mutations during the lifetime of a patient. (Castro et al., 2007; Duesberg et 
al., 2005; Duesberg et al., 2000). However, these theories do not explain the long latent 
periods in cancer development and more importantly, despite more than two decades of 
effort, they have failed to identify a particular sets of gene mutations that occur in every 
instance of gastric tumour development.  
It is evident that gastric cancer is the consequence of a multistep process involving different 
genetic and epigenetic changes in numerous genes. Host genetic background and 
environmental factors also play an important role in the pathogenesis of the disease. The 
majority of genetic alterations contributing to the malignant transformation were observed 
in growth regulatory genes, and in genes involved in cell cycle progression and arrest. 
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polymorphism rs1801376. Our results showed that this difference was significant only for 
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number and species of genes mutated in all subtypes of gastric adenocarcinomas, or even 
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of cancer cells. The idea that mutations in a few specific genes are necessary and sufficient to 
cause the disease in any of the most common human cancer forms was opposed by 
observation that random mutations accumulate much faster inside genetically unstable 
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However, exact genetic steps involved in the stomach carcinogenesis still remain uncertain. 
Different histological forms, as well as different aetiologies point to different genetic 
pathways for intestinal and diffuse tumours. To date, no single genomic abnormality is 
known to be specific to sporadic gastric cancer, or to any of its histological subtypes. Some 
of the genetic changes occur commonly in both major types, intestinal and diffuse, but some 
differ depending on the histological type. Even more, recent studies supported the idea that 
there are subgroups where MSI, CIN, suppressor, and methylator pathways overlap during 
the development of malignant phenotype. In conclusion, further research is required, with 
emphasis on collecting as many genetic changes as possible, which could aid in deciphering 
the molecular mechanisms of gastric cancer and in the development of suitable methods for 
screening, risk assessment and prognostic evaluation.  
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1. Introduction 
Genetic susceptibility seems to play an important role in some gastric cancers. In some rare 
cases, gastric cancer can be one part of familial cancer syndromes. A well-known example is 
the family of Napoleon since the Emperor himself as well as his father and his grandfather 
had gastric cancer. Generally, hereditary factors include germline mutations of E-cadherin, 
APC, p53 or mismatch repair genes like hMLH1 or hMSH2. Gatekeeper genes like E-
cadherin and APC encode signaling proteins important to cellular proliferation and 
differentiation while protein products from caretaker genes like p53 or mismatch repair 
genes are important to maintain the integrality and fidelity of the genome. In addition to 
gene mutations, gene polymorphisms have been shown to be associated with the 
susceptibility of gastric cancer (El-Omar et al., 2000; Persson et al., 2011). Interestingly, most 
of these genes are encoding proinflammatory cytokines, strongly indicating the importance 
of inflammation to the initiation and progression of gastric cancer.  
Environment factors play important roles in the pathogenesis of gastric cancer by affecting 
the inflammation in the stomach. The infection of Helicobacter pylori is apparently one of 
the primary risk factors of gastric cancer. In 1994, the World Health Organization and the 
International Agency for Research on Cancer Consensus group classified H. pylori as a type 
I carcinogen in human beings. Although numerous studies reported the growth promoting 
effect of H. pylori or its derived proteins in vitro, no direct evidence about the interaction of 
H. pylori with cancer initiating or stem cells have been presented. In contrast, accumulating 
reports indicated that the inflammation induced by H. pylori infection is the key to gastric 
carcinogenesis. Thus, it was believed that H. pylori infection is the initial step in the 
stepwise process of gastric carcinogenesis starting from chronic gastritis, gastric atrophy, 
intestinal metaplasia, dysplasia to gastric carcinoma. Consistently, diets rich in fruit and 
vegetables is protective factors of gastric cancer since vitamin C are helpful to attenuate 
inflammation while inflammation-promoting factors such as smoking, foods with high salts 
and nitrite could facilitate the development of gastric cancer by promoting chronic 
inflammation.  
Microenvironments in chronic inflammatory tissues are rich in growth factors and cytokines 
important to promote the perpetuation of tumor growth by epigenetically reprogramming 
cancer stem cells. In addition, there are some DNA damage inducing agents such as reactive 
oxygen and nitrogen species (RONS) that can cause genomic alterations, promoting the 
accumulation of mutations in proliferating cancer stem cells (Meira et al., 2008). On the other 
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1. Introduction 
Genetic susceptibility seems to play an important role in some gastric cancers. In some rare 
cases, gastric cancer can be one part of familial cancer syndromes. A well-known example is 
the family of Napoleon since the Emperor himself as well as his father and his grandfather 
had gastric cancer. Generally, hereditary factors include germline mutations of E-cadherin, 
APC, p53 or mismatch repair genes like hMLH1 or hMSH2. Gatekeeper genes like E-
cadherin and APC encode signaling proteins important to cellular proliferation and 
differentiation while protein products from caretaker genes like p53 or mismatch repair 
genes are important to maintain the integrality and fidelity of the genome. In addition to 
gene mutations, gene polymorphisms have been shown to be associated with the 
susceptibility of gastric cancer (El-Omar et al., 2000; Persson et al., 2011). Interestingly, most 
of these genes are encoding proinflammatory cytokines, strongly indicating the importance 
of inflammation to the initiation and progression of gastric cancer.  
Environment factors play important roles in the pathogenesis of gastric cancer by affecting 
the inflammation in the stomach. The infection of Helicobacter pylori is apparently one of 
the primary risk factors of gastric cancer. In 1994, the World Health Organization and the 
International Agency for Research on Cancer Consensus group classified H. pylori as a type 
I carcinogen in human beings. Although numerous studies reported the growth promoting 
effect of H. pylori or its derived proteins in vitro, no direct evidence about the interaction of 
H. pylori with cancer initiating or stem cells have been presented. In contrast, accumulating 
reports indicated that the inflammation induced by H. pylori infection is the key to gastric 
carcinogenesis. Thus, it was believed that H. pylori infection is the initial step in the 
stepwise process of gastric carcinogenesis starting from chronic gastritis, gastric atrophy, 
intestinal metaplasia, dysplasia to gastric carcinoma. Consistently, diets rich in fruit and 
vegetables is protective factors of gastric cancer since vitamin C are helpful to attenuate 
inflammation while inflammation-promoting factors such as smoking, foods with high salts 
and nitrite could facilitate the development of gastric cancer by promoting chronic 
inflammation.  
Microenvironments in chronic inflammatory tissues are rich in growth factors and cytokines 
important to promote the perpetuation of tumor growth by epigenetically reprogramming 
cancer stem cells. In addition, there are some DNA damage inducing agents such as reactive 
oxygen and nitrogen species (RONS) that can cause genomic alterations, promoting the 
accumulation of mutations in proliferating cancer stem cells (Meira et al., 2008). On the other 
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hand, cancer cells during their progression can not only circumvent inhibitory signals from 
immune cells in inflammatory microenvironments but also suppress the anti-tumor immune 
response, eventually transforming the inflammation microenvironment into tumor 
permissive microenvironment, the niche for the survival and expansion of cancer stem cells 
(Wang and Jin, 2010). 
Tumor promoting factors in tumor-permissive microenvironments can reprogram 
epigenetic regulatory network in cancer cells through various signaling pathways that 
deregulated in both inflammation and carcinogenesis, such as NF-kB pathway and IL6-
STAT3 pathway (Pikarsky et al., 2004; Yu et al., 2009a). However, epigenetic changes 
directly controlled by intracellular signaling pathways can immediately reform cellular 
response to extracellular signals and therefore most likely precede genetic changes that take 
several cell divisions to be fixed. Similar to genetic changes, epigenetic changes can also 
affect the activity of many signaling pathways critical to cancer development. By doing so, 
epigenetic trans-generation of extracellular signals plays important roles in the initiation of 
many sporadic cancers (Figure 1).  
 
 
Fig. 1. Gastric cancer is resulting from the accumulation of genetic and epigenetic changes. 
Genetic factors such as polymorphism of genes encoding cytokines affect the pathogenesis 
of inflammation induced by environmental factors such as H. Pylori infection. Bioactive 
factors enriched in inflammatory microenvironments such as IL-6, INF-α and other 
prosurvival and anti-apoptotic signals could reprogram epigenetic regulatory network to 
promote genetic changes and the subsequent malignant transformation of stem or 
progenitor cells. The interaction of transformed stem cells with microenvironment gradually 
transformed microenvironment into tumor permissive microenvironment and stem cells 
into cancer stem cells.  
2. Epigenetic view of gastric carcinogenesis 
Epigenetic information is defined as cellular information heritable during cell division in 
addition to DNA sequence. Epigenetic network regulates the expression or function but not 
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the sequence of genes. Up to date, the major components of epigenetic regulatory network 
include DNA methylation, non-coding RNAs mainly microRNAs and histone modifications. 
Similar to genetic changes, some of epigenetic changes are important to maintain the 
malignant phenotypes of cancer cells and thereby could be named as driver epigenetic 
changes while the others are passenger epigenetic changes since they are passively altered 
during cancer development.  
 
Mechanism Name Scale 
Bisulfite dependent MS-PCR Single Gene 
BGS Single Gene 
MDFS Single Gene 
Cobra Single Gene 
Bisulfite independent Enzyme digestion-Southern Blot Single Gene 
Enzyme digestion-PCR Single Gene 
RLGS Genome wide 
aPRIMES Genome wide 
MB-PCR Single Gene 
MB-Array/-sequencing Genome wide 
Table 1. Methods to detect DNA methylation 
3. Aberrant DNA methylation in gastric carcinogenesis 
DNA methylation is a type of chemical modification with the covalent addition of a methyl 
group to the fifth position of cytosine predominantly within the CpG dinucleotides. As one 
of the major mechanisms of epigenetic regulation, DNA methylation is involved in a 
number of important biological processes including linage-specific gene expression, parental 
or maternal imprinting and tumor suppressor gene silencing in carcinogenesis (Bird, 1986; 
Jones, 2002). Aberrant DNA methylation is deeply involved in gastric carcinogenesis by 
affecting various cellular processes including signal transduction, cell cycle regulation and 
gene expression. In addition to driver methylations, there are passenger methylations that 
could be used as the biomarkers for the detection or monitoring of cancer development and 
progression instead of the screening or defining of novel tumor suppressor genes. The genes 
silenced by DNA methylation in gastric cancer have been intensively discussed and thus 
will not be included here (Choi and Wu, 2005; Tamura, 2006). Instead, the potential 
application of DNA methylation in the detection of gastric cancer will be overviewed after 
the brief introduction of general approaches to detect DNA methylation. 
3.1 General approaches to detect DNA methylation  
In general, the approaches to detect DNA methylation could be grouped into two classes: 
bisulfite-dependent methods and bisulfite-independent methods (Table 1). Methylated DNA 
could be differentiated from unmethylated DNA by bisulfite DNA modification or 
restriction enzyme digestion. Bisulfite treatment could change unmethylated cytosine into 
uracil while left methylated cytosine unchanged. DNAs with different methylation status 
respond to the digestion of methylation-sensitive restriction enzymes differently, making it 
possible to detect DNA methylation indirectly by analyzing the products of enzyme 
digestion.  
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After the conversion of unmethylated cytosine into uracil by bisulfite treatment, methylated 
DNA could be amplified by methylation specific-PCR (MS-PCR) with specifically designed 
primers (Herman et al., 1996). The advantage of this method includes the fast detection of 
DNA methylation with high sensitivity and specificity. The main disadvantage is the low 
level of resolution to determine the methylation of particular CpG sites only in the 3’-
terminus of primers. The pattern of multiple methylated CpG sites could be determined by 
bisulfite genome sequencing in which PCR products with methylation non-selective primers 
will be directly sequenced or sequenced indirectly after TA cloning. Alternatively, 
methylation could be quantified by MethyLight in which methylation or unmethylation 
specific probes were used in PCR amplification (Eads et al., 2000). Other quantitative 
methods include MS-HRM (Methylation-sensitive high resolution melting) which takes the 
advantage of the differences in melting of PCR products from methylated and unmethylated 
DNA while methylation-dependent fragment separation (MDFS) could detect DNA 
methylation by comparing differential migration times of PCR products in electrophoresis 
(Boyd et al., 2006; Wojdacz and Dobrovic, 2007). In the method termed Cobra (combined 
Bisulfite Restriction Analysis), PCR products from bisulfite-treated DNAs will be digested 
by restriction enzymes like BstUI and the resulting fraction could directly reflect the 
percentage of methylated and unchanged CpGs at sites that will be cut by the enzymes. It is 
relatively sensitive and small amount of DNAs from tiny tissues could be used for Cobra 
analysis (Xiong and Laird, 1997). However, it is semi-quantitative and restricted to analyze 
CpGs only in special sites of particular restriction enzymes. Overall, the efficiency of 
bisulfite conversion which is a complicated and time consuming procedure with relatively 
low sensitivity and high false positive rate is the critical factor for bisulfite dependent 
approaches to quantify DNA methylation. 
In bisulfite independent groups, methylated DNAs are differentiated from unmethylated 
DNA by either enzyme digestion or affinity enrichment. In contrast to other quantification 
methods like MSP, enzyme digestion based methods could analyze the methylation pattern 
of multiple CpGs sites. The resulting products from methylation-sensitive restriction 
enzymes could be further analyzed by Souther blot or PCR at the single gene level and 
RLGS (restriction landmark genomic scanning) or aPRIMES (array based profiling of 
reference independent methylation status) in genome-wide level to screening novel 
methylated sites. The influence of digestion efficiency could be adjusted by the internal 
control which could not be cut by the particular enzyme irrespective of DNA methylation. 
Methylated DNA could also be analyzed by PCR, sequencing or array based hybridization 
after being enriched by anti-5-methylcytosine antibody or methylation binding domain 
(MBD) containing proteins. It could yield the information including both the level and 
pattern of DNA methylation with physiological relevance.  
3.2 DNA methylation as biomarkers for gastric cancer 
Although there are many studies reporting that methylation of particular genes could be 
useful to predict the prognosis of gastric cancer, few of them were validated to be superior 
to classical prognosis prediction factors such as TNM staging (Liu et al., 2010; Yu et al., 
2009b). Therefore, the clinical application of DNA methylation in prognosis predication of 
gastric cancer remains uncertain. In contrast, the detection of methylated DNA markers is 
believed to be useful to detect newly and relapsed gastric cancer, thus representing a 
promising approach of developing non-invasive detection for gastric cancer progression 
(Corvalan and Maturana, 2010; Laird, 2003).  
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Biomarker detection in peritoneal fluid is clinically important and feasible to determine the 
micrometastesis to the peritoneum of gastric cancer which is the most frequent event in 
recurrent gastric cancer and often associated with resistance to chemotherapy and poor 
prognosis. The detection of peritoneal micrometastasis is critical for patients to take timely 
and correct treatment based on an accurate diagnosis. Based on the quantitatively detection 
of methylated DNAs with the MethyLight method, DNA methylation in peritoneal fluids 
was found to be able to detect occult neoplastic cells in the peritoneum (Hiraki et al., 2011; 
Hiraki et al., 2010). Among 11 genes reported to be methylated in gastric cancer, BNIP3, 
CHFR, CYP1B1, MINT25, SFRP2, and RASSF2 were specifically methylated in tumor tissues 
but not adjacent non-tumor tissues. Interestingly, the methylation status of all six genes 
were significantly different among three different groups: patients with tumor invasion 
under muscularis propria (MP) (n=42, methylation percentage: 0-5%), patients with tumor 
invasion beyond the MP (n=45, methylation percentage: 0-15%) and patients with 
histologically or cytologically confirmed peritoneal metastasis (n = 20, methylation 
percentage: 15-45%). Among 45 patients with tumor invasion beyond the MP, 3 of 9 patients 
with methylation in any of 6 genes were diagnosed as peritoneal recurrence later while only 
1 out of 35 patients without methylation in any of 6 genes developed peritoneal metastasis 
at least 8 months after surgery (Hiraki et al., 2011). Other potential methylation markers of 
peritoneal metastasis of gastric cancer include RUNX3 which was silenced by DNA 
methylation in 100% of peritoneal metastases of gastric cancers and 75% of primary gastric 
cancers but not normal gastric mucosa (Sakakura et al., 2005).  
In addition to detect methylated DNA in peritoneal fluids, researchers have endeavored to 
develop sensitive methods to quantify methylated DNA in peripheral bloods. It is 
promising to identify sensitive circulating biomarkers to detect early gastric cancer at a 
curable stage.  
In a qualitative analysis of methylated p16, E-cadherin, and retinoic acid receptor-1 
(RARbeta) in serum, 52 patients (48%) of the 109 preoperative gastric cancer patients 
showed hypermethylation of at least one gene while no methylation of any of three genes 
was detected in control sera (Ikoma et al., 2007). Furthermore, methylation of three genes 
was detected in 2 of the 3 patients with recurrence, indicating that the detection of the 
methylated DNA in circulation could facilitate the early detection of newly and recurrent 
gastric cancer. The methylations of p16, Reprimo as well as RASSF1A were also proposed as 
potential biomarkers for early detection of gastric cancer (Abbaszadegan et al., 2008; Bernal 
et al., 2008; Wang et al., 2008). 
The quantitative analysis of RUNX3 methylation in serum revealed that methylated RUNX3 
was detected in 29% (19/65) of gastric cancer patients and the serum level of methylated 
RUNX3 was concordant with tumor burden as well as disease stage, histology, lymphatic 
and vascular invasion (Sakakura et al., 2009). In addition, it seems to be more sensitive than 
serum level of carcinoembryonic antigen (CEA) as a biomarker for the detection of gastric 
cancer. However, the methylation of RUNX3 is not specific to gastric cancer and methylated 
RUNX3 could be detected in patients with various cancers such as breast cancer and lung 
cancer, indicating that methylation of RUNX3 could be more useful in monitoring the 
progression or recurrence of gastric cancer than in screening asymptomatic patients with 
early gastric cancer (Tan et al., 2007). Similarly, preferential methylation in the serum DNA 
of gastric cancer patients was noted in APC (17%), E-cadherin (13%), hMLH1 (41%) and 
TIMP3 (17%) genes and patients with advanced gastric cancer tended to have higher 
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concentrations of methylated APC, TIMP3 and hMLH1 in the serum (Leung et al., 2005). 
Overall, methylations in at least one of these markers were detected in the serum of 33 
patients (55%) while no methylation was detected in normal subjects. The combined use of 
APC and E-cadherin methylation markers identified a subgroup of gastric cancer patients 
with worse prognosis (Leung et al., 2005). 
Similar to diver mutations, methylations in critical or driver genes are most likely not 
specific to gastric cancer. The value of driver methylation in the screening of gastric cancer is 
certainly controversial. Most of potential biomarkers, however, are usually transformed 
from functional studies. Many passenger methylations were, thus, discarded for further 
validation of their potential as indicators of gastric cancer development. Many biomarkers 
currently used in clinic, such as AFP, CEA and CA-125, are not functional oncogenes or 
tumor suppressors per se. To identify biomarkers for clinical application, more attention 
should be paid to those passenger methylations instead of driver methylations although 
they are probably not important to the development or progression of gastric cancer in 
function. In addition, quantitative MSP is currently the most often used approach to detect 
DNA methylated in blood. It would be more interesting to see the progress on the 
biomarkers identified by methods based on affinity enrichment since methylation contents 
with physiological relevance instead of single or few methylated sites could be determined. 
4. MicroRNAs deregulated in gastric carcinogenesis 
Although there are some discrepancies in the microRNA profiling of cell lines and primary 
tissues, microRNAome as a whole is downregulated in human carcinogenesis. It was 
believed that the general downregulation of microRNAs in cancer cells is mainly caused by 
the impaired post-transcriptional maturation of microRNAs starting from primary 
microRNA transcripts rather than the transcriptional of microRNA genes (Croce, 2009; Lee 
et al., 2008; Slezak-Prochazka et al., 2010; Thomson et al., 2006; White et al., 2005; Winter et 
al., 2009). The functions of microprocessors necessary and sufficient for processing 
microRNA precursors are generally suppressed in cancer cells partially due to the reduced 
expression of Drosha and Dicer, two major enzymes responsible for the maturation of 
microRNAs (Dedes et al., 2011; Hwang et al., 2009; Karube et al., 2005; Lee et al., 2008; Lin et 
al., 2010; Merritt et al., 2008). In addition, proteins with tumor suppressing functions like 
p53 were found to participate in the maturation of microRNAs (Bikkavilli and Malbon, 2010; 
Davis et al., 2008; Suzuki et al., 2009). 
In contrast to genome-wide downregulation of microRNAs, some microRNAs are 
specifically upregulated in cancer cells. MicroRNAs have been implicated in the control of 
many fundamental cellular and physiological processes such as cellular differentiation and 
proliferation, stem cell maintenance and tissue development. By acting as oncogenes or 
tumor suppressors, microRNAs also play a significant role in cellular transformation and 
carcinogenesis (Inui et al., 2010; Wiemer, 2007; Wu et al., 2010). In the next, we will briefly 
overview the very recent studies on the relevance of microRNAs deregulated in gastric 
carcinogenesis to signal transduction, cell cycle and apoptosis control, and transcriptional 
regulation.  
4.1 MicroRNAs in signal transduction 
MiR-204 and probably miR-211 are downregulated in gastric cancer, contributing to the 
aberrant Ras activation by inhibiting the expression of ezrin (Lam et al., 2011). As a 
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membrane-cytoskeleton linker protein, ezrin can promote Ras activation by stimulating the 
assembly of SOS-Ras complex (Morrison et al., 2007). Therefore, downregulation of miR-204 
in gastric cancer represents a new mechanism of aberrant Ras activation which was often 
attributed to Ras mutations in many other cancers. CDC42, one Ras-related small G protein 
that plays important roles in the regulation of cell motility and tumor metastasis, was found 
to be targeted by miR-137 in gastric cancer cells (Chen et al., 2011). MiR-137 was 
downregulated in many cancers including gastric cancer probably due to the 
hypermethylation of its promoter. As the upstream regulator of MAPK signaling, EGF 
receptor ERBB2 was found as the direct target of miR-125a-5p (Nishida et al., 2011). While 
miR-125a-5p could potently suppress the proliferation of gastric cancer cells, low expression 
levels of miR-125a-5p were associated with enhanced malignant potential such as tumor 
size, tumor invasion and liver metastasis. By blocking apoptosis and promoting cell 
survival, NF-kappaB pathway plays important roles in both inflammation and cancer and is 
often activated in gastric carcinogenesis. NF-kappaB1 is directly targeted by miR-9 which 
was downregulated in gastric carcinomas (Wan et al., 2010). MiR-516a-3p can block 
metastatic dissemination of gastric cancer cells and was downregulated in highly metastatic 
gastric carcinoma cells. It can suppress the expression of sulfatase 1 which is known to 
promote the activation of wnt/beta-catenin signaling pathway by removing 6-O-sulfates 
from heparan sulfate proteoglycans on the cell surface and causing the release of membrane-
bound wnt ligands from plasma membrane (Takei et al., 2011). The G-protein coupled 
receptor of gastrin, cholecystokinin B receptor (CCKBR), is regulated by miR-148b which 
was downregulated in gastric cancer (Song et al., 2011). Restored expression of miR-148b in 
gastric cancer cells inhibited cell growth both in vitro and in vivo.  
4.2 MicroRNAs in cell cycle and apoptosis control 
Cell cycle checkpoints consist of many proteins including cyclins, cyclin dependent kinases 
(CDKs) and CDK inhibitors (CKIs) to secure the integrity and fidelity of genome during cell 
mitosis. It was found that members of same family of CKIs could be regulated by 
microRNAs in one cluster. For example, miR-25 targeted p57 (Kip2) and the other two 
microRNAs in this cluster suppressed the expression of p21 (Cip1); while miR-222 and miR-
221 cluster regulated both p27 (Kip1) and p57 (Kim et al., 2009). MicroRNAs in one cluster 
usually display similar pattern of expression, therefore ensuring the effect to attenuate the 
function of targeted proteins by interacting with different regions in 3’-UTR of the same 
gene. Cyclin G1 was targeted by miR-122 which was downregulated in gastric cancer and 
colorectal cancer probably due to aberrant activation of wnt signaling (Fornari et al., 2009; 
Wang et al., 2009).  
As a direct target of p53, miR-34 was downregulated in gastric cancer. MiR-34 could inhibit 
the growth of gastric cancer cells by targeting anti-apoptotic oncoprotein Bcl-2 (Ji et al., 
2008). Bcl-2 was also targeted by miR-181b, which was downregulated in multidrug-
resistant human gastric cancer cell line SGC7901/vincristine (VCR). Enforced miR-181b 
expression reduced Bcl-2 protein level and sensitized SGC7901/VCR to VCR-induced 
apoptosis (Zhu et al., 2010). The novel tumor suppressor protein programmed cell death 4 
(PDCD4) was downregulated in several human solid cancer types. PDCD4 was the target of 
miR-21 which was upregulated in gastric cancer in response to the activation of NF-kB 
signaling by smoking and many other factors such as inflammation (Motoyama et al., 2010).  
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
60
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membrane-cytoskeleton linker protein, ezrin can promote Ras activation by stimulating the 
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usually display similar pattern of expression, therefore ensuring the effect to attenuate the 
function of targeted proteins by interacting with different regions in 3’-UTR of the same 
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Wang et al., 2009).  
As a direct target of p53, miR-34 was downregulated in gastric cancer. MiR-34 could inhibit 
the growth of gastric cancer cells by targeting anti-apoptotic oncoprotein Bcl-2 (Ji et al., 
2008). Bcl-2 was also targeted by miR-181b, which was downregulated in multidrug-
resistant human gastric cancer cell line SGC7901/vincristine (VCR). Enforced miR-181b 
expression reduced Bcl-2 protein level and sensitized SGC7901/VCR to VCR-induced 
apoptosis (Zhu et al., 2010). The novel tumor suppressor protein programmed cell death 4 
(PDCD4) was downregulated in several human solid cancer types. PDCD4 was the target of 
miR-21 which was upregulated in gastric cancer in response to the activation of NF-kB 
signaling by smoking and many other factors such as inflammation (Motoyama et al., 2010).  
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4.3 MicroRNAs in transcription regulation 
SRY (sex-determining region Y)-box 2 (SOX2) is a crucial transcription factor for the 
maintenance of stem cell pluripotency and the determination of cell fate. Its expression was 
reduced in gastric cancer cells due to the upregulation of miR-126 (Otsubo et al., 2011). 
Enhanced expression of miR-126 significantly promoted both anchorage-dependent and -
independent growth of gastric cancer cells by reducing SOX2 expression. Similarly, SOX4 
was upregulated in gastric cancers compared with benign gastric tissues probably resulting 
from the epigenetic silencing of miR-129-2 (Shen et al., 2010). Restoration of miR-129-2 
induced apoptosis of gastric cancer cells.  
In addition to transcription factors that regulate gene expression through direct interaction 
with DNA, many other proteins especially in the epigenetic regulatory network are also 
targeted by microRNAs. As one component in the polycomb complex, EZH2 plays 
important roles in stem cell homeostasis as well as cancer development. It has been proven 
to be upregulated in many cancers including gastric cancer. Such an upregulation is at least 
partially caused by the downregulation of miR-101 (Varambally et al., 2008; Wang et al., 
2010). Restoration of miR-101 expression in gastric cancer cells led to the significant 
inhibition of cellular proliferation, migration and invasion as well as tumorigenicity. 
Another chromatin remodeling protein ING4 (Inhibitor of growth family, member 4) was 
targeted by miR-650 which was downregulated in gastric cancer and could promote 
tumorigenesis and proliferation of gastric cancer cells (Zhang et al., 2010). Methyl-CpG-
binding protein MeCP2 could promote cancer development by initiating the assembly of 
transcription inhibitory complex to silence the expression of tumor suppressors. It was 
found to be the direct target of miR-212 which was downregulated in gastric cancer (Wada 
et al., 2010). Transfection of the miR-212 precursor into gastric cancer cells induced 
significant decrease of cell growth in vitro. In addition to methylated DNA binding proteins 
and histone modification related proteins, DNA methyltransferases (DNMTs) were directly 
targeted by microRNAs as well (Ng et al., 2009b). MiR-143 was frequently downregulated in 
gastric cancer and many other cancers and one target directly regulated by miR-143 was 
turned out to be DNA methyltranserase-3A (DNMT-3A) (Takagi et al., 2009). The 
transcription of DNMT-3A was resulted from aberrant Ras activation. Therefore, 
downregulation of miR-143 could be in concert with Ras activation to promote 
carcinogenesis by increasing the expression of DNMTs to promote hypermethylation-
mediated silencing of tumor suppressors.  
4.4 Deregulated microRNAs as biomarkers for gastric cancer 
The number of microRNAs deregulated in gastric cancer is still increasing (Hou et al., 2011; 
Lee and Dutta, 2009; Wu et al., 2010). Many other microRNAs important to gastric 
carcinogenesis were not included due to the limitation of the space. For example, 
macrophage migration inhibitory factor (MIF) which plays important roles in the 
transformation of tumor-permissive microenvironment was targeted by miR-451 and miR-
451 was downregulated in gastric cancer. The downregulation of miR-451 was associated 
with worse prognosis and restoration of miR-451 expression in gastric cancer cells reduced 
cell proliferation and increased sensitivity to radiation (Bandres et al., 2009). Microsatellite 
instability (MSI) was believed to be one important feature of some gastric cancers. MSI was 
usually caused by the mutations in mismatch repair (MMR) genes or reduced expression of 
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MMRs. A microRNA contribution to MSI was recently identified. MiR-155 which was 
overexpressed in gastric cancers could target the expression of several MMR genes, such as 
hMSH2, hMSH6, and hMLH1 (Valeri et al., 2010). 
The clarification of their biological relevance will certainly deepen our understanding of 
carcinogenesis so that new and effective therapeutics could be developed. Different 
microRNAs could regulate gene expression by targeting different sites in the 3’-UTR of the 
same gene and a single microRNA could target more than one gene. Computational 
predictions indicate over 50% of human protein-coding genes might be regulated by 
microRNAs although there are only several hundred of microRNAs in human genome. In 
addition, microRNA could regulate gene expression by interacting with 5’-UTR even other 
elements in the gene, making it challenging to understand the biological relevance of 
microRNAs.  
Interestingly, microRNAs were also recognized as the next generation of biomarkers for the 
diagnosis and prognosis prediction of cancers due to the development of methods to 
quantify microRNA expression in both tissues and bloods. Realtime RT-PCR and in situ 
hybridization could detect the expression of microRNA in tissues quantitatively or semi-
quantitatively. Many studies have confirmed that microRNAs could be used for prognosis 
prediction (Iorio et al., 2008). For example, miR-125a-5p expression was found to be an 
independent prognostic factor and its lower expression in tumor tissues was often 
associated with shorter survival (Nishida et al., 2011). In a screening with a large cohort of 
353 gastric samples, miR-125b, miR-199a and miR-100 were found to be related with the 
progression of gastric cancer while the downregulation of let-7g and miR-433 and the 
upregulation of miR-214 were associated with unfavorable outcome in overall survival 
independent of clinical covariates, including depth of invasion, lymph-node metastasis, and 
stage (Ueda et al., 2010). Based on the study of a relative small scale cohort of 160 gastric 
cancer patients, a signature consisting of miR-10b, miR-21, miR-223, miR-338, let-7a, miR-
30a-5p and miR-126 was found as an independent predictor of overall survival and relapse-
free survival (Li et al., 2010). Six microRNAs including miR-103, miR-21, miR-145, miR-106b, 
miR-146a and miR-148a were screened out from a total of 857 microRNA probes to separate 
node-positive from node-negative gastric cancers, indicating that these six miRNAs may be 
useful for the decision-making of doctors by the prediction of potential lymph node 
metastasis (Tchernitsa et al., 2010). Other microRNAs such as miR-27a was also related with 
the lymph node metastasis of gastric cancer (Katada et al., 2009). However, no microRNA 
signature was commonly accepted to predict the prognosis of gastric cancer since results 
from different labs were usually different. This could be due to the different methods used 
in different labs. Alternatively, the ethnic variation could be one of the reasons. Large scale 
multi-centered clinical trials will be warranted to validate the relevance of microRNA based 
signature to the prognosis predication of gastric cancer. 
Given the stability in nature, microRNAs in peripheral blood or other body fluids were 
recognized as the ideal biomarkers for various cancers (Ng et al., 2009a). The plasma 
miRNA levels usually reflected the expression level of microRNAs in tumor tissues 
(Tsujiura et al., 2010). Microarray and new generations of sequencing platforms have been 
widely used to screen circulating microRNAs for the diagnosis of gastric cancer. Solexa 
sequencing of microRNAs in serum from 20 patients with gastric cancer and 20 age- and 
gender-matched tumour-free controls revealed 19 miRNAs specifically upregulated in 
gastric cancer. Five of them including miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p 
were confirmed by qRT-PCR analysis. In a validation set consisting of 142 serum samples 
from gastric cancer patients and 105 control serum samples, the quantification of serum 
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gastric cancer. Five of them including miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p 
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level of these five microRNAs could successfully separate gastric cancer cases from normal 
donors. The areas under the receiver operating characteristic (ROC) curve of this five-
microRNA signature was even markedly higher than these of widely used biomarkers such 
as serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), 
indicating that expression levels of this serum miRNA-based biomarker could be potential 
biomarkers for the detection of gastric cancer (Liu et al., 2011). Other reports indicated that 
plasma level of miR-17, miR-106b, and miR-106a could also be useful for the detection of 
gastric cancer (Tsujiura et al., 2010; Zhou et al., 2010). Currently, the detection of circulating 
microRNAs has received a great deal of attention for its potential application for the early 
detection and postoperative recurrence prediction of gastric cancer. Although approaches 
based on the detection of circulating nucleic acid have been approved for the clinical 
application, microRNAs based methods are still in their infancy. The stability of microRNAs 
and the sensitivity of microRNA detection certainly make microRNAs promising 
biomarkers for cancer detection or monitoring. More clinical trials will be needed to confirm 
the values of microRNA biomarkers in screening high-risk individuals for early detection of 
gastric cancer by further invasive examinations such as gastroendoscopy.  
5. Conclusions and perspectives 
In recent years, it has become apparent that gastric cancer is resulting from the 
accumulation of both genetic and epigenetic changes. Chronic inflammation gradually 
renders inflammatory microenvironment into tumor permissive, allowing the survival and 
growth of cancer initiating cells with reprogrammed epigenetic regulatory network. As the 
major components of epigenetic regulatory network, DNA methylation and microRNA are 
deregulated in cancer initiating cells. Although the mechanisms underlying aberrant DNA 
methylation as well as dysregulated microRNA expression are largely unknown, changes in 
patterns of DNA methylation and microRNA expression are believed to contribute to the 
initiation and progression of gastric cancer by altering the expression of genes important to 
control apoptosis, cellular proliferation and differentiation. Approaches to renormalize 
methylation patterns in both global levels such as DNA methyltransferases inhibitors or 
histone deacetyltransferases inhibitors (HDACi) or targeted therapeutics have been 
developed as novel strategies to treat cancer. Despite its promising future in cancer 
prevention and intervention, the great promise of cancer epigenetics currently lies in the 
potential in diagnostics in which epigenetic biomarkers would be helpful for risk 
assessment, early detection, prognosis prediction and monitoring of treatment response as 
well as disease relapse. The quantification of DNA methylation and microRNAs in 
peripheral blood has received a great deal of attention recently. With the progress in the 
technology of genome-wide analysis such as new generation of sequencing, more and more 
epigenetic biomarkers specific to gastric cancer will be identified in the peripheral blood, 
allowing the development of epigenetic biomarker panel alone or in combination with other 
biochemical biomarkers for the detection and monitoring of gastric cancer.  
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and the sensitivity of microRNA detection certainly make microRNAs promising 
biomarkers for cancer detection or monitoring. More clinical trials will be needed to confirm 
the values of microRNA biomarkers in screening high-risk individuals for early detection of 
gastric cancer by further invasive examinations such as gastroendoscopy.  
5. Conclusions and perspectives 
In recent years, it has become apparent that gastric cancer is resulting from the 
accumulation of both genetic and epigenetic changes. Chronic inflammation gradually 
renders inflammatory microenvironment into tumor permissive, allowing the survival and 
growth of cancer initiating cells with reprogrammed epigenetic regulatory network. As the 
major components of epigenetic regulatory network, DNA methylation and microRNA are 
deregulated in cancer initiating cells. Although the mechanisms underlying aberrant DNA 
methylation as well as dysregulated microRNA expression are largely unknown, changes in 
patterns of DNA methylation and microRNA expression are believed to contribute to the 
initiation and progression of gastric cancer by altering the expression of genes important to 
control apoptosis, cellular proliferation and differentiation. Approaches to renormalize 
methylation patterns in both global levels such as DNA methyltransferases inhibitors or 
histone deacetyltransferases inhibitors (HDACi) or targeted therapeutics have been 
developed as novel strategies to treat cancer. Despite its promising future in cancer 
prevention and intervention, the great promise of cancer epigenetics currently lies in the 
potential in diagnostics in which epigenetic biomarkers would be helpful for risk 
assessment, early detection, prognosis prediction and monitoring of treatment response as 
well as disease relapse. The quantification of DNA methylation and microRNAs in 
peripheral blood has received a great deal of attention recently. With the progress in the 
technology of genome-wide analysis such as new generation of sequencing, more and more 
epigenetic biomarkers specific to gastric cancer will be identified in the peripheral blood, 
allowing the development of epigenetic biomarker panel alone or in combination with other 
biochemical biomarkers for the detection and monitoring of gastric cancer.  
6. References 
Abbaszadegan, M.R., Moaven, O., Sima, H.R., Ghafarzadegan, K., A'Rabi, A., Forghani, 
M.N., Raziee, H.R., Mashhadinejad, A., Jafarzadeh, M., Esmaili-Shandiz, E., et al. 
(2008). p16 promoter hypermethylation: a useful serum marker for early detection 
of gastric cancer. World J Gastroenterol 14, 2055-2060. 
 
The Epigenetic Aspect of Gastric Cancer 
 
65 
Bandres, E., Bitarte, N., Arias, F., Agorreta, J., Fortes, P., Agirre, X., Zarate, R., Diaz-
Gonzalez, J.A., Ramirez, N., Sola, J.J., et al. (2009). microRNA-451 regulates 
macrophage migration inhibitory factor production and proliferation of 
gastrointestinal cancer cells. Clin Cancer Res 15, 2281-2290. 
Bernal, C., Aguayo, F., Villarroel, C., Vargas, M., Diaz, I., Ossandon, F.J., Santibanez, E., 
Palma, M., Aravena, E., Barrientos, C., et al. (2008). Reprimo as a potential 
biomarker for early detection in gastric cancer. Clin Cancer Res 14, 6264-6269. 
Bikkavilli, R.K., and Malbon, C.C. (2010). Dishevelled-KSRP complex regulates Wnt 
signaling through post-transcriptional stabilization of beta-catenin mRNA. J Cell 
Sci 123, 1352-1362. 
Bird, A.P. (1986). CpG-rich islands and the function of DNA methylation. Nature 321, 209-
213. 
Boyd, V.L., Moody, K.I., Karger, A.E., Livak, K.J., Zon, G., and Burns, J.W. (2006). 
Methylation-dependent fragment separation: direct detection of DNA methylation 
by capillary electrophoresis of PCR products from bisulfite-converted genomic 
DNA. Anal Biochem 354, 266-273. 
Chen, Q., Chen, X., Zhang, M., Fan, Q., Luo, S., and Cao, X. (2011). miR-137 Is Frequently 
Down-Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42. Dig Dis 
Sci. 
Choi, I.S., and Wu, T.T. (2005). Epigenetic alterations in gastric carcinogenesis. Cell Res 15, 
247-254. 
Corvalan, A.H., and Maturana, M.J. (2010). Recent patents of DNA methylation biomarkers 
in gastrointestinal oncology. Recent Pat DNA Gene Seq 4, 202-209. 
Croce, C.M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nat 
Rev Genet 10, 704-714. 
Davis, B.N., Hilyard, A.C., Lagna, G., and Hata, A. (2008). SMAD proteins control 
DROSHA-mediated microRNA maturation. Nature 454, 56-61. 
Dedes, K.J., Natrajan, R., Lambros, M.B., Geyer, F.C., Lopez-Garcia, M.A., Savage, K., Jones, 
R.L., and Reis-Filho, J.S. (2011). Down-regulation of the miRNA master regulators 
Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J 
Cancer 47, 138-150. 
Eads, C.A., Danenberg, K.D., Kawakami, K., Saltz, L.B., Blake, C., Shibata, D., Danenberg, 
P.V., and Laird, P.W. (2000). MethyLight: a high-throughput assay to measure 
DNA methylation. Nucleic Acids Res 28, E32. 
El-Omar, E.M., Carrington, M., Chow, W.H., McColl, K.E., Bream, J.H., Young, H.A., 
Herrera, J., Lissowska, J., Yuan, C.C., Rothman, N., et al. (2000). Interleukin-1 
polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-
402. 
Fornari, F., Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, 
G.A., Grazi, G.L., Croce, C.M., Tavolari, S., et al. (2009). MiR-122/cyclin G1 
interaction modulates p53 activity and affects doxorubicin sensitivity of human 
hepatocarcinoma cells. Cancer Res 69, 5761-5767. 
Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D., and Baylin, S.B. (1996). Methylation-
specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl 
Acad Sci U S A 93, 9821-9826. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
66
Hiraki, M., Kitajima, Y., Koga, Y., Tanaka, T., Nakamura, J., Hashiguchi, K., Noshiro, H., and 
Miyazaki, K. (2011). Aberrant Gene Methylation Is a Biomarker for the Detection of 
Cancer Cells in Peritoneal Wash Samples from Advanced Gastric Cancer Patients. 
Ann Surg Oncol. 
Hiraki, M., Kitajima, Y., Sato, S., Nakamura, J., Hashiguchi, K., Noshiro, H., and Miyazaki, 
K. (2010). Aberrant gene methylation in the peritoneal fluid is a risk factor 
predicting peritoneal recurrence in gastric cancer. World J Gastroenterol 16, 330-
338. 
Hou, Z., Xie, L., Yu, L., Qian, X., and Liu, B. (2011). MicroRNA-146a is down-regulated in 
gastric cancer and regulates cell proliferation and apoptosis. Med Oncol. 
Hwang, H.W., Wentzel, E.A., and Mendell, J.T. (2009). Cell-cell contact globally activates 
microRNA biogenesis. Proc Natl Acad Sci U S A 106, 7016-7021. 
Ikoma, H., Ichikawa, D., Daito, I., Nobuyuki, T., Koike, H., Okamoto, K., Ochiai, T., Ueda, 
Y., Yamagishi, H., and Otsuji, E. (2007). Clinical application of methylation specific-
polymerase chain reaction in serum of patients with gastric cancer. 
Hepatogastroenterology 54, 946-950. 
Inui, M., Martello, G., and Piccolo, S. (2010). MicroRNA control of signal transduction. Nat 
Rev Mol Cell Biol 11, 252-263. 
Iorio, M.V., Casalini, P., Tagliabue, E., Menard, S., and Croce, C.M. (2008). MicroRNA 
profiling as a tool to understand prognosis, therapy response and resistance in 
breast cancer. Eur J Cancer 44, 2753-2759. 
Ji, Q., Hao, X., Meng, Y., Zhang, M., Desano, J., Fan, D., and Xu, L. (2008). Restoration of 
tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. 
BMC Cancer 8, 266. 
Jones, P.A. (2002). DNA methylation and cancer. Oncogene 21, 5358-5360. 
Karube, Y., Tanaka, H., Osada, H., Tomida, S., Tatematsu, Y., Yanagisawa, K., Yatabe, Y., 
Takamizawa, J., Miyoshi, S., Mitsudomi, T., et al. (2005). Reduced expression of 
Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 96, 111-
115. 
Katada, T., Ishiguro, H., Kuwabara, Y., Kimura, M., Mitui, A., Mori, Y., Ogawa, R., Harata, 
K., and Fujii, Y. (2009). microRNA expression profile in undifferentiated gastric 
cancer. Int J Oncol 34, 537-542. 
Kim, Y.K., Yu, J., Han, T.S., Park, S.Y., Namkoong, B., Kim, D.H., Hur, K., Yoo, M.W., Lee, 
H.J., Yang, H.K., et al. (2009). Functional links between clustered microRNAs: 
suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic 
Acids Res 37, 1672-1681. 
Laird, P.W. (2003). The power and the promise of DNA methylation markers. Nat Rev 
Cancer 3, 253-266. 
Lam, E.K., Wang, X., Shin, V.Y., Zhang, S., Morrison, H., Sun, J., Ng, E.K., Yu, J., and Jin, H. 
(2011). A microRNA contribution to aberrant Ras activation in gastric cancer. Am J 
Transl Res 3, 209-218. 
Lee, E.J., Baek, M., Gusev, Y., Brackett, D.J., Nuovo, G.J., and Schmittgen, T.D. (2008). 
Systematic evaluation of microRNA processing patterns in tissues, cell lines, and 
tumors. RNA 14, 35-42. 
Lee, Y.S., and Dutta, A. (2009). MicroRNAs in cancer. Annu Rev Pathol 4, 199-227. 
 
The Epigenetic Aspect of Gastric Cancer 
 
67 
Leung, W.K., To, K.F., Chu, E.S., Chan, M.W., Bai, A.H., Ng, E.K., Chan, F.K., and Sung, J.J. 
(2005). Potential diagnostic and prognostic values of detecting promoter 
hypermethylation in the serum of patients with gastric cancer. Br J Cancer 92, 2190-
2194. 
Li, X., Zhang, Y., Ding, J., Wu, K., and Fan, D. (2010). Survival prediction of gastric cancer by 
a seven-microRNA signature. Gut 59, 579-585. 
Lin, R.J., Lin, Y.C., Chen, J., Kuo, H.H., Chen, Y.Y., Diccianni, M.B., London, W.B., Chang, 
C.H., and Yu, A.L. (2010). microRNA signature and expression of Dicer and Drosha 
can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 70, 
7841-7850. 
Liu, R., Zhang, C., Hu, Z., Li, G., Wang, C., Yang, C., Huang, D., Chen, X., Zhang, H., 
Zhuang, R., et al. (2011). A five-microRNA signature identified from genome-wide 
serum microRNA expression profiling serves as a fingerprint for gastric cancer 
diagnosis. Eur J Cancer 47, 784-791. 
Liu, X., Wang, X., Zhang, J., Lam, E.K., Shin, V.Y., Cheng, A.S., Yu, J., Chan, F.K., Sung, J.J., 
and Jin, H.C. (2010). Warburg effect revisited: an epigenetic link between glycolysis 
and gastric carcinogenesis. Oncogene 29, 442-450. 
Meira, L.B., Bugni, J.M., Green, S.L., Lee, C.W., Pang, B., Borenshtein, D., Rickman, B.H., 
Rogers, A.B., Moroski-Erkul, C.A., McFaline, J.L., et al. (2008). DNA damage 
induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin 
Invest 118, 2516-2525. 
Merritt, W.M., Lin, Y.G., Han, L.Y., Kamat, A.A., Spannuth, W.A., Schmandt, R., Urbauer, 
D., Pennacchio, L.A., Cheng, J.F., Nick, A.M., et al. (2008). Dicer, Drosha, and 
outcomes in patients with ovarian cancer. N Engl J Med 359, 2641-2650. 
Morrison, H., Sperka, T., Manent, J., Giovannini, M., Ponta, H., and Herrlich, P. (2007). 
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of 
Ras and Rac. Cancer Res 67, 520-527. 
Motoyama, K., Inoue, H., Mimori, K., Tanaka, F., Kojima, K., Uetake, H., Sugihara, K., and 
Mori, M. (2010). Clinicopathological and prognostic significance of PDCD4 and 
microRNA-21 in human gastric cancer. Int J Oncol 36, 1089-1095. 
Ng, E.K., Chong, W.W., Jin, H., Lam, E.K., Shin, V.Y., Yu, J., Poon, T.C., Ng, S.S., and Sung, 
J.J. (2009a). Differential expression of microRNAs in plasma of patients with 
colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-
1381. 
Ng, E.K., Tsang, W.P., Ng, S.S., Jin, H.C., Yu, J., Li, J.J., Rocken, C., Ebert, M.P., Kwok, T.T., 
and Sung, J.J. (2009b). MicroRNA-143 targets DNA methyltransferases 3A in 
colorectal cancer. Br J Cancer 101, 699-706. 
Nishida, N., Mimori, K., Fabbri, M., Yokobori, T., Sudo, T., Tanaka, F., Shibata, K., Ishii, H., 
Doki, Y., and Mori, M. (2011). MicroRNA-125a-5p is an independent prognostic 
factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells 
in combination with trastuzumab. Clin Cancer Res. 
Otsubo, T., Akiyama, Y., Hashimoto, Y., Shimada, S., Goto, K., and Yuasa, Y. (2011). 
MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. 
PLoS One 6, e16617. 
Persson, C., Canedo, P., Machado, J.C., El-Omar, E.M., and Forman, D. (2011). 
Polymorphisms in inflammatory response genes and their association with gastric 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
66
Hiraki, M., Kitajima, Y., Koga, Y., Tanaka, T., Nakamura, J., Hashiguchi, K., Noshiro, H., and 
Miyazaki, K. (2011). Aberrant Gene Methylation Is a Biomarker for the Detection of 
Cancer Cells in Peritoneal Wash Samples from Advanced Gastric Cancer Patients. 
Ann Surg Oncol. 
Hiraki, M., Kitajima, Y., Sato, S., Nakamura, J., Hashiguchi, K., Noshiro, H., and Miyazaki, 
K. (2010). Aberrant gene methylation in the peritoneal fluid is a risk factor 
predicting peritoneal recurrence in gastric cancer. World J Gastroenterol 16, 330-
338. 
Hou, Z., Xie, L., Yu, L., Qian, X., and Liu, B. (2011). MicroRNA-146a is down-regulated in 
gastric cancer and regulates cell proliferation and apoptosis. Med Oncol. 
Hwang, H.W., Wentzel, E.A., and Mendell, J.T. (2009). Cell-cell contact globally activates 
microRNA biogenesis. Proc Natl Acad Sci U S A 106, 7016-7021. 
Ikoma, H., Ichikawa, D., Daito, I., Nobuyuki, T., Koike, H., Okamoto, K., Ochiai, T., Ueda, 
Y., Yamagishi, H., and Otsuji, E. (2007). Clinical application of methylation specific-
polymerase chain reaction in serum of patients with gastric cancer. 
Hepatogastroenterology 54, 946-950. 
Inui, M., Martello, G., and Piccolo, S. (2010). MicroRNA control of signal transduction. Nat 
Rev Mol Cell Biol 11, 252-263. 
Iorio, M.V., Casalini, P., Tagliabue, E., Menard, S., and Croce, C.M. (2008). MicroRNA 
profiling as a tool to understand prognosis, therapy response and resistance in 
breast cancer. Eur J Cancer 44, 2753-2759. 
Ji, Q., Hao, X., Meng, Y., Zhang, M., Desano, J., Fan, D., and Xu, L. (2008). Restoration of 
tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. 
BMC Cancer 8, 266. 
Jones, P.A. (2002). DNA methylation and cancer. Oncogene 21, 5358-5360. 
Karube, Y., Tanaka, H., Osada, H., Tomida, S., Tatematsu, Y., Yanagisawa, K., Yatabe, Y., 
Takamizawa, J., Miyoshi, S., Mitsudomi, T., et al. (2005). Reduced expression of 
Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 96, 111-
115. 
Katada, T., Ishiguro, H., Kuwabara, Y., Kimura, M., Mitui, A., Mori, Y., Ogawa, R., Harata, 
K., and Fujii, Y. (2009). microRNA expression profile in undifferentiated gastric 
cancer. Int J Oncol 34, 537-542. 
Kim, Y.K., Yu, J., Han, T.S., Park, S.Y., Namkoong, B., Kim, D.H., Hur, K., Yoo, M.W., Lee, 
H.J., Yang, H.K., et al. (2009). Functional links between clustered microRNAs: 
suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic 
Acids Res 37, 1672-1681. 
Laird, P.W. (2003). The power and the promise of DNA methylation markers. Nat Rev 
Cancer 3, 253-266. 
Lam, E.K., Wang, X., Shin, V.Y., Zhang, S., Morrison, H., Sun, J., Ng, E.K., Yu, J., and Jin, H. 
(2011). A microRNA contribution to aberrant Ras activation in gastric cancer. Am J 
Transl Res 3, 209-218. 
Lee, E.J., Baek, M., Gusev, Y., Brackett, D.J., Nuovo, G.J., and Schmittgen, T.D. (2008). 
Systematic evaluation of microRNA processing patterns in tissues, cell lines, and 
tumors. RNA 14, 35-42. 
Lee, Y.S., and Dutta, A. (2009). MicroRNAs in cancer. Annu Rev Pathol 4, 199-227. 
 
The Epigenetic Aspect of Gastric Cancer 
 
67 
Leung, W.K., To, K.F., Chu, E.S., Chan, M.W., Bai, A.H., Ng, E.K., Chan, F.K., and Sung, J.J. 
(2005). Potential diagnostic and prognostic values of detecting promoter 
hypermethylation in the serum of patients with gastric cancer. Br J Cancer 92, 2190-
2194. 
Li, X., Zhang, Y., Ding, J., Wu, K., and Fan, D. (2010). Survival prediction of gastric cancer by 
a seven-microRNA signature. Gut 59, 579-585. 
Lin, R.J., Lin, Y.C., Chen, J., Kuo, H.H., Chen, Y.Y., Diccianni, M.B., London, W.B., Chang, 
C.H., and Yu, A.L. (2010). microRNA signature and expression of Dicer and Drosha 
can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 70, 
7841-7850. 
Liu, R., Zhang, C., Hu, Z., Li, G., Wang, C., Yang, C., Huang, D., Chen, X., Zhang, H., 
Zhuang, R., et al. (2011). A five-microRNA signature identified from genome-wide 
serum microRNA expression profiling serves as a fingerprint for gastric cancer 
diagnosis. Eur J Cancer 47, 784-791. 
Liu, X., Wang, X., Zhang, J., Lam, E.K., Shin, V.Y., Cheng, A.S., Yu, J., Chan, F.K., Sung, J.J., 
and Jin, H.C. (2010). Warburg effect revisited: an epigenetic link between glycolysis 
and gastric carcinogenesis. Oncogene 29, 442-450. 
Meira, L.B., Bugni, J.M., Green, S.L., Lee, C.W., Pang, B., Borenshtein, D., Rickman, B.H., 
Rogers, A.B., Moroski-Erkul, C.A., McFaline, J.L., et al. (2008). DNA damage 
induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin 
Invest 118, 2516-2525. 
Merritt, W.M., Lin, Y.G., Han, L.Y., Kamat, A.A., Spannuth, W.A., Schmandt, R., Urbauer, 
D., Pennacchio, L.A., Cheng, J.F., Nick, A.M., et al. (2008). Dicer, Drosha, and 
outcomes in patients with ovarian cancer. N Engl J Med 359, 2641-2650. 
Morrison, H., Sperka, T., Manent, J., Giovannini, M., Ponta, H., and Herrlich, P. (2007). 
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of 
Ras and Rac. Cancer Res 67, 520-527. 
Motoyama, K., Inoue, H., Mimori, K., Tanaka, F., Kojima, K., Uetake, H., Sugihara, K., and 
Mori, M. (2010). Clinicopathological and prognostic significance of PDCD4 and 
microRNA-21 in human gastric cancer. Int J Oncol 36, 1089-1095. 
Ng, E.K., Chong, W.W., Jin, H., Lam, E.K., Shin, V.Y., Yu, J., Poon, T.C., Ng, S.S., and Sung, 
J.J. (2009a). Differential expression of microRNAs in plasma of patients with 
colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-
1381. 
Ng, E.K., Tsang, W.P., Ng, S.S., Jin, H.C., Yu, J., Li, J.J., Rocken, C., Ebert, M.P., Kwok, T.T., 
and Sung, J.J. (2009b). MicroRNA-143 targets DNA methyltransferases 3A in 
colorectal cancer. Br J Cancer 101, 699-706. 
Nishida, N., Mimori, K., Fabbri, M., Yokobori, T., Sudo, T., Tanaka, F., Shibata, K., Ishii, H., 
Doki, Y., and Mori, M. (2011). MicroRNA-125a-5p is an independent prognostic 
factor in gastric cancer,and inhibits the proliferation of human gastric cancer cells 
in combination with trastuzumab. Clin Cancer Res. 
Otsubo, T., Akiyama, Y., Hashimoto, Y., Shimada, S., Goto, K., and Yuasa, Y. (2011). 
MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. 
PLoS One 6, e16617. 
Persson, C., Canedo, P., Machado, J.C., El-Omar, E.M., and Forman, D. (2011). 
Polymorphisms in inflammatory response genes and their association with gastric 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
68
cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 173, 259-
270. 
Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., 
Urieli-Shoval, S., Galun, E., and Ben-Neriah, Y. (2004). NF-kappaB functions as a 
tumour promoter in inflammation-associated cancer. Nature 431, 461-466. 
Sakakura, C., Hamada, T., Miyagawa, K., Nishio, M., Miyashita, A., Nagata, H., Ida, H., 
Yazumi, S., Otsuji, E., Chiba, T., et al. (2009). Quantitative analysis of tumor-derived 
methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer 
Res 29, 2619-2625. 
Sakakura, C., Hasegawa, K., Miyagawa, K., Nakashima, S., Yoshikawa, T., Kin, S., Nakase, 
Y., Yazumi, S., Yamagishi, H., Okanoue, T., et al. (2005). Possible involvement of 
RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11, 
6479-6488. 
Shen, R., Pan, S., Qi, S., Lin, X., and Cheng, S. (2010). Epigenetic repression of microRNA-
129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res 
Commun 394, 1047-1052. 
Slezak-Prochazka, I., Durmus, S., Kroesen, B.J., and van den Berg, A. (2010). MicroRNAs, 
macrocontrol: regulation of miRNA processing. RNA 16, 1087-1095. 
Song, Y.X., Yue, Z.Y., Wang, Z.N., Xu, Y.Y., Luo, Y., Xu, H.M., Zhang, X., Jiang, L., Xing, 
C.Z., and Zhang, Y. (2011). MicroRNA-148b is frequently down-regulated in gastric 
cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer 
10, 1. 
Suzuki, H.I., Yamagata, K., Sugimoto, K., Iwamoto, T., Kato, S., and Miyazono, K. (2009). 
Modulation of microRNA processing by p53. Nature 460, 529-533. 
Takagi, T., Iio, A., Nakagawa, Y., Naoe, T., Tanigawa, N., and Akao, Y. (2009). Decreased 
expression of microRNA-143 and -145 in human gastric cancers. Oncology 77, 12-
21. 
Takei, Y., Takigahira, M., Mihara, K., Tarumi, Y., and Yanagihara, K. (2011). The Metastasis-
Associated microRNA miR-516a-3p Is a Novel Therapeutic Target for Inhibiting 
Peritoneal Dissemination of Human Scirrhous Gastric Cancer. Cancer Res 71, 1442-
1453. 
Tamura, G. (2006). Alterations of tumor suppressor and tumor-related genes in the 
development and progression of gastric cancer. World J Gastroenterol 12, 192-198. 
Tan, S.H., Ida, H., Lau, Q.C., Goh, B.C., Chieng, W.S., Loh, M., and Ito, Y. (2007). Detection 
of promoter hypermethylation in serum samples of cancer patients by methylation-
specific polymerase chain reaction for tumour suppressor genes including RUNX3. 
Oncol Rep 18, 1225-1230. 
Tchernitsa, O., Kasajima, A., Schafer, R., Kuban, R.J., Ungethum, U., Gyorffy, B., Neumann, 
U., Simon, E., Weichert, W., Ebert, M.P., et al. (2010). Systematic evaluation of the 
miRNA-ome and its downstream effects on mRNA expression identifies gastric 
cancer progression. J Pathol 222, 310-319. 
Thomson, J.M., Newman, M., Parker, J.S., Morin-Kensicki, E.M., Wright, T., and Hammond, 
S.M. (2006). Extensive post-transcriptional regulation of microRNAs and its 
implications for cancer. Genes Dev 20, 2202-2207. 
 
The Epigenetic Aspect of Gastric Cancer 
 
69 
Tsujiura, M., Ichikawa, D., Komatsu, S., Shiozaki, A., Takeshita, H., Kosuga, T., Konishi, H., 
Morimura, R., Deguchi, K., Fujiwara, H., et al. (2010). Circulating microRNAs in 
plasma of patients with gastric cancers. Br J Cancer 102, 1174-1179. 
Ueda, T., Volinia, S., Okumura, H., Shimizu, M., Taccioli, C., Rossi, S., Alder, H., Liu, C.G., 
Oue, N., Yasui, W., et al. (2010). Relation between microRNA expression and 
progression and prognosis of gastric cancer: a microRNA expression analysis. 
Lancet Oncol 11, 136-146. 
Ushijima, T., and Sasako, M. (2004). Focus on gastric cancer. Cancer Cell 5, 121-125. 
Valeri, N., Gasparini, P., Fabbri, M., Braconi, C., Veronese, A., Lovat, F., Adair, B., Vannini, 
I., Fanini, F., Bottoni, A., et al. (2010). Modulation of mismatch repair and genomic 
stability by miR-155. Proc Natl Acad Sci U S A 107, 6982-6987. 
Varambally, S., Cao, Q., Mani, R.S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., 
Jing, X., Ramnarayanan, K., et al. (2008). Genomic loss of microRNA-101 leads to 
overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-
1699. 
Wada, R., Akiyama, Y., Hashimoto, Y., Fukamachi, H., and Yuasa, Y. (2010). miR-212 is 
downregulated and suppresses methyl-CpG-binding protein MeCP2 in human 
gastric cancer. Int J Cancer 127, 1106-1114. 
Wan, H.Y., Guo, L.M., Liu, T., Liu, M., Li, X., and Tang, H. (2010). Regulation of the 
transcription factor NF-kappaB1 by microRNA-9 in human gastric 
adenocarcinoma. Mol Cancer 9, 16. 
Wang, H.J., Ruan, H.J., He, X.J., Ma, Y.Y., Jiang, X.T., Xia, Y.J., Ye, Z.Y., and Tao, H.Q. (2010). 
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration 
and invasion. Eur J Cancer. 
Wang, X., and Jin, H. (2010). The epigenetic basis of Warburg effect. Epigenetics 5. 
Wang, X., Lam, E.K., Zhang, J., Jin, H., and Sung, J.J. (2009). MicroRNA-122a functions as a 
novel tumor suppressor downstream of adenomatous polyposis coli in 
gastrointestinal cancers. Biochem Biophys Res Commun 387, 376-380. 
Wang, Y.C., Yu, Z.H., Liu, C., Xu, L.Z., Yu, W., Lu, J., Zhu, R.M., Li, G.L., Xia, X.Y., Wei, 
X.W., et al. (2008). Detection of RASSF1A promoter hypermethylation in serum 
from gastric and colorectal adenocarcinoma patients. World J Gastroenterol 14, 
3074-3080. 
White, P.S., Thompson, P.M., Gotoh, T., Okawa, E.R., Igarashi, J., Kok, M., Winter, C., 
Gregory, S.G., Hogarty, M.D., Maris, J.M., et al. (2005). Definition and 
characterization of a region of 1p36.3 consistently deleted in neuroblastoma. 
Oncogene 24, 2684-2694. 
Wiemer, E.A. (2007). The role of microRNAs in cancer: no small matter. Eur J Cancer 43, 
1529-1544. 
Winter, J., Jung, S., Keller, S., Gregory, R.I., and Diederichs, S. (2009). Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11, 
228-234. 
Wojdacz, T.K., and Dobrovic, A. (2007). Methylation-sensitive high resolution melting (MS-
HRM): a new approach for sensitive and high-throughput assessment of 
methylation. Nucleic Acids Res 35, e41. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
68
cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 173, 259-
270. 
Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., 
Urieli-Shoval, S., Galun, E., and Ben-Neriah, Y. (2004). NF-kappaB functions as a 
tumour promoter in inflammation-associated cancer. Nature 431, 461-466. 
Sakakura, C., Hamada, T., Miyagawa, K., Nishio, M., Miyashita, A., Nagata, H., Ida, H., 
Yazumi, S., Otsuji, E., Chiba, T., et al. (2009). Quantitative analysis of tumor-derived 
methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer 
Res 29, 2619-2625. 
Sakakura, C., Hasegawa, K., Miyagawa, K., Nakashima, S., Yoshikawa, T., Kin, S., Nakase, 
Y., Yazumi, S., Yamagishi, H., Okanoue, T., et al. (2005). Possible involvement of 
RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11, 
6479-6488. 
Shen, R., Pan, S., Qi, S., Lin, X., and Cheng, S. (2010). Epigenetic repression of microRNA-
129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res 
Commun 394, 1047-1052. 
Slezak-Prochazka, I., Durmus, S., Kroesen, B.J., and van den Berg, A. (2010). MicroRNAs, 
macrocontrol: regulation of miRNA processing. RNA 16, 1087-1095. 
Song, Y.X., Yue, Z.Y., Wang, Z.N., Xu, Y.Y., Luo, Y., Xu, H.M., Zhang, X., Jiang, L., Xing, 
C.Z., and Zhang, Y. (2011). MicroRNA-148b is frequently down-regulated in gastric 
cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer 
10, 1. 
Suzuki, H.I., Yamagata, K., Sugimoto, K., Iwamoto, T., Kato, S., and Miyazono, K. (2009). 
Modulation of microRNA processing by p53. Nature 460, 529-533. 
Takagi, T., Iio, A., Nakagawa, Y., Naoe, T., Tanigawa, N., and Akao, Y. (2009). Decreased 
expression of microRNA-143 and -145 in human gastric cancers. Oncology 77, 12-
21. 
Takei, Y., Takigahira, M., Mihara, K., Tarumi, Y., and Yanagihara, K. (2011). The Metastasis-
Associated microRNA miR-516a-3p Is a Novel Therapeutic Target for Inhibiting 
Peritoneal Dissemination of Human Scirrhous Gastric Cancer. Cancer Res 71, 1442-
1453. 
Tamura, G. (2006). Alterations of tumor suppressor and tumor-related genes in the 
development and progression of gastric cancer. World J Gastroenterol 12, 192-198. 
Tan, S.H., Ida, H., Lau, Q.C., Goh, B.C., Chieng, W.S., Loh, M., and Ito, Y. (2007). Detection 
of promoter hypermethylation in serum samples of cancer patients by methylation-
specific polymerase chain reaction for tumour suppressor genes including RUNX3. 
Oncol Rep 18, 1225-1230. 
Tchernitsa, O., Kasajima, A., Schafer, R., Kuban, R.J., Ungethum, U., Gyorffy, B., Neumann, 
U., Simon, E., Weichert, W., Ebert, M.P., et al. (2010). Systematic evaluation of the 
miRNA-ome and its downstream effects on mRNA expression identifies gastric 
cancer progression. J Pathol 222, 310-319. 
Thomson, J.M., Newman, M., Parker, J.S., Morin-Kensicki, E.M., Wright, T., and Hammond, 
S.M. (2006). Extensive post-transcriptional regulation of microRNAs and its 
implications for cancer. Genes Dev 20, 2202-2207. 
 
The Epigenetic Aspect of Gastric Cancer 
 
69 
Tsujiura, M., Ichikawa, D., Komatsu, S., Shiozaki, A., Takeshita, H., Kosuga, T., Konishi, H., 
Morimura, R., Deguchi, K., Fujiwara, H., et al. (2010). Circulating microRNAs in 
plasma of patients with gastric cancers. Br J Cancer 102, 1174-1179. 
Ueda, T., Volinia, S., Okumura, H., Shimizu, M., Taccioli, C., Rossi, S., Alder, H., Liu, C.G., 
Oue, N., Yasui, W., et al. (2010). Relation between microRNA expression and 
progression and prognosis of gastric cancer: a microRNA expression analysis. 
Lancet Oncol 11, 136-146. 
Ushijima, T., and Sasako, M. (2004). Focus on gastric cancer. Cancer Cell 5, 121-125. 
Valeri, N., Gasparini, P., Fabbri, M., Braconi, C., Veronese, A., Lovat, F., Adair, B., Vannini, 
I., Fanini, F., Bottoni, A., et al. (2010). Modulation of mismatch repair and genomic 
stability by miR-155. Proc Natl Acad Sci U S A 107, 6982-6987. 
Varambally, S., Cao, Q., Mani, R.S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., 
Jing, X., Ramnarayanan, K., et al. (2008). Genomic loss of microRNA-101 leads to 
overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-
1699. 
Wada, R., Akiyama, Y., Hashimoto, Y., Fukamachi, H., and Yuasa, Y. (2010). miR-212 is 
downregulated and suppresses methyl-CpG-binding protein MeCP2 in human 
gastric cancer. Int J Cancer 127, 1106-1114. 
Wan, H.Y., Guo, L.M., Liu, T., Liu, M., Li, X., and Tang, H. (2010). Regulation of the 
transcription factor NF-kappaB1 by microRNA-9 in human gastric 
adenocarcinoma. Mol Cancer 9, 16. 
Wang, H.J., Ruan, H.J., He, X.J., Ma, Y.Y., Jiang, X.T., Xia, Y.J., Ye, Z.Y., and Tao, H.Q. (2010). 
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration 
and invasion. Eur J Cancer. 
Wang, X., and Jin, H. (2010). The epigenetic basis of Warburg effect. Epigenetics 5. 
Wang, X., Lam, E.K., Zhang, J., Jin, H., and Sung, J.J. (2009). MicroRNA-122a functions as a 
novel tumor suppressor downstream of adenomatous polyposis coli in 
gastrointestinal cancers. Biochem Biophys Res Commun 387, 376-380. 
Wang, Y.C., Yu, Z.H., Liu, C., Xu, L.Z., Yu, W., Lu, J., Zhu, R.M., Li, G.L., Xia, X.Y., Wei, 
X.W., et al. (2008). Detection of RASSF1A promoter hypermethylation in serum 
from gastric and colorectal adenocarcinoma patients. World J Gastroenterol 14, 
3074-3080. 
White, P.S., Thompson, P.M., Gotoh, T., Okawa, E.R., Igarashi, J., Kok, M., Winter, C., 
Gregory, S.G., Hogarty, M.D., Maris, J.M., et al. (2005). Definition and 
characterization of a region of 1p36.3 consistently deleted in neuroblastoma. 
Oncogene 24, 2684-2694. 
Wiemer, E.A. (2007). The role of microRNAs in cancer: no small matter. Eur J Cancer 43, 
1529-1544. 
Winter, J., Jung, S., Keller, S., Gregory, R.I., and Diederichs, S. (2009). Many roads to 
maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11, 
228-234. 
Wojdacz, T.K., and Dobrovic, A. (2007). Methylation-sensitive high resolution melting (MS-
HRM): a new approach for sensitive and high-throughput assessment of 
methylation. Nucleic Acids Res 35, e41. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
70
Wu, W.K., Lee, C.W., Cho, C.H., Fan, D., Wu, K., Yu, J., and Sung, J.J. (2010). MicroRNA 
dysregulation in gastric cancer: a new player enters the game. Oncogene 29, 5761-
5771. 
Xiong, Z., and Laird, P.W. (1997). COBRA: a sensitive and quantitative DNA methylation 
assay. Nucleic Acids Res 25, 2532-2534. 
Yu, H., Pardoll, D., and Jove, R. (2009a). STATs in cancer inflammation and immunity: a 
leading role for STAT3. Nat Rev Cancer 9, 798-809. 
Yu, J., Cheng, Y.Y., Tao, Q., Cheung, K.F., Lam, C.N., Geng, H., Tian, L.W., Wong, Y.P., 
Tong, J.H., Ying, J.M., et al. (2009b). Methylation of protocadherin 10, a novel tumor 
suppressor, is associated with poor prognosis in patients with gastric cancer. 
Gastroenterology 136, 640-651 e641. 
Zhang, X., Zhu, W., Zhang, J., Huo, S., Zhou, L., Gu, Z., and Zhang, M. (2010). MicroRNA-
650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res 
Commun 395, 275-280. 
Zhou, H., Guo, J.M., Lou, Y.R., Zhang, X.J., Zhong, F.D., Jiang, Z., Cheng, J., and Xiao, B.X. 
(2010). Detection of circulating tumor cells in peripheral blood from patients with 
gastric cancer using microRNA as a marker. J Mol Med 88, 709-717. 
Zhu, W., Shan, X., Wang, T., Shu, Y., and Liu, P. (2010). miR-181b modulates multidrug 
resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127, 2520-2529. 
4 
Molecular Features and Their Clinical 
Implications on Gastric Adenocarcinoma 
Yves Dittmar and Utz Settmacher 
University Hospital Jena 
Germany  
1. Introduction  
Gastric cancer is one of the most frequent malignant tumors worldwide. It is known to have 
a poor prognosis leading to more than 600.000 fatalities every year. This dilemma is caused 
mainly by the late onset of clinical symptoms. Thus, when gastric cancer is diagnosed, more 
than 50% of patients cannot be cured. 
Even in those cases where cure by surgery can be achieved, the prognosis is poor due to the 
high incidence of early recurrence of the primary tumor as well as the development of 
metachronous metastases. The attempt to improve survival by extended surgical 
procedures, such as extensive lymph node removal did not have a significant impact on 
survival leading medical professionals to regard advanced gastric cancer as a systemic 
rather than a locally confined disease. Therefore, over the last two decades the importance of 
chemotherapy as a part of the curative treatment strategy was became more evident. The 
findings of molecular research show that gastric cancer has a very heterogenous biology 
with a broad variety of signalling pathways and chromosomal imbalances involved. With 
the growing insight into the molecular biology of gastric cancer it became clear that every 
single gastric cancer has to be regarded as an individual entity which can change its 
molecular behavior over time. This chapter presents the current knowledge of the molecular 
profile of gastric cancer. The most important basic signalling pathways that are known to 
play critical roles in the development as well as the progression of gastric cancer are 
discussed. Furthermore, the currently available molecular targets and their clinical relevance 
are reviewed in this chapter. 
2. Chromosomal imbalances in gastric cancer 
To date, the TNM system and the classification according to Lauren are the “gold standard” 
tools to predict survival and to define the treatment strategy in patients with gastric cancer. 
However, there is a wide range of clinical outcomes in patients with similar TNM stages. 
Therefore, it seems to be important to improve the characterization of gastric cancer by 
using molecular criteria [1].  
The development as well as the progression of gastric cancer is the result based on the 
interplay between the host genetic profile and the environment. The precise transfer of 
genetic information requires accurate replication, DNA mismatch repair and the segregation 
of replicated DNA strands. Whereas an impaired replication is not compatible with cellular 
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survival, the uneven distribution of chromosomes in tumor cells is termed aneuploidia and 
can be frequently observed in gastric cancer tissue. Defects in the mismatch repair system 
can gradually lead to chromosomal imbalances. Functional losses of MLH1 and MSH2 are 
known to cause multiple somatic mutations which may present microsatellite instability and 
may lead to tumor formation at multiple locations at a younger age in the colon /rectum 
(Lynch syndrome). Most frequently, the hypermethylation of CpG islands in the promoter 
region of these mismatch repair genes is the underlying mechanism of loss of function. This 
type of tumor development is called microsatellite mutator phenotype and has also been 
described in gastric cancer by several authors [2,3]. The other type of tumor development 
based on chromosomal imbalances is the chromosomal/ intrachromosomal instability type 
leading to amplifications and deletions of whole chromosomes as well as chromosome 
cytobands potentially harbouring tumor suppressor genes or oncogenes. The following 
locations have been observed to be frequently amplified in gastric cancer: 3p22, 4q25, 8q24, 
11p13, and 20q13. Losses have been documented most commonly at 1p36 and 9p21 [4]. 
Furthermore, it has been reported that intestinal type gastric cancer according to Lauren´s 
classification has a higher degree of chromosomal aberrations than the diffuse type. 
Furthermore, a relationship between clinical outcome and the degree of chromosomal 
aberrations in intestinal type gastric cancer was observed [5].  
Another level of chromosomal assessment is the detection of gross chromosomal imbalances 
by using flow cytometry. The loss or amplification of complete chromosomes is known to be 
a frequently occurring event in cancer development [6]. Non-diploid status of chromosomes 
has been shown to be present in about 20% of gastric cancer cases. Patients with a non-
diploid chromosome status have a significantly poorer survival than those who present with 
a diploid status [1]. 
Additionally, there is a growing body of evidence that the epigenetic level of regulation of 
gene expression plays an important role in cancer development. The chromatine 
remodelling machinery contains in particular enzymes that modify histons [7]. Recently, it 
has been shown that the histone demethylase RBP2 is upregulated in gastric cancer and that 
depletion of that enzyme causes senescence of resident tumor cells [8]. 
3. Hereditary gastric cancer 
In 10% of all gastric cancer cases, a familial clustering of the disease can be observed but 
only 1 -3% are of hereditary origin. In those cases where no histological finding is available 
the term “familial gastric cancer” is used [9]. The following syndromes include patients with 
available histology and are known to be associated with both familial clustering and certain 
germline mutations: hereditary diffuse gastric cancer, familial diffuse gastric cancer and 
familial intestinal gastric cancer. Furthermore, there are several syndromes which may 
include early onset gastric cancer in addition to other tumor manifestations: Lynch 
syndrome, Li-Fraumeni syndrome, Li-Fraumeni-like syndrome. Peutz-Jeghers syndrome 
and the familial adenomatous polyposis (FAP). 
Hereditary diffuse gastric cancer develops from germline mutations in the CDH-1 gene 
(about one third of cases) coding for E-cadherin, an important cell adhesion molecule on the 
lateral surface of the cellular membrane, whereas in two thirds of the cases the underlying 
mutation cannot be identified [9,10]. The inactivation of the CDH-1 gene may be triggered 
by epigenetic mechanisms (hypermethylation of the promoter region) as well as by a genetic 
mechanism (loss of heterocygosity plus CDH-1 mutation). The syndrome is associated with 
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early onset and gastric cancer lesions growing in multiple locations as well as with lobular 
breast carcinoma. The International Gastric Cancer Linkage Consortium defined two main 
criteria to identify patients susceptible for hereditary diffuse gastric cancer from the 
population: 2 cases of diffuse gastric cancer in first or second degree relatives (at least one of 
them to be younger than 50 years at the time of diagnosis) or 3 cases of diffuse gastric cancer 
in first or second degree relatives independently of the age at the time of diagnosis. Families 
with numerous cases of diffuse gastric cancer who do not fulfil these abovementioned 
criteria are considered to be familial diffuse gastric cancer [11]. 
The majority of cases of familial intestinal gastric cancer is associated with Lynch syndrome 
which is also termed hereditary non-polyposis colorectal cancer (HNPCC) [12,13]. 
Therefore, Caldas and co-workers suggested to identify patients with risk for familial 
intestinal gastric cancer by using the HNPCC-related Amsterdam criteria in countries with a 
high incidence of gastric cancer. In contrast, countries with a lower incidence should use the 
criteria analogous to hereditary diffuse gastric cancer [13]. 
Lynch syndrome is caused by germline mutations in genes associated to the mismatch 
repair (MMR) machinery. Most frequently, alterations of the MLH gene family (MutL-
homolog) or the MSH gene family (MutS-homolog) are responsible for the defective MMR. 
These two proteins form heterodimers that recognize mismatched bases selectively within 
the newly synthesized daughter DNA strand which can be removed subsequently by 
exonucleases. Appoximately 5 – 8% (depending on gender and the mutated gene) of 
patients with Lynch syndrome develop gastric cancer during their life time [12,14]. 
The Li-Fraumeni syndrome as well as the Li-Fraumeni-like syndrome originate from 
germline mutations of the TP53 gene. About 250 different mutations of that gene have been 
identified to cause a broad variety of tumor diseases, the majority of them being missense 
mutations leading to a molecule that cannot bind to the DNA [15]. There is a broad variety 
of tumor diseases which can develop based on that syndrome including breast cancer, 
adrenal tumors, sarcomas and gastric cancer. The Li-Fraumeni syndrome and the Li-
Fraumeni-like syndrome are distinguished by several clinical based criteria. Recently it has 
been demonstrated that the DNA repair gene BRCA2 might be another molecular 
mechanism of causing these syndromes [16]. 
Peutz-Jeghers syndrome (STK11 gene, coding for serin-threonin kinase 11) and the FAP 
(associated to the APC gene) can are associated with gastric cancer in rare cases. 
4. Dysregulation of signalling pathways 
Non-hereditary gastric cancer has a complex and multistep carcinogenesis in which – 
among numerous other factors – signalling pathways are involved. The dysregulation of 
these signalling pathways may lead to activation of genes that code for proteins regulating 
growth processes, such as cell division, differentiation, epithelial-mesenchymal transition 
and proliferation. Several studies on the molecular development as well as the progression 
of gastric cancer show clearly that there are differences in the biological behavior between 
young and elderly people. According to the classification of Lauren, intestinal gastric cancer 
with differentiated glandular growth pattern presents with a profile of dysregulated 
signalling pathways that can be distinguished from the diffuse type gastric cancer. 
Furthermore, there appears to be a difference between cancer of the upper stomach as 
compared to that of the lower stomach. 
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4.1 Tyrosine kinase signalling 
4.1.1 The epidermal growth factor receptor (EGFR) family and downstream signalling  
Epidermal growth factor receptor is a member of the ErbB receptor family and normally 
regulates gastric mucosa proliferation. Under normal conditions, two receptor molecules 
form dimers as a result of ligand binding and phosphorylate each other via their tyrosin 
kinase activity. Every heterodimer has its own effector molecule (see Fig. 1). One important 
pathway is the activation of the guanine exchange factor SOS which subsequently activates 
the MEK-ERK MAP kinase pathway leading to the expression of proliferation-promoting 
transcription factors, such as AP-1, ELK-1 and c-fos. Alternative signal transduction 
pathways downstream of the EGF receptor family are STAT and PKB (protein kinase B). An 
important downstream effector of PKB is the mTOR complex 1. Active mTOR complex 1 
leads via expression of specific mRNA stabilizing proteins and of ribosomal subunit S6 to 
increased proliferation. 
In summary, EGFR related signals promote many cellular activities towards tumor growth, 
in particular proliferation, migration, adhesion, apoptosis and differentiation [17]. 
 
 
Fig. 1. The members of the EGF receptor family and their typical ligands 
Dysregulation of signalling pathways downstream of the EGFR is frequently observed in 
gastric cancer. Therefore, currently two main subgroups of targeted drugs exist: first the 
inhibition of the receptor by blocking the ligand binding site and second the inhibition of the 
intracellular tyrosin kinase activity of the receptor molecule. For the first-mentioned 
mechanism the monoclonal antibodies cetuximab, matuzumab and panitumumab have 
been developed. Gefitinib and erlotinib are tyrosin kinase inhibitors. 
The ErbB2 receptor (Her2/Neu) can dimerize without a binding ligand and, thus, cannot be 
inhibited by antibodies against the ligand binding site. About one third of all tumors express 
ErbB2. In up to 27% of gastric cancer cases an overexpressed ErBB2 can be detected [18]. 
ErbB2 is overexpressed more frequently in intestinal type gastric cancers as compared to 
diffuse type gastric cancer. Furthermore, younger patients show less frequent ErbB2 
overexpression than elderly patients [19]. The humanized antibody trastuzumab inhibits the 
ErbB2 receptor and has been shown to provide a significant survival benefit in ErbB2-
positive cases [20].  
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Recently, it has been shown in vivo and in vitro on gastric cancer cell lines that the mTOR 
specific inhibitor rapamycin is effective in those cases which are resistant to EGFR 
inhibitors. Moreover, when administered in combination with cetuximab it can restore the 
anticancer effects of EGFR inhibition. Thus, rapamycin alone or in combination with other 
agents may provide a new target for the clinical use in the future [21]. 
K-ras, BRAF and SOS mutations are detected only in few gastric cancer cases [22]. 
Nevertheless the novel k-ras inhibitor tipifernib should be mentioned. K-ras mutations 
result in a continuosly active k-ras protein. Tipifernib inhibits the enzyme 
farnesyltransferase which forms an essential step in the posttranscriptional modification and 
thereby downregulates the k-ras signal. The clinical outcome of tipifernib administration in 
advanced gastric cancer is currently investigated in a phase 2 trial and might be a potential 
target-specific therapy for selected gastric cancer cases in the future, too [23]. 
4.1.2 Vascular endothelial growth factor (VEGF) and tumor angiogenesis 
When tumors grow larger than 1-2mm in diameter, further tumor growth requires the 
development of new blood vessels in the tumor environment. This tumor-related 
angiogenesis is different from physiological angiogenesis in terms of distinct vessel 
architecture, vascular permeability as well as a different interplay between endothelial cells 
and perivascular cells. One of the most potent angiogenesis-promoting factors is VEGF. 
VEGF is expressed as a result of tissue hypoxia. It promotes its biological effects (inhibition 
of apoptosis and proliferation of endothelial cells, increased endothelial cell migration) via 
binding to the VEGF receptor. Synchronously with the once initiated tumor angiogenesis the 
development of metastases is promoted. 
Overexpression of VEGF has been reported in gastric cancer cases. 
Currently, 4 different mechanisms of VEGF signalling inhibition can be distinguished: 
VEGF-inhibiting antibodies (bevacizumab), soluble VEGF receptors (aflibercept), VEGFR-
inhibiting antibodies (IMC-1121B) and VEGFR tyrosin kinase inhibitors (vatalinib, cediranib, 
sunitinib, sorafenib). 
To date, for gastric cancer no angiogenesis-inhibiting agent has been approved worldwide. 
But a growing experience with angiogenesis-inhibiting agents in colorectal cancer 
demonstrates a survival benefit with acceptable adverse effects [24]. 
4.1.3 Hepatocellular growth factor (HGF) and gastric cancer 
HGF signals induce a broad variety of biological features, such as morphogenesis, adhesion, 
migration, remodelling of extracellular matrix and are also involved in tumor angiogenesis 
[25]. It is known to be one of the key players in tissue regeneration following injury. Under 
physiological conditions, HGF is secreted in a paracrine manner most commonly by 
mesenchymal cells. Its target, the HGF receptor (HGFR or MET) is usually present on the 
surface of epithelial cells. Several cytokines, such as interleukin-1 and -6, tumour necrosis 
factor-α and transforming growth factor-β (TGFβ) that are released into the reactive 
interstitium (wound healing, cancer) induce the upregulation of HGF and HGFR expression. 
Furthermore, HGF is a strong antagonist of liver fibrosis by inhibiting the TGFβ signal as 
well as by pro-apoptotic effects on myofibroblasts. [26]. Intracellular signal transduction is 
similar to the EGFR signalling pathways. 
In gastric cancer, the upregulation of the HGF signalling is an event which predominantly 
occurs at advanced stages, in particular in those who have liver metastases [27]. About 23% 
of patients with gastric cancer have an overexpression of c-met [28]. 
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There are currently no substances available for clinical use that inhibit the HGF signalling 
pathway but the effect of the novel agent XL880 (a tyrosin kinase inhibitor) on poorly 
differentiated gastric cancer is currently investigated. Furthermore, antibodies against HGF 
and MET are planned [29]. 
4.1.4 Fibroblast growth factor and its receptor FGFR in gastric cancer 
Like EGFR and HGFR, the fibroblast growth factor receptor belongs to the large family of 
receptor tyrosin kinases. To date, 23 different isoforms (FGF 1-23) and 4 receptor subtypes 
(FGFR 1-4) have been identified. FGFR2 or k-sam has been reported to be overexpressed in 
poorly differentiated gastric cancer The MAP-kinase pathway, the AKT pathway as well as 
NFAT signalling and activation of protein kinase C are the most prominent subsequent 
intracellular transduction pathways. Recently it has been shown that the receptor of 
keratinocyte growth factor on epithelial cells is identical with FGFR2. The amplification of 
the k-sam gene has been detected in poorly differentiated diffuse gastric cancer in about 
50% of cases resulting in a poor prognosis [30,31]. In contrast, it is rarely present in intestinal 
type gastric cancer. 
The novel FGFR2 inhibitor Ki23057 showed considerable antiproliferative effects in the 
mouse model and might become an effective target-specific agent in the future. 
4.1.5 Vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF) 
and its receptor PDGFR in gastric cancer 
VEGF and PDGF are key players of angiogenesis. Whereas VEGF promotes 
neoangiogenesis, PDGF has its impacts on the maintainance of microvessels. Both factors are 
secreted by tumor cells and act on the surrounding tumor microenvironment. There are 
protein families for both factors, the most important subtypes in gastric cancer are VEGF-A 
and PDGF-B. The signals are mediated via binding to VEGF- and PDGF receptors which 
have an autophosphorylating tyrosin kinase activity and subsequently initiate intracellular 
signal cascades that result in migration, proliferation and angiogenesis. 
The overexpression of both signal molecules has been shown to be correlating to each 
other in gastric cancer. PDGF-B seems to play a more important role in intestinal type 
gastric cancer whereas VEGF-A is more important for angiogenesis in diffuse type gastric 
cancer [32]. 
The PDGF receptor can be inhibited by imatinib. Imatinib is a specific tyrosin kinase 
inhibitor that is frequently used in gastrointestinal stroma tumors. A potential treatment 
option in the future might be the novel multiple receptor tyrosine kinase inhibitor 
LY2457546 which has been shown to have anti-tumor effects in animal models recently.[33] 
4.2 Proteinase-activated receptors (PAR) in gastric cancer 
Proteinase-activated receptors belong to the family of G-protein coupled receptors. The 
receptor is activated by serin-proteases, such as thrypsin and thrombin by removing an N-
terminal segment on the extracellular space. The thus created neo-N-terminal end 
subsequently serves as an intramolecular ligand that binds to the binding domaine. The 
signal  is then transferred to the intracellular space leading to activation of several signal 
transduction pathways. In gastric cancer cell lines, PAR2 has been shown to trans-activate 
the EGF receptor. This effect could not be blocked by EGFR inhibitors [34]. To date, there are 
no inhibitors of PAR evaluated for clinical use. 
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4.3 WNT signalling and the involvement of E-caherin 
The WNT signalling pathway belongs to the most important signalling systems and is 
evolutionary highly conserved. It plays a central role in embryonic differentiation processes. 
In adults, WNT activity can be detected within the stem cell niche of the gastrointestinal 
tract. Furthermore, there is a growing body of evidence that the WNT signalling pathway is 
a key player in the progression of tumors. The signal originates in the extracellular space 
with the binding of WNT (several subtypes exist) to its receptor frizzled. In co-operation 
with the co-receptor LRP the signal is  then transduced to the intracellular space. From here, 
4 different signalling cascades can be activated, which is shown in more detail in Tab. 1. In 
the classical or canonical WNT pathway the WNT signal leads to the destabilization of the 
multiprotein complex consisting of Axin, GSK3B and APC. GSK3b normally phosphorylizes 
beta catenin which in turn leads to the degradation of beta catenin. Intact beta catenin 
moves to the nucleus and binds to TCF/ LEF complex which constitutes a transcription 
factor with the subsequent expression of specific genes. 
 
WNT sub-pathway Targets Biological effects 
Canonical WNT/ beta catenin 
pathway 
Cyclin D1, c-myc, 




WNT/JNK Pathway = planar 
cell polarity pathway (PCP) 
Cytosceleton Cytosceletal remodelling, cell 
polarity 
WNT/ calcium pathway PKC, PLC Cell adhesion 
Asymmetric cell division 
pathway 
Mitotic spindle Asymmetric cell division 
Table 2. Several pathways downstream to the WNT signal 
It is of importance to know that the WNT signalling pathway is part of a complex network 
of signal transduction which is controlled and regulated by a multitude of factors belonging 
to different pathways. In particular, a complex crosstalk between WNT, E-cadherin and 
beta-catenin has been described. E-cadherin inhibits dimerisation and activation of the 
EGFR via binding to EGFR monomers. On the other hand, activation of EGFR leads to the 
internalization of E-cadherin-beta-catenin complexes which in turn induces expression of 
WNT dependent target genes [35].  
About 30% of gastric cancer cases show an overexpression of beta-catenin which is 
associated with poorer prognosis than beta-catenin-negative gastric cancer. The loss of APC 
function which is essential for the beta-catenin degradation is observed in about 20% of 
gastric cancer cases. The downregulation of SFRP – an inhibitor of the WNT receptor – by 
methylation of the promoter region has been described to occur in gastric cancer, too [17,36]. 
To date, there are no WNT specific anticancer drugs available. Recently, it has been 
demonstrated that differentiation-inducing factors downregulate the WNT pathway by 
activating the GSK3B in several cancer cell lines [37]. 
4.4 Sonic hedgehog signalling pathway (SHH) 
The basic structure of SHH shows some similarity with the WNT pathway: An extracellular 
ligand (SHH) binds to a receptor at the cell surface (patched) which transduces the signal 
into the cell. Thereby, an intracellular signal transducer (smoothened) is activated which in 
turn deactivates a multiprotein complex (fused, suppressor of fused, coastal and others). 
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This deactivation leads to accumulation of a nuclear factor (Gli) which is normally degraded 
by the functional multiprotein complex. Eventually, specific genes encoding proteins, such 
as cyclin D2, patched and Gli (positive feedback) are activated. There is a ample crosstalk 
with other signalling pathways, in particular the expression of TGF-beta (TGF-beta 
pathway), the expression of SFRP1 (WNT pathway) and FOXL1 (bone morphogenic 
pathway).  
The sonic hedgehog signalling plays a central role in embryonic development and has been 
shown to be upregulated in a broad variety of malignant tumors [38]. The overexpression of 
both Gli and the receptor patched have been reported in two thirds of gastric cancer cases. It 
has been shown that SHH expression is stronger in intestinal type gastric cancer and tubular 
growth pattern than in diffuse type gastric cancer and mucinous or undifferentiated growth 
pattern [39]. SHH is also overexpressed in non-malignant lesions, such as gastric adenomas 
or intestinal metasplasia. Due to the upregulation of SHH signalling at an early stage of 
cancer development it might serve as an early diagnostic tool in patients who have an 
increased risk for the development of gastric cancer. 
The SHH signalling pathway theoretically could be blocked by cyclopamine. This substance 
was first discovered on sheep that fed on a certain lilieaceous plant (veratrum californicum) 
and delivered lambs with only one eye, reflecting the crucial role of SHH in the 
differentiation of embryonic body axes. Currently the design of a fully synthetic 
cyclopamine analogon is underway. Another potential inhibitor of SHH signal might be 
HMG reductase inhibitors, such as statins. HMG reductase inhibitors are necessary to 
process the functional SHH molecule. To date, there are no studies available on the effect of 
statin-dependent downregulation of SHH signals by statins and its effects on clinical 
outcome in the field of gastric cancer. 
4.5 Notch signalling pathway and gastric cancer 
Notch signalling belongs to the morphogenic embryonic signalling pathways. Notch is 
involved in the regulation of cellular proliferation, apoptosis and differentiation. It 
participates in organ development and mediates lateral inhibition of neighboring cells. The 
receptor (notch) and its activating ligand (delta) are located on the cell surface of two 
different cells. The binding of delta to its receptor notch leads to a two-step cleavage of the 
receptor. The intracellular receptor residue then moves to the nucleus where it forms a 
complex with other proteins and in turn promotes specific gene expression. Notch-specific 
target genes encode for several members of the Hes-family (regulation of embryonic 
neurodermal development), CD 25 (interleukin receptor 2, parts of the T-cell receptor), 
GATA3 (transcription factor for T-cell maturation), c-myc, cyclin D1, p21 bcl-2 [40-46]. 
Upregulated notch signalling by the ligand Jagged1 has been reported to occur frequently in 
gastric cancer. This upregulation was associated with poorer survival. To date, there is no 
target-specific treatment introduced in the current literature.  
4.6 The transforming growth factor beta (TGFbeta)/ bone morphogenic protein (BMP) 
family and signalling pathways in gastric cancer 
TGFbeta-signalling is another member of the family of embryonic developmental pathways. 
In cancers, TGFbeta signalling has a bivalent function: at an early tumor stage it serves as a 
tumor suppressor by inhibiting proliferation and promoting cellular differentiation as well 
as apoptosis. These processes are regulated via theRunx3 and the SMAD4 protein [17]. 
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During cancer progression, the corresponding genes are silenced by methylation or 
otherwise undergo loss of function. The tumor suppressive function changes dramatically in 
advanced tumor stages where BMP promotes tumor angiogenesis, cell motility and the 
interaction of tumor cells with the interstitium. Furthermore, the immune response is 
suppressed by BMP [47,48]. The tumor promoting function is realized via several MAP 
kinase signalling pathways. 
Similarly, BMP signals have bivalent functions: whereas BMP is upregulated in gastric 
inflammation it is downregulated in gastric cancer. On the other hand, BMP2 has been 
shown to promote tumor cell motility and, thus, invasiveness of gastric cancer. Furthermore, 
activins that constitute another subgroup of the TGFbeta/ BMP superfamily have tumor 
suppressive effects via activation of several caspases (pro-apoptotic),  activation of p21 (cell 
cycle arrest) and downregulation of bcl-2 (anti-apoptotic) [49]. In summary, TGFbeta, BMP 
and activin signals can be regarded as a tumor suppressive mechanism restricted to certain 
stages of tumor progression [17]. 
In scirrhous gastric cancer cell lines it has been observed that treatment with two novel 
TGFbeta receptor 1 inhibitors (Ki26894 and A-77) decreases biological tumor progression 
features, such as invasiveness and epithelial-mesenchymal transition. These compounds are 
potential targeted drugs for metastatic scirrhous gastric cancer in the future [17,50,51]. 
4.7 Cell cycle dysregulation in gastric cancer 
The cell cycle is strictly regulated by a broad variety of controlling factors. To move the cell 
cycle machinery forward, several checkpoints that control the entry to the next cell cycle 
phase have to be passed [52]. The most important checkpoint is the G1/S-checkpoint which 
regulates the initiation of cell division [53]. Under physiological conditions growth factors 
and other signals are needed to open the gate but in cancer cells the cell cycle can be active 
without the presence of activating signals and furthermore might be accelerated by 
overexpressed growth factors as mentioned above. Figure 2 illustrates the different 
checkpoints as an overview. 
Both cyclin D and E in combination with the corresponding cyclin dependent kinase CDK 
4/6 and CDK2 are essential for the S phase entry and the subsequent activation of the 
retinoblastoma protein [54]. Both cyclin D1 and 2 are known to be frequently upregulated in 
gastric cancer [17,54]. Cyclin D subtypes are downstream targets of several signalling 
pathways (Notch, SHH, WNT) whereas cyclin E has been reported to be upregulated by 
gene amplification in about 15% of gastric cancer cases [55]. 
The TP-53 tumor suppressor gene is due to its various functions also called the “guardian 
of the genome”. The protein p53 recognizes signals that point to DNA damage, initiates 
cell cycle arrest for damage repair (by activating target genes that encode for p21), 
functions as a transcription factor that activates expression of DNA repair genes and also 
can promote cell death via apoptosis in cases of irreparable DNA damage [56]. About 50% 
of all tumors and 40% of gastric cancer cases present with TP-53 mutations resulting in a 
loss of p53 function. Loss of p53 is frequently associated with advanced tumor stages and 
undifferentiated tumors reflecting the increased accumulation of mutations within the 
tumor cell genome [57]. 
The loss of function of the tumor suppressor p21 occurs in 60% of gastric cancer cases and is 
associated with increased invasiveness, metastasis and poor prognosis. Moreover, the 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
78
This deactivation leads to accumulation of a nuclear factor (Gli) which is normally degraded 
by the functional multiprotein complex. Eventually, specific genes encoding proteins, such 
as cyclin D2, patched and Gli (positive feedback) are activated. There is a ample crosstalk 
with other signalling pathways, in particular the expression of TGF-beta (TGF-beta 
pathway), the expression of SFRP1 (WNT pathway) and FOXL1 (bone morphogenic 
pathway).  
The sonic hedgehog signalling plays a central role in embryonic development and has been 
shown to be upregulated in a broad variety of malignant tumors [38]. The overexpression of 
both Gli and the receptor patched have been reported in two thirds of gastric cancer cases. It 
has been shown that SHH expression is stronger in intestinal type gastric cancer and tubular 
growth pattern than in diffuse type gastric cancer and mucinous or undifferentiated growth 
pattern [39]. SHH is also overexpressed in non-malignant lesions, such as gastric adenomas 
or intestinal metasplasia. Due to the upregulation of SHH signalling at an early stage of 
cancer development it might serve as an early diagnostic tool in patients who have an 
increased risk for the development of gastric cancer. 
The SHH signalling pathway theoretically could be blocked by cyclopamine. This substance 
was first discovered on sheep that fed on a certain lilieaceous plant (veratrum californicum) 
and delivered lambs with only one eye, reflecting the crucial role of SHH in the 
differentiation of embryonic body axes. Currently the design of a fully synthetic 
cyclopamine analogon is underway. Another potential inhibitor of SHH signal might be 
HMG reductase inhibitors, such as statins. HMG reductase inhibitors are necessary to 
process the functional SHH molecule. To date, there are no studies available on the effect of 
statin-dependent downregulation of SHH signals by statins and its effects on clinical 
outcome in the field of gastric cancer. 
4.5 Notch signalling pathway and gastric cancer 
Notch signalling belongs to the morphogenic embryonic signalling pathways. Notch is 
involved in the regulation of cellular proliferation, apoptosis and differentiation. It 
participates in organ development and mediates lateral inhibition of neighboring cells. The 
receptor (notch) and its activating ligand (delta) are located on the cell surface of two 
different cells. The binding of delta to its receptor notch leads to a two-step cleavage of the 
receptor. The intracellular receptor residue then moves to the nucleus where it forms a 
complex with other proteins and in turn promotes specific gene expression. Notch-specific 
target genes encode for several members of the Hes-family (regulation of embryonic 
neurodermal development), CD 25 (interleukin receptor 2, parts of the T-cell receptor), 
GATA3 (transcription factor for T-cell maturation), c-myc, cyclin D1, p21 bcl-2 [40-46]. 
Upregulated notch signalling by the ligand Jagged1 has been reported to occur frequently in 
gastric cancer. This upregulation was associated with poorer survival. To date, there is no 
target-specific treatment introduced in the current literature.  
4.6 The transforming growth factor beta (TGFbeta)/ bone morphogenic protein (BMP) 
family and signalling pathways in gastric cancer 
TGFbeta-signalling is another member of the family of embryonic developmental pathways. 
In cancers, TGFbeta signalling has a bivalent function: at an early tumor stage it serves as a 
tumor suppressor by inhibiting proliferation and promoting cellular differentiation as well 
as apoptosis. These processes are regulated via theRunx3 and the SMAD4 protein [17]. 
 
Molecular Features and Their Clinical Implications on Gastric Adenocarcinoma 
 
79 
During cancer progression, the corresponding genes are silenced by methylation or 
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incidence of that loss increases with advancing tumor stages. The p27 which is an inhibitor 
of the CDK4-cyclinD complex and the CDK2-cyclinE complex as well arrest the cell cycle at 
the restriction checkpoint [58]. The loss of p27 similarly to p21, occurs in gastric cancer in 
dependence of tumor stage and predicts poor prognosis [59].  
 
 
Fig. 2. Checkpoints of cell cycle 
4.8 Nuclear factor kappa B in gastric cancer  
Nuclear factor kappa B (NFkappaB) is a quick-time transcription factor that modulates the 
immune reaction and regulates proliferation and apoptosis. Extracellular signals 
(interleukin 1beta, tumor necrosis factor alpha via their receptors) as well as free radicals, 
bacterial and viral antigens are transmitted to the nucleus within minutes. This is 
accomplished by storing NFkappaB bound to a complex (IkappaB) in the cytoplasma from 
which NFkappa B is mobilized via inactivation of IkappaB by a IkappaB specific kinase 
(IKK). The free NFkappaB molecule can then move within the nucleus and activate specific 
genes like cytokines (IL-6, IL-1beta, TNF), chemokines (IL-8, CCL2, CCL3), enzymes (iNOS, 
COX-2) and adhesion molecules (VCAM-1, ICAM-1, CEACAM-1) which in turn promote 
inflammatory processes [60]. 
NFkappaB plays a central role in inflammatory cancers. Dysregulation of the NFkappaB has 
been observed in gastric cancer to be associated with increased proliferation, genomic 
instability and drug resistance [61,62]. 
There is a variety of phytochemicals, such as silibinin, resveratrol and catechins which are 
known to suppress the activation of NFkappaB. Also, several poly-phenol bonds (green tea) 
can act as anti-cancer drugs. Furthermore, inhibitors of IKK are studied at a preclinical 
stage [60].  
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4.9 S-100 proteins in gastric cancer 
The S-100 protein family currently counts 21 members which are responsible for various 
cellular functions, in particular they are assumed to be second messenger molecules which 
interact with numerous different molecules. S-100A2, 3, 4, 7 and 10 have been observed to be 
overexpressed in gastric cancer.  
S-100A4 is regulated by epigenetic mechanisms and by beta-catenin. Overexpressed S-100A4 
was associated with advanced tumor stages, diffuse type gastric cancer and increased 
incidence of tumor lymph node involvement [63]. S-100A4 has been demonstrated to be 
upregulated predominantly in early stages of gastric cancer [64], other studies associated 
this protein to metastasis in several tumors and, therefore, it is also named metastasin. S-
100A4 has a multitude of binding partners, such as E-cadherin, p53, actin and p37 among 
many others. Interestingly, S-100A4 is one of the strongest molecular based predictors of 
survival in patients with ovarian carcinoma, pancreatic cancer and gastric cancer [65]. 
Moreover, calcyclin-binding protein has been shown to inhibit proliferation and 
invasiveness in gastric cancer by promoting S-100-protein ubiquitinylation which might be a 
potential target-specific treatment option in the future [66]. 
4.10 Dysregulated DNA repair mechanisms 
The accurate transfer of genetic information through the DNA replication and cell division 
machinery is dependent on both, exact DNA synthesis procedure and sufficient DNA 
damage repair systems. Moreover, the DNA is permanently  exposed to toxic metabolites, 
such as oxygen radicals and to physical stress, such as ultraviolet radiation. In addition, 
spontaneous mutations and DNA methylation occur. In particular, 4 basic mechanisms of 
DNA repair exist: 1.) the single base excision system, 2.) mismatch repair system, 3.) the 
nucleotide excision repair system and 4.) the double strand break repair system. 
The single base excision system removes defective and modified bases. Therefore, two 
mechanisms exist: either the aberrant base is recognized and selectively removed by specific 
DNA glycosylases resulting in an apurinic or apyrimidic ribosyl residue which is in turn 
cleaved by a AP endonuclease; or the base is repaired directly without removing. 
The mismatch repair system recognizes mismatched single bases, small single strand loops 
and the recombination of non-homologous sequences. Heterodimers from MLH2, 3 and 6 
recognize and bind to those DNA loci which in turn leads to the recruitment of further 
proteins (helicase, single strand binding protein, MSH, and others) forming a protein 
complex. Hereditary defects in this system are known as as the Lynch syndrome. 
The nucleotide excision repair system in particular is responsible for recognizing and 
repairing DNA damage that is caused by solar radiation. As a logical consequence those 
patients who have genetic defects concerning this system primarily present with dermal 
diseases due to the direct exposition of the skin to solar radiation (e.g. xeroderma 
pigmentosum). It is the only one repair system that is able to remove bulky adducts (dimers 
of pyrimidin and cyclobutan) and remove up to 32 nucleotides. More than 30 genes are 
involved in that repair mechanism system.  
The double strand break repair system can either act with homologous recombination (HR) 
immediately behind the replication fork or can act with non-homologous endjoining 
(NHEJ). The first mechanism requires a sister chromatide which is not available during G0 
and G1 phase, therefore in these phases of cell cycle only NHEJ can be performed. The 
frequently discussed tumor suppessor proteins BRCA1 and 2 are involved in the HR repair 
system [67,68]. 
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Defective DNA repair systems cause the accumulation of mutations which can lead to 
transformation provided that the mutation provides a selection benefit. Therefore, it is not 
surprising that genetic defects in DNA repair are associated with the development of 
malignant tumors, as it is the case in about 15% of all colorectal cancer cases as well as in 
other tumor entities like ovarian carcinoma and endometrial carcinoma. For gastric cancer it 
has been reported that about 8% of sporadic cases show microsatellite instability pointing to 
defective DNA mismatch repair [69]. 
PARP inhibitors which block the enzyme poly(ADP-ribose) polymerase might a become 
potential target specific therapy in cases of mutated BRCA1 and 2. The substance psoralen 
that induces interstrand crosslinks is investigated in preclinical studies [67].  
5. Conclusion 
A growing body of knowledge about the biological behavior as well as the molecular nature 
of gastric cancer is available in the current literature. Although there are only few targeted 
treatment strategies implemented in the clinical routine a large number of studies dedicated 
to molecular based strategies is currently underway. 
This chapter also implicates that there is a complex pattern of molecular mechanisms that 
extend the interpretation of gastric cancer in addition to classifications that are exclusively 
based on macroscopic and histological findings. The pattern of genetic imbalances and of 
dysregulated pathways is of essential importance to treat patients in a more individualized 
fashion. 
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1. Introduction 
Gastric cancer (GC) is the most of common cancers, and is especially common in the Andean 
region of South America and in the Far East (Parkin, Pisani and Ferlay 1999). It can spread 
throughout the stomach and to other organs, including the esophagus, lungs, lymph nodes 
or liver. Therefore, gastric cancer is the second leading cause of cancer-related death in the 
world (Kim et al. 2011). Currently, it remains as one of common cancer types and still be a 
leading cause of cancer-related death. The development and progression of gastric cancer 
have been characterized by multiple genetic mutations of proto-oncogenes and tumor-
suppressor genes (Wu et al. 2010, Wang et al. 2010).  
MicroRNAs (miRNAs) are endogenous non-protein-coding short RNAs of 21-23 
nucleotides (Kim, 2005; Bartel, 2004). It was initially discovered in Caenorhabditis elegans 
and thousands have been identified in many organisms, including human, mammals, 
invertebrates, insects, plants and viruses. In humans, miRNAs play important roles in 
cellular physiology, development, and disease by negatively regulating gene expression 
(Kim, 2005; Bartel, 2004). miRNAs regulate their target genes through targeting 3-UTR 
region of the gene. While miRNA is imperfect pairing with target gene mRNAs, it may 
lead to translational repression. Therefore, when perfectly paired with targeting genes, 
the result was cleavage of the target mRNAs. Depending on their respective target genes, 
miRNAs could act as tumor-suppressive or in an oncogenesis role. Tumor suppressive 
miRNAs have usually repressed growth-promoting genes, and oncogenic miRNAs 
targeted cell growth inhibiting genes.  
Previous studies have used an miRNA profiling approach to investigate the function of the 
miRNA in gastric cancer, showing many miRNAs aberrantly overexpressed or 
downregulated in gastric cancer progression. Various mechanisms contribute to miRNA 
aberrant expression during gastric carcinogenesis, including genetic mutation, epigenetic 
silencing and deregulated transcriptional activity. In this review, we will discuss the 
detailed mechanisms of miRNA deregulation, such as epigenetic alteration and transcriptional 
activity in gastric cancer progression. Based on their target genes, we further discuss miRNAs 
involved in important biological process related to cell growth, cell cycles, apoptosis and cell 
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migration. These miRNA candidates can be used as candidate biomarkers for the detection 
of gastric cancer and monitoring recurrence. 
2. Alteration of miRNA in gastric cancer 
Since miRNA had been shown as a significant factor during gastric cancer progress, global 
miRNA expression profiles have been performed using microarray, real-time PCR, or next-
generation sequencing approaches. The identified dysregulated miRNAs in gastric cancer 
are listed in Table 1 (Katada et al., 2009a; Guo et al., 2009; Ueda et al., 2010; Ribeiro-dos-
Santos et al., 2010; Luo et al., 2009; Tsukamoto et al., 2010). 
 
 
Table 1. Summary of the dysregulation of miRNAs in gastric cancer 
However, the factors causing miRNA dysregulation are very complex. The process is 
composed of multiple steps, including (1) pri-miRNA transcriptional regulation; (2) miRNA 
maturation process; (3) genetic alteration. The miRNAs serve as tumor suppressors or 
oncogenes depending on their target genes. Therefore, we have reviewed previous studies 
which have elucidated the mechanism of dysregulated miRNAs and their confirmed targets 
during gastric cancer progress, and we have listed these important studies in Table 2.     
3. Mechanism of miRNA deregulation in gastric cancer 
There is a lot of information on aberrantly expressed miRNAs and their tumorigenic effect 
in gastric cancers, but the clear mechanisms of such miRNA deregulation remain poorly 
understood. Recent studies have identified some possible mechanisms including epigenetic 
alteration and deregulated transcription. 
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3.1 Epigenetic regulation of miRNAs expression in gastric cancer  
Epigenetic regulation includes histone modification and DNA methylation, processes which 
are involved in regulation of cell growth and development in mammals. DNA methylation 
 
 
Table 2. Studies confirming aberrant miRNAs expressed in gastric carcinoma 
plays an important role in regulation of gene expression through establishing and 
maintaining the DNA methylation status of gene promoters. Previous studies have 
demonstrated that abnormal methylation patterns lead to gastric carcinogenesis through the 
hypermethylated promoter of tumor suppressor genes (Watanabe & Maekawa, 2010). The 
basic transcription mechanism of miRNA is fundamentally similar to that of classic protein-
coding genes, hence, the hypermethylated promoter region of tumor-suppressive miRNAs 
may result in gastric cancer formation and progression. Recently, we identified the 48 
methylation-regulated miRNAs in AGS cells using a real-time PCR microRNA expression 
profile (Tsai et al., 2009). In this profile, our laboratory first identified a primate-specific 
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miRNA cluster (C19MC) comprising 46 pre-miRNAs, C19MC, which could be co-regulated 
in placenta tissue by methylating its distal CpG-rich domain (Tsai et al., 2009; Noguer-Dance 
et al., 2010). A recent study showed that C19MC displays a maternal-specific methylation 
imprint acquired in oocytes (Noguer-Dance et al., 2010). Saito et al. reported that epigenetic 
activation of miR-512-5p induces suppression of Mcl-1, resulting in apoptosis of gastric cancer 
cells (Saito et al., 2009). Accumulating evidence indicates that several tumor-suppressive 
miRNAs have been shown to contain the aberrant hypermethylation of their promoter 
regions in human cancers, including miR-9, miR-34b/c, miR-129, miR-137, miR-181C, miR-
199a, miR-212, miR-512 and miR-516 (Cheung et al., 2011; Luo et al., 2009; Saito et al., 2009; 




Fig. 1. Schematic diagram depicting miRNA dysregulation and its function in gastric 
carcinogenesis. 
Hypermethylation silencing miR-129 expression is associated with a poor clinical outcome 
in gastric cancer, and restoration of miR-129 downregulated SOX4 and Cdk6 expression. 
Overexpression of miR-129-2 could inhibit cell growth and induce apoptosis through 
suppression of its target genes in gastric cancer cells (Shen et al., 2010; Tsai et al., 2011; Wu et 
al., 2010a). Hypermethylation leads miR-9 underexpression and affects cell growth and the 
cell cycle through regulating NF-B1, CDX2, RAB34 (Luo et al., 2009; Rotkrua et al., 2011; 
Wan et al., 2010). Transfection of an anti-miR-9 molecule significantly inhibited cell growth 
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by promoting G1 cell cycle arrest in MKN45 cells similarly to the effect of CDX2 (Rotkrua et 
al., 2011).  
Tumor-specific transcriptional repression via promoter hypermethylation is often associated 
with the silencing of tumor suppressive miRNA. Interestingly, a DNA-methylation-
dependent transcriptional regulation of oncomir, miR-196b, was dramatically overexpressed 
in gastric cancer tissue samples with a hypomethylated promoter (Tsai et al., 2010). 
Therefore, DNA methylation plays a critical role in gastric cancer, and involved in the 
control of the imprinting genes during developmental stages, or tumor-suppressive 
miRNAs / oncomirs in gastric tumor development (Figure 2). 
 
 
Fig. 2. Schematic diagram depicting miRNA regulation by DNA methylation in gastric 
carcinogenesis. 
3.2 Deregulated transcription of miRNAs in gastric cancer 
Like the classic protein-coding genes, the possibility of up- or downregulation of miRNAs 
could also be controlled by transcription factors. E2F1 transcription factor could directly 
upregulate the transcription of miR-106b-25 cluster in gastric cancer cells. Conversely, miR-
106b and miR-93 regulate E2F1 expression, establishing a miRNA-directed negative 
feedback loop (Petrocca et al., 2008). Shin et al. found that miR-16 and miR-21 are directly 
regulated by the transcription factor NF-B in nicotine-treated gastric cancer cells (Shin et 
al., 2011). miR-34 was thereby demonstrated to be involved in the network and tumor 
suppressing pathways of p53 as a downstream target of p53 (Ji et al., 2008). Alteration of 
genes involved in miRNA processing could also contribute to miRNA deregulation. Recent 
studies reported that both Ago2 and TNRC6A are related to the execution of the gene-
silencing function of miRNA, and are observed in gastric cancer with high microsatellite 
instability (Kim et al., 2010). It has been reported the expression of Dicer1 and Drosha are 
different in non-neoplastic and neoplastic gastric tissues (Tchernitsa et al., 2010). 
4. Putative role of miRNAs in gastric cancer 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
90
miRNA cluster (C19MC) comprising 46 pre-miRNAs, C19MC, which could be co-regulated 
in placenta tissue by methylating its distal CpG-rich domain (Tsai et al., 2009; Noguer-Dance 
et al., 2010). A recent study showed that C19MC displays a maternal-specific methylation 
imprint acquired in oocytes (Noguer-Dance et al., 2010). Saito et al. reported that epigenetic 
activation of miR-512-5p induces suppression of Mcl-1, resulting in apoptosis of gastric cancer 
cells (Saito et al., 2009). Accumulating evidence indicates that several tumor-suppressive 
miRNAs have been shown to contain the aberrant hypermethylation of their promoter 
regions in human cancers, including miR-9, miR-34b/c, miR-129, miR-137, miR-181C, miR-
199a, miR-212, miR-512 and miR-516 (Cheung et al., 2011; Luo et al., 2009; Saito et al., 2009; 




Fig. 1. Schematic diagram depicting miRNA dysregulation and its function in gastric 
carcinogenesis. 
Hypermethylation silencing miR-129 expression is associated with a poor clinical outcome 
in gastric cancer, and restoration of miR-129 downregulated SOX4 and Cdk6 expression. 
Overexpression of miR-129-2 could inhibit cell growth and induce apoptosis through 
suppression of its target genes in gastric cancer cells (Shen et al., 2010; Tsai et al., 2011; Wu et 
al., 2010a). Hypermethylation leads miR-9 underexpression and affects cell growth and the 
cell cycle through regulating NF-B1, CDX2, RAB34 (Luo et al., 2009; Rotkrua et al., 2011; 
Wan et al., 2010). Transfection of an anti-miR-9 molecule significantly inhibited cell growth 
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by promoting G1 cell cycle arrest in MKN45 cells similarly to the effect of CDX2 (Rotkrua et 
al., 2011).  
Tumor-specific transcriptional repression via promoter hypermethylation is often associated 
with the silencing of tumor suppressive miRNA. Interestingly, a DNA-methylation-
dependent transcriptional regulation of oncomir, miR-196b, was dramatically overexpressed 
in gastric cancer tissue samples with a hypomethylated promoter (Tsai et al., 2010). 
Therefore, DNA methylation plays a critical role in gastric cancer, and involved in the 
control of the imprinting genes during developmental stages, or tumor-suppressive 
miRNAs / oncomirs in gastric tumor development (Figure 2). 
 
 
Fig. 2. Schematic diagram depicting miRNA regulation by DNA methylation in gastric 
carcinogenesis. 
3.2 Deregulated transcription of miRNAs in gastric cancer 
Like the classic protein-coding genes, the possibility of up- or downregulation of miRNAs 
could also be controlled by transcription factors. E2F1 transcription factor could directly 
upregulate the transcription of miR-106b-25 cluster in gastric cancer cells. Conversely, miR-
106b and miR-93 regulate E2F1 expression, establishing a miRNA-directed negative 
feedback loop (Petrocca et al., 2008). Shin et al. found that miR-16 and miR-21 are directly 
regulated by the transcription factor NF-B in nicotine-treated gastric cancer cells (Shin et 
al., 2011). miR-34 was thereby demonstrated to be involved in the network and tumor 
suppressing pathways of p53 as a downstream target of p53 (Ji et al., 2008). Alteration of 
genes involved in miRNA processing could also contribute to miRNA deregulation. Recent 
studies reported that both Ago2 and TNRC6A are related to the execution of the gene-
silencing function of miRNA, and are observed in gastric cancer with high microsatellite 
instability (Kim et al., 2010). It has been reported the expression of Dicer1 and Drosha are 
different in non-neoplastic and neoplastic gastric tissues (Tchernitsa et al., 2010). 
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Previous studies revealed a broad variety of oncogenes and tumor suppressor genes 
regulated by different miRNAs in gastric cancer cells. Recent research has revealed evidence 
showing that miRNAs play roles in the initiation and progression of cancer (Volinia et al., 
2006). Some of these miRNAs modulate expression of known oncogenes or tumor 
suppressor genes, whereas others function as so-called onco-miRs or tumor-suppressor-
miRs. Furthermore, evidence for regulation of carcinogenesis by miRNAs has been 
obtained, including promotion of proliferation, migration, invasion and anti-apoptosis. 
4.1 miRNAs and the cell cycle 
Increased cell proliferation is a common feature of gastric carcinogenesis. The miR-222-221 
and miR-106b-25 clusters have been found abnormally upregulated in gastric cancer tissues 
and reported to suppress the p21 family of CDK inhibitors (p57Kip2, p21Cip1, and p27Kip1) 
(Kim et al., 2009). Ectopic expression of miR-222-221 and miR-106b-25 clusters result in 
activation of CDK2 activity and facilitates the G1/S phase transition. Inhibition of miR-372-
suppressed proliferation, arrested the cell cycle at G2/M phase, and increased apoptosis 
through downregulation of a tumor suppressor gene, LATS2 in gastric cancer cells (Cho et 
al., 2009). Deregulation of E2F1 activity is characteristic of gastric tumorigenesis and Guo et 
al. found that overexpression of miR-331-3p blocked G1/S transition in gastric cancer cell 
lines. miR-331-3p functions in cell cycle control by targeting cell cycle-related molecule E2F1 
(Guo et al., 2010). A previous study provided evidence that downregulation of miR-663 in 
tumor cells may contribute to aberrant cell hyperplasia by indirectly affected upregulation 
of cyclin B, leading to the development of gastric cancer. Therefore, miR-663 might function 
as a potent suppressor of tumor growth (Pan et al., 2010). miR-126 was significantly 
downregulated in gastric cancer tissues. Ectopic expression of miR-126 potently inhibited 
cell growth by inducing cell cycle arrest in G0/G1 phase in gastric cancer cells. miR-126 may 
function as a tumor suppressor, and was capable of regulating Crk in gastric cancer (Feng et 
al., 2010). Restoration of the miR-137 expression downregulated the Cdc42 expression and 
induced cell cycle G1 arrest in gastric cancer cells. The miR-137 expression was found to be 
inversely correlated with CDC42 expression in gastric cancer. miR-137 is downregulated in 
gastric cancer and is a indirectly negative regulator of Cdc42 (Chen et al., 2011). Cyclin-
dependent kinase 6 (CDK6) is found to be upregulated in gastric cancer and has been 
implicated in tumor initiation and progression. Feng et al. have identified miR-107 as a 
potential regulator of CDK6 expression. Ectopic expression of miR-107 reduced both mRNA 
and protein expression levels of CDK6, inhibited proliferation, induced G1 cell cycle arrest. 
miR-107 may have a tumor suppressor function by directly targeting CDK6 to inhibit the 
proliferation in gastric cancer cells (Feng et al., 2011). Otsubo et al. demonstrated that SRY 
(sex determining region Y)-box 2 (SOX2)  plays important roles in growth inhibition through 
cell cycle arrest and apoptosis, and that SOX2 expression is frequently downregulated in 
gastric cancers. They found miR-126 targets SOX2 in gastric cancer cells. Aberrant 
overexpression of miR-126 and consequent SOX2 downregulation may contribute to gastric 
carcinogenesis (Otsubo et al., 2011). These findings suggest that aberrant miRNA expression 
may enhance cell-cycle progression through direct or indirect regulation of cell-cycle 
regulators. 
4.2 miRNAs and apoptosis 
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Escape from the process of apoptosis is a hallmark of cellular transformation. miRNA 
dysregulation has been shown to regulate apoptosis by altering the expression of Bcl-2 
family members in gastric cancer. Disturbances in apoptotic pathways lead to uncontrolled 
cell proliferation which indicates a critical step in tumor development.  
Forced expression of miR-21 significantly promoted cell proliferation and inhibited 
apoptosis in gastric cancer cells. Zhang et al. have identified RECK as the direct target of 
miR-21. RECK is a tumor-suppressor gene in gastric cancer and the oncogenic effect of miR-
21 may be mediated by regulation of RECK (Zhang et al., 2008). miR-218 expression was 
reduced significantly in gastric cancer tissues and overexpression of miR-218 inhibited cell 
proliferation and induced apoptosis in gastric cancer cells through direct targeting of 
Epidermal growth factor receptor-coamplified and overexpressed protein (ECOP), a positive 
regulator of NF-B transcriptional activity. Overexpression of miR-218 also inhibited NF-B 
transcriptional activation and transcription of cyclooxygenase-2, a proliferative and anti-
apoptotic gene regulated by NF-B (Gao et al., 2010). Overexpression of miR-150 in gastric 
cancer could promote proliferation and growth of cancer cells through directly targeting the 
tumor-suppressor EGR2, whose activation induces apoptosis (Wu et al., 2010b). 
RUNX3 is an important tumor suppressor that is inactivated in many cancer types. miR-
130b expression was significantly higher in gastric tumors, and overexpression of miR-130b 
has also been reported to suppress TGF-mediated Bim expression and apoptosis by 
targeting RUNX3 in gastric cancer cells (Lai et al., 2010). miR-375 was greatly 
downregulated in gastric cancer tissues, and its ectopic expression in gastric carcinoma cells 
reduced cell viability via the caspase dependent apoptosis pathway. miR-375 suppresses the 
Akt phosphorylation pathway through direct targeting of PDK1, a kinase that 
phosphorylates Akt. In addition to PDK1, miR-375 also targets 14-3-3zeta, a potent anti-
apoptotic gene, indicating that miR-375 is a candidate tumor suppressor miRNA in gastric 
carcinoma (Tsukamoto et al., 2010).  
Chen et al. previously found that miRNA-200c could not only induce the expression of E-
cadherin, but also increase the sensitivity of gastric cancer cells to cisplatin. miRNA-200c can 
indirectly regulate apoptosis through E-cadherin in gastric cancer cells, which may be a 
possible mechanism of miRNA-200c in inhibiting proliferation (Chen et al., 2010). SOX2 
plays important roles in growth inhibition through cell cycle arrest and apoptosis, and that 
SOX2 expression is downregulated in gastric cancers. Otsubo et al. revealed that miR-126 
inhibited SOX2 expression by targeting two binding sites in the 3'-untranslated region (3'-
UTR) of SOX2 mRNA. In addition, the authors found that expression of the placenta-specific 
1 (PLAC1) gene was significantly downregulated by SOX2. These results indicate that miR-
126 is a novel miRNA that targets SOX2, and PLAC1 may be a novel downstream target 
gene of SOX2 in gastric cancer cells (Otsubo et al., 2011). Hou et al. showed decreased 
expression of miR-146a in gastric cancer and low expression of miR-146a was correlated 
with increased tumor size and poor differentiation. Overall survival time of patients with 
high miR-146a expression was significantly longer than that of patients with low expression 
of miR-146a. Overexpression of miR-146a inhibited cell proliferation and induced apoptosis 
in gastric cancer cells. miR-146a has potential as a novel suppressor gene in gastric cancer 
(Hou et al., 2011). 
4.3 miRNAs and proliferation 
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Epidermal growth factor receptor-coamplified and overexpressed protein (ECOP), a positive 
regulator of NF-B transcriptional activity. Overexpression of miR-218 also inhibited NF-B 
transcriptional activation and transcription of cyclooxygenase-2, a proliferative and anti-
apoptotic gene regulated by NF-B (Gao et al., 2010). Overexpression of miR-150 in gastric 
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reduced cell viability via the caspase dependent apoptosis pathway. miR-375 suppresses the 
Akt phosphorylation pathway through direct targeting of PDK1, a kinase that 
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indirectly regulate apoptosis through E-cadherin in gastric cancer cells, which may be a 
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plays important roles in growth inhibition through cell cycle arrest and apoptosis, and that 
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1 (PLAC1) gene was significantly downregulated by SOX2. These results indicate that miR-
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miR-27a is upregulated in human gastric adenocarcinoma and was identified as an 
oncogenic miRNA in a gastric cancer cell line, in which it targets the tumor suppressor 
prohibitin, an evolutionary conserved and ubiquitous protein interacting with pRb and its 
family members. Downregulation of prohibitin by miR-27a may explain why suppression of 
miR-27a can inhibit gastric cancer cell growth (Liu et al., 2009). In p53-mutant human gastric 
cancer cells, overexpression of miR-34 increases caspase-3 activation and impairs the 
tumorsphere formation and growth, accumulating the cells in G1 phase. Restoration of miR-
34 expression resulted in a downregulation of Bcl-2, Notch1 and HMGA2, indicating that 
miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation pathways (Ji 
et al., 2008). The expression of oncogene macrophage migration inhibitory factor (MIF) has 
been shown to be targeted by miR-451, whose expression is downregulated in gastric 
cancer. Bandres and colleagues show that the restoration of miR-451 in gastric cancer cells 
led to downregulation of the MIF gene, which is accompanied by reduction in cell 
proliferation and increased sensitivity to radiotherapy. In addition, a significant inverse 
correlation was found between miR-451 and MIF expression in gastric cancer biopsies 
(Bandres et al., 2009). Human miR-141, a member of the miR-200 family, has been reported 
to be associated with various tumorigenesis processes. Du et al. found that miR-141 was 
expressed at significantly low levels in primary gastric cancer, and overexpression of miR-
141 could inhibit the proliferation of gastric cancer cell lines. These results suggest that miR-
141 may be involved in the development of gastric cancer through its inhibitory effect on 
cell proliferation (Du et al., 2009). 
miR-9 was downregulated in gastric cancer and targeted NF-B1 and thereby suppressing 
NF-B transcriptional activity. Restoration of miR-9 expression suppressed the proliferation 
of gastric cancer cells. NF-B has been shown to be directly targeted by miRNA in gastric 
cancer. Aberrant activation of NF-B signaling as a result of miRNA dysregulation may be 
an important molecular event in gastric tumorigenesis (Wan et al., 2010). Besides PDK1 and 
14-3-3zeta, forced expression of miR-375 in gastric cancer cells significantly reduced the 
protein level of Janus kinase 2 (JAK2), indicating that JAK2 may be a miR-375 target gene. 
Moreover, ectopic expression of JAK2 can partially reverse the inhibition of cell proliferation 
caused by miR-375 and a significant inverse correlation between miR-375 expression and 
JAK2 protein level in gastric cancer (Ding et al., 2010). 
Zhang et al. show that miR-650 is involved in lymphatic and distant metastasis in human 
gastric cancer. Ectopic expression of miR-650 promotes tumorigenesis and proliferation of 
gastric cancer cells through directly targeting the Inhibitor of Growth 4 (ING4) protein 
(Zhang et al., 2010). Ectopic expression of miR-29s significantly reduced the expression of 
Cdc42 and its downstream molecular PAK1 phosphorylation levels, and inhibited 
proliferation and migration in gastric cancer cells (Lang et al., 2010). miR-221 and miR-222 
were discovered to induce cell growth and cell cycle progression via direct targeting of 
p27Kip1 in various human cancers. Upregulation of miR-221 and miR-222 induced the 
malignant phenotype of gastric cancer cells, in addition, knockdown of miR-221 and miR-
222 inhibited cell growth and invasion and increased the radiosensitivity of gastric cancer 
cells. These results demonstrate that miR-221 and miR-222 regulate radiosensitivity, and cell 
growth and invasion, possibly via direct modulation of PTEN expression (Chun-Zhi et al., 
2010). Previous study showed that miR-23a was significantly upregulated in gastric 
adenocarcinoma tissues and miR-23a has been found to function as a growth-promoting 
factor in gastric cancer cells. Zhu et al. identified IL6R as a direct target gene for miR-23a 
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and demonstrated that miR-23a can target IL6R and promote the growth activity of gastric 
adenocarcinoma cells in vitro (Zhu et al., 2010a). Song et al. found that miR-199a is highly 
expressed in gastric cancer tissues. miR-199a positively regulated gastric cancer cell 
proliferation through directly targeting the mitogen-activated protein kinase kinase kinase 
11. The level of miR-199a expression in gastric cancer significantly correlated with clinical 
progression (Song et al., 2010). Expression of miR-203 was not significant in gastric cancer 
tissues compared to non-tumor counterparts, but miR-203 was correlated with tumor size, 
macroscopic type, and pT stage and miR-203 can inhibit the cell proliferation in gastric 
cancer cells. miR-203 may be associated with the proliferation of gastric cancers (Chiang et 
al., 2011). 
Ectopic miR-16 or miR-21 expression has exhibited an effect on cell proliferation, and is 
mediated via EP2/4 receptors (Shin et al., 2011). MicroRNA microarray analyses revealed 
that miR-192 and -215 were significantly more upregulated in gastric carcinomas than in 
non-neoplastic stomach. In addition, expression levels of ALCAM were significantly lower 
in gastric cancers. Western blotting and luciferase assays were performed to confirm direct 
activated leukocyte cell adhesion molecule (ALCAM) targeting by miR-192 and -215. Both 
miR-192 and -215 are overexpressed in vivo and exert cell growth -promoting effects in vitro 
(Jin et al., 2010). Previous studies have revealed that miR-148a and miR-152 are significantly 
downregulated in gastrointestinal cancers. The purpose of this study was to elucidate the 
molecular mechanisms by which miR-148b acts as a tumor suppressor in gastric cancer. 
Song et al. showed significant downregulation of miR-148b in gastric cancer tissues and four 
gastric cancer cell lines. The authors also found that miR-148b could inhibit cell proliferation 
in vitro and suppress tumorigenicity in vivo. CCKBR was identified as a target of miR-148b 
in cells, and inverse correlation was observed between the expression of CCKBR protein and 
miR-148b in gastric cancer tissues. These findings indicated that miR-148b targets CCKBR 
and is significant in suppressing gastric cancer cell growth (Song et al., 2011). Ectopic 
expression of CDX2, a caudal-related homeobox protein, is known to be associated with the 
development of gastric tumorigenesis. The inverse correlation between the miR-9 and CDX2 
protein levels was demonstrated in gastric cancer cell lines. Inhibition of miR-9 significantly 
inhibited cell growth by promoting G1 cell cycle arrest in gastric cancer cells. Therefore, 
miR-9 might directly repress CDX2 expression resulting in the promotion of cell 
proliferation in gastric cancers (Rotkrua et al., 2011).  
4.4 miRNA and metastasis 
Migration and invasion are essential aspects of cancer cells metastasis. The high mobility 
group A2 (HMGA2) overexpression is a hallmark of gastric cancer. Motoyama and 
colleagues demonstrated that HMGA2 is negatively regulated by the let-7 miRNA family in 
gastric cancer cell lines. There is an inverse relationship between the expression of let-7 and 
HMGA2 in gastric cancer cell lines and primary gastric cancer tissues. High expression of 
HMGA2 in gastric cancer correlates with tumor invasion and is an independent prognostic 
factor (Motoyama et al., 2008). Zhang et al. also demonstrated that knockdown of miR-21 
significantly decreased cell invasion and migration of gastric cancer cells (Zhang et al., 
2008). miR-27a was found correlated between the tumor size and lymph node metastasis 
and may be associated with the prognosis in undifferentiated gastric cancer patients (Katada 
et al., 2009b). Downregulation of miR-218 is also implicated in metastatic gastric cancer. 
Robo1, one of several Slit receptors, is negatively regulated by miR-218. It has been shown 
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HMGA2 in gastric cancer cell lines and primary gastric cancer tissues. High expression of 
HMGA2 in gastric cancer correlates with tumor invasion and is an independent prognostic 
factor (Motoyama et al., 2008). Zhang et al. also demonstrated that knockdown of miR-21 
significantly decreased cell invasion and migration of gastric cancer cells (Zhang et al., 
2008). miR-27a was found correlated between the tumor size and lymph node metastasis 
and may be associated with the prognosis in undifferentiated gastric cancer patients (Katada 
et al., 2009b). Downregulation of miR-218 is also implicated in metastatic gastric cancer. 
Robo1, one of several Slit receptors, is negatively regulated by miR-218. It has been shown 
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that reduced expression of miR-218 in gastric cancer results in upregulation of its target 
Robo1, one of several Slit receptors, enhancing Slit/Robo1 signaling. Tie et al. demonstrated 
that restoration of miR-218 expression inhibits invasion and metastasis of gastric cancer cells 
in vitro and in vivo (Tie et al., 2010). Lang et al. found that ectopic expression of miRNA-29s 
inhibited migration in gastric cancer cells. Members of the miR-29 family can obviously 
inhibit migration and invasion of gastric cancer cells by targeting Cdc42 (Lang et al., 2010). 
The expression of let-7a was significantly lower in gastric carcinomas with lymph node 
metastasis than in those without metastasis (Zhu et al., 2010c). let-7 miRNAs generally play 
a tumor-suppressive role as shown in targeting oncogenes such as RAS and HMGA2 
(Ohshima et al., 2010). The expression of miR-101 is downregulated in gastric cancer tissues 
and cells, and ectopic expression of miR-101 significantly inhibits cellular migration and 
invasion of gastric cancer cells. miR-101 may inversely regulate EZH2, Cox-2, Mcl-1 and Fos. 
These might indicate that miR-101 may function as a tumor suppressor in gastric cancer, as 
it has an inhibitory role in cellular proliferation and metastasis (Wang et al., 2010). Li et al. 
demonstrate that miR-107 is frequently upregulated in gastric cancers and its 
overexpression is significantly associated with gastric cancer metastasis. Furthermore, 
subsequent investigation characterized DRCE1 as a direct target of miR-107. These results 
suggested that miR-107 is an oncogene miRNA promoting gastric cancer metastasis through 
downregulation of DRCE1 (Li et al., 2010). miR-199a is highly expressed in metastatic gastric 
cancer tissues. MiR-199a positively regulated gastric cancer migration and invasion. Further 
studies showed that mitogen-activated protein kinase kinase kinase 11 was significantly 
downregulated by miR-199a and the level of miR-199a expression in gastric cancer 
significantly correlated with clinical progression (Song et al., 2010). Expression levels of both 
miR-192 and -215 were significantly higher in gastric cancer. miR-215 inhibits activated 
leukocyte cell adhesion molecule (ALCAM) expression at the posttranscriptional level. In 
addition, expression levels of ALCAM were significantly lower in gastric cancer. 
Overexpression of miR-192or -215 and ALCAM knockdown significantly increased the 
migration of gastric cancer cells (Jin et al., 2010). Takei et al. defined miR-516a-3p involved 
in cancer metastasis as a candidate anti-metastatic miRNA. Sulfatase1 is known to remove 6-
O-sulfates from heparan sulfate proteoglycans on the cell surface, causing release of 
membrane-bound Wnt ligands from cells. The authors documented that Sulfatase1 as a 
direct target of miR-516a-3p (Takei et al., 2011). Feng et al. identified miR-107 as a regulator 
of CDK6 expression. Expression of miR-107 in gastric cancer cell lines was found inversely 
correlated with CDK6 expression. Ectopic expression of miR-107 reduced expression of 
CDK6 and blocked invasion in the gastric cancer cells (Feng et al., 2011).. 
4.5 Multidrug resistance (MDR) 
Xia and colleagues demonstrated significant correlations between miRNA expression 
patterns and multidrug resistance, suggesting that miRNAs may play a role in 
chemoresistance. Up- or downregulation of several miRNAs can lead to modified sensitivity 
to anticancer treatments. miR-15b and miR-16 were downregulated in a multidrug resistant 
gastric cancer cell line. Enforced overexpression of miR-15b or miR-16 caused a significant 
increase of apoptosis after vincristine (VCR) therapy. The chemotherapy-sensitizing effect of 
miR-15b and miR-16 were mediated by modulation of apoptosis via targeting BCL2 (Xia et 
al., 2008). Zhu et al. investigated the role of miR-181b in the development of multidrug 
resistance in human the gastric cancer cell line. miR-181b was downregulated in the 
multidrug resistant human gastric cancer cell line. Enforced miR-181b expression reduced 
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BCL2 protein level and sensitized gastric cancer cells to VCR-induced and cisplatin (CDDP)-
induced apoptosis. These findings suggest that miR-181b could play a role in the 
development of MDR in gastric cancer cells by targeting BCL2 (Zhu et al., 2010b). 
5. miRNAs as biomarkers in gastric cancer 
Most patients have advanced gastric cancer at diagnosis, resulting in a high frequency cause 
of death. The survival and prognosis of gastric cancer patients depends on stage of gastric 
cancer (Fujita, 2009). Unfortunately, highly sensitive and specific biomarkers for diagnosis 
and detection of gastric cancer in early stages are lacking. Therefore, it is essential to identify 
molecular biomarkers for early diagnosis and effective monitoring of the progression of 
gastric cancer, as well as for prospective development of therapeutic pharmacological 
reagents. miRNA is a putative candidate to improve diagnostic sensitivity of tumor markers 
for early stage tumors is beneficial for improving the survival rate of gastric cancer patients. 
Accumulating studies have shown the diagnostic and prognostic values of miRNAs in 
gastric cancer. In our study, clinicopathological analysis indicated that low expression of 
miR-34b and miR-129 is associated with a poor clinical prognosis feature (Tsai et al., 2011). 
Ueda et al. reported that low expression of let-7g and miR-433 and high expression of miR-
214 were associated with poor outcome (Ueda et al., 2010). Katada et al. indicated that miR-
20b or 150 overexpression in undifferentiated gastric cancer, and high level expression is 
associated with poor survival in patients (Katada et al., 2009a). A recent study analyzed the 
miRNA expression profile in 65 gastric cancer patients, 29 patients with recurrence and 36 
patients without recurrence. Their results indicated that the combination of miR-375 and 
miR-142 could predict recurrence risk for GC patients (Zhang et al., 2011). 
Recent studies have shown that quantities of circulating miRNAs exist in body fluids, 
including blood, and these miRNAs are derived generally from cell debris or transporting 
exosomes (Chen et al., 2008; Gilad et al., 2008). Chim et al. and Gilad et al. both demonstrate 
that the high abundance of placental miRNA in serum could reflect pregnancy conditions in 
maternal blood (Chim et al., 2008; Gilad et al., 2008). Mitchell et al. demonstrated that 
circulating miRNAs in serum are released from solid tumor, which could serve as a means 
for cancer detection (Mitchell et al., 2008). This cumulative evidence indicated that 
circulating miRNAs in blood might show promise as useful non-invasive biomarkers for 
diagnosis of gastric cancers. Liu et al. (Liu et al., 2011) identified a profile of five serum 
miRNAs (miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p) as a biomarker for GC 
detection and their expression level was well correlated to tumor stage. In large-scale 
analysis, the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) 
were significantly higher in GC patients, and significantly decreased in pre-operative serum 
compared with post-operative serum (Tsukamoto et al., 2010). Concluding above result, 
circulating miRNAs have a good potential to be  novel biomarkers for the detection of 
gastric cancer and monitoring recurrence. 
6. Conclusion 
miRNAs represent a recently identified class of small, noncoding RNA molecules which 
control gene expression at post-transcriptional levels. In the past decade, there is a lot of 
evidence on the critical role of deregulated miRNAs in the pathogenesis and progression of 
human tumors, dysregulation of miRNA occurs in gastric cancer as well as other malignant 
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O-sulfates from heparan sulfate proteoglycans on the cell surface, causing release of 
membrane-bound Wnt ligands from cells. The authors documented that Sulfatase1 as a 
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associated with poor survival in patients (Katada et al., 2009a). A recent study analyzed the 
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patients without recurrence. Their results indicated that the combination of miR-375 and 
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that the high abundance of placental miRNA in serum could reflect pregnancy conditions in 
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control gene expression at post-transcriptional levels. In the past decade, there is a lot of 
evidence on the critical role of deregulated miRNAs in the pathogenesis and progression of 
human tumors, dysregulation of miRNA occurs in gastric cancer as well as other malignant 
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diseases. The mechanisms by which miRNA takes part in tumor promotion and progression 
are various and complex. Most of researchers focus on common signaling mechanisms that 
control cell proliferation, apoptosis and metastasis. The association of miRNA deregulation 
explains great potential of utilizing miRNAs as targets for therapeutic intervention. 
Gene profiling studies have demonstrated a number of significantly deregulated miRNAs 
and identified signatures of both diagnostic and prognostic value in gastric cancer. It has 
been shown that alterations in miRNA expression profiles can be used to estimate and 
monitor the success of potential therapeutic modalities. miRNAs play a role in the 
complicated gene regulation networks, and regulate the expression of multiple genes. Using 
miRNAs in combination with existing therapeutic strategies may synergistically affect the 
results of cancer treatment and improve survival of patients. Therefore, additional studies 
have to be carried out in future to verify the safety and efficiency of such treatment 
combinations in clinical therapies. 
7. References 
Bandres, E., N. Bitarte, F. Arias, J. Agorreta, P. Fortes, X. Agirre, R. Zarate, J. A. Diaz-
Gonzalez, N. Ramirez, J. J. Sola, P. Jimenez, J. Rodriguez & J. Garcia-Foncillas 
(2009) microRNA-451 regulates macrophage migration inhibitory factor production 
and proliferation of gastrointestinal cancer cells. Clinical cancer research : an official 
journal of the American Association for Cancer Research, Vol.15, pp. 2281-90, ISSN 1078-
0432 
Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
Vol.116, 281-97. 
Chen, Q., X. Chen, M. Zhang, Q. Fan, S. Luo & X. Cao (2011) miR-137 Is Frequently Down-
Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42. Dig Dis Sci. 
Vol.116, pp. 281-97, ISSN 0092-8674 
Chen, X., Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang, J. Guo, Y. Zhang, J. Chen, X. Guo, Q. Li, X. Li, 
W. Wang, Y. Zhang, J. Wang, X. Jiang, Y. Xiang, C. Xu, P. Zheng, J. Zhang, R. Li, H. 
Zhang, X. Shang, T. Gong, G. Ning, J. Wang, K. Zen, J. Zhang & C. Y. Zhang (2008) 
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis 
of cancer and other diseases. Cell Res, Vol.18, pp. 997-1006, ISSN 1748-7838 
Chen, Y., J. Zuo, Y. Liu, H. Gao & W. Liu (2010) Inhibitory effects of miRNA-200c on 
chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP 
cells. Chinese journal of cancer, Vol.29, pp. 1006-11, ISSN 1944-446X 
Cheung, H. H., A. J. Davis, T. L. Lee, A. L. Pang, S. Nagrani, O. M. Rennert & W. Y. Chan 
(2011) Methylation of an intronic region regulates miR-199a in testicular tumor 
malignancy. Oncogene. , Vol.15, pp. 63-70, ISSN 1476-5594 
Chiang, Y., Y. Song, Z. Wang, Y. Chen, Z. Yue, H. Xu, C. Xing & Z. Liu (2011) Aberrant 
expression of miR-203 and its clinical significance in gastric and colorectal cancers. 
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the 
Alimentary Tract, Vol.15, pp. 63-70, ISSN 
Chim, S. S., T. K. Shing, E. C. Hung, T. Y. Leung, T. K. Lau, R. W. Chiu & Y. M. Lo (2008) 
Detection and characterization of placental microRNAs in maternal plasma. Clin 
Chem, Vol.54, pp. 482-90, ISSN 0009-9147 
Cho, W. J., J. M. Shin, J. S. Kim, M. R. Lee, K. S. Hong, J. H. Lee, K. H. Koo, J. W. Park & K. S. 
Kim (2009) miR-372 regulates cell cycle and apoptosis of ags human gastric cancer 
 
miRNAs in Gastric Cancer 
 
99 
cell line through direct regulation of LATS2. Mol Cells, Vol.28, pp. 521-7, ISSN 0219-
1032 
Chun-Zhi, Z., H. Lei, Z. An-Ling, F. Yan-Chao, Y. Xiao, W. Guang-Xiu, J. Zhi-Fan, P. Pei-Yu, 
Z. Qing-Yu & K. Chun-Sheng (2010) MicroRNA-221 and microRNA-222 regulate 
gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC 
Cancer, Vol.10, pp. 367, ISSN 
Ding, L., Y. Xu, W. Zhang, Y. Deng, M. Si, Y. Du, H. Yao, X. Liu, Y. Ke, J. Si & T. Zhou (2010) 
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by 
targeting JAK2. Cell Res, Vol.20, pp. 784-93, ISSN 1748-7838 
Du, Y., Y. Xu, L. Ding, H. Yao, H. Yu, T. Zhou & J. Si (2009) Down-regulation of miR-141 in 
gastric cancer and its involvement in cell growth. J Gastroenterol, Vol.44, pp. 556-61, 
ISSN 0944-1174 
Feng, L., Y. Xie, H. Zhang & Y. Wu (2011) miR-107 targets cyclin-dependent kinase 6 
expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. 
Med Oncol. ISSN 1559-131X 
Feng, R., X. Chen, Y. Yu, L. Su, B. Yu, J. Li, Q. Cai, M. Yan, B. Liu & Z. Zhu (2010) miR-126 
functions as a tumour suppressor in human gastric cancer. Cancer Lett, Vol.298, pp. 
50-63, ISSN 1872-7980 
Fujita, T. (2009) Gastric cancer. Lancet, Vol.374, pp. 1593-4; author reply pp. 1594-5, ISSN 
1474-547X 
Gao, C., Z. Zhang, W. Liu, S. Xiao, W. Gu & H. Lu (2010) Reduced microRNA-218 
expression is associated with high nuclear factor kappa B activation in gastric 
cancer. Cancer, Vol.116, pp. 41-9, ISSN 0008-543X 
Gilad, S., E. Meiri, Y. Yogev, S. Benjamin, D. Lebanony, N. Yerushalmi, H. Benjamin, M. 
Kushnir, H. Cholakh, N. Melamed, Z. Bentwich, M. Hod, Y. Goren & A. Chajut 
(2008) Serum microRNAs are promising novel biomarkers. PLoS One, Vol.3, pp. 
e3148, ISSN 1932-6203 
Guo, J., Y. Miao, B. Xiao, R. Huan, Z. Jiang, D. Meng & Y. Wang (2009) Differential 
expression of microRNA species in human gastric cancer versus non-tumorous 
tissues. J Gastroenterol Hepatol, Vol.24, pp. 652-7, ISSN 1440-1746 
Guo, X., L. Guo, J. Ji, J. Zhang, J. Zhang, X. Chen, Q. Cai, J. Li, Q. Gu, B. Liu, Z. Zhu & Y. Yu 
(2010) miRNA-331-3p directly targets E2F1 and induces growth arrest in human 
gastric cancer. Biochem Biophys Res Commun, Vol.398, pp. 1-6, ISSN 1090-2104 
Guo, X., C. Jing, L. Li, L. Zhang, Y. Shi, J. Wang, J. Liu & C. Li (2011) Down-regulation of 
VEZT gene expression in human gastric cancer involves promoter methylation and 
miR-43c. Biochem Biophys Res Commun, Vol.404, pp. 622-7, ISSN 1090-2104 
Hashimoto, Y., Y. Akiyama, T. Otsubo, S. Shimada & Y. Yuasa (2010) Involvement of 
epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis, 
Vol.31, pp. 777-84, ISSN 1460-2180 
Hou, Z., L. Xie, L. Yu, X. Qian & B. Liu (2011) MicroRNA-146a is down-regulated in gastric 
cancer and regulates cell proliferation and apoptosis. Med Oncol. ISSN 1559-131X 
Ji, Q., X. Hao, Y. Meng, M. Zhang, J. Desano, D. Fan & L. Xu (2008) Restoration of tumor 
suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC 
Cancer, Vol.8, pp.266, ISSN 1471-2407 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
98
diseases. The mechanisms by which miRNA takes part in tumor promotion and progression 
are various and complex. Most of researchers focus on common signaling mechanisms that 
control cell proliferation, apoptosis and metastasis. The association of miRNA deregulation 
explains great potential of utilizing miRNAs as targets for therapeutic intervention. 
Gene profiling studies have demonstrated a number of significantly deregulated miRNAs 
and identified signatures of both diagnostic and prognostic value in gastric cancer. It has 
been shown that alterations in miRNA expression profiles can be used to estimate and 
monitor the success of potential therapeutic modalities. miRNAs play a role in the 
complicated gene regulation networks, and regulate the expression of multiple genes. Using 
miRNAs in combination with existing therapeutic strategies may synergistically affect the 
results of cancer treatment and improve survival of patients. Therefore, additional studies 
have to be carried out in future to verify the safety and efficiency of such treatment 
combinations in clinical therapies. 
7. References 
Bandres, E., N. Bitarte, F. Arias, J. Agorreta, P. Fortes, X. Agirre, R. Zarate, J. A. Diaz-
Gonzalez, N. Ramirez, J. J. Sola, P. Jimenez, J. Rodriguez & J. Garcia-Foncillas 
(2009) microRNA-451 regulates macrophage migration inhibitory factor production 
and proliferation of gastrointestinal cancer cells. Clinical cancer research : an official 
journal of the American Association for Cancer Research, Vol.15, pp. 2281-90, ISSN 1078-
0432 
Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
Vol.116, 281-97. 
Chen, Q., X. Chen, M. Zhang, Q. Fan, S. Luo & X. Cao (2011) miR-137 Is Frequently Down-
Regulated in Gastric Cancer and Is a Negative Regulator of Cdc42. Dig Dis Sci. 
Vol.116, pp. 281-97, ISSN 0092-8674 
Chen, X., Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang, J. Guo, Y. Zhang, J. Chen, X. Guo, Q. Li, X. Li, 
W. Wang, Y. Zhang, J. Wang, X. Jiang, Y. Xiang, C. Xu, P. Zheng, J. Zhang, R. Li, H. 
Zhang, X. Shang, T. Gong, G. Ning, J. Wang, K. Zen, J. Zhang & C. Y. Zhang (2008) 
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis 
of cancer and other diseases. Cell Res, Vol.18, pp. 997-1006, ISSN 1748-7838 
Chen, Y., J. Zuo, Y. Liu, H. Gao & W. Liu (2010) Inhibitory effects of miRNA-200c on 
chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP 
cells. Chinese journal of cancer, Vol.29, pp. 1006-11, ISSN 1944-446X 
Cheung, H. H., A. J. Davis, T. L. Lee, A. L. Pang, S. Nagrani, O. M. Rennert & W. Y. Chan 
(2011) Methylation of an intronic region regulates miR-199a in testicular tumor 
malignancy. Oncogene. , Vol.15, pp. 63-70, ISSN 1476-5594 
Chiang, Y., Y. Song, Z. Wang, Y. Chen, Z. Yue, H. Xu, C. Xing & Z. Liu (2011) Aberrant 
expression of miR-203 and its clinical significance in gastric and colorectal cancers. 
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the 
Alimentary Tract, Vol.15, pp. 63-70, ISSN 
Chim, S. S., T. K. Shing, E. C. Hung, T. Y. Leung, T. K. Lau, R. W. Chiu & Y. M. Lo (2008) 
Detection and characterization of placental microRNAs in maternal plasma. Clin 
Chem, Vol.54, pp. 482-90, ISSN 0009-9147 
Cho, W. J., J. M. Shin, J. S. Kim, M. R. Lee, K. S. Hong, J. H. Lee, K. H. Koo, J. W. Park & K. S. 
Kim (2009) miR-372 regulates cell cycle and apoptosis of ags human gastric cancer 
 
miRNAs in Gastric Cancer 
 
99 
cell line through direct regulation of LATS2. Mol Cells, Vol.28, pp. 521-7, ISSN 0219-
1032 
Chun-Zhi, Z., H. Lei, Z. An-Ling, F. Yan-Chao, Y. Xiao, W. Guang-Xiu, J. Zhi-Fan, P. Pei-Yu, 
Z. Qing-Yu & K. Chun-Sheng (2010) MicroRNA-221 and microRNA-222 regulate 
gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC 
Cancer, Vol.10, pp. 367, ISSN 
Ding, L., Y. Xu, W. Zhang, Y. Deng, M. Si, Y. Du, H. Yao, X. Liu, Y. Ke, J. Si & T. Zhou (2010) 
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by 
targeting JAK2. Cell Res, Vol.20, pp. 784-93, ISSN 1748-7838 
Du, Y., Y. Xu, L. Ding, H. Yao, H. Yu, T. Zhou & J. Si (2009) Down-regulation of miR-141 in 
gastric cancer and its involvement in cell growth. J Gastroenterol, Vol.44, pp. 556-61, 
ISSN 0944-1174 
Feng, L., Y. Xie, H. Zhang & Y. Wu (2011) miR-107 targets cyclin-dependent kinase 6 
expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. 
Med Oncol. ISSN 1559-131X 
Feng, R., X. Chen, Y. Yu, L. Su, B. Yu, J. Li, Q. Cai, M. Yan, B. Liu & Z. Zhu (2010) miR-126 
functions as a tumour suppressor in human gastric cancer. Cancer Lett, Vol.298, pp. 
50-63, ISSN 1872-7980 
Fujita, T. (2009) Gastric cancer. Lancet, Vol.374, pp. 1593-4; author reply pp. 1594-5, ISSN 
1474-547X 
Gao, C., Z. Zhang, W. Liu, S. Xiao, W. Gu & H. Lu (2010) Reduced microRNA-218 
expression is associated with high nuclear factor kappa B activation in gastric 
cancer. Cancer, Vol.116, pp. 41-9, ISSN 0008-543X 
Gilad, S., E. Meiri, Y. Yogev, S. Benjamin, D. Lebanony, N. Yerushalmi, H. Benjamin, M. 
Kushnir, H. Cholakh, N. Melamed, Z. Bentwich, M. Hod, Y. Goren & A. Chajut 
(2008) Serum microRNAs are promising novel biomarkers. PLoS One, Vol.3, pp. 
e3148, ISSN 1932-6203 
Guo, J., Y. Miao, B. Xiao, R. Huan, Z. Jiang, D. Meng & Y. Wang (2009) Differential 
expression of microRNA species in human gastric cancer versus non-tumorous 
tissues. J Gastroenterol Hepatol, Vol.24, pp. 652-7, ISSN 1440-1746 
Guo, X., L. Guo, J. Ji, J. Zhang, J. Zhang, X. Chen, Q. Cai, J. Li, Q. Gu, B. Liu, Z. Zhu & Y. Yu 
(2010) miRNA-331-3p directly targets E2F1 and induces growth arrest in human 
gastric cancer. Biochem Biophys Res Commun, Vol.398, pp. 1-6, ISSN 1090-2104 
Guo, X., C. Jing, L. Li, L. Zhang, Y. Shi, J. Wang, J. Liu & C. Li (2011) Down-regulation of 
VEZT gene expression in human gastric cancer involves promoter methylation and 
miR-43c. Biochem Biophys Res Commun, Vol.404, pp. 622-7, ISSN 1090-2104 
Hashimoto, Y., Y. Akiyama, T. Otsubo, S. Shimada & Y. Yuasa (2010) Involvement of 
epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis, 
Vol.31, pp. 777-84, ISSN 1460-2180 
Hou, Z., L. Xie, L. Yu, X. Qian & B. Liu (2011) MicroRNA-146a is down-regulated in gastric 
cancer and regulates cell proliferation and apoptosis. Med Oncol. ISSN 1559-131X 
Ji, Q., X. Hao, Y. Meng, M. Zhang, J. Desano, D. Fan & L. Xu (2008) Restoration of tumor 
suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC 
Cancer, Vol.8, pp.266, ISSN 1471-2407 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
100 
Jiang, Z., J. Guo, B. Xiao, Y. Miao, R. Huang, D. Li & Y. Zhang (2010) Increased expression of 
miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol, 
Vol.45, pp. 17-23, ISSN 1435-5922 
Jin, Z., F. M. Selaru, Y. Cheng, T. Kan, R. Agarwal, Y. Mori, A. V. Olaru, J. Yang, S. David, J. 
P. Hamilton, J. M. Abraham, J. Harmon, M. Duncan, E. A. Montgomery & S. J. 
Meltzer (2010) MicroRNA-192 and -215 are upregulated in human gastric cancer in 
vivo and suppress ALCAM expression in vitro. Oncogene. Vol. pp. , ISSN 1476-5594 
Katada, T., H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitui, Y. Mori, R. Ogawa, K. Harata & 
Y. Fujii (2009) microRNA expression profile in undifferentiated gastric cancer. 
International journal of oncology, Vol.34, pp. 537-42, ISSN 1019-6439 
Kim, J., S. Y. Min, H. E. Lee & W. H. Kim (2011) Aberrant DNA methylation and tumor 
suppressive activity of the EBF3 gene in gastric carcinoma. International journal of 
cancer. Journal international du cancer, ISSN 1097-0215 
Kim, M. S., J. E. Oh, Y. R. Kim, S. W. Park, M. R. Kang, S. S. Kim, C. H. Ahn, N. J. Yoo & S. 
H. Lee (2010) Somatic mutations and losses of expression of microRNA regulation-
related genes AGO2 and TNRC6A in gastric and colorectal cancers. The Journal of 
pathology, Vol.221, pp. 139-46, ISSN 1096-9896 
Kim, V. N. (2005) Small RNAs: classification, biogenesis, and function. Mol Cells, Vol.19, pp. 
1-15, ISSN 1016-8478 
Kim, Y. K., J. Yu, T. S. Han, S. Y. Park, B. Namkoong, D. H. Kim, K. Hur, M. W. Yoo, H. J. 
Lee, H. K. Yang & V. N. Kim (2009) Functional links between clustered microRNAs: 
suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic 
Acids Res, Vol.37, pp. 1672-81, ISSN 1362-4962 
Lai, K. W., K. X. Koh, M. Loh, K. Tada, M. M. Subramaniam, X. Y. Lim, A. Vaithilingam, M. 
Salto-Tellez, B. Iacopetta, Y. Ito & R. Soong (2010) MicroRNA-130b regulates the 
tumour suppressor RUNX3 in gastric cancer. Eur J Cancer, Vol.46, pp. 1456-63, ISSN 
1879-0852 
Lang, N., M. Liu, Q. L. Tang, X. Chen, Z. Liu & F. Bi (2010) Effects of microRNA-29 family 
members on proliferation and invasion of gastric cancer cell lines. Chin J Cancer, 
Vol.29, pp. 603-10, ISSN 1944-446X 
Li, X., Y. Zhang, Y. Shi, G. Dong, J. Liang, Y. Han, X. Wang, Q. Zhao, J. Ding, K. Wu & D. 
Fan (2010) MicroRNA-107, an Oncogene MicroRNA that Regulates Tumor Invasion 
and Metastasis By Targeting DICER1 in Gastric Cancer: MiR-107 promotes gastric 
cancer invasion and metastasis. J Cell Mol Med. Vol. pp. , ISSN 1582-4934 
Liu, R., C. Zhang, Z. Hu, G. Li, C. Wang, C. Yang, D. Huang, X. Chen, H. Zhang, R. Zhuang, 
T. Deng, H. Liu, J. Yin, S. Wang, K. Zen, Y. Ba & C. Y. Zhang (2011) A five-
microRNA signature identified from genome-wide serum microRNA expression 
profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer, Vol.47, 
pp. 784-91, ISSN 1879-0852 
Liu, T., H. Tang, Y. Lang, M. Liu & X. Li (2009) MicroRNA-27a functions as an oncogene in 
gastric adenocarcinoma by targeting prohibitin. Cancer Lett, Vol.273, pp. 233-42, 
ISSN 1872-7980 
Luo, H., H. Zhang, Z. Zhang, X. Zhang, B. Ning, J. Guo, N. Nie, B. Liu & X. Wu (2009) 
Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer 
Res, Vol.28, pp. 82, ISSN 1756-9966 
 
miRNAs in Gastric Cancer 
 
101 
Mitchell, P. S., R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-
Agadjanyan, A. Peterson, J. Noteboom, K. C. O'Briant, A. Allen, D. W. Lin, N. 
Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, 
P. S. Nelson, D. B. Martin & M. Tewari (2008) Circulating microRNAs as stable 
blood-based markers for cancer detection. Proc Natl Acad Sci U S A, Vol.105, pp. 
10513-8, ISSN 1091-6490 
Motoyama, K., H. Inoue, K. Mimori, F. Tanaka, K. Kojima, H. Uetake, K. Sugihara & M. 
Mori (2010) Clinicopathological and prognostic significance of PDCD4 and 
microRNA-21 in human gastric cancer. Int J Oncol, Vol.36, pp. 1089-95, ISSN 1791-
2423 
Motoyama, K., H. Inoue, Y. Nakamura, H. Uetake, K. Sugihara & M. Mori (2008) Clinical 
significance of high mobility group A2 in human gastric cancer and its relationship 
to let-7 microRNA family. Clin Cancer Res, Vol.14, pp. 2334-40, ISSN 1078-0432 
Nishida, N., K. Mimori, M. Fabbri, T. Yokobori, T. Sudo, F. Tanaka, K. Shibata, H. Ishii, Y. 
Doki & M. Mori (2011) MicroRNA-125a-5p is an independent prognostic factor in 
gastric cancer,and inhibits the proliferation of human gastric cancer cells in 
combination with trastuzumab. Clin Cancer Res. ISSN 1078-0432 
Noguer-Dance, M., S. Abu-Amero, M. Al-Khtib, A. Lefevre, P. Coullin, G. E. Moore & J. 
Cavaille (2010) The primate-specific microRNA gene cluster (C19MC) is imprinted 
in the placenta. Hum Mol Genet, Vol.19, pp. 3566-82, ISSN 1460-2083 
Ohshima, K., K. Inoue, A. Fujiwara, K. Hatakeyama, K. Kanto, Y. Watanabe, K. Muramatsu, 
Y. Fukuda, S. Ogura, K. Yamaguchi & T. Mochizuki (2010) Let-7 microRNA family 
is selectively secreted into the extracellular environment via exosomes in a 
metastatic gastric cancer cell line. PLoS One, Vol.5, pp. e13247, ISSN 1932-6203 
Otsubo, T., Y. Akiyama, Y. Hashimoto, S. Shimada, K. Goto & Y. Yuasa (2011) MicroRNA-
126 Inhibits SOX2 Expression and Contributes to Gastric Carcinogenesis. PLoS One, 
Vol.6, pp. e16617, ISSN 1932-6203 
Pan, J., H. Hu, Z. Zhou, L. Sun, L. Peng, L. Yu, J. Liu, Z. Yang & Y. Ran (2010) Tumor-
suppressive mir-663 gene induces mitotic catastrophe growth arrest in human 
gastric cancer cells. Oncology reports, Vol.24, pp. 105-12, ISSN 1791-2431 
Parkin, D. M., P. Pisani & J. Ferlay (1999) Global cancer statistics. CA: a cancer journal for 
clinicians, Vol.49, pp. 33-64, ISSN 0007-9235 
Petrocca, F., R. Visone, M. R. Onelli, M. H. Shah, M. S. Nicoloso, I. de Martino, D. Iliopoulos, 
E. Pilozzi, C. G. Liu, M. Negrini, L. Cavazzini, S. Volinia, H. Alder, L. P. Ruco, G. 
Baldassarre, C. M. Croce & A. Vecchione (2008) E2F1-regulated microRNAs impair 
TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell, 
Vol.13, pp. 272-86, ISSN 1878-3686 
Ribeiro-dos-Santos, A., A. S. Khayat, A. Silva, D. O. Alencar, J. Lobato, L. Luz, D. G. 
Pinheiro, L. Varuzza, M. Assumpcao, P. Assumpcao, S. Santos, D. L. Zanette, W. A. 
Silva, Jr., R. Burbano & S. Darnet (2010) Ultra-deep sequencing reveals the 
microRNA expression pattern of the human stomach. PLoS One, Vol.5, pp. e13205, 
ISSN 1932-6203 
Rotkrua, P., Y. Akiyama, Y. Hashimoto, T. Otsubo & Y. Yuasa (2011) MiR-9 down-regulates 
CDX2 expression in gastric cancer cells. Int J Cancer. Vol. pp. , ISSN 1097-0215 
Saito, Y., H. Suzuki, H. Tsugawa, I. Nakagawa, J. Matsuzaki, Y. Kanai & T. Hibi (2009) 
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
100 
Jiang, Z., J. Guo, B. Xiao, Y. Miao, R. Huang, D. Li & Y. Zhang (2010) Increased expression of 
miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol, 
Vol.45, pp. 17-23, ISSN 1435-5922 
Jin, Z., F. M. Selaru, Y. Cheng, T. Kan, R. Agarwal, Y. Mori, A. V. Olaru, J. Yang, S. David, J. 
P. Hamilton, J. M. Abraham, J. Harmon, M. Duncan, E. A. Montgomery & S. J. 
Meltzer (2010) MicroRNA-192 and -215 are upregulated in human gastric cancer in 
vivo and suppress ALCAM expression in vitro. Oncogene. Vol. pp. , ISSN 1476-5594 
Katada, T., H. Ishiguro, Y. Kuwabara, M. Kimura, A. Mitui, Y. Mori, R. Ogawa, K. Harata & 
Y. Fujii (2009) microRNA expression profile in undifferentiated gastric cancer. 
International journal of oncology, Vol.34, pp. 537-42, ISSN 1019-6439 
Kim, J., S. Y. Min, H. E. Lee & W. H. Kim (2011) Aberrant DNA methylation and tumor 
suppressive activity of the EBF3 gene in gastric carcinoma. International journal of 
cancer. Journal international du cancer, ISSN 1097-0215 
Kim, M. S., J. E. Oh, Y. R. Kim, S. W. Park, M. R. Kang, S. S. Kim, C. H. Ahn, N. J. Yoo & S. 
H. Lee (2010) Somatic mutations and losses of expression of microRNA regulation-
related genes AGO2 and TNRC6A in gastric and colorectal cancers. The Journal of 
pathology, Vol.221, pp. 139-46, ISSN 1096-9896 
Kim, V. N. (2005) Small RNAs: classification, biogenesis, and function. Mol Cells, Vol.19, pp. 
1-15, ISSN 1016-8478 
Kim, Y. K., J. Yu, T. S. Han, S. Y. Park, B. Namkoong, D. H. Kim, K. Hur, M. W. Yoo, H. J. 
Lee, H. K. Yang & V. N. Kim (2009) Functional links between clustered microRNAs: 
suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic 
Acids Res, Vol.37, pp. 1672-81, ISSN 1362-4962 
Lai, K. W., K. X. Koh, M. Loh, K. Tada, M. M. Subramaniam, X. Y. Lim, A. Vaithilingam, M. 
Salto-Tellez, B. Iacopetta, Y. Ito & R. Soong (2010) MicroRNA-130b regulates the 
tumour suppressor RUNX3 in gastric cancer. Eur J Cancer, Vol.46, pp. 1456-63, ISSN 
1879-0852 
Lang, N., M. Liu, Q. L. Tang, X. Chen, Z. Liu & F. Bi (2010) Effects of microRNA-29 family 
members on proliferation and invasion of gastric cancer cell lines. Chin J Cancer, 
Vol.29, pp. 603-10, ISSN 1944-446X 
Li, X., Y. Zhang, Y. Shi, G. Dong, J. Liang, Y. Han, X. Wang, Q. Zhao, J. Ding, K. Wu & D. 
Fan (2010) MicroRNA-107, an Oncogene MicroRNA that Regulates Tumor Invasion 
and Metastasis By Targeting DICER1 in Gastric Cancer: MiR-107 promotes gastric 
cancer invasion and metastasis. J Cell Mol Med. Vol. pp. , ISSN 1582-4934 
Liu, R., C. Zhang, Z. Hu, G. Li, C. Wang, C. Yang, D. Huang, X. Chen, H. Zhang, R. Zhuang, 
T. Deng, H. Liu, J. Yin, S. Wang, K. Zen, Y. Ba & C. Y. Zhang (2011) A five-
microRNA signature identified from genome-wide serum microRNA expression 
profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer, Vol.47, 
pp. 784-91, ISSN 1879-0852 
Liu, T., H. Tang, Y. Lang, M. Liu & X. Li (2009) MicroRNA-27a functions as an oncogene in 
gastric adenocarcinoma by targeting prohibitin. Cancer Lett, Vol.273, pp. 233-42, 
ISSN 1872-7980 
Luo, H., H. Zhang, Z. Zhang, X. Zhang, B. Ning, J. Guo, N. Nie, B. Liu & X. Wu (2009) 
Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer 
Res, Vol.28, pp. 82, ISSN 1756-9966 
 
miRNAs in Gastric Cancer 
 
101 
Mitchell, P. S., R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-
Agadjanyan, A. Peterson, J. Noteboom, K. C. O'Briant, A. Allen, D. W. Lin, N. 
Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, 
P. S. Nelson, D. B. Martin & M. Tewari (2008) Circulating microRNAs as stable 
blood-based markers for cancer detection. Proc Natl Acad Sci U S A, Vol.105, pp. 
10513-8, ISSN 1091-6490 
Motoyama, K., H. Inoue, K. Mimori, F. Tanaka, K. Kojima, H. Uetake, K. Sugihara & M. 
Mori (2010) Clinicopathological and prognostic significance of PDCD4 and 
microRNA-21 in human gastric cancer. Int J Oncol, Vol.36, pp. 1089-95, ISSN 1791-
2423 
Motoyama, K., H. Inoue, Y. Nakamura, H. Uetake, K. Sugihara & M. Mori (2008) Clinical 
significance of high mobility group A2 in human gastric cancer and its relationship 
to let-7 microRNA family. Clin Cancer Res, Vol.14, pp. 2334-40, ISSN 1078-0432 
Nishida, N., K. Mimori, M. Fabbri, T. Yokobori, T. Sudo, F. Tanaka, K. Shibata, H. Ishii, Y. 
Doki & M. Mori (2011) MicroRNA-125a-5p is an independent prognostic factor in 
gastric cancer,and inhibits the proliferation of human gastric cancer cells in 
combination with trastuzumab. Clin Cancer Res. ISSN 1078-0432 
Noguer-Dance, M., S. Abu-Amero, M. Al-Khtib, A. Lefevre, P. Coullin, G. E. Moore & J. 
Cavaille (2010) The primate-specific microRNA gene cluster (C19MC) is imprinted 
in the placenta. Hum Mol Genet, Vol.19, pp. 3566-82, ISSN 1460-2083 
Ohshima, K., K. Inoue, A. Fujiwara, K. Hatakeyama, K. Kanto, Y. Watanabe, K. Muramatsu, 
Y. Fukuda, S. Ogura, K. Yamaguchi & T. Mochizuki (2010) Let-7 microRNA family 
is selectively secreted into the extracellular environment via exosomes in a 
metastatic gastric cancer cell line. PLoS One, Vol.5, pp. e13247, ISSN 1932-6203 
Otsubo, T., Y. Akiyama, Y. Hashimoto, S. Shimada, K. Goto & Y. Yuasa (2011) MicroRNA-
126 Inhibits SOX2 Expression and Contributes to Gastric Carcinogenesis. PLoS One, 
Vol.6, pp. e16617, ISSN 1932-6203 
Pan, J., H. Hu, Z. Zhou, L. Sun, L. Peng, L. Yu, J. Liu, Z. Yang & Y. Ran (2010) Tumor-
suppressive mir-663 gene induces mitotic catastrophe growth arrest in human 
gastric cancer cells. Oncology reports, Vol.24, pp. 105-12, ISSN 1791-2431 
Parkin, D. M., P. Pisani & J. Ferlay (1999) Global cancer statistics. CA: a cancer journal for 
clinicians, Vol.49, pp. 33-64, ISSN 0007-9235 
Petrocca, F., R. Visone, M. R. Onelli, M. H. Shah, M. S. Nicoloso, I. de Martino, D. Iliopoulos, 
E. Pilozzi, C. G. Liu, M. Negrini, L. Cavazzini, S. Volinia, H. Alder, L. P. Ruco, G. 
Baldassarre, C. M. Croce & A. Vecchione (2008) E2F1-regulated microRNAs impair 
TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell, 
Vol.13, pp. 272-86, ISSN 1878-3686 
Ribeiro-dos-Santos, A., A. S. Khayat, A. Silva, D. O. Alencar, J. Lobato, L. Luz, D. G. 
Pinheiro, L. Varuzza, M. Assumpcao, P. Assumpcao, S. Santos, D. L. Zanette, W. A. 
Silva, Jr., R. Burbano & S. Darnet (2010) Ultra-deep sequencing reveals the 
microRNA expression pattern of the human stomach. PLoS One, Vol.5, pp. e13205, 
ISSN 1932-6203 
Rotkrua, P., Y. Akiyama, Y. Hashimoto, T. Otsubo & Y. Yuasa (2011) MiR-9 down-regulates 
CDX2 expression in gastric cancer cells. Int J Cancer. Vol. pp. , ISSN 1097-0215 
Saito, Y., H. Suzuki, H. Tsugawa, I. Nakagawa, J. Matsuzaki, Y. Kanai & T. Hibi (2009) 
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
102 
microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. 
Oncogene, Vol.28, pp. 2738-44, ISSN 1476-5594 
Shen, R., S. Pan, S. Qi, X. Lin & S. Cheng (2010) Epigenetic repression of microRNA-129-2 
leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun, 394, 
pp. 1047-52, ISSN 1090-2104 
Shin, V. Y., H. Jin, E. K. Ng, A. S. Cheng, W. W. Chong, C. Y. Wong, W. K. Leung, J. J. Sung 
& K. M. Chu (2011) NF-kappaB targets miR-16 and miR-21 in gastric cancer: 
involvement of prostaglandin E receptors. Carcinogenesis, Vol.32, pp. 240-5, ISSN 
1460-2180 
Shinozaki, A., T. Sakatani, T. Ushiku, R. Hino, M. Isogai, S. Ishikawa, H. Uozaki, K. Takada 
& M. Fukayama (2010) Downregulation of microRNA-200 in EBV-associated gastric 
carcinoma. Cancer Res, Vol.70, pp. 4719-27, ISSN 1538-7445 
Song, G., H. Zeng, J. Li, L. Xiao, Y. He, Y. Tang & Y. Li (2010) miR-199a regulates the tumor 
suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. Biol 
Pharm Bull, Vol.33, pp. 1822-7, ISSN 1347-5215 
Song, Y. X., Z. Y. Yue, Z. N. Wang, Y. Y. Xu, Y. Luo, H. M. Xu, X. Zhang, L. Jiang, C. Z. Xing 
& Y. Zhang (2011) MicroRNA-148b is frequently down-regulated in gastric cancer 
and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer, Vol.10, 
pp. 1, ISSN 1476-4598 
Suzuki, H., E. Yamamoto, M. Nojima, M. Kai, H. O. Yamano, K. Yoshikawa, T. Kimura, T. 
Kudo, E. Harada, T. Sugai, H. Takamaru, T. Niinuma, R. Maruyama, H. Yamamoto, 
T. Tokino, K. Imai, M. Toyota & Y. Shinomura (2010) Methylation-associated 
silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic 
field defect. Carcinogenesis, Vol.31, pp. 2066-73, ISSN 1460-2180 
Takei, Y., M. Takigahira, K. Mihara, Y. Tarumi & K. Yanagihara (2011) The Metastasis-
Associated microRNA miR-516a-3p Is a Novel Therapeutic Target for Inhibiting 
Peritoneal Dissemination of Human Scirrhous Gastric Cancer. Cancer Res, Vol.71, 
pp. 1442-1453, ISSN 1538-7445 
Tchernitsa, O., A. Kasajima, R. Schafer, R. J. Kuban, U. Ungethum, B. Gyorffy, U. Neumann, 
E. Simon, W. Weichert, M. P. Ebert & C. Rocken (2010) Systematic evaluation of the 
miRNA-ome and its downstream effects on mRNA expression identifies gastric 
cancer progression. The Journal of pathology, Vol.222, pp. 310-9, ISSN 1096-9896 
Tie, J., Y. Pan, L. Zhao, K. Wu, J. Liu, S. Sun, X. Guo, B. Wang, Y. Gang, Y. Zhang, Q. Li, T. 
Qiao, Q. Zhao, Y. Nie & D. Fan (2010) MiR-218 inhibits invasion and metastasis of 
gastric cancer by targeting the Robo1 receptor. PLoS Genet, Vol. 6, pp. e1000879, 
ISSN 1553-7404 
Tsai, K. W., L. Y. Hu, C. W. Wu, S. C. Li, C. H. Lai, H. W. Kao, W. L. Fang & W. C. Lin (2010) 
Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes 
Cancer, Vol.49, pp. 969-80, ISSN 1098-2264 
Tsai, K. W., H. W. Kao, H. C. Chen, S. J. Chen & W. C. Lin (2009) Epigenetic control of the 
expression of a primate-specific microRNA cluster in human cancer cells. 
Epigenetics, 4, pp. 587-92, ISSN 1559-2308 
Tsai, K. W., C. W. Wu, L. Y. Hu, S. C. Li, Y. L. Liao, C. H. Lai, H. W. Kao, W. L. Fang, K. H. 
Huang, W. C. Chan & W. C. Lin (2011) Epigenetic regulation of miR-34b and miR-
129 expression in gastric cancer. Int J Cancer. ISSN 1097-0215 
 
miRNAs in Gastric Cancer 
 
103 
Tsukamoto, Y., C. Nakada, T. Noguchi, M. Tanigawa, L. T. Nguyen, T. Uchida, N. Hijiya, K. 
Matsuura, T. Fujioka, M. Seto & M. Moriyama (2010) MicroRNA-375 is 
downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 
and 14-3-3zeta. Cancer Res, Vol.70, pp. 2339-49, ISSN 1538-7445 
Ueda, T., S. Volinia, H. Okumura, M. Shimizu, C. Taccioli, S. Rossi, H. Alder, C. G. Liu, N. 
Oue, W. Yasui, K. Yoshida, H. Sasaki, S. Nomura, Y. Seto, M. Kaminishi, G. A. 
Calin & C. M. Croce (2010) Relation between microRNA expression and 
progression and prognosis of gastric cancer: a microRNA expression analysis. 
Lancet Oncol, Vol.11, pp. 136-46, ISSN 1474-5488 
Varambally, S., Q. Cao, R. S. Mani, S. Shankar, X. Wang, B. Ateeq, B. Laxman, X. Cao, X. 
Jing, K. Ramnarayanan, J. C. Brenner, J. Yu, J. H. Kim, B. Han, P. Tan, C. Kumar-
Sinha, R. J. Lonigro, N. Palanisamy, C. A. Maher & A. M. Chinnaiyan (2008) 
Genomic loss of microRNA-101 leads to overexpression of histone 
methyltransferase EZH2 in cancer. Science, Vol.322, pp. 1695-9, ISSN 1095-9203 
Volinia, S., G. A. Calin, C. G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. 
Roldo, M. Ferracin, R. L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, 
M. Negrini, C. C. Harris & C. M. Croce (2006) A microRNA expression signature of 
human solid tumors defines cancer gene targets. Proceedings of the National Academy 
of Sciences of the United States of America, Vol.103, pp. 2257-61, ISSN 0027-8424 
Wada, R., Y. Akiyama, Y. Hashimoto, H. Fukamachi & Y. Yuasa (2010) miR-212 is 
downregulated and suppresses methyl-CpG-binding protein MeCP2 in human 
gastric cancer. Int J Cancer, Vol.127, pp. 1106-14, ISSN 1097-0215 
Wan, H. Y., L. M. Guo, T. Liu, M. Liu, X. Li & H. Tang (2010) Regulation of the transcription 
factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer, 
Vol.9, pp. 16, ISSN 1476-4598 
Wang, H. J., H. J. Ruan, X. J. He, Y. Y. Ma, X. T. Jiang, Y. J. Xia, Z. Y. Ye & H. Q. Tao (2010) 
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration 
and invasion. Eur J Cancer. ISSN 1879-0852 
Wang, J., Q. Wang, H. Liu, B. Hu, W. Zhou & Y. Cheng (2010) MicroRNA expression and its 
implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer 
letters, Vol.297,  pp.137-43, ISSN 1872-7980 
Watanabe, Y. & M. Maekawa (2010) Methylation of DNA in cancer. Adv Clin Chem, Vol.52, 
pp. 145-67, ISSN 0065-2423 
Wu, J., J. Qian, C. Li, L. Kwok, F. Cheng, P. Liu, C. Perdomo, D. Kotton, C. Vaziri, C. 
Anderlind, A. Spira, W. V. Cardoso & J. Lu (2010a) miR-129 regulates cell 
proliferation by downregulating Cdk6 expression. Cell Cycle, Vol.9, pp. 1809-18, 
ISSN 1551-4005 
Wu, Q., H. Jin, Z. Yang, G. Luo, Y. Lu, K. Li, G. Ren, T. Su, Y. Pan, B. Feng, Z. Xue, X. Wang 
& D. Fan (2010b) MiR-150 promotes gastric cancer proliferation by negatively 
regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun, Vol.392, pp. 
340-5, ISSN 1090-2104 
Wu, W. K., C. W. Lee, C. H. Cho, D. Fan, K. Wu, J. Yu & J. J. Sung (2010) MicroRNA 
dysregulation in gastric cancer: a new player enters the game. Oncogene, Vol.29, pp. 
5761-71, ISSN 1476-5594 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
102 
microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. 
Oncogene, Vol.28, pp. 2738-44, ISSN 1476-5594 
Shen, R., S. Pan, S. Qi, X. Lin & S. Cheng (2010) Epigenetic repression of microRNA-129-2 
leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun, 394, 
pp. 1047-52, ISSN 1090-2104 
Shin, V. Y., H. Jin, E. K. Ng, A. S. Cheng, W. W. Chong, C. Y. Wong, W. K. Leung, J. J. Sung 
& K. M. Chu (2011) NF-kappaB targets miR-16 and miR-21 in gastric cancer: 
involvement of prostaglandin E receptors. Carcinogenesis, Vol.32, pp. 240-5, ISSN 
1460-2180 
Shinozaki, A., T. Sakatani, T. Ushiku, R. Hino, M. Isogai, S. Ishikawa, H. Uozaki, K. Takada 
& M. Fukayama (2010) Downregulation of microRNA-200 in EBV-associated gastric 
carcinoma. Cancer Res, Vol.70, pp. 4719-27, ISSN 1538-7445 
Song, G., H. Zeng, J. Li, L. Xiao, Y. He, Y. Tang & Y. Li (2010) miR-199a regulates the tumor 
suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. Biol 
Pharm Bull, Vol.33, pp. 1822-7, ISSN 1347-5215 
Song, Y. X., Z. Y. Yue, Z. N. Wang, Y. Y. Xu, Y. Luo, H. M. Xu, X. Zhang, L. Jiang, C. Z. Xing 
& Y. Zhang (2011) MicroRNA-148b is frequently down-regulated in gastric cancer 
and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer, Vol.10, 
pp. 1, ISSN 1476-4598 
Suzuki, H., E. Yamamoto, M. Nojima, M. Kai, H. O. Yamano, K. Yoshikawa, T. Kimura, T. 
Kudo, E. Harada, T. Sugai, H. Takamaru, T. Niinuma, R. Maruyama, H. Yamamoto, 
T. Tokino, K. Imai, M. Toyota & Y. Shinomura (2010) Methylation-associated 
silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic 
field defect. Carcinogenesis, Vol.31, pp. 2066-73, ISSN 1460-2180 
Takei, Y., M. Takigahira, K. Mihara, Y. Tarumi & K. Yanagihara (2011) The Metastasis-
Associated microRNA miR-516a-3p Is a Novel Therapeutic Target for Inhibiting 
Peritoneal Dissemination of Human Scirrhous Gastric Cancer. Cancer Res, Vol.71, 
pp. 1442-1453, ISSN 1538-7445 
Tchernitsa, O., A. Kasajima, R. Schafer, R. J. Kuban, U. Ungethum, B. Gyorffy, U. Neumann, 
E. Simon, W. Weichert, M. P. Ebert & C. Rocken (2010) Systematic evaluation of the 
miRNA-ome and its downstream effects on mRNA expression identifies gastric 
cancer progression. The Journal of pathology, Vol.222, pp. 310-9, ISSN 1096-9896 
Tie, J., Y. Pan, L. Zhao, K. Wu, J. Liu, S. Sun, X. Guo, B. Wang, Y. Gang, Y. Zhang, Q. Li, T. 
Qiao, Q. Zhao, Y. Nie & D. Fan (2010) MiR-218 inhibits invasion and metastasis of 
gastric cancer by targeting the Robo1 receptor. PLoS Genet, Vol. 6, pp. e1000879, 
ISSN 1553-7404 
Tsai, K. W., L. Y. Hu, C. W. Wu, S. C. Li, C. H. Lai, H. W. Kao, W. L. Fang & W. C. Lin (2010) 
Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes 
Cancer, Vol.49, pp. 969-80, ISSN 1098-2264 
Tsai, K. W., H. W. Kao, H. C. Chen, S. J. Chen & W. C. Lin (2009) Epigenetic control of the 
expression of a primate-specific microRNA cluster in human cancer cells. 
Epigenetics, 4, pp. 587-92, ISSN 1559-2308 
Tsai, K. W., C. W. Wu, L. Y. Hu, S. C. Li, Y. L. Liao, C. H. Lai, H. W. Kao, W. L. Fang, K. H. 
Huang, W. C. Chan & W. C. Lin (2011) Epigenetic regulation of miR-34b and miR-
129 expression in gastric cancer. Int J Cancer. ISSN 1097-0215 
 
miRNAs in Gastric Cancer 
 
103 
Tsukamoto, Y., C. Nakada, T. Noguchi, M. Tanigawa, L. T. Nguyen, T. Uchida, N. Hijiya, K. 
Matsuura, T. Fujioka, M. Seto & M. Moriyama (2010) MicroRNA-375 is 
downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 
and 14-3-3zeta. Cancer Res, Vol.70, pp. 2339-49, ISSN 1538-7445 
Ueda, T., S. Volinia, H. Okumura, M. Shimizu, C. Taccioli, S. Rossi, H. Alder, C. G. Liu, N. 
Oue, W. Yasui, K. Yoshida, H. Sasaki, S. Nomura, Y. Seto, M. Kaminishi, G. A. 
Calin & C. M. Croce (2010) Relation between microRNA expression and 
progression and prognosis of gastric cancer: a microRNA expression analysis. 
Lancet Oncol, Vol.11, pp. 136-46, ISSN 1474-5488 
Varambally, S., Q. Cao, R. S. Mani, S. Shankar, X. Wang, B. Ateeq, B. Laxman, X. Cao, X. 
Jing, K. Ramnarayanan, J. C. Brenner, J. Yu, J. H. Kim, B. Han, P. Tan, C. Kumar-
Sinha, R. J. Lonigro, N. Palanisamy, C. A. Maher & A. M. Chinnaiyan (2008) 
Genomic loss of microRNA-101 leads to overexpression of histone 
methyltransferase EZH2 in cancer. Science, Vol.322, pp. 1695-9, ISSN 1095-9203 
Volinia, S., G. A. Calin, C. G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. 
Roldo, M. Ferracin, R. L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, 
M. Negrini, C. C. Harris & C. M. Croce (2006) A microRNA expression signature of 
human solid tumors defines cancer gene targets. Proceedings of the National Academy 
of Sciences of the United States of America, Vol.103, pp. 2257-61, ISSN 0027-8424 
Wada, R., Y. Akiyama, Y. Hashimoto, H. Fukamachi & Y. Yuasa (2010) miR-212 is 
downregulated and suppresses methyl-CpG-binding protein MeCP2 in human 
gastric cancer. Int J Cancer, Vol.127, pp. 1106-14, ISSN 1097-0215 
Wan, H. Y., L. M. Guo, T. Liu, M. Liu, X. Li & H. Tang (2010) Regulation of the transcription 
factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer, 
Vol.9, pp. 16, ISSN 1476-4598 
Wang, H. J., H. J. Ruan, X. J. He, Y. Y. Ma, X. T. Jiang, Y. J. Xia, Z. Y. Ye & H. Q. Tao (2010) 
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration 
and invasion. Eur J Cancer. ISSN 1879-0852 
Wang, J., Q. Wang, H. Liu, B. Hu, W. Zhou & Y. Cheng (2010) MicroRNA expression and its 
implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer 
letters, Vol.297,  pp.137-43, ISSN 1872-7980 
Watanabe, Y. & M. Maekawa (2010) Methylation of DNA in cancer. Adv Clin Chem, Vol.52, 
pp. 145-67, ISSN 0065-2423 
Wu, J., J. Qian, C. Li, L. Kwok, F. Cheng, P. Liu, C. Perdomo, D. Kotton, C. Vaziri, C. 
Anderlind, A. Spira, W. V. Cardoso & J. Lu (2010a) miR-129 regulates cell 
proliferation by downregulating Cdk6 expression. Cell Cycle, Vol.9, pp. 1809-18, 
ISSN 1551-4005 
Wu, Q., H. Jin, Z. Yang, G. Luo, Y. Lu, K. Li, G. Ren, T. Su, Y. Pan, B. Feng, Z. Xue, X. Wang 
& D. Fan (2010b) MiR-150 promotes gastric cancer proliferation by negatively 
regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun, Vol.392, pp. 
340-5, ISSN 1090-2104 
Wu, W. K., C. W. Lee, C. H. Cho, D. Fan, K. Wu, J. Yu & J. J. Sung (2010) MicroRNA 
dysregulation in gastric cancer: a new player enters the game. Oncogene, Vol.29, pp. 
5761-71, ISSN 1476-5594 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
104 
Xia, L., D. Zhang, R. Du, Y. Pan, L. Zhao, S. Sun, L. Hong, J. Liu & D. Fan (2008) miR-15b 
and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric 
cancer cells. Int J Cancer, Vol.123, pp. 372-9, ISSN 1097-0215 
Xu, L., F. Wang, X. F. Xu, W. H. Mo, Y. J. Xia, R. Wan, X. P. Wang & C. Y. Guo (2010) Down-
regulation of miR-212 expression by DNA hypermethylation in human gastric 
cancer cells. Med Oncol. ISSN 1559-131X 
Yang, Q., Z. Jie, H. Cao, A. R. Greenlee, C. Yang, F. Zou & Y. Jiang (2011) Low-level 
expression of let-7a in gastric cancer and its involvement in tumorigenesis by 
targeting RAB40C. Carcinogenesis. ISSN 1460-2180 
Zhang, X., Z. Yan, J. Zhang, L. Gong, W. Li, J. Cui, Y. Liu, Z. Gao, J. Li, L. Shen & Y. Lu 
(2011) Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for 
recurrence risk in gastric cancer patients following surgical resection. Ann Oncol. 
ISSN 1569-8041 
Zhang, X., W. Zhu, J. Zhang, S. Huo, L. Zhou, Z. Gu & M. Zhang (2010) MicroRNA-650 
targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res 
Commun, Vol.395, pp. 275-80, ISSN 1090-2104 
Zhang, Z., Z. Li, C. Gao, P. Chen, J. Chen, W. Liu, S. Xiao & H. Lu (2008) miR-21 plays a 
pivotal role in gastric cancer pathogenesis and progression. Laboratory investigation; 
a journal of technical methods and pathology, Vol.88, pp. 1358-66, ISSN 1530-0307 
Zhu, L. H., T. Liu, H. Tang, R. Q. Tian, C. Su, M. Liu & X. Li (2010a) MicroRNA-23a 
promotes the growth of gastric adenocarcinoma cell line MGC803 and 
downregulates interleukin-6 receptor. The FEBS journal, Vol.277, pp. 3726-34, ISSN 
1742-4658 
Zhu, W., X. Shan, T. Wang, Y. Shu & P. Liu (2010b) miR-181b modulates multidrug 
resistance by targeting BCL2 in human cancer cell lines. Int J Cancer, Vol.127, pp. 
2520-9, ISSN 1097-0215 
Zhu, W., D. Zhu, S. Lu, T. Wang, J. Wang, B. Jiang, Y. Shu & P. Liu (2011) miR-497 
modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med 
Oncol. Vol. pp, ISSN 1559-131X 
Zhu, Y. M., Z. X. Zhong & Z. M. Liu (2010c) Relationship between let-7a and gastric mucosa 
cancerization and its significance. World journal of gastroenterology : WJG, Vol.16, pp. 
3325-9, ISSN 1007-9327 
6 
Integrin and E-Cadherin Expression Alterations 
as a Possible Reason of Undifferentiated-Type  
Gastric Carcinoma Diversity 
Natalia Yanchenko and Hiroyuki Sugihara 
Shiga University of Medical Science, Department of Pathology 
 (Division of Molecular and Diagnostic Pathology) 
Japan 
1. Introduction 
Undifferentiated-type gastric carcinoma (UGC), according to the Japanese classification of 
gastric carcinoma (GC) (Japanese Gastric Cancer Association, 1998), is a type that poorly 
develops a tubular component. Relationship between Japanese and other classifications was 
discussed previously (Natsagdorj et al., 2008). The etiology and histogenetic pathways of 
UGC are still less elucidated than in GC with predominant tubular component 
(differentiated type GC, DGC), despite the notable advances of molecular technology and 
remarkable increase of percentage of UGC in the whole GC pool due to decrease of DGC 
and growth of UGC incidence worldwide in the last two decades (Crew & Neugut 2006; 
Kaneko & Yoshimura, 2001; Sidoni, 2005).  
Histological structure of UGCs is also more complicated than that of DGC and trends to 
display remarkable diversity due to combination of signet-ring cells, poorly differentiated, 
tubular and mucinous components; cohesive and dissociative cell arrangement; areas with 
scirrhous and non-scirrhous stroma. Additionally, cancer cells are intermingled with 
inflammatory cells (especially in mucosal area of early UGC)  and stromal cells (especially in 
extramucosal areas). 
Possible reason of UGCs histological diversity is contribution of at least two processes to 
UGC local growth and invasion, i.e. individual migration of dissociative cells and cohort-
type migration of cell-clusters (Friedl & Wolf, 2003; Nabeshima et al., 1999). It could be 
supposed, that both individual and cohort migrations depend on cell-extracellular matrix 
(ECM) interaction and could be studied from the position of cell-ECM receptors integrins. 
Cohort-type migration demands, additionally, “localized modulation of cell-cell adhesion” 
(Friedl & Wolf, 2003; Nabeshima et al., 1999), which could be changed allowing cell groups 
or scanty tubular structures to penetrate environmental tissues. Such cell-cell adhesion 
could be studied from the position of cadherin-phenotype alteration. 
Integrin and E-cadherin phenotype was proved to undergo remarkable changes during 
tumor progression of GC and other carcinomas, being related to various clinicopathological 
tumor features linked with tumors invasive properties (Choi et al., 2009; Hazan et al., 2004; 
Stefansson et al., 2004; Yanchenko et al., 2009; Yang et al., 2008). However, most studies 
were performed at the tumors array without specification of their individual features and 
the precise interrelationship between integrin and cadherin phenotype alteration and UGCs 
histopathological diversity has not been elucidated yet.  
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the precise interrelationship between integrin and cadherin phenotype alteration and UGCs 
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Why is the precise analysis of UGCs histology so important? Tumor invasion and growth is 
a process, however in pathology we commonly deal with its result, i.e. tumor with its 
individual features. Some of those features, e.g. scirrhous stroma, were already proved to be 
linked with high invasiveness and poor prognosis (Guszczyn &  Sobolewski, 2004). 
However, the  role and prognostic significance of other tumor components, for example 
signet-ring cell (SRC) component in tumor progression is still unclear.  Whereas early SRC 
carcinomas are rather dormant tumors with predominantly spreading growth, advanced 
SRC are linked with LN prominent LN metastazing and poor outcome (Humar et al., 2007; 
Hyung et al., 2002; Kim et al., 1997; Li et al. 2007).  
One more example is the area of layer arrangement of SRC and poorly differentiated cells, 
called layered structures (LS), in mucosal areas of some UGCs. LSs have been proved to be 
the only one reliable histological sign of primary genesis of UGC from early SRC 
carcinomas. UGCs aroused from  dedifferentiated tubular GC lack LS (Humar et al., 2007; 
Natsagdorj et al., 2008; Sugihara et al., 1987).  Biological behavior of advanced GC arisen 
from early SRC (primary UGC) and via tubular GC dedifferentiation was proved to be 
different (Natsagdorj et al., 2008), and it could be supposed that presence and extension of 
LS could predict tumor aggressiveness. 
To clarify the invasive potential of UGC and interrelationship between tumor histology and 
cell-cell and cell-ECM interaction alterations we introduce precise quantitated analysis of 
histological structure of each individual  UGC case, supplemented by integrated 
immunohistochemical analysis of  integrin and E-cadherin phenotype alterations. 
2. Materials and methods 
2.1 Materials 
We used 30 randomly selected cases with fresh resection specimens of UGC (13 early and 17 
advanced). In early UGC group 10 cases were diagnosed as signet-ring cell carcinomas (SIG) 
and demonstrated LS in the mucosa; 3 cases were poorly differentiated adenocarcinoma 
(POR), one of them with remarkable tubular component. In advanced UGC group 1 case 
was diagnosed as SIG and 16 as POR, most of which were accompanied with some SRCs 
and/or tubular component. Nine of advanced UGC had remnants of LS in the mucosa. 
To study integrin expression, tissue samples were snap-frozen in liquid nitrogen and then 
stored at –80°C until sectioning. Serial 4-μm-thick sections were cut at –22°C and placed in 
plastic boxes for storage at –80°C until further processing. To study expression of other 
antigens, we used 10% formalin-fixed paraffin-embedded tissues and cut them into 2-μm-
thick sections. 
2.2 Method 
2.2.1 Quantitative tumor structure analysis 
To analyze tumor histotype, each tumor was cut through into 0.52-3 cm blocks (Fig. 1A), 
the entire HE (hematoxylin and eosin) stained 2 μm-thick slices (one from each block) was 
scanned using Nikon Super COOLSCAN 5000 ED film scanner at a resolution of 2000 dpi. 
Scanned slice area was mapped at the microscope control (Fig. 1A, B, C) according to: (1) 
invasion depth (mucosal, submucosal [sm], muscularis propria [mp] and subserosal 
/adventitial [ss] areas); (2) tumor histotype (signet-ring cell, poorly differentiated, tubular 
and mucinous components); (3) cell cohesiveness (cohesive and dissociative component); (4) 
stromal development (scirrhous and non-scirrhous areas). Lymphatic and venous invasion 
areas were marked separately. Different tumor areas were assessed using 
analysis/measuring feature of Adobe Photoshop CS4 Extended Edition (Adobe Systems, 
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A – Early UGC with spreading (#e11) and penetrating pattern of invasion. Green areas at the photos of 
stomachs at the left designate tumor invasion areas. Mapped slices at the right demonstrate superficial 
(mucosal) spreading of relatively dormant case #e11, vs. rapid sm penetration of case #e13. Color key to 
slices mapping refer to all pictures (A, B, C, E). B –  example of slices mapping demonstrate the 
histological structures designated as tubular, poorly differentiated (POR), cohesive signet-ring cell (SIG) 
and other components. Cytokeratin (CK) staining (as well as in picture D) supplemented HE slices 
when identity of tumor cells is not obvious. M, SM, MP, SS – invasion depth. C – unusually extensive 
lymphatic penetration (mapped in yellow).  Cells in the lymphatic vessels are SRC (lower microphoto), 
although tumor consists mostly of POR component (mapped in green). D – case demonstrating  that 
dissociative cell arrangement is not always means scirrhous stroma development. E – case 
demonstrating rather rare mixture of nodules with cohesive cell arrangement and areas with scirrhous 
stroma. 
Fig. 1. Blocks and slices mapping; examples of UGCs structure.  
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A – Early UGC with spreading (#e11) and penetrating pattern of invasion. Green areas at the photos of 
stomachs at the left designate tumor invasion areas. Mapped slices at the right demonstrate superficial 
(mucosal) spreading of relatively dormant case #e11, vs. rapid sm penetration of case #e13. Color key to 
slices mapping refer to all pictures (A, B, C, E). B –  example of slices mapping demonstrate the 
histological structures designated as tubular, poorly differentiated (POR), cohesive signet-ring cell (SIG) 
and other components. Cytokeratin (CK) staining (as well as in picture D) supplemented HE slices 
when identity of tumor cells is not obvious. M, SM, MP, SS – invasion depth. C – unusually extensive 
lymphatic penetration (mapped in yellow).  Cells in the lymphatic vessels are SRC (lower microphoto), 
although tumor consists mostly of POR component (mapped in green). D – case demonstrating  that 
dissociative cell arrangement is not always means scirrhous stroma development. E – case 
demonstrating rather rare mixture of nodules with cohesive cell arrangement and areas with scirrhous 
stroma. 
Fig. 1. Blocks and slices mapping; examples of UGCs structure.  
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Mountain View, CA). “Vertical” invasion area (Area V) was calculated as a sum of all slices 
areas. The percentage of each area was calculated as a percentage of the corresponded area 
in the whole tumor area at this slice, e.g. 
mucosal areaPercentage of mucosal area  




We also assessed some other clinicopathological UGC features related to tumor 
invasiveness, such as:  (1) “horizontal” spreading area (Area H); the spreading area at each 
slice was mapped at stomach wall photograph and then assessed using analysis/measuring 
feature of Adobe Photoshop (Fig. 1A); (2) the number of lymph node (LN) metastasis, (3) 
invasion front shape (α, β, γ-invasion according to Japanese classification of GC) (Japanese 
Gastric Cancer Association, 1998). 
2.2.2 Immunohistochemical study of integrin expression (frozen section processing) 
To study integrin expression we used double APAAP staining with subsequent image 
analysis, which was introduced earlier (Yanchenko et al., 2009). Briefly, acetone fixed frozen 
sections were stained for integrin and, after heating, for cytokeratin (CK) to discriminate 
cancer cell from inflammatory and stromal cells. Microphotos were taken after first and 
second steps and processed with Adobe Photoshop. For the estimation of the fraction of 
positive cells, cancer cells positive for integrin were counted within 100 cytokeratin-positive 
cancer cells, in mucosal, submucosal and deeper areas. 
2.2.3 Immunohistochemical study of integrin expression (paraffin-embedded section 
processing) 
Automated staining using Ventana Discovery XT autostainer (Ventana Japan, Yokohama, 
Japan) was performed for staining of E-cadherins. As HECD-1 antibody, often used for E-
cadherin extracellular domain staining, could not be used for automated staining, it was 
replaced by G-10 (Table 1), the results were comparative with HECD-1 manual staining with 
autoclave-based antigen retrieval in citric acid. 
To discriminate cancerous cells from non-cancerous cells in UGC, where cancerous calls are 
often intermingled with stromal and inflammatory cells, we used an epithelial marker 
cytokeratin, as was described previously for integrin study (Yanchenko et al., 2009). After 
automated cadherin staining slices underwent 15 minute trypsin-based antigen retrieval 
(trypsin was obtained from Histofine, Tokyo, Japan) with subsequent overnight anti-
cytokeratin antibody incubation. 
Since E-cadherin was expressed only by epithelial cells, we could omit image processing, 
necessary for study of mesenchymal and ubiquitous proteins (Yanchenko et al., 2009), and it 
was possible to estimate the fraction of cadherin-positive cells within 100 cytokeratin-
positive cancer cells in mucosal, submucosal and deeper areas without taking intermediate 
microphotograph. 
Antibodies, used for integrins and E-cadherin staining are listed in Table 1.  
Controls. For a positive control we used: (1) normal tissue of the same stomach sample (for 
proteins which normally occur in stomach tissue), (2) specimen from our collection, proved 
to be positive for this protein (for abnormal proteins). For a negative control, every 
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processed glass contained one serial section of the same sample (frozen tissues) or we used 
separate slice of the same sample (paraffin-embedded tissues), which was stained with an 






α1 IS TS2/7 1:50 Santa Cruz Biotechnology, Inc, Santa Cruz, CA 
α2 IS P1E6 1:200 Chemicon International, Inc., Temecula, CA 
α3 IS J143 1:40 GeneTex, Inc., San Antonio, TX 
α5 IS SAM-1 1:10 Chemicon International, Inc., Temecula, CA 
α6 IS 4F10 1:20 Chemicon International, Inc., Temecula, CA 
αV IS LM142 13C2 
1:1000 
1:20 Chemicon International, Inc., Temecula, CA 
β1 IS K-20 DF5 
1:50 
1:100 
Santa Cruz Biotechnology, Inc, Santa Cruz, CA 
BIOMOL International, L.P., Plymouth 
Meeting, PA 
β4 IS 3E1 1:2500 Chemicon International, Inc., Temecula, CA 
αVβ3 integrin P1F6 1:1000 Chemicon International, Inc., Temecula, CA 
αVβ5 integrin LM609 1:200 Chemicon International, Inc., Temecula, CA 
αVβ6 integrin E7P6 1:200 Chemicon International, Inc., Temecula, CA 
E-cadherin ID AEC-36 1:1500 BD Biosciences, San Jose, CA 
E-cadherinED HECD-1 1:500 1:50 
Takara Shuzo CO., LND, Otsu, Japan 
Abcam, Cambridge, MA 
E-cadherinED G-10 1:100 Santa Cruz Biotechnology, Inc, Santa Cruz, CA 
Cytokeratins (1-




ted Histofine, Tokyo, Japan 
Table 1. Primary mouse antibodies. IS – integrin subunit,  ID - intracellular domain; ED -  
extracellular domain. 
2.3 Calculation and statistical analysis 
“Normal” or “preserved” expression means that more than 95% of tumor cells expressed 
this receptor at the same manner as NN epithelium (positive for normal proteins and 
negative for abnormal). “Weak alteration” means that no more than 1/3 (0-33%) of tumor 
cells demonstrated altered expression pattern. “Moderate alteration” designates alteration in 
34-66% of tumor cells, and in cases with “strong alteration” the percentage of abnormally 
expressing cells is more than 2/3 (>67%). 
Descriptive statistical parameters, including means and standard errors, were calculated 
with the standard method (using descriptive statistics package, Microsoft Excel). To 
compare early and advanced UGCs, the statistical significance of differences between means 
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was calculated using Student's unpaired t-test. To prove the mutual correlation between 
protein expression and UGC features, correlation coefficient R was calculated (using the 
same statistics package, Microsoft Excel). Mean values throughout this report are expressed 
as means ± standard error. A probability (P-value) less than 0.05 was considered significant 
in all methods, including correlation analysis. 
3. Results 
3.1 Histological structure of UGC: UGC diversity analysis 
3.1.1 Invasion depth 
According to the invasion depth pattern, UGC could be divided into several groups (Fig. 2):  
Early UGC:  1) E(m) – intramucosal tumors, submucosal (sm) involvement less than 1% of 
the total tumor Area V (12 cases); 2) E(sm) – predominantly intramucosal with some 
submucosal invasion (1 case).  
Advanced UGC: 3) A(sm) - mostly submucosal (3 cases), 4) A(sm/mp) - with equal 
submucosal and muscularis propria (mp) portions (9 cases), 5) A(mp) - with prominent 
muscularis propria portion (5 cases). 
 
 
Fig. 2. Invasion depth patterns All UGC cases are arranged along x-axis. Cases are divided 
into 5 groups according to the proportion of m, sm, and mp component in their structure. 
Bars depict the percentage of correspondent components in whole tumor. Bars are arranged 
above and below x-axis only for better representation, i.e. location below the axis does not 
mean negative values.  Line graphs depict tumor size and are plotted  at secondary (right) y-
axis.  
3.1.2 UGCs histotype 
3.1.2.1 Signet-ring cell and poorly differentiated components, layer structures  
Histotype of tumor was as follows (Fig. 3): (1) SIG – predominantly signet-ring cell (SRC) 
tumors, were SRC comprised more than 55% of carcinoma area: 11 cases, among them 10 
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early and 1 advanced cases (77% of early and 6% of advanced UGC, respectively); (2) POR – 
predominantly poorly differentiated tumors (poorly differentiated cells comprised more 
than 55% of carcinoma area): 19 cases, 3 early and 16 advanced (23% of early and 94% of 
advanced UGC, respectively).  
 
 
Fig. 3. UGCs histotypes (for explanation see Fig. 2). Enclosed crosses depict percentage of LS 
in mucosal part.  
Ten (77%) early UGCs and 9 (53%) advanced UGCs demonstrated layer structures (LS) in 
the mucosa (Fig. 3). However, in early carcinomas LS formed the most part (88%±5%) of 
tumor area, whereas in advanced carcinomas they were replaced by poorly differentiated 
component and remained only in 5% ± 3% of mucosal part. 
 
 
Fig. 4. Variants of layered structures in early carcinomas. 
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A SRC component percentage correlated in early UGC with bigger tumor horizontal 
invasion area (R=0.58) and spreading growth (R=0.71) (see Fig. 1A, case #e11) submucosal 
invasion risk in such tumors was lower (R=0.55). On the other hand, in advanced UGC SRC 
was linked to smaller tumor size (R=0.60), and spreading in the submucosa (R=0.71), but not 
to the muscularis propria (R=0.64) (compare Fig. 2 and Fig. 3, cases #a01, #a03).  
In advanced UGC LS remnants percentage in mucosa correlated with smaller tumor size 
(Area V, R=0.54) and mucosal vs extramucosal portion prevalence (R=0.76), those tumors 
had smaller tendency to invade muscularis propria (R=0.49) (compare cases #a03, #a05, 
a#06 with LS remnants and cases #a14-16 without LS at Fig. 2 and Fig. 3) 
Only in advanced UGC without LS in the mucosa, a SRC component correlated with 
lymphatic invasion (R=0.99), venous invasion (R=0.82) and LN metastasis number (R=0.71). 
In one of such tumors lymphatic invasion comprised 13% of the whole tumor area and 
consisted mostly of SRC, whereas the whole tumor was mostly poorly differentiated (Fig. 
1C, Fig. 3 case #02). 
3.1.2.2 Tubular component 
A tubular component (TC) was found in 5 (38%) early and 10 (59%) advanced UGC and 
ranged from 0.01% to 41.46% of the whole tumor area (Area V) (Fig. 3). In early UGC TC 
was higher in bigger tumors (R=0.55), with tendency to submucosal and lymphatic vessel 
invasion (R=1.00), and less layer structures portion (R=0.55). In advanced UGC presence of 
TC did not correlate with local invasion features, but was linked to bigger number of LN 
metastasis (R=0.54). 
3.1.2.3 Mucinous component 
A mucinous component was found in 2 (15%) early and 7 (41%) advanced UGC ranged from 
0.03% to 6.62%  of the whole tumor area (Area V) (Fig. 3). In advanced UGC it appeared 
mostly in tumors with developed SRC component (R=0.57). 
 
 
Fig. 5. Cohesive cell arrangement, scirrhous stroma, and invasion front (for explanation see 
Fig. 2) 
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3.1.3 Cell cohesiveness 
Areas with cohesive cell arrangement were observed in 2 (15%) of early and 15 (88%) of 
advanced UGC, ranging from 1% to 79% of the whole tumor area. 1 (8%) early and 5 (29%) 
advanced UGC were predominantly (>60% of Area V) cohesive (Fig. 5). As could be 
expected, advanced UGC with bigger cohesive component were smaller in size (Area V; 
R=0.64), had higher mucosal (vs extramucosal) portion (R=0.77) (at Fig. 5 compare sizes and 
mucosal portion of cases a#03 and a#12 with “pure dissociative” cases #a08 and #a10). The 
only early case #e13 with cohesive poorly differentiated growth had the highest percentage 
of tubular component (Fig. 3), and demonstrated the biggest submucosal invasion portion 
(Fig. 2), despite rather small horizontally spreading area (Fig. 1A). 
3.1.4 Stromal component 
Scirrhous component was present in 10 (59%) advanced UGC and was prominent (>30% of 
the whole tumor area) in 5 of them, correlating with bigger tumor size (Area V; R=0.50) (Fig. 
5, compare cases #a04, #a07, #a08 and #a10 with other advanced UGC).  
Despite scirrhous component inversely correlated with cohesive growth pattern (R=0.55), 
and it could be seen from the Fig. 5 that in most tumor of cohesive cell arrangement and 
scirrhous stroma were mutually exclusive components, non-cohesive cell arrangement did 
not always mean scirrhous stroma development, and 3 of advanced UGC were mostly 
(>98%) non-cohesive, but did not demonstrate scirrhous stroma (Fig. 1D,  Fig. 5, cases a#05, 
a#09, a#16). Additionally, case #a14 partially demonstrated a pattern  that could be named 
“scirrhous-nodular”, where nodules of cohesive tumor cells were surrounded by scirrhous 
stroma. (Fig. 1E, Fig. 5). 
3.1.5 Invasion front  
Invasion front was clearly seen in all slices (α-INF) only case #e13, mostly cohesive tumor, 
other early UGC demonstrated fuzzy infiltration front (β-INF) (Fig. 5). 6 (35%) of advanced 
UGC, mostly with prevailed cohesive component, had clearly seen invasive front in 
cohesive areas and fuzzy or indistinguishable front in non-cohesive areas (β-INF). Other 
advanced UGC exhibited γ-INF and most of their borders were unclear (Fig. 5).  
Less distinct borders / invasion fronts correlated not only with dissociative growth pattern 
(in advanced UGC), but with such signs of local invasion tendency as bigger tumor size 
(R=0.60); and extramucosal (vs mucosal) growth prevalence (R=0.66) (Fig. 5). 
3.2 E-cadherin expression and UGC histopathological features  
Average percentage of E-cadherin positive cells (Table 2) had no significant difference in 
early and advanced UGC.  
 
 E-cadherin (internal domain) E-cadherin (external domain) 
NN expression pattern strongly positive moderately positive, except some surface cells 
Early UGC 0.84±0.08 0.44±0.08 
Advanced UGC 0.56±0.11 0.28±0.07 
T-test NS NS 
Table 2. Percentage of cancer cells positive for internal and external domains of E-cadherin 
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Average percentage of E-cadherin positive cells (Table 2) had no significant difference in 
early and advanced UGC.  
 
 E-cadherin (internal domain) E-cadherin (external domain) 
NN expression pattern strongly positive moderately positive, except some surface cells 
Early UGC 0.84±0.08 0.44±0.08 
Advanced UGC 0.56±0.11 0.28±0.07 
T-test NS NS 
Table 2. Percentage of cancer cells positive for internal and external domains of E-cadherin 
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However, the pool of UGC was rather heterogenous in E-cadherin preservation or loss (Fig. 
6). Around a half of UGC (early and advanced) preserved normal expression of internal 
domain, and around a quarter of them preserved normal pattern of external domain 
expression (Fig. 6, see first bars at graphs). On the other hand, almost quarter of cases (23%: 
1 (8%) early, 6 (35%) advanced) showed strong loss of internal E-cadherin domain 
expression and almost half of cases (47%: 4 (31%) early, 10 (59%) advanced) demonstrated 
strong loss of external domain (Fig. 6, see last bars at graphs). 
 
 
Fig. 6. UGC distribution according E-cadherin expression pattern. All UGC cases are 
arranged along x-axis. Bars represent percentage of UGC cases in the whole UGC group 
(e.g. 7 of 13 early UGC demonstrate normal expression of external E-cadherin domain, so 
the correspondent bar equals 54%). Lines are trends of cadherin and integrin distribution. 
 
 
Fig. 7. Loss of E-cadherin expression in cohesive tumor. Left: cytokeratin staining. Right: 
same area, stained for E-cadherin (internal domain). 
Tumors with preserved E-cadherin expression (both domains) trended to have smaller size 
(AreaV, R=0.37), with less mp portion (R=0.36). External domain of E-cadherin was stronger 
preserved in those advanced UGC with LS, which demonstrated minor tubular component 
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(R=0.73) (such as the case a#08, Fig. 3). Intriguingly, the tendency to lose internal domain 
was stronger in all tumors with more prominent cohesive component (R=0,41), all advanced 
UGC with total E-cadherin loss  were mostly cohesive [Fig. 7 and Fig. 3, cases a#03, a#06, 
a#11, a#12, a#15]. 
Loss of external and internal E-cadherin domains correlated with each other (R=0.78), being 
more severe for external domain (Fig. 6).  
3.3 Integrins expression and UGC histopathological features 
Non-neoplastic (NN) pattern of integrin expression was described earlier (Yanchenko et al., 
2009), briefly see Table 3.  
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areas of plastic changes. 
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3.3.1 Epithelial integrins  
All integrin subunits, common for normal stomach epithelium (α2, α3, α6, β1, β4) similar 
to internal domain of E-cadherin, demonstrated strong trend to be preserved both in early 
and advanced UGC (Table 3). However, unlike E-cadherin, none of the UGC cases 
demonstrated total loss of any normal integrins and most of cases showed normal or 
weakly depressed epithelial integrin expression (Fig. 8). Also, in contrast to E-cadherin, 
epithelial integrins did not demonstrate any tendency to be preserved more in tumors 
with weaker invasive potential. Strictly epithelial integrin subunits (α2, α6, β4) expression 
correlated with each other (R=0.48), i.e. they trended to be preserved better in the same 
tumors.  
3.3.2 Mesenchymal integrins 
α1 integrin (collagen receptor) expressed stronger in advanced carcinomas, whereas  
α5 (fibronectin receptor) did not reveal such tendency (Table 3). However, both  
subunits expressed rather weakly (Fig. 8). In the whole UGC pool, α1 correlated with  
such signs of higher local invasive potential as bigger tumor size (AreaV, R=0.51), 
prevalence of extramucosal over mucosal portion (R=0.50), as well as with bigger number 
of LN metastasis (R=0.39). α5 integrin subunit did not demonstrate such linkage with 
invasion features, correlating only with bigger tumor size (AreaH, R=0.57) in advanced 
UGC. 
Regarding  prevailed histotype (SIG or POR) α1 and α5 demonstrated different tendencies. 
α1 in all UGC pool trended to express in mostly poorly differentiated tumors with smaller 
SRC and LS component (R=0.53) (Fig. 9A, poorly differentiated tumor [left pair] is positive; 
SRC tumor [right pair] is negative) , whereas α5 in early UGC expressed stronger in SRC 
areas (Fig. 9B). In advanced UGC α5 demonstrated the same trend as α1, but it was non-
significant. Both mesenchymal integrins expressed stronger in UGCs with prominent 
scirrhous component (α1 R= 0.50, α5 R=0.64) (Fig. 9C). 
3.3.3 αV group 
Like mesenchymal integrin subunit, percentage of cells, expressing each individual 
integrin of this group was low, being significantly higher in advanced UGC only for αVβ5 
integrin (Table 3). αV subunit, which formed a part of all three integrins, as well as paired 
with two other β subunits (β1, β8), was expressed more often (Table 3). Tumors, 
expressing αVβ3 and αVβ6 integrins, expressed them in mostly in a weak manner (Fig. 8). 
Percentage of tumors with moderate or strong expression of αVβ5 integrins and αV 
subunit was higher (Fig. 8). 
In a whole tumor group αV integrin subunit expression demonstrated linkage with such 
local invasive features as bigger tumor size (R=0.50), prevalence of extramucosal (especially, 
mp) growth (R=0.44), as well as with γ-INF (R=0.56) and veins invasion (R=0.37). αVβ5 
integrin was also expressed more frequently if tumors with prevailed mp portion (R=0.42) 
and unclear invasion front (γ-INF, R=0.37). αV subunit was rarely seen in advanced 
cohesive UGC (R=0.74) (Fig. 10A) and advanced UGC with developed signet-ring cell 
(R=0.53) and mucinous component (R=0.57). Tubular component in advanced carcinomas 
was linked with stronger αVβ6 expression (R=0.51) (Fig. 10B: only tubular, but not poorly 
differentiated component of the tumor expresses αVβ6). 
Integrin and E-Cadherin Expression Alterations as a Possible Reason 




Fig. 9. Mesenchymal integrin expression. Microphotos of each area were taken twice: after 
staining for integrin (left photo in each pair; integrins are stained with magenta)  and after 
staining for cytokeratins (2nd  step of double staining,  right photo, CK are stained with 
purple-blue). Double staining was performed for better quantitative assessment of integrin 
positive cells in frozen samples of UGC with poor morphological representation (for details 
see Yanchenko N. et al, 2009). Symbols in the bottom-left corner of each microphoto depict 
the intensity of integrin staining. 
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Fig. 10. aV-group integrin expression (for explanations see Fig. 9). 
4. Discussion 
4.1 Quantitative analysis proves loss of gastric differentiation and its impact into 
UGCs progression 
Precise quantitative analysis provided plenty of data regarding UGCs structure and its 
impact into tumor progression. It quantitatively proved empirically observed  tendency to 
lose gastric-cell differentiation while tumor invades in extramucosal areas, as we 
demonstrated substitution of relatively differentiated SRC component (in early carcinomas) 
by poorly differentiated component in advanced UGC.  
Layered arrangement of SRC in mucosa, which reflects rudimentary gastric-mucosal 
differentiation (Natsagdorj et al., 2008; Sugihara et al., 1987)  and is predominant in most 
early carcinomas, also demonstrated a tendency to be disorganised in advanced UGCs, and 
mucosal portions of  those “primary” UGC which arose form LS-abundant early UGC 
almost totally lose this relatively ordered layered arrangement. Additionally, the more 
significantly advanced tumor loses LS, the more clearly it demonstrates the tendency for 
penetrative vs. spreading growth.  
However, even those tiny remnants of LS are very important as they were shown to be 
necessary for prediction of the prognostic role of SRC component.  We could conclude that 
the tendency for lymphatic (and venous) penetration, considered to be reason of poor 
prognosis in advanced SRC (Humar et al., 2007; Hyung et al., 2002; Kim et al., 1997; Li et al. 
2007) is observed only in advanced “secondary” UGCs, arose form dedifferentiated tubular 
carcinomas, but not in advance “primary” UGCs. 
On the other hand, from the position of local invasive features prominent SRC component, 
in both early and advanced UGCs could be considered as favourable prognostic feature, as 
SRC demonstrated a tendency to spread in connective tissue (lamina propria in early UGCs 
or submucosa in advanced UGCs), but not penetrate muscle layers. We could suppose that 
one of the probable reasons observed in this study is lack of abnormal mesenchymal (α1 and 
α5) and aV-integrins (shown to be essential for mp penetration) in SRC. 
Diffuse α5 integrin subunit expression in SRC areas of early carcinomas, was not associated 
with local invasive features and probably reflected its role in reparative (Herard et al., 1996) 
and inflammatory (Liebert et al., 1994) processes rather in invasion, as its ligand fibronectin 
is topographically associated with the front of invasion of GC (David et al., 1993).  
4.2 E-cadherin loss in cohesive component of UGC 
As could be expected, UGCs we predominantly cohesive cell arrangement and clearly seen 
invasion front demonstrated less aggressive behaviour. Surprisingly they also demonstrated 
Integrin and E-Cadherin Expression Alterations as a Possible Reason 
of Undifferentiated-Type Gastric Carcinoma Diversity 
 
119 
significantly higher tendency to lose E-cadherin expression than tumors with predominantly 
dissociative cell arrangement. This findings demonstrate that significance of solely E-
cadherin down-regulation in cell dissociation could be rather questionable, especially in 
advanced UGC.   
Simultaneously observed low expression of abnormal (mesenchymal and especially αV 
integrins) in highly cohesive tumors with compact, non-dissociative cell arrangement could 
mean that for dissociation and spreading UGC cells need not only to lose cell-cell adhesion 
but also to acquire abnormal cell-ECM contacts and motility mechanisms. 
Previously, E-cadherin loss (extracellular domain was studied) was proved to be obligatory 
first step of carcinogenesis in hereditary diffuse GC, in sporadic early GC however such E-
cadherin loss was considered as important, however optional event (Humar et al., 2007). 
Our data also proved that E-cadherin loss is not a critical requirement for tumor 
progression, as we demonstrated remarkable preservation of E-cadherin in both early and 
advanced sporadic UGC. Moreover, expression of E-cadherin in mucosal parts of advanced 
tumors with E-cadherin-negative extramucosal parts could mean that E-cadherin loss in 
such tumors is a secondary event, supporting the idea of gradual alteration of E-cadherin 
with UGC progression (Nakamura et al., 2005). 
4.3 Scirrhous stromal component and mesenchymal integrin gain  
Dissociative cell arrangement was clearly demonstrated to be not necessarily accompanied   
scirrhous stroma development, and even some cohesive tumors could develop areas of 
scirrhous stroma. However,  in all  cases scirrhous stroma prevalence contributed to local 
invasiveness. Possible reason of this findings is stronger expression of mesenchymal (α1, 
α5), but not epithelial (α2, αVβ6) collagen and fibronectin receptors in scirrhous areas. It 
could be supposed that stronger desmoplastic response recruits integrins responsible for 
mesenchymal fibroblast-like movements, albeit  fibronectin production is not directly linked 
to desmoplastic response (David et al., 1993). 
Epithelial fibronectin receptor αVβ6 in the whole tumor was not correlated with scirrhous 
stroma development, as its expression was shown to be confined to invasion front (Breuss et 
al., 1995). However, αVβ6 association with tubular component in advanced UGC supports 
the idea of the its predominant role for cohort migration, which was proved to depend on 
fibronectin (Shimao et al., 1999). 
4.4 E-cadherin down-regulation is more important than epithelial integrin down-
regulation 
In all UGCs studied normal epithelial integrin phenotype seems to be more stable than E-
cadherin expression and did not demonstrate linkage with tumor invasiveness. One of the 
possible reasons of the absence of significant relationship between expression of normal 
integrin and tumor behavior is impossibility to predict their role in tumor spreading. They 
are characterised by broad range of modulation of their functions by external and internal 
signals, e.g. α3β1 and α6β4 integrins could form both sedentary and moving contacts, 
enhancing both anti- and pro-invasive properties of cancer cells (Giannelli et al., 2002). 
Conversely, E-cadherin is responsible only for homophilic adhesion and acting only as 
invasion suppressor, and its significant alteration causes an increase of local invasive 
features of UGC. However, as was mentioned above, even total loss of cell-cell adhesiveness 
without abnormal integrin gain does not lead to highly invasive phenotype. 
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From the position of the whole integrin phenotype, gain of abnormal integrins seems to be 
more important for UGC growth and invasion, than normal epithelial integrins down-
regulation. Even minute or moderate gain of both mesenchymal and αV group integrins is 
linked with local invasion features such as tendency to penetrate deeper in muscularis 
propria, accompanied by γ infiltration pattern, linked with more rapid growth in UGC (our 
data) and poor prognosis of ovarian tumors (Spannuth et. al., 2005).  
5. Conclusion 
Thorough quantitated analysis of UGC histology, supplemented by simultaneous analysis 
of the integrin and E-cadherin phenotype, pioneered in this study, revealed not only tight 
correlation between UGCs histological components (such as signet-ring cell component, 
layer structures, cohesive cell arrangement, and scirrhous stromal  development)  and tumor 
invasive features, but also proposed E-cadherin down-regulation and abnormal 
(mesenchymal and αV-group) integrin up-regulation as the possible reason of this 
correlation. 
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1. Introduction 
Mucins are large, highly O-glycosylated proteins that are present at the surface of most 
epithelial cells and are involved in the protection and lubrication of the epithelium (Gendler 
and Spicer 1995). The expression of mucin genes is organ-and cell-type specific. The 
increased expression and altered glycosylation of mucins influence cellular growth, 
differentiation, transformation, adhesion and immune surveillance (Hollingworth and 
swanson 2004) and are associated with the development of cancer. Mucins have been 
implicated in the biologic behavior and progression of several cancers. During 
carcinogenesis, aberrant glycosylation leads to the development of tumor subpopulations 
with different adhesion properties (Taniguchi et al. 1996; Hiraiwa et al. 1996). Alterations of 
mucins during the pathogenesis of cancer have been well documented (Hakomori et al. 
2002). The under glycosylation of mucins results in the creation of tumor associated cryptic 
carbohydrate core structures Tn, sialyl Tn and T (Taylor-Papadimitriou et al. 1999).  
The Gram-negative bacterium Helicobacter pyroli infects over 50% of the world’s 
population and causes various gastric diseases such as chronic gastritis, peptic ulcer and 
gastric cancer. Peripheral lymph node addressin (PNAd) containing 6-sulfo sialyl Lewis X-
capped O-glycans on high endothelial venule (HEV)-like vessels are closely associated with 
pathogenesis of H pyroli-related diseases. The α1,4 GlcNAc-capped O-glycans expressed by 
gastric gland mucous cell-derived mucin prevents colonization of H pyroli. Thus, the 
differential expression of distinct O-glycans in stomach provides therapeutic potentialities 
based on specific carbohydrate modulation (Nakayama et al. 1999; Reis et al. 2000 and 
Kobayashi et al. 2009). 
Werther et al. (1996) examined the frequency of sialyl Tn expression and its prognostic value 
in gastric cancer by immunohistochemical analysis of 340 gastric tumors and found that 
sialyl Tn expression is a marker of gastric cancer progression suggesting that cancer 
associated mucins play a role in the malignant behavior of the tumor. Santos-Silva et al. 
(2005) have reported that polymorphism in the MUC1 tandem repeat exerts influence on the 
expression of cryptic carbohydrate core structures in gastric cancer cells and the aggressive 
gastric tumors tend to express T antigen. Immunohistochemical study of Amado et al. (1998) 
for the expression of dimeric sialyl Lewisx in 97 gastric carcinomas revealed a correlation 
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between high expression of dimeric sialyl Lewisx and venous invasion and poor outcome in 
gastric cancer patients. Petretti et al (1999) studied RNA expression of several 
glycosyltransferases in surgical specimens of gastric carcinomas and found significant 
enhancement in the expression of ST3Gal IV and FucT IV. 
A comprehensive study by Carvalho et al. (1999) on mucin expression in a panel of gastric 
carcinoma cell lines found no apparent relationship between the mucin core proteins and 
the simple mucin type or Lewisx carbohydrate antigens that are expressed in each cell line. 
Thus there exists a complexity in glycosyltransferase activities which lead to several tumor- 
associated carbohydrate structures in gastric carcinoma.  
 A comparative study of gene-expression profiles of adenocarcinoma metastases and 
primary adenocarcinomas (Ramaswamy et al. 2003) indicated that a subset of primary 
tumors resembled metastatic tumors with respect to a gene-expression signature and that 
solid tumors carrying this gene-expression signature were most likely to be associated with 
metastasis and poor clinical outcome. These results further suggested that the metastatic 
potential of human tumors is encoded in the bulk of a primary tumor and thus challenged 
the notion that metastases arise from rare cells within a primary tumor that have the ability 
to metastasize (Poste et al. 1980). Thus, it became obvious that a very consistent change of 
some biological events in a primary tumor as opposed to the normal tissue has the 
possibility of being related to the malignant potential of the tumor. Recently, we examined 
the patterns of glycosyl- and glycan-sulfotransferase activities in several cancer cell lines and 
the resulting data strongly suggested an association of unique carbohydrate structures with 
signature potential in individual cancers (Chandrasekaran et al. 2006). The present study 
was aimed to identify the glycosyl- or sulfotransferase which exhibits the most marked and 
consistent change of activity in gastric tumorigenesis, by comparing the pattern of various 
glycosyl and glycan: sulfotransferase activities in tumorous and normal gastric tissues of 
each patient in ten gastric carcinoma cases. 
2. Materials and methods 
2.1 Tissue specimens 
Human gastric tumor specimens were obtained during surgical procedures at Roswell Park 
Cancer Institute and stored frozen within 1h at -70°C. We studied the gastric tumor as well 
as non-tumor stomach tissue specimens from the same patient in ten gastric carcinoma cases 
and, in addition, two gastric tumor specimens in which case normal stomach tissue 
specimens were unavailable. The Pathology report on the tumors is presented in Table 1 and 
Table 4.  
When the samples were collected from Pathology, a portion of the sample adjacent to that 
used for enzyme assay was fixed in formalin and embedded in paraffin. Slides were 
prepared from the paraffin blocks, and stained with hematoxylin and eosin by standard 
procedures. A board-certified pathologist studied the slides to determine the distribution of 
cell types within the tumor tissue compared to the control tissue from the same case 
(although in three cases non-tumor tissue was not available). Due to the invasiveness of the 
gastric cancer in these cases, both the tumor and the non-tumor tissue samples generally 
contained smooth muscle. The smooth muscle component existed at roughly equivalent 
percentage in the tumor sample and non-tumor control on a case by case basis sometimes 
being a little larger in either tumor or non-tumor sample. The major difference between the 
normal and tumor sample in this study was that the tumor contained malignant epithelial 
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cells, and the normal never did. With the exception of case 10, the amount of protein 
solubilized from the tumor and the corresponding non-tumor specimen by Triton X-100 did 
not vary much as evident from the values reported in Table 1. Thus, it becomes evident that 
a comparison of each glycosyltransferase and glycan:sulfotransferase activity per mg protein 
of the tissue extract between tumor and the corresponding non-tumor specimen is quite 










N       T 
Specimen 
Wt. (g) 
N       T 
Protein (mg) in 
Triton X-100 
solubilized 
extract /g tissue 
N          T 
1 Overlapping lesion of stomach  30         40 3.5      1.9 52.8      67.4 
2 Lesser curvature of stomach, NOS 3A 30          50 1.9      2.5 58.5     53.6 
3 Lesser curvature of stomach, NOS 3A 20          30 4.2      1.9 54.6      42.2 
4 Lesser curvature of stomach, NOS 2 N/A      70 6.0      1.0 60.0      41.0 
5 Gastric antrum 3A 20          20 0.8      0.8 80.0       80.0 
6 Gastric antrum 1B 20          30 0.8      0.6 60.4       67.5 
7 Gastric antrum 2 10            0 1.7      0.5 52.4       82.8 
8 Body of stomach 3A 10          10 0.6      2.1 68.9       80.2 
9 Body of stomach 1B 20          10 0.6      2.0 52.9       86.9 
10 Cardia, NOS 3A 40          30 1.9      2.3 112.0       23.5 
11 Stomach, NOS 4 N/A      60 N/A    3.6                58.3 
12 Lesser curvature of stomach, NOS  N/A        0 N/A    3.5                76.8 
N; Non-tumor gastric tissue; T:  Tumor gastric tissue N/A Not available 
Table 1. The cancer site, stage and the details of the gastric tumor and non-tumor specimens 
from 12 patients 
2.2 Acceptor compounds 
The synthetic compounds used as acceptors in this study have already been used in our 
earlier studies (Chandrasekaran et al. 1995; 1996; 2001; 2004; 2005; 2006) and, thus, are well-
documented acceptors for measuring the reported enzyme activities. 
2.3 Processing of tissue specimens 
The tissues were homogenized at 4°C with 4 volumes of 0.1 M Tris Maleate pH 7.2, 0.1% 
NaN3 using kinematica. After adjusting the concentration of TritonX-100 to 2%, these 
homogenates were mixed in the cold room for 1h using Speci-Mix (Thermolyne) and then 
centrifuged at 20,000g for 1h at 4°C. The clear fat-free supernatant was stored frozen at -20°C 
until use. Aliquots of 10µL from this extract were used in assays run in duplicates.  
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centrifuged at 20,000g for 1h at 4°C. The clear fat-free supernatant was stored frozen at -20°C 
until use. Aliquots of 10µL from this extract were used in assays run in duplicates.  
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2.4 Enzyme assays 
Glycosyltransferase activity in tumor extract was determined by mixing the tumor extracts 
with acceptor and radiolabeled monosaccharide donor under the reaction conditions 
detailed below, followed by separation of unreacted donor from the radioactive product 
using anionic or hydrophobic chromatography. In all cases, the radioactive content of 
isolated products was determined by using 3a70 scintillation cocktail (research Products 
International, Mount Prospect, IL) and a Beckman LS9000 scintillation counter. Controls for 
each assay contained the reaction mixture with everything except the acceptor. Radioactivity 
of control was subtracted from that of product to obtain the results presented in the Tables. 
All assays were run in duplicate. Results from duplicate runs did not vary by more than 5%. 
The following are the conditions for individual enzymatic assays. Reaction temperature in 
all cases was 37°C.  
2.5 Sialyltransferase 
α2,3- and α2,6 sialyltransferase (ST) assay reactions proceeded for 2h in a mixture containing 
100mM sodium cacodylate buffer (pH 6.0), 7.5mM acceptor, CMP-[9-3H] NeuAc (typically 
0.2μCi) and 10μl tumor extract in a total volume of 20μl (Chandrasekaran et al. 1995, 2005). 
2.6 Gal/GalNAc transferases 
βGlcNAc: β1,4Gal-T and αGalNAc:β1,3Gal-T assay mixtures in duplicate contained 0.1M 
Hepes-NaOH pH 7.0, 7mM ATP, 20mM Mn acetate, 1mM UDP-Gal. UDP [14C] Gal (0.05μCi; 
327mCi/mmol; Amersham), 0.5mM acceptor (unless otherwise stated) and 10μl tumor 
extract in a total volume of 20μL (Chandrasekaran et al. 2001). It was incubated for 4h;  
βGlcNAc:β1,4GalNAc-T assay mixtures in duplicate contained 0.1M Hepes-NaOH ph7.0, 
7mM ATP, 20mM Mn acetate, UDP [3H] GalNAc (0.20μCi; 7.8Ci/mmol: New England 
Nuclear Corp.)  7.5mM acceptor and incubated for 4h (Chandrasekaran et al. 2001).  
2.7 Fucosyltransferases 
α1,2,  α1,3- , α1,4-fucosyltransferase  and FT VI  assay reactions were carried out for 2h in a 
reaction mixture containing 50mM Hepes buffer (pH 7.5), 5mM MnC12, 7mM ATP, 3mM 
NaN3, 3mM synthetic acceptor, 0.05μCi GDP-[14C]Fuc (290mCi/mmol) and 10μl tumor 
extract in a total volume of 20μl (Chandrasekaran et al. 1996).   
2.8 Glycan: sulfotransferases 
Sulfotransferase (Sulfo-T) assay reactions took 2h and required a mixture containing 100mM 
Tris-Maleate (pH 7.2), 5mM Mg Acetate, 5mM ATP, 10mM NaF, 10mM BAL, 7.5mM 
acceptor, 0.5μCi of [35S]PAPS (specific activity 2.4Ci/mmol) and 10μl of tumor extract in a 
total volume of 30μl (Chandrasekaran et al. 2004).  
2.9 Chromatographic methods 
Dowex-1-Cl or Sep-Pak C18 cartridges were used to isolate radiolabeled product from the 
reaction mixture. For Gal-T, GalNAc-T and FT assays, the incubation mixture was diluted 
with 1ml water and passed through a 1ml bed volume of Dowex-1-Cl column 
(Chandrasekaran et al. 1996, 2001). The column was washed twice with 1ml water. The 
breakthrough and the water wash contained the [14C]-galactosylated or [14C]-fucosylated 
products formed with neutral acceptors. 3ml of 0.1M NaCl was used to obtain [14C]-
fucosylated products from sialylated acceptors after water elution. For sialyltransferase 
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assays, the radioactive products from benzylglycosides were separated by hydrophobic 
chromatography on Sep-Pak C18 cartridge (Water, Milford, MA), and elution of the product 
was done with 3ml methanol (Chandrasekaran et al. 2005; Palcic et al. 1998). For 
sulfotransferase assays, elution of the [35S]-sulfated compound from Dowex-1-Cl column 
could be achieved by 3ml of 0.2M NaCl (Chandrasekaran et al. 2001). 
2.10 Effect of divalent cations on gastric tumor Gal: 3-O-sulfotransferase activity 
For seeing the effect of divalent cations on Gal: 3-O-sulfotransferase activity the incubation 
mixture contained varying concentration (1-50mM) of Mg acetate, Mn acetate or Ca acetate 
under the standard incubation conditions. Gal3Sulfo-T4 activity was assayed using 3-O-Me 
Galβ1, 4 GlcNAcβ1,6(Galβ1,3)GalNAcα-O-Bn as the acceptor. Gal3Sulfo-T2 activity   was 
measured with the acceptor Galβ1, 4 GlcNAcβ1, 6(3-O-MeGalβ1, 3)GalNAcα-O-Bn. 
2.11 N-Acetylglucosaminltransferase assay 
The reaction mixture (30μl) contained 5mM acceptor, 70 mM Hepes-NaOH pH7.0, 7mM 
GlcNAc 1, 5 lactone, 14mM Mn acetate, 5mM ATP, 2mM NaN3, 0.2μCi UDP-[6-3H] GlcNAc 
(NEN-Dupont) and 15μl tumor extract and incubated for 4h at 37°C. The radioactive 
products from benzyl glycosides were separated by hydrophobic chromatography on Sep-
Pak C18 cartridge and from allyl glycoside by Biogel P2 column chromatography as 
described above. 
2.12 β N-acetylhexosaminidase treatment 
10 μl of the [6-3H] N-acetyl glucosamine containing products were incubated at 37°C for 20h with 
0.1 unit of this enzyme as recommended by supplier (GLYKO) in a reaction volume of 20μl.  
2.13 β1, 3Galactosidase (recombinant enzyme from calbiochem) treatment 
10 μl of the [6-3H] N-acetyl glucosamine containing product from Galβ1, 3 (GlcNAc β 1, 6) 
GalNAc α O-Al was mixed with 10μl of 0.1M citrate buffer-0.1% BSA pH 5.0 and 10μl (20 
mU) recombinant enzyme and incubated at 37°C for 20h. 
2.14 Lectin-agarose chromatography 
PNA-agarose (Sigma), ConA-agarose (Sigma) and GSL II-agarose (Vector) columns of 5 ml 
bed volume were used under conditions as recommended by suppliers. 
2.15 Thin layer chromatography 
TLC was carried out on Silica gel GHLF (250 μm scored 20x20cm; Analtech, Newark DE). 
The solvent systems A [1 propanol/NH4OH/H2O (12/2/5 V/V)] and B [n-butanol/acetic 
acid/H2O (3/2/1)] were used. The acceptor compounds were located on the plates by 
spraying with sulfuric acid in ethanol and heating at 100°C. The radioactive products were 
located by scraping 0.5cm width segments of silica gel and soaking them in 2 ml water in 
vials followed by liquid scintillation counting. 
3. Results 
3.1 Non-reducing terminal of complex carbohydrate chains 
Several glycosyltransferases and glycan-sulfotransferases act on the non-reducing terminal 
of mucin Core2 tetra-and tri-saccharides and Globo backbone unit of gangliosides, core 1 
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2.4 Enzyme assays 
Glycosyltransferase activity in tumor extract was determined by mixing the tumor extracts 
with acceptor and radiolabeled monosaccharide donor under the reaction conditions 
detailed below, followed by separation of unreacted donor from the radioactive product 
using anionic or hydrophobic chromatography. In all cases, the radioactive content of 
isolated products was determined by using 3a70 scintillation cocktail (research Products 
International, Mount Prospect, IL) and a Beckman LS9000 scintillation counter. Controls for 
each assay contained the reaction mixture with everything except the acceptor. Radioactivity 
of control was subtracted from that of product to obtain the results presented in the Tables. 
All assays were run in duplicate. Results from duplicate runs did not vary by more than 5%. 
The following are the conditions for individual enzymatic assays. Reaction temperature in 
all cases was 37°C.  
2.5 Sialyltransferase 
α2,3- and α2,6 sialyltransferase (ST) assay reactions proceeded for 2h in a mixture containing 
100mM sodium cacodylate buffer (pH 6.0), 7.5mM acceptor, CMP-[9-3H] NeuAc (typically 
0.2μCi) and 10μl tumor extract in a total volume of 20μl (Chandrasekaran et al. 1995, 2005). 
2.6 Gal/GalNAc transferases 
βGlcNAc: β1,4Gal-T and αGalNAc:β1,3Gal-T assay mixtures in duplicate contained 0.1M 
Hepes-NaOH pH 7.0, 7mM ATP, 20mM Mn acetate, 1mM UDP-Gal. UDP [14C] Gal (0.05μCi; 
327mCi/mmol; Amersham), 0.5mM acceptor (unless otherwise stated) and 10μl tumor 
extract in a total volume of 20μL (Chandrasekaran et al. 2001). It was incubated for 4h;  
βGlcNAc:β1,4GalNAc-T assay mixtures in duplicate contained 0.1M Hepes-NaOH ph7.0, 
7mM ATP, 20mM Mn acetate, UDP [3H] GalNAc (0.20μCi; 7.8Ci/mmol: New England 
Nuclear Corp.)  7.5mM acceptor and incubated for 4h (Chandrasekaran et al. 2001).  
2.7 Fucosyltransferases 
α1,2,  α1,3- , α1,4-fucosyltransferase  and FT VI  assay reactions were carried out for 2h in a 
reaction mixture containing 50mM Hepes buffer (pH 7.5), 5mM MnC12, 7mM ATP, 3mM 
NaN3, 3mM synthetic acceptor, 0.05μCi GDP-[14C]Fuc (290mCi/mmol) and 10μl tumor 
extract in a total volume of 20μl (Chandrasekaran et al. 1996).   
2.8 Glycan: sulfotransferases 
Sulfotransferase (Sulfo-T) assay reactions took 2h and required a mixture containing 100mM 
Tris-Maleate (pH 7.2), 5mM Mg Acetate, 5mM ATP, 10mM NaF, 10mM BAL, 7.5mM 
acceptor, 0.5μCi of [35S]PAPS (specific activity 2.4Ci/mmol) and 10μl of tumor extract in a 
total volume of 30μl (Chandrasekaran et al. 2004).  
2.9 Chromatographic methods 
Dowex-1-Cl or Sep-Pak C18 cartridges were used to isolate radiolabeled product from the 
reaction mixture. For Gal-T, GalNAc-T and FT assays, the incubation mixture was diluted 
with 1ml water and passed through a 1ml bed volume of Dowex-1-Cl column 
(Chandrasekaran et al. 1996, 2001). The column was washed twice with 1ml water. The 
breakthrough and the water wash contained the [14C]-galactosylated or [14C]-fucosylated 
products formed with neutral acceptors. 3ml of 0.1M NaCl was used to obtain [14C]-
fucosylated products from sialylated acceptors after water elution. For sialyltransferase 
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assays, the radioactive products from benzylglycosides were separated by hydrophobic 
chromatography on Sep-Pak C18 cartridge (Water, Milford, MA), and elution of the product 
was done with 3ml methanol (Chandrasekaran et al. 2005; Palcic et al. 1998). For 
sulfotransferase assays, elution of the [35S]-sulfated compound from Dowex-1-Cl column 
could be achieved by 3ml of 0.2M NaCl (Chandrasekaran et al. 2001). 
2.10 Effect of divalent cations on gastric tumor Gal: 3-O-sulfotransferase activity 
For seeing the effect of divalent cations on Gal: 3-O-sulfotransferase activity the incubation 
mixture contained varying concentration (1-50mM) of Mg acetate, Mn acetate or Ca acetate 
under the standard incubation conditions. Gal3Sulfo-T4 activity was assayed using 3-O-Me 
Galβ1, 4 GlcNAcβ1,6(Galβ1,3)GalNAcα-O-Bn as the acceptor. Gal3Sulfo-T2 activity   was 
measured with the acceptor Galβ1, 4 GlcNAcβ1, 6(3-O-MeGalβ1, 3)GalNAcα-O-Bn. 
2.11 N-Acetylglucosaminltransferase assay 
The reaction mixture (30μl) contained 5mM acceptor, 70 mM Hepes-NaOH pH7.0, 7mM 
GlcNAc 1, 5 lactone, 14mM Mn acetate, 5mM ATP, 2mM NaN3, 0.2μCi UDP-[6-3H] GlcNAc 
(NEN-Dupont) and 15μl tumor extract and incubated for 4h at 37°C. The radioactive 
products from benzyl glycosides were separated by hydrophobic chromatography on Sep-
Pak C18 cartridge and from allyl glycoside by Biogel P2 column chromatography as 
described above. 
2.12 β N-acetylhexosaminidase treatment 
10 μl of the [6-3H] N-acetyl glucosamine containing products were incubated at 37°C for 20h with 
0.1 unit of this enzyme as recommended by supplier (GLYKO) in a reaction volume of 20μl.  
2.13 β1, 3Galactosidase (recombinant enzyme from calbiochem) treatment 
10 μl of the [6-3H] N-acetyl glucosamine containing product from Galβ1, 3 (GlcNAc β 1, 6) 
GalNAc α O-Al was mixed with 10μl of 0.1M citrate buffer-0.1% BSA pH 5.0 and 10μl (20 
mU) recombinant enzyme and incubated at 37°C for 20h. 
2.14 Lectin-agarose chromatography 
PNA-agarose (Sigma), ConA-agarose (Sigma) and GSL II-agarose (Vector) columns of 5 ml 
bed volume were used under conditions as recommended by suppliers. 
2.15 Thin layer chromatography 
TLC was carried out on Silica gel GHLF (250 μm scored 20x20cm; Analtech, Newark DE). 
The solvent systems A [1 propanol/NH4OH/H2O (12/2/5 V/V)] and B [n-butanol/acetic 
acid/H2O (3/2/1)] were used. The acceptor compounds were located on the plates by 
spraying with sulfuric acid in ethanol and heating at 100°C. The radioactive products were 
located by scraping 0.5cm width segments of silica gel and soaking them in 2 ml water in 
vials followed by liquid scintillation counting. 
3. Results 
3.1 Non-reducing terminal of complex carbohydrate chains 
Several glycosyltransferases and glycan-sulfotransferases act on the non-reducing terminal 
of mucin Core2 tetra-and tri-saccharides and Globo backbone unit of gangliosides, core 1 
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disaccharide and Asparagine  linked complex carbohydrate chains terminating in Gal 
residues,  leading to a complexity of cancer-associated terminal glycan structures as shown 
in Table 2. Hence, we examined the levels of many of these enzyme activities in gastric 
tumor tissue as well as non-tumor gastric tissue of the same patient in ten gastric cancer 
cases for identifying any significant consistent change in any of these enzyme activities in 
gastric cancer. The specific acceptor compounds used in the present study for assaying the 
enzymes are reported in Table 3. The results on various enzyme levels are presented in 
Tables 4 and 5. 
 
Carbohydrate chain terminal Modifying  glycosyl-and sulfo-
transferases 
1. *GlcNAcβ1,6(Galβ1,3)GalNAcα-O-Ser/Thr 
(mucin core2 trisaccharide) 





(mucin core2 tetrasaccharide) 
b) Asparagine  linked complex carbohydrate chains 
terminating in *Gal residues 
 
Gal3SulfoT2;  Gal3SulfoT3 






c) *Galβ1,3 GalNAcα-O-Ser/Thr  
(mucin core1 disaccharide) 
d) *Galβ1,3 GalNAcβ 1,3 Galα-O-R  
(Globo unit of gangliosides) 
 
Gal3SulfoT4; ST3Gal  I 




* Denotes the terminal unit utilized by the enzyme to transfer monosaccharide or sulfate 
Table 2. Glycosyl-and sulfo-transferases involved in carbohydride chain terminal 
modification 
3.2 Fucosyltransferase activities in gastric carcinoma 
α1,3-FT contributed the major FT activity in both normal and tumor specimens in all cases. 
In nine cases, the tumor specimens as compared to normal (with the exception case 10) 
contained lower α1,3-FT activity (a decrease of 10-60%). There was a marked reduction (40-
90%) of α1, 2-FT activity in seven cancer cases (2, 3, 4, 5, 6, 7 and 9). Thus, it is interesting to 
note that a decrease of α 1, 3- and α 1, 2- FT activities occurred in the same specimens. On 
the other hand, α1,4-FT activity and FTVI activity were present in increased level in the 
same five cancer cases (1, 3, 4, 7 and 10) and in decreased level in the same five cases (2, 5, 6, 
8 and 9). Four tumor specimens (cases 7, 4, 1 and 10) which include two Signet ring cell CA 
and two mucin producing adenocarcinoma exhibited high elevation of FTVI activity (8.9, 
10.5, 51.4 and 199.5 fold respectively) as compared to the corresponding normal specimen. 
Further, a highly noteworthy finding is that the gastrointestinal stromal tumor specimen 
(case 12) was distinct in having a low level of α1, 3-FT activity and negligible amounts of α1, 
4-FT, α1,2-FT and FTVI activities as compared to other tumor specimens. 
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Glycosyl- or Sulfo-transferases    Acceptors  
 Fucosyltransferases: 
                α 1, 2-FT 
                α 1, 3-FT 
                α 1, 4-FT 
                FTVI 
 
Gal β-O-Bn 
2-O-Me Gal β 1, 4 GlcNAc 
2-O-Me Gal β 1, 3 GlcNAc 





3-O-Me Gal β 1, 4 GlcNAc β 1, 6 (Gal β 1, 3) GalNAc 
α-O-Bn 
2-O-Me Gal β 1, 3 GlcNAc β-O-Bn 
Gal β 1, 4 GlcNAc β 1, 6 (3-O-Me Gal β 1, 3) GalNAc 
α-O-Bn [corrected for ST3(N) activity] 
 
β Gal/GalNAc transferase: 
β 1, 4 Gal-T 
β 1, 4 GalNAc-T 
α GalNAc: β 1, 3 Gal-T 
3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Bn 
3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Bn 
4-Fluoro GlcNAc β 1, 6 GalNAc α-O-Bn 
Glycan: Sulfotransferases 
Gal 3 Sulfo-T2 
Gal 3 Sulfo-T4 
GlcNAc 6 Sulfo-T 
Gal β 1, 4 GlcNAc β 1, 6 (3-O-Me Gal β 1, 3) GalNAc 
α-O-Bn 
3-O-Me Gal β 1, 4 GlcNAc β 1, 6 (Gal β 1, 3) GalNAc 
α-O-Bn 
GlcNAc β 1, 3 Gal β 1, 4 Glc 
Table 3. Specific acceptors for measuring Glycosyl- and Sulfo- transferase activities in gastric 
tumor and non-tumor specimens 
3.3 Sialyltransferase activities in gastric carcinoma 
ST3 (O) activity, which forms 3'-sialyl T hapten (NeuAcα2, 3Galβ1, 3GalNAcα) was the 
predominant sialyltransferase activity in all gastric tissue specimens. This activity increased 
(1.7-172.0 fold) in six (cases 2, 3, 4, 6, 9 and 10) and decreased in four (cases 1, 5, 7 and 8) 
gastric tissue specimens. ST6(N) activity synthesizing 6'-LacNAc type 2 unit 
(NeuAcα2,6Galβ1,4GlcNAcβ-) ranged 4% - 78% of the ST3(O) activity in the tumor tissue 
specimens studied and ST3(N) activity forming 3'-sialyl LacNAc was even far less than 
ST6(N) activity. Three out of four tumor specimens from Signet ring cell carcinoma (cases 2, 
3 and 4) and three out of five tumor specimens from adenocarcinoma (cases 6, 9 and 10) 
showed an increased level of ST3 (O) activity. Two cases of Signet ring cell CA (1 and 3) and 
three cases of adinocarcinoma (7, 8 and 9) showed significant ST6 (N) activity in the range 
8.2 – 78.0% of ST3 (O) activity. 
3.4 β-GlcNAc : β1,4-Gal/GalNAc and α-GalNAc : β1,3-Gal transferase activities in 
gastric carcinoma 
Three tumor specimens (cases 3, 4 and 10) while exhibiting an increase in β1, 4Gal-T activity, 
other tumor specimens contained lower level of this activity than the corresponding normal 
specimens. Six tumor specimens (cases 3, 4, 5, 6, 8 and 10) showed an increased level of β1, 
4GalNAc-T activity. It is remarkable that two tumor specimens (cases 5 and 6) from 
adenocarcinoma contained only 30% and 40% level of α-GalNAc: β1, 3Gal-T activity as 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
128 
disaccharide and Asparagine  linked complex carbohydrate chains terminating in Gal 
residues,  leading to a complexity of cancer-associated terminal glycan structures as shown 
in Table 2. Hence, we examined the levels of many of these enzyme activities in gastric 
tumor tissue as well as non-tumor gastric tissue of the same patient in ten gastric cancer 
cases for identifying any significant consistent change in any of these enzyme activities in 
gastric cancer. The specific acceptor compounds used in the present study for assaying the 
enzymes are reported in Table 3. The results on various enzyme levels are presented in 
Tables 4 and 5. 
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1. *GlcNAcβ1,6(Galβ1,3)GalNAcα-O-Ser/Thr 
(mucin core2 trisaccharide) 
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b) Asparagine  linked complex carbohydrate chains 
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(mucin core1 disaccharide) 
d) *Galβ1,3 GalNAcβ 1,3 Galα-O-R  
(Globo unit of gangliosides) 
 
Gal3SulfoT4; ST3Gal  I 




* Denotes the terminal unit utilized by the enzyme to transfer monosaccharide or sulfate 
Table 2. Glycosyl-and sulfo-transferases involved in carbohydride chain terminal 
modification 
3.2 Fucosyltransferase activities in gastric carcinoma 
α1,3-FT contributed the major FT activity in both normal and tumor specimens in all cases. 
In nine cases, the tumor specimens as compared to normal (with the exception case 10) 
contained lower α1,3-FT activity (a decrease of 10-60%). There was a marked reduction (40-
90%) of α1, 2-FT activity in seven cancer cases (2, 3, 4, 5, 6, 7 and 9). Thus, it is interesting to 
note that a decrease of α 1, 3- and α 1, 2- FT activities occurred in the same specimens. On 
the other hand, α1,4-FT activity and FTVI activity were present in increased level in the 
same five cancer cases (1, 3, 4, 7 and 10) and in decreased level in the same five cases (2, 5, 6, 
8 and 9). Four tumor specimens (cases 7, 4, 1 and 10) which include two Signet ring cell CA 
and two mucin producing adenocarcinoma exhibited high elevation of FTVI activity (8.9, 
10.5, 51.4 and 199.5 fold respectively) as compared to the corresponding normal specimen. 
Further, a highly noteworthy finding is that the gastrointestinal stromal tumor specimen 
(case 12) was distinct in having a low level of α1, 3-FT activity and negligible amounts of α1, 
4-FT, α1,2-FT and FTVI activities as compared to other tumor specimens. 
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                α 1, 3-FT 
                α 1, 4-FT 
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Table 3. Specific acceptors for measuring Glycosyl- and Sulfo- transferase activities in gastric 
tumor and non-tumor specimens 
3.3 Sialyltransferase activities in gastric carcinoma 
ST3 (O) activity, which forms 3'-sialyl T hapten (NeuAcα2, 3Galβ1, 3GalNAcα) was the 
predominant sialyltransferase activity in all gastric tissue specimens. This activity increased 
(1.7-172.0 fold) in six (cases 2, 3, 4, 6, 9 and 10) and decreased in four (cases 1, 5, 7 and 8) 
gastric tissue specimens. ST6(N) activity synthesizing 6'-LacNAc type 2 unit 
(NeuAcα2,6Galβ1,4GlcNAcβ-) ranged 4% - 78% of the ST3(O) activity in the tumor tissue 
specimens studied and ST3(N) activity forming 3'-sialyl LacNAc was even far less than 
ST6(N) activity. Three out of four tumor specimens from Signet ring cell carcinoma (cases 2, 
3 and 4) and three out of five tumor specimens from adenocarcinoma (cases 6, 9 and 10) 
showed an increased level of ST3 (O) activity. Two cases of Signet ring cell CA (1 and 3) and 
three cases of adinocarcinoma (7, 8 and 9) showed significant ST6 (N) activity in the range 
8.2 – 78.0% of ST3 (O) activity. 
3.4 β-GlcNAc : β1,4-Gal/GalNAc and α-GalNAc : β1,3-Gal transferase activities in 
gastric carcinoma 
Three tumor specimens (cases 3, 4 and 10) while exhibiting an increase in β1, 4Gal-T activity, 
other tumor specimens contained lower level of this activity than the corresponding normal 
specimens. Six tumor specimens (cases 3, 4, 5, 6, 8 and 10) showed an increased level of β1, 
4GalNAc-T activity. It is remarkable that two tumor specimens (cases 5 and 6) from 
adenocarcinoma contained only 30% and 40% level of α-GalNAc: β1, 3Gal-T activity as 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
130 
compared to the normal specimens. On the contrary, the tumor specimen of case 10 as 
compared to other tumor specimens had a high level of this activity, which exceeded even 
the levels of its β1, 4Gal/GalNAc-T activities. The level of αGalNAc : β1,3Gal-T activity was 




 Glycosyltransferase activities in Tissue specimens: Incorporation 
of [14C] or [3H] monosaccharides (CPMx10-3) into the enzyme 
specific acceptor catalyzed by 1mg protein of the tissue extract 
  1 2 3 4 5 6 7 8 9 10 11 12 
Fucosyl-
transferases 




































































































































































































































































             












































































































N: Non-tumor gastric tissue; T: Tumor gastric tissueValues in parentheses indicate fold of enzyme 
activity in tumor with respect to the normal 
Table 4. The levels of glycosyltransferase activities in human gastric non-tumor and tumor 
specimens 
Exploring the Utility of Carbohydrate Associated Transferase 






Tumor Histology Differen- tiation 
 Sulfotransferase activities in tissue 
specimens: Incorporation of 35S-sulfate 
(CPMx10-3) into enzyme specific acceptors 
catalyzed by 1mg protein of the tissue 
extract 
Gal3sulfo T2 Gal3sulfo T4 GlcNAc6  sulfo T  
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specimens 
3.5 Glycan: Sulfotransferase activities in gastric carcinoma 
Both Gal3Sulfo-T4 activity specific for Galβ1, 3GalNAcα- and Gal3Sulfo-T2 activity utilizing 
mainly Galβ1,4GlcNAcβ- were found, respectively, at 2.4→61.7 fold and 1.7→156.7 fold 
elevated level in all the gastric tumor specimens studied. On the other hand, an increased 
level of GlcNAc6-Sulfo-T activity was also evident but to a lesser extent in nine gastric 
tumor specimens. Five tumor specimens, all from adinocarcinoma (cases 5, 6 7, 9 and 10) 
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compared to the normal specimens. On the contrary, the tumor specimen of case 10 as 
compared to other tumor specimens had a high level of this activity, which exceeded even 
the levels of its β1, 4Gal/GalNAc-T activities. The level of αGalNAc : β1,3Gal-T activity was 
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activity in tumor with respect to the normal 
Table 4. The levels of glycosyltransferase activities in human gastric non-tumor and tumor 
specimens 
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mainly Galβ1,4GlcNAcβ- were found, respectively, at 2.4→61.7 fold and 1.7→156.7 fold 
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contained predominantly Gal3Sulfo-T4 while Gal3Sulfo-T2 dominated in three specimens of 
Signet ring cell CA(cases 1, 2 and 3). 
3.6 The identity of Gal: 3-O-Sulfo transferases in human gastric tumor specimens 
Acceptor specificities:  A consistent marked elevated Gal: 3-O-Sulfotransferase activities in 
gastric tumors prompted us to establish further the identity of these enzymes with the known 
cloned Gal3Sulfotransferases (Chandrasekaran et. al. 2004). We studied four tumor specimens 
(cases 2, 3, 6 and 7) for acceptor specificities and the results are presented in Table 6.  
 
 
Table 6. Establishing the identity of Gal : 3-O-Sulfotransferases in Human Gastric Tumor 
Specimens 
The values in parentheses are the actual CPM designated as 100% for the acceptor Galβ1, 
3GalNAcα-O-Al in the cases 6 and 7 and for the acceptor Galβ1,4GlcNAc in the cases of 2 
and 3 
Gal3Sulfo-Ts of tumor specimens from cases 2 and 3 showed low activity towards Galβ1, 
3GalNAcα-O-Al and that from cases 6 and 7 very low activity towards Galβ1, 4GlclNAc. 
Tumor specimens 6 and 7 contained mostly Gal3Sulfo-T4 (Chandrasekaran et. al. 2004). 
Gal3Sulfo-Ts of tumor specimens 2 and 3 were found to be less active towards Fetuin 
triantennary asialo glycopeptides, which was established as the best acceptor in our earlier 
studies for Gal3Sulfo-T3 (Chandrasekaran et. al. 2004). Further, the above enzymes were 
very active towards Galβ1, 3GalNAcβ1, 3Galα-O-Me whereas Gal3Sulfo-T3 showed very 
low activity towards this acceptor.  Gal3Sulfo-Ts of tumor specimens 2 and 3 were found to 
have the identity of cloned Gal3Sulfo-T2 (Chandrasekaran et. al. 2004). 
Influence of divalent metal ions (see Fig 1):  None of the divalent metal ions Ca2+, Mn2+ and 
Mg2+ had any significant stimulating effect on Gal3Sulfo-T of tumor specimen 7. In fact, a 
gradual decline in enzyme activity was noticed upon increasing the concentration of Mn2+ in 
the reaction mixture. Thus, this enzyme resembled Gal3Sulfotransferase from breast tumor 
(Chandrasekaran et. al. 1997) as well as the cloned Gal3Sulfo-T4 (Chandrasekaran et. al. 
2004). On the other hand, the metal ions Ca2+, Mn2+ and Mg2+ stimulated the activity of 
tumor specimen 3. Mn2+ stimulated the activity between 5-20mM and then the activity 
decreased reaching the initial level at 50mM. This pattern of influence by Mn2+ on the 
activity was quite similar to that of Gal3Sulfotransferase from colon tissue (Chandrasekaran 
et. al. 1997) and cloned Gal3Sulfo-T2 (Chandrasekaran et. al. 2004). On the contrary, the 
activity of cloned Gal3Sulfo-T3 was stimulated by Mn2+ reaching the maximum at 40-50mM 
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(Chandrasekaran et. al. 2004). Thus, Gal3Sulfo-T of tumor specimen 7 was similar to 
GalSuflo-T4 and that of tumor specimen 3 closely resembled Gal3Sulfo-T2. 
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A. Case 7 tumor specimen; B. Case 3 tumor specimen ● Mn;  Mg; ○ Ca 
Fig. 1. Influence of divalent metal ions on gastric tumor Gal3 Sulfotransferase activities.  
3.7 Identification of human gastric tissue α- GlcNAc transferase acting on terminal 
GlcNAc residue 
The present investigation identified two N-acetylglucosaminyltransferase activities in 
gastric tissues using mucin core 2 tri- and tetra-saccharides as acceptors as reported in Table 
7. An increased level (1.5-8.5 fold) of GlcNAc transferase activity on mucin core 2 
tetrasaccharide was observed in three gastric tumor specimens as compared to that of the 
corresponding non-tumor specimens. Further, the level of this enzyme is about two-fold as 
compared to the corresponding activity of the other enzyme. The linkages of [6-3H] GlcNAc 
residues attached to mucin core 2 tri- and tetra-saccharides were further examined by 







 Incorporation [6-3H] GlcNAc (CPM x 10-3) catalyzed by 1 mg protein of 
the tissue extract 
 
Gal β 1, 3 (GlcNAc β 1, 6)  
GalNAc α-O-Al 
 
Gal β 1, 3 (Gal β 1, 4 GlcNAc β 1, 6)  
GalNAc α-O-Bn 












  5 N 
T 
15.7 





  2.1 
15.0 
  2.7 
23.0 
11 T  7.0 16.4 
Table 7. The levels of human gastric tissue N-Acetylglucosaminyltransferase activities 
towards mucin core 2 tri-and tetra-saccharides 
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A. Case 7 tumor specimen; B. Case 3 tumor specimen ● Mn;  Mg; ○ Ca 
Fig. 1. Influence of divalent metal ions on gastric tumor Gal3 Sulfotransferase activities.  
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3.8 TLC studies 
Fig 2 A (lanes A, B, C and D respectively) shows the mobilities (solvent system A) of the 
acceptor 3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAcα-O-Bn, the [6-3H] GlcNAc containing 
product, [6-3H] GlcNAc containing product incubated with and without β-N-acetyl 
hexosaminidase (Jack bean). Lanes B, C and D show that the radioactive products have the 
same mobility. It is evident from these results that β-N-acetyl hexosaminidase (Jack bean) 
was not able to hydrolyze the [6-3H] GlcNAc containing product. Fig 2 B (lanes A and 
B)shows the mobilities (solvent system B) of 3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAcα-O-
Bn and 3-O-Me Gal β 1, 3 (Gal β 1, 4 GlcNAc β 1, 6) GalNAcα-O-Bn. Lane c shows the 
mobilities of 3-O-Sulfo Gal β 1, 3 (Gal β 1, 4  GlcNAc β 1, 6) GalNAcα-O-Bn and Std. 
GlcNAc. Lanes D, E and F show respectively the mobilities of [6-3H] GlcNAc containing 
product from 3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAcα-O-Bn,  3-O-Me Gal β 1, 3 (Gal β 1, 
4, GlcNAc β 1, 6) GalNAcα-O-Bn and 3-O-Sulfo Gal β 1, 3 (Gal β 1, 4, GlcNAc β 1, 6) 
GalNAcα-O-Bn  after treatment with β-N-acetyl hexosaminidase (Jack bean). It is clear that 
[6-3H] GlcNAc was released only from the radioactive products arising from the last two 
acceptors (Lanes E and F) indicating that [6-3H] GlcNAc is β linked to mucin core 2 
tetrasaccharide . Fig 2 C lane A shows the mobilities (Solvent system B) of acceptor Gal β 1, 
3 (GlcNAc β 1, 6) GalNAcα-O-Al and Std. GlcNAc. Treatment with recombinant β 1, 3 
Galactosidase resulted in the removal of Gal as evident from the faster mobility of the 
radioactive product (lane C). β-N-Acetylhexosaminidase (Jack bean) did not act on the 
radioactive product (compare lanes E and F). 
3.9 Lectin-agarose chromatography 
The primary sugar specificity of PNA is Gal linked β 1, 3to GalNAc. ConA binds Man and 
Glc and GSL II binds terminal GlcNAc but these lectins have additional structural 
requirements for binding. Fig 3 shows PNA-agarose  affinity chromatography of [6-3H] 
GlcNAc containing product from Gal β 1, 3 (GlcNAc β 1, 6) GalNAcα-O-Al. More than 90% 
of the product binds to this column as shown in Fig 3 A indicating that [6-3H] GlcNAc is not 
transferred to the Gal terminal. The radioactive product after recombinant β 1, 3 
Galactosidase treatment was subjected to PNA-agarose affinity chromatography and it 
showed > 90% non-binding to this column. On the contrary to these results, Nakayama et al. 
(1999) without showing data just mentioned in their paper that their cloned human α 1, 4 N-
acetylglucosaminyltransferase acted only on the Gal moiety of mucin core 2 trisaccharide. 
We find that [6-3H] GlcNAc linkage to β 1, 6 linked GlcNAc in mucin core 2 is completely 
resistant to Jack bean β-N-acetyl hexosaminidase which has a broad specificity cleaving non-
reducing terminal β 1- 2, 3, 4 or 6 linked GlcNAc and GalNAc residues (Li and Li 1970). This 
enzyme was also able to cleave very efficiently GlcNAc linked β 1, 4 to GlcNAc (N, Nʹ-
Diacetylchitobiose) (Li and Li 1970). Thus GlcNAc transferred to β 1, 6 linked GlcNAc has 
been found to be in α-linkage. Nakayama et al. (1999) reported that α 1, 4 GlcNAc-T was 
responsible for the formation of GlcNAc α 1, 4 Gal β-R which in turn was responsible for 
class III mucin ConA reactivity. In this connection, it is noteworthy that the present study 
found that the radioactive compound [6-3H] GlcNAc α GlcNAc β 1, 6 (Gal β 1, 3) GalNAc α-
O-Al did not bind to ConA-agarose as well as GSL II-agarose (Fig 4 A and B). After the 
removal of Gal by recombinant β 1, 3 galactosidase treatment, the resulting radioactive 
compound still did not bind to GSL II-agarose (Fig 4 C). 
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A B C 
20 59 180 181 20 80 135 104 20 62 96 155 102   
19 48 110 174 19 67 115 78 19 97 62 74 106   
18 55 106 213 18 46 125 81 18 95 67 102 109   
17 62 114 147 17 72 806 433 17 98 100 119 94   
16 
 
85 154 80 16 63 2996 2503 16 114 99 83 107   
15 81 180 159 15 55 1954 2238 15 84 106 90 115   
14 527 170 208 14 63 303 414 14 83 703 219 247   
13 482 1861 1910 13 67 108 79 13 233 2942 158 265   
12 69 218 313 12 54 75 51 12 142 249 123 100   
11 50 78 121 11 48 107 52 11 95 97 114 136   
10 55 132 102 10 74 92 99 10 109 125 233 86   
9 50 66 152 9 85 134 136 9 816 400 3217 1404   
8 48 85 97 8 435 288 240 8 3550 392 997 2988   
7 54 79 106 7 512 109 98 7 287 84 109 136   
6 40 71 109 6 58 93 52 6 150 62 116 127   
5 49 97 110 5 44 108 51 5 113 84 124 137   
4 42 127 118 4 58 97 62 4 130 84 98 102   
3 49 148 108 3 47 89 47 3 94 69 102 98   
2 47 68 139 2 42 79 62 2 108 63 137 104   
1 48 114 153 1 50 115 66 1 85 72 128 121   
   A     B     C     D   A    B   C     D     E      F     A      B      C      D      E 
Fig. 2. TLC Identification of βGlcNAc:  αGlcNAc transferase activity in human gastric tumor 
Fig. 2  A (solvent system A).  
A: Acceptor compound 3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Bn 
B: [6-3H] GlcNAc containing product resulting from A 
C and D: B incubated with and without β N-acetylhexosaminidase (Jack bean)  
Fig. 2. B (solvent system B). 
A: 3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Bn 
B: 3-O-Me Gal β 1, 3 (Gal β 1, 4 GlcNAc β 1, 6) GalNAc α-O-Bn 
C: 3-O-Sulfo Gal β 1, 3 (Gal β 1, 4 GlcNAc β 1, 6) GalNAc α-O-Bn and Std. GlcNAc 
D, E and F: [6-3H] GlcNAc containing products resulting from A, B and C respectively after 
β N- acetylhexosaminidase(Jack bean) treatment 
Fig. 2. C (Solvent system B). 
A: The acceptor Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Al and Std. GlcNAc 
B:  [6-3H] GlcNAc containing product resulting from the acceptor in A 
C:  B after β 1, 3 galactosidase (recombinant) treatment  
D and E:  B incubated with and without β N- acetylhexosaminidase (Jack bean)  
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Fig. 2. TLC Identification of βGlcNAc:  αGlcNAc transferase activity in human gastric tumor 
Fig. 2  A (solvent system A).  
A: Acceptor compound 3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Bn 
B: [6-3H] GlcNAc containing product resulting from A 
C and D: B incubated with and without β N-acetylhexosaminidase (Jack bean)  
Fig. 2. B (solvent system B). 
A: 3-O-Me Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Bn 
B: 3-O-Me Gal β 1, 3 (Gal β 1, 4 GlcNAc β 1, 6) GalNAc α-O-Bn 
C: 3-O-Sulfo Gal β 1, 3 (Gal β 1, 4 GlcNAc β 1, 6) GalNAc α-O-Bn and Std. GlcNAc 
D, E and F: [6-3H] GlcNAc containing products resulting from A, B and C respectively after 
β N- acetylhexosaminidase(Jack bean) treatment 
Fig. 2. C (Solvent system B). 
A: The acceptor Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-O-Al and Std. GlcNAc 
B:  [6-3H] GlcNAc containing product resulting from the acceptor in A 
C:  B after β 1, 3 galactosidase (recombinant) treatment  
D and E:  B incubated with and without β N- acetylhexosaminidase (Jack bean)  
 




A:  [6-3H] GlcNAc containing product resulting from the acceptor Gal β 1, 3 (GlcNAc β 1, 6) GalNAc α-
O-Al 
B:  β 1, 3 galactosidase (recombinant) treated [6-3H] GlcNAc containing product 
Fig. 3. PNA-agarose affinity chromatography of [6-3H] GlcNAc containing product 
 
 
Affinity chromatography of [6-3H] GlcNAc containing product resulting from the acceptor Gal β 1, 3 
(GlcNAc β 1, 6) GalNAc α-O-Al  on A: Con A-agarose; B: GSL II-agarose; C: GSL II-agarose after β 1, 3 
galactosidase (recombinant) treatment 
Fig. 4. Chromatography on ConA-agarose and GSL II-agarose 
4. Discussion 
Many risk factors have been associated with the development of gastric cancer, and the 
pathogenesis is most likely multifactorial. One postulation on the development of this 
disease involves a succession of histologic changes that commence with atrophic gastritis, 
advance to mucosal metaplasia, and eventually result in a malignancy (Layke et al. 2004). 
Tumor development and growth can be viewed as uncontrolled tissue growth. Tumor 
growth relies on blood supply by the blood vessels (Kobayashi et al. 2003). It has been 
known that a growing tumor secretes factors that induce blood vessel growth (i.e., 
neovascularization) to support its own growth and survival (Folkman et al. 1995). A 
primary cell type of the blood vessels, especially microvessels in a tumor, is an endothelial 
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cell. Therefore, focus has been to discover factors that specifically control endothelial cell 
proliferation (Davis et al. 2003). The roles of other factors are just beginning to be 
understood (Sogn et al. 2005). The tumor microenvironment needs to be completely 
characterized for understanding its role in tumor progression and metastasis (Sogn et al. 
2005). Glycoproteins play a role in pathological processes due to immunological response to 
the altered oligosaccharides (Fukuda et al. 1996). They have roles in cell adhesion during 
inflammation and metastasis (Fukuda et al. 1996). Hence it is anticipated that glycoproteins 
may have a definite role in tumor microenvironment.  
Recently an important role for galectins in cancer micrometastasis became evident from the 
report of Khaldoyandidi, et al. (2003) that interactions between T-antigen of breast cancer 
cells and galectin-3 mediate both homotypic and heterotypic intercellular adhesion of 
metastatic breast cancer cells under conditions of flow in vitro and in vivo. A substitution of 
sulfate at C-3 position of β-galactosyl residue in T-hapten enhanced its binding efficiency 
about 15 fold towards galectin-4 and 3 fold towards galectin-3 (Ideo et al. 2002). Similarly, 
the studies of our laboratory on galectin specificities showed that 3-O-Sulfo Galβ1, 4GlcNAc 
as compared to Galβ1, 4GlcNAc was 3 fold more efficient in binding to galectin-1 (Allen et 
al. 1998). Thus, the enhancement of the binding ability to galectins by 3-O-Sulfation of β-
galactosyl residues appears to be a common characteristic of galectin family. In addition, 3'-
sialylation Core1 in contrast to 3'-sulfated Core1 had very weak affinity for galectin-4 (Ideo 
et al. 2002). Hippo et al. (2001) analyzed six gastric cancer cell lines by Northern Blot and 
observed an up-regulation of galectin-4. Sulfatide was found as a major acidic glycolipid in 
human gastric mucosa (Natomi et al. 1993) and the expression of cerebroside 
sulfotransferase mRNA in endoscopic bioptic specimens of eleven gastric cancer cases was 
reported by Kobayashi et al. (1999). The present study finds several fold consistent increase 
in Gal3Sulfotransferase activity in gastric tumor. The resulting 3-O-Sulfogalactosyl residues 
in gastric tumor cell glycoproteins and glycolipids may facilitate the interaction of gastric 
tumor cells with galectin-4, resulting in intercellular homotypic and heterotypic adhesion of 
gastric cancer cells. 
5. Conclusion 
It becomes evident from the present study that among the various transferases, which can 
modify the terminal Gal residues in carbohydrate chains as shown in Table 2, only 
Gal3Sulfotransferases show a consistent several fold elevated activity in all gastric tumor 
specimens: Gal3-sulfo-T4 (Gal3-sulfortransferase specific for Galβ1,3GalNAcα-O-Ser/Thr) 
and GlcNAc6-Sulfo-T are apparently associated with poorly differentiated gastric 
adenocarcinoma whereas poorly differentiated Signet ring cell gastric carcinoma expresses a 
high level of Gal3Sulfo-T2, a Gal3Sulfotransferase acting on Galβ1,4GlcNAcβ- terminal unit. 
The most consistent change in glycosyltransferase activity could be found only with α1, 2-
FT. A significant decrease in this activity was seen in the range 40 – 90% in seven gastric 
tumor specimens. Thus, the present study was able to show that down regulation of α1,2-FT 
activity accompanied by induction of Gal3-O-Sulfotransferase activities acting on Gal 
terminals could be involved in the facile sulfation of carbohydrate chains, which may 
contribute to the microenvironment suitable for interaction with galectin-4 in promoting 
tumor growth and metastasis. Furthermore, the sulfation of Gal terminal as well as GlcNAc 
residues would render the carbohydrate chains strong anionic charge, resistance to 
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understood (Sogn et al. 2005). The tumor microenvironment needs to be completely 
characterized for understanding its role in tumor progression and metastasis (Sogn et al. 
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degradation by sialidases, galactosidases and hexosaminidases and this would increase their 
half-life in receptor-mediated glycoprotein clearance.  
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lead to cell and tissue damage. It has been suggested that HER pathway activation can 
contribute to the development of resistance to cancer therapies (Zhou, 1992; Liang, 2003). 
Under normal conditions the activation of the EGFR family is controlled by spatial and 
periodic expression of its ligands, which belong to the EGF-related peptide growth family, 
such as EGF, heparin-binding EGF (HB-EGF), transforming growth factor alpha (TNF-α) 
and neuroregulin. These growth factors are synthesized as transmembrane precursors 
released from the cell surface by proteolytic cleavage and subsequently activate RTKs of the 
EGFR family in an autocrine or paracrine fashion. Despite the abundance of ligands 
identified for EGFR, ErbB3 and ErbB4, no direct ligand for HER2 has been discovered. 
Instead, HER2 functions as a homo or heterodimer with other members of the EGFR family 
through interaction with anonistic ligands, such as EGF, HB-EGF and TNF-α (Iwamoto, 
2006).  
Constant activation of receptor kinases leads to excessive activation of the signaling 
pathway. The causes of kinase over-expression can vary, mutations, autocrine kinase 
activation or amplification, for example. Elevated signal transfer activity can be connected to 
an increased risk of tumor development and malignancy (Walles, 1999). 
2. HER 1/ EGFR/ HERA/c-erbB1 
Epidermal growth factor receptor (EGFR) is one of four receptors in the pathway of 
epidermal growth factor transfer (HER, human epidermal growth factor receptor). It is a 
transmembrane glycoprotein consisting of 1186 amino acid residues. The gene encoding 
ErbB1 is located on chromosome 7 at p12.3-12.1. The emergence of mutation in this region 
leads to the appearance of mutated forms of EGFR. Three variants of these forms have been 
identified: I, II, III, with the mutation variant III (ΔEGFR) being most common. It involves 
the loss of the ligand binding site and leads to permanent spontaneous activation of the 
tyrosine kinase domain (Wojtukiewicz, 2010). 
The EGFR has three domains: extracellular, transmembrane and intracellular. The 
extracellular domain contains relatively high levels of cysteine residue. It is a site of mitogen 
activator binding (ligands ErbB1) ex. epidermal growth factor (EGF), tumor necrosis factor α 
(TNF α), and heparin binding EGF - (HB-EGF). After the ligand attaches to the EGFR there is 
a change in the conformational isomerism of the receptor particle and dimerization takes 
place. This interaction allows for the greatest utilization of the characteristics of various 
combining receptors (Wojtukiewicz, 2010). 
3. HER1/EGFR in gastric cancer 
Experiments using monoclonal antibodies against c-erbB1 have been carried out during the 
treatment of different tumors. Among others, tumor fighting properties of the monoclonal 
human-mouse chimera antibody have been used to neutralize cancer cells in the large 
intestine both in vitro and in vivo. The antibody, in the second phase of the experiment, has 
been adapted for patients with head, neck and lung tumors (Ghaderi, 2002). 
Meta-analysis showed the expression of c-erbB1 in gastric cancer in the range from 7.1% to 
as high as 80.0%. Positive correlation has been shown between the expression of this 
receptor and the diameter of the tumor, local invasion of the tumor and the spread of cancer 
cells to surrounding lymph nodes. Additionally, a relationship has been discovered between 
the stage of the tumor and the expression of c-erbB1. These results suggest c-erbB1 
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involvement in the progression of gastric cancer in patients from Iran and can be considered 
to be a prognosticating factor in these tumors. Similarly, high expression of c-erbB1 and its 
positive correlation with those prognosticating factors can become useful tools for 
diagnosing and prognosis in gastric patients from Iran. As a result it has been suggested that 
the expression of this receptor should be monitored as part of routine patient screening 
(Ghaderi, 2002). 
4. c-erbB2, HER2/neu 
HER2/neu is a proto-oncogene encoding transmembrane tyrosine kinase with a mass of 185 
kDa. c-erbB-2 is encoded by a gene located on chromosome 17 (Ghaderi, 2002). Located on 
the cell membrane it binds with its extracellular growth factor ligands to HER-2 which leads 
to dimer formation with another HER-2 molecule or with HER-1, HER-3 or HER-4. 
Dimerization causes phosphorylation of tyrosine residue in the cytoplasmic domain of the 
receptor and a further activation of the intracellular transfer pathway, which regulates 
various biological reactions, including cell proliferation, differentiation, movement and 
survival. High expression of c-erbB-2 has been described in various types of tumors such as 
breast cancer, ovarian cancer, lung cancer, salivary gland cancer, cancer of the large 
intestine, prostate cancer and pancreatic cancer. It has also been suggested that this protein 
is an indicator of an unfavorable outcome ( Satiroglu- Tufan, 2006). 
ErbB2 does not have its own ligands and plays the role of a co-activator in relation to the 
other proteins of the ERBB family. Its basic signaling results from the ability to react with 
other ERBB receptors. The receptor can undergo stabilization as well as transactivation 
through the ligands specific to ERBB1 and ERBB3, which allows ERBB2 to take part in signal 
transfer. Heterodimers created by ERBB2 are considered to be particularly active (Citki, 
2003; Lee, 2001). 
Attachment of various ligands to the extracellular domain initiates the cascading of signal 
transduction. The ligand attaching to the EGFR induces homodimerization and 
heterodimerization with other types of HER proteins. HER2 does not attach to any known 
ligand but it is a preferred partner of heterodimerization for other members of the HER family. 
The HER2 gene, located adjacent to the topoisomerase IIa, is related to the oncogene v-erbB of 
the avian erythroblastosis virus. In tumors HER2 behaves like an oncogene, mainly because 
high level of gene amplification induces over-expression of the protein on the cell membrane 
and which then acquires characteristics typical to atypical cells (Gravalos, 2008). 
In normal cell signal transduction Her2 plays a role of a growth factor and is connected with 
the regulation of cell growth, survival and differentiation. Its downstream signaling can be 
activated by point mutations, gene amplification or gene over-expression. There exists a 
hypothesis that high ERBB2 expression aids spontaneous dimerization which contributes to 
ERBB2 activation and downstream signaling (Arrington, 2009). 
Amplification of the ERBB2 gene and/or the over-expression of its protein have been 
discovered in 20-30% of breast cancers. Over-expression of HER2, along with negative 
estrogen reception and early metastasis of these cancers, is treated as an independent factor 
predicting survivability and recurrence of the disease (Arrington, 2009). 
5. HER2 in gastric cancer 
HER2 expression in gastric cancer was described for the first time in 1986 (Gravalos, 2008). 
In breast tumors ERBB2 functions as an oncogene, with gene amplification and protein over-
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expression in the cell membrane. Not only is gene amplification an indicator of unfavorable 
prognosis it is also a predictive marker for therapies using the monoclonal antibody 
trastuzumab on patients with breast cancer with metastases. Amplification of ERBB2 has 
been found not only in breast cancers but in other malignant tumors such ovarian cancer, 
lung cancer, cancer of the large intestine and gastric cancer. With the use of 
immunohistochemistry, in gastric cancer the expression of ERBB2 has been shown in 5.2- 
22.6% of cases, while the percentage of ERBB2 amplification with the use of fluorescent in 
situ hybridization (FISH) was within the range of 3.8-12.2%. However, clinical significance 
of ERBB2 amplification/overexpression in gastric cancer patients is still unclear (Barros-
Silva, 2009). 
An anomaly most commonly found in tumors is gene amplification with an increase of 
HER2 protein expression. In people with gastric cancer HER2 over-expression/amplification 
is detected in 15-59% of advanced tumors. In gastric cancer the up-regulation of HER2 
expression can control the cell cycle, cell movement and invasion through several 
intracellular paths. HER2 signaling plays a fundamental role in the development, 
progression and metastasis of gastric cancer (Lee, 2010). 
When the HER2 signal spreads from the cell surface to the intracellular effectors it requires a 
signal transducer and activates Grb2 (growth factor receptor- bound 2). It is thought that 
Grb2, which facilitates HER2 signaling, plays a fundamental role in the development of 
breast cancer, its progression and metastasis. Janes et al. (1994) have shown that in breast 
cancer cells HER2 over-expression was connected with the Grb2-SOS1 complex, which 
activated the Raf/MEK/MAPK pathway through Ras. However, the role of Grb2 and its 
connection to HER2 were seldom described in gastric cancer. Yu et al. (2009) have shown 
that Grb2 overexpression in the main mass of the tumor as well as in metastasis occurs late 
in the process of gastric cancer development. Overexpression of Grb2, however, was 
connected with unfavorable prognosis for these patients. Researchers have also shown a 
significant correlation between Grb2 and HER2 in stomach tumors (Yu, 2009). 
Bao et al. (2010) utilized RNA interference in gastric cancer from SGC-7901 and MNK-45 
cultures to halt the activity of the HER2 oncogene. Through this work they have shown that 
HER2 is not only closely connected to tumor growth but also to its invasiveness. Even as 
Sarna-HER2 stopped the growth of gastric cancer cells, HER2 reduced the migration and 
invasiveness of cancer cells. By comparing the HER2- knockdown group with the control 
group the researchers discovered the presence of several markers of metastasis: COL1A1, 
ACTA2, E- katherine, MMP-2 and MMP-9. The knockdown of HER2 was accompanied by 
significant deregulation of MMP-1, despite unchanged levels of MMP-2 and MMP-9. They 
also demonstrated that HER2 can regulate MMP-1 expression at the transcription level. 
HER2 does not increase transcription activity through Myc, SRY, CREB or NF-κB 
attachment sites. This could be caused by downstream particles that have not been detected 
in bioinformatic analysis and which have the ability to attach to the MMP-1 promoter region 
and to regulate its transcription activity. Another interesting phenomenon was the fact that 
when MMP-1 was reduced the invasiveness of cells was nearly completely blocked. 
However, transcription of the MMP-1 expressing vector into shRNA-HER2 cells, which 
displayed a low ability for metastasis, resulted in only a partial restoration of the 
invasiveness of these cells. This data shows that MMP-1 is a downstream effector of HER2 
and that HER2 can have an influence on other particles connected to metastasis, with the 
exception of MMP-1 (Bao, 2010). 
 




The ERBB3 encoding gene is located on the 12 chromosome at q13. The proteins encoded by 
it show a low activity of tyrosine kinase. In comparison to ERBB2 and ERBB4, ERBB3 
displays a much lower homologation of the endothelial and cytoplast domains with the 
ERBB1 receptor, (Kraus, 1989; Lebeau, 2001). In all probability the ERBB3 by itself does not 
function as an oncogene, but increase of its expression can strengthen the oncogenic effect 
caused by the over expression of the ERBB2 receptor (Alimandii, 1995). 
7. HER3 in gastric cancer 
The expression of the HER3 protein is very often observed in advanced gastric tumors. It 
has been shown that HER3 expression is connected with gastric cancer progression and 
prognoses, while the HER1 or HER2 expression did not show a similar relationship. In the 
conducted in vitro experiments, HER3 blocking caused the decrease of the downstream 
signals and the death of tumor cells. It would seem that HER3 could be potentially useful in 
clinical treatment of cancer patients, especially those with stomach tumors. HER3 is 
associated with the signals mediated from HER1 or HER2, and it may be also associated 
with the resistance to anti-HER1 or anti-HER2 therapies. High expression of the HER3 
protein could be an indicator of an unfavorable prognosis for gastric cancer patients. 
Positive staining has been observed more often in advanced tumors with high malignancy 
when compared to early stage cancers, which can point to the involvement of this protein in 
the progression process of the disease. Co-expression of HER3 and HER2 has not been 
connected to gastric cancer prediction. The creation of a heterodimer of HER3/HER1 has 
been observed in gastric cancer cells. What is more, a relationship between the expression of 
HER3 and HER1 proteins has been observed. The expression of HER1 has been accepted as 
a prognosis indicator for patients with gastric cancer. The expression of HER3 protein had a 
stronger correlation with remote metastases and the survival time of gastric cancer patients 
then HER1 expression. The role of the HER4 protein expression in gastric cancer has not 
been determined. A positive immunohistochemical reaction to this protein has been equally 
often observed in early stage and in advanced gastric cancer. A recent study of gastric 
cancer cells show that the GER family kinases were targets of amplified fibroblast growth 
factor receptor 2, and the inhibition of HER3 which resulted in the loss of cell proliferation 
initiated by the fibroblast growth factor receptor 2. For this reason, therapies involving 
blocking of HER3 can become part of the new strategy in gastric cancer treatment, along 
with therapies using anti-HER1 and anti-HER2 treatments (Hayashi, 2008). 
Kabayashi et al. (2003) demonstrated that activation of phosphoinositide-3-kinase 
(P13K)/Akt triggered by phosphorylation of HER3 was important for dedifferentiatiated 
phenotypes of gastric cancer cell cultures. They also showed that HER3 signal pathway 
contributed to the development of dedifferentiated carcinomas by promoting motility and 
invasion of adenocarcinoma cells. This evidence supports the possible involvement of HER3 
in the dedifferentiation process of gastric cancer. 
8. HER4  
The gene encoding ERBB4 is located on chromosome 2 at q33.3-34 (Zimonjic, 1995). This 
gene is activated after combining with a neuroregulator, betacellulin and heparin-binding 
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EGF-like growth factor. Its activation leads to cell proliferation, chemotaxis or differentiation 
through the utilization of particular signal transferring proteins like P13K kinase and Shc 
(Carpentre, 2003). Even though the ERBB4 structure and function is similar to other 
members of the ERBB family it is still unclear what role, general or specific, ERBB4 plays in 
human tumor development. Protooncogenes, including EGFR and ERBB2, are most often 
evaluated in the light of mutation presence in tumors (Lynch, 2004; Peaz, 2004; Pao, 2004; 
Stephens, 2004; Shigama, 2005). For this reason it can be assumed that ERBB4 as a 
protooncogene is also subject to mutation in human tumors (Soung, 2006).  
Tvorogov et al (2009) has shown that 2 of 10 mutations destroy the catalytic activity of 
ERBB4 tyrosine kinase. However, despite losing tyrosine kinase activity, two mutated 
receptors were still able to form a "working" heterodimer with ERBB2 and to activate 
mitogen-actived protein kinase Erk and phosphoinositide 3-kinase/Akt pathway. The 
mutant receptors were able to activate Erk and phosphoinositide 3-kinase/Akt signaling 
pathway to a similar extent as the wild-type ERBB4. ERBB4 kinase activity was required for 
NRG-induced activation of the signal transducer and activator of transcription 5 (STAT5), 
resulting in failure of ERBB4 mutants to activate STAT5 (Tvorogov, 2009). Whereas Erk and 
phosphoinositide 3-kinase/Akt pathway have been implicated in the survival and 
proliferation of cancer cells, the role of STAT5 signaling in cancer is not yet fully 
understood, however increased STAT5 signaling has been associated with transformation. 
(Yu, 2004). 
9. HER4 in gastric cancer 
The role of ERBB4 in the process of carcinogenesis has not been completely defined. YH Soung 
et al. (2006) described ERBB4 kinase domain mutation in gastric, breast, lung and large 
intestine tumors. It is the first report describing mutation of the ERBB4 kinase domain in 
human tumors. The location of the mutation in the kinase domain, a location very important 
for functioning, can suggest that the discovery of ERBB4 mutation could be a change in 
function. (Soung, 2006). Stephens et al. (2005) found ERBB4 mutation in 1 of 25 studied breast 
tumors and it was found outside the kinase domain. Soung et al. (2006) has shown a 
convergence in the presence of ERBB4 and K-RAS mutations in gastric cancer, which can occur 
and could play a role in the process of pathogenesis of gastric cancer. These observations are 
different from previous observations where the K-RAS mutation in patients with lung cancer 
was not connected to neither EGFR nor ERBB2 mutations (Kosaka, 2004). The presence of 
ERBB4 mutation in commonly appearing human tumors, can act as a green light to initiate 
research into introduction of therapies aimed at eliminating mutated ERBB4.  
HER4 gene expression was higher in cancerous tissue in comparison to healthy tissue of a 
gastric tumor (Kataoka , 2008). 
10. HER2 amplification 
The amplification of the oncogene HER2 is an important biomarker in identification of 
patients who could react to HER2 therapy using the humanized monoclonal antibody 
transtuzumab (herceptin). Fluorescence in situ hybridization (FISH) or chromogenic in situ 
hybridization (CISH) can be used to assess weather tissue samples contain gene 
amplification. The FISH method is currently considered to be the "gold standard” in HER2 
amplification detection. This method has a high sensitivity (96.5%) and specificity (100%) 
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(Pauletti, 1996). An additional advantage of this method is that it can be used on small 
samples and cuttings preserved in formaldehyde or paraffin. FISH facilitates the direct 
display of gene amplification in the cell nucleus and enables gene and chromosome count 
on a cell-by-cell basis (Park, 2006). CISH is an attractive alternative to FISH. Tissue 
preparation and the process of sample hybridization are the same for both methods. These 
techniques differ in the method of detection which in CISH involves the initiation of a 
reaction with peroxidase which can be seen with the help of an optical microscope and that 
allows for an easy assessment of tissues and amplification products. Additionally, CISH 
allows the creation of a permanent record and is much cheaper than FISH. Since CISH is a 
relatively new method, the comparison between CISH and FISH is still being made in the 
clinical setting (Park, 2006). 
Wolf- Yadlin et al. (2006) made an attempt at explaining different effects of HER2 
amplification in carcinomas with different growth patterns. These researches suggested that 
HER2 overexpression causes an increase in cell migration but has a minimal effect on 
proliferation of cells being stimulated by the epidermal growth factor (EGF) or heregulin. 
For this reason HER2 amplification can increase cell migration in expanding tumors, while 
infiltrative carcinomas, which posses high invasive potential, do not gain additional 
advantages with HER2 amplification.  
Many researchers have shown that HER2 overexpression can be used as a prognostic factor 
for gastric cancer patients. The multi-variative analysis study performed by Brien et al. 
(1998) showed that the pathological stage and HER2 gene amplification are independent 
prognostic factors for survivability. Allgayer et al. (2000) confirmed the importance of HER2 
status as a prognostic factor in a prospective study of gastric cancer. They have 
demonstrated a significant association between the level of HER2 expression and shorter 
recovery and overall survival. 
11. Therapies using antibodies against the her family members 
11.1 Trastuzumab (herceptin)  
Trastuzumab (herceptin) is a recombined humanized monoclonal antibody anti-HER2mAb 
(rhuMAb HER2) with particle mass of 145531.5 g/mol. It was engineered from a cloned 
human IgG, with structure and antigen-binding residues of a potent murine mAb 4D5. 
Exact mechanics of how it behaves are not known, however it has been speculated that it 
plays a role in blocking the division of the HER2 receptor and dimerization; impedes the 
intracellular transference path P13K; has an anti-angiogenic effect by modulating the effects 
of pro and anti-angiogenic factors; or arresting cell proliferation in the G1 phase (Baselga, 
2009;Valabrega, 2007; Hayashi, 2008). 
Usually tastuzumab is well tolerated. When administered during therapy as the only 
medication side effects such as bone marrow suppression, nausea and vomiting or baldness 
are seldom observed (Hudis, 2007). However, trastuzumab therapy is connected with an 
increased risk of cardiotoxicity. This heart disorder is the most part reversible after 
discontinuation of the drug (Okines, 2010). 
It has been shown that in patients with HER2 positive breast cancer, herceptin treatment 
does extend survival time. Among breast cancer patients with metastases, high HER2 
expression and presence of amplification signified better effectiveness of trastuzumab 
therapy (Slamon, 2001).  
HER2 status is usually determined by immunohistochemistry (IHC) and/or in situ 
hybridization. In IHC the four-tiered scoring system described originally for the Food and 
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Drug Administration (FDA), the HerceptTest, has been approved. Samples scored as 0 and 
1+ are negative, 2+ as equivocal and 3+ as positive. However, the American Society of 
Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines require in-
house validation of 1+ and 3+ samples with ISH before a certified laboratory can confine 
ISH retesting to 2+ samples (Batran, 2008). Recently, a modification of the HercepTest 




Staining pattern HER2 
expression surgical specimen biopsy specimen 
0 no reactivity or membranous reactivity in <10% of tumor cells
no reactivity or membranous 
reactivity in any tumor cell negative 
+1 
faint  barely perceptible 
membranous reactivity in 
≥10% of tumor cells; cells are 
reactive only in part of their 
membrane
tumor cell clusters with faint  
barely perceptible membranous 
reactivity, regardless of percentage 




basolateral or lateral 
membranous reactivity in 
≥10% of tumor cells 
tumor cell clusters with weak-to-
moderate complete, basolateral or 
lateral membranous reactivity, 




strong complete, basolateral or 
lateral membranous reactivity 
in ≥10% of tumor cells 
tumor cell clusters with strong 
complete, basolateral or lateral 
membranous reactivity, regardless 
of percentage of tumor cells stained 
positive 
Table 1. Recommended scoring system to evaluate immunohistochemistry staining patterns 
in patients with advanced gastric cancer. (Yoon, 2011). 
 
 
Fig. 1. HER2 testing algorithm in metastatic gastric and esophagogastric junction cancers. 
FISH: Fluorescence in situ hybridization; IHC: Immunohistochemistry (Yoon, 2011). 
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11.2 Cetuximab (anti-epidermal growth factor receptor monoclonal antibody)  
Cetuximab is a class IgG1 monoclonal antibody designed to bind with the epidermal growth 
factor receptor (GFR) (Martinelli, 2009). Cetuximab binds to the extracellular domain of the 
EGFR in its non-active configuration and competes to bind with the receptor through 
sealing the ligand binding site. This interaction of the antibody and the receptor prevents 
dimerization of the receptor and so blocks the tyrosine kinase activation dependant on the 
EGFR ligand. Additionally cetuximab induces EGFR internalization, downregulation and 
degradation. By provoking an anti-cancer response dependant on the immune system, 
cetuximab represses the proliferation of cancer cells (stops the G1 phase), the production of 
vascular endothelial growth factor (VEGF), tumor dependant angiogenesis and the invasion 
of cancer cells (Ciardiello, 2008; Lordick, 2010). 
The monoclonal antibody cetuximab has demonstrated antitumor efficacy both as a 
monotherapy and when combined with chemotherapy. (Lenz, 2006; Van Custen, 2007). 
Importantly, cetuximab treatment partially indicates that EGFR may improve resistance to 
irinotecan-based chemotherapy in a group of patients (Cuninghtam, 2004). Previous studies 
also reported that the EGFR TKI gefitinib worked well in combination with topo I inhibitors 
and platinum agents (Nagashima, 2006; Braun, 2005; Stewart, 2004; Van Schaeybroech, 2005). 
Pinto et al. (2009) published the results of the II phase of a study concerned with the 
treatment of patients with advanced gastric cancer with the drug combination: cetuximab 
and cisplatin. The response to this combination of drugs, observed at 41%, was higher than 
treatment with cisplatin or docetaxel alone. These researches have also shown that the entire 
progression rate was approximately eight months and was longer than during treatment 
with irinotecan or %- fluorouracil. Similar results were obtained by Lordick et al. (2010), 
with an average disease progression rate of 7.6 months. A slightly shorter disease 
progression time (about 5.5 months) and a response to treatment with cetuximab at 50% 
were observed by Han et al. (2009) in their research.  
11.3 Lapatinib  
Lapatinib is a potent ATP - a competitive inhibitor that simultaneously inhibits both EGFR 
and HER2. In cell-free biochemical kinase assays, lapatinib inhibits the recombinant EGFR 
and HER2 tyrosine kinase by 50% at concentrations of 10.8 and 9.3 nmol/L, respectively. In 
cell-based assays, lapatinib inhibits the growth of HER2-overexpressing BT474 breast cancer 
cells at comparably low concentrations of 100 nmol/L (Konecny, 2006).  
Lapatinib showed significant results when combined with trastuzumab in HER2- amplified 
gastric cancer cells. The combination of lapatinib and trastuzumab induces nearly complete 
tumor regression in all of the mice that have been treated. Those effects were much more 
pronounced than either lapatinib or trastuzumab alone (Wainberg, 2010). Although results 
of Wainberg et al. (2010) were only preliminary, they support the ongoing investigation of 
lapatinib in gastric cancer as well as its possible combination with trastuzumab in HER2- 
amplified disease. The addition of anti-HER2 therapy to standard chemotherapy could have 
direct clinical benefit and makes the investigation of additional anti-HER2 therapies in 
upper gastrointestinal cancers, very desirable (Wainberg, 2010). 
HER2 amplification is an important prognosis factor for the growth inhibitory activity of 
lapatinib in gastric cancer. Kim et al. (2008) has shown that lapatinib inhibits the 
phosphorylation of EGFR and HER2, and through this also impedes signal transfer from 
Akt and Erk in the gastric cancer cells sensitive to lapatinib. Lapatinib halted the G1 phase 
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of the cell cycle in cell cultures SNU-216, NCI-N87 and SNU-484, which displayed a growth 
inhibitory effect at higher concentrations. Furthermore, cMyc reduction and p27kip1 
induction were also observed after lapatinib treatment. Conversely, the induction of 
apoptosis by lapatinib is linked to the inhibition of the Akt pathway, rather than the Erk 
pathway (Kim, 2008). Lapatinib blocks Erk phosphorylation through the stimulation of the 
IGF-1 ligand. However, the inhibitory effects for IGF-1- stimulated phosphorylation of the 
IGF-1 receptor were not seen in SNU-484. It could be that lapatinib inhibits the downstream 
signaling of the phosphorylated IGF-1 receptor via EGFR, considering that it is a complex 
between the IGF-1 receptor and EGFR which activates the Erk pathway (Kim, 2008). 
Lapatinib, in combination with 5-FU, is currently used as the prodrug capecitabine in 
treating patients with breast cancers with HER2 expression in a clinical investigation of solid 
tumors (Geyer, 2006). It has been shown that lapatinib exhibits a high anticancer 
effectiveness in cells with high EGFR or HER2 expression (Rusnak, 2007; Konecny, 2006). 
Overexpression and/or amplification of HER2 in patients with breast cancer have been 
determined to be important prognostic factors in treating with lapatinib (Konecny, 2006). 
11.4 Gefitinib 
Gefitinib is an orally active, quinazoline tyrosine kinase inhibitor, selective for EGFR. Its 
anticancer effectiveness has been shown in lung cancer treatment. Somatic mutations within 
the ATP- binding pocket of the tyrosine kinase domain of the EGFR, including small in-
frame deletions and missense substitutions, are present in lung adenocarcinomas and confer 
responsiveness to gefitinib in lung cancer patients (Lynch, 2004; Paez, 2004). Yokoyama et al. 
(2006), have shown for the first time that cell cultures (GLM-1, GLM-2 i GLM-4, NCI-N87) of 
gastric cancers were more sensitive to gefitinib than traztuzumab. Gefitinib induced 
apoptosis in cells demonstrating HER2 overexpression, something that has not been 
observed in commonly used gastric cancer cell cultures without HER2 expression.  
It still seems unclear why gefitinib, an EGFR inhibitor, displays anticancer properties with 
gastric cancer cells that are HER2 positive but not those that are EGFR positive. Anido et al. 
(2003) have put forward a hypothesis that gefitinib prevents the formation of HER2/HER3 
heterodimers by taking part in the sequestration of HER2 and HER3 with inactive 
(nonphosphorylated) EGFR/HER2 and EGFR/HER3 heterodimers. Yokoyama et al. (2006) 
has shown that gefitinib can selectively arrest the phosphorylation of Akt only in cells with 
HER2 overexpression, although cells with low HER2 expression also displayed constitutive 
activation of P13K/Akt pathway. This suggests that gefitinib can selectively block activated 
P13K/Akt pathways only because it is simply driven by HER2 overexpression along with 
relatively high expression of HER3, which permits the formation of the HER2/HER3 
heterodimer (Yokoyama, 2006). The other interesting discovery made by these researchers 
has been the claim that gastric cancer cell cultures with HER2 overexpression become 
resistant to gefitinib. Gefitinib resistant cells of the GLM-1R culture have displayed an 
increase of EGFR expression and a more differentiated morphology in comparison to 
parental cells of the GLM-1 culture. The Shs and Erk1/2, upstream and downstream 
signaling molecules of the MAPK pathway, were also upregulated in GLM-1R cells. 
Additionally, the inhibition of the phosphorylation of Akt in GLM-1 parental cells in 
response to gefitinib treatment was weakened when the path Ras/MAPK was highly 
stimulated by higher concentrations of EGF. These observations can suggest that the 
pathway EGFR-Ras-MAPK is really (but in moderation) activated in compensation for the 
blockage of the HER2-P13K-Akt pathway in GML-1R cells, which results in persistent 
growth when gefitinib is present and the build up of resistance (Yokoyama, 2006). 
 
Human Epidermal Growth Factor Receptor Family (HER) in Gastric Cancer 
 
151 
12. Immunohistochemical evaluation expression of her2 and her1/egfr 
Many investigators subsequently evaluated HER2 status in gastric cancer cells by IHC 
(immunohistochemistry). The frequency of HER2 overexpression was varied widely from 8 
to 31 %. The consensus of almost all reports is that the majority of positive cases are the 
intestinal type histologically. Methods of IHC which evaluate for HER2 status in gastric 
cancer have not been standardized and that is a wide range in the frequency of 
overexpression, furthermore, there have been few reports claiming to have demonstrated 
HER2 gene amplification in gastric cancer (Sato, 1997; Takehana, 2002). 
There are conflicting results in studies of HER2 with regard to its relationship to prognosis 
in gastric cancer patients. Some studies have reported that HER2 overexpression is a poor 
prognostic factor for gastric cancer (Uchino, 1993; Chariyalertsah, 1994; Mizutani, 1993). DI 
Park 2006 demonstrated that HER2 is an prognostic parameter in gastric cancer. Similar 
finding demonstrated Yonemura et al. (1991, 1991). They showed that immunoreactivity to 
HER2 can be an independent prognostic value in gastric cancer. Mizutani et al. (1993) 
reported significantly poorer prognoses for patients suffering from early gastric cancer who 
were HER2 positive in IHC. However, other studies have failed to fund any association with 
prognosis whatsoever (Hilton, 1992; Kołodziejczyk, 1994; Tateishi, 1992; Sasano, 1993). Orita 
et al. (1997) elucidated prognostic significance of the expression of c-erbB-2 oncogene in 
gastric cancer patients. They found out that c-erbB-2 protein expression was associated with 
considerably shorter postoperative survival time. In patients with positive and negative c-
erbB-2 expression, a 5-year survival reached 29% and 47%, respectively. Similar results have 
been reported by some other authors (Tsugawa, 1998; Nakajima, 1999; Pinto-de-Sousa, 
2002). These data suggest that c-erbB-2 expression can be a prognostic factor for gastric 
cancer patients. However, according to other studies, c-erbB-2 does not exert a significant 
effect on the overall survival time of gastric cancer patients (Gurel, 1999; Polakowski, 1999). 
The first preliminary data concerning the level of EGFR in the gastric wall were described 
by Yasiu et al. (1988), indicating an increase in the level of EGFR in neoplastic tissue 
compared to normal mucus. Similar observations have been reported by other authors 
(Kopp, 2002; Coyle, 1999). Kopp et al. (2002) suggested that in case of chronic inflammation 
or tissue damage the physiological effect of the ligand for the EGF-receptor pathway, 
associated with the regulation of regeneration and healing in the gastric mucus, may 
additionally stimulate the process of neoplastic transformation in the gastric mucus and 
tumor progression. We observed EGFR expression in 50% of the evaluated cases of gastric 
cancer. High expression was observed mainly in the intestinal type and poorly 
differentiated cancers, as well as in those infiltrating the whole gastric wall or at least into 
the muscular layer. However, we found no statistical significance. As reported by Gamboza-
Dominguez et al. (2004), lack or low expression of EGFR protein was significantly correlated 
with prolonged postoperative survival time, as compared to the moderate and strong 
expression.  
13. Conclusion 
Signaling through the HER pathway plays a fundamental role in the regulation of cell 
growth, proliferation, migration and survival of neoplastic cells. Moreover, HER signaling 
can be activated as a response to different therapies used to treat cancer, like chemotherapy 
or radiation therapy, and can lead to cell and tissue damage. Elevated signal transfer activity 
can be connected to an increased risk of tumor development and malignancy. Positive 
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correlation has been shown between the expression of these receptors and the local invasion 
of the tumor, lymph nodes metastases and stage of gastric cancer. .Overexpression of these 
factors may be a prognosticating factor in these tumors. As a result it has been suggested 
that the expression of HER family receptors should be monitored as part of routine patient 
screening. It was suggested, that blocking of the action of GER family receptors can be used 
in the treatment of gastric cancer. These agents, combined with chemiotherapy and other 
targeted can be used in the future as a oncological therapy. 
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1. Introduction 
The inflammation is linked to tumorigenesis by a variety of molecules. The prostaglandins, 
cytokines, nuclear factor-kappa B (NF-kappa B), chemokines, angiogenic growth factors, 
and free radicals, are key factors involved in that process. Reactive oxygen and nitrogen 
species play a crucial role in the progression from normal gastric mucosa to cancer. 
Oxidative stress is associated with gastric disorders such as chronic gastritis, peptic ulcers, 
gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. During 
malignant transformation, the increased oxygen radicals generation initiates lipid 
peroxidation and DNA and proteins oxidation processes causing DNA and proteins 
structural and functional damages that lead finally to the loss of cell integrity. The major 
interest in elucidating the role of oxidative stress in a range of diseases has focused attention 
on drugs that can prevent the generation of reactive oxygen species or enhance their 
metabolism. The response to such interventions can give insight into the underlying role of 
reactive oxygen species in the pathophysiology and may point to future therapeutic targets. 
In this chapter, we present the most updated knowledge on free radicals and antioxidants in 
gastric cancer.  
2. Free radicals 
Free radicals are molecules containing unpaired electrons such as O2•, •OH, ROO•, and 
RO• (Figure 1). They are unstable and highly reactive components. Proteins, lipids, and 
nucleic acids are subject to oxidation by reactive oxygen species (ROS) generated during 
normal metabolism and even more so under conditions of oxidative stress. The intracellular 
levels of oxidized proteins have been shown to increase during aging and in the 
development of many age-related diseases, including Alzheimer’s disease, rheumatoid 
arthritis, atherosclerosis, and Parkinson’s disease (Khan et al, 2004) (Table 1). Moreover, an 
increase in intracellular ROS leads to initiation of various types of cell death (Yuyama et al., 
2003). 
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Fig. 1. Reactive oxygen species (ROS) and reactive nitrogen species (RNS). 
Generation of oxygen as superoxide, hydrogen peroxide and hydroxyl radicals are involved 
in killing microorganisms by leukocytes. However, these same reactive oxygen species may 
damage cells (Babior et al, 1973). To counteract these oxidants, cells have several antioxidant 
enzymes including superoxide dismutase (SOD; EC 1.15.1.I), glutathione peroxidase (GSH-
PX) and catalase. Eukaryotic cells have two forms of SOD; one found in the mitochondrial 
matrix, the manganese SOD (Mn-SOD), and another found predominantly in the cytosol, the 
copper-zinc SOD (Cu/Zn-SOD). Prokaryotes have another, iron SOD (Marklund, 1984). 
These enzymes dismutate superoxide to H2O2, which is then converted to water by either 
catalase or GHX-PX. The GSH-PX uses the reduced glutathione to convert H2O2 to water as 
well as to convert lipid peroxide to lipid metabolites and eicosenoids. A delicate balance 
exists between expression of each SOD and GHX-PX to provide cellular resistance to 
oxidative stress (Kelner & Bagnell, 1990). It has been shown that in some cancers, reduced 
expression of Mn-SOD is due to mutations in the promoter of the gene, while in other types 
of cancer, reduced levels of Mn-SOD are due to abnormal methylation, loss of 
heterozygosity or mutation in the coding sequence (Hernandez-Saavedra & McCord, 2003). 
These different mechanisms cause the chaotic results about SOD in malignant tumors 
including gastric cancer, colorectal cancer and other gastrointestinal tumors (Hwang et al, 
2007; Skrzydlewska et al, 2003; Tandon et al, 2004).  
Proteins are ubiquitous in all cells and tissues, constituting more than 50% of the dry weight 
of cells, and are susceptible to oxidative/nitrosative modifications. When reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) levels exceed the cellular antioxidant 
capacity, a deleterious condition known as oxidative/nitrosative stress occurs (Figures 2 & 
3). It describes a status in which cellular antioxidant defenses are insufficient to keep the 
levels of ROS/RNS below a toxic threshold. This may be either due to excessive production 
of ROS/RNS, loss of antioxidant defenses or both. Unchecked, excessive ROS/RNS 
generation can lead to the destruction of cellular components including proteins, and 
ultimately cell death via apoptosis or necrosis (Giustarini et al, 2004). 
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Condition                                                                                                                        Reference  
 
Cancer                                                                                                                      Hofseth, (2008). 
Cigarette Smoking                                                   Pasupathi et al, (2009) & El-Zayadi, (2006). 
Aging                                                                                                           Adiga & Adiga, (2009). 
Atherosclerosis                                          Shaikh & Suryakar, (2009) &  Sumathi et al, (2010). 
Rheumatoid Arthritis                                                       Shinde et al, (2010) & Ahmed, (2005). 
Diabetes                                                                                                             Kundu et al, (2011). 
Infertility                                                                                                              Duru et al, (2001). 
Asthma                                                                                                               Fabian et al, (2011). 
COPD                                                                                                  Hakhamaneshi et al, (2007). 
Neurodegeneration                                                                                     Abraham et al, (2005). 
Acute Ischaemic Stroke                                                                                    Aygul et al, (2006). 
Epilepsy                                                                                               Hamed & Abdellah, (2004). 
Skin disease                                                                                                    Aly & Shahin (2010). 
Schistosomiasis Infection                                                                                    Rizk et al, (2006). 
Alcoholic Liver Disease                                                                             Maithreyi et al, (2010). 
Esophagitis                                                                                                     Jiménez et al, (2005). 
Table 1. Some clinical situations that are associated with altered oxidative/antioxidative 
balance as evidenced in the mentioned studies.   
 
 
Fig. 2. The balance between free radicals levels and antioxidant defense system is favoring 
the health. On the contrary, the imbalance between them is leading to the oxidative stress 
and hence to the damage of cellular compartments and consequently to the disease.  
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3. Cancer and free radicals 
Malignancy comprises a diverse set of diseases that not only originate from almost every 
tissue but also display remarkable heterogeneity in presentation and prognosis. Despite this 
immense range of clinical characteristics, all human tumors share a limited set of behaviors 
that define the malignant state (Hanahan &Weinberg, 2000). Among these hallmarks, 
unlimited replicative potential and widespread genomic disarray are among the most 
common characteristics exhibited by human cancer cells. Although numerous distinct 
molecular pathways regulate specific aspects of each of these phenotypes, emerging 
evidence now implicates that the oxidative stress and the programmed cell death are 
essential determinant s of the cell life span.  
A role of free radicals has been proposed in the pathogenesis of numerous diseases as 
indicating above including cancer of different organs such as breast, gastric, colon, 
multiple myeloma, ovarian, renal, skin, leukemia, biliary, thyroid, and lung cancer (Table 
2 & Figure 3). 
 
Cancer                                                                           Reference  
 
Prostate Cancer 
Renal Cell Carcinoma 
Breast Cancer 













Pace et al, (2010). 
Soini et al, (2006). 
Yeon et al, (2011). 
Elsing et al, (2011). 
Sangeetha et al, (2010). 
Tandon et al, (2004). 
Gayathri et al, (2009). 
Lee et al, (2001). 
Koduru et al, (2010).  
Gupta et al, (2010). 
Beevi et al, (2007). 
Bentz, (2007). 
Cooke et al, (2007). 
Dwivedi et al, (2008). 
Kato et al, (2003). 
Table 2. Oxidative stress as a result of altered oxidative/antioxidative balance is proposed as 
key factor in the pathogenesis of different tumors as shown above. 
4. Gastric cancer 
4.1 Epidemiology 
Gastric carcinoma was the major cancer burden worldwide in the twentieth century. Its 
etiology and pathogenesis were obscure. Several events have changed that outlook, and 
currently, it ranks in the second place of mortality from cancer, after lung cancer. In the 
United States, the number of cases has remained around 20,000 for several years. The 
geographic distribution of gastric cancer is spotty. Areas of highest risk have traditionally 
been Japan, Korea, China, Eastern Europe, and the Andean regions of the Americas. In 
contrast, Australia, Africa, the coastal regions of the Americas, and Southern Asia have 
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Fig. 3. The link between the dose of oxidative stress and the dependant effect on tumor 
promotion, mutagenesis and the apoptosis/necrosis (modified from Valko et al, 2007). 
traditionally been areas of low risk. Western Europe and North America, with considerably 
higher risk several decades ago, have experienced a marked decrease since then, and at the 
present time are considered areas of low risk (reviewed in Correa et al, (2009).  
4.2 Risk and protective factors 
As reported earlier (Karagianni & Triantafillidis, 2010), the available evidence is indicating a 
probable protective role of vegetables, especially allium vegetables, fish, and fruit 
consumption against gastric cancer risk. It also seems probable that high salt intake 
increases gastric cancer risk. Furthermore, the available evidence is suggestive of a 
protective role of pulses and foods containing selenium. Limited, but still suggestive 
evidence exists concerning an inverse association between chilli, processed meat, smoked 
foods and grilled or barbecued animal foods with gastric cancer risk. Moreover, it has also 
been proposed that reducing the prevalence of smoking, obesity and gastroesophageal 
reflux could decrease the incidence of gastric cancer (Engel et al, 2003). Recently, it was 
reported that the salt intake is an important dietary risk factor for gastric cancer regardless 
of H. pylori infection and virulence, smoking, tumor site and histological type (Peleteiro et al, 
2011). 
Meta-analysis is a statistical methodology that can combine the results from multiple studies 
that investigating the same rationale. The utility of the meta-analysis is to conclude a clear 
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statement from these conflicting studies. Meta-analysis consists of three basic steps. The first 
step is the systematic search of the literature to identify the studies according to certain 
criteria. The second one to extract the numerical data from each study for the experimental 
versus control subjects in randomized clinical trials, on various outcomes and their 
difference. Finally, the third step is carried out to calculate the parameters and reflect their 
statistical confidence. Recently, numerous meta-analysis studies were publicized concerning 
with gastric cancer investigation. A recent meta-analysis showed that a high intake of 
pickled vegetables may increase gastric cancer risk and their data suggested that a high 
consumption of fresh vegetables is important to reduce gastric cancer risk (Kim et al, 2010). 
It was evidenced recently in this type of studies that nonsteroidal anti-inflammatory drugs 
(NSAIDs), including aspirin is associated with a decrease in the development of gastric 
cancer. The associations were more obvious after they adjusted for several risk factors that 
are known to contribute to the development of gastric cancer (Tian et al, 2010). Reduced risk 
of noncardia gastric cancer is associated with the regular use of aspirin especially among 
Caucasians (Yang et al., 2010). Dairy product consumption (Huang et al, 2009), and 
Helicobacter pylori eradication treatment (Fuccio et al, 2009), might decrease the risk of gastric 
cancer. 
4.3 Oxidative stress 
Reactive oxygen species are closely associated with the intracellular signal cascade, thus 
strongly implicating involvement in tumor progression. The antioxidant enzymes activities 
such as GSH-PX, SOD, G6PD (glucose-6-phosphate dehydrogenase), MDA and GR were 
found to be related with malignant phenotype in gastric cancer and colorectal cancer (Kekec 
et al, 2009). The increase in oxidative stress in gastric carcinoma was evidenced by 
significant rise in plasma lipid peroxidation marker MDA measured as TBARS. There was a 
significant fall in serum albumin level in patients due to its protective effect against 
deleterious oxidative damage (Reddy et al, 2009). The source of cellular ROS production 
includes activated phagocytes for examples neutrophils and macrophages. The level of 
myeloperoxidase (MPO) (enzyme of granulocyte) and TAS (total antioxidant status) was 
evaluated in the plasma of gastric carcinoma patients. MPO is a measurement of neutrophils 
activation and synthesis of ROS.  In gastric carcinoma patients before and after operation (1 
and 10 day) MPO concentration was 3 times higher in comparison to the control group, but 
TAS level was decreased. These results suggest the presence of prolonged oxidative stress in 
malignant disease but it requires long time observation after surgery (Czygier et al, 2010). It 
was indicated that gastric cancer patients were characterized by increased the advanced 
oxidation protein products (AOPP) levels (Noyan et al, 2009). 
Increased level of lipid peroxidation and significant differences in glutathione level and 
glutathione peroxidase, glutathione -S-transferase and glutathione reductase activities were 
observed in serum taken before and after surgery from patients with gastrointestinal tract 
tumors compared to those in control serum of healthy blood donors. Increase of lipid 
peroxidation and changes in GSH level and related enzyme activities, suggest oxidative 
stress in patients with gastrointestinal tract tumors. These alterations reflect the presence of 
functional defense mechanism against oxidative stress related firmly to the glutathione 
metabolism. The impaired antioxidant system may favor accumulation of free radicals 
(Ścibior et al, 2008). It has been found that low levels of essential antioxidants in the 
circulation are associated with an increased risk of cancer (Diplock, 1991). Persistent 
generation of reactive oxygen species such as superoxide, H2O2, and hydroxyl radicals is an 
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inevitable consequence of mitochondrial respiration in aerobic organisms, whose ATP 
requirements are correlated with the level of metabolic activity. Several potential 
mechanisms are thought to contribute to the increased ROS in cancer cells. First, oncogenic 
signals have been shown to cause increased ROS generation. The oncogene c-myc, for 
example, increases ROS generation, induces DNA damage, and mitigates p53 function.  
Another possible mechanism by which cancer cells generate increased amounts of ROS may 
involve malfunction of the mitochondrial respiratory chain. Since the mitochondrial DNA 
(mtDNA) codes for 13 components of the respiration complexes and contains no introns, 
mutations of mtDNA are likely to affect the function of its encoded proteins and lead 
to malfunction of the mitochondrial respiratory chain. It is also known that mtDNA is more 
vulnerable to damage than nuclear DNA, and mtDNA mutations are frequently detected in 
cancer cells (reviewed in Pelicano et al, 2004).  
4.3.1 Helicobacter pylori 
Helicobacter pylori (H. pylori) infection (Figures 4 & 5), the main cause of chronic gastritis, 
increases gastric cancer risk. It was reported that H. pylori is implicated in many diseases in 
addition to the gastric cancer (Abdel-Hady et al, 2007; El-Masry et al, 2010; El-Shahat et al, 
2005).The infection causes inflammatory cells to produce reactive oxygen metabolites that 
may damage DNA and promote carcinogenesis. It was showed that H. pylori water extract 
induces tumor formation via reactive oxygen species production (Ishikawa et al, 2006). 
Successful eradication treatment of H. pylori prevents the production of reactive oxygen 
metabolites (Farkas et al, 2005; Mashimo et al, 2006). In a recent study, a close relationship 
was demonstrated between the plasma malondialdehyde and nitric oxide levels, gastric 
histopathology and genotypes of H. pylori (Tiwari et al, 2010). In patients with H. pylori 
infection, NO metabolites concentration was increase demonstrating a positive correlation 
with grade of inflammatory lesions in gastric mucosa. The effective antibacterial therapy 
causes the decrease of NO metabolites concentration in gastric juice, especially in patients 
with chronic active gastritis. Eradication decreases the grade of lesions in gastric mucosa just 
in 12 months after effective antibacterial therapy (Walecka-Kapica et al, 2008). 
8-Hydroxy-2'-deoxyguanosine (8-oxo-dG) levels in the gastric mucosa were increased in 
carriers of H. pylori, and were further increased in subjects infected with strains positive for 
the cagA gene, encoding the cytotoxin-associated protein, cagA. Oxidative DNA damage 
was more pronounced in males, in older subjects, and in H. pylori-positive subjects suffering 
from gastric dysplasia. Moreover, 8-oxo-dG levels were significantly higher in a small subset 
of subjects having a homozygous variant allele of the 8-oxoguanosine-glycosylase 1 (OGG1) 
gene, encoding the enzyme removing 8-oxo-dG from DNA. Conversely, they were not 
significantly elevated in glutathione S-transferase M1 (GSTM1)-null subjects. Thus, both 
bacterial and host gene polymorphisms affect oxidative stress and DNA damage, which is 
believed to represent a key mechanism in the pathogenesis of gastric cancer. The interplay 
between bacterial and host gene polymorphisms may explain why gastric cancer only 
occurs in a small fraction of H. pylori-infected individuals (Izzotti et al, 2007). 
The mRNA of inflammatory markers and oxidant and antioxidant enzymes was 
investigated in gastritis, gastric ulcer and gastric cancer in gastric biopsy of patients infected 
with H. pylori and the results showed that the oxidant status in gastritis is different in the 
three lesions slightly. In gastritis, a significant expression of TNF-α (tumor necrosis factor-
α), IL-8 (interleukin-8), IL-12, Nox1 (NADH oxidase 1) and iNOS (pathogen-inducible nitric 
oxide synthase) was detected. In gastric ulcer, a significant expression for TNF-α, IL-8, IL-12 
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and Nox1 was observed, while in gastric cancer a significant expression for TNF-α, IL-8, IL-
1β, IL-10, IL-12, iNOS and Nox1 was evidenced. The oxidant status in gastritis was the only 
condition where TNF-α and IL-8 expression was associated to H. pylori virulence suggesting 
that they are the main oxidant stress markers responsible to trigger an increase in ROS levels 
that contributes to decrease the expression of the MnSOD and GSH-PX in gastritis (Augusto 
et al, 2007)( see Figure 6). 
 
 
Fig. 4. Presence of H. pylori in corpus section stained with hematoxylin and eosin. M; Mucus 
secreting cells & HP; H. pylori (from Abusini et al, 2009). 
There are three possible mechanisms by which H. pylori infection leads to loss of genomic 
integrity and promote carcinogenesis (Figure 7). The first is the increase in DNA damage 
and decrease in repair activity. The second is the mutations in mtDNA. The last is the 
induction of a transient mutator phenotype resulting in mutations in the DNA upon 
infection with H. pylori. Due to H. pylori infection and to inflammatory response, increased 
amounts of ROS are generated in the gastric epithelial cells that induce oxidative damage in 
the DNA. H. pylori infection also leads to methylation of gene promoters, causing gene 
silencing and is associated with several other DNA alterations such as chromosomal 
instability, p53 mutations, influence on the expression of p53 and c-Myc, as well as MSI. At 
the same time, infection leads to a deficiency in the activity of major repair pathways. The 
increase in DNA damage coupled to the decrease in repair activity may be two of the key 
factors involved in the induction of a transient mutator phenotype that could contribute to 
nuclear and mtDNA mutations. The appearance of mtDNA mutations after H. pylori 
infection might be partly due the down-regulation of BER. BER is one of the best 
characterized DNA repair pathways in the mitochondria. Several proteins involved in BER 
have been described in mitochondria, such as DNA glycosylases, APE1, polymerase γ and 
DNA ligase III . It was observed that APE1 expression is down-regulated in gastric cells 
infected with H. pylori, suggesting an imbalance between generation and repair of AP sites. 
This could be one the mechanisms behind the induction of mtDNA mutations, which may 
lead to the impairment of oxidative phosphorylation, cell damage, and disease (reviewed in 
Machado et al, 2010). 
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Fig. 5. Multi-step development of intestinal-type gastric adenocarcinoma. Helicobacter pylori 
cag pathogenicity island within H. pylori strains and host polymorphisms that promote high 
expression levels of the cytokine interleukin-lβ augment the risk for gastric adenocarcinoma 
(adapted from Israel & Peek, 2006). It is well known that gastric cancer is associated with 
alterations of oncogenes and tumor suppressor genes. Furthermore, prostaglandins, 
cytokines, nuclear factor-kappa B, chemokines, angiogenic growth factors, and free radicals 
are involved in GC pathogenesis.  
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Fig. 6. mRNA expression of inflammatory markers and both oxidant and antioxidant 
enzymes in gastric biopsy samples of Helicobacter pylori infected patients with gastritis, 
gastric ulcer and gastric cancer. This figure was produced based on the data presented in 
table 2 of Augusto et al, (2007) publication with permission of Rightslink, Copyright 
Clearance Center (CCC), and Elsevier.  
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Fig. 7. Proposed model for the development of gastric cancer (adapted from Machado et al, 
2010). Microsatellite instability (MSI) is simple repetitive sequences or microsatellites may 
undergo length alterations. MMR is the DNA mismatch repair pathway. MSI can lead to 
deficiency of MMR. H. pylori gastritis might lead to a deficiency of MMR in gastric 
epithelium that may increase the risk of mutation accumulation in the gastric mucosa cells 
during chronic H. pylori infection. Base excision repair (BER) is another major repair 
pathway critical for the maintenance of genome stability as it repairs a number of 
endogenously generated DNA lesions. Therefore, it is possible that this repair pathway 
plays an important role ensuring genetic stability in gastric cells. BER removes various 
forms of base damage such as oxidation, methylation, deamination, depurination and 
hydroxylation. BER is initiated by DNA glycosylases that recognize and cleave the damaged 
bases, creating abasic (AP) sites. The AP sites created are cytotoxic and mutagenic and are, 
therefore, further processed by DNA glycosylases with AP-lyase activity or by APE1. The 
single nucleotide gap is filled and the nick sealed to complete the repair reaction. It was 
suggested that increased levels of cellular damage and death due to reactive oxygen species 
would lead to increased inflammation and consequently to the production of more ROS and 
tumor-promoting cytokines. It also strongly indicates that one mechanism underlying 
genetic instability caused by H. pylori infection is deregulation of central DNA repair 
pathways (see Machado et al, 2010). 
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4.3.2 Smoking 
Tobacco smoke contains many toxic, carcinogenic and mutagenic chemicals, as well as stable 
and unstable free radicals and reactive oxygen species (ROS) in the particulate and the gas 
phase with the potential for biological oxidative damage. Epidemiological evidence 
established that smoking is one of the most important extrinsic factor of premature morbidity 
and mortality (Valavanidis et al, 2009). It was estimated that the number of gastric cancer cases 
attributable to tobacco smoking occurring worldwide, in total, over 80,000 cases of gastric 
cancer (11% of all estimated cases) may be attributed to tobacco smoking each year. The 
majority of published studies reported a positive association between gastric cancer and 
cigarette smoking. Meta-analysis suggested a risk of stomach cancer among smokers of the 
order of 1.5–1.6 as compared to non-smokers (Trédaniel et al, 1997). 
Thiobarbituric acid reactive substances (TBARS) level was found higher in smokers than 
non-smoking gastric cancer patients. The activities of superoxide dismutase, catalase, 
glutathione peroxidase, glutathione-S-transferase, reduced glutathione, and vitamins A, 
E and C were decreased in gastric cancer patients who were smokers as compared to other 
groups (p < 0.001). The lipid peroxidation and possible breakdown of antioxidant status in 
the cigarette smoking may increase the risk of gastric cancer. Thus, chronic smoking 
enhances erythrocyte lipid peroxidation in gastric carcinoma patients with concomitant 
failure of both plasma and erythrocyte antioxidant defense mechanisms. The low 
antioxidant status of healthy smokers may predispose them to oxidant-mediated tissue 
damage, which may increase the risk of gastric cancer (Pasupathi et al, (2009). It was 
concluded that the TNF-alpha-857 C/T polymorphism may play an independent role in 
gastric carcinogenesis and the risk for gastric cancer by TNF genetic effect is pronounced by 
cigarette smoking (Yang et al, 2009). Recently, it was detected that the cigarette smoking was 
associated with risk of oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, 
gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma (Steevens et al, 2010). 
Plasma levels of MDA were significantly increased but melatonin content of the blood was 
significantly decreased in smokers as compared to nonsmokers. It seems that melatonin can 
reduce free radical damage to the respiratory system induced by cigarette smoke (Ozguner 
et al, 2005). A significant decrease in free malondialdehyde levels in light smokers after one 
month phytonutrient supplementation was achieved (Bamonti et al, 2006). The effect of the 
consumption of a pear, an apple and 200 ml orange juice, during 26 days, on total plasma 
antioxidant capacity and lipid profile of chronic smokers and non-smoking healthy adults 
was analyzed. Fruit consumption increased total plasma antioxidant capacity in non-
smokers, but not in smokers. In non-smokers, total cholesterol, high-density lipoprotein-
cholesterol, and low-density lipoprotein-cholesterol increased significantly; while in 
smokers, total cholesterol and low-density lipoprotein-cholesterol decreased (Alvarez-
Parrilla et al, 2010). Antioxidant-rich food was found to modulate positively the cellular 
stress defense of smokers (Bohn et al, 2010). 
5. Antioxidants 
ROS are generated during normal aerobic metabolism and increased levels are present 
during oxidative stress. It has been proposed that ROS is necessary for life and essential for 
the regulation of essential physiologic functions. However, at high concentrations, ROS are 
cytotoxic. ROS are important in cell differentiation, apoptosis, and cell proliferation. These 
functions are regulated by redox-sensitive signal transduction pathways. The amount of 
antioxidants in the cells is high and so cells prevent or repair the damages caused by 
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Fig. 8. The antioxidant content is different from food to another. Dried fruits (dates, raisins, 
and prunes), vegetables (red cabbages, spinach, and garlic), fruits (red grape, different types 
of berries, red apple, and red plum) and juices such as orange juices are among the foods 
with highest antioxidant content. Furthermore, drinks such as espresso coffee and oils such 
as soybean and virgin olive oil are rich sources of antioxidants. On the other hand, the most 
powerful natural foods to scavenge the oxygen free radicals and to inhibit the lipid 
peroxidation are blackberry, orange, lemon, strawberry, kiwi, garlic, green pepper, and 
cabbages (Miller et al, 2000; Pellegrini et al, 2003).      
ROS. ROS-induced damage can result in cell death, mutations, chromosomal aberrations 
and also carcinogenesis (Cerutti, 1985). The antioxidants are antioxidant enzymes and some 
vitamins (Figures 8-12). There are three major types of antioxidant enzymes in mammalian 
cells: superoxide dismutase, catalase, and peroxidase, of which glutathione peroxidase is the 
most important component of these (Hurt et al, 2007) (Figure 12). Both endogenous and 
exogenous antioxidants play an important and interdependent role in preventing cancer. 
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Fig. 9. Antioxidant vitamins include vitamin A, E, and C. The ascorbic acid is the only one 
feature of the ROS scavenging capacity of fresh fruit and vegetable juices. Other free radical 
scavengers present in fruits and vegetables are flavonoids, carotenoids, organic acids 
(cinnamic acid and gallic acid), vitamin E, and sulfhydryl compounds. A well balanced diet 
of fruit and vegetables may enhance the antioxidant defenses against ROS induced injuries 
to cells and tissues (Leonard et al, 2002). 
It was evidenced that the MnSOD Val-9Ala polymorphism may contribute to cancer 
development through a disturbed antioxidant balance, where the decreased consumption 
level of dietary antioxidant s is an essential contributing factor (Li et al, 2005 & Wang et al, 
2009). It was showed that ascorbic acid protects against gastric cancer by scavenging 
reactive radical species which would otherwise react with DNA, with resultant genetic 
damage (Drake et al, 1996). Vitamin C-releasing acetylsalicylic acid in comparison with 
plain acetylsalicylic acid induces less gastric mucosal damage and this protective effect is 
probably due to the attenuation of oxidative stress in gastric mucosa (Konturek et al, 2004). 
High dietary antioxidant quercetin intake is inversely related to the risk of noncardia gastric 
adenocarcinoma, and the protection appears to be particularly strong for women exposed to 
oxidative stress, such as tobacco smoking (Ekstrom et al, 2011). Treatment with Allopurinol 
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(inhibits the enzyme xanthine oxidase which is responsible for the formation of superoxide 
radicals and scavenges hydroxyl radicals) and dimethyl sulphoxide (DMSO; scavenges 
hydroxyl radicals) was found to provide gastric cancer patients with a survival advantage 
(Salim, 1992). In was observed upon following up 29,133 male smokers that the higher 
dietary intake of retinol was protective, but dietary intake of α-tocopherol and γ-tocopherol 
increased risk of gastric cardia cancer. Higher intakes of fruits, vitamin C, tocopherols, and 
lycopene were protective against gastric noncardia cancer (Nouraie et al, 2005).   
 
 
Fig. 10. Vitamins with antioxidant activity in three dimensional structures. 
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Fig. 11. Fruits and vegetables are sources of polyphenolic compounds called flavonoids. The 
flavonoid family is flavonols, flavones, flavan-3-ols, isoflavones, flavanones and 
anthocyanidins (A). Flavonols and flavones are synthesized in plant tissues and it comprises 
quercetin, myricetin, kaempferol and isorhamnetin, while a more limited number of fruits 
and vegetables contain the structurally-related flavones, apigenin and luteolin (B). 
Flavonoids are known to have antioxidant activity and various foods are containing such 
components as blueberry, onion, lettuce, tomato, and tea (Crozier et al, 2000). Tea is a good 
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Fig. 12. Potential mechanism for the interaction between MnSOD and antioxidant status in 
cancer development (modified from Li et al, 2005 & Wang et al, 2009). In mitochondria, the 
ROS is dismutated by MnSOD into oxygen and hydrogen peroxide (H2O2), which is further 
detoxified to water (H2O) by mitochondrial glutathione peroxidase (GSH-PX) (an enzyme 
requiring selenium) and catalase (CAT). High levels of MnSOD expression may lead to 
increased O2 and H2O2, and induce toxicity if glutathione peroxidase activity is low due to 
inadequate selenium or dietary antioxidant intake. The normal pathway is shown above and 
the altered one is shown below. 
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6. Conclusions 
Gastric cancer ranks the second leading cause of cancer-specific mortality worldwide. It has 
a poor prognosis; 5-year survival rate of gastric cancer is less than 20%-25% in the USA, 
Europe, and China (Hartgrink et al, 2009). Cells in tissues and organs are continuously 
subjected to oxidative stress and free radicals on a daily basis. This free radical attack has 
exogenous or endogenous (intracellular) origin. The cells withstand and counteract this 
occurrence by the use of several and different defense mechanisms ranging from free radical 
scavengers like glutathione (GSH), vitamins C and E and antioxidant enzymes like catalase, 
superoxide dismutase and various peroxidases to sophisticated and elaborate DNA repair 
mechanisms (Kryston et al, 2011). Reactive oxygen species along with reactive nitrogen 
species are well recognized for playing a dual role as both deleterious and beneficial species. 
The “two-faced” character of ROS is substantiated by growing body of evidence that ROS 
within cells act as secondary messengers in intracellular signalling cascades, which induce 
and maintain the oncogenic phenotype of cancer cells, however, ROS can also induce 
cellular senescence and apoptosis and can therefore function as anti-tumourigenic species. 
The cumulative production is common for many types of cancer cell that are linked with 
altered redox regulation of cellular signalling pathways. Oxidative stress induces a cellular 
redox imbalance which has been found to be present in various cancer cells compared with 
normal cells; the redox imbalance thus may be related to oncogenic stimulation. DNA 
mutation is a critical step in carcinogenesis and elevated levels of oxidative DNA lesions (8-
OH-G) have been noted in various tumors, strongly implicating such damage in the etiology 
of cancer (Valko et al, 2006). Finally, the eradication treatment for H. pylori, smoking 
quitting, eating of fresh and dried fruits with high antioxidant content such as dates, raisins, 
and prunes, and avoiding the salts and pickled vegetables, all are seemingly  justifiable 
means for reduction the gastric cancer prevalence and for general health. Further studies are 
warranted to explore the effect of different combinations of antioxidants on the healthy 
heavy smokers to find out if these compounds can protect them or lessen both the gastric 
cancer incidence and the other debilitating diseases associated with smoking. 
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1. Introduction  
Recent advances in tumor immunology have established the concept of tumor 
immunosurveillance, and cancers are considered to have developed after overcoming these 
host immunosurveillance mechanisms. As a result, established cancers are in an 
immunosuppressive microenvironment (Dunn et al. 2004; Finn 2008). 
 
 
Fig. 1. Histology of conventional gastric cancer. A) Area inside conventional gastric cancer 
(well differentiated tubular adenocarcinoma). The stromal area is infiltrated by scanty 
tumor-infiltrating lymphocytes, a basic feature of cancer. B) Area of invasive margin in the 
same case. Note the presence of tumor-infiltrating lymphocytes along the invasive margin 
(asterisks). An arrow indicates the direction of invasion. 
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This concept implies that established tumors are either devoid of immune cell infiltrate (Fig. 
1A) or, if present, the immune cell infiltrate is suppressed. Routine histopathological 
examination reveals that human cancer tissues are infiltrated to varying degrees by tumor-
infiltrating lymphocytes, which if present, usually accumulate along the invasive margin 
(tumor-host interface) (Fig. 1B). In contrast, the stroma inside tumors tends to be devoid of 
tumor-infiltrating lymphocytes (Fig. 1A). Unraveling the biological significance of tumor-
infiltrating lymphocytes is not straightforward because of the complexity of the cellular 
compositions of tumor-infiltrating lymphocytes themselves (Yu and Fu 2006). In several 
cancers, it is known that higher levels of tumor-infiltrating lymphocytes are prognostic of 
longer survival rates in patients (Naito et al. 1998; Sato et al. 2005; Galon et al. 2006; Sharma 
et al. 2007). Thus it appears likely that tumor-infiltrating lymphocytes may possess anti-
tumor activity that alleviates cancer aggressiveness.  
2. Gastric cancers with lymphoid stroma  
Cancers with prominent tumor-infiltrating lymphocytic responses exist as extreme variants 
in tumor pathology; medullary carcinoma of the breast and nasopharyngeal carcinoma 
(“lymphoepithelial carcinoma”) are two such examples. In gastric cancer, such variants are 
designated “gastric cancers with lymphoid stroma” or “lymphoepithelioma-like 
cancer”.Such cancers are characterized by poorly differentiated cancer cells with a syncytial  
 
 
Fig. 2. A-C.  A, B) Histology of lymphocyte-rich gastric cancer (typical case of 
lymphoepithelioma-like cancer). Low (A) and high power magnification (B). Note massive 
infiltration by lymphocytes, and poorly differentiated cancer cells. C) Occasionally formed 
lymph follicle with a germinal center. 
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appearance and massive lymphoid infiltrate (Fig. 2A, B). Formation of lymph follicles 
containing a germinal center is usually observed (Fig. 2C). The prognosis for typical cases is 
better than that for conventional gastric cancer cases (Watanabe et al. 1976; Minamoto et al. 
1990). This suggests that the lymphoid stroma may produce an antitumor immune response. 
Most gastric cancers with lymphoid stroma are associated with Epstein-Barr virus (EB virus) 
(Tokunaga et al. 1993; Fukayama et al. 2010). It should be noted, however, that not all 
Epstein-Barr virus-associated gastric cancers have lymphoid stroma. In this chapter, 
attention is focused on how lymphoid infiltrate occurs in gastric cancers.  
3. Cellular composition of the lymphocyte-rich stroma  
The term “lymphocyte-rich gastric cancers” used here includes typical gastric cancers with 
lymphoid stroma (Fig. 2 A-C) and other types of gastric cancers associated with tumor-
infiltrating lymphocytic responses in nearly whole stroma. The lymphocyte-rich gastric 
cancers are consistently infiltrated by CD3+ T cells (Fig. 3A), among which both CD8+ and 
CD4+ T cells are present. Key antigen presenting cells, the CD83+ myeloid-derived dendritic 
cells (Heath and Carbone 2009) are also distributed in the T cell-rich stroma of the 
lymphocyte-rich gastric cancers (Fig. 3B). B-lymphocytes are not generally abundant in the 
tissue (Fig. 3C), except in areas containing lymphoid follicles where abundant B-cell 
populations are observed. Saiki et al.’s (1996) finding that approximately 13% of CD8+ T 
cells exhibited Ki-67 immunoreactivity implies that active immune responses with 
lymphocyte proliferative activity take place in lymphocyte-rich gastric cancers.  
 
 
Fig. 3. Single immunohistochemistry of lymphocyte-rich gastric cancers for CD3 (A), CD83 
(B), and CD20 (C) (signals shown with brown, hematoxylin-nuclear counterstaining). Note 
abundance of T-lymphocytes with mature dendritic cells. B-lymphocytes are not abundant.  
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Fig. 4. A-D. Single immunohistochemistry of lymphocyte-rich gastric cancers for CXCR3 
(A), CCR4 (B), and CXCL9 (C and D) (signals shown with brown, hematoxylin-nuclear 
counterstaining). A) Note abundance of CXCR3-positive lymphocytes. B) Expression of 
chemokine receptor CCR4 is sparse, which is mainly expressed by Th2 cell and regulatory T 
cells C) CXCL9 is mainly localized in stromal cells in lymphocyte-rich stroma. D) Only a 
part of cancer cells expresses CXCL9. 
 




Fig. 4. E, F. Double staining of lymphocyte-rich gastric cancer for CXCL9 (brown) and 
CXCR3 (blue). Low power (E) and high power magnification (F) reveals that CXCL3+ 
stromal cells are in close contact with CXCR3+ lymphocytes; this is reminiscent of a dendritic 
cell-T cell distribution in the secondary lymphoid tissues such as lymph nodes. 
4. Expression of chemokine CXCL9 and receptor CXCR3 in lymphocyte-rich 
gastric cancers 
Chemokines are chemotactic cytokines, which cause migration of leukocytes and other cells 
that express cognate chemokine receptors (Zlotnik and Yoshie 2000; Murphy et al. 2000; 
Allen et al. 2007). Chemokines and their receptors play important roles in inflammation, 
lymphoid organogenesis and cancer cell invasion and/or metastasis. The chemokine 
receptor CXCR3 and two of its cognate ligands, CXCL9 (MIG) and CXCL10 (IP10) are 
described here because CXCR3 is widely expressed by T helper type 1 (Th1) cells and CD8+ 
T cells (Zlotnik and Yoshie, 2000; Ohtani et al. 2009).  
By immunohistochemistry, CXCR3+ lymphocytes are abundant in the lymphoid stroma of 
lymphocyte-rich gastric cancers (Fig. 4A), which contrasts markedly with the sparse 
distribution of CCR4+ cells (Fig. 4B). This suggests a predominance of Th1 cells over Th2 
cells in this tissue. CXCR3+ cells are sparse in the lymphoid follicles (B-cell zone). The 
CXCR3-ligands, CXCL9 and CXCL10, are mainly expressed by dendritic-shaped “stromal 
cells” that were distributed in CXCR3+ cell-rich lymphoid stroma (Fig. 4C). CXCL9 and 
CXCL10 are also expressed in only a small portion of cancer cells (Fig. 4D). Of the two, 
CXCL9 is more frequently observed in stromal cells of lymphocyte-rich gastric cancers than 
CXCL10. The author has designated this type of distribution “CXCR3+ T cell-CXCL9+ 
stromal cell clustering”, which is clearly observed by double staining (Fig. 4E) (Ohtani et al. 
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2009, 2010). At higher magnification, a close cell-to-cell contact between CXCL9+ stromal 
cells and CXCR3+ cells is revealed (Fig. 2F). This clustering, reminiscent of T cell-dendritic 
cell clustering in the secondary lymphoid tissues, is confined to lymphocyte-rich gastric 
cancers, but not conventional gastric cancers. Hence, the results thus far suggest that the Th1 
response is dominant and that CXCL9+ stromal cells are important for large-scale infiltration 
by CXCR3+ T cells. 
5. Cell identification of CXCL9+ stromal cells 
The shape of CXCL9+ stromal cells suggests that they may be dendritic cells. CD83+ mature, 
myeloid-derived dendritic cells are in fact found to be distributed in lymphocyte-rich gastric 
cancers (Fig. 3B). However, double immunohistochemistry reveals that only 10-20% of 
CXCL9+ stromal cells co-express CD83 (Fig. 5A), and half of CXCL9+ stromal cells co-
expresses fascin (a wide marker of dendritic cells) (Fig. 5B). DC-Lamp, another marker of 
mature dendritic cells, is expressed also in a part of CXCL9+ stromal cells (Fig. 5C). A half of 
CXCL9+ stromal cells expresses CD68, a marker of macrophages including immature 
dendritic cells. 
These data suggest that only a minor part of CXCL9+ stromal cell populations comprises 
mature, myeloid-derived dendritic cells, but more than half are stromal cells (probably 





Fig. 5. A and B. A) Double staining for CD83 and CXCL9.  An arrow indicates CD83+ 
(brown) mature dendritic cells also expressing CXCL9 (blue). B) Double staining for fascin 
(brown) and CXCL9 (blue). Arrows indicate fascin+ dendritic cells co-expressing CXCL9. 
These data suggest that a part of CXCL9-positive stromal cells are dendritic cells. 
 




Fig. 5. C and D. C) Double staining for CXCL9 and DC-lamp (using frozen section). Arrows 
indicateDC-Lamp+ mature dendritic cells (blue) also expressing CXCL9 (brown) Double 
staining for CXCL9 (brown) and CD68 (blue). Arrows indicate double positive cells. These 
cells may be macrophages or immature dendritic cells. 
6. Proliferative activity of T cells in close contact with CXCL9+ stromal cells 
The proliferative activity of T cells in the histopathological samples can be assessed using Ki-67 
immunohistochemistry. As shown in Fig. 6A, double staining reveals that CD45RO+ T cells 
(red) and CXCL9+ stromal cells (dark blue) exhibit close cell-to-cell contact (similar to Fig. 2B). 
Fig. 6B has Ki-67 immunostaining (brown) added to the double staining. This triple staining 
shows that CD45RO+(red)Ki-67+(brown) cells exist in close contact to CXCL9+ stromal cells 
(dark blue) (Fig. 6B, arrows). Approximately 10% of CD45RO+ cells co-express Ki-67. This 
indicates that CD45RO+ T cells in close contact with CXCL9+ stromal cells have proliferative 
activity. Taking account of the well-characterized T-cell and dendritic cell interactions, the data 
here imply that when CXCR3+ T cells are in close contact with CXCL9+ stromal cells, they may 
receive proliferative stimuli. Therefore, the lymphoid stroma is not a mere aggregation of 
lymphocytes, but a place where significant T cell–stromal cell interactions can occur.  
7. Similarity to the regional lymph nodes 
Given that peripheral tissue (with inflammatory changes) has a close connection with 
regional lymph nodes, it is important to compare potential changes occurring between 
gastric cancers and regional lymph nodes. As shown in figure 7A, CXCL9+ stromal cells are 
abundantly distributed in the T-cell zone in the regional lymph nodes of lymphocyte-rich 
gastric cancers. In contrast, regional lymph nodes in conventional gastric cancers show only 
sporadic expression of CXCL9+ cells (Fig. 7B). Hence, histopathological identification of 
CXCL9+ cells in both primary tumor and regional lymph nodes suggests that a functional 
relationship exists between them.  
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Fig. 6. Immunohistochemical analyses for proliferative activity of T cells in lymphocyte-rich 
gastric cancer. A) Double staining for CD45RO (red) and CXCL9 (dark blue), revealing that 
CXCL9+ stromal cells are in close contact with CD45RO+ T cells (similar to the results shown 
in Fig. 2B). B) Triple staining for CD45RO (red) + CXCL9 (dark blue) + Ki-67 (brown). 
Arrows indicate Ki-67+ T cells (brown and red) that are in close contact with CXCL9+ 
stromal cells (dark blue). This suggests that T cells in close contact with CXCL9+ cells are 
proliferating in lymphocyte-rich gastric cancers. 
 




Fig. 7. Immunohistochemistry for CXCL9 in regional lymph nodes in lymphocyte-rich- (A) 
and conventional (B) gastric cancers. Note the abundance of CXCL9+ stromal cells in 
regional lymph nodes in lymphocyte-rich gastric cancers (A), contrasted by sparse 
distribution of CXCL9+ stromal cells (arrows) in regional lymph node of conventional 
gastric cancer (B). GerC in (B) and (C) represents germinal centers. 
8. Regulatory T cells 
The data thus far suggests the presence of pro-immune responses in lymphocyte-rich gastric 
cancers. However, current opinion on tumor immune evasion mechanisms maintains that 
immunosuppressive factors play a major role. Regulatory T-cells are one type of cell that 
exerts a suppressive function, and forkhead box protein-3 (Foxp3) is a reliable marker of the 
cells (Zou 2006). In gastric cancer, diffuse distribution of regulatory T cells is associated with 
a poorer prognosis of patients (Mizukami et al. 2008a,b). Fig. 8A shows the distribution of 
Foxp3+ regulatory T-cell in lymphocyte-rich gastric cancer. Using Foxp3 as a marker, 
quantitative immunohistochemistry shows a small increase in the number of regulatory T-
cells in lymphocyte-rich gastric cancers, compared with conventional gastric cancers (Fig. 
8B). This sharply contrasts with a marked increase in CXCR3+ lymphocytes observed in 
lymphocyte-rich gastric cancers compared with conventional gastric cancers (Fig. 8C). 
Hence, the ratio of CXCR3+ lymphocytes/regulatory T-cells is higher in lymphocyte-rich 
gastric cancers than in conventional gastric cancers. Overall, this suggests that the lymphoid 
stroma in lymphocyte-rich gastric cancers is shifted towards a pro-immune status compared 
with conventional gastric cancers. And, it is clear that immunosuppressive aspects of 
lymphoid stroma cannot be explained by a mere increase in regulatory T-cells alone.  
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Fig. 8. Analysis on regulatory T cells. A) Immunohistochemitry for Foxp3 reveals that 
regulatory T-cells are also distributed in lymphocyte-rich gastric cancer. B) However, 
regulatory T-cells are mildly elevated in lymphocyte-rich gastric cancers than in 
conventional gastric cancer.  (C) There are a sharp increase in the number of CXCR3+ cells 
in lymphocyte-rich gastric cancers as compared with conventional gastric cancer (error 
bars for panels B and C are the mean ± standard error). Methods of B) and C). 
Immunohistochemistry for Foxp3 was performed on routine histopathological slides. The 
numbers of Foxp3+ cells per unit area (0.0625 mm2) were counted manually suing a 40x 
objective lens. At least three areas were counted. In lymphocyte-rich gastric cancer, areas 
with average infiltration were counted. In conventional gastric cancers, the most densely 
infiltrated areas were counted. Conv, conventional gastric cancer. Ly-rich, lymphocyter-
rich gastric cancer. Verticals bar in B) and C) represent number of cells per unit area 
(0.0625 mm2). 
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Next the immunohistochemical distribution of chemokine CCL22 (MDC) is described. 
CCL22 is one of the cognate ligands of CCR4 which is frequently expressed by regulatory T-
cells and Th2 cells. CCL22 is focally expressed by mature dendritic cells in lymphocyte-rich 
gastric cancers, but not in conventional gastric cancers (Ohtani et al. 2010). It is generally 
believed that tumor-derived CCL22 promotes accumulation of CCR4+ regulatory T-cells, 
which subverts immune responses in cancer (Menetrier-Caux et al. 2009). Tan et al. (2011) 
suggested that regulatory T-cells can promote tumor metastasis through RANKL, a 
mechanism distinct from an immunoregulatory one. Therefore, it is conceivable that 
dendritic cells in lymphocyte-rich gastric cancers may have both tumor-inhibitory and 
tumor-promoting properties  
 
 
Fig. 9. Schematic summary of the results. Lymphocyte-rich gastric cancers are characterized 
by an abundance of CXCR3+ T cells with CXCL9+ stromal cells (CXCR3+ T cell-CXCL9+ 
stromal cell clustering). Dendritic cells are also distributed in the section. Together with the 
formation of lymphoid follicles with germinal centers, these data suggest that the stroma of 
lymphocyte-rich gastric cancer is a tertiary lymphoid tissue. 
9. Conclusions 
Fig. 9 is a schematic summary of this chapter. This depicts stromal elements of lymphocyte-
rich gastric cancers. T cells are predominant in this lymphoid stroma, where chemokine 
CXCL9 and chemokine receptor CXCR3 are expressed by stromal cells and T cells, 
respectively, to form CXCL9+ stromal cell-CXCR3+ T cell clustering. Mature, myeloid-derived 
dendritic cells are also distributed in the tissue. A part of CXCL9+ cells corresponds to these 
mature dendritic cells. However, a large part of CXCL9+ stromal cells remains unclassified. 
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Regulatory T-cells are also present, but their relative density is lower in lymphocyte-rich 
gastric cancers than in conventional gastric cancers. Together with the occasional formation of 
lymph follicles with a germinal center, the lymphoid stroma in lymphocyte-rich gastric cancer 
is judged to be similar to the secondary lymphoid tissue (i.e., lymph nodes or Peyer patches). 
Lymphoid tissues newly formed in the peripheral tissues during chronic inflammation are 
designated “tertiary lymphoid tissues” (Aloisi et al. 2006). The author proposes, therefore, that 
lymphoid stroma in lymphocyte-rich gastric cancer can be regarded as tertiary lymphoid 
tissue (Ohtani et al. 2009). Hence, immunostimulatory aspects of lymphocyte-rich gastric 
cancers have been clarified in this chapter. A mere increase of regulatory T-cells is not 
observed in lymphocyte-rich gastric cancer. Further analyses of the immunoregulatory aspects 
of lymphoid stroma are now required because immunosubversion is considered to be a major 
obstacle to successful immunotherapy of cancer.  
10. Acknowledgments 
The author is grateful to Drs. Osamu Yoshie, Masaaki Miyazawa, Takashi Nakayama, 
Fuminori Katou, Eiichi Sato, Noriko Kimura, Hiroshi Naganuma, and Yuriko Saiki for their 
cooperation. Clerical assistance by Ms. Fumiko Date is also greatly appreciated.  
11. References 
Allen SJ, Crown SE, Handel TM. (2007) Chemokine: receptor structure, interactions, and 
antagonism. Annu Rev Immunol 25:787-820. 
Aloisi F, Pujol-Borrell R. (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat 
Rev Immunol 6:205-217. 
Dunn GP, Old LJ, Schreiber RD. (2004) The three Es of cancer immunoediting. Annu Rev 
Immunol 22:329-360. 
Yu P, Fu YX. (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 86:231-
245. 
Finn OJ. Cancer immunology. (2008) N Engl J Med. 358(25):2704-2715. 
Fukayama M. (2010) Epstein-Barr virus and gastric carcinoma. Pathol Int. 60(5): 
337-350. 
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini 
M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, 
Trajanoski Z, Fridman WH, Pagès F. (2006) Type, density, and location of 
immune cells within human colorectal tumors predict clinical outcome. Science 
313(5795):1960-1964. 
Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at 
body surfaces. (2009) Nat Immunol. 10:1237-1244. 
Ménétrier-Caux C, Gobert M, Caux C. (2009) Differences in tumor regulatory T-cell 
localization and activation status impact patient outcome. Cancer Res. 69(20):7895-
7898. 
Minamoto T, Mai M, Watanabe K, Ooi A, Kitamura T, Takahashi Y, Ueda H, Ogino T, 
Nakanishi I. (1990) Medullary carcinoma with lymphocytic infiltration of the 
stomach. Clinicopathologic study of 27 cases and immunohistochemical 
 
Immune Cell Responses in Gastric Carcinoma: An Analysis Based on Histopathology 
 
199 
analysis of the subpopulations of infiltrating lymphocytes in the tumor.  Cancer 
66:945-952. 
Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. (2008) 
Localization pattern of Foxp3+ regulatory T cells is associated with clinical 
behaviour in gastric cancer. Br J Cancer. 98:148-153.  
Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. (2008) CCL17 
and CCL22 chemokines within tumor microenvironment are related to 
accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 122:2286-
2293.  
Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, 
Oppenheim JJ, Power CA. (2000) International union of pharmacology. XXII. 
Nomenclature for chemokine receptors. Pharmacol Rev. 52(1):145-76. 
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. (1998) CD8+ T-cells 
infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. 
Cancer Res 58:3491-3494. 
Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. (2009) Abundant expression of CXCL9 
(MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T 
cells in lymphocyte-rich gastric carcinoma. J Pathol 217:21-31. 
Ohtani H and Yoshie O. (2010) Morphometric analysis of the balance between CXCR3+ T 
cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric 
cancers. Virchows Arch 456:615-623. 
Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H. (1996) Immunophenotypical 
characterization of Epstein-Barr virus-associated gastric carcinoma:   
Massive infiltration by proliferating CD8+ T-lymphocytes.  Lab Invest 75: 
67-76. 
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, 
Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani 
H, Old LJ, Odunsi K. (2005) Intraepithelial CD8+ tumor-infiltrating 
lymphocytes and a high CD8+/regulatory T cell ratio are associated with 
favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-
18543. 
Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr 
H, Old LJ, Sato E. (2007) CD8 tumor-infiltrating lymphocytes are predictive of 
survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 
104:3967-3972. 
Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M.(2011) 
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis 
through RANKL-RANK signaling. Nature 470:548-553.   
Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. (1993) Epstein-Barr virus 
in gastric carcinoma. Am J Pathol. 143:1250-1254. 
Watanabe H, Enjoji M, Imai T. (1976) Gastric carcinoma with lymphoid stroma.  
Its morphologic characteristics and prognostic correlations. Cancer 38: 
232-243. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
198 
Regulatory T-cells are also present, but their relative density is lower in lymphocyte-rich 
gastric cancers than in conventional gastric cancers. Together with the occasional formation of 
lymph follicles with a germinal center, the lymphoid stroma in lymphocyte-rich gastric cancer 
is judged to be similar to the secondary lymphoid tissue (i.e., lymph nodes or Peyer patches). 
Lymphoid tissues newly formed in the peripheral tissues during chronic inflammation are 
designated “tertiary lymphoid tissues” (Aloisi et al. 2006). The author proposes, therefore, that 
lymphoid stroma in lymphocyte-rich gastric cancer can be regarded as tertiary lymphoid 
tissue (Ohtani et al. 2009). Hence, immunostimulatory aspects of lymphocyte-rich gastric 
cancers have been clarified in this chapter. A mere increase of regulatory T-cells is not 
observed in lymphocyte-rich gastric cancer. Further analyses of the immunoregulatory aspects 
of lymphoid stroma are now required because immunosubversion is considered to be a major 
obstacle to successful immunotherapy of cancer.  
10. Acknowledgments 
The author is grateful to Drs. Osamu Yoshie, Masaaki Miyazawa, Takashi Nakayama, 
Fuminori Katou, Eiichi Sato, Noriko Kimura, Hiroshi Naganuma, and Yuriko Saiki for their 
cooperation. Clerical assistance by Ms. Fumiko Date is also greatly appreciated.  
11. References 
Allen SJ, Crown SE, Handel TM. (2007) Chemokine: receptor structure, interactions, and 
antagonism. Annu Rev Immunol 25:787-820. 
Aloisi F, Pujol-Borrell R. (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat 
Rev Immunol 6:205-217. 
Dunn GP, Old LJ, Schreiber RD. (2004) The three Es of cancer immunoediting. Annu Rev 
Immunol 22:329-360. 
Yu P, Fu YX. (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 86:231-
245. 
Finn OJ. Cancer immunology. (2008) N Engl J Med. 358(25):2704-2715. 
Fukayama M. (2010) Epstein-Barr virus and gastric carcinoma. Pathol Int. 60(5): 
337-350. 
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini 
M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, 
Trajanoski Z, Fridman WH, Pagès F. (2006) Type, density, and location of 
immune cells within human colorectal tumors predict clinical outcome. Science 
313(5795):1960-1964. 
Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at 
body surfaces. (2009) Nat Immunol. 10:1237-1244. 
Ménétrier-Caux C, Gobert M, Caux C. (2009) Differences in tumor regulatory T-cell 
localization and activation status impact patient outcome. Cancer Res. 69(20):7895-
7898. 
Minamoto T, Mai M, Watanabe K, Ooi A, Kitamura T, Takahashi Y, Ueda H, Ogino T, 
Nakanishi I. (1990) Medullary carcinoma with lymphocytic infiltration of the 
stomach. Clinicopathologic study of 27 cases and immunohistochemical 
 
Immune Cell Responses in Gastric Carcinoma: An Analysis Based on Histopathology 
 
199 
analysis of the subpopulations of infiltrating lymphocytes in the tumor.  Cancer 
66:945-952. 
Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. (2008) 
Localization pattern of Foxp3+ regulatory T cells is associated with clinical 
behaviour in gastric cancer. Br J Cancer. 98:148-153.  
Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. (2008) CCL17 
and CCL22 chemokines within tumor microenvironment are related to 
accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 122:2286-
2293.  
Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, 
Oppenheim JJ, Power CA. (2000) International union of pharmacology. XXII. 
Nomenclature for chemokine receptors. Pharmacol Rev. 52(1):145-76. 
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. (1998) CD8+ T-cells 
infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. 
Cancer Res 58:3491-3494. 
Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. (2009) Abundant expression of CXCL9 
(MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T 
cells in lymphocyte-rich gastric carcinoma. J Pathol 217:21-31. 
Ohtani H and Yoshie O. (2010) Morphometric analysis of the balance between CXCR3+ T 
cells and FOXP3+ regulatory T cells in lymphocyte-rich and conventional gastric 
cancers. Virchows Arch 456:615-623. 
Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H. (1996) Immunophenotypical 
characterization of Epstein-Barr virus-associated gastric carcinoma:   
Massive infiltration by proliferating CD8+ T-lymphocytes.  Lab Invest 75: 
67-76. 
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, 
Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani 
H, Old LJ, Odunsi K. (2005) Intraepithelial CD8+ tumor-infiltrating 
lymphocytes and a high CD8+/regulatory T cell ratio are associated with 
favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-
18543. 
Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr 
H, Old LJ, Sato E. (2007) CD8 tumor-infiltrating lymphocytes are predictive of 
survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 
104:3967-3972. 
Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M.(2011) 
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis 
through RANKL-RANK signaling. Nature 470:548-553.   
Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. (1993) Epstein-Barr virus 
in gastric carcinoma. Am J Pathol. 143:1250-1254. 
Watanabe H, Enjoji M, Imai T. (1976) Gastric carcinoma with lymphoid stroma.  
Its morphologic characteristics and prognostic correlations. Cancer 38: 
232-243. 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
200 
Zlotnik A, Yoshie O. (2000) Chemokines: a new classification system and their role in 
immunity. Immunity. 12(2):121-7. 
Zou W. (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 
6:295-307. 
11 
Immunohistochemical Profile  
of Mucins in Gastric Carcinoma 
Daniela Lazăr1, Sorina Tăban2 and Sorin Ursoniu3 
1Department of Gastroenterology,  
2Department of Pathology,  
3Department of Public Health. University of Medicine and Pharmacy 
„Victor Babeş” Timişoara 
Romania 
1. Introduction 
Gastric cancer represents the second leading cause of cancer related death (after lung cancer) 
despite a global decline in both its incidence and mortality since the late half of the 20th 
century (Kelley & Duggan, 2003; Zheng et al., 2008). This type of cancer continues nowadays 
to be a major health problem due to the slow decrease in incidence in Asia and its high 
mortality in the western countries (Roukos et al., 2002). The overall prognosis is reserved, 
depending on the TNM stage in the moment of diagnosis and somewhat on its histological 
type (Lauren, 1965). 
Based on morphological characteristics focused on gland formation and histogenetic 
background, gastric adenocarcinomas are divided into intestinal and diffuse types using the 
Lauren classification system (Lauren, 1965), or as differentiated and undifferentiated using 
the Nakamura classification system (Nakamura et al., 1968). Intestinal-type adenocarcinoma 
is considered to be equivalent to differentiated adenocarcinoma and the diffuse-type to the 
undifferentiated adenocarcinoma. 
These different types of gastric carcinomas express particular biological behaviours. 
Helicobacter pylori infection leads to the development of chronic atrophic gastritis and 
intestinal metaplasia (Byrd et al., 1997). Usually the intestinal-type gastric carcinoma arises 
on the background of intestinal metaplasia (Stemmermann, 1994; Tahara, 1993), and, by 
contrary, the diffuse-type on the background of gastric mucosa without intestinal 
metaplasia (Nakamura et al., 1968). The diffuse-type, as classified according to the Lauren 
system (non-solid type of poorly differentiated adenocarcinoma and the signet-ring cell 
carcinoma according to a Japanese classification system) (Japanese Gastric Cancer 
Association, 1996), do not show glandular formation, can be further divided into two 
subtypes. In the first one, the tumor is predominantly composed of signet-ring cells (>50%) 
(signet-ring cell carcinomas) and in the other one, the adenocarcinoma contains few signet-
ring cells (<50%) (non-signet ring cell carcinomas). Although these histological types can 
usually be distinguished using standard stainings, new advances in histochemical and 
immunohistochemical reactions using gastric and small intestinal cell markers determined 
emerging of gastric cancer classification into different phenotypes, according to mucin 
expression (Tatematsu et al., 1990). 
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Much effort is being carried out to identify markers with biological and therapeutical 
significance in gastric cancer. Mucins are expressed by various epithelial cell types, both 
normal and malignant.  Mucins, high-weight glycoproteins, represent major components of 
the mucus layer which protects the gastric epithelium against chemical and mechanical 
aggressions (Corfiefd et al., 2000; Moniaux et al., 2001). In humans, at least 14 genes were 
identified, coding proteins of mucins, called MUC1, MUC2, MUC3, MUC4, MUC5AC, 
MUC5B, MUC6, MUC7, MUC8, MUC9, MUC11, MUC12, MUC13 and MUC16 (Pinto-de-
Sousa et al., 2002; Silva et al., 2002). They are classified into two groups: membrane bound 
including MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13 and MUC 17, and secreted or 
gel forming including MUC2, MUC5AC, MUC5B and MUC6 (Fowler et al., 2001). All these 
mucins present common structural characteristics, but are distinct in their tandem repeat 
peptides. Abnormal expression of mucins has been reported to accompany cancer 
development, influence cellular growth, differentiation, transformation, adhesion, invasion 
and immune surveillance (De Bolos et al., 1995). 
MUC1 is involved with cell signaling, immuno-regulation and inhibition of cell-cell and cell-
matrix adhesion (Rakha et al., 2005; Wesseling et al., 1996). MUC1 cytoplasmic domain has 
been observed to interact with β-catenin through a similar mode found in E-cadherin, by 
this way inhibiting the formation of E-cadherin- β-catenin complex (Yamamoto et al., 1997). 
By this action, MUC1 may participate in tumor cell detachment, invasion and metastases, 
being associated with aggressive tumor behavior and poor prognosis. There have been 
reported interactions between MUC1 and members of EGFR family (Rahn et al., 2001). The 
cytoplasmic domain has a role of signaling mediator of tyrosine kinase receptors 
(phosphorylated MUC1-Grb2/SOS complex) (Schroeder et al., 2001). MUC1 is present on 
the apical surface of secretory epithelia, but in the malignant tissues is variable in amount 
and cellular localization (Pandey et al., 1995). The high aberrant MUC1 expression in tumors 
leads to antigenically recognizable epitopes on the MUC1 molecules and stimulation of the 
immune response, making MUC1 a potential immunotherapeutic target (Gendler, 2001). 
MUC2 and MUC5AC are important proteins for producing the mucus that protects and 
lubricates epithelial surfaces. MUC2 is the major secretory glycoprotein expressed 
abundantly by intestinal and airway epithelium (Gum et al., 1994). Its expression is a 
common feature of all mucinous carcinomas derived from different organs, including 
stomach, colon, breast and prostate, acting as a potential prognostic marker (Utsunomiya et 
al., 1998; Yamashita et al., 1993; Zhang et al., 1998).  
MUC5AC is found mainly in the mucosal layer of the cardia, fundus and antrum of the 
stomach, with the role of epithelia protection (Ho et al., 1995). Tumor phenotypes are 
classified on the basis of the expression of various markers, such as CD10 as a marker for the 
brush border on the luminal surface of enterocytes, mucin 2 (MUC2) as a marker of 
intestinal goblet cells, MUC5AC or human gastric mucin (HGM) as a marker of surface 
gastric epithelium (foveolar cells) and MUC6 as a marker for pyloric glands (Namikawa & 
Hanazaki, 2010).  
CD10 and MUC2 are considered diagnostic markers of the intestinal phenotype and 
MUC5AC, HGM and MUC6 are markers of the gastric phenotype. Gastric cancer 
phenotypes can be classified into four groups, depending on the combination of mucin 
expression: intestinal type, gastric type, combined type and unclassified type (Shiroshita et 
al., 2004). 
Intestinal metaplasia can be divided into incomplete (precancerous lesion), consisted by the 
presence of goblet cells in the gastric gland, and complete (not a precancerous lesion), 
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consisted by the presence of both enterocytes and goblet cells (Kawachi et al., 1974; Segura & 
Montero, 1983; Tosi et al., 1993). Based on the type of intestinal metaplasia, there are four 
phenotypes of gastric cancer: complete intestinal type, incomplete intestinal type, gastric 
type and unclassified type. The complete intestinal type is positive for CD10 and MUC2, 
and negative for MUC5AC. The incomplete intestinal phenotype is positive for CD10 and 
MUC5AC, or positive for MUC2 alone. The gastric type is positive for MUC5AC, and 
negative for CD10 and MUC2. Unclassified phenotypes are negative for CD10, MUC2, 
MUC5AC and MUC6. This classification based on mucin phenotype is important for 
assessing the biological behavior of gastric carcinomas and different therapeutic options 
(Namikawa & Hanazaki, 2010). 
Gastric-type mucins are mucins specific to the gastric mucosa, although differentiated 
gastric adenocarcinomas change their mucin phenotype as they grow and invade deeper 
into the gastric wall. Recent reports reveal an incidence of 7.9-23.9% for the gastric-type 
differentiated adenocarcinomas among early gastric cancers (Kabashima et al., 2002; Koseki 
et al., 2000; Matsuoka et al., 2003). This type of early cancer tends to form larger tumors and 
exhibit higher rates of submucosal invasion in comparison with the intestinal-type 
(Matsuoka et al., 2003). 
Gastric- and intestinal-types of differentiated gastric adenocarcinoma present differences in 
terms of their biological behavior. Usually, gastric-type tumors show scirrhous infiltration 
and intestinal-type carcinomas show a solid growth inside the wall (Oda et al., 2003; 
Shimoda et al., 1991). Some authors reported a significantly poorer prognosis in patients 
with advanced gastric cancer presenting gastric-type tumors vs. intestinal-type carcinomas, 
associated with increased malignant potential in the early phase of invasion and metastasis 
(Tajima et al., 2001). Koseki et al. (2000) have reported a significantly higher incidence of 
lymphatic invasion, venous invasion, and lymph node metastasis in the gastric-type. For 
these reasons, even in the early phase of the gastric-type, the decision to perform endoscopic 
mucosal/submucosal resection or minimal surgical procedures as a curative treatment 
should be carefully taken (Namikawa & Hanazaki, 2010).  
The undifferentiated gastric adenocarcinoma show no clinicopathological differences 
between gastric and intestinal phenotypes. However, gastric-types present different growth 
patterns compared with intestinal-type tumors (Kabashima et al., 2005), showing a tendency 
to spread through the middle layer of the mucosa. 
Recent studies have reported a different genetic background of patients with differentiated 
gastric adenocarcinomas for gastric-type compared to intestinal-type (Endoh et al., 2000; 
Fiocca et al., 2001; Matsuoka et al., 2003; Sugai et al., 2004). Overexpression of p53 protein is 
a common feature in differentiated adenocarcinoma (in both gastric- and intestinal 
phenotypes), but is rare in undifferentiated carcinoma (Matsuoka et al., 2003; Sugai et al., 
2004). Data suggest that differentiation to gastric gland cells is related to the presence of 
microsatellite instability (MSI), whereas differentiation to intestinal epithelial cells is related 
to mutations in APC gene (Endoh et al., 2000; Tajima et al., 2006; Yamazaki et al., 2006). 
Usually, the phenotype of gastric cancer tends to imitate the surrounding mucosa, with 
gastric-type cancers arising in areas expressing gastric-type or mixed-type mucins 
(Kabashima et al., 2000). Intestinal metaplasia surrounding gastric-phenotype of 
differentiated adenocarcinoma seems to be immature or incomplete, compared with gastric-
intestinal or intestinal phenotype (Egashira et al., 1999). 
Pinto-de-Sousa et al (2002) showed that the mucin phenotype is associated with the tumor 
site. In the study of Toki et al (2010), the signet ring cell carcinomas and non-signet ring cell 
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carcinomas were most frequently encountered in the upper or middle segments of the 
stomach. Over 95% of the advanced gastric cancers had either a G or GI phenotype. Pinto-
de-Sousa et al (2002) studied the mucin phenotypes of 23 diffuse-type adenocarcinomas and 
showed that the MUC5AC expression rate in these tumors was significantly higher than that 
in the unclassified and expansive adenocarcinomas. Reis et al (1997), studying the 
expression of MUC5AC in early gastric cancers, demonstrate at least some G phenotype 
cells in the initial stages of the tumors. 
Some studies show that the expression rates of the GI and I phenotypes in the cases of 
undifferentiated advanced gastric cancers were encountered in over half of the cases (Baresi 
et al., 2006; Tajima et al., 2001; Toki et al., 2010). Studies reported that the progression of the 
signet ring cell carcinomas was associated with a phenotype shift from the G-type to the I-
type in order to progress to the deep layer (Bamba et al., 2001; Tian et al., 2007; Yamachika et 
al., 1997; Yamagishi et al., 2004). It is also suggested that the morphological features of the 
signet ring cells change and are subsequently classified as non-signet ring cell carcinomas 
during tumor progression (Toki et al., 2010). 
In the present research we aimed to assess the profile of mucins in gastric carcinomas 
through immunohistochemical reactions using anti- MUC1, MUC2, and MUC5AC 
monoclonal antibodies. The purpose of this study is to compare the expression of mucins 
with clinicopathological factors and outcome of patients. 
2. Material and method 
From the total of 256 patients (186 males and 79 females), diagnosed clinically and 
histopathologically with gastric cancer in the period 1998-2002 that underwent surgical 
interventions in the Departments of Surgery of the Emergency County Clinical Hospital 
Timisoara, there were 67 patients selected. A prospective study was performed on this 
group, regarding the evolution and aggressiveness of gastric cancer, on a period of 5 years. 
Surgical interventions, performed with curative or palliative intention, were not preceded 
by chemotherapy or radiotherapy. The patients or their relatives were contacted 
periodically, on the phone or by medical letter, at 6-month intervals, survival being 
monitored on a variable period, between one month and 68 months. Patients who died 
postoperatively through various complications, or due to other conditions, were excluded 
from the study. Clinical and morphological (macroscopic and microscopic) data were 
collected for each case. Gastric carcinomas were classified and interpreted according to the 
evaluation protocol recommended by the American Joint Committee on Cancer (AJCC) and 
International Union against Cancer (UICC). 
Survival time was calculated from the month of surgery until the month of death or 
confirmation of survival, and survival rate was represented by the percentage of survivals at 
the end of the interval monitored (in years and months). Out of the total of cases included in 
the prospective study, 6 patients died at variable intervals, between 7 and 26 months, due to 
other medical causes, being excluded from the study. 
Immediately after excision, specimens were fixed in 10% neutral buffered formalin, 
embedded in paraffin wax, cut into 3 μm paraffin sections and stained with haematoxylin 
and eosin (HE) for routine light microscopy. For immunohistochemical staining, additional 
3 μm thick sections were cut from paraffin-embedded tissue and placed on poly-L-lysine-
coated glass slides. For the determination of mucin phenotypes, immunostaining was done 
for MUC 1 (monoclonal antibody Ab-5, MH1, Thermo Scientific), MUC2 (monoclonal 
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antibody Ab-2, M53, Thermo Scientific) and MUC5AC (monoclonal antibody Ab-1, 45M1, 
Thermo Scientific). Immunohistochemistry used the UltraVision Detection System, 
HRP/DAB (Ready-To-Use).  The nuclear counterstaining was accomplished using Mayer’s 
hematoxylin. According to their immunoreactivity, the cases were classified in 2 categories: 
• negative cases (negative or positive immunoreactions in less than 5% of cells examined); 
• positive cases (positive immunoreactions in more than 5% of cells examined). 
Statistical analysis was performed using STATA 9.2 software (Statacorp, Texas, USA). 
Frequencies and percentages are shown for categorical data. Chi-square test was used to 
compare categorical data.  Survival time was calculated as the time from cancer diagnosis to 
death, censoring at the date of last contact. The Kaplan-Meier method was used to compute 
5-year survival rates and disease-specific survival curves were drawn. Differences between 
survival curves were determined by log-rank test. Survival analysis was performed using a 
Cox proportional hazards model. A P-value <0.05 was considered statistically significant, 
and hazard ratios (HR) with their respective 95% confidence interval (CI) were calculated. 
3. Results 
The final group consisted of 61 patients (43 males and 18 females) who presented ages 
between 30 and 80 (average age = 59.34 years). The main clinicopathological features of 
cases of gastric cancer investigated are presented in Table 1. In the peritumoral mucosa, 
MUC1 reactivity was detected in specialized glands of the gastric body (Fig. 1), in the 
pyloric glands (Fig. 2), and at the level of the antrum, in surface mucous cells and mucous 
neck cells. 
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MUC5AC is expressed strongly in the foveolar epithelium of gastric antrum and body (Fig. 
3 and Fig. 4). MUC2, an intestinal-type mucin, was identified only on foci of intestinal 
metaplasia of gastric mucosa (in goblet cells – Fig. 5).   
The expression of mucins in gastric carcinomas studied is heterogeneous and includes 
mucins synthesized normally by the gastric mucosa, as well as intestinal mucins expressed 
“de novo”. We identified 41 cases with positive immune reactions for MUC1 (67.2%), 25 




Fig. 1. MUC1-positive immunoreaction in specialized glands of the gastric body. DABx200. 
 
 
Fig. 2. MUC1 positive immunoreaction in pyloric glands. DABx200. 
 















Fig. 4. MUC1-positive secretion in gastric glands; negative metaplastic foci. MUC1 
immunoreaction, DABx200. 
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Graphic 1. Expression of mucins in gastric carcinomas 
3.1 Immunohistochemical expression of MUC1 in gastric carcinomas 
MUC1 antigen is expressed in most cases at the apical pole of cells and intraluminally (Fig. 
6), and occasionally diffusely intracytoplasmatic (Fig. 7).  
Our results do not show a relationship between the expression of MUC1 and gender of 
patients, but reveal greater immunopositive results in patients with ages over 61 (78.1%) in 
comparison with patients under 60 (55.2%) (P=0.057 borderline statistical significance) 
(Table 2). According to the location of tumors, we noted MUC1 positive immunoreactions in 
64.5% of antral carcinomas, in 73.3% of body carcinomas, in 70% of carcinomas extended in 
the entire stomach, in 66.7% of carcinomas developed on the gastric stump and in 50% of 
carcinomas of the cardia. 
 







+  (%) 
n=41 
Gender 
Males 13 30 (69.8%) 
0.511 
Females 7 11 (61.1%) 
Age 
≤ 60 years 13 16 (55.2%) 
0.057 
≥ 61 years 7 25 (78.1%) 
Location 
Antrum 11 20 (64.5%) 
0.956 
Body 4 11 (73.3%) 
Pangastric 3 7 (70%) 
Cardia 1 1 (50%)  
Gastric stump 1 2 (66.7%) 
Table 2. Relationship between gender of patients, age of patients and MUC1 expression 
Classifying the tumors studied according to Lauren, we observed the greater frequency of 
MUC1-positive immune reactions (without reaching statistical significance) in carcinomas 
with glandular differentiation (73.7% - Fig. 8) (Table 3). The diffuse type of carcinoma 




Fig. 6. MUC1-positive immunoreaction intra luminally and at the apical pole of malignant 
cells. DABx200. 
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Fig. 6. MUC1-positive immunoreaction intra luminally and at the apical pole of malignant 
cells. DABx200. 
 




Fig. 7. MUC1 synthesis at the apical pole and intracitoplasmatical. MUC1 immunoreaction, 
DABx400. 
Classifying the tumors studied according to Lauren, we observed the greater frequency of 
MUC1-positive immune reactions (without reaching statistical significance) in carcinomas 
with glandular differentiation (73.7% - Fig. 8) (Table 3). The diffuse type of carcinoma 




Fig. 8. Intestinal type of gastric carcinoma. MUC1 immunoreaction, DABx400. 
 




Fig. 9. Diffuse type of gastric carcinoma. MUC1 immunoreaction, DABx400. 
From the histological forms, tubular and papillary adenocarcinomas (Fig. 10) became 
positive in a great number of cases (78.6% and 80%). For the mucinous adenocarcinoma we 
encountered 62.5% positive cases. The poorly differentiated forms, such as signet-ring cell 
carcinoma and anaplastic carcinoma (Fig. 11 and 12), expressed MUC1 in 53% and 33.3% of 
cases. In our study, the differences in MUC1 expression between various histological types 




P -  
n=20 
+ (%)  
n=41 
Lauren classification 
Intestinal type 10 28 (73.7%) 
0.318 Diffuse type 8 9 (53%) 
Mixed type 2 4 (66.7%) 
Histological type 
TA 6 22 (78.6%) 
0.265 
PA 1 4 (80%) 
MA 3 5 (62.5%) 
SRCC 8 9 (53%) 
AC 2 1 (33.3%) 
Tumor grade 
G1 0 2 (100%) 
0.468 G2 8 12 (60%) 
G3 12 27 (69.2%) 
Lymphovascular 
invasion 
Present 13 25 (65.8%) 0.761 
Absent 7 16 (69.6%) 
TA-tubular adenocarcinoma; PA-papillary adenocarcinoma; MA-mucinous adenocarcinoma; SRCC- 
signet-ring cell carcinoma; AC- anaplastic carcinoma 
Table 3. Relationship between the histological type, tumor grade, lymphovascular invasion 
and expression of MUC1 
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Fig. 10. Papillary adenocarcinoma. MUC1 immunoreaction, DABx200. 
 
 
Fig. 11. Anaplastic carcinoma. MUC1 immunoreaction, DABx200. 
The immunohistochemical expression of MUC1 is not correlated with the tumor histological 
grade and lymphovascular invasion. G1 carcinomas became positive for MUC1 in 100% of 
cases, but the result obtained could be influenced by the small number of cases included in 
this category. 
From our data does not result a correlation between the MUC1 positive immune reaction 
and the level of tumor invasion (pT stage), the presence of distance metastases (pM stage) 
and pTNM staging (Table 4). However, we noted a largerer number of positive 
immunoreactions in cases with lymph node metastases (31 carcinomas – 72.1%) in 
comparison with tumors without metastases (10 cases – 55.6%), although not reaching 
statistical significance. 
 




Fig. 12. Anaplastic carcinoma. MUC1 immunoreaction, DABx400. 
Our results regarding survival of patients at 5 years demonstrate the role of MUC1 over-
expression as a prognosis factor in gastric carcinomas. Patients with carcinomas which 
became positive for MUC1 survived significantly less than patients with MUC1 negative 









Tis 0 1 (100%) 
0.870 
T1 1 3 (75%) 
T2 3 6 (66.7%) 
T3 7 10 (58.8%) 
T4 9 21 (70%) 
pN 
N0 8 10 (55.6%) 
0.636 N1 5 11 (68.7%) 
N2 6 17 (74%) 
N3 1 3 (75%) 
pM M0 16 31 (66%) 0.702 
M1 4 10 (71.4%) 
pTNM 
0 0 1 (100%) 
0.884 
IA 1 2 (66.7%) 
IB 1 4 (80%) 
II 2 5 (71.4%) 
IIIA 3 8 (72.7%) 
IIIB 2 6 (75%) 
IV 11 15 (57.7%) 
Table 4. Relationship between TNM staging and expression of MUC1 
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Muc1 = 0 (negative expression); Muc1 = 1 (positive expression) 
Graphic 2. Survival at 5 years according to the MUC1 expression 
A significant difference was also obtained by calculating the average survival in months, in 
the postoperative period, between the two types of patients (Graphic 3): 
• for patients with MUC1-positive carcinomas: 12 months;  
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Graphic 3. Average survival of patients according to the MUC1 expression 
Patients with MUC1 positive carcinomas were about two times more likely to die than those 
with MUC1 negative carcinomas (HR=2.30; 95%CI: 1.24-4.26; P=0.008).  
3.2 Immunohistochemical expression of MUC2 in gastric carcinomas 
Positive immunoreaction for MUC2 was observed only in malignant cells (intracytoplasmic) 
and in goblet cells from foci of intestinal metaplasia of gastric peritumoral mucosa (Fig. 13). 
We did not note the synthesis of MUC2 in epithelial cells of the normal gastric mucosa. 
From the results obtained we conclude the absence of a relationship between the age and 
gender of patients and the immunohistochemical expression of MUC2 (Table 5). 
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According to the tumor location we noted MUC2 positive immunoreactions in 41.9% of 
antral carcinomas, 40% of gastric body carcinomas, 30% of pangastric carcinomas, and 25% 
of carcinomas developed on the gastric stump. We noted the tumors developed at the level 
of the cardia which expressed MUC2 in 100% of cases, suggesting the existence of a possible 
correlation between the overexpression of MUC2 and the cardial location of gastric 




P -  
n=36 
+  (%) 
n=25 
Gender 
Males 25 18 (41.9%) 
0.830 
Females 11 7 (38.9%) 
Age 
≤ 60 years 18 11 (37.9%) 
0.644 
≥ 61 years 18 14 (43.7%) 
Location 
Antrum 18 13 (41.9%) 
0.483 
Body 9 6 (40%) 
Pangastric 7 3 (30%) 
Cardia 0 2 (100%) 
Gastric stump 2 1 (25%) 
Table 5. MUC2 expression and clinicopathological factors in gastric cancer 
 
 
Fig. 13. Intracytoplasmic synthesis of MUC2 in tumoral cells and metaplastic foci. MUC2 
immunoreaction, DABx100. 
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Fig. 14. Intestinal-type of gastric carcinoma. MUC2 immunoreaction, DABx100. 
According to the Lauren classification, we noticed a greater immune positivity in intestinal-
type carcinomas (47.4% - Fig. 14) and in mixed-type carcinomas (50%), in comparison with 










Intestinal type 20 18 (47.4%) 
0.225 Diffuse type 13 4 (23.5%) 
Mixed type 3 3 (50%) 
Histological type 
TA 17 11 (39.3%) 
0.052 
PA 3 2 (40%) 
MA 1 7 (87.5%) 
SRCC 13 4 (23.5%) 
AC 2 1 (33.3%) 
Tumor grade 
G1 1 1 (50%) 
0.859 G2 11 9 (45%) 
G3 24 15 (38.5%) 
Lymphovascular 
invasion 
Present 22 16 (42.1%) 0.819 Absent 14 9 (39.1%) 
TA-tubular adenocarcinoma; PA-papillary adenocarcinoma; MA-mucinous adenocarcinoma; SRCC- 
signet-ring cell carcinoma; AC- anaplastic carcinoma 
Table 6. MUC2 expression and clinicopathological factors in gastric cancer 
Overexpression of MUC2 is correlated (P=0.052 borderline statistical significance) with 
mucinous adenocarcinoma as histological form, being identified in 87.5% of cases (Fig. 16). 
From histological forms that are associated most rarely with the secretion of MUC2, we 
should mention the signet-ring cell carcinoma (23.5%). The data obtained are not suggestive 
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for a relationship between the tumor histological grade or lymphovascular invasion and the 
immunohistochemical expression of MUC2. 
 
 
Fig. 15. Diffuse type of gastric carcinoma. MUC2 immunoreaction, DABx200. 
 
 
Fig. 16. Mucinous adenocarcinoma. MUC2 intensely positive immunoreaction, DABx200. 
Based on the results obtained, we cannot point to the existence of a relationship between the 
pT, pN, pM, and pTNM factors, and the MUC2 immunoreaction in the gastric carcinomas 
examined (Table 7). 
The immunohistochemical expression of MUC2 does not influence survival at 5 years of 
patients (16% for MUC2 positive patients vs. 16.7% for MUC2 negative patients) (P = 0.7568) 
(Graphic 4).  
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+ (%)  
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pT 
Tis 1 0 (0%) 
0.927 
T1 2 2 (50%) 
T2 5 4 (44.4%) 
T3 10 7 (41.2%) 
T4 18 12(40%) 
pN 
N0 10 8 (44.4%) 
0.953 N1 10 6 (37.5%) 
N2 14 9 (39.1%) 
N3 2 2 (50%) 
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0 1 0 (0%) 
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Average survivals calculated in months show the lack of correlation between the prognosis 
of patients and the immunohistochemical expression of MUC2 (16 months for patients with 
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Graphic 5. Average survival of patients according to expression of MUC2 
3.3 Immunohistochemical expression of MUC5AC in gastric carcinomas 
Immunohistochemical reactions performed with the anti-MUC5AC antibody have 
demonstrated the strong expression of the foveolar epithelium of the gastric antrum and 
body (Fig. 17), as well as in the cytoplasms of malignant cells from 43 gastric carcinomas 
(70.5% - Fig. 18). 
The results obtained do not show a relationship between the age or gender of patients and 
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Body 5 10 (66.7%) 
Pangastric 4 6 (60%) 
Cardia 2 0 (0%) 
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Table 8. Expression of MUC5AC and clinicopathological factors in gastric cancer 
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Fig. 18. MUC5AC immune reactivity in the cytoplasm of malignant cells. DABx200. 
Analysis of MUC5AC according to location of tumors demonstrated the most frequent 
immunoreactivity of the antibody in antral carcinomas (80.6%) (without statistical 
significance). We identified positive immunoreactions in 66.7% of gastric body carcinomas, 
60% of pangastric carcinomas and 66.7% of carcinomas developed on the gastric stump. 
Cardial tumors did not express the MUC5AC antigen.  
The diffuse type of gastric carcinoma, as well as the signet-ring cell carcinoma, presented in 
a very high percentage (88.2%) MUC5AC positive immunoreactions (Tab. 9 – Fig. 19). Our 
results seem to show that MUC5AC is expressed mostly in the signet-ring cell carcinoma, 
but the differences between the histological subtypes did not reach statistical significance. 
According to the tumor histological grade, we noted 50% positive reactions in well-
differentiated carcinomas, 70% positive reactions in moderately differentiated carcinomas 
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and 71.8% in poorly differentiated carcinomas. We noted no relationship between the 
lymphovascular invasion and the expression of MUC5AC. 
 
 










Intestinal type 14 24(63.2%) 
0.165 Diffuse type 2 15 (88.2%) 
Mixed type 2 4 (66.7%) 
Histological type 
TA 20 18 (64.3%) 
0.082 
PA 2 3 (60%) 
MA 3 5 (62.5%) 
SRCC 2 15 (88.2%) 
AC 1 2 (66.7%) 
Tumor grade 
G1 1 1 (50%) 
0.958 G2 6 14 (70%) 
G3 11 28 (71.8%) 
Lymphovascular 
invasion 
Present 12 26 (68.4%) 0.649 
Absent 6 17 (73.9%) 
TA-tubular adenocarcinoma; PA-papillary adenocarcinoma; MA-mucinous adenocarcinoma; SRCC- 
signet-ring cell carcinoma; AC- anaplastic carcinoma 
Table 9. Expression of MUC5AC and clinicopathological factors in gastric cancer 
Our results, similar with those obtained in analyzing MUC2, did not show the existence of 
a correlation between the level of tumor invasion, the presence of lymph node or distant 
metastases, the pTNM stage and the immunohistochemical expression of MUC5AC  
(Table 10). 
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+ (%)  
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pT 
Tis 0 1 (100%) 
0.489 
T1 1 3 (75%) 
T2 2 7 (77.8%) 
T3 3 14 (82.4%) 
T4 12 18 (60%) 
pN 
N0 5 13 (72.2%) 
0.992 N1 5 11 (68.8%) 
N2 7 16 (69.6%) 
N3 1 3 (75%) 
pM M0 14 33 (70.2%) 0.930 
M1 4 10 (71.4%) 
pTNM 
0 0 1 (100%) 
0.985 
IA 1 2 (66.7%) 
IB 1 4 (80%) 
II 2 5 (71.4%) 
IIIA 4 7 (63.6%) 
IIIB 2 6 (75%) 
IV 8 18 (69.2%) 
Table 10. Expression of MUC5AC and clinicopathological factors in gastric cancer 
The expression of MUC5AC does not constitute a prognostic factor in our study, the 
survival rate at 5 years being 16.3% for MUC5AC positive patients vs. 16.7% for MUC5AC 
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The average survival rates, calculated in months, were of 18 months for patients with 
MUC5AC-positive carcinomas and 16.05 months for patients with MUC5AC-negative 
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Graphic 7. Average survival rate (in months) according to the expression of MUC5AC 
4. Discussions 
The genes of mucins are expressed in normal cells and tissues. The stomach offers a very 
good example of expressing mucins. MUC1 can be identified in mucous cells of the surface 
epithelium and neck of glands at the level of the antrum, but also in the pyloric and oxyntic 
glands in the gastric body (Ho et al., 1995; Pinto-De-Sousa, 2002). The MUC5AC mucin is 
expressed strongly in the foveolar epithelium of the antrum and body and MUC5AC is 
limited to mucous neck cells of gastric body glands and pyloric glands of the antrum (Ho et 
al., 1995; Pinto-De-Sousa, 2002; Silva et al., 2002). The expression of mucins in gastric 
carcinomas is heterogeneous, including mucins synthesized normally by the gastric mucosa 
(MUC1, MUC5AC and MUC6), as well as intestinal mucins synthesized de novo (MUC2) 
(Baldus et al., 1998; Ho et al., 1993; Reis, 1997, 1998). Some authors suggested that the 
heterogeneous pattern of expression would offer information regarding the evolution of 
various forms of gastric cancer. 
The progression of tumorigenesis involves abnormalities in the expressions of cyclins and 
other cell-cycle related genes (Ioachim, 2008). Abnormalities have been found for cyclins D1, 
A, E and their co-operating partners (cyclin-dependent kinase), that promote cell cycle 
progression (Handa et al., 1999; Ioachim, 2008). These progressive factors can be inhibited 
by blockers, such as p21, p27 and p57, p16, p15 and p18. Key regulators of progression 
through the G1 phase of the cell cycle are cyclin D1, cyclin E, p53, p21 and p27 (Gamboa-
Dominguez et al., 2007; Mrena et al., 2006). Sugai et al. (2010), analyzing 190 gastric 
intramucosal differentiated-type cancers have suggested that the cellular mucin phenotypes 
are dependent on distinct cell cycle-related alteration. It was proposed a novel 
carcinogenesis model that relies on the mucin phenotype. Based on abnormalities of cell-
cycle related proteins, overexpressions of p53 and cyclin A characterize gastric phenotype 
cancers, whereas overexpression of p27 is associated with the development of intestinal-
phenotype cancers and overexpression of cyclin A with the mixt phenotype cancers. 
Mucin and mucin O-glycosylation have attracted attention for their role in the adhesion of 
bacteria, cell-cell adhesion, and cancer cell metastization (Hollingsworth & Swanson, 2004). 
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The expression of mucins is often altered in cancer, with frequent aberrant glycosylation, 
resulting immature structures and exposure of the peptide backbone (Ferreira et al.,   ;Reis et 
al., 1998). These structures are useful markers of premalignant and malignant cells. Gomez 
et al (Gomes et al., 2009) have studied the pattern of expression of UDP-N-acetyl-D-
galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 (ppGal NAc-T6) in gastric 
mucosa, intestinal metaplasia and gastric carcinoma. ppGal NAc-T6 was expressed in 
normal mucosa (both antrum and body region), in 52% of the cases with intestinal 
metaplasia and had a heterogeneous expression in gastric carcinomas, being present in 79% 
of case. Its expression in gastric carcinomas was associated with venous invasion. 
In our study we aimed to evaluate the profile of mucins in gastric carcinomas in the study 
group, through immunohistochemical reactions, using monoclonal anti-MUC1, MUC2, and 
MUC5AC antibodies. The purpose of the study is to compare the expression of mucins with 
clinicopathological factors and with the outcome of patients. In accordance with other works 
(Pinto-De-Sousa, 2002), the data obtained show that the immunohistochemical expression of 
mucins is associated with some characteristics of differentiation in gastric carcinomas. We 
noted the alteration of the profile of normal gastric mucins and the overexpression of 
intestinal mucin in the various forms of cancer. 
In the peritumoral mucosa, the MUC1 immunoreactivity was detected in the specialized 
glands of the gastric body, in the pyloric glands, and at the level of the antrum (in surface 
mucous cells and neck mucous cells). Amongst the carcinomas studied we identified 41 
cases with positive immunoreactions for MUC1, representing 67.2%. Using two specific 
monoclonal antibodies, Pinto-de-Sousa (2002) obtained positive reactions in 89% of cases 
with HFMG1 antibody and 50 of cases with SM3 antibody (which recognizes only the non-
glycosylated forms of MUC1). Generally, the immunoreactivity for MUC1 varies in different 
studies between 24.3% and 100% (Gürbüz et al., 2002). The MUC1 antigen was expressed in 
most cases at the apical pole of cells and intraluminally, and occasionally diffusely 
intracytoplasmatic. Our results do not show a relationship between the expression of MUC1 
and the gender of patients or the location of tumors, but reveal a greater immune positivity 
in patients with ages over 61 (78.1%), in comparison with patients under 60 years of age 
(55.2%) (borderline statistical significance). 
Classifying the tumors studied, according to Lauren, we noticed a greater frequency of 
MUC1 positive immunoreactions in carcinomas with glandular differentiation (73.7%), 
although without reaching statistical significance. Concordant results were obtained by 
Gürbüz Y et al. (2002), Lee HS et al. (2001), Machado JC et al. (2000), Reis CA et al. (1998), 
Utsunomiya T et al. (1998). The diffuse type of carcinoma became positive in 53% of cases, 
and for the non-classifiable type we obtained an intermediate value (66.7%). Reis CA et al. 
(1998) note the significant association between the immune reactivity of SM3 and the non-
classifiable gastric carcinoma. 
In our study, the differences in MUC1 expression between various histological types were 
not statistically significant. Also, in the study of Pinto-De-Sousa et al (2002), the expression 
of HMFG1 and SM3 antibodies was not correlated with histological forms of gastric cancer. 
The immunohistochemical expression of MUC1 is not correlated with the tumor histological 
grade and lymphovascular invasion. The G1 carcinomas became positive for MUC1 in 100% 
of cases, but the result obtained could be influenced by the small number of cases included 
in this category. 
No correlation results from our study between the MUC1 immunoreaction and the level of 
tumor invasion (pT stage), the presence of distance metastases (pM stage) and pTNM 
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staging. We noted, however, a greater number of positive immune reactions in cases with 
lymph node metastases (31 carcinomas – 72.1%), in comparison with tumors without lymph 
node metastases (10 cases – 55.6%), but without statistical significance. The correlation 
between MUC1 positivity and the presence of lymph node metastasis was observed by 
Zhang HK et al. (2004), together with the association between MUC1 and the advanced age 
of patients with gastric tumors of large dimensions. 
In epithelial cancer cells, MUC1 is over-expressed, aberrantly glycosylated with short 
oligosaccharides and also loses its apical polarization and becomes expressed over the entire 
cell surface (Hilkens et al., 1992; Kim & Gum, 1996; Lloyd et al., 1996; Wesseling et al., 1996). 
MUC1 is an endogenous ligand of galectin-3 (an apoptosis inhibitor) in cancer cells (colon 
cancer), the interaction occurring via binding the galectin-3 to the oncofetal Thomsen-
Friedenreich carbohydrate (TF) antigen on MUC1 (Yu et al., 2007). The increased expression 
of MUC1 and TF antigen are both associated with high metastatic potential of the cancer cell 
and poor prognosis (Nakamori et al., 1994). Over-expression of MUC1 promotes tumor cell 
release from primary tumor sites by inhibiting E-cadherin-mediated cell-cell and integrin-
mediated cancer extracellular matrix interactions (Kondo et al., 1998). Thus, MUC1 may 
promote the formation of cancer cell aggregates/emboli and prolong the survival of 
disseminated cells in the circulation and contributes to cancer cell haematogenous 
dissemination (Zhao et al., 2010). 
The role of MUC1 in invasion and metastasis has been shown in different models. The 
cytoplasmic tail of MUC1 was reported to enhance the invasion in breast cancer cells 
expressing wild-type GSK-3β and β-catenin (Lillehoj et al, 2003), suggesting possible 
interactions between these proteins. MUC1 expression is associated with increased steady-
state levels of β-catenin in the cytoplasm and nucleus of breast carcinoma cells by blocking 
the GSK-3β-mediated phosphorylation of β-catenin, and preventing proteosomal 
degradation (Schroeder et al., 2003). It is possible that the cytoplasmic tail of MUC1 enables 
interaction between different regulators or alternatively might compete for or sequester β-
catenin. In some cell types, the MUC1 cytoplasmic tail is also involved in the transcriptional 
activation of β-catenin-TCF-binding sites and transcriptional activation of cyclin D1 (Huang 
et al., 2005). MUC1 may play an antiapoptotic role in response to cellular stresses by 
stimulating Akt and the antiapoptotic protein Bcl-X to attenuate genotoxin-induced 
apoptosis (Raina et al., 2004). Recent reports suggest that this MUC1-mediated 
carcinogenesis is likely through the TGF-α signaling pathway (Pochampalli et al., 2007). 
MUC1 is immunogenic in its hypoglycosylated form expressed on tumors, and the tumor-
bearing patients generate both cellular and humoral immune responses to this antigen 
(Coronella-Wood & Hersh, 2003; Vlad et al., 2004). High levels of anti-MUC1 antibodies are 
associated with a better prognosis in some adenocarcinomas (Kurtenkov et al., 2007; Silk & 
Finn, 2007), an observation that has made MUC1 an attractive candidate for vaccines against 
these malignancies. Prophylactic vaccination is the most desirable strategy to prevent 
malignant diseases. Several vaccine trials involving MUC1 have been conducted, but none 
have resulted in therapeutically beneficial immune responses (Silk & Finn, 2007). 
Identification and understanding of the host factors that influence naturally occurring 
immune responses is an important prerequisite to successfully designing a vaccine that 
would induce therapeutic responses.  
For MUC1 there are significant interindividual differences in naturally occurring antibody 
responses (Cramer et al., 2005). Recent studies in humans have shown that immune 
responsiveness to a variety of antigens- infectious agents, vaccines, autoantigens, including 
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associated with a better prognosis in some adenocarcinomas (Kurtenkov et al., 2007; Silk & 
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For MUC1 there are significant interindividual differences in naturally occurring antibody 
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some tumor-associated antigens- are associated with particular GM and KM allotypes, 
hereditary antigenic determinants of  γ and κ chains, respectively (Kameda et al., 1998; 
Pandey, 2001; Pertovaara et al., 2004). Pandey et al. (2008) have studied 169 Caucasian 
subjects with gastric cancer that were allotyped for several GM and KM markers. Their 
results have revealed that GM 3 23 5,13 phenotype is highly significantly associated with 
MUC1 IgG levels; subjects with this phenotype had lower antibody levels compared with 
those having other phenotypes. This phenotype had an interactive effect with KM 
phenotypes on the levels of IgG antibodies to this antigen. Association of non- GM 3 23 5,13 
phenotypes with high responsiveness to MUC1 could aid in identifying subjects who are 
more likely to benefit from MUC1-based vaccines. For individuals with the low responder 
phenotype, MUC1 could be fused with appropriate adjuvants, such as heat shock proteins, 
in order to conceive a vaccine that could potentially generate high antibody responses in the 
majority of population (Li et al., 2006; Pandey et al., 2004). 
In accordance with Reis CA et al (1998) and Baldus SE at al (1998), our results regarding the 
survival of patients at 5 years prove the association between the overexpression of MUC1 
and the worse prognosis. Patients with carcinomas which became positive for MUC1 
survived at 5 years significantly less (12.2%) than patients with MUC1-negative carcinomas 
(25%). A significant difference was also obtained by calculating, in months, the average 
survival in the postoperative period: for patients with MUC1-positive carcinomas – 12 
months; for patients with MUC1-negative carcinomas – 28.5 months. 
The results regarding the prognostic role for the immunohistochemical expression of MUC1 
are contradictory. Studying a group of 94 gastric carcinomas, Pinto-De-Sousa et al. (2002) 
did not observe a relationship between MUC1 and the prognosis of patients. 
The immunohistochemical reactions performed with the anti-MUC5AC antibody 
demonstrated a strong expression in the foveolar epithelium of the antrum and gastric body, 
as well as in the cytoplasms of malignant cells in 43 gastric carcinomas (70.5%). 
The results obtained do not show a relationship between the age or gender of patients and 
the expression of MUC5AC. The analysis of MUC5AC according to the location of tumors 
demonstrated a frequent immunoreactivity of the antibody in antral carcinomas (80.6%), but 
without reaching statistical significance. Cardial tumors did not express the MUC5AC 
antigen. 
The diffuse type of gastric carcinoma, as well as “signet-ring” cell carcinoma, presented in a 
very high percentage (88.2%) MUC5AC-positive immune reactions. Our results seem to 
show that MUC5AC is expressed mostly in the signet-ring cell carcinoma, but the 
differences between the histological subtypes did not reach statistical significance. The 
association between the expression of MUC5AC and the diffuse type carcinoma is 
mentioned also by other authors (Pinto-De-Sousa et al., 2002), suggesting keeping certain 
features of tumor differentiation in the gastric mucosa. Some studies signal the strong 
correlation between the immunoreactivity of MUC5AC and the tumors with infiltrative 
growth pattern (Gürbüz et al., 2002). This association reflects the modality of growth and 
invasion in diffuse type carcinomas. 
We did not note a relationship between the tumor histological grade, the lymphovascular 
invasion and the expression of MUC5AC. Our results did not show the existence of a 
correlation between the level of tumor invasion, the presence of lymph node or distance 
metastases, the pTNM stage, and the immunohistochemical expression of MUC5AC. 
In accordance with Pinto-De-Sousa`s results (2002), the expression of MUC5AC in our study 
does not constitute a prognostic factor, survival rates at 5 years being of 16.3% for patients 
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with MUC5AC-positive carcinomas, and 16.7% for patients with MUC5AC-negative 
carcinomas. In the studies of Reis CA et al. (1998) and Hatori & Kushima (2002), the 
expression of MUC5AC was much frequently observed in incipient gastric carcinomas 
(100%) in comparison with advanced carcinomas (58.6%). The authors conclude that all 
gastric carcinomas are characterized by a “gastric” phenotype in the first stages of 
tumorigenesis. The average survival rates, calculated in months, were of 18 months for 
patients with MUC5AC-positive carcinomas, and 16.05 months for patients with MUC5AC-
negative carcinomas, the two values being relatively close. 
Several papers have described the relationship between mucin and pancreatic cancer, de 
novo expression of MUC5AC frequently occurring in intraductal papillary mucinous 
tumors and pancreatic adenocarcinoma (Kanno et al., 2006; Kim et al., 2002), while Takikita 
et al. (2009) reported that borderline statistically significant associations are seen between 
MUC5AC positivity and shorter survival time in patients with pancreatic cancer. Yamazoe S 
et al. (2010) demonstrated that suppression of MUC5AC reduced adhesive, invasive and 
metastatic potential of pancreatic cancer cell lines. MUC5AC might contribute to the 
progression of pancreatic cancer by inducing adhesiveness and invasiveness in extracellular 
matrix via VEGF overexpression.  
Immune positivation for MUC2 was observed in our study only in malignant cells 
(intracytoplasmic) and in goblet cells in foci of intestinal metaplasia of peritumoral gastric 
mucosa. We did not note the MUC2 synthesis in epithelial cells of the normal gastric 
mucosa. Our results show that MUC2 intestinal mucine is expressed aberrantly in 25 gastric 
carcinomas (40% of cases). 
Tumors developed at the level of the cardia expressed MUC2 in 100% of cases, suggesting 
the existence of a possible correlation between the overexpression of MUC2 and the cardial 
location of gastric carcinomas, but these data needs further confirmation by a larger number 
of cases. 
According to the Lauren classification, we noted a greater immune positivation in intestinal-
type carcinomas and mixed-type in comparison with diffuse-type carcinomas, but without 
reaching statistical significance. 
In accordance with results of other studies (Pinto-De-Sousa et al., 2002; Reis et al., 2000), 
overexpression of MUC2 is correlated significantly (borderline statistical significance) with 
mucinous adenocarcinoma, being identified in 87.5% of cases. Overexpression of MUC2 was 
also described in colonic, pancreatic, mammary and ovarian mucinous carcinomas (Hanski 
et al., 1997). Immunoreactivity of MUC2 is tightly correlated with the presence of goblet 
cells. This fact suggests that the predominant cellular population in mucinous carcinoma 
consists of goblet cells. 
Choi JS et al (2009) have studied human mucin gene expression and mucin phenotypes in 
mucinous and non-mucinous gastric carcinomas. Mucin gene expression profiles differed in 
nucinous vs. non-mucinous tumors. MUC2 was related distinctively to mucinous 
carcinomas and was expressed in 95.5% of these tumors, whereas it was observed in only 
33.4% of non-mucinous carcinomas, suggesting that MUC2 is closely related to the 
mucinous histology and that it may play a role in the histogenesis of mucinous gastric 
carcinomas. MUC2 is expressed in normal colonic and small intestinal mucosa, but is not 
expressed in normal gastric mucosa. When intestinal metaplasia occurs in the stomach, 
MUC 2 is expressed in the goblet cells. In this study, mucinous gastric carcinomas were 
characterized by MUC1 negativity, MUC2 positivity, MUC5AC negativity, and MUC6 
negativity compared with non-mucinous tumors. Mucinous carcinomas were categorized as 
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intestinal mucin phenotype in 60.9%, mixed phenotype in 34.6%, and gastric phenotype in 
2.3%. Patients who had the gastric or mixed phenotype had a shorter median survival than 
patients who had the intestinal phenotype, although the survival curves were not 
significantly different. 
Data obtained in our study are not suggestive for a relationship between the tumor 
histological grade or lymphovascular invasion and the immunohistochemical expression of 
MUC2. Based on the results obtained, we cannot state the existence of a relationship 
between the pT, pN, pM, pTNM factors and the MUC2 immunoreaction in the gastric 
carcinomas examined. 
The immunohistochemical expression of MUC2 does not influence survival at 5 years of 
patients, survival rates at 5 years being of  16% for patients with MUC2-positive carcinomas 
and 16.7% for patients with MUC2-negative carcinomas. Average survivals calculated in 
months show the lack of correlation between the prognosis of patients and the 
immunohistochemical expression of MUC2 (16 months for patients with MUC2-positive 
carcinomas and 18.4 months for patients with MUC2-negative carcinomas). 
Immunohistochemical evaluation of the pattern of mucins can be considered an important 
method of interpretation and understanding of various clinical and pathological entities of 
gastric cancer. The expression of the intestinal mucin MUC2 was shown much more 
frequently in carcinomas located at the level of the cardia (100%), in comparison with antral 
tumors (41.9%), gastric body tumors (40%), pangastric tumors (30%), or tumors developed 
at the level of the gastric blunt (25%). This result suggests that cardial tumors are diagnosed 
and resected in advanced pTNM stages. In accordance with Ho and colab. (28), the data 
obtained in our study confirm the hypothesis according to which the heterogeneous 
expression of mucins and the “de novo” synthesis of non-gastric mucins correspond to 
advanced stages of gastric cancer. 
Gastric carcinomas located at the level of the antrum express MUC5AC in a significantly 
greater proportion (80.6%) in comparison with tumors of the gastric body (66.7%), 
pangastric (60%) or cardial (0%). This high percentage could be due either to the slightly 
more advanced tumor stage in comparison with proximal carcinomas, either to the high 
frequency of diffuse-type carcinomas, located in the distal stomach. 
5. Conclusions 
The immunohistochemical evaluation of the pattern of mucines can be considered as an 
important method of interpreting and understanding the various clinical and pathological 
entities of gastric cancer. 
The immunohistochemical expression of mucines is correlated with the histological type of 
gastric carcinoma (MUC1 with carcinomas with glandular differentiation, MUC2 with the 
mucinous carcinoma, and MUC5AC with the diffuse type of gastric carcinoma and the ring 
cell carcinoma). Our results suggest the different carcinogenesis of these histological types. 
In our study, the immunohistochemical expression of MUC1 constitutes an important 
prognostic factor, survival at 5 years of patients with MUC1-positive carcinomas being 
significantly lower than survival at 5 years of patients with MUC1-negative carcinomas. 
Patients with MUC1 positive carcinomas were about two times more likely to die than those 
with MUC1 negative carcinomas. 
The results obtained show that the immunohistochemical expressions of MUC2 and 
MUC5AC do not constitute prognostic factors in assessing the patients with gastric cancers. 
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According to the immunoreactivity of MUC2, the gastric mucinous carcinoma develops 
from a cellular population consisting predominantly of goblet cells. 
The data obtained in our study confirms the hypothesis according to which the 
heterogeneous expression of mucines and the “de novo” synthesis of non-gastric mucines 
correspond to advanced stages of gastric cancer. 
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 12 
Genetic Factors Involved in the Genesis of 
Helicobacter Pylori-Induced Gastric Cancer 
Asahi Hishida 
Nagoya University Graduate School of Medicine 
Japan 
1. Introduction 
Gastric cancer is the second most frequent cause of cancer-related mortality in the world, 
and is the most common malignancy of the gastrointestinal tract in East Asian populations 
(Parkin et al., 1997; Parkin et al. 1999). Helicobacter pylori (H. pylori) is an established risk 
factor for developing gastric cancer and its precancerous lesions, which was evidenced by 
numerous epidemiological studies (Hamilton & Aaltonen, 2000; Tsuji et al., 2006). More than 
50% of the world’s population is estimated to be infected with this bacterium (Danesh, 
1999). It is demonstrated that the risk of the subjects with H. pylori infection is from 2- to 6-
fold (Eslick et al., 1999). In addition, some trials on H. pylori eradication revealed that cure of 
its infection reduces the gastric cancer development in high-risk populations (Fukase et al., 
2008; Wong et al., 2004). 
2. Genetic factors involved in the genesis of Helicobacter pylori-induced 
gastric cancer 
Accumulated evidence has shown that there are three steps in gastric carcinogenesis: H. 
pylori infection, development of gastric precancerous lesions, and gastric carcinogenesis 
(Hamajima et al., 2006). For each of these three steps there are specific genetic traits that 
influence the process interacting with lifestyle factors (Figure 1).  
2.1 Genetic traits for the persistence of Helicobacter pylori infection 
H. pylori is transmitted from person to person through the oral-oral or fecal-oral route 
mainly during the childhood. 
Such factors as will directly affect the H. pylori transmission like sewage systems are also 
essential determinants of the infection. Although there is limited supporting biological 
evidence, some lifestyle factors such as salty food intake, low fruits intake, or smoking 
might play a role in persistent H. pylori infection. 
Genetic traits could influence persistent H. pylori infection interacting with lifestyle factors. 
2.1.1 Genetic polymorphisms of the molecules associated with gastric acid secretion 
Gastric acid is secreted from parietal cells, and regulated by histamine, gastrin, and acetyl 
choline. It is known that IL-1β and TNF-α, proinflammatory cytokines, inhibit gastric acid 
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Fig. 1. Steps in Helicobacter pylori-induced gastric cancer. 
secretion (Beales et al., 1998), and H. pylori infected patients showed a marked increase in IL-
1β mRNA in mucosa (Wang et al., 1999). A recent study demonstrated that IL-1β decreased 
gastrin level (Chakravorty et al., 2009), elucidating the mechanism of the acid secretion 
reduction due to H. pylori infection. IL-1β induces TNF-α, and vice versa. Although IL-1β 
and TNF-α have several roles, polymorphisms connected to both molecules are classified as 
one group in this chapter (Table 1).  
 
 
Fig. 2. Signal pathways from Helicobacter pylori infection to pro-inflammatory gene 
expression. 
IL-1A 
IL-1A making a cluster in chromosome 2q14 with IL-1B and IL-1RN has two single 
nucleotide polymorphisms (SNPs) of C-889T and G4845T, as well as a 46-bp variable 
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number of tandem repeats (VNTR) polymorphism (Bailly et al., 1993). It was reported that 
the combination IL-1A -889TT and IL-1B -511T (-511TT or -511TC) was related to high 
plasma levels of IL-1β (Hullkonen et al., 2000). The association with H. pylori infection was 
examined only for a Japanese population (Hamajima et al., 2001), providing no association 
of IL-1A C-889T (Table 1). In the study, the association with 46-bp VNTR polymorphism was 
not examined, because the polymorphism was not found among Japanese (Hamajima et al., 
2002a). Polymorphism G4845T was reported to be linked with C-889T (Armitage et al., 
2000). 
IL-1B 
Three polymorphisms of IL-1B T-511C, C-31T, and C3954T located in chromosome 2q14, 
have been studied for many diseases. It is known that -511T and -511C are tightly linked 
with -31C and -31T, respectively (Hamajima et al., 2001a). An electrophoretic mobility-shift 
assay demonstrated that C-31T was a functional polymorphism (El-Omar et al., 2000), while 
C3954T is unlikely to be functional.  
We conducted four studies for Japanese and Japanese Brazilians, all of which showed a 
similar result, that those with -31TT had a higher risk of H. pylori seropositivity (Hamajima 
et al., 2001a; Hamajima et al., 2002b; Uno et al., 2002). The risk elevation was marked for 
smokers except one study (Hamajima et al., 2002b). Since cigarette smoke includes about 
4,000 chemicals, many genes may be upregulated or downregulated. A study on C-31T in 
Brazil showed a higher seropositive rate for those with -31TT genotype, though not 
significant (Queiroz et al., 2009). Concerning T-511C polymorphism, no associations were 
found among Japanese (Kato et al., 2001) and Koreans (Kim et al., 2006), while a Chinese 
study reported a significant association with -511T allele (-511TT + -511TC) (Liou, 2007), 
which was linked to -31C allele.  
IL-1RI 
There are two receptors for IL-1β; IL-1RI and IL-1RII. The former transduces the signal, but 
the latter does not. IL-1RI in 2q12 has reportedly four polymorphisms; C-116T (RFLP-A), C-
90T, T49C, and RFLP-B at an unknown site (Bergholdt et al., 1995). There were no reports on 
the association between these polymorphisms and H. pylori seropositivity, except our study 
for C-116T indicating no association (Hamajima et al., 2003a). 
IL-1RN 
IL-1RN has an 86-bp VNTR polymorphism. Among 241 Japanese, the allele frequency was 
4.1% for 2 repeat allele, 0.2% for 3 repeat allele, 94.6% for 4 repeat allele, and 1.0% for 5 
repeat allele (Hamajima et al., 2001a). No significant differences in H. pylori soropositivity 
among different genotypes of IL-1RN 86-bp VNTR were observed for Japanese, Koreans, 
and Chinese (Hamajima et al., 2001a; Kim et al., 2006; Liou et al., 2007). Since the minor 
alleles are rare for the three ethnic groups, statistical power of these studies was not enough.  
TNF-A 
TNF-A and TNF-B genes are located between HLA-B and HLA-DR on 6p21.3. In the 
promoter area of TNF-A, G-238A, G-244A, G-308A, C-857T, C-863A, and T-1031C were 
reported (Kamizono et al., 2000; Yamaguchi et al., 2001). Among East Asians, -238A, -244A 
and -308A alleles were rare (2.0%, 0.0% and 1.7%, respectively in Japanese (Kamizono et al., 
2000; Yamaguchi et al., 2001)), and C-863A was tightly linked with T-1031C (Higuchi et al., 
1998). The functions of these alleles were controversial, but -308A was regarded as a high 
expression allele (D’Alfonso et al., 1994). 
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Subjects (Reference)          aOR or HP% 
IL-1A C-889T CC  CT/TT 
241 Japanese (Hamajima, 2001a) 62% (n=201) 68% (n=39) / (n=1) 
IL-1B C-31T   CC  CT  TT 
241 Japanese (Hamajima, 2001a) 1   (n=42)  2.32* (n=133)  2.46* (n=66) 
55 smokers 1   (n=16)  6.18* (n=27)  22.9* (n=12) 
465 Japanese (Uno, 2002) 1   (n=116) 0.97 (n=183) 1.73* (n=163)  
  80 ever smokers 1    (n=23) 1.68 (n=34) 5.29* (n=22)  
547 Japanese (Hamajima, 2002a) 1    (n=116) 1.32 (n=237) 1.35   (n=178) 
127 smokers 1    (n=23) 1.12 (n=60) 1.01   (n=41) 
963 Jpn. Brazil. (Uno, 2002) 1    (n=226) 1.30 (n=432) 1.45* (n=289) 
124 smokers 1    (n=ND) 2.45 (n=ND) 3.49* (n=ND) 
541 Brazil. (Queiroz, 2009) 64% (n=112) 71% (n=265) 67%   (n=164) 
IL-1B T-511C TT   TC  CC 
499 Japanese (Kato, 2001) 52%  (n=113) 54% (n=243) 53%   (n=143) 
474 Koreans (Kim, 2006) 86%  (n=131)  86% (n=259)  88%   (n=84) 
663 Chinese (Liou, 2007) 67%  (n=148) 64% (n=343) 55%*  (n=172) 
IL-1RI C-116T CC  CT  TT 
241 Japanese (Hamajima, 2003a) 65%  (n=93) 58% (n=114) 72%  (n=32) 
IL-1RN VNTR 4rpt/4rpt 2rpt  Others 
241 Japanese (Hamajima, 2001a) 62%  (n=217) -  67%  (n=24) 
474 Koreans (Kim, 2006) -  80%  (n=60) 87%  (n=414) 
663 Chinese (Liou, 2007) -  66% (n=53) 61%  (n=540) 
540 Brazil. (Queiroz, 2009) 67%  (n=378) 70%  (n=162) - 
TNF-A T-1031C TT   TC  CC 
1,374 Japanese (Hamajima, 2003a) 1    (n=952) 0.92  (n=385) 0.43* (n=34) 
963 Jpn. Brazil. (Atsuta, 2006) 1.18  (n=648) 0.96  (n=269) 1  (n=31) 
TNF-A C-857T CC CT TT 
1,374 Japanese (Hamajima, 2003a) 1  (n=931) 1.06  (n=373) 1.69  (n=42) 
963 Jpn. Brazil. (Atsuta, 2006) 1  (n=613) 1.17  (n=301) 1.21  (n=36) 
TNF-A -1031 & -857 CC&CC    TT&CC      TC&CT      TT&TT 
1,374 Japanese (Hamajima, 2003a) 1(n=34)  2.37*(n=595)  2.84*(n=76)  3.63*(n=42) 
963 Jpn. Brazil. (Atsuta, 2006) 1(n=30)  1.08 (n=377)  1.03 (n=67)   1.27 (n=35) 
253 ever smokers 1(n=11)  2.01 (n=102)  1.76 (17)      2.30 (n=5) 
TNF-A G-308A GG  GA  AA 
393 Germans (Kunstmann, 1999) 52%  (n=277) 56%  (n=89) 56% (n=18) 
792 Italians (Zambon, 2005) 54%  (n=ND) 61%*  (n=ND) -    (n=ND) 
474 Koreans (Kim, 2006) 86%  (n=400) 89% for GA(n=59)/AA(n=2) 
539 Brazil. (Queiroz, 2009) 70%  (n=403) 66%  (n=123) 46%  (n=13) 
TNF-B A252G AA AG GG 
1,374 Japanese (Hamajima, 2003a) 1   (n=501) 1.05  (n=656) 1.05  (n=204) 
*: statistically significant (p<0.05), Jpn. Brazil.: Japanese Brazilians, and ND: not described.  
Table 1. Genetic polymorphis of molekuls potentially related with gastric acid secretion, 
reported on the associations with Helicobacter pyloriinfections: sex-age-ajusted odd ratio 
(aOR) or seropositive percentage (HP%) 
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Among the studies reported on the TNF-A polymorphisms (Queiroz et al., 2009; Kim et al., 
2006; Hamajima et al., 2003b; Atsuta et al., 2006; Kunsmann et al, 1999; Zambon et al., 2005), 
significant associations were found for T-1031C and for the combination of T-1031C and A-
857T among 1,374 Japanese (Hamajima et al., 2003), as well as for G-308A among 792 Italians 
(Zambon et al., 2005). If -1031T and -857T are the high expression alleles, the findings of the 
studies on TNF-A seemed rather consistent to indicate that high TNF-α expression favors 
persistent H. pylori infection. 
TNF-B 
TNF-B A252G, whose G allele is strongly linked with TNF-A -857C allele in Japanese 
(Hamajima et al., 2003b), was not associated with seropositivity, as shown in Table 1. 
Another polymorphism, TNF-B Thr26Asn, was found to link completely with A252G. 
2.1.2 Genetic polymorphisms of molecules associated with innate immune responses 
Innate immune responses have not completely been understood. The polymorphisms of the 
molecules possibly involved in the innate immune responses are selected in this section 
(Table 2). 
CD14 
CD14, located in chromosome 5q31.1, has a polymorphism C-159T. Serum soluble CD14 was 
reported to be significantly higher in those with -159TT (n=42, median=4.5μg/ml) than in 
those with -159CC (n=67, median=4.1μg/ml) (Baldini et al., 1999). Although the 
polymorphism seemed functional, no association was found with H. pylori seropositivity 
(Hamajima et al., 2003a). 
CXCR2 
CXCR2 in 2q35 was reported to have three polymophisms; C785T causing a silent codon 
change in leucine, and T1208C and G1440A in the 3’ untranslated region of exon 3 (Renzoni 
et al., 2000). These polymorphisms are tightly linked, forming a haplotype with 785C, 1208T, 
and 1440G. Accordingly, any polymorphism of the three may be used for a pilot association 
study on disease risk. No significant difference was observed in the seropositive rate among 
the three genotypes of C785T in Japan (Hamajima et al., 2003a). 
IL-2 
T-330G of IL-2 gene on chromosome 4q26-27 was reported to be a functional polymorphism; 
the production was higher in -330GG genotype than in TT genotype (Williams et al., 1988; 
Hoffmann et al., 2001). The -330TT was at a higher risk of gastric atrophy (Togawa et al., 
2005) and less frequent among Asians (38% out of 29 individuals) than among Caucasians 
(51% out of 199 individuals) (Hoffmann et al., 2002). While the polymorphism was not 
associated with H. pylori seropositivity among Japanese (Togawa et al., 2005), -330TT 
genotype was significantly associated with the seropositivity relative to -330C allele 
(CC+CT) among Brazilians (Queiroz et al., 2009).  
IL-4 
IL-4 C-33T on chromosome 5q31.1 was reported to be functional; IL-4 protein production 
was higher in -33TT genotype than in -33CC genotype (Nakashima et al., 2002). Our dataset 
showed no association with H. pylori seropositivity in Japanese (Togawa et al., 2005). 
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Among the studies reported on the TNF-A polymorphisms (Queiroz et al., 2009; Kim et al., 
2006; Hamajima et al., 2003b; Atsuta et al., 2006; Kunsmann et al, 1999; Zambon et al., 2005), 
significant associations were found for T-1031C and for the combination of T-1031C and A-
857T among 1,374 Japanese (Hamajima et al., 2003), as well as for G-308A among 792 Italians 
(Zambon et al., 2005). If -1031T and -857T are the high expression alleles, the findings of the 
studies on TNF-A seemed rather consistent to indicate that high TNF-α expression favors 
persistent H. pylori infection. 
TNF-B 
TNF-B A252G, whose G allele is strongly linked with TNF-A -857C allele in Japanese 
(Hamajima et al., 2003b), was not associated with seropositivity, as shown in Table 1. 
Another polymorphism, TNF-B Thr26Asn, was found to link completely with A252G. 
2.1.2 Genetic polymorphisms of molecules associated with innate immune responses 
Innate immune responses have not completely been understood. The polymorphisms of the 
molecules possibly involved in the innate immune responses are selected in this section 
(Table 2). 
CD14 
CD14, located in chromosome 5q31.1, has a polymorphism C-159T. Serum soluble CD14 was 
reported to be significantly higher in those with -159TT (n=42, median=4.5μg/ml) than in 
those with -159CC (n=67, median=4.1μg/ml) (Baldini et al., 1999). Although the 
polymorphism seemed functional, no association was found with H. pylori seropositivity 
(Hamajima et al., 2003a). 
CXCR2 
CXCR2 in 2q35 was reported to have three polymophisms; C785T causing a silent codon 
change in leucine, and T1208C and G1440A in the 3’ untranslated region of exon 3 (Renzoni 
et al., 2000). These polymorphisms are tightly linked, forming a haplotype with 785C, 1208T, 
and 1440G. Accordingly, any polymorphism of the three may be used for a pilot association 
study on disease risk. No significant difference was observed in the seropositive rate among 
the three genotypes of C785T in Japan (Hamajima et al., 2003a). 
IL-2 
T-330G of IL-2 gene on chromosome 4q26-27 was reported to be a functional polymorphism; 
the production was higher in -330GG genotype than in TT genotype (Williams et al., 1988; 
Hoffmann et al., 2001). The -330TT was at a higher risk of gastric atrophy (Togawa et al., 
2005) and less frequent among Asians (38% out of 29 individuals) than among Caucasians 
(51% out of 199 individuals) (Hoffmann et al., 2002). While the polymorphism was not 
associated with H. pylori seropositivity among Japanese (Togawa et al., 2005), -330TT 
genotype was significantly associated with the seropositivity relative to -330C allele 
(CC+CT) among Brazilians (Queiroz et al., 2009).  
IL-4 
IL-4 C-33T on chromosome 5q31.1 was reported to be functional; IL-4 protein production 
was higher in -33TT genotype than in -33CC genotype (Nakashima et al., 2002). Our dataset 
showed no association with H. pylori seropositivity in Japanese (Togawa et al., 2005). 
 




IL-8 located in chromosome 4q12-q21 was reported to have nine polymorphisms (four in 5’ 
upstream regions, four at introns, and one in 3’ downstream region). Among Europeans, 
two haplotypes, one with -1722delT, -251A, 396G, 781T, 1633T, and 2767T termed 
delTAGTTT in the order of those polymorphisms, and the other with delTTTCCA, are 
dominant with frequencies of 0.41 and 0.52, respectively. The haplotypes are more diverse 
among Africans; delTAGCCA (frequency 0.36), delTATCCA (0.19), insTATCCA (0.18), and 
delTTTCCA (0.10), respectively (Hull et al., 2001), but the genotyping of T-251A and T396G 
is sufficient for classifying the haplotypes even among Africans. Among Japanese, there was 
a strong linkage between the two polymorphisms; 396TT was found in 90.0% of 110 
individuals with -251TT, 396TG in 90.5% of 95 individuals with -251TA, and 396GG in 100% 
of 22 individuals with -251AA (Hamajima et al., 2003c), indicating that T-251A is a good 
marker for Japanese. 
Although a study on IL-8 expression found that the A allele had a higher expression than 
the T allele (Hull et al., 2001). Plasma IL-8 levels was found to be higher in A allele carriers 
among those with H. pylori seronegative, but lower among the seropositives without gastric 
atrophy (Naito et al., 2010). Although no significant association was found with the 
seropositivity, the point estimate of the adjusted odds ratio was less than unity for the A 
allele carriers (Hamajima et al., 2003c). 
IL-10 
IL-10 G-1082A and T-819C polymorphisms were reported to influence the expression of IL-
10 mapped on 1q31-32; -1082A and -819T are high expression alleles (Turner et al., 1997; 
Helminen et al., 2001). There is a large difference in -1082G allele frequency among different 
regions; 0.51 in Belfast, 0.52 in Glasgow, and 0.47 in Strasbourg (Donger et al., 2001), but 0.04 
among Japanese(Ito et al., 2000). We found that there was no significant association between 
T-819C and H. pylori seropositivity. 
As mentioned, a high level of IL-10 and a lower level of IL-8 create favorable conditions for 
prolonging the H. pylori infection in human gastric mucosa. Accordingly, the combination of 
IL-8 -251TT (the low expression genotype) and IL-10 -819TT (the high expression genotype) 
was expected to be favorable for persistent H. pylori infection. Among three studies, one 
study demonstrated that the other combinations were at a significantly lower risk of the 
persistent infection (Hamajima et al., 2003c), but another study was opposite (Hamajima et 
al., 2003a). When smokers were selected, the genotype combinations other than IL-8 -251TT 
and IL-10 -819TT were at a lower risk in the three studies, though not significant for two 
studies (Table 2). 
IL-13 
IL-13 is a Th2 cytokine, whose gene is located in 5q31. Closely linked polymorphisms, A-
1512C, C-1111T, and Arg130Gln, have been examined for disease risk (Beghe et al., 2009). 
Although the association between gastric atrophy development and C-1111T was observed 
(Togawa et al., 2005), there was no association with the seropositivity. 
MPO 
Myeloperoxidase (MPO) is a lysosomal enzyme in polymorphonuclear leukocytes and 
monocytes. It produces hypochlorous acid to kill a wide range of organisms. While 
mutations, Arg569Trp, Val173Cys, or Met251Thr of MPO located in 17q23.1 cause fatal 
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diseases such as chronic granulomatous disease due to severe enzyme activity deficiency 
(Nauseef et al., 1994), MPO G-463A exhibits less influential, but the transcription level of A 
allele was reported to be one twenty-fifth of G allele (Piedrafita et al., 1996). Two studies 
showed the A allele carriers were at a lower risk of the seropositivity, though not significant 
(Hamajima et al, 2001b; Katsuda et al, 2003). Intuitively, low enzyme activity seemed to 
provide a favorable situation, but the results were opposite. 
NF-KB2 
NF-KB2 encoding NF-κB2 (p100) has a Ins/Del polymorphism at -10G (or 1867GG/G), as 
well as two polymorphisms with a rare minor allele (Shinohara et al., 2001). Although the 
function of Ins/Del -10G has not been demonstrated, no association was found with H. 
pylori seropositivity (Hamajima et al., 2003a). 
NOS2 
Nitric oxide synthase (NOS) was three isozymes; neuronal constitutive NOS (nNOS) 
encoded by NOS1, inducible NOS (iNOS) encoded by NOS2, and endothelial constitutive 
NOS (enNOS) encoded by NOS3. There were several polymorphisms reported for NOS2 in 
chromosome 17cen-q11.2, such as C-1173T, G-954C, (TAAA)n, and (CCTTT)n. A C150T 
(Ser608Leu) polymorphism at exon 16 was reported to have an association with type 1 
diabetes (Johannsen et al., 2001), but the association with H. pylori was not observed among 
Japanese (Goto et al., 2006a). There were no studies with the other polymorphisms of NOS2. 
NQO1 
NQO1 is an obligate two-electron reductase, whose gene is located in chromosome 16q22 
(Ross et al., 2000). The gene has a functional polymorphism C609T (Pro187Ser); the T allele 
has no enzyme activity (Siegel et al., 1999). The CC genotype was found that to favor 
persistent H. pylori infection among Japanese (Goto et al., 2005). 
ODC 
ODC in chromosome 2p25, encoding ornitine decarboxylase, has a functional polymorphism 
G317A in intron 1; the expression was higher in the A allele than in the G allele (Guo et al., 
2000). Aspirin chemoprevention of colorectal adenoma recurrence was reported to be more 
effective among those with 317AA than those with the other genotypes. The 317AA 
genotype was 5-7% in Europe and the United States (Hubner et al., 2008), while it was 36% 
in Japan (Goto et al., 2007). The association with H. pylori seropositivity was not observed 
among Japanese (Goto et al., 2007).   
TLR2 
Arg677Trp, Arg753Gln, and Ins/Del at -196 to -174 were reported as polymorphisms of 
TLR2 on chromosome 4q32 (Queiroz et al., 2009; Tahara et al., 2007). Although the minor 
allele was rare, the association with Arg753Gln was examined among Brazilians. They 
found no association with the polymorphism (Queiroz et al., 2009). 
TLR4 
In TLR4 on chromosome 9q32-33, two polymorphisms, Asp299Gly and Thr399Ile, have been 
reported. The 299Gly/399Ile allele is less sensitive to LSP than 299Asp/399Thr allele, 
resulting in lower NF-κB activity (Arbour et al., 2000). The LPS-hyposensitive allele was 
found to be 5.9% among 879 blood donors in England (Read et al., 2001), but not found 
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py g j ( ) p p g ( )
Subjects [Reference]          aOR or HP% 
CD14 T-159C TT  TC  CC 
1,374 Japanese (Hamajima, 2003a) 1 (n=413) 0.94  (n=678) 1.16  (n=413) 
CXCR2 C785T   CC  CT  TT 
241 Japanese (Hamajima, 2003a) 65%  (n=110) 63%  (n=100) 56%  (n=25) 
IL-2 T-330G GG  GT  TT 
  454 Japanese (Togawa, 2005) 1    (n=45) 1.10  (n=196) 1.15  (n=202) 
541 Brazil. (Queiroz, 2009) 70%  (n=27) 63% (n=221) 72%*  (n=293) 
IL-4 C-33T CC  CT  TT 
  454 Japanese (Togawa, 2005) 1 (n=42) 1.43  (n=183) 1.25  (n=227) 
IL-8 T-251A TT   TA  AA 
454 Japanese (Hamajima, 2003c) 1 (n=234) 0.86 (n=177) 0.70 (n=37) 
IL-10 T-819C TT  TC  CC 
454 Japanese (Hamajima, 2003c) 1 (n=220) 0.67 (n=177) 0.82 (n=37) 
IL-8 & IL-10 TT&TT Others 
454 Japanese (Hamajima, 2003c) 1    (n=115) 0.62*  (n=327) 
  65 smokers 1 (n=ND) 0.13*  (n=ND) 
241 Japanese (Hamajima, 2003a) 1    (n=57) 1.04  (n=178) 
  55 smokers 1    (n=ND) 0.45  (n=ND) 
679 Japanese (Hamajima, 2003a) 1    (n=164) 1.49*  (n=507) 
158 smokers 1    (n=ND) 0.89  (n=ND) 
IL-13 C-1111T CC  CT  TT 
  454 Japanese (Togawa, 2005) 1   (n=310) 0.73  (n=127) 1.09  (n=11) 
MPO G-463A GG   GA/AA 
241 Japanese (Hamajima, 2001b) 1    (n=192) 0.69  (n=47)/(n=2) 
454 Japanese (Katsuda, 2003) 1    (n=354) 0.84  (n=77)/(n=6) 
NF-KB2 -10G InsIns InsDel DelDel 
1,374 Japanese (Hamajima, 2003a) 1    (n=513) 1.03  (n=648) 1.15  (n=199) 
NOS2 C150T (Ser608Leu) CC  CT  TT  
454 Japanese (Goto, 2006a) No association 
NQO1 C609T (Pro187Ser) TT   TC  CC 
241 Japanese (Goto, 2005a) 1 (n=48) 1.13  (n=107) 2.42*  (n=86) 
454 Japanese (Goto, 2005a) 1 (n=83) 1.57  (n=210) 1.70  (n=153) 
ODC A317G AA   AG  GG 
465 Japanese (Goto, 2007) 1    (n=167) 1.09  (n=229) 1.02  (n=69) 
TLR2 Arg753Gln ArgArg ArgGln GlnGln 
541 Brazil. (Queiroz, 2009) 68%  (n=531) 70% (n=10) -    (n=0) 
TLR4 Asp299Gly AspAsp AspGly GlyGly 
541 Brazil. (Queiroz, 2009) 68% (n=490) 71% (n=51) -    (n=0) 
TLR4 G3725C GG  GC  CC 
1,592 Japanese (Hishida, 2009a) 1 (n=827) 0.95  (n=474) 0.72  (n=90)  
TLR5 Arg392Ter ArgArg ArgTer TerTer 
541 Brazil. (Queiroz, 2009) 68% (n=504) 71% (n=34) 67% (n=3) 
* Statistically significant (p<0.05), Jpn. Brazil.: Japanese Brazilians, Brazil.: Brazilians  
Table 2. Genetic polymorphisms of molecules potentially involved in innate responses, 
reported on the associations with Helicobacter pylori infection: sex-age-adjusted odds ratio 
(aOR) or seropositive percentage (HP%) 
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among 275 Japanese (Tahara et al., 2007). For Japanese, G3725C in 3’UTR was reported to 
have an association with periodontitis. We found that the polymorphism had an association 
with severe gastric atrophy, but did not with persistent H. pylori infection (Hishida et al., 
2009a). 
TLR5 
A polymorphism TLR5 Arg392Ter on chromosome 1q41-42 was examined for the 
association among Brazilans (Queiroz et al., 2009). There was no significant association in 
the study. 
2.1.3 Genetic polymorphisms of molecules associated with adhesion to epithelial 
cells 
BabA of H. pylori binds of H type I and Lewis b antigen carbohydrate structure on human 
epithelial cells. H type I is synthesized from Type I precursor with secretor enzyme encoded 
by FUT2, and further metabolized to Lewis b with Lewis enzyme encoded by FUT3. Both 
enzymes are fucosyltransferase. 
FUT2 (secretor gene) 
Although many polymorphisms were reported, main alleles of FUT2 located in 19q13.3 are 
Se1 (357C, 385A, 571C, 628C), Se2 (357T, 385A, 571C, 628C), sej (357T, 385T, 571C, 628C), se3 
(357C, 385A, 571T, 628C), se4 (357C, 385A, 571C, 628T), and se5 (combined with a 
pseudogene). Se1 and Se2 exhibit full enzyme activity, while sej shows very low activity, 
and se3, se4, and se5 reveal no activity. Accordingly, Se1 and Se2 are denoted by Se, and the 
others by se. Among Caucasians, se3 and se4 are common se alleles, whereas in East Asians 
se5 and sej are main se alleles (Narimatsu et al., 1998). Since those with sese genotype cannot 
synthesize H type I nor Lewis b, they were expected to have the lower seropositive rate. Our 
first study fitted the expectation (Ikehara et al., 2001), but it was not confirmed in the second 
and third datasets (Hamajima et al., 2002b). Those with sese genotype was reported to be 
resistance for Norwalk virus infection (Lindesmith L et al., 2003). 
 
Subjects [Reference]               aOR 
FUT2  SeSe  Sese  sese 
241 Japanese (Ikehara, 2001) 1  (n=61) 0.79  (n=127) 0.35*  (n=51) 
679 Japanese (Hamajima, 2002c) 1  (n=170) 1.51* (n=328) 1.50  (n=181) 
464 Japanese (Hamajima, 2002c) 1  (n=139) 1.57  (n=218) 1.29  (n=107) 
FUT3 LeLe  Lele  lele 
241 Japanese (Hamajima, 2002c) 1  (n=124) 1.95* (n=98) 2.80  (n=17) 
679 Japanese (Hamajima, 2002c) 1  (n=353) 0.98  (n=251) 1.31  (n=59) 
424 Japanese (Hamajima, 2002c) 1  (n=235) 1.06  (n=155) 1.40  (n=33) 
* Statistically significant (p<0.05)  
Table 3. Genetic polymorphisms of other miscellaneous molecules, reported on the 
associations with Helicobacter pylori infection: sex-age-adjusted odds ratio (aOR) or 
seropositive percentage (HP%) 
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among 275 Japanese (Tahara et al., 2007). For Japanese, G3725C in 3’UTR was reported to 
have an association with periodontitis. We found that the polymorphism had an association 
with severe gastric atrophy, but did not with persistent H. pylori infection (Hishida et al., 
2009a). 
TLR5 
A polymorphism TLR5 Arg392Ter on chromosome 1q41-42 was examined for the 
association among Brazilans (Queiroz et al., 2009). There was no significant association in 
the study. 
2.1.3 Genetic polymorphisms of molecules associated with adhesion to epithelial 
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BabA of H. pylori binds of H type I and Lewis b antigen carbohydrate structure on human 
epithelial cells. H type I is synthesized from Type I precursor with secretor enzyme encoded 
by FUT2, and further metabolized to Lewis b with Lewis enzyme encoded by FUT3. Both 
enzymes are fucosyltransferase. 
FUT2 (secretor gene) 
Although many polymorphisms were reported, main alleles of FUT2 located in 19q13.3 are 
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(357C, 385A, 571T, 628C), se4 (357C, 385A, 571C, 628T), and se5 (combined with a 
pseudogene). Se1 and Se2 exhibit full enzyme activity, while sej shows very low activity, 
and se3, se4, and se5 reveal no activity. Accordingly, Se1 and Se2 are denoted by Se, and the 
others by se. Among Caucasians, se3 and se4 are common se alleles, whereas in East Asians 
se5 and sej are main se alleles (Narimatsu et al., 1998). Since those with sese genotype cannot 
synthesize H type I nor Lewis b, they were expected to have the lower seropositive rate. Our 
first study fitted the expectation (Ikehara et al., 2001), but it was not confirmed in the second 
and third datasets (Hamajima et al., 2002b). Those with sese genotype was reported to be 
resistance for Norwalk virus infection (Lindesmith L et al., 2003). 
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FUT3 (Lewis gene) 
FUT3 has three polymorphisms; T59G, G508A, and T1067A. An Le allele is defined as one 
with 59T, 508G, and 1067T, an le1 allele with 59G, 508A, and 1067T, an le2 allele with 59G, 
508G, and 1067A, and an le3 allele with 59G, 508G, and 1067T. The le1 and le2, denoted by le, 
lack enzyme activity. Since le3 shows almost full enzyme activity, it is grouped into Le 
(Narimatsu et al., 1998). The LeLe genotype, which may disturb the synthesis of H type I by 
FUT2 through sharing the same substrate (type I precursor), showed the lower 
seropositivity in the first dataset, while the finding was not reproduced by the second and 
third datasets (Hamajima et al., 2002b) (Table 3).  
2.2 Genetic predisposition to Helicobacter pylori-induced gastric precancerous 
lesions 
The presence of gastric lesions outside the tumor was recognized as gastric precancerous 
lesions in gastrectomy specimens or biopsies taken by flexible gastroscopes, which lead to 
the development of a model of gastric carcinogenesis generally accepted. Long-term follow-
up of cohorts in high-risk populations has documented the dynamics of gastric 
precancerous process. Severe gastric atrophy, corpus-predominant gastritis, intestinal 
metaplasia and dysplasia are well-recognized predominant predispositions to gastric cancer 
(Correa P, 1988; Uemura et al., 2001). 
There seems to be a considerable variation in the extent of these gastric damages due to H. 
pylori infection from one subject to another, suggesting that genetic factors are playing 
important roles in the long-term outcome of H. pylori infection. 
Although biological mechanisms underlying the genesis of gastric precancerous conditions 
remain largely unknown, both direct effects by the virulence factors of H. pylori, such as 
cytotoxin-associated gene A (CagA), and indirect effects derived from pro-inflammatory 
immune response by the host seem to be involved (Takahashi et al., 2007) (Table 4). 
2.2.1 Cag pathogenicity island-related genes and their polymorphisms 
The main effects of H. pylori virulence factors on the development of gastric precancerous 
lesions may be represented by the CagA. CagA is a 120 to 145-kDa H. pylori protein 
encoded by the cagA gene, which is localized at one end of the cag pathogenicity island 
(cagPAI), a 40-kb DNA segment considered to be horizontally transfected to the H. pylori 
genome (Censini et al., 1996; Akopyants et al., 1998). CagA is delivered from H. pylori 
bacterium into host cell cytoplasms through the type IV secretion system and undergoes 
tyrosine phosphorylation. In the injected gastric epithelial cells, CagA induces cellular 
spreading and elongation called the ‘hummingbird phenotype’, which is thought to play 
important roles in H. pylori-induced gastric carcinogenesis.  In this CagA-dependent 
morphologic transformation of gastric epithelial cells, a key molecule SHP-2 (src 
homology 2 domain-containing protein tyrosine phosphatase-2) is required. Binding of 
tyrosine phosphorylated CagA to the SH2 domains of SHP-2 causes a conformational 
change in SHP-2 itself which leads to the aberrant activation of SHP-2 phosphatase. SHP-2 
plays a major role in intracellular signaling provoked by various growth factors, 
hormones or cytokines, and is widely expressed in both embryonic and adult tissues 
(Higashi et al., 2002). SHP-2 is required for full activation of the Ras-MAP kinase cascade 
in response to growth factor-receptor interaction and plays an important role in cell 
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morphogenesis as well as cell mortility (Higashi et al., 2002), which might partly explain 
the mechanism for the formation of hummingbird phenotype. 
Meanwhile, CagA is shown to disrupt the tight junctions and causes loss of epithelial apical-
basolateral polarity through the specific interaction of CagA with partitioning-defective-1 
(PAR1)/ microtubule affinity-regulating kinase-2 (MARK2) (Sadaat et al., 2007) (Figure 3). 
PAR1b is localized to the basolateral membrane in normal polarized epithelial cells, while 
atypical protein kinase C (aPKC) complex is localized specifically to the apical membrane. 
When CagA is delivered and injected into normal polarized gastric epithelial cells, CagA 
inhibits the kinase activity of PAR1b by binding directly to its kinase domain, which 
subsequently leads to junctional and polarity defects followed by the disorganization of the 
epithelial monolayer (Sadaat et al., 2007). PAR1b exists as a homodimer in the cells, and two 
CagA protein bind to a PAR1b dimer, which is also essential for stable CagA-SHP2 
interaction. 
Recently, a cytosilic pattern recognition receptor, nucleotide-binding oligomerization 
domain protein 1 (NOD1), was found to respond to peptidoglycan delivered by H. pylori 
cagPAI (Viala et al., 2004). NOD1 is known to sense the essential gamma-D-glutamyl-meso-
diaminopimelic acid (i.E.-DAP) dipeptide, which is uniquely contained in peptidoglycan of 
all gram negative and certain gram-positive bacteria (Neel et al., 2003). 
As the precise relationship of gastric precancerous lesions like gastric atrophy (GA) and 
intestinal metaplasia (IM) with these cagPAI-associated molecules is largely left unknown, 
further investigations are required to clarify the roles of these cagPAI-related molecules in 
the genesis of gastric precancerous lesions.  
PTPN11 (Protein tyrosine phosphatase, non-receptor type, 11) 
The PTPN11 G/A polymorphism at intron 3 (rs2301756), is a G-to-A single nucleotide 
substitution at 223 bp upstream of exon 4 in the PTPN11 gene encoding SHP-2 at 
chromosome 12q24.1. The biological function of this polymorphism has not yet been 
reported. The first dataset showed that one (11.1%) out of 9 infected individuals with the AA 
genotype had gastric atrophy, while 134 (56.1%) among 239 infected with the G allele had 
atrophy (Goto et al., 2006a). Our recent report of 1,636 non-cancer Japanese subjects 
demonstrated that the risk of severe gastric atrophy was significantly reduced for those with 
at least one A allele of this PTPN11 G/A polymorphism at intron 3 (OR = 0.62, 95% CI = 
0.42-0.90), confirming the association of this PTPN11 gene polymorphism with the risk of 
gastric precancerous lesions in H. pylori-infected subjects (Hishida et al., 2009a). If the 
polymorphism is functional or linked to a functional one, the association can be biologically 
explained by the difference in the strength of signal transduction through the CagA-SHP2 
complex. According to the NCBI dbSNP, the frequencies of the G allele of rs2301756, high 
risk allele for gastric atrophy, is 0.802 among 1,484 Japanese and 0.917 among 48 Chinese, 
while the corresponding was 0.348 among 46 African American and 0.064 among 46 
Caucasians, indicating that Japanese and Chinese become high risk ethnic groups through 
CagA-positive H. pylori infection, if the hypothesis that the G allele confers stronger signals 
via the CagA-SHP2 interaction is true. 
NOD1 
Recent report revealed that the carriage of the NOD1 G796A (E266K) mutation increases the 
susceptibility for gastric atrophy strikingly: OR = 34.2 in NOD1 796AA and OR = 13.35 in 
NOD1 796GA compared to subjects with NOD1 796GG (Kara et al., 2010). 
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FUT3 (Lewis gene) 
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remain largely unknown, both direct effects by the virulence factors of H. pylori, such as 
cytotoxin-associated gene A (CagA), and indirect effects derived from pro-inflammatory 
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important roles in H. pylori-induced gastric carcinogenesis.  In this CagA-dependent 
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morphogenesis as well as cell mortility (Higashi et al., 2002), which might partly explain 
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cagPAI (Viala et al., 2004). NOD1 is known to sense the essential gamma-D-glutamyl-meso-
diaminopimelic acid (i.E.-DAP) dipeptide, which is uniquely contained in peptidoglycan of 
all gram negative and certain gram-positive bacteria (Neel et al., 2003). 
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intestinal metaplasia (IM) with these cagPAI-associated molecules is largely left unknown, 
further investigations are required to clarify the roles of these cagPAI-related molecules in 
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chromosome 12q24.1. The biological function of this polymorphism has not yet been 
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0.42-0.90), confirming the association of this PTPN11 gene polymorphism with the risk of 
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2.2.2 Immune related genes and their polymorphisms 
For the effects of pro-inflammatory immune response by the hosts, TLR4 is known to 
recognize lipopolysaccharide (LPS) of gram-negative bacteria and is proved to play 
important roles in H. pylori infection through the interaction of macrophage/monocyte 
TLR4 with H. pylori LPS. The initial recognition of LPS and subsequent signaling by TLR4 is 
supported by several accessory proteins: LPS first binds to lipopolysaccharide-binding 
protein (LBP) which works as an opsonin for CD14 which then acts as a catalyst for the 
binding of LPS to MD-2. The signal induced by LPS/MD-2/TLR4 complex is transmitted 
through myeloid differentiation factor 88 (MyD88), interleukin (IL)-1 receptor associated 
kinase (IRAK), tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) and 
inhibitory κB kinase (IKK) to nuclear factor (NF)- κB, leading to the production of pro-
inflammatory cytokines such as IL-1A, IL-1B, IL-6 or TNF-A. The human immune system is 
also balanced by the anti-inflammatory cytokines like IL-10, IL-4 or IL-13 which are 
controlled by regulatory T-cells. In these inflammatory processes, augmented expression of 
inducible nitric oxide synthase (iNOS) is shown to play important roles in the generation of 
oxygen radicals, while overexpressed cyclooxygenase-2 (COX-2) is demonstrated to 
contribute to the proliferation of the gastric epithelium through the up-regulation of cell-
cycles as well as to the propagation of gastric inflammation via the prostaglandin pathways. 
The induction of iNOS is also supposed to be modulated by the activity of protein kinase C-
eta (PRKCH) via the phosphorylation of nuclear factor-kappa B (NF-kB) or activator 
protein-1 (AP-1) (Pham et al., 2003a; Pham et al., 2003b). 
 Oxidative DNA damage is also supposed to play important roles in the pathogenesis of H. 
pylori-induced gastric mucosal damage, where 8-OHdG is a potential sensitive marker of 
DNA oxidation (Farinati et al., 2008). The damaged bases in DNA are mainly repaired by 
the base excision repair (BER) system; the accumulation of 8-Hydroxy-2’-deoxyguanosine 
(8-OHdG) or 2-hydroxyadenine (2-OH-A) in DNA is prevented by the co-operation of mutT 
human homolog-1 (MTH1), 8-hydroxyguanine DNA glycosylase (OGG1) and mutY human 
homolog (MUTYH) (Nakabeppu et al., 2004). The number of studies that investigated the 
contribution of these molecules involved in inflammatory response, such as innate immune 
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response, oxygen radical production, oxidative DNA damage repair processes, together 
with cell-cycle regulation and/or cell proliferation in the genesis of H. pylori-induced gastric 
precancerous lesions is also limited, requiring further biological investigations in the near 
future. 
TLR4 
One study in Caucasians showed that the TLR4 +896 A/G polymorphism (rs4986790) was 
associated with the risk of gastric atrophy, where the TLR4 +896 G carriers had an 11-fold 
increased risk of gastric atrophy with hypochlorhydria (Hold et al., 2007). Subsequent 
Japanese study also clarified the possible association between another genetic variation in 
TLR4 gene, the TLR4 +3725G/C polymorphism (rs11536889), and the risk of severe gastric 
atrophy in Japanese (Hishida et al., 2009a), suggesting the significance of genetic variations 
in host innate immunity due to TLR4 polymorphisms also in East Asian populations. 
CD14 
There is one single nucleotide polymorphism in the promoter region of the CD14 gene, 
CD14 C-159T polymorphism, which is critical for CD14 expression (Zhang et al., 1994). 
Recent study by one Japanese group demonstrated that CD14 promoter -159TT and T carrier 
were associated with lower risk of gastric atrophy in H. pylori-infected subjects who were 61 
years or older (Tahara et al., 2007). 
IL-2 and IL-13 
IL-2 T-330G polymorphism was demonstrated to be a functional polymorphism (Williams et 
al., 1988), with higher IL-2 production in GG genotype than in TT genotype (Hoffmann et al., 
2001). Those with TT genotype were shown to be at a higher risk of gastric atrophy (Togawa 
et al., 2005), who were less frequent in Asians (38% out of 29 individuals) than in Caucasians 
(51% out of 199 individuals) (Hoffmann et al., 2002). 
IL-13 gene in chromosome 5q31 has several polymorphisms; at least 3 polymorphisms at the 
promoter region, 2 polymorphisms at intron 1, Arg130Gln, and 4 polymorphisms at 3’ UTR 
of exon 4 have been reported (Howard et al., 2001). The -1111TT genotype was shown to 
harbor increased binding ability of nuclear proteins, and was also reported to be associated 
with asthma (Howard et al., 2001; Van der Pouw Kraan et al, 1999). As for the risk of gastric 
atrophy, -1111TT was found to be a low risk genotype (Togawa et al., 2005). The biological 
mechanism involved was not yet clarified. 
IL-4R 
One study of Venezuelan subjects revealed that those with homozygotes with the low 
activity allele (GG) of the A398G polymorphism in the IL-4R gene (rs1805010) had a 
modestly increased risk of gastric atrophy (OR = 1.52, 95% CI = 1.05-2.21) (Kato et al., 2006), 
suggesting the role of genetic variability in the anti-inflammatory mediators in the genesis of 
H. pylori-induced gastric precancerous lesions. 
iNOS C150T (rs2297518) and PRKCH rs3783799 G/A polymorphisms: PRKCH is shown to 
be involved in oxidative stress, by activating iNOS and nitric oxide production (Pham et al., 
2003). The associations of the polymorphisms in these two genes (iNOS C150T [rs2297518] 
and PRKCH rs3783799 G/A polymorphisms) with the risk of gastric atrophy were 
investigated in Japanese population, which revealed that those with PRKCH rs3783799 AA 
genotype were at significantly higher risk of severe gastric atrophy (OR = 2.37, 95% CI = 
1.11-5.05) (Goto et al., 2010), while there were no significant association between the iNOS 
C150T polymorphism and risk of gastric atrophy (Goto et al., 2006b). 
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2.2.3 Other miscellaneous genes and their polymorphisms 
Recently, it was reported that the loss expression of sonic hedgehog (Shh), a regulatory gene 
essential for developmental patterning, and aberrant expressions of caudal-type homeobox 
transcription factor 2 (CDX2), a master regulatory gene of intestinal development and 
differentiation, in H. pylori-induced atrophic gastritis are the early events correlated with the 
occurrence of intestinal metaplasia, which can be reversible by the eradication of H. pylori. In 
accordance with these findings, CDX2 expression has been demonstrated to be associated 
with intestinal phenotypes in gastric cancers (Shiotani et al., 2008). 
Another important tumor suppressor gene in intestinal-type gastric cancer is runt-related 
gene 3 (RUNX3) encoding a subunit of polyomavirus enhancer binding protein 2 (Li et al., 
2002), since expression of RUNX3 is greatly reduced in intestinal metaplasias in human 
stomachs (Oshio et al., 2004) and RUNX3-/- mouse gastric epithelial cells have a potential to 
differentiate into CDX-2 positive intestinal type cells (Oshio et al., 2004). Li and colleagues 
(Li et al., 2002; Levanon et al., 2003) reported that the gastric mucosa of RUNX3 null mice 
showed hyperplasia, indicating that loss of RUNX3 leads to gastric carcinogenesis in 
humans. Consistent with this, an analysis of RUNX3 in human stomach cancer cell lines and 
primary human tumours revealed hemizygosity in 40% of the tumours examined, and 
silencing by promoter hypermethylation in 60% of the tumours, and this figure increased up 
to 90% in the advanced stage tumours. It is shown that the RUNX3-/- mouse gastric mucosa 
exhibits hyperplasias due to the stimulated proliferation and suppressed apoptosis in the 
cells, suggesting that RUNX3 is an attractive candidate as a tumor suppressor of gastric 
cancer. The CpG island of RUNX3 P2 promoter is hypermethylated in human and mouse 
gastric cancer cell lines and in primary human tumors (Li et al, 2002; Waki et al., 2003), also 
suggesting the tumor suppressor function of RUNX3 in the etiology of stomach cancer. 
Heat-shock protein (HSP) 70 plays essential roles in cellular response to a variety of 
environmental stresses by acting as molecular chaperons in the folding of newly synthesized 
proteins in cells and assist in the folding of damaged proteins (Becker et al., 1994). HSP 
expression in the gastric mucosa is shown to be attenuated by H. pylori infection and aspirin 
intake, and one HSP inducer geranylgeranylacetone (GGA) reportedly protects gastric 
mucosa from iNOS induced by H. pylori infection (Yeo et al., 2004), suggesting that HSP has 
important roles in protecting gastric mucosa against H. pylori or aspirin induced injuries. 
Gastric carcinogenesis can also be regarded as a multistep process that initiates with the 
disregulation of normal controls of apoptoisis and cell proliferation, in which FAS receptor-
ligand system is shown to be a key regulator of apoptosis (Hsu et al., 2008). 
Pepsinogen C (PGC), alternatively called pepsinogen II or gastricsin, an inactive precursor 
of pepsin C, is an aspartic protease specifically produced by the gastric chief cells, cardiac 
cells, pylori cells and Brunner’s glands from late infant stages to adulthood period. PGC is 
considered to be a differentiation marker of gastric epithelium, whose changes in expression 
may reflect the severity of gastric mucosal damage (Samloff et al., 1982). 
RUNX3  
Among H. pylori seropositive subjects, we found a significant association between RUNX3 
rs760805 T/A polymorphism and the risk of gastric atrophy with the age- and sex-adjusted 
OR of 1.51 (95% CI 1.11-2.05, P=0.008) in TA, 1.59 (95% CI 1.08-2.33, P=0.019) in AA, and 1.53 
(95% CI 1.14-2.05, P=0.004) in TA+AA, compared with TT genotype (Hishida et al., 2009b). 
This finding was in accordance with the recent biological report that RUNX3 expression 
correlated with chief cell differentiation in human gastric cancers (Ogasawara et al., 2009). 
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Polymorphism Function Rs number Subjects (Reference) OR and/or GA%
IL-1B  C-31T 5'UTR rs1143627 253 Japanese (Atsuta, 2006) CC (54%),CT (52%),TT (56%)
" 455 Jpn.Brazil. (Uno, 2004) CC ,CT :0.61,TT :0.58 CC (36%), CT (31%), TT (21%)
" 1,328Venezuelan (Kato, 2007) TT,CT :1.01,CC :0.91
IL-2  T-330G 5'UTR rs2069762 244 Japanese (Togawa, 2005) GG ,TG :1.64,TT :2.78 *GG (38%),TG (50%),TT (62%)
IL-4  C-33T 5'UTR rs2070874 249 Japanese (Togawa, 2005) CC ,CT :2.47,TT :1.80 CC (38%),CT (60%),TT (53%)
IL-4  T-590C 5'UTR rs2243250 1,301 Venezuelan (Kato, 2006) TT ,CT :0.82,CC :0.81
IL-4R  C-3223T 5'UTR rs2057768 1,301 Venezuelan (Kato, 2006) CC ,CT :0.97,TT :1.01
IL-4R  A398G Non-synonimous (Ile50Val) rs1805010 1,301 Venezuelan (Kato, 2006) AA ,AG :1.14,GG :1.52*
IL-6  G-174C 5'UTR rs1800795 1,315 Venezuelan (Kato, 2007) GG ,CG :0.98,CC : 0.57
IL-8  T-251A 5'UTR rs4073 1,347 Venezuelan (Kato, 2007) TT ,AT :0.98,AA :1.07
IL-10  G-1082A 5'UTR rs1800896 1,301Venezuelan (Kato, 2006) GG ,AG :1.05,AA :1.14
IL-13  C-1111T 5'UTR rs1800925 248 Japanese (Togawa, 2005) CC ,CT+TT :0.41 *CC (59%),CT+TT (45%)
TNF-A  T-1031C 5'UTR rs4647198 455 Jpn.Brazil. (Atsuta, 2006) CC (29%),TC (33%),TT (34%)
               C-857T 5'UTR rs1799724 456 Jpn.Brazil. (Atsuta, 2006) CC (32%),CT (36%),TT (39%)
             -1031&-857 455 Jpn.Brazil. (Atsuta, 2006) CC&CC (29%),TT&CC (33%),TC&CT (43%),TT&TT (39%)
               G-308A 5'UTR rs1800629 1,327 Venezuelan (Kato, 2006) GG,AG+AA :1.27
MCP1  G-2518A 5'UTR rs1024611 1,311 Venezuelan (Kato, 2007) AA ,AG :1.02, GG :1.18
PTPN11  G/A at intron3 intron rs2301756 248 Japanese (Goto, 2006a) GG ,GA :0.70,AA :0.09 *GG (59%),GA (49%),AA (11%)
" 979 Japanese (Hishida, 2009a) GG ,GA+AA :0.62‡ *GG (22%),GA+AA (15%)‡
NOD1  G796A Non-synonimous (Glu266Lys) rs2075820 150 Turks (Kara, 2010) GG ,GA : 13.35*,AA :34.2*
TLR4  A+896G Non-synonimous (Asp299Gly) rs4986790 103 Caucasians (Hold, 2007) AA ,AG :11.0* AA (36%),AG (87%)§
" 717 Venezuelan (Kato, 2007) GlyGly/ AspGly,AspAsp : 1.53
TLR4  G+3725C 3'UTR rs11536889 980 Japanese (Hishida, 2009b) GG,GC+CC:1.33 GG(18%),GC+CC(22%)‡
CD14  C-159T(C-260T) 5'UTR rs2569190 717 Venezuelan (Kato, 2007) CC,CT+TT :1.06
PRKCH  rs3783799 G/A intron rs3783799 1,638 Japanese (Goto, 2010) GG ,GA :0.99,AA :2.37*
iNOS  C150T Non-synonimous (Ser608Leu) rs2297518 250 Japanese (Goto, 2006a) CC ,CT+TT :0.75
RUNX3  T/A at intron3 intron rs760805 938 Japanese (Hishida, 2009) TT ,TA :1.51*,AA :1.59*TT (46%),TA (56%),AA (56%)
HSP70-2  A/B (A1267G) Synonimous (Gln351Gln) rs1061581 137 Japanese (Tahara, 2009) BB (45%),AA+AB (67%)‡
FAS  G-1377A 5'UTR rs2234767 109 Taiwanese (Hsu, 2008) No association
FAS  A-670G 5'UTR rs1800682 109 Taiwanese (Hsu, 2008) No association
FASL  T-844C 5'UTR rs763110 109 Taiwanese (Hsu, 2008) TT ,TC+CC :9.4*
PGC  Ins/Del Ins/Del (unknown) 86 Chinese (Pham, 2003) DD (90%),others(50%)*
NQO1  C609T Non-synonimous (Pro187Ser) rs1800682 396 Japanese (Goto, 2005a) TT ,CT :1.25,CC :1.23
GSTM1 Ins/Del (unknown) 396 Japanese (Goto, 2005a) Null ,Present :1.35
GSTT1 Ins/Del rs71748309 396 Japanese (Goto, 2005a) Null ,Present :0.87
ACE  Ins/Del Ins/Del rs1799752 271 Japanese (Goto, 2005c) II ,ID :1.12,DD :0.99
RANTES  C-471T 5'UTR rs2107538 344 Germans (Hellmig, 2005) No association
SDHC  JST173800 C/G 3'UTR rs3813632 249 Japanese (Goto, 2006c) CC ,GC :1.26,GG :0.51 CC (53%), GC (59%), GG (38%)
IFNGR1  G-611A 5'UTR rs1327474 805 Portugese (Canedo, 2008) GG ,GA :1.2,AA :1.2
IFNGR1 C-56T 5'UTR rs2234711 814 Portugese (Canedo, 2008) CC ,CT :1.4,TT :1.3
 
Table 4. Polymorphisms associated with gastric atrophy Helicobacter pylori seropositives. 
Polymorphisms of other miscellaneous genes 
HSP 70-2 
It is shown that the AA genotype of HSP 70-2 A/B polymorphism (PsiI polymorphism, 
corresponding to A1267G polymorphism) had the highest level of mRNA expression 
compared with the other genotypes (AB or BB). Recently one Japanese group reported that 
the BB genotype of HSP 70-2 gene is significantly associated with the reduced risk of severe 
gastric atrophy in H. pylori infected older subjects (Tahara et al., 2009), indicating the 
importance of this HSP polymorphism in the genesis of H. pylori-induced gastric 
precancerous lesions. 
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Table 4. Polymorphisms associated with gastric atrophy Helicobacter pylori seropositives. 
Polymorphisms of other miscellaneous genes 
HSP 70-2 
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gastric atrophy in H. pylori infected older subjects (Tahara et al., 2009), indicating the 
importance of this HSP polymorphism in the genesis of H. pylori-induced gastric 
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Lately one study group in Taiwan investigated the relations between precancerous gastric 
lesions and polymorphisms in the promoter regions of the death pathway genes FAS and 
FASL (FAS G-1377A, FAS A-670G and FASL T-844C) in 109 H. pylori-infected Taiwanese 
individuals, and found that FASL -844 C allele significantly increased the risk of atrophy in 
the gastric corpus, with an adjusted OR of 5.0 (95% CI = 1.5-6.8) (Hsu et al., 2008). 
PGC 
Recent study among Chinese demonstrated that subjects with PGC Del/Del genotype of the 
PGC ins/del polymorphism were at significantly higher risk of atrophic gastritis (OR=3.11; 
95%CI 1.44-6.71), and H. pylori-seropositive subjects with PGC Del/Del genotype had 
significantly elevated risk of atrophic gastritis (OR=11.16; 95%CI 1.37-90.84) with the 
interaction of 6.48 (Sun et al., 2009), suggesting the positive link between PGC gene 
polymorphism and H. pylori-induced gastric atrophy. 
2.3 Genetic factors for Helicobacter pylori-induced gastric carcinogenesis 
To date, many genetic polymorphisms have been examined on the associations with gastric 
cancer in case-control studies with the mixed cases (H. pylori-related and H. pylori-unrelated) 
and controls at different stages (unexposed to H. pylori, exposed but uninfected, infected but 
without gastric atrophy, and with gastric atrophy), as shown in Fig. 5. Since those case-
control studies compared genotype frequencies between the mixed cases and heterogeneous 
controls, the estimated odds ratios did not reflect any distinct step to gastric cancer. Controls 
unexposed to H. pylori have the same genotype frequency as the average among the 
exposed, which reduces the difference in the genotype frequency between the uninfected 
and infected. In order to measure the associations between genotypes and H. pylori infection, 
the studies are to be conducted at a region where the exposure to the bacterium was highly 
prevalent. Usual case-control studies could provide the estimates for the final step (ie, literal 
carcinogenesis), when genotype frequency is different between gastric atrophy and gastric 
cancer, and the same among the uninfected, infected, and those with gastric atrophy. 
Table 5 lists the polymorphisms reported on gastric cancer risk, adopted from Gonzalez et 
al.(Gonzalez et al., 2002) and recent studies(Ebert et al., 2005; Geddert et al., 2005; Li et al., 
2005; Tsukino et al., 2002; Sugimoto et al., 2005; Gao et al., 2002; Wu et al., 2002; Goto et al., 
2005; Lai et al., 2005a; Lee et al., 2004; Savage et al., 2004; Lai et al., 2005b; Lacasana-Navarro 
et al., 2006; Kim et al., 2005; Hamajima et al., 2002a; Duarte et al., 2005). The ORs are listed in 
case of being significant. Accordingly, it should be noted that there were many insignificant 
studies behind Table 5. 
There are several studies to demonstrate the risks of both gastric atrophy and gastric cancer 
in comparison with the same controls without gastric atrophy. Individuals with IL-8 -251A 
allele had OR=1.50 with 95% confidence interval (95%CI)=0.98-2.23 for gastric atrophy and 
OR=1.50 with 95%CI=1.00-2.25, indicating that the risk elevation was due to the risk for 
gastric atrophy, not for the step from gastric atrophy to gastric cancer.(Taguchi et al., 2005) 
The direct comparisons between controls with gastric atrophy and cases with gastric cancer 
were reported; no associations for p53 Arg72Pro (Hiyama et al., 2002; Chung et al., 2006), 
and for PTPN11 G/A at intron 3 (Goto et al., 2006a). 
Lifestyle factors may interact with the genotypes in the final step. Biologically, the 
interactions of smoking, fresh vegetables/fruits and salty food with polymorphisms of 
carcinogen-metabolic enzyme and DNA repair enzymes are very plausible. 
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Polymorphism                    Country(Reference)                                                   OR (95%CI) 
ACE I/D                             Germany (Ebert, 2005)                                              DD, DI:0.55 (0.31-0.96),  
 II:0.20 (0.08-0.54) 
cyclinD1 G870A                       Germany(Geddert, 2005)                                                                        significant association (p=0.003) 
CYP1A1 Ile/Val                       China(Li, 2005) IleIle, ValVal:4.84 (1.24-22.07) 
CYP2C6 *1/*4                         Japan(Tsukino, 2002) *1*1/*1*4, *4*4:3.14 (1.05-9.41) 
CYP2C19 *1/*2/*3                     Japan(Sugimoto, 2005)                                                                         * 1*1, no*1:1.98 (1.07-3.65) 
CYP2E1 RsaI                          Japan*                                               
Brazil*  
China(Gao, 2002) 
E-cadherin C-160A                  Taiwan(Wu, 2002) CC, AA:0.20 (0.06-0.56) 
EGF A61G                           Japan(Goto, 2005)   
GSTM1present/null                        UK*                                  present, null:2.9 (1.25-6.73) 
 Japan* present, null:1.70 (1.05-2.8) 
 Iran* present, null:2.3 (1.15-4.95) 
Poland* 
China(Li, 2005)         present, null:2.81 (1.39-5.71) 
Taiwan(Lai, 2005) present, null:1.75 (1.04-2.96) 
GSTM3 IVS6del3                      Poland* 
GSTP1 I105V                          Japan* 
Poland* 
GSTT1 present/null               China*                        present, null:2.5 (1.01-6.2) 
 Poland*     present, null:3.1 (1.5-6.5)  
      among current smokers 
 Japan* 
IL-1B C-1473G      Korea (Lai, 2005) 
C-511T                         Poland(El-Omar, 2000)        CC, CT:1.8 (1.3-2.4), 
      TT:2.6 (1.7-3.9) 
 Portugal*     CC, CT/TT:1.7 (1.1-2.7) 
 Taiwan(Wu, 2003) 
      C3954T                        Poland(El-Omar, 2000) 
IL-1RN 86-bp VNTR                     Poland(El-Omar, 2000)          4rpt4rpt, 2rp2rp:3.7 (2.4-5.7) 
Taiwan(Wu, 2003) 
IL-1B C-511T+      Portugal*     CC+LL/L2rpt,  
IL-1RN 86-bp VNTR                       CT/TT+2rpt2rp:9.0 (3.5-23.0) 
IL-2 G-384T, G114T   China(Savage, 2004) 
IL-4 C-590T                           Taiwan(Wu, 2003; Lai, 2005) 
RP1/RP2                        Taiwan(Lai, 2005) 
IL-4R Ile50Val                         Taiwan(Wu, 2003) 
     Gln576Arg                       Taiwan(Wu, 2003) 
IL-10 G-1082A                         Taiwan(Wu, 2003)  AA, AG:2.14 (1.07-4.30) 
China(Savage, 2004)  
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T-819C                         Taiwan(Wu, 2003)  TT, TC:1.83 (1.23-2.71), 
                                                   CC:1.95 (1.03-3.69) 
 China(Savage, 2004) 
MK G-2669A                         Taiwan(Lai, 2005) 
MTHFR C677T        China*     CC, TT:1.87 (1.00-3.48) 
 Mexico(Lacasana-Navarro, 2006)      CC, TT:1.62 (1.00-2.59) 
C677T, A1298C   Korea(Kim, 2005) 
MUC1 VNTR                         Portugal*     Large, Small: 4.3 (1.8-10.5) 
MUC6 VNTR        Portugal*     Large, Small: p<0.05 
MYCL1 EcoRI        Japan*     LL, LS:1.55 (1.03-2.34) 
 Japan*     LL, LS/SS:3.09 (1.33-7.21)  
NAT1               UK*     slow, rapid:2.6 (1.3-5.3) 
 Japan* 
NAT2               UK* 
 Japan* 
NQO1 C609T        Japan(Hamajima, 2002d) 
OGG1 Ser327Cys     Japan* 
 Brazil* 
p16INK4A C540G            Germany(Geddert, 2005)  
C570G       Taiwan(Lai, 2005) 
p21 codon31          Taiwan(Lai, 2005) 
p53 codon72                         Taiwan(Lai, 2005)       significant association (p=0.02) 
PPARγ Pro12Ala(C/G)                    China(Liao, 2006)       CC, CG/GG:2.5 (1.1-5.8) 
TFF2 VNTR           Portugal*  
TNF-A G-308A         Korea* 
 Taiwan(Wu, 2003) 
       G-238A        Korea*  
 Taiwan(Wu, 2003) 
XRCC1 Arg194Trp    Brazil(Duarte, 2005)  
       Arg399Gln       Brazil(Duarte, 2005) 
Arg194Trp+   China*     TrpTrp+ArgArg, ArgArg+ 
Arg399Gln      ArgGln/GlnGln:1.73 (1.12-2.69) 
XRCC3 Thr241Met    Brazil(Duarte, 2005) 
 
* Studies cited in the review by Gonzalez et al. (2002).  
L: alleles longer than 2rpt   
Table 5. Polymorphisms reported on the associations with gastric risk> only singnificant are 
with odds ratio (OR) and 95% confidence interval (95%CI). 
3. Conclusion 
It is clear that H. pylori-related gastric cancer develops through several steps including the 
infection, gastric atrophy, (histologically intestinal metaplasia, dysplasia) and cancer. 
Lifestyle factors such as smoking and diet could influence one or more steps. On the other 
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hand, genotypes may be step-specific because the biological process is distinct in the 
different steps. Accumulated findings on the associations between gastric cancer risk and 
polymorphism genotypes demonstrated that the strength of associations varied among the 
studies. Since usual case-control studies examined the mixed effects on these steps, the 
inconsistent findings may be natural. In addition, the diversity of lifestyle interacting with 
the genotypes among the different study subjects may enlarge the inconsistency. In order to 
elucidate the genetic traits of H. pylori-related gastric cancer, the studies on each step taking 
into account of the lifestyle factors will be requested. Such studies will produce useful 
information for gastric cancer prevention. 
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1. Introduction  
Gastric carcinoma (GC) remains one of the most malignant tumors either in morbidity or 
mortality rates around the world (IARC, 2002). Development of GC is influenced by 
multiple factors including genetic, biological, social, and psychological ones, etc.., however, 
the function mechanisms of which are too sophisticated and still under explorations 
(Matysiak-Budnik & Mégraud, 2006). Similar to other malignant tumors, GC leads to death 
mainly due to system or organ failure because of cancer advancement and metastasis. 
Chemotherapy-based regimens combined with radiological and immunomodulating 
therapies are fundamental but unsatisfactory because most GC patients are in advanced 
stage when diagnosed, although radical operation throws those at early stage a light of 
prolonged survival and even clinical cure (Quiros & Bui, 2009). As for prophylaxis, many 
reports have mentioned the protective role of eradication of Helicobacter pylori, which has 
been identified as a definite carcinogen for GC, but few evidences proved a successful H. 
pylori vaccine showing effects on GC prevention, just as Hepatitis B virus vaccine on 
prevention of primary hepatocellular carcinoma (IARC, 1994; Murakami et al., 2005; Cai et 
al., 2005; Di Bisceglie 2009).  
H. pylori, a stomach colonizing spiral gram-negative bacterium, interacts with the host in a 
multiplicity of ways during its adhesion, colonization, invasion, and induction of 
inflammatory and immune responses (Peek 2005). The great majority of researchers link H. 
pylori infection with development or even recurrence of GC according to some clinical trials, 
meta-analyses, and in vitro experiments (Wong et al., 2004; Fukase et al., 2008). However, a 
few recent studies have disclosed the other side of the coin, in which positive H. pylori status 
appears to be associated with better outlook in GC patients (Meimarakis et al., 2006; Marrelli 
et al., 2009). Therefore, H. pylori probably factually play a bi-directional role in GC just like a 
double-edged sword. To learn about both edges of H. pylori infection will provides us with 
new sights in vaccine design, prevention, and even therapy of GC. 
Herein, we try to re-elucidate the relationship between H. pylori and GC from novel angles, 
in which GC consists of H. pylori-related (Hp-GC) and non-H. pylori-related (nHp-GC) ones, 
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the function mechanisms of which are too sophisticated and still under explorations 
(Matysiak-Budnik & Mégraud, 2006). Similar to other malignant tumors, GC leads to death 
mainly due to system or organ failure because of cancer advancement and metastasis. 
Chemotherapy-based regimens combined with radiological and immunomodulating 
therapies are fundamental but unsatisfactory because most GC patients are in advanced 
stage when diagnosed, although radical operation throws those at early stage a light of 
prolonged survival and even clinical cure (Quiros & Bui, 2009). As for prophylaxis, many 
reports have mentioned the protective role of eradication of Helicobacter pylori, which has 
been identified as a definite carcinogen for GC, but few evidences proved a successful H. 
pylori vaccine showing effects on GC prevention, just as Hepatitis B virus vaccine on 
prevention of primary hepatocellular carcinoma (IARC, 1994; Murakami et al., 2005; Cai et 
al., 2005; Di Bisceglie 2009).  
H. pylori, a stomach colonizing spiral gram-negative bacterium, interacts with the host in a 
multiplicity of ways during its adhesion, colonization, invasion, and induction of 
inflammatory and immune responses (Peek 2005). The great majority of researchers link H. 
pylori infection with development or even recurrence of GC according to some clinical trials, 
meta-analyses, and in vitro experiments (Wong et al., 2004; Fukase et al., 2008). However, a 
few recent studies have disclosed the other side of the coin, in which positive H. pylori status 
appears to be associated with better outlook in GC patients (Meimarakis et al., 2006; Marrelli 
et al., 2009). Therefore, H. pylori probably factually play a bi-directional role in GC just like a 
double-edged sword. To learn about both edges of H. pylori infection will provides us with 
new sights in vaccine design, prevention, and even therapy of GC. 
Herein, we try to re-elucidate the relationship between H. pylori and GC from novel angles, 
in which GC consists of H. pylori-related (Hp-GC) and non-H. pylori-related (nHp-GC) ones, 
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and in which roles of the infection are divided into two parts including harmful and 
beneficial ones.  
2. H. pylori virulence factors 
H. pylori infection usually initiates from bacterial invasion, colonization, and expression and 
translocation of virulence factors, and persists through induction and maintenance of 
complex responses at certain levels in the host (Peek 2005). Herein, virulence factors 
extensively mean pathogenic components and contain those contributing to bacterial 
survival within the host, which are ever called as maintenance factors sometimes. According 
to the complete genome published and continuously updated since 1997, H. pylori (26695 
strain) is of about 1.67 Mb in length with 1576 protein-coding genes, many of which encode 
virulent products associated with H. pylori pathogenesis (Tomb et al., 1997).  
The cytotoxin-associated gene (cag) pathogenicity island (PAI), one of most well known 
virulence components, is of about 35 Kb with 26 open reading frames and is present in 
about 60% H. pylori strains in Europe and United States (Tomb et al., 1997; Peek 2005). 
Among all Cag PAI products, the CagA (Cag26) has been identified with relatively clear 
functions in development of GC (Huang et al., 2003). The involved carcinogenic mechanisms 
of CagA mainly include activation of certain signalling pathways such as Ras, SHP2, ERK, 
MAPK and JAK/STAT3, activation of C-terminal Src kinase and inhibition of Src activity, 
enhancement of epithelial gene transcription, disruption of cellular polarity, and 
morphological changes and final transformation of gastric epithelial cells (GECs) (Mimuro 
et al., 2002; Higashi et al., 2002; Selbach et al., 2002; Bagnoli et al., 2005; Lee et al., 2010).  
Vacuolating toxin (vacA) of about 3.9 Kb is an independent key virulence determinant for H. 
pylori pathogenesis (Tomb et al., 1997). Around 60% of H. pylori strains produce detectable 
amounts of VacA in vitro, although this gene is present in all strains (Konturek et al., 2009). 
Cytotoxic activity of VacA varys considerably in different strains due to various gene 
subtypes based on sequence diversities in the N-terminal (allele types s1a, s1b, s1c, or s2) 
and middle regions (allele types m1 or m2) (Atherton et al., 1995; Peek 2005). It has been 
demonstrated that infection with vacA s1 and m1 strains are associated with an increased 
risk of GC (Gerhard et al., 1999). VacA plays a role in carcinogenesis probably through 
inducing vacuolation and cellular detachment, permeabilizing epithelial cells, promoting 
apoptosis, and suppressing T-cell proliferation and activation (Peek 2005).  
Outer membrane proteins (OMP) represent a large family of adhesins and participate in H. 
pylori infection mainly by mediating bacterial adherence and colonization in gastric mucosa 
(Odenbreit 2005). As one of OMP members, blood-group antigen-binding adhesin (BabA) 
can bind the blood-group antigen Lewis b on host epithelial cell membranes, and those 
strains possessing the encoding gene babA2 are associated with high risk of GC (Oliveira et 
al., 2003; Konturek et al., 2009). Lipopolysaccharide (LPS), another cell wall component, can 
disrupt stomach mucosa and involve in the organism survival and persistence of H. pylori 
infection (Grebowska et al., 2008). Moreover, the LPS O-antigen mimics human Lewisx and 
Lewisy blood-group antigens, which also mediate bacterial adhesion and colonization and 
alternatively cause immune cross-reactivity (Moran 1996; Appelmelk et al., 2001).  
There are still many other important virulence factors related with H. pylori infection and 
even carcinogenesis. Urease, an approximately 560-kDa hexameric enzyme consisting of 30-
kDa UreA and 64-kDa UreB subunits, is produced abundantly by all H. pylori isolates 
(Turbett et al., 1992). Urease is independently essential for colonization and persistent 
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survival of the germ because it crucially contributes to local pH homeostasis within the 
stomach lumen (Stingl et al., 2002; Mollenhauer-Rektorschek et al., 2002). The induced by 
contact with epithelium factor Antigen (IceA), with two major allelic sequence variants of 
IceA1 and IceA2, is an independent strain-specific H. pylori locus significantly associated 
with distal GC (Kidd et al., 2001). IceA1 leads to relatively severer gastric inflammation and 
tissue damage following production induced by bacterial contact with GECs, which exists in 
72% of the H. pylori isolates in a Chinese population (Sheu et al., 2002). Flagella are bacterial 
motile structures with two types of filaments, that are encoded by flaA and flaB genes and 
functionaly regulated by flgE and flbA genes (Dunn et al., 1997). Normal expression and 
interaction of these virulence factors are required for bacterial motility or colonization 
during H. pylori infection. 
Notably, H. pylori plays pathogenic or carcinogenic roles as an integrity, although its 
multiple virulence components have their own special contributions at various infection 
stages. The co-interactions among the virulence factors are likewise important for 
pathogenesis but may be so complex or always ignored and need further explorations. In 
addition, cross-interactions between H. pylori and the host are very vital for infection or 
carcinogenesis, which mainly contain inflammatory and immune responses, and genetic or 
phenotypic alterations (McNamara & El-Omar, 2008). 
3. Inflammatory responses 
H. pylori infection is firstly characterized by acute or chronic activation of inflammatory cells 
and release of multiple cytokines including pro-inflammatory and inflammatory ones (Peek 
2005). The spectrum and relative levels of cytokines, to a certain extent, reflect the intensity 
of the host response to infection, which may result in different outcomes including gastric 
mucosal inflammation, injury, ulcer, and even cancer. 
Cytokines such as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β) / IL-1 receptor 
antagonist (IL-1RN), IL-6, IL-8 and IL-10 are always significantly up-regulated in stomach 
mucosa, gastric fluids and the sera of H. pylori-infected patients and play vital functions in 
gastritis, metaplasia, dysplasia and carcinogenesis (McNamara & El-Omar, 2008). TNF-α 
and IL-1 are the most relevant factors consistently confirmed in animal models and various 
populations. TNF-α can markedly potentiate apoptosis, activate signalling pathways, 
influence mucosal inflammation and stimulate gastric acid secretion (Ierardi et al., 2003). 
Moreover, H. pylori causes sensitization of GECs for TNF-related apoptosis-inducing ligand 
(TRAIL)-mediated apoptosis, besides direct induction of apoptosis and inhibition of DNA 
synthesis (Tsai & Hsu, 2010). The H. pylori infection strengthens IL-1 functions in the 
carcinogenic process through complex pathways. IL-1β and IL-1RN as key pro-
inflammatory genotypes of IL-1, which is a powerful gastric acid suppressor, can increase 
the risk of atrophic gastritis (AG) and both intestinal and diffuse types of non-cardia GC 
(Starzyńska et al., 2006; Rad et al., 2004). IL-1β with significantly higher level in neoplasm 
than in normal mucosa, involves in the carcinogenesis by stimulating hyper-proliferation in 
GECs via tyrosine kinase signalling (Beales 2002). H. pylori-induced gastritis is possibly 
driven in an IL-6-dependent fashion (Jackson et al., 2006). IL-6 participates in activation of 
the STAT3 signalling pathway by the translocated CagA in host cells, which may play a role 
in gastric carcinogenesis (Bronte-Tinkew et al., 2009). IL-6 level in the serum is related with 
GC status and its level in the tumor correlates significantly with lymphatic invasion and the 
depth of invasion (Kai et al., 2005). As for IL-8, its level in cancer tissues is more than double 
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fold in advanced GC than that in early GC irrespective of H. pylori status (Yamaoka et al., 
2001). IL-8 modulates gastric acid secretion, promotes the proliferation, enhances the FasL-
induced apoptosis, and mutually and dependently activates NF-κB (Konturek et al., 2002; 
Varro et al., 2004; Guo et al., 2006). Moreover, IL-8 as a potent leukocyte chemoattractant, 
contributes to mucosal tissue injury and induces the upregulation and phosphorylation of 
EGFR and subsequent signalling events, which plays an fundamental role in carcinogenic 
mechanisms (Kassai et al., 1999; Beswick & Reyes, 2008). IL-10 inhibits the FasL-induced 
apoptosis in GECs though without significant effect on the transcription of Fas (Guo et al., 
2006). IL-11 activates the STAT3 like IL-6 and concomitantly increases proliferation of GECs 
(Jackson et al., 2007). 
Some other molecules including cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), nitric 
oxide (NO), inducible NO synthase (iNOS), monocyte chemoattractant protein 1 (MCP1), 
and hepatocyte growth factor (HGF) and c-MET also relate to GC-associated inflammatory 
responses (Zhuang X et al., 2001; Futagami et al., 2008; Snider & Cardelli, 2009; Cho et al., 
2010). COX-2 as a key mediator in inflammation and cancer formation, together with PGE2, 
one of its major products, are remarkably up-regulated in H. pylori-related gastritis, GC, and 
precancerous lesions including atrophy, intestinal metaplasia (IM) and dysplasia of the 
stomach (Dong et al., 2009; Walduck et al., 2009; Zhang et al., 2009). COX-2 can be induced 
by gastrin, growth factors, inflammatory cytokines and reactive oxygen species in GECs 
(Seo et al., 2007). The overexpression of COX-2 may continue to exist in metaplastic or 
dysplastic mucosa even after successful H. pylori eradication, which increases the risk for 
carcinogenesis and indicates that COX-2 has a crucial role in not only Hp-GC but also nHp-
GC (Tsuji et al., 2006). COX-2 overexpression is even thought as a biomarker of intestinal 
type and earlier stage of GC and an independent prognostic factor for worse survival (Park 
et al., 2009). COX-2 induces carcinogenesis mainly by inhibiting apoptosis, increasing 
proliferation and enhancing angiogenesis through multiple pathways including Wnt 
signalling, p38MAPK / ATF-2 pathway, TLR2 / TLR9 and c-Src-dependent NF-κB 
activation, MMP-9 and VEGF activation, proteinase-activated receptor-2 signalling, PPARγ 
inhibition, and so on (Leung et al., 2003; Chang  et al., 2004 & 2005; Huang et al., 2006; Li et 
al., 2009; Zhang et al., 2009; ). PGE2, a downstream mediator with central roles in the 
mentioned COX-2 pathways, plays important functions in both inflammation and 
carcinogenesis. PGE2 participates in IL-8 production in GECs, facilitates H. pylori 
colonization and persistent infection, and suppresses the immune functions of CD4 (+) T-
helper 1 cells by silencing IL-2 gene transcription, which may help accelerate the tumor 
formation (Takehara et al., 2006; Toller et al., 2010).  
During chronic H. pylori infection, there are still excessive amounts of reactive oxygen and 
nitrogen species containing NO and iNOS, which play crucial roles in the stepwise process 
of GC (Son et al., 2001; Tiwari et al., 2010). NO as an important endogenous carcinogenic 
factor, correlates with gastric hypoacidity, inhibits p53 expression, increases genetic and 
epigenetic changes by mediating mutation or DNA methylation, and perturbs the balance 
between apoptosis and proliferation in GECs (McGee & Mobley, 2000; Lamarque et al., 2003; 
Shiotani et al., 2004; Chen et al., 2006; Katayama et al., 2009; ). Being one of independent 
prognostic factors, the iNOS overexpression is induced by H. pylori infection with 
involvements of TNF-α, Ras, AP-1, c-Fos and c-Jun, and related to apoptosis, angiogenesis, 
tumor progression, and poor survival in GC especially of the intestinal type (Tatemichi et 
al., 1998; Rieder et al., 2003; Chen et al., 2006; Cho et al., 2010). MCP-1 is significantly higher 
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at mRNA level in poorly differentiated GC, which has effect on COX-2 expression and 
subsequent PGE2 and VEGF production (Futagami et al., 2008). HGF is more frequently 
detected in GC tissue than in normal mucosa and shows a concentration-dependent increase 
under the stimulation of gastrin (Konturek et al., 2001 & 2003). Being the receptor of HGF, c-
Met is activated by H. pylori, involved in malignant transformation of gastric mucosa and 
invasive growth of tumor cells, and strongly implicated in late-stage cancer progression and 
worse prognosis (Zhuang X et al., 2001; Churin et al., 2003; Snider & Cardelli, 2009). In 
addition, H. pylori-mediated GEC invasion depends on c-Met activation, besides on 
increased activities of MMP-2 and MMP-9 (Oliveira et al., 2006). The c-Met interacts with 
CagA and suppresses the phosphatidylinositol 3-kinase/Akt pathway, which then leads to 
β-catenin activation and NF-κB signalling (Suzuki et al., 2009). 
4. Immune responses 
Another critical aspect of interactions between H. pylori and the host are immune responses, 
which consist of special and unspecialized ones. In fact, immune and inflammatory 
responses overlap each other especially in roles of many cytokines mentioned above during 
the infection and carcinogenesis. Herein we mainly focus on important alterations in 
antibody responses, status of immune cells, balance of cytokines, autoimmune reactions and 
immune tolerance. 
4.1 Antibody responses 
A significantly higher seroprevalence has been found in H. pylori-infected patients with 
gastritis, duodenal ulcer, or GC (Przyklenk et al., 1990). Some scientists have concluded that 
higher H. pylori seroprevalence is present in GC patients at early stages of tumor 
development compared those at advanced stages, whereas others have not (Lin et al., 1993; 
Klaamas et al., 1996; Komoto et al., 1998). Seropositivity of anti-H. pylori IgG is highly 
prevalent with 76% at 0-4 years and 99% by > or = 18 years of age in a rural population of 
Africa, where the immunological response is Th2-dominant, which may partly explain the 
lower risk of Hp-GC (Mbulaiteye et al., 2006). The immune serum-treated H. pylori cannot be 
eliminated in vitro by primary human macrophages, although serum enhances the bacteria 
uptake (Keep et al., 2010). Antibodies are not only dispensable for protection, but they 
impair both the elimination of bacteria and the development of gastritis. This effect appears 
to be IgA-dependent and is not a function of specific IgM or IgG antibodies (Akhiani 2005).  
The major antibodies responsive to H. pylori include IgA and IgG. GC patients elicit different 
anti-H. pylori IgG and IgA responses than the patients with atrophic and superficial gastritis 
(Manojlovic et al., 2008). IgA>IgG ratio and lower IgG is significantly more frequent in 
patients with GC and gastric lymphoma than those with gastritis and duodenal ulcer. 
Correspondingly, higher IgG and IgA levels are often observed in patients with duodenal 
ulcer or non-atrophic gastritis (Manojlovic et al., 2004 & 2008). As for subclass of IgG 
response, the IgG1 is lower in GC and AG patients than in gastritis ones; IgG2 is lower for 
patients with GC localized in the corpus. The IgG1 response in GC patients is correlated 
with H. pylori CagA status (Vorobjova et al., 2006). CagA-positive H. pylori strains also seem 
to markedly frequently induce an IgA response than CagA-negative strains. The presence of 
serum IgA antibodies likely indicates more severe late outcome of H. pylori infection 
(Rautelin et al., 2000). Anti-CagA antibodies are always higher in GC and AG compared 
with non-atrophic gastritis. As reported, Hp-GC patients are of 2-3 folds higher in CagA 
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prevalent with 76% at 0-4 years and 99% by > or = 18 years of age in a rural population of 
Africa, where the immunological response is Th2-dominant, which may partly explain the 
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ulcer or non-atrophic gastritis (Manojlovic et al., 2004 & 2008). As for subclass of IgG 
response, the IgG1 is lower in GC and AG patients than in gastritis ones; IgG2 is lower for 
patients with GC localized in the corpus. The IgG1 response in GC patients is correlated 
with H. pylori CagA status (Vorobjova et al., 2006). CagA-positive H. pylori strains also seem 
to markedly frequently induce an IgA response than CagA-negative strains. The presence of 
serum IgA antibodies likely indicates more severe late outcome of H. pylori infection 
(Rautelin et al., 2000). Anti-CagA antibodies are always higher in GC and AG compared 
with non-atrophic gastritis. As reported, Hp-GC patients are of 2-3 folds higher in CagA 
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seropositivity than age-matched H. pylori-positive non-GC controls. In addition, anti-CagA 
antibodies are significantly more prevalent among individuals with elevated titres of H. 
pylori-related IgA than in those only with IgG, with the exception of a small subgroup who 
later develop GC (Rautelin et al., 2000).  
Heat shock protein (HSP) 60 may be associated with H. pylori-related gastritis and gastric 
carcinogenesis. The positivity rate for anti-HSP60 antibody is markedly higher not only in 
H. pylori-positive patients than in H. pylori-negative ones, but also in GC patients, especially 
of the diffuse type, than in H. pylori-positive non-GC patients (Tanaka et al., 2009). The 
isocitrate dehydrogenase (ICD) of H. pylori, as an antigen interacting with the host immune 
system subsequent to a possible autolytic release, significantly elicits humoral immune 
response and reveals high serum antibody titers in patients with gastritis and ulcer (Hussain 
et al., 2008). In addition, the H. pylori-induced inflammation  leads to aberrant glycosylation 
and demasking of core peptide epitope of mucin 1 (MUC1), which could enhance the host 
immune responses (Klaamas et al., 2007). IgG immune response to tumor-associated MUC1 
is up-regulated among H. pylori-infected individuals and related with a higher degree of 
inflammation in gastric mucosa. The level of anti-MUC1 IgG is positively correlated with 
that of anti-H. pylori IgG in both blood donors and patients with benign diseases, whereas 
the anti-MUC1 IgM level is not (Klaamas et al., 2007). Moreover, the anti-MUC1 IgG level is 
notablely higher in GC patients than in blood donors, irrespective of H. pylori status or 
cancer stage. In some individuals, the H. pylori infection may stimulate specific response to 
tumor-associated MUC1 peptide thus modulating tumor immunity (Klaamas et al., 2007).  
4.2 Status of immune cells 
The infiltration of T, B and macrophage cells always increases at the gastric site of infection 
with H. pylori. The status of T cells and macrophage are closely associated with local and 
system protective immune responses including native and acquired ones, whereas B cells 
mainly play more roles in antibody responses and deregulated and exhaustive H. pylori-
induced T cell-dependent B-cell activation even supports the onset of stomach B-cell 
lymphoma (D'Elios et al., 2005).  
The tumor-infiltrating lymphocytes (TIL) from primary tumors have been isolated and 
analyzed to characterize the anti-tumor immune responses in GC patients (van den Engel et 
al., 2006). The CD3 (+) T cell population contains 50% CD4 (+) and 39% CD8 (+) cells. The 
number of CD19 (+) B cells significantly increases but that of CD3 (+) T cells significantly 
decreases in intestinal compared to diffuse type of GC. Most of T cell cultures derived from 
isolated TILs in Hp-GC patients secrete both IFN-γ and IL-5 when stimulated with 
autologous tumor cells (van den Engel et al., 2006).  
There is a significant tendency of Th1/Th2 polarization in patients with H. pylori infection, 
especially of those with CagA positive strains (Wang et al., 2007). Protection against H. pylori 
infection including inhibition of bacterial colonization, is mainly mediated by CD4 (+) Th1 
cell -mediated immunity (Inoue et al., 2009). Th1-mediated cellular immunity is associated 
with earlier stages of GC, while Th2-mediated humoral immunity dominates the advanced 
stages and is negatively associated with an abundance of regulatory T-cells (Treg) (Wang et 
al., 2007).  
Treg cells of positive CD4, CD25 and Foxp3, suppress the host immune response to H. pylori 
infection and have been identified as the major regulatory factor of adaptive immune 
responses (Kandulski et al., 2010). Vaccine-induced protection against H. pylori correlates 
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with an augmented local recall response in the gastric mucosa, reduced amount of Treg, and 
increased proportions of neutrophils and CD4 (+) T cells (Becher et al., 2010). The CD4 (+) T 
cells isolated from stomachs of vaccinated mice can proliferate in vitro in response to H. 
pylori antigen, and secrete Th1 cytokines, particularly IFN-γ. The efficiency of these vaccines 
relates to the alteration of gastric immune responses, from a homogeneous Th1 response to a 
mixed Th1 and Th2 response (Ernst et al., 2001). The functions of Treg cells are either 
mediated by direct cell-cell contact or by secretions of the immune-modulating TGF-β1 and 
IL-10 cytokines (Kandulski et al., 2010). Treg is involved in bacterial persistence, increased in 
H. pylori-associated gastritis, and even positively related with the grade of chronic 
inflammation and the number of lymphoid follicles (Jang 2010). Treg is also markedly 
elevated in patients with GC compared to those with chronic gastritis and gastric dysplasia. 
Additionally, H. pylori may direct immunosuppression of T cells and regulate the host 
immune responses through activation of Treg and dendritic cells (Blanchard et al., 2004). 
Macrophages are essential components of innate immunity, and their apoptosis will impair 
the host mucosal defense to microbes (Asim et al., 2010). H. pylori infection leads to a rapid 
infiltration of macrophages into the mouse stomach. H. pylori also activates TLR-2 and TLR-
4 in macrophages, and subsequently induces the secretion of distinct cytokines including IL-
2, IL-6 and IFN-α (Obonyo et al., 2007). However, the bacteria remain viable when 
internalized by GECs or even macrophages, which indicates the killing defects in the host 
due to inhibition of the phagosome maturation (Keep et al., 2010). In addition, H. pylori 
induces the formation of a specific phospho-c-Fos c-Jun activator protein-1 (AP-1) complex 
in gastric macrophages by an ERK-dependent way, that causes apoptosis and contributes to 
immune escape of the germ (Asim et al., 2010). 
Several H. pylori proteins can impair macrophage and T cell functions in vitro through 
unclear mechanisms (Zabaleta et al., 2004). VacA, known as a toxic protein with vacuolating 
activity, can induce apoptosis in GECs, affect antigen presentation by B lymphocytes, inhibit 
T cell activation and proliferation, and modulate the T cell-mediated cytokine responses, 
which mainly target the adapted immune system (Gebert et al., 2004). CagA is also capable 
of preventing hydroxyurea-induced B-cell apoptosis by reducing p53 accumulation 
(Umehara et al., 2003). The arginase may impair T cell functions through inhibiting 
proliferation and the TCR zeta-chain (CD3zeta) expression, besides its role in urea 
production (Zabaleta et al., 2004).  
4.3 Network of cytokines 
H. pylori-stimulated host inflammatory and immune responses lead to release of a large 
amount of cytokines, which contribute to the loss of balance between cell proliferation and 
apoptosis prior to many gastric lesions including AG and GC. There is a shift from Th1 
(IFN-γ, TNF-α and IL-12) towards Th2 (IL-4, IL-10 and IL-6)-type immune response in 
patients with GC and dysplasia (Marotti et al., 2008). IL-13 is recently described as a central 
mediator of Th2-dominant immune response and may be implicated in different outcomes 
of H. pylori infection (Marotti et al., 2008). TGF-β and IL-10 are two vital anti-inflammatory 
cytokines that regulate mucosal immunity in various infectious diseases (Wu et al., 2007). 
The local and systemic T-cell response in Hp-GC patients is mainly characterized by 
production of IL-10 (Lundin et al., 2007). When stimulated with H. pylori antigens, T cells 
from both peripheral blood and gastric mucosa produce significantly higher amounts of IL-
10 in Hp-GC patients than in H. pylori-infected asymptomatic subjects. In addition, the 
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seropositivity than age-matched H. pylori-positive non-GC controls. In addition, anti-CagA 
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stages and is negatively associated with an abundance of regulatory T-cells (Treg) (Wang et 
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infection and have been identified as the major regulatory factor of adaptive immune 
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with an augmented local recall response in the gastric mucosa, reduced amount of Treg, and 
increased proportions of neutrophils and CD4 (+) T cells (Becher et al., 2010). The CD4 (+) T 
cells isolated from stomachs of vaccinated mice can proliferate in vitro in response to H. 
pylori antigen, and secrete Th1 cytokines, particularly IFN-γ. The efficiency of these vaccines 
relates to the alteration of gastric immune responses, from a homogeneous Th1 response to a 
mixed Th1 and Th2 response (Ernst et al., 2001). The functions of Treg cells are either 
mediated by direct cell-cell contact or by secretions of the immune-modulating TGF-β1 and 
IL-10 cytokines (Kandulski et al., 2010). Treg is involved in bacterial persistence, increased in 
H. pylori-associated gastritis, and even positively related with the grade of chronic 
inflammation and the number of lymphoid follicles (Jang 2010). Treg is also markedly 
elevated in patients with GC compared to those with chronic gastritis and gastric dysplasia. 
Additionally, H. pylori may direct immunosuppression of T cells and regulate the host 
immune responses through activation of Treg and dendritic cells (Blanchard et al., 2004). 
Macrophages are essential components of innate immunity, and their apoptosis will impair 
the host mucosal defense to microbes (Asim et al., 2010). H. pylori infection leads to a rapid 
infiltration of macrophages into the mouse stomach. H. pylori also activates TLR-2 and TLR-
4 in macrophages, and subsequently induces the secretion of distinct cytokines including IL-
2, IL-6 and IFN-α (Obonyo et al., 2007). However, the bacteria remain viable when 
internalized by GECs or even macrophages, which indicates the killing defects in the host 
due to inhibition of the phagosome maturation (Keep et al., 2010). In addition, H. pylori 
induces the formation of a specific phospho-c-Fos c-Jun activator protein-1 (AP-1) complex 
in gastric macrophages by an ERK-dependent way, that causes apoptosis and contributes to 
immune escape of the germ (Asim et al., 2010). 
Several H. pylori proteins can impair macrophage and T cell functions in vitro through 
unclear mechanisms (Zabaleta et al., 2004). VacA, known as a toxic protein with vacuolating 
activity, can induce apoptosis in GECs, affect antigen presentation by B lymphocytes, inhibit 
T cell activation and proliferation, and modulate the T cell-mediated cytokine responses, 
which mainly target the adapted immune system (Gebert et al., 2004). CagA is also capable 
of preventing hydroxyurea-induced B-cell apoptosis by reducing p53 accumulation 
(Umehara et al., 2003). The arginase may impair T cell functions through inhibiting 
proliferation and the TCR zeta-chain (CD3zeta) expression, besides its role in urea 
production (Zabaleta et al., 2004).  
4.3 Network of cytokines 
H. pylori-stimulated host inflammatory and immune responses lead to release of a large 
amount of cytokines, which contribute to the loss of balance between cell proliferation and 
apoptosis prior to many gastric lesions including AG and GC. There is a shift from Th1 
(IFN-γ, TNF-α and IL-12) towards Th2 (IL-4, IL-10 and IL-6)-type immune response in 
patients with GC and dysplasia (Marotti et al., 2008). IL-13 is recently described as a central 
mediator of Th2-dominant immune response and may be implicated in different outcomes 
of H. pylori infection (Marotti et al., 2008). TGF-β and IL-10 are two vital anti-inflammatory 
cytokines that regulate mucosal immunity in various infectious diseases (Wu et al., 2007). 
The local and systemic T-cell response in Hp-GC patients is mainly characterized by 
production of IL-10 (Lundin et al., 2007). When stimulated with H. pylori antigens, T cells 
from both peripheral blood and gastric mucosa produce significantly higher amounts of IL-
10 in Hp-GC patients than in H. pylori-infected asymptomatic subjects. In addition, the 
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frequency of activated CD8 (+) T cells is markedly reduced in stomach mucosa of GC 
patients compared to asymptomatic individuals (Lundin et al., 2007). Therefore, the 
increased production of the suppressive cytokine IL-10 in Hp-GC patients may lead to a 
diminished local cytotoxic anti-tumor T-cell response and even contributes to cancer 
progression.  
A predominant H. pylori-specific Th1 response associates with peptic ulcer, whereas 
combined secretion of both Th1 and Th2 cytokines are present in simple gastritis (D'Elios et 
al., 2005). In H. pylori-infected mice, the local Th1-type response might alter the systemic 
Th1/Th2-type cytokine balance under particular physiopathological conditions of active 
tissue and/or vascular formation, such as pregnancy (Rossi et al., 2004). H. pylori neutrophil-
activating protein is able to recruit leukocytes and stimulate neutrophils or monocytes to 
release IL-12, a key cytokine for the differentiation of naive Th cells into the Th1 phenotype 
(D'Elios et al., 2007). During H. pylori infection, activated macrophages produce IL-18, which 
stimulates the IFN-γ secretion by NK and T cells (Kawabata et al., 2001). Nevertheless, Th1 
immune response in the stomach may destroy the proliferation / apoptosis balance and 
promote the severity of H. pylori-induced gastric lesions (Xia et al., 2001; Vivas et al., 2008). 
In the host, the innate immune response usually represents by TLRs and Nod-like receptors 
that recognize their specific ligands, activate transcription factors including NF-kB, AP-1 
and CREB-1, and induce inflammatory cytokines such as IL-8, IL-12, IL-6, IL-1β, IL-18, TNF-
α and IL-10 (Sánchez-Zauco et al., 2010). Amounts of the tumor suppressor p53 and the 
major innate immune hub protein TRAF-6 reduce in H. pylori-infected gastric cells, and 
coincide with a partially cagPAI-dependent decrease in the expression and activity of 
deubiqutinating enzyme USP7, which indicates that H. pylori may also influence some 
immunity-associated cytokines through interfering in the host ubiquitin pathways (Coombs 
et al., 2010).  
During H. pylori infection, significant overexpression of MHC II antigen-presenting genes, 
IL-7R ubiquitin-D, CXCR4, lactoferrin immune response-related genes, CXCL-2 and -13, 
CCL18 chemokine ligand, and VCAM-1 genes have been established (Galamb et al., 2008). 
In addition, IL-23p19 up-regulation is confirmed in gastric biopsies from both H. pylori 
infected-mice and patients with chronic gastritis (Vivas et al., 2008). CCR6 is markedly 
upregulated in CD3 (+) T cells infiltrating the gastric mucosa and has been reported to 
mediate lymphocyte homeostasis and immune responses in mucosal tissue (Wu et al., 2007; 
Tsai & Hsu, 2010). CCL20, the ligand to CCR6, selectively expresses in inflamed stomach 
tissues and is upregulated in response to H. pylori in GECs stimulated by IL-1β and TNF-α. 
Furthermore, recombinant CCL20 induces lymphocyte chemotaxis migration in fresh gastric 
T cells in vitro (Wu et al., 2007). The interaction between CCR6 and CCL20 plays a potential 
role in recruiting T cells to inflamed gastric epithelium during H. pylori infection (Tsai & 
Hsu, 2010). 
4.4 Autoimmune and immune tolerance 
H. pylori has evolved means to structurally alter its surface characteristics to evade innate 
and adaptive immune responses (Nilsson et al., 2006). H. pylori expresses mimicry of some 
ABO blood group antigens (Moran et al., 2010). Additionally, CagA, VacA and BabA can 
mimic and bind to specific receptors or surface molecules on GECs and platelets (Höcker & 
Hohenberġer 2003; Takahashi et al., 2004; Hennig et al., 2004; Baldari et al., 2005). It has been 
shown that anti-CagA, anti-VacA and anti-BabA antibodies targeting both H. pylori 
components and host mimic molecules can be detected in the majority of GC patients with 
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increased levels (Rudi et al., 1997; Vaucher et al., 2000; Sokic-Milutinovic et al., 2004). H. 
pylori LPS is of underacylation and underphosphorylation and has significantly lower 
endotoxic and immuno-activities, which may lead to the infection chronicity (Moran et al., 
2010). H. pylori produces LPS O-antigen units that can be posttranslationally fucosylated to 
generate Lewis antigens, which are also found on human GECs, and this molecular mimicry 
induces autoreactive antibodies (Nilsson et al., 2006). Circulating anti-Lewis antibody is 
detected in the sera of GC patients but not in H. pylori-negative control subjects (Hynes et al., 
2005). Absorption of the sera with outer membrane vesicles decreases anti-Lewis 
autoantibody level. The ability of these vesicles to absorb anti-Lewis autoantibody indicates 
that they partly play a role in putative autoimmune aspects of H. pylori pathogenesis (Hynes 
et al., 2005). 
As reported, C57BL/6 mice infected with CagA (+) H. pylori during the neonatal period tend 
to be protected from preneoplastic lesions, compared to those infected with the same strain 
at 5-6 weeks of age (Arnold et al., 2011). This protection results from the development of H. 
pylori-specific peripheral immunologic tolerance, which is mediated by long-lived inducible 
Treg and controls the local CD4 (+) T-cell responses that trigger premalignant 
transformation. Moreover, both the biased ratio of Treg to T-effector cells in the neonatal 
period and prolonged low-dose exposure to antigens contribute to the development of 
immune tolerance to H. pylori (Arnold et al., 2011). In addition, exposure of cells to most 
microbial pathogens can up-regulate HSPs, whereas H. pylori decreases expression of HSPs 
including HSP8, HSP70, HSP60, and heat shock factor 1 (HSF-1). The down-regulation of 
HSPs may be a mechanism of immune evasion that promotes chronic H. pylori infection 
(Axsen et al., 2009). NO / iNOS as one part of the host innate defense system, determines 
the killing efficiency of H. pylori by macrophages. H. pylori up-regulates arginase II (Arg2) 
expression, resulting in reduction of NO / iNOS production and decreased killing of the 
germ by macrophages, which implicates another potential mechanism of the immune 
evasion of H. pylori (Lewis et al., 2010). 
5. Genetic and phenotypic alterations 
Some polymorphisms of certain genes including IL-1, IL-4, IL-6, IL-8, IL-10, TNF, iNOS and 
COX-2, which likely differ in various host species, play important roles in the inflammation, 
immune responses, and gastric carcinogenesis, besides in susceptibility to H. pylori infection. 
The GC risk-associated alleles are more prevalent in certain subjects of special human races, 
geographic regions, and H. pylori infection status. Thus, genetic and phenotypic 
backgrounds of H. pylori may interact with mentioned host factors and influence the related 
biological or pathological processes. 
5.1 IL-1 
IL-1β and IL-1RN polymorphisms relate to the development of GC and H. pylori infection 
markedly increases the risk, which supports the association of these polymorphisms with 
risk of Hp-GC (Al-Moundhri et al., 2006). Either infection with vacA s1 (+), vacA m1 (+) and 
cagA (+) strains or the host genotype of IL-1β -511T homozygous for IL-1RN2/2 allele is 
associated with an increased GC risk (Figueiredo et al., 2002). Individuals with 
polymorphisms in IL-1 and TNF-α genes have the highest risk of GC, when they are 
simultaneously infected by virulent H. pylori strains of cagA (+), vacA s1 (+), vacA m1 (+) 
and babA2 (+). As for IL-1 gene, the odds of developing GC are greatest in those with 
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frequency of activated CD8 (+) T cells is markedly reduced in stomach mucosa of GC 
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mimic and bind to specific receptors or surface molecules on GECs and platelets (Höcker & 
Hohenberġer 2003; Takahashi et al., 2004; Hennig et al., 2004; Baldari et al., 2005). It has been 
shown that anti-CagA, anti-VacA and anti-BabA antibodies targeting both H. pylori 
components and host mimic molecules can be detected in the majority of GC patients with 
 
A Double-Edged Sword: Roles of Helicobacter Pylori in Gastric Carcinoma 
 
273 
increased levels (Rudi et al., 1997; Vaucher et al., 2000; Sokic-Milutinovic et al., 2004). H. 
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Some polymorphisms of certain genes including IL-1, IL-4, IL-6, IL-8, IL-10, TNF, iNOS and 
COX-2, which likely differ in various host species, play important roles in the inflammation, 
immune responses, and gastric carcinogenesis, besides in susceptibility to H. pylori infection. 
The GC risk-associated alleles are more prevalent in certain subjects of special human races, 
geographic regions, and H. pylori infection status. Thus, genetic and phenotypic 
backgrounds of H. pylori may interact with mentioned host factors and influence the related 
biological or pathological processes. 
5.1 IL-1 
IL-1β and IL-1RN polymorphisms relate to the development of GC and H. pylori infection 
markedly increases the risk, which supports the association of these polymorphisms with 
risk of Hp-GC (Al-Moundhri et al., 2006). Either infection with vacA s1 (+), vacA m1 (+) and 
cagA (+) strains or the host genotype of IL-1β -511T homozygous for IL-1RN2/2 allele is 
associated with an increased GC risk (Figueiredo et al., 2002). Individuals with 
polymorphisms in IL-1 and TNF-α genes have the highest risk of GC, when they are 
simultaneously infected by virulent H. pylori strains of cagA (+), vacA s1 (+), vacA m1 (+) 
and babA2 (+). As for IL-1 gene, the odds of developing GC are greatest in those with 
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combination of high-risk bacterial / host genotypes such as vacA s1 / IL-1β -511T, vacA m1 
/ IL-1β -511T, cagA (+) / IL-1β -511T, vacA s1 / IL-1RN2/2, vacA m1 / IL-1RN2/2, and 
cagA (+) / IL-1RN2/2 (Figueiredo et al., 2002).  
IL-1β -511T/-31C (+) and IL-1RN2 (+) polymorphisms are associated with severe degrees of 
inflammation, prevalence of IM and AG, and increased expression of IL-1β, which plays a 
central role in GC development (Rad et al., 2004). The combined prevalence of H. pylori 
infection and IL-1β -511T genotype has a strong association with GC risk in both Latino and 
Chinese populations (Morgan et al., 2006; Feng et al., 2008). The IL-1β -511T/T carrier status 
enhances hypermethylation of multiple CpG island loci and increases the risk for Hp-GC of 
non-cardiac type as an independent risk factor in a Chinese population (Li et al., 2007; Yoo 
et al., 2010). IL-1β -511C allele is related with increased risk of AG and GC in Peru (Gehmert 
et al., 2009). IL-1β -511C/C polymorphism enhances IL-1β production in the antrum, and 
involves in the development of nHp-GC in North Indian (Kumar et al., 2009). In a Korean 
population, combined effects of H. pylori infection and IL-1β -511C/-31T polymorphisms 
with enhanced mucosal IL-1β production contribute to the development of intestinal-type 
GC (Chang et al., 2005). IL-1β -511CC/-31TT variants also increase GC risk in a Chinese 
population, especially of those with H. pylori infection (Yang et al., 2004). Nevertheless, IL-
1β -511/-31 alleles are not associated with GC risk in Japan and IL-1β -511T-to-C genotype is 
not associated with GC in a multistep carcinogenesis model (Kato et al., 2001; Sugimoto et 
al., 2007). In addition, none of the variants of IL-1β -511C>T, -31T>C, -1464G>C and -
3737C>T, is individually or in its haplotype configuration linked to GC in a Caucasian 
population (Wex et al., 2010).  
IL-1β -31C/+3954T haplotypes are more likely detected with IM or dysplasia of the stomach 
and relate to GC risk in African Americans, but not in Caucasians, Swedes and Italians (Palli 
et al., 2005; Camargo et al., 2006; Persson et al., 2009; Zabaleta et al., 2011). In Mexico, IL-1β -
31C allele increases high-grade dysplasia and is an independent risk factor for GC (Garza-
González et al., 2003). The IL-1β -31CC carriers have an increased risk of intestinal-type GC 
among CagA-positive subjects, compared to those with IL-1β -31TT. Among CagA-negative 
subjects, however, there is no mentioned association (Sicinschi et al., 2006). IL-1β 1473C>G is 
significantly associated with GC among Koreans (Lee et al., 2004). In Japan, IL-1β +3953 
polymorphism can influence the cancer risk of gastric corpus (Sakuma et al., 2005). Carriers 
of IL-1β +3954T or IL-1RN2 heterozygote allele cause increased GC risk in a Costa Rican 
population, although IL-1β -31, IL-1β -511 and IL-10 polymorphisms do not (Alpízar-
Alpízar et al., 2005).  
IL-1RN1/2 genotype is significantly and independently associated with GC (Erzin et al., 2008). 
IL-1RN2 allele relates to GC especially in H. pylori-positive patients of an Omani Arab 
population (Al-Moundhri et al., 2006). In Italy, multivariate analyses have shown a notable 
increase in GC risk for the IL-1RN2 / IL-1β -31T haplotype carriers (Palli et al., 2005). H. pylori-
infected individuals with carriers of IL-1RN2 show high risks for both intestinal and diffuse 
types of GC in Asia (Chen et al., 2004). IL-1RN2 and IL-1β -511T may contribute to intestinal 
GC in the absence of concomitant H. pylori infection (Ruzzo et al., 2005). IL-1RN2/2 and IL-1β -
31C genotypes relate to higher GC risk in Caucasians (Garza-González et al., 2003). The IL-
1RN2/2 genotype is strongly associated with early-stage GC, and involves in the development 
of nHp-GC in North Indian (Glas et al., 2004; Kumar et al., 2009). IL-1RN 2R/2R and Ex5-35C 
genotypes are related to an increased risk of Hp-GC of non-cardia type (Crusius et al., 2008). 
However, IL-1β -511, IL-1RN and IL-2 polymorphisms do not significantly contribute to GC in 
Korean patients (Shin et al., 2008). In Mexico, IL-1RN2/2 is also not associated with either 
high-grade dysplasia or risk of GC (Garza-González et al., 2003). 
 




As for subtypes of GC in Taiwanese Chinese, the high IL-10 producer genotype is 
significantly linked with the risk of cardia type or advanced stage (Wu et al., 2003). The 
ATA/GCC haplotype of IL-10 -1082/-819/-592 significantly increases GC risk compared 
with ATA/ATA haplotype (Sugimoto et al., 2007). The -1082G/-819C/-592C alleles (GCC 
haplotype) usually lead to higher mucosal IL-10 mRNA level than ATA haplotype and are 
associated with colonization by more virulent H. pylori strains of cagA (+), vacA s1 (+), and 
babA2 (+) (Rad et al., 2004). IL-10 -1082 AG+GG but not -819 or -592 polymorphisms, 
markedly increase GC risk in China, especially in patients with H. pylori infection (Xiao et 
al., 2009). In a low prevalence province of China, the -1082G* allele is related with 
significantly increased risk of Hp-GC, whereas the higher susceptibility to GC in -1082 
AG+GG genotype does not show a synergism with H. pylori status in another population of 
northern China (Bai et al., 2008). In Korean, the frequency of -1082G carriers is higher in 
diffuse-type GC or benign gastric ulcer (BGU), regardless of H. pylori infection (Kang et al., 
2009). Moreover, IL-10 -819CC and IL-1RN 9589TT genotypes are of inverse association with 
H. pylori seropositivity among cases with chronic AG, an established precursor of GC (Gao 
et al., 2009). The IL-10 819C allele is related with IM in H. pylori-positive subjects of a 
Singapore-Chinese population (Zhu et al., 2009).  
In H. pylori-infected Japanese, the frequency of -592AA homozygote showing concomitant 
carriage of HLA DRB1*0405-DQB1*0401 is notably higher in intestinal-type GC. In addition, 
the HLA class II and -592A/C polymorphism synergistically affect the susceptibility to GC 
(Ando et al., 2009). IL-10 -592C/A, IL-1β +3954T/C and IL-1RN*2/L are individually 
associated with GC in Costa Rican regions, and a combination of these cytokine 
polymorphisms with H. pylori vacA s1b / m1 genotypes further increased the risk (Con et 
al., 2009). IL-10 -592/-1082 alleles are not linked with high-grade dysplasia or GC risk in a 
Mexican population, though relate to high GC risk in Caucasians; whereas carriers with two 
or more risk-associated alleles of IL-10 -592C, IL-1β -31C and IL-1RN2 are at increased risk 
for intestinal-type GC in Mexico, compared to those with 0 or 1 mentioned allele (Garza-
González et al., 2003). In Korean, the presence of IL10 -592C/A as opposed to A/A is one of 
risk factors for IM. The -592CC is associated with more than doubling of the risk for 
intestinal-type GC. Furthermore, a synergistic effect has been observed between IL-10 -
592A/A and IL-8 -251A/A with respect to the development of GC or BGU (Kang et al., 
2009). IL-10 -819C and -592C alleles are associated with increased GC risk in Japan, but -1082 
polymorphism not (Sugimoto et al., 2007). The -819TT genotype relates to IM and non-
cardia GC in an Italian population (Zambon et al., 2005). 
Data from Korea have even suggested that the association between IL-10 genetic 
polymorphisms and GC risk is modified by soybean product intake (Ko et al., 2009). The 
combined effect between low intake of soybean products and -1082AG/GG, -819TC/CC or -
592GG/GA variants will increase the risk for GC. As for subgroups, the CCG haplotype has 
an increased risk of GC relative to ATA haplotype among subjects with low intake of 
soybean products (Ko et al., 2009). 
5.3 IL-4, IL-6 and IL-8 
There is a moderately increased risk for Hp-GC of non-cardia type in IL-4R -29429T variant 
(Crusius JB et al., 2008). In Taiwanese Chinese, a higher risk of developing cardia or diffuse-
type GC is observed for the carrier of IL-4 -590CT/CC genotype (Wu et al., 2003). IL-4 -168C 
and -590T alleles and IL-6 -174G/G haplotype significantly relate to the risk of non-cardia 
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combination of high-risk bacterial / host genotypes such as vacA s1 / IL-1β -511T, vacA m1 
/ IL-1β -511T, cagA (+) / IL-1β -511T, vacA s1 / IL-1RN2/2, vacA m1 / IL-1RN2/2, and 
cagA (+) / IL-1RN2/2 (Figueiredo et al., 2002).  
IL-1β -511T/-31C (+) and IL-1RN2 (+) polymorphisms are associated with severe degrees of 
inflammation, prevalence of IM and AG, and increased expression of IL-1β, which plays a 
central role in GC development (Rad et al., 2004). The combined prevalence of H. pylori 
infection and IL-1β -511T genotype has a strong association with GC risk in both Latino and 
Chinese populations (Morgan et al., 2006; Feng et al., 2008). The IL-1β -511T/T carrier status 
enhances hypermethylation of multiple CpG island loci and increases the risk for Hp-GC of 
non-cardiac type as an independent risk factor in a Chinese population (Li et al., 2007; Yoo 
et al., 2010). IL-1β -511C allele is related with increased risk of AG and GC in Peru (Gehmert 
et al., 2009). IL-1β -511C/C polymorphism enhances IL-1β production in the antrum, and 
involves in the development of nHp-GC in North Indian (Kumar et al., 2009). In a Korean 
population, combined effects of H. pylori infection and IL-1β -511C/-31T polymorphisms 
with enhanced mucosal IL-1β production contribute to the development of intestinal-type 
GC (Chang et al., 2005). IL-1β -511CC/-31TT variants also increase GC risk in a Chinese 
population, especially of those with H. pylori infection (Yang et al., 2004). Nevertheless, IL-
1β -511/-31 alleles are not associated with GC risk in Japan and IL-1β -511T-to-C genotype is 
not associated with GC in a multistep carcinogenesis model (Kato et al., 2001; Sugimoto et 
al., 2007). In addition, none of the variants of IL-1β -511C>T, -31T>C, -1464G>C and -
3737C>T, is individually or in its haplotype configuration linked to GC in a Caucasian 
population (Wex et al., 2010).  
IL-1β -31C/+3954T haplotypes are more likely detected with IM or dysplasia of the stomach 
and relate to GC risk in African Americans, but not in Caucasians, Swedes and Italians (Palli 
et al., 2005; Camargo et al., 2006; Persson et al., 2009; Zabaleta et al., 2011). In Mexico, IL-1β -
31C allele increases high-grade dysplasia and is an independent risk factor for GC (Garza-
González et al., 2003). The IL-1β -31CC carriers have an increased risk of intestinal-type GC 
among CagA-positive subjects, compared to those with IL-1β -31TT. Among CagA-negative 
subjects, however, there is no mentioned association (Sicinschi et al., 2006). IL-1β 1473C>G is 
significantly associated with GC among Koreans (Lee et al., 2004). In Japan, IL-1β +3953 
polymorphism can influence the cancer risk of gastric corpus (Sakuma et al., 2005). Carriers 
of IL-1β +3954T or IL-1RN2 heterozygote allele cause increased GC risk in a Costa Rican 
population, although IL-1β -31, IL-1β -511 and IL-10 polymorphisms do not (Alpízar-
Alpízar et al., 2005).  
IL-1RN1/2 genotype is significantly and independently associated with GC (Erzin et al., 2008). 
IL-1RN2 allele relates to GC especially in H. pylori-positive patients of an Omani Arab 
population (Al-Moundhri et al., 2006). In Italy, multivariate analyses have shown a notable 
increase in GC risk for the IL-1RN2 / IL-1β -31T haplotype carriers (Palli et al., 2005). H. pylori-
infected individuals with carriers of IL-1RN2 show high risks for both intestinal and diffuse 
types of GC in Asia (Chen et al., 2004). IL-1RN2 and IL-1β -511T may contribute to intestinal 
GC in the absence of concomitant H. pylori infection (Ruzzo et al., 2005). IL-1RN2/2 and IL-1β -
31C genotypes relate to higher GC risk in Caucasians (Garza-González et al., 2003). The IL-
1RN2/2 genotype is strongly associated with early-stage GC, and involves in the development 
of nHp-GC in North Indian (Glas et al., 2004; Kumar et al., 2009). IL-1RN 2R/2R and Ex5-35C 
genotypes are related to an increased risk of Hp-GC of non-cardia type (Crusius et al., 2008). 
However, IL-1β -511, IL-1RN and IL-2 polymorphisms do not significantly contribute to GC in 
Korean patients (Shin et al., 2008). In Mexico, IL-1RN2/2 is also not associated with either 
high-grade dysplasia or risk of GC (Garza-González et al., 2003). 
 




As for subtypes of GC in Taiwanese Chinese, the high IL-10 producer genotype is 
significantly linked with the risk of cardia type or advanced stage (Wu et al., 2003). The 
ATA/GCC haplotype of IL-10 -1082/-819/-592 significantly increases GC risk compared 
with ATA/ATA haplotype (Sugimoto et al., 2007). The -1082G/-819C/-592C alleles (GCC 
haplotype) usually lead to higher mucosal IL-10 mRNA level than ATA haplotype and are 
associated with colonization by more virulent H. pylori strains of cagA (+), vacA s1 (+), and 
babA2 (+) (Rad et al., 2004). IL-10 -1082 AG+GG but not -819 or -592 polymorphisms, 
markedly increase GC risk in China, especially in patients with H. pylori infection (Xiao et 
al., 2009). In a low prevalence province of China, the -1082G* allele is related with 
significantly increased risk of Hp-GC, whereas the higher susceptibility to GC in -1082 
AG+GG genotype does not show a synergism with H. pylori status in another population of 
northern China (Bai et al., 2008). In Korean, the frequency of -1082G carriers is higher in 
diffuse-type GC or benign gastric ulcer (BGU), regardless of H. pylori infection (Kang et al., 
2009). Moreover, IL-10 -819CC and IL-1RN 9589TT genotypes are of inverse association with 
H. pylori seropositivity among cases with chronic AG, an established precursor of GC (Gao 
et al., 2009). The IL-10 819C allele is related with IM in H. pylori-positive subjects of a 
Singapore-Chinese population (Zhu et al., 2009).  
In H. pylori-infected Japanese, the frequency of -592AA homozygote showing concomitant 
carriage of HLA DRB1*0405-DQB1*0401 is notably higher in intestinal-type GC. In addition, 
the HLA class II and -592A/C polymorphism synergistically affect the susceptibility to GC 
(Ando et al., 2009). IL-10 -592C/A, IL-1β +3954T/C and IL-1RN*2/L are individually 
associated with GC in Costa Rican regions, and a combination of these cytokine 
polymorphisms with H. pylori vacA s1b / m1 genotypes further increased the risk (Con et 
al., 2009). IL-10 -592/-1082 alleles are not linked with high-grade dysplasia or GC risk in a 
Mexican population, though relate to high GC risk in Caucasians; whereas carriers with two 
or more risk-associated alleles of IL-10 -592C, IL-1β -31C and IL-1RN2 are at increased risk 
for intestinal-type GC in Mexico, compared to those with 0 or 1 mentioned allele (Garza-
González et al., 2003). In Korean, the presence of IL10 -592C/A as opposed to A/A is one of 
risk factors for IM. The -592CC is associated with more than doubling of the risk for 
intestinal-type GC. Furthermore, a synergistic effect has been observed between IL-10 -
592A/A and IL-8 -251A/A with respect to the development of GC or BGU (Kang et al., 
2009). IL-10 -819C and -592C alleles are associated with increased GC risk in Japan, but -1082 
polymorphism not (Sugimoto et al., 2007). The -819TT genotype relates to IM and non-
cardia GC in an Italian population (Zambon et al., 2005). 
Data from Korea have even suggested that the association between IL-10 genetic 
polymorphisms and GC risk is modified by soybean product intake (Ko et al., 2009). The 
combined effect between low intake of soybean products and -1082AG/GG, -819TC/CC or -
592GG/GA variants will increase the risk for GC. As for subgroups, the CCG haplotype has 
an increased risk of GC relative to ATA haplotype among subjects with low intake of 
soybean products (Ko et al., 2009). 
5.3 IL-4, IL-6 and IL-8 
There is a moderately increased risk for Hp-GC of non-cardia type in IL-4R -29429T variant 
(Crusius JB et al., 2008). In Taiwanese Chinese, a higher risk of developing cardia or diffuse-
type GC is observed for the carrier of IL-4 -590CT/CC genotype (Wu et al., 2003). IL-4 -168C 
and -590T alleles and IL-6 -174G/G haplotype significantly relate to the risk of non-cardia 
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GC (Sugimoto et al., 2010). The IL-6 -174G allele is markedly higher in patients with GC than 
those with chronic gastritis (Gatti et al., 2007).  
IL-8 -251A allele significantly increases the risk of gastric dysplasia in Venezuelan subjects, 
especially of those infected with CagA (+) H. pylori, which suggests a role of interactions 
between host and bacterial genetic factors in the development of precancerous lesions (Kato 
et al., 2006). Similarly in a Mexican population, the -251A genotype has a significant effect 
on the prevalence of dysplasia and may be related to distal GC, especially when H. pylori 
CagA is present (Garza-Gonzalez et al., 2007). IL-8 -251A/T allele and polymorphisms in 
vacA gene are involved in limiting the infection outcome to gastritis and peptic ulcer or in 
favoring cancer onset in Iranian patients (Kamali-Sarvestani et al., 2006). The -251T>A 
polymorphism is usually associated with higher IL-8 expression, severe neutrophil 
infiltration and increased risk of AG and GC in Japan, but not with GC risk in a Portuguese 
population (Taguchi et al., 2005; Canedo et al., 2008). The IL-8 -251A polymorphism may be 
associated with progression of AG in H. pylori-infected patients, and increase the risks for 
GC and gastric ulcer in Japanese people (Ohyauchi et al., 2005). The -251A/A genotype, 
which is more common in H. pylori-positive patients with GC or BGU than in H. pylori-
positive controls, increases the risk for upper-third location, diffuse, poorly differentiated, 
lymph node and liver metastasis, and p53-mutated subtypes of GC (Taguchi et al., 2005; 
Kang et al., 2009). The high-risk IL-8 -251T allele is related with >2-fold increased risk for 
GC of diffused and mixed types (Lee et al., 2005). In addition, the -251T/T genotype 
significantly relates to increased risk of GC with high frequency of microsatellite instability 
(Shirai et al., 2006).  
5.4 TNF 
Polymorphisms of TNF-α -857TT and -1031TT, besides CD14, CXC chemokine receptor 2 
(CXCR2), IL-1 RI, NF-κB2, and TLR-4, have the potential to influence persistent H. pylori 
infection (Hamajima et al., 2003). TNF-α -857T/-863A/-1031C alleles are associated with 
increased risks for gastric ulcer and GC in Japan (Sugimoto et al., 2007). In a Korean 
population, the -857C/T variant is independently and significantly related to an increased 
risk of GC regardless of smoking status. However, all haplotype-pairs including TCT or 
CCC of -863C/A and -1031T/C are linked with a higher GC risk only among smokers (Yang 
et al., 2009). TNF-α -308 genotypes correlate to higher risk of GC in Caucasians, but not to 
high-grade dysplasia or increased risk of GC in Mexican population (Garza-González et al., 
2003). The -308A allele increases the risk for GC development but is only weakly associated 
with the early-stage diffuse-type GC (Glas et al., 2004). The -308G/A haplotype relates to an 
increased IL-8 expression and the susceptibility to GC in several studies. In Poland, GC risk 
is dramatically relevant to the TNF-α -308G>A and IFN-γ R2 Ex7-128C>T polymorphisms, 
but not to IL-1α -889C>T and IL-12α IVS2-798T>A, IVS2-701C>A and Ex7+277G>A variants 
(Hou et al., 2007). Risk of GC is also markedly elevated in Chinese subjects carrying the 
TNF-α -308 AG genotype (Lu et al., 2005). In addition, polymorphisms in TNF-β (*A and 
+252G/G) and HSP70-1 (*C and +190C/G) show a significant gene-dose effect as risk 
markers from preneoplastic lesions to GC in Mexican (Partida-Rodríguez et al., 2010). 
5.5 Other cytokine genes 
NOS2 -954G/C (especially -954GC+CC) polymorphism but not Ser608Leu is associated with 
higher risk of GC in a Brazilian population (Jorge et al., 2010). The iNOS C150T is related 
with the risk of Hp-GC, but not with gastric atrophy or H. pylori seropositivity in a Japanese 
population. Considering the location of GC, there are significant differences between the 
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controls and non-cardia group for iNOS -150C/T and C/T + T/T (Goto et al., 2006). The 
iNOS promoter polymorphism of long CCTTT repeat notably upregulates its mRNA level 
and leads to increased risk of intestinal-type GC in Japanese women, especially of those with 
IL-1β -31 polymorphism and without smoking history (Tatemichi et al., 2005). 
In the high incidence Hexi area of Gansu Province in China, COX-2 -899G>C polymorphism 
may be a risk factor for GC, and the -899C carrier genotype and H. pylori infection possibly 
have a synergistic effect on GC. However, COX-2 587G>A is not related with GC risk (Zhu 
et al., 2011). COX-2 -1195AA polymorphism also plays an important role in developing GC 
in another high-risk Chinese population (Zhang et al., 2006). COX-2 -765G>C polymorphism 
might be a marker for genetic susceptibility to GC in northern India, regardless of H. pylori 
infection (Saxena et al., 2008). Moreover, the lymphotoxin-α NcoI A/G heterozygous 
genotype correlates to H. pylori infection in noncardia GC patients of Chinese Han 
population (Li et al., 2005). And in Cauca population, the glutathione S-transferase M1 
homozygous deletion polymorphism is related to increased GC risk (Torres et al., 2004). 
6. Beneficial edge of the sword 
In recent years, increasing data have indicated that patients with Hp-GC prospectively have 
a better outlook than those with nHp-GC (Meimarakis et al., 2006; Marrelli et al., 2009). H. 
pylori infection must play certain roles as the other edge of the sword, which is beneficial for 
the host and counteracts its harmfulness in pathological lesions including gastritis, GC, and 
lymphoma. However, up to date, the corresponding studies and results are still limited 
because of multiple influencing factors including traditional unilateral opinions. 
The positive interaction between H. pylori and the host should be the radical factor in 
leading to changes of local and system immune responses. There is a high H. pylori 
prevalence but a low GC risk in H. pylori-infected than in uninfected Mexican children, 
which may be attributed to significantly higher infiltration of macrophages and T and B 
cells, a balanced increase of CD4, CD8, and CD20 lymphocytes, but decreased levels of 
activated mast cells, neutrophil and mononuclear cells (Muñoz et al., 2007). During H. pylori 
infection, both the number of local CD4 (+) T cells and MHC II expression by the GECs 
increase, and GECs can process and present antigens to CD4 (+) T cells as a new kind of 
local antigen presenting cells (APC) (Barrera et al., 2002). Therefore, H. pylori infection in the 
host may alter natural immune mechanisms against cancer.  
The humeral immune response induced by H. pylori is predominately IgG1 subclass 
(suggestive of a Th2 response) and likely protects against the development of GC, although 
it is not essential for bacterial eradication (Segal et al., 2001). As reported, the antibody level 
of anti- Thomsen-Friedenreich antigen (TAg) in GC patients is significantly lower than that 
in normal blood donors (Klaamas et al., 2002). However, TAg-specific IgG immune response 
is up-regulated exclusively in H. pylori-infected individuals, which may contribute to the 
significantly better survival of Hp-GC patients at early stage than that of nHp-GC ones at 
the same stage. Better survival is also noted in H. pylori seropositive IgM strong responders 
at approximately 40-60 months of observation, though the anti-T IgM level is not 
significantly related to the survival (Kurtenkov et al., 2003). In addition, the stimulation of 
H. pylori-related autoantibodies in antigen processing and presentation and subsequent T-
cell activation and proliferation improves host immune status. On the other hand, in an 
autoimmune response, autoantibodies can induce the cross-reaction against those localized 
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GC (Sugimoto et al., 2010). The IL-6 -174G allele is markedly higher in patients with GC than 
those with chronic gastritis (Gatti et al., 2007).  
IL-8 -251A allele significantly increases the risk of gastric dysplasia in Venezuelan subjects, 
especially of those infected with CagA (+) H. pylori, which suggests a role of interactions 
between host and bacterial genetic factors in the development of precancerous lesions (Kato 
et al., 2006). Similarly in a Mexican population, the -251A genotype has a significant effect 
on the prevalence of dysplasia and may be related to distal GC, especially when H. pylori 
CagA is present (Garza-Gonzalez et al., 2007). IL-8 -251A/T allele and polymorphisms in 
vacA gene are involved in limiting the infection outcome to gastritis and peptic ulcer or in 
favoring cancer onset in Iranian patients (Kamali-Sarvestani et al., 2006). The -251T>A 
polymorphism is usually associated with higher IL-8 expression, severe neutrophil 
infiltration and increased risk of AG and GC in Japan, but not with GC risk in a Portuguese 
population (Taguchi et al., 2005; Canedo et al., 2008). The IL-8 -251A polymorphism may be 
associated with progression of AG in H. pylori-infected patients, and increase the risks for 
GC and gastric ulcer in Japanese people (Ohyauchi et al., 2005). The -251A/A genotype, 
which is more common in H. pylori-positive patients with GC or BGU than in H. pylori-
positive controls, increases the risk for upper-third location, diffuse, poorly differentiated, 
lymph node and liver metastasis, and p53-mutated subtypes of GC (Taguchi et al., 2005; 
Kang et al., 2009). The high-risk IL-8 -251T allele is related with >2-fold increased risk for 
GC of diffused and mixed types (Lee et al., 2005). In addition, the -251T/T genotype 
significantly relates to increased risk of GC with high frequency of microsatellite instability 
(Shirai et al., 2006).  
5.4 TNF 
Polymorphisms of TNF-α -857TT and -1031TT, besides CD14, CXC chemokine receptor 2 
(CXCR2), IL-1 RI, NF-κB2, and TLR-4, have the potential to influence persistent H. pylori 
infection (Hamajima et al., 2003). TNF-α -857T/-863A/-1031C alleles are associated with 
increased risks for gastric ulcer and GC in Japan (Sugimoto et al., 2007). In a Korean 
population, the -857C/T variant is independently and significantly related to an increased 
risk of GC regardless of smoking status. However, all haplotype-pairs including TCT or 
CCC of -863C/A and -1031T/C are linked with a higher GC risk only among smokers (Yang 
et al., 2009). TNF-α -308 genotypes correlate to higher risk of GC in Caucasians, but not to 
high-grade dysplasia or increased risk of GC in Mexican population (Garza-González et al., 
2003). The -308A allele increases the risk for GC development but is only weakly associated 
with the early-stage diffuse-type GC (Glas et al., 2004). The -308G/A haplotype relates to an 
increased IL-8 expression and the susceptibility to GC in several studies. In Poland, GC risk 
is dramatically relevant to the TNF-α -308G>A and IFN-γ R2 Ex7-128C>T polymorphisms, 
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NOS2 -954G/C (especially -954GC+CC) polymorphism but not Ser608Leu is associated with 
higher risk of GC in a Brazilian population (Jorge et al., 2010). The iNOS C150T is related 
with the risk of Hp-GC, but not with gastric atrophy or H. pylori seropositivity in a Japanese 
population. Considering the location of GC, there are significant differences between the 
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controls and non-cardia group for iNOS -150C/T and C/T + T/T (Goto et al., 2006). The 
iNOS promoter polymorphism of long CCTTT repeat notably upregulates its mRNA level 
and leads to increased risk of intestinal-type GC in Japanese women, especially of those with 
IL-1β -31 polymorphism and without smoking history (Tatemichi et al., 2005). 
In the high incidence Hexi area of Gansu Province in China, COX-2 -899G>C polymorphism 
may be a risk factor for GC, and the -899C carrier genotype and H. pylori infection possibly 
have a synergistic effect on GC. However, COX-2 587G>A is not related with GC risk (Zhu 
et al., 2011). COX-2 -1195AA polymorphism also plays an important role in developing GC 
in another high-risk Chinese population (Zhang et al., 2006). COX-2 -765G>C polymorphism 
might be a marker for genetic susceptibility to GC in northern India, regardless of H. pylori 
infection (Saxena et al., 2008). Moreover, the lymphotoxin-α NcoI A/G heterozygous 
genotype correlates to H. pylori infection in noncardia GC patients of Chinese Han 
population (Li et al., 2005). And in Cauca population, the glutathione S-transferase M1 
homozygous deletion polymorphism is related to increased GC risk (Torres et al., 2004). 
6. Beneficial edge of the sword 
In recent years, increasing data have indicated that patients with Hp-GC prospectively have 
a better outlook than those with nHp-GC (Meimarakis et al., 2006; Marrelli et al., 2009). H. 
pylori infection must play certain roles as the other edge of the sword, which is beneficial for 
the host and counteracts its harmfulness in pathological lesions including gastritis, GC, and 
lymphoma. However, up to date, the corresponding studies and results are still limited 
because of multiple influencing factors including traditional unilateral opinions. 
The positive interaction between H. pylori and the host should be the radical factor in 
leading to changes of local and system immune responses. There is a high H. pylori 
prevalence but a low GC risk in H. pylori-infected than in uninfected Mexican children, 
which may be attributed to significantly higher infiltration of macrophages and T and B 
cells, a balanced increase of CD4, CD8, and CD20 lymphocytes, but decreased levels of 
activated mast cells, neutrophil and mononuclear cells (Muñoz et al., 2007). During H. pylori 
infection, both the number of local CD4 (+) T cells and MHC II expression by the GECs 
increase, and GECs can process and present antigens to CD4 (+) T cells as a new kind of 
local antigen presenting cells (APC) (Barrera et al., 2002). Therefore, H. pylori infection in the 
host may alter natural immune mechanisms against cancer.  
The humeral immune response induced by H. pylori is predominately IgG1 subclass 
(suggestive of a Th2 response) and likely protects against the development of GC, although 
it is not essential for bacterial eradication (Segal et al., 2001). As reported, the antibody level 
of anti- Thomsen-Friedenreich antigen (TAg) in GC patients is significantly lower than that 
in normal blood donors (Klaamas et al., 2002). However, TAg-specific IgG immune response 
is up-regulated exclusively in H. pylori-infected individuals, which may contribute to the 
significantly better survival of Hp-GC patients at early stage than that of nHp-GC ones at 
the same stage. Better survival is also noted in H. pylori seropositive IgM strong responders 
at approximately 40-60 months of observation, though the anti-T IgM level is not 
significantly related to the survival (Kurtenkov et al., 2003). In addition, the stimulation of 
H. pylori-related autoantibodies in antigen processing and presentation and subsequent T-
cell activation and proliferation improves host immune status. On the other hand, in an 
autoimmune response, autoantibodies can induce the cross-reaction against those localized 
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or circulating GC cells, which are characterized by mimic or absorbed H. pylori antigens, and 
lead to the killing and even suppressing of metastasis of cancer cells (Xue et al., 2008). Thus, 
it is hypothesized that autoimmune responses induced by H. pylori components may help 
improve the prognosis of GC patients. 
Several models, including delayed type hypersensitivity in immune mice, and spontaneous 
clearance of H. pylori from IL-10 and phagocyte oxidase mice, provide evidence that severe 
inflammation may be sufficient to eradicate the germ (Blanchard et al., 2004). H. pylori LPS 
can dramatically initiate inflammatory responses and cause severe pathological changes not 
only in vitro but also in vivo. However, increased levels of TNF-α and IL-10, as well as a 
strong antigen specific Th1 response including, IFN-γ, IL-2 and high IgG2a serum titers are 
simultaneously observed in mice inoculated with H. pylori LPS+ sonicate. Mice that received 
LPS- sonicate are strongly Th2 biased in their immune response, with significantly more IL-4 
than IFN-γ and serum IgG1 titers higher than IgG2a (Taylor et al., 2006). Accordingly, H. 
pylori-induced inflammatory responses potentially have positive functions in resisting 
certain cancer-advancement-related biological processes post the development of GC and 
showing better outlook in those patients, although they have played fundamental roles 
during the phase of cancer formation.  
Interestingly, the COX-2 expression induced by H. pylori still seems to be able to attenuate 
the degree of AG, the initial event of GC, though it plays a role in gastric carcinogenesis 
(Hahm et al., 2002). COX-2-dependent PGE2 also shows a protective effect during the 
oncogenic process of Hp-GC in that it can prevent H. pylori-induced gastric preneoplasia 
and reverse preexisting lesions by suppressing IFN-γ expression (Toller et al., 2010). As 
confirmed, the protective effect is always accompanied by increased bacterial colonization in 
models, which is attributed to the IL-2-dependent immunosuppressive effects of PGE2 on 
CD4 (+) Th1 cells in migration, proliferation and cytokine secretion. Therefore, PGE2 has an 
important immunomodulatory role during H. pylori infection, preventing excessive local 
immune responses and the associated immunopathology by inhibiting the effector functions 
of pathogenic Th1 cells (Toller et al., 2010). 
Certain genetic and phenotypic polymorphisms also show beneficial effects in improving 
the prognosis of GC patients, which might differ in various populations and need further 
confirmation. IL-6 -572G carrier is found to have a protective effect against IM 
development as compared with C/C (Kim et al., 2008). IL-8 -251AA genotype confers a 
decreased risk for Hp-GC of non-cardia type, mainly of the intestinal type (Crusius et al., 
2008). IL-10 -592C/C is an independent factor associated with a decreased risk of 
intestinal-type GC by multivariate analysis (Kang et al., 2009). When analyzed together 
with host genetic factors, the presence of the IL-1β -31TT genotype emerges as a protective 
factor against gastric malignant disorders (Erzin et al., 2008). Based on a review of 25 case-
control studies in Caucasian, Asian and African populations, IL-1β and NAT1 variants are 
most consistently associated with increased GC risk, which may account for up to 48% of 
attributable risk of GC, but HLA-DQ, TNF and CYP2E polymorphisms may confer certain 
protection against GC (González et al., 2002). However, a comprehensive analysis of 207 
SNPs of 11 Cytokine genes including IL-1α, IL-1β, IL-1RN, IL-4, IL-4R, IL-8, IL-10, IL-12, 
TNF-α, TNF-β, and IFN-γ, has revealed that just variations in IL-4 (984 and 2983 AA/GA) 
and IL-1RN (-1102 and 6110 CG/GA) diplotypes are negatively associated with the risk of 
Hp-GC (Seno et al., 2007). 
 




The majority of GC relates to chronic inflammation induced by H. pylori infection, in which 
many bacterial virulence factors including Cag PAI, VacA, OMP, LPS, urease, IceA, and 
flagella components participate with fundamental roles through a complex network of 
inflammatory cytokines, multiple signalling pathways, and even some genetic or 
phenotypic polymorphisms of the host. Gastric carcinogenesis, especially of the intestinal-
type tumor, is a multistep process of mucosal alterations leading from gastritis via glandular 
atrophy, IM and dysplasia to invasive carcinoma (Bornschein et al., 2010). There is a 
potential ‘point of no return’ during this process, which means a situation when certain 
alterations are no longer reversible by H. pylori eradication and progression to GC have to 
continue (Vieth et al., 2006; Bornschein et al., 2010). Thus, the gastric carcinogenesis is 
actually divided into two phases; one is of reversible pre-the-‘point of no return’, and the 
other is of irreversible post-the-‘point of no return’. During the first phase, H. pylori works 
with more roles as a confirmed carcinogen according to traditional opinion; whereas in the 
second phase, the inflammation has been switched to H. pylori-independent carcinogenesis 
with GC as the destination. 
Considering the host-bacterium cross-talk background and described double functions of 
both inflammatory / immune responses and genetic / phenotypic polymorphisms, a novel 
angle should be adopted to analyze the roles of H. pylori as a double-edged sword in GC. H. 
pylori is more harmful in promoting carcinogenesis prior to the ‘point of no return’, 
however, may be more beneficial for improving the host outlook post the development of 
GC. Based on this theory, H. pylori eradication may be performed at proper stage to protect 
against GC, and more efficient vaccines of prophylaxis and therapeutic ones might be 
designed and used to prevent the advancement of GC and improve the prognosis, which 
needs further confirmation by large from-bench-to-bed studies. 
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In the last 80 years, the incidence of gastric cancer and gastric cancer-related mortality has 
decreased significantly. However, gastric cancer is the 4th most common  cancer and the 2nd 
common cause of cancer associated mortality in the world (Crew, K.D. Neugut, A.I., 2006, 
Ferlay, J., et al., 2010, Ferlay, J., et al., 2010, Jemal, A., et al., 2010, Krejs, G.J., 2010, Malvezzi, 
M., et al., 2010, Sasako, M., et al., 2010, Shin, H.R., et al., 2010). Gastric cancer according to 
anatomic location in the stomach, proximal (cardia) and distal (noncardia) is divided into 2 
groups. Although decreasing, distal located tumors are still the most common type in 
developing countries. While there is an increase in proximal located tumors, the distal 
located gastric cancers have been decreasing in western societies (Ferlay, J., et al., 2010, 
Krejs, G.J., 2010, Malvezzi, M., et al., 2010). More than 90% of gastric cancers are 
adenocarcinomas and can be either intestinal, or diffuse type (Crew, K.D. Neugut, A.I., 2006, 
Krejs, G.J., 2010).  
The incidence vary significantly throughout the world. More than half of all gastric cancers 
in the world are seen in eastern Asia (Sasako, M., et al., 2010).  Korea and Japan had the 
highest incidence countries. While its incidence is 60/100.000 for men and 25/100.000 for 
women in Korea and Japan (Long, N., et al., 2010),  it is around 5/100.000 for Australia and 
New Zealand (Crew, K.D. Neugut, A.I., 2006, Ferlay, J., et al., 2010, Krejs, G.J., 2010, 
Malvezzi, M., et al., 2010, Sasako, M., et al., 2010, Shin, H.R., et al., 2010). Often seen in 
whites aged 60-80, the male to female ratio is 2:1, which rises up to 5:1 for proximal tumors 
(Krejs, G.J., 2010). The main risk factors related to the development of gastric cancer are 
Helicobacter pylori infection, dietary factors, tobacco use and obesity (Crew, K.D. Neugut, 
A.I., 2006, Krejs, G.J., 2010, Sasako, M., et al., 2010).  Having been the most important cancer-
related mortality in the United States in the 1930s for both sexes, its incidence and mortality 
rates have dramatically decreased over the years. For the year 2010, 21.000 new cases and 
11.000 deaths from stomach cancer are estimated in the United States (Jemal, A., et al., 2010).   
As the 4th most common cause of cancer-related deaths, gastric cancer incidence and 
mortality rates among the European countries also show significant variations  (Ferlay, J., et 
al., 2010, Krejs, G.J., 2010, Malvezzi, M., et al., 2010). The incidence of stomach cancer in men 
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is 8/100.000 and in women 3-4/100.000 in European Union (EU) countries. For Russia, these 
rates are 25 and 10 and for United Kingdom (UK) 5-6, and 2-3, respectively. Although 
decreased in major European countries, mortality rates still high in eastern and southern 
Europe with an estimated new cases of 150.000  and gastric cancer-related mortality 116.000 
for the year 2008 (Ferlay, J., et al., 2010).  
1.2 Surgical therapy 
There is no doubt that the only curative treatment option for gastric cancer is gastrectomy 
and regional lymph node dissection (Swan, R. Miner, T.J., 2006, Tanizawa, Y. Terashima, M., 
2010), although the most appropriate surgery and lymph node dissection are still 
controversial. The debate about surgical approach and extent of lymph node dissection 
continuing. In early gastric cancer, which is confined to the mucosa or submucosa, in Japan 
and Korea in particular, endoscopic mucosal dissection and endoscopic submucuosal 
resection is the usual management (Deprez, P.H., et al., 2010, Kim, J.J., et al., 2007).  
Although there are some discussions, subtotal gastrectomy and total gastrectomy is 
considered to be similar in terms of survival. The complex lymph nodes of stomach are 
classified by Japanese Gastric Cancer Association. According to this classification regional 
lymph nodes are divided to 3 groups according to the location of the primary tumor and 
lymph node dissection is separated into the D0, D1, D2 and D3. Perigastric lymph nodes 
have been recognized as D1 and the ones around the main branches of the celiac axis as D2 
(Japanese Gastric Cancer, A., 1998). The extent of lymph node dissection in gastric cancer 
surgery is one of the most controversial issues. D2 dissection was performed as a standard 
approach in Japan, Korea, and some Western countries. D1 dissection is done in many 
western countries.  One of the most well-known studies on this subject is the work of Dutch 
Gastric Cancer Group. In this study comparing D1 and D2 dissections, a 5-year overall 
survival and risk of relapse were similar, but perioperative mortality and complication rates 
were statistically significantly higher in D2 arm (Bonenkamp, J.J., et al., 1999). In a meta-
analysis, the benefit of the addition of paraaortic lymphadenectomy (PALD) to D2 
dissection was discussed and concluded that additional PALD didn’t show survival benefit 
and  was evaluated as less secure (Chen, X.Z., et al., 2010).   
D2 dissection and D2 with PALD were compared. While surgery related complication rate 
were similar between D2 and PALD groups, 5-year overall survival rates were 69.2% in D2 
arm and 70.3% in PALD arm [HR (hazard ratio) 1.03, CI (confidence interval) 0.77-1.37, p = 
0.85] (Sasako, M., et al., 2008).  
The 15 year results of Dutch study was recently published. The median follow-up was 15.2 
years.  D1 arm had higher locoregional relapse rate and higher gastric cancer related death 
rate (182, 48%) than D2 arm (123, 37%) (p =0.01). However, the overall survival rate of the 
D1 arm at 15 years  (21%, 85 of 380) and D2 arm (29%, 98 of 331) were similar (p = 0.34) 
(Songun, I., et al., 2010). You can see key elements of related trials in Table 1. 
In the meta-analysis of Yang and colleagues, it was shown that splenectomy didn’t have 
benefit and is not recommended as a routine practice (Yang, K., et al., 2009). However, 
current National Comprehensive Cancer Network (NCCN) guideline recommends D1 
(perigastric lymph nodes) and D2 (along  in with named vessels of celiac axis) dissection, 
with a goal of at least 15 lymph nodes removed at moderate to high volume centers (Ajani, 
J.A., 2011). Although D2 procedure has a higher postoperative mortality and morbidity, it is 
being applied as a standard approach with confidence at many large centers. 
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Table 1. Major randomized controlled trials comparing D1 with D2/D3 (Tanizawa, Y. 
Terashima, M., 2010) 
1.3 Prognostic factors and relapse pattern 
Based on 10 year results of the “German Gastric Cancer Study,” (Siewert, J.R., et al., 1998) 
they evaluated prognostic factors and they showed that lymph node ratio (ratio between 
positive and removed nodes; p<0.0001), residual tumor category (R0, Rl, R2; p <0.0001), pT-
category (pTl, pT2, pT3 and pT4; p<0.0001, postoperative complications (p<0.0001), distant 
metastases (MO, Ml; p=0.003) affected prognosis. In a prospective multicenter study; it was 
shown that nodal status, depth of invasion, limited or extended lymphadenectomy (D1 vs. 
D2-D3), tumor location (lower vs. upper) and age were independent predictors of 
recurrence (Marrelli, D., et al., 2005). It was also shown that T (T2 vs. T3, risk ratio 3.55, 95% 
CI 1.98-6.44 and p: 0.001) and histological type (intestinal vs. diffuse/mixed, risk ratio 2.11, 
95% CI 1.25-2.95 and p: 0.021) were independent prognostics indicator in node negative 
gastric cancer patients (Baiocchi, G.L., et al., 2010).  Depth of tumor invasion and nodal 
involvement are considered the most important prognostic factors (Marrelli, D., et al., 2005). 
Although in many cases surgical treatment is the primary treatment, usually locoregional, 
hematogenous, and peritoneal recurrences are seen and in patients with developing relapse 
an effective treatment option isn’t available (Marrelli, D., et al., 2005). Studies have 
demonstrated that at least half of all patients who undergo curative resection will have 
locoregional, peritoneal or distant recurrence (Table 2) (Baiocchi, G.L., et al., 2010, 
Bonenkamp, J.J., et al., 1999, Buzzoni, R., et al., 2006, D'Angelica, M., et al., 2004, de 
Manzoni, G., et al., 2003, Kattan, M.W., et al., 2003, Marrelli, D., et al., 2005, Otsuji, E., et al., 
2004, Wang, S.Y., et al., 2009), meaning that surgery alone was unable to eradicate all 
locoregional disease in the majority of patients. 
Therefore in addition to surgical resection, the need for systemic and local therapies are 
apparent. Various preoperative, perioperative and postoperative regimens, chemotherapy 
(CT), radiotherapy (RT) or combining therapy, have been designed to eradicate microscopic 
disease.  
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is 8/100.000 and in women 3-4/100.000 in European Union (EU) countries. For Russia, these 
rates are 25 and 10 and for United Kingdom (UK) 5-6, and 2-3, respectively. Although 
decreased in major European countries, mortality rates still high in eastern and southern 
Europe with an estimated new cases of 150.000  and gastric cancer-related mortality 116.000 
for the year 2008 (Ferlay, J., et al., 2010).  
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and regional lymph node dissection (Swan, R. Miner, T.J., 2006, Tanizawa, Y. Terashima, M., 
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controversial. The debate about surgical approach and extent of lymph node dissection 
continuing. In early gastric cancer, which is confined to the mucosa or submucosa, in Japan 
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resection is the usual management (Deprez, P.H., et al., 2010, Kim, J.J., et al., 2007).  
Although there are some discussions, subtotal gastrectomy and total gastrectomy is 
considered to be similar in terms of survival. The complex lymph nodes of stomach are 
classified by Japanese Gastric Cancer Association. According to this classification regional 
lymph nodes are divided to 3 groups according to the location of the primary tumor and 
lymph node dissection is separated into the D0, D1, D2 and D3. Perigastric lymph nodes 
have been recognized as D1 and the ones around the main branches of the celiac axis as D2 
(Japanese Gastric Cancer, A., 1998). The extent of lymph node dissection in gastric cancer 
surgery is one of the most controversial issues. D2 dissection was performed as a standard 
approach in Japan, Korea, and some Western countries. D1 dissection is done in many 
western countries.  One of the most well-known studies on this subject is the work of Dutch 
Gastric Cancer Group. In this study comparing D1 and D2 dissections, a 5-year overall 
survival and risk of relapse were similar, but perioperative mortality and complication rates 
were statistically significantly higher in D2 arm (Bonenkamp, J.J., et al., 1999). In a meta-
analysis, the benefit of the addition of paraaortic lymphadenectomy (PALD) to D2 
dissection was discussed and concluded that additional PALD didn’t show survival benefit 
and  was evaluated as less secure (Chen, X.Z., et al., 2010).   
D2 dissection and D2 with PALD were compared. While surgery related complication rate 
were similar between D2 and PALD groups, 5-year overall survival rates were 69.2% in D2 
arm and 70.3% in PALD arm [HR (hazard ratio) 1.03, CI (confidence interval) 0.77-1.37, p = 
0.85] (Sasako, M., et al., 2008).  
The 15 year results of Dutch study was recently published. The median follow-up was 15.2 
years.  D1 arm had higher locoregional relapse rate and higher gastric cancer related death 
rate (182, 48%) than D2 arm (123, 37%) (p =0.01). However, the overall survival rate of the 
D1 arm at 15 years  (21%, 85 of 380) and D2 arm (29%, 98 of 331) were similar (p = 0.34) 
(Songun, I., et al., 2010). You can see key elements of related trials in Table 1. 
In the meta-analysis of Yang and colleagues, it was shown that splenectomy didn’t have 
benefit and is not recommended as a routine practice (Yang, K., et al., 2009). However, 
current National Comprehensive Cancer Network (NCCN) guideline recommends D1 
(perigastric lymph nodes) and D2 (along  in with named vessels of celiac axis) dissection, 
with a goal of at least 15 lymph nodes removed at moderate to high volume centers (Ajani, 
J.A., 2011). Although D2 procedure has a higher postoperative mortality and morbidity, it is 
being applied as a standard approach with confidence at many large centers. 
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Table 1. Major randomized controlled trials comparing D1 with D2/D3 (Tanizawa, Y. 
Terashima, M., 2010) 
1.3 Prognostic factors and relapse pattern 
Based on 10 year results of the “German Gastric Cancer Study,” (Siewert, J.R., et al., 1998) 
they evaluated prognostic factors and they showed that lymph node ratio (ratio between 
positive and removed nodes; p<0.0001), residual tumor category (R0, Rl, R2; p <0.0001), pT-
category (pTl, pT2, pT3 and pT4; p<0.0001, postoperative complications (p<0.0001), distant 
metastases (MO, Ml; p=0.003) affected prognosis. In a prospective multicenter study; it was 
shown that nodal status, depth of invasion, limited or extended lymphadenectomy (D1 vs. 
D2-D3), tumor location (lower vs. upper) and age were independent predictors of 
recurrence (Marrelli, D., et al., 2005). It was also shown that T (T2 vs. T3, risk ratio 3.55, 95% 
CI 1.98-6.44 and p: 0.001) and histological type (intestinal vs. diffuse/mixed, risk ratio 2.11, 
95% CI 1.25-2.95 and p: 0.021) were independent prognostics indicator in node negative 
gastric cancer patients (Baiocchi, G.L., et al., 2010).  Depth of tumor invasion and nodal 
involvement are considered the most important prognostic factors (Marrelli, D., et al., 2005). 
Although in many cases surgical treatment is the primary treatment, usually locoregional, 
hematogenous, and peritoneal recurrences are seen and in patients with developing relapse 
an effective treatment option isn’t available (Marrelli, D., et al., 2005). Studies have 
demonstrated that at least half of all patients who undergo curative resection will have 
locoregional, peritoneal or distant recurrence (Table 2) (Baiocchi, G.L., et al., 2010, 
Bonenkamp, J.J., et al., 1999, Buzzoni, R., et al., 2006, D'Angelica, M., et al., 2004, de 
Manzoni, G., et al., 2003, Kattan, M.W., et al., 2003, Marrelli, D., et al., 2005, Otsuji, E., et al., 
2004, Wang, S.Y., et al., 2009), meaning that surgery alone was unable to eradicate all 
locoregional disease in the majority of patients. 
Therefore in addition to surgical resection, the need for systemic and local therapies are 
apparent. Various preoperative, perioperative and postoperative regimens, chemotherapy 
(CT), radiotherapy (RT) or combining therapy, have been designed to eradicate microscopic 
disease.  
 





Types of relapse (%) 
Locoregional Peritoneal Distant Multiple-sites 
(Marrelli, D., et al., 2005) 23.7 16.2 17.2 7.8 
(Buzzoni, R., et al., 2006) 15.8 N.S 34.5 N.S 
(Otsuji, E., et al., 2004) 16.0 54.0 31.0 N.S 
(Wang, S.Y., et al., 2009) 9.5 23.3 20.6 46.6 
(de Manzoni, G., et al., 2003) 32.7 18.1 40 9 
(D'Angelica, M., et al., 2004) 25.9 13.6 28.1 32.5 
(Sakuramoto, S., et al., 2007)* 11.5 15.8 11.3 N.S. 
(Macdonald, J.S., et al., 2001)* 29.0 72.0 18.0 N.S. 
N.S.: not specified *Site of first relapse,  
Table 2. Type of relapse after curative resection  
The majority of patients with gastric cancer are diagnosed at advanced stages. Even in 
patients are diagnosed at an early stage, 5-year survival rate of patients undergoing surgery 
alone is low. While the 5 year survival rates are about 70.0% in patients with stage IA, it is 
20.0% in patients  with stage III  (Edge, S. Byrd, D., 2010). Therefore, it is clear that 
treatments in addition to surgery for gastric cancer are needed. For this reason, a lot of 
studies in terms of neoadjuvant, perioperative, or adjuvant RT, CT or combined approaches 
have been tried. 
1.4 Possible therapeutic strategies to improve outcome of surgical therapy 
CT, RT or combinations of the 2 can therotically be applied before (neoadjuvant) or after 
(adjuvant) the curative surgery. Being applied earlier in time, neoadjuvant therapy is 
expected to down stage the disease and increase the rate of curative resection and eradicate 
possible micrometastases, which are undetectable at the beginning of the treatment. In 
addition, pre-surgical patients usually have better performance status and can be expected 
to tolerate  treatments better. However on the other hand, patients with initially resectable 
disease could loose their chance of curative surgery and postsurgical mortality may be 
increased. One other pitfall of neoadjuvant therapy is imperfectness of clinical staging. 
There is a possibility to give unnecessay oncological treatments to patients with very early 
stages of cancer who would not have otherwise receive based on pathological staging . Prior 
to surgery, yet the normal anatomy and blood flow, target volumes of RT could be more 
easily detected.  However, more patients have metastatic disease at surgery than patients 
undergoing preoperative reviews. Two randomized important studies on this subject were 
the Magic and Holland trials (Cunningham, D., et al., 2006, Hartgrink, H.H., et al., 2004). 
In the adjuvant setting, pathological staging is known. There is no danger of giving 
unnecessary treatment. However, patients can tolerate adjuvant therapies less and CT or RT 
could not be applied at effective doses. In addition, blood flow to the gastric bed may be 
decreased after surgery which leads to tissue hypoxia. Hypoxic tumor cells do not 
proliferate to the extend at which non-hypoxic tumors do. Since many chemotherapeutics 
and RT are more effective on hypoxic cells, adjuvant therapeutic strategies may be less 
effective than expected. 
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2. Neoadjuvant trials 
2.1 Neoadjuvant radiotherapy 
Neoadjuvant randomized clinical trial evaluating the efficacy of RT alone is limited. Zhang 
et al. randomized 370 patients with gastric adenocarcinoma of cardia to surgery alone or RT 
and surgery group. In the RT arm patients, underwent surgery 2-4 weeks after 40 Gy.  The 
rate of tumor resectability and ratio of T2 tumor were more in RT arm with 11.0% decrease 
of T4 tumors. Five- and 10-year survival rates for RT plus surgery and surgery alone groups 
were 30.1%, 19.7% and 20.2%, 13.3%; respectively and these differences were statistically 
significant. No significant difference was observed between 2 group in term of surgical 
complication rates (Zhang, Z.X., et al., 1998). 
In another study preoperative RT in resectable gastric cancer, there were 51 patients in both 
RT plus surgery and surgery alone arms and the total doses of RT was 20 Gy and was given 
in 5 fractions. Although,  statistically insignificant, 5- and 10-year survival rates were 39.0%, 
32.0% and 30.0%, 18.0% for the preoperative RT and surgery alone groups, respectively.  
Although concentrated preoperative RT was safe, wasn’t enough to provide survival 
advantage (Skoropad, V., et al., 2002).  
Fiorica et al. were evaluated 9 randomized trials (with these two above study, 4 neoadjuvant 
and 5 adjuvant trials). In this meta-analysis; 3-year (HR 0.57, CI 95% 0.43 – 0.76; p= 0.0001) 
and 5-year (HR 0.62 CI 95% 0.46 – 0.84; p= 0.002) survival advantage were observed with 
preoperative RT. Although there was increasing trend in postoperative mortality for 
preoperative RT group, these difference wasn’t statistically significant  (HR 0.61 CI 95% 0.24 
– 1.57; p= 0.31) (Fiorica, F., et al., 2007).   
2.2 Neoadjuvant chemo(-radio)therapy 
The CT regimens have been used in patients with metastatic disease has led the way for 
regimens which could be used as neoadjuvant CT. The first randomized controlled 
neoadjuvant CT trial was Dutch randomized FAMTX (5-Fluorouracil, doxorubicin and 
Methotrexate)  trial. There were 56 patients and FAMTX regimen was used. The ratio of 
resectability was similar and at median follow-up of 83 months the median survival is 18 
months for FAMTX group vs. 30 months in surgery alone group (p=0.17). This trial could 
not show a beneficial effect of pre-operative FAMTX, even  preoperative CT tends to have 
negative effect (Hartgrink, H.H., et al., 2004). However, it is clear that FAMTX regimen isn’t 
an effective treatment option for today. In addition, fewer patients have been taken than 
planned in this study,  25.0% of patients did not receive the planned treatment because of 
toxicity associated with CT.   
The MAGIC trial is one of the most important neoadjuvant CT studies. In this study ECF 
(epirubicin, cisplatin, and infusional 5-fluorouracil) regimen, which is more effective than 
FAMTX regimen in patients with metastatic disease, was used. ECF CT regimen was 
compared surgery alone. Patients with resectable adenocarcinoma of the stomach, 
esophagogastric junction, or lower esophagus were ranomized to either perioperative CT 
and surgery (250 patients) or surgery alone (253 patients). CT consisted of 3 preoperative 
and 3 postoperative cycles of intravenous epirubicin (50 mg per square meter of body-
surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous 
infusion of fluorouracil (200 mg per square meter per day) for 21 days (Cunningham, D., et 
al., 2006). Of patients, 90.7% completed preoperative CT, but only 103 of 208 (49.5%) who 
completed preoperative CT and surgery also completed postoperative treatment. The 
curative resection rates were similar; 69.3% in the perioperative CT group and 66.4% in the 
surgery group. There was a greater proportion of stage T1 and T2 tumors and less advanced 
 





Types of relapse (%) 
Locoregional Peritoneal Distant Multiple-sites 
(Marrelli, D., et al., 2005) 23.7 16.2 17.2 7.8 
(Buzzoni, R., et al., 2006) 15.8 N.S 34.5 N.S 
(Otsuji, E., et al., 2004) 16.0 54.0 31.0 N.S 
(Wang, S.Y., et al., 2009) 9.5 23.3 20.6 46.6 
(de Manzoni, G., et al., 2003) 32.7 18.1 40 9 
(D'Angelica, M., et al., 2004) 25.9 13.6 28.1 32.5 
(Sakuramoto, S., et al., 2007)* 11.5 15.8 11.3 N.S. 
(Macdonald, J.S., et al., 2001)* 29.0 72.0 18.0 N.S. 
N.S.: not specified *Site of first relapse,  
Table 2. Type of relapse after curative resection  
The majority of patients with gastric cancer are diagnosed at advanced stages. Even in 
patients are diagnosed at an early stage, 5-year survival rate of patients undergoing surgery 
alone is low. While the 5 year survival rates are about 70.0% in patients with stage IA, it is 
20.0% in patients  with stage III  (Edge, S. Byrd, D., 2010). Therefore, it is clear that 
treatments in addition to surgery for gastric cancer are needed. For this reason, a lot of 
studies in terms of neoadjuvant, perioperative, or adjuvant RT, CT or combined approaches 
have been tried. 
1.4 Possible therapeutic strategies to improve outcome of surgical therapy 
CT, RT or combinations of the 2 can therotically be applied before (neoadjuvant) or after 
(adjuvant) the curative surgery. Being applied earlier in time, neoadjuvant therapy is 
expected to down stage the disease and increase the rate of curative resection and eradicate 
possible micrometastases, which are undetectable at the beginning of the treatment. In 
addition, pre-surgical patients usually have better performance status and can be expected 
to tolerate  treatments better. However on the other hand, patients with initially resectable 
disease could loose their chance of curative surgery and postsurgical mortality may be 
increased. One other pitfall of neoadjuvant therapy is imperfectness of clinical staging. 
There is a possibility to give unnecessay oncological treatments to patients with very early 
stages of cancer who would not have otherwise receive based on pathological staging . Prior 
to surgery, yet the normal anatomy and blood flow, target volumes of RT could be more 
easily detected.  However, more patients have metastatic disease at surgery than patients 
undergoing preoperative reviews. Two randomized important studies on this subject were 
the Magic and Holland trials (Cunningham, D., et al., 2006, Hartgrink, H.H., et al., 2004). 
In the adjuvant setting, pathological staging is known. There is no danger of giving 
unnecessary treatment. However, patients can tolerate adjuvant therapies less and CT or RT 
could not be applied at effective doses. In addition, blood flow to the gastric bed may be 
decreased after surgery which leads to tissue hypoxia. Hypoxic tumor cells do not 
proliferate to the extend at which non-hypoxic tumors do. Since many chemotherapeutics 
and RT are more effective on hypoxic cells, adjuvant therapeutic strategies may be less 
effective than expected. 
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2. Neoadjuvant trials 
2.1 Neoadjuvant radiotherapy 
Neoadjuvant randomized clinical trial evaluating the efficacy of RT alone is limited. Zhang 
et al. randomized 370 patients with gastric adenocarcinoma of cardia to surgery alone or RT 
and surgery group. In the RT arm patients, underwent surgery 2-4 weeks after 40 Gy.  The 
rate of tumor resectability and ratio of T2 tumor were more in RT arm with 11.0% decrease 
of T4 tumors. Five- and 10-year survival rates for RT plus surgery and surgery alone groups 
were 30.1%, 19.7% and 20.2%, 13.3%; respectively and these differences were statistically 
significant. No significant difference was observed between 2 group in term of surgical 
complication rates (Zhang, Z.X., et al., 1998). 
In another study preoperative RT in resectable gastric cancer, there were 51 patients in both 
RT plus surgery and surgery alone arms and the total doses of RT was 20 Gy and was given 
in 5 fractions. Although,  statistically insignificant, 5- and 10-year survival rates were 39.0%, 
32.0% and 30.0%, 18.0% for the preoperative RT and surgery alone groups, respectively.  
Although concentrated preoperative RT was safe, wasn’t enough to provide survival 
advantage (Skoropad, V., et al., 2002).  
Fiorica et al. were evaluated 9 randomized trials (with these two above study, 4 neoadjuvant 
and 5 adjuvant trials). In this meta-analysis; 3-year (HR 0.57, CI 95% 0.43 – 0.76; p= 0.0001) 
and 5-year (HR 0.62 CI 95% 0.46 – 0.84; p= 0.002) survival advantage were observed with 
preoperative RT. Although there was increasing trend in postoperative mortality for 
preoperative RT group, these difference wasn’t statistically significant  (HR 0.61 CI 95% 0.24 
– 1.57; p= 0.31) (Fiorica, F., et al., 2007).   
2.2 Neoadjuvant chemo(-radio)therapy 
The CT regimens have been used in patients with metastatic disease has led the way for 
regimens which could be used as neoadjuvant CT. The first randomized controlled 
neoadjuvant CT trial was Dutch randomized FAMTX (5-Fluorouracil, doxorubicin and 
Methotrexate)  trial. There were 56 patients and FAMTX regimen was used. The ratio of 
resectability was similar and at median follow-up of 83 months the median survival is 18 
months for FAMTX group vs. 30 months in surgery alone group (p=0.17). This trial could 
not show a beneficial effect of pre-operative FAMTX, even  preoperative CT tends to have 
negative effect (Hartgrink, H.H., et al., 2004). However, it is clear that FAMTX regimen isn’t 
an effective treatment option for today. In addition, fewer patients have been taken than 
planned in this study,  25.0% of patients did not receive the planned treatment because of 
toxicity associated with CT.   
The MAGIC trial is one of the most important neoadjuvant CT studies. In this study ECF 
(epirubicin, cisplatin, and infusional 5-fluorouracil) regimen, which is more effective than 
FAMTX regimen in patients with metastatic disease, was used. ECF CT regimen was 
compared surgery alone. Patients with resectable adenocarcinoma of the stomach, 
esophagogastric junction, or lower esophagus were ranomized to either perioperative CT 
and surgery (250 patients) or surgery alone (253 patients). CT consisted of 3 preoperative 
and 3 postoperative cycles of intravenous epirubicin (50 mg per square meter of body-
surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous 
infusion of fluorouracil (200 mg per square meter per day) for 21 days (Cunningham, D., et 
al., 2006). Of patients, 90.7% completed preoperative CT, but only 103 of 208 (49.5%) who 
completed preoperative CT and surgery also completed postoperative treatment. The 
curative resection rates were similar; 69.3% in the perioperative CT group and 66.4% in the 
surgery group. There was a greater proportion of stage T1 and T2 tumors and less advanced 
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nodal disease in the perioperative-CT group. The perioperative-CT group had a higher 
likelihood of overall survival (hazard ratio for death, 0.75; 95% CI, 0.60 to 0.93; p= 0.009; 5-
year survival rate, 36% vs. 23%) and of progression-free survival (hazard ratio for 
progression, 0.66; 95% CI, 0.53 to 0.81; p<0.001). 
3.1 Adjuvant chemotherapy 
Numerous clinical trials concerning adjuvant CT for gastric cancer have been conducted 
with different CT regimens.  The results of adjuvant CT trials are conflicting as well, 
majority being negative with disparities between asian and western ones. Geographic  
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(Schuhmach
er, C.P., et 
al., 2001) 
42 3 or 4 cycles of Et-D-C N.S. 0 73.8 19.1 28.4
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*Statistically significant, C:cisplatin, FU:fluorouracil, FA: folinic asid, RT: radiotherapy, D: doxorubicin, 
Et:etoposide, N.S.: not specified, N.R.:not reached, MTX: methoterxate, #PR or pCR, PR: partial 
response, pCR: pathologic complete response, E:epirubicin, T:docetaxel, FAMTX: fluorouracil, 
doxorubicin, methoterxate  
Table 3. Major randomized controlled Neoadjuvant trials 
 
Gastric Carcinoma Neoadjuvant and Adjuvant Therapy 
 
303 
variation, small sample sized studies, differences in the surgical techniques account for these 
conflicting results. However, this does not mean that adjuvant chemotherapies are useless. 
Compared to current counterparts, CT regimens used in those old studies are relatively-
weaker regimes. Many studies are undepowered. Many meta-analyses investigating the role 
of adjuvant CT for gastric cancer have been performed to overcome such inconsistencies. 
 
Author  Year No. of studies Patients OR/HR 
(95%CI) 
(Hermans, J., et al., 
1993) 
1993 11 2096 0.88 (0.78-1.08) 
(Earle, C.C. Maroun, 
J.A., 1999) 
1999 13 1990 0.80 (0,66-0,97)* 
 (Mari, E., et al., 2000) 2000 21 3658 0,82 (0,75-0,89)* 
(Liu, T.S., et al., 2008) 2008 23 4919 0,85 (0,80-0,90)* 
(Paoletti, X., et al., 
2010) 
2010 17 3838 0,82 (0,76-0,90)* 
OR: Odds ratio, * statistically significant values for survival 
Table 4. Meta-analyses of adjuvant chemotherapy in gastric cancer 
A meta-analysis was conducted on 13 randomized trials of adjuvant CT in gastric cancer 
concluded that adjuvant CT might produce a small survival benefit with a borderline 
statistical significance (Earle, C.C. Maroun, J.A., 1999). The trials in this meta-analysis were 
all performed in Western countries. Marie et al reviewed 20 clinical trials of adjuvant CT 
compared with surgery alone published between 1983 and 1999. Reviewers suggested that 
CT reduced the risk of death by 18% (HR 0.82, 95% CI: 0.75-0.89) and addition of 
anthracyclines to 5-FU did not show a statistically significant improvement when compared 
with other regimens (Mari, E., et al., 2000). The meta-analysis published in 2008 by Liu et al. 
based on 23 randomized clinical trial included 4919 patients (2441 in the adjuvant CT arm, 
2478 in the observation arm). The study showed relative risk on death of 0.85 (95%CI: 0.80-
0.90) which favored the survival role of adjuvant CT.  The authors of this meta-analysis 
concluded that NNT (number needed to treat) was 14, indicating that 14 patients would 
need to receive adjuvant therapy to prevent one death (Liu, T.S., et al., 2008). However, 
meta-analyses mentioned above were restricted since they were based on the review of the 
literature rather than original individual patient data. Recently, an individual patient level 
meta-analysis of randomized control trials was published by GASTRIC (Global 
Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group.  The 
meta-analysis based on 17 trials (including 3838 patients) comparing adjuvant CT with 
surgery alone for resectable gastric carcinoma. In the study four groups of CT regimens 
were defined: 1) monochemotherapy agents 2) fluorouracil, mitomycin C and other 
therapies without anthracyclines 3) fluorouracil, mitomycin C, and anthracyclines 4) other 
polychemotherapy regimens.  The study revealed statistically significant benefit associated 
with adjuvant CT both for overall survival (OS) (HR, 0.82; 95% CI, 0.76-0.90) and disease-
free survival (DFS) (HR, 0.82; 95% CI, 0.75-0.90, P<.001, for both). There was no significant 
difference between 4 CT regimens in terms of OS and DFS. The reviewers suggested that, 
adjuvant fluorouracil –based CT, even as monotherapy, had improved overall survival after 
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nodal disease in the perioperative-CT group. The perioperative-CT group had a higher 
likelihood of overall survival (hazard ratio for death, 0.75; 95% CI, 0.60 to 0.93; p= 0.009; 5-
year survival rate, 36% vs. 23%) and of progression-free survival (hazard ratio for 
progression, 0.66; 95% CI, 0.53 to 0.81; p<0.001). 
3.1 Adjuvant chemotherapy 
Numerous clinical trials concerning adjuvant CT for gastric cancer have been conducted 
with different CT regimens.  The results of adjuvant CT trials are conflicting as well, 
majority being negative with disparities between asian and western ones. Geographic  
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variation, small sample sized studies, differences in the surgical techniques account for these 
conflicting results. However, this does not mean that adjuvant chemotherapies are useless. 
Compared to current counterparts, CT regimens used in those old studies are relatively-
weaker regimes. Many studies are undepowered. Many meta-analyses investigating the role 
of adjuvant CT for gastric cancer have been performed to overcome such inconsistencies. 
 
Author  Year No. of studies Patients OR/HR 
(95%CI) 
(Hermans, J., et al., 
1993) 
1993 11 2096 0.88 (0.78-1.08) 
(Earle, C.C. Maroun, 
J.A., 1999) 
1999 13 1990 0.80 (0,66-0,97)* 
 (Mari, E., et al., 2000) 2000 21 3658 0,82 (0,75-0,89)* 
(Liu, T.S., et al., 2008) 2008 23 4919 0,85 (0,80-0,90)* 
(Paoletti, X., et al., 
2010) 
2010 17 3838 0,82 (0,76-0,90)* 
OR: Odds ratio, * statistically significant values for survival 
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meta-analyses mentioned above were restricted since they were based on the review of the 
literature rather than original individual patient data. Recently, an individual patient level 
meta-analysis of randomized control trials was published by GASTRIC (Global 
Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group.  The 
meta-analysis based on 17 trials (including 3838 patients) comparing adjuvant CT with 
surgery alone for resectable gastric carcinoma. In the study four groups of CT regimens 
were defined: 1) monochemotherapy agents 2) fluorouracil, mitomycin C and other 
therapies without anthracyclines 3) fluorouracil, mitomycin C, and anthracyclines 4) other 
polychemotherapy regimens.  The study revealed statistically significant benefit associated 
with adjuvant CT both for overall survival (OS) (HR, 0.82; 95% CI, 0.76-0.90) and disease-
free survival (DFS) (HR, 0.82; 95% CI, 0.75-0.90, P<.001, for both). There was no significant 
difference between 4 CT regimens in terms of OS and DFS. The reviewers suggested that, 
adjuvant fluorouracil –based CT, even as monotherapy, had improved overall survival after 
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curative resection of gastric cancer (Paoletti, X., et al., 2010). Also in the meta-analyses of 
Sun et al. the pooled HR for overall survival was 0.78 (95 per cent confidence interval 0.71 to 
0.85) in favor of CT (Sun, P., et al., 2009). 
S-1 is an orally active combination of tegafur, gimercil and oteracil that has an appropriate 
bio-availability for using after gastrectomy. The Japanese randomized phase 3 trial assessed 
the efficacy of S-1 monotherapy as adjuvant CT in resected gastric cancer. In the study 
conducted by Sakuramoto et al. 1059 patients with stage 2-3 gastric cancer randomized to 
surgery only or adjuvant therapy with S-1 after extended (D2) gastrectomy. In the interim 
analysis after median follow-up of 2 years both overall survival and relapse-free survival 
differed between two groups favoring adjuvant CT arm, so the data and safety monitoring 
committee recommended early discontinuation of the trial. The study disclosed that the 
hazard ratio for death in the S1 group, as compared to surgery only group was 0.68 (95% CI, 
0.52-0.87, P=0.003) and 3-year overall survival of 80.1% vs. 70.1% respectively. The authors 
suggested that S-1 was potent adjuvant CT for East Asian patients who underwent D2 
dissection for locally advanced gastric cancer (Sakuramoto, S., et al., 2007). After this trial 
adjuvant CT without radiation therapy has been the standard in Japan.  
In conclusion, adjuvant CT may be considered in patients with locally advanced gastric 
cancer after curative surgery who had not received neoadjuvant treatment and not 
candidate for chemoradition therapy. 
3.2 Adjuvant radiotherapy 
One randomized clinical trial evaluated the role of adjuvant RT after curative resection in 
gastric cancer (without concurrent CT). According to the trial performed by British Stomach 
Cancer Group 436 patients with resected gastric cancer were stratified to no adjuvant 
treatment or adjuvant RT or adjuvant CT with adriamycin, 5-FU and mitomycin C. The five 
year survival rates were as follows: for surgery alone 20%, for surgery plus RT 12.0%, for 
surgery plus CT 19.0%. No advantage in terms of survival in either adjuvant arm was 
observed, but RT offered an advantage in reducing local recurrence as compared to surgery 
only group (local recurrence rates were 27.0% versus 10.0% favoring surgery plus RT 
(Hallissey, M.T., et al., 1994). 
3.3 Adjuvant chemoradiotherapy 
Gastric cancer can recur loco-regionally, or systemically. The review from Memorial Sloan-
Kettering Cancer (MSKCC) demonstrated patterns of relapse of 1172 patients who 
underwent potentially curative surgery from July 1985 through June 2000 (D'Angelica, M., 
et al., 2004). Among 496 patients who had a recurrence, whole data on recurrence was 
obtained in 367 patients.  Loco-regional sites were a component of relapse in 54.0% of 
patients including the anastomosis, lymph nodes and the gastric bed. Distant sites and 
peritoneal relapse were documented in 51.0% and 29.0% of patients, respectively. Since 
adjuvant RT alone did not appear to confer advantage in terms of survival, RT combined 
with CT was evaluated in randomized clinical trials. The rationale to use CRT in the 
adjuvant setting in gastric cancer is not only to control loco-regional recurrence but also 
distant metastases. First, when used concurrently with RT chemotherapeutic agents may act 
as a radio-sensitizer. Second, CT may improve systemic control by eliminating microscopic 
distant metastasis. Various mechanisms are responsible for the interaction between CT and 
RT. Ionizing radiation induces DNA base damage, alkali-labile sites, single-strand breaks, 
and double strand breaks. Double strand breaks are the most important damage among 
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them and causes tumor-kill whether remains unrepaired. Chemotherapeutic agents that 
inhibit DNA repair, including fluorouracil, cisplatin, irinotecan, can improve radiation 
cytotoxicity synergistically. CT can also act by restraining post-radiation damage repair. The 
phase of the cell cycle is another determinant of radio-sensitivity. While cells in G2-M phase 
are most radiosensitive, cells in the S phase of the cell cycle are the most radio-resistant 
(Terasima, T. Tolmach, L.J., 1961). CT and RT also produce synergistic effect by targeting 
different phases of the cell cycle when used concurrently. Moreover, drugs such as taxanes 
has the ability to block the cell cycle at the G2-M phase so that enhances the radiation effect 
(Tishler, R.B., et al., 1992).  
Several randomized trials assessed the effectiveness of chemo-radiation after curative 
surgery. Dent et al. performed randomized trial including 142 patients with all stages of 
gastric carcinoma. The patients in Division I (T1-3, N1-2, and M0) were assigned to control 
and RT plus 5-FU group. Division II (T4, M1) was randomized into three groups; a control 
group, RT plus 5-FU, thiotepa for six months. After 4.5 year’s follow-up the control and 
treatment groups did not differ with respect to survival rate in neither Division I nor 
Division II (Dent, D.M., et al., 1979). In the randomized trial conducted by Bleiberg and 
colleagues, 115 patients who underwent curative and palliative surgery were stratified into 
four treatment groups. Patients received RT alone or in combination with short-term and/or 
long term 5-FU infusion. Statistically differences were determined in terms of overall 
survival but the difference in survival disappeared when comparisons adjusted for 
prognostic factors (Bleiberg, H., et al., 1989). In the study by Moertel and co-workers 62 
patients with resectable but poor prognosis gastric carcinoma were randomized to surgery 
versus surgery plus adjuvant treatment with 5-FU plus radiation. Although both five-year 
survival rates and local-regional recurrence favored treatment arm results did not reach 
statistical significance (Moertel, C.G., et al., 1984). 
The largest trial evaluating the use of postoperative chemoradiation was U.S. Intergroup 
0116 trial (Macdonald, J.S., et al., 2001). In this study 556 patients with curatively resected 
gastric or gastroesophageal junction adenocarcinoma (stage Ib through IV M0) were 
randomized to surgery alone or adjuvant combined chemoradiotherapy (CRT). The 
adjuvant treatment consisted of one course of 5-FU 425 mg/m2/d and leucovorin 20 
mg/m2/d, daily for five days, followed one month later by 45 Gy of radiation during 5 
weeks with 5-FU 425 mg/m2/d and leucovorin 20 mg/m2/d on days 1 through 4 and last 3 
days of radiation. One month after completion of RT 2 more 5-day cycles of CT (5-FU 425 
mg/m2/d plus leucovorin 20 mg/m2/d) were administered. After a median follow-up of 5 
years, the median duration of survival was 36 and 27 months in the CRT and surgery-only 
groups, respectively. The 3-year survival rates were 50% versus 41% favoring adjuvant 
treatment. The 3-year rates of relapse free survival increased from 31.0% to 48.0% in the CRT 
group. Improvements both in overall and relapse free survival were statistically significant. 
Grades 3 and 4 toxic effects (mostly, hematologic and gastrointestinal) occurred in 41.0% 
and 32.0% of chemo-RT groups, respectively. Three patients (%1) died as a result of toxic 
effect of the treatment. The extent of the surgical resection was an important issue in the 
study protocol. Although, D2 dissection was recommended, only 10.0% of patients 
underwent a D2 dissection, 54.0% of the patients underwent D0 dissection (in which all of 
the N1 nodes were not resected). When patients relapse patterns were examined, local-
regional recurrence was higher in the surgery only group, despite the higher distant 
metastasis rates detected in the CRT group (statistical assessment of the relapse sites were 
not included in the study). The study demonstrated that the benefit of CRT in the adjuvant 
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curative resection of gastric cancer (Paoletti, X., et al., 2010). Also in the meta-analyses of 
Sun et al. the pooled HR for overall survival was 0.78 (95 per cent confidence interval 0.71 to 
0.85) in favor of CT (Sun, P., et al., 2009). 
S-1 is an orally active combination of tegafur, gimercil and oteracil that has an appropriate 
bio-availability for using after gastrectomy. The Japanese randomized phase 3 trial assessed 
the efficacy of S-1 monotherapy as adjuvant CT in resected gastric cancer. In the study 
conducted by Sakuramoto et al. 1059 patients with stage 2-3 gastric cancer randomized to 
surgery only or adjuvant therapy with S-1 after extended (D2) gastrectomy. In the interim 
analysis after median follow-up of 2 years both overall survival and relapse-free survival 
differed between two groups favoring adjuvant CT arm, so the data and safety monitoring 
committee recommended early discontinuation of the trial. The study disclosed that the 
hazard ratio for death in the S1 group, as compared to surgery only group was 0.68 (95% CI, 
0.52-0.87, P=0.003) and 3-year overall survival of 80.1% vs. 70.1% respectively. The authors 
suggested that S-1 was potent adjuvant CT for East Asian patients who underwent D2 
dissection for locally advanced gastric cancer (Sakuramoto, S., et al., 2007). After this trial 
adjuvant CT without radiation therapy has been the standard in Japan.  
In conclusion, adjuvant CT may be considered in patients with locally advanced gastric 
cancer after curative surgery who had not received neoadjuvant treatment and not 
candidate for chemoradition therapy. 
3.2 Adjuvant radiotherapy 
One randomized clinical trial evaluated the role of adjuvant RT after curative resection in 
gastric cancer (without concurrent CT). According to the trial performed by British Stomach 
Cancer Group 436 patients with resected gastric cancer were stratified to no adjuvant 
treatment or adjuvant RT or adjuvant CT with adriamycin, 5-FU and mitomycin C. The five 
year survival rates were as follows: for surgery alone 20%, for surgery plus RT 12.0%, for 
surgery plus CT 19.0%. No advantage in terms of survival in either adjuvant arm was 
observed, but RT offered an advantage in reducing local recurrence as compared to surgery 
only group (local recurrence rates were 27.0% versus 10.0% favoring surgery plus RT 
(Hallissey, M.T., et al., 1994). 
3.3 Adjuvant chemoradiotherapy 
Gastric cancer can recur loco-regionally, or systemically. The review from Memorial Sloan-
Kettering Cancer (MSKCC) demonstrated patterns of relapse of 1172 patients who 
underwent potentially curative surgery from July 1985 through June 2000 (D'Angelica, M., 
et al., 2004). Among 496 patients who had a recurrence, whole data on recurrence was 
obtained in 367 patients.  Loco-regional sites were a component of relapse in 54.0% of 
patients including the anastomosis, lymph nodes and the gastric bed. Distant sites and 
peritoneal relapse were documented in 51.0% and 29.0% of patients, respectively. Since 
adjuvant RT alone did not appear to confer advantage in terms of survival, RT combined 
with CT was evaluated in randomized clinical trials. The rationale to use CRT in the 
adjuvant setting in gastric cancer is not only to control loco-regional recurrence but also 
distant metastases. First, when used concurrently with RT chemotherapeutic agents may act 
as a radio-sensitizer. Second, CT may improve systemic control by eliminating microscopic 
distant metastasis. Various mechanisms are responsible for the interaction between CT and 
RT. Ionizing radiation induces DNA base damage, alkali-labile sites, single-strand breaks, 
and double strand breaks. Double strand breaks are the most important damage among 
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them and causes tumor-kill whether remains unrepaired. Chemotherapeutic agents that 
inhibit DNA repair, including fluorouracil, cisplatin, irinotecan, can improve radiation 
cytotoxicity synergistically. CT can also act by restraining post-radiation damage repair. The 
phase of the cell cycle is another determinant of radio-sensitivity. While cells in G2-M phase 
are most radiosensitive, cells in the S phase of the cell cycle are the most radio-resistant 
(Terasima, T. Tolmach, L.J., 1961). CT and RT also produce synergistic effect by targeting 
different phases of the cell cycle when used concurrently. Moreover, drugs such as taxanes 
has the ability to block the cell cycle at the G2-M phase so that enhances the radiation effect 
(Tishler, R.B., et al., 1992).  
Several randomized trials assessed the effectiveness of chemo-radiation after curative 
surgery. Dent et al. performed randomized trial including 142 patients with all stages of 
gastric carcinoma. The patients in Division I (T1-3, N1-2, and M0) were assigned to control 
and RT plus 5-FU group. Division II (T4, M1) was randomized into three groups; a control 
group, RT plus 5-FU, thiotepa for six months. After 4.5 year’s follow-up the control and 
treatment groups did not differ with respect to survival rate in neither Division I nor 
Division II (Dent, D.M., et al., 1979). In the randomized trial conducted by Bleiberg and 
colleagues, 115 patients who underwent curative and palliative surgery were stratified into 
four treatment groups. Patients received RT alone or in combination with short-term and/or 
long term 5-FU infusion. Statistically differences were determined in terms of overall 
survival but the difference in survival disappeared when comparisons adjusted for 
prognostic factors (Bleiberg, H., et al., 1989). In the study by Moertel and co-workers 62 
patients with resectable but poor prognosis gastric carcinoma were randomized to surgery 
versus surgery plus adjuvant treatment with 5-FU plus radiation. Although both five-year 
survival rates and local-regional recurrence favored treatment arm results did not reach 
statistical significance (Moertel, C.G., et al., 1984). 
The largest trial evaluating the use of postoperative chemoradiation was U.S. Intergroup 
0116 trial (Macdonald, J.S., et al., 2001). In this study 556 patients with curatively resected 
gastric or gastroesophageal junction adenocarcinoma (stage Ib through IV M0) were 
randomized to surgery alone or adjuvant combined chemoradiotherapy (CRT). The 
adjuvant treatment consisted of one course of 5-FU 425 mg/m2/d and leucovorin 20 
mg/m2/d, daily for five days, followed one month later by 45 Gy of radiation during 5 
weeks with 5-FU 425 mg/m2/d and leucovorin 20 mg/m2/d on days 1 through 4 and last 3 
days of radiation. One month after completion of RT 2 more 5-day cycles of CT (5-FU 425 
mg/m2/d plus leucovorin 20 mg/m2/d) were administered. After a median follow-up of 5 
years, the median duration of survival was 36 and 27 months in the CRT and surgery-only 
groups, respectively. The 3-year survival rates were 50% versus 41% favoring adjuvant 
treatment. The 3-year rates of relapse free survival increased from 31.0% to 48.0% in the CRT 
group. Improvements both in overall and relapse free survival were statistically significant. 
Grades 3 and 4 toxic effects (mostly, hematologic and gastrointestinal) occurred in 41.0% 
and 32.0% of chemo-RT groups, respectively. Three patients (%1) died as a result of toxic 
effect of the treatment. The extent of the surgical resection was an important issue in the 
study protocol. Although, D2 dissection was recommended, only 10.0% of patients 
underwent a D2 dissection, 54.0% of the patients underwent D0 dissection (in which all of 
the N1 nodes were not resected). When patients relapse patterns were examined, local-
regional recurrence was higher in the surgery only group, despite the higher distant 
metastasis rates detected in the CRT group (statistical assessment of the relapse sites were 
not included in the study). The study demonstrated that the benefit of CRT in the adjuvant 
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setting was mainly apparent by reducing loco-regional recurrence. At the end of the study 
Macdonald et al. suggested that, postoperative CRT should be considered for all patients at 
high risk for recurrence of adenocarcinoma of the stomach or gastro-esophageal junction 
who undergone curative resection. 
4. Intra-peritoneal chemotherapy      
Peritoneal spread of tumor cells is frequently seen in the course of gastric carcinoma. The 
expected median survival time is approximately 3 to 6 months when peritoneal 
carcinomatosis and ascites become evident (Sakata, Y., et al., 1998). The rationale to use 
peritoneal route to prevent and/or treat the peritoneal spread is to deliver higher 
concentrations of CT within peritoneal cavity without marked systemic toxicity. Several 
randomized trials assessed the role of intra-peritoneal CT with different aspects regarding 
the timing of drug administration, the type of chemotherapeutic agents and the impact of 
hyperthermia. At least two meta-analyses of randomized clinical trials on adjuvant intra-
peritoneal CT for curatively resected gastric cancer showed clinical benefit of this treatment. 
The meta-analysis by Xu and colleagues included eleven trials involving 1161 cases (Xu, 
D.Z., et al., 2004). All included trials were randomized, controlled trials that compared 
surgery plus intra-peritoneal CT with or without activated carbon particles with surgery 
alone. No other adjuvant treatment including oral or parenteral CT, RT or chemo-
immunotherapy was used in the adjuvant group. In the study 609 patients were assigned to 
the treatment group and 552 to the control group. Most of the studies used mitomycin C 
with or without carbon particles as a chemotherapeutic agent. The pooled odds ratio was 
0.51 with a 95% confidence interval (0.40-0.65). Moreover, in the subgroup analysis trials 
that used intra-peritoneal hyperthermic chemoperfusion or CT with activated carbon 
particles was more effective than the trials without hyperthermia and carbon particles. The 
other meta-analysis performed by Yan and coworkers also involved 13 randomized control 
trials that compared surgery plus intra-peritoneal CT to surgery alone (Yan, T.D., et al., 
2007). The trials included patients with locally advanced gastric cancer without distant 
metastasis. In the study intra-peritoneal chemotherapies grouped in five categories 
according to the timing of the procedure and whether hyperthermia was used. The 1st group 
was composed of trials assessing the role of hyperthermic intra-operative intra-peritoneal 
CT (HIIC). The 2nd group involved trials investigating normothermic intra-operative intra-
peritoneal CT (NIIC). The 3rd group was composed of trials exploring the efficiency of early 
postoperative intra-peritoneal CT (EPIC). The 4th group included combined forms and the 
5th group included the trials of delayed postoperative intra-peritoneal CT (DPIC). The study 
showed significant survival benefit in favor of HIIC (Hamazoe, R., et al., 1994) (HR:0.60; 
95% CI;0.43-0.83) and HIIC combined with EPIC (Gao Z, J.Z., Zhou F, 2002, Wei, G., et al., 
2005) (HR:0.45;95%CI:0.29-0.68). The improved survival provided by NIIC did not reach 
statistical significance (Rosen, H.R., et al., 1998, Takahashi, T., et al., 1995, Yonemura, Y., et 
al., 2001) (HR:0.67;95% CI:044-1.01; p=0.06), no benefit was found either with EPIC 
(HR:0.64;95% CI:037-1.10) or DPIC (HR:0.89;95% CI:0.51-1.55). The meta-analysis did not 
show significant difference in perioperative mortality between the 2 arms. The incidence of 
intra-abdominal abscess was significantly higher among patients in the intra-peritoneal CT 
arm. Though none of the individual trial showed increased incidence in terms of 
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neutropenia the meta-analysis found intra-peritoneal chemotherapy associated with 
increased risk of neutropenia. The authors of the meta-analysis concluded that HIIC with or 
without EPIC after resection of advanced gastric cancer was associated with improved 
overall survival at the expense of  increased risk of intra-abdominal abscess and 
neutropenia. 
5. Current standard of care in the world 
Surgical resection with lymph node dissection is the primary treatment of early gastric 
cancer. Total gastrectomy is preferred for tumors arising from proximal stomach or tumors 
infiltrating stomach diffusely. For distal gastric cancers subtotal gastrectomy is procedure of 
choice due to fewer complications, lower morbidity and similar survival compared with 
total gastrectomy (Bozzetti, F., et al., 1999). Endoscopic mucosal resection is the standard 
treatment in Japan for early gastric cancer limited to mucosa without lymph node 
involvement  (Soetikno, R., et al., 2005). 
The extent of lymph node dissection still remains to be a matter of debate.  Although 
gastrectomy with D2 lymphadenectomy is the standard treatment in Japan, in Western 
studies extensive lymphadenectomy have not provided survival benefit when compared 
with D1 lymph node dissection (Bonenkamp, J.J., et al., 1999). D2 dissection is more and 
more adopted in western societies. 
 In United Kingdom and most of the parts of Europe perioperative CT with ECF regimen 
became the standard of care, based on the results of the MAGIC trial. This approach is also 
recommended with level 1 evidence in United States (U.S.) for patients with T2 or higher 
tumors.  
The results of INT-0116 trial changed standard of care in United States from observation to 
chemo-radiation after curative resection of gastric cancer without evidence of metastasis. 
Patients with T3, T4 or node positive tumors are recommended to be treated with RT (45-50 
Gy) concurrent with 5-FU plus 5-FU (with leucovorin) after curative resection in U.S., 
although this approach has not been accepted in most of Europe and Japan. 
In Japanese population adjuvant CT with S-1 was detected to improve survival after gastric 
resection with D2 lymph-node dissection in stage II-III gastric cancer. Though it seems to be 
feasible adjuvant treatment option in East Asian patients, there is not enough data to 
recommend this approach in Western population. 
6. Future directions   
Despite advances both in adjuvant and metastatic setting, overall survival in gastric cancer 
remains to be poor. New agents and new schedules which have been proved to be effective 
are being integrated into trials of neoadjuvant or adjuvant trials. Emerging data from clinical 
trials evaluating combination chemotherapies and new molecular targeted therapies has 
shown clinical benefit especially in metastatic disease. The efficacy of these novel therapies 
should be confirmed in well designed prospective randomized clinical trials.  
Newer chemotherapeutic agents, namely taxanes, oral fluoropyrimidines (UFT, S1, 
capecitabine) and irinotecan have widely searched in advanced stages of gastric cancer. 
Naturally, it is expected that the most effective and tolerable chemotherapeutic strategies in 
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setting was mainly apparent by reducing loco-regional recurrence. At the end of the study 
Macdonald et al. suggested that, postoperative CRT should be considered for all patients at 
high risk for recurrence of adenocarcinoma of the stomach or gastro-esophageal junction 
who undergone curative resection. 
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Peritoneal spread of tumor cells is frequently seen in the course of gastric carcinoma. The 
expected median survival time is approximately 3 to 6 months when peritoneal 
carcinomatosis and ascites become evident (Sakata, Y., et al., 1998). The rationale to use 
peritoneal route to prevent and/or treat the peritoneal spread is to deliver higher 
concentrations of CT within peritoneal cavity without marked systemic toxicity. Several 
randomized trials assessed the role of intra-peritoneal CT with different aspects regarding 
the timing of drug administration, the type of chemotherapeutic agents and the impact of 
hyperthermia. At least two meta-analyses of randomized clinical trials on adjuvant intra-
peritoneal CT for curatively resected gastric cancer showed clinical benefit of this treatment. 
The meta-analysis by Xu and colleagues included eleven trials involving 1161 cases (Xu, 
D.Z., et al., 2004). All included trials were randomized, controlled trials that compared 
surgery plus intra-peritoneal CT with or without activated carbon particles with surgery 
alone. No other adjuvant treatment including oral or parenteral CT, RT or chemo-
immunotherapy was used in the adjuvant group. In the study 609 patients were assigned to 
the treatment group and 552 to the control group. Most of the studies used mitomycin C 
with or without carbon particles as a chemotherapeutic agent. The pooled odds ratio was 
0.51 with a 95% confidence interval (0.40-0.65). Moreover, in the subgroup analysis trials 
that used intra-peritoneal hyperthermic chemoperfusion or CT with activated carbon 
particles was more effective than the trials without hyperthermia and carbon particles. The 
other meta-analysis performed by Yan and coworkers also involved 13 randomized control 
trials that compared surgery plus intra-peritoneal CT to surgery alone (Yan, T.D., et al., 
2007). The trials included patients with locally advanced gastric cancer without distant 
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peritoneal CT (NIIC). The 3rd group was composed of trials exploring the efficiency of early 
postoperative intra-peritoneal CT (EPIC). The 4th group included combined forms and the 
5th group included the trials of delayed postoperative intra-peritoneal CT (DPIC). The study 
showed significant survival benefit in favor of HIIC (Hamazoe, R., et al., 1994) (HR:0.60; 
95% CI;0.43-0.83) and HIIC combined with EPIC (Gao Z, J.Z., Zhou F, 2002, Wei, G., et al., 
2005) (HR:0.45;95%CI:0.29-0.68). The improved survival provided by NIIC did not reach 
statistical significance (Rosen, H.R., et al., 1998, Takahashi, T., et al., 1995, Yonemura, Y., et 
al., 2001) (HR:0.67;95% CI:044-1.01; p=0.06), no benefit was found either with EPIC 
(HR:0.64;95% CI:037-1.10) or DPIC (HR:0.89;95% CI:0.51-1.55). The meta-analysis did not 
show significant difference in perioperative mortality between the 2 arms. The incidence of 
intra-abdominal abscess was significantly higher among patients in the intra-peritoneal CT 
arm. Though none of the individual trial showed increased incidence in terms of 
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neutropenia the meta-analysis found intra-peritoneal chemotherapy associated with 
increased risk of neutropenia. The authors of the meta-analysis concluded that HIIC with or 
without EPIC after resection of advanced gastric cancer was associated with improved 
overall survival at the expense of  increased risk of intra-abdominal abscess and 
neutropenia. 
5. Current standard of care in the world 
Surgical resection with lymph node dissection is the primary treatment of early gastric 
cancer. Total gastrectomy is preferred for tumors arising from proximal stomach or tumors 
infiltrating stomach diffusely. For distal gastric cancers subtotal gastrectomy is procedure of 
choice due to fewer complications, lower morbidity and similar survival compared with 
total gastrectomy (Bozzetti, F., et al., 1999). Endoscopic mucosal resection is the standard 
treatment in Japan for early gastric cancer limited to mucosa without lymph node 
involvement  (Soetikno, R., et al., 2005). 
The extent of lymph node dissection still remains to be a matter of debate.  Although 
gastrectomy with D2 lymphadenectomy is the standard treatment in Japan, in Western 
studies extensive lymphadenectomy have not provided survival benefit when compared 
with D1 lymph node dissection (Bonenkamp, J.J., et al., 1999). D2 dissection is more and 
more adopted in western societies. 
 In United Kingdom and most of the parts of Europe perioperative CT with ECF regimen 
became the standard of care, based on the results of the MAGIC trial. This approach is also 
recommended with level 1 evidence in United States (U.S.) for patients with T2 or higher 
tumors.  
The results of INT-0116 trial changed standard of care in United States from observation to 
chemo-radiation after curative resection of gastric cancer without evidence of metastasis. 
Patients with T3, T4 or node positive tumors are recommended to be treated with RT (45-50 
Gy) concurrent with 5-FU plus 5-FU (with leucovorin) after curative resection in U.S., 
although this approach has not been accepted in most of Europe and Japan. 
In Japanese population adjuvant CT with S-1 was detected to improve survival after gastric 
resection with D2 lymph-node dissection in stage II-III gastric cancer. Though it seems to be 
feasible adjuvant treatment option in East Asian patients, there is not enough data to 
recommend this approach in Western population. 
6. Future directions   
Despite advances both in adjuvant and metastatic setting, overall survival in gastric cancer 
remains to be poor. New agents and new schedules which have been proved to be effective 
are being integrated into trials of neoadjuvant or adjuvant trials. Emerging data from clinical 
trials evaluating combination chemotherapies and new molecular targeted therapies has 
shown clinical benefit especially in metastatic disease. The efficacy of these novel therapies 
should be confirmed in well designed prospective randomized clinical trials.  
Newer chemotherapeutic agents, namely taxanes, oral fluoropyrimidines (UFT, S1, 
capecitabine) and irinotecan have widely searched in advanced stages of gastric cancer. 
Naturally, it is expected that the most effective and tolerable chemotherapeutic strategies in 
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the metastatic setting should be evaluated in earlier stages. In the V325 trial by Van Cutsem 
et al. the combination of docetaxel, cisplatin and 5-FU (DCF), was significantly superior than 
cisplatin plus 5-FU (CF) in terms of OS, time to tumor progression and response rate (Van 
Cutsem, E., et al., 2006). In the phase II randomized trial (NEOTAX) DCF combination CT 
will be evaluated as a neoadjuvant therapy in locally advanced gastric adenocarcinoma 
(Clinicaltrials.gov number is NCT00343239). The objective of this study is to determine the 
impact of DCF combination CT on R0 resection rate in gastric cancer. Patient recruitment is 
over and the first results are expected in January 2012. 
In the large CRITICS trial, the question of whether adjuvant CRT with weekly cisplatin  and 
capecitabine after 3 cycles of neoadjuvant ECC (epirubicin, cisplatin and capecitabine) and 
surgery in comparison with 3 more cycles of the neoadjuvant schedule (clinicaltrials.gov no: 
NCT00407186). Nearly 800 patients are expected to be recruited and the first results are 
awaited in 2013. 
The rationale to combine targeted therapies with CT is to improve the efficacy with 
acceptable toxicity. Epidermal growth factor receptor 2 (also known as HER-2) has become 
important target in gastric cancer. Trastuzumab, a fully humanized monoclonal antibody 
against HER-2, was recently evaluated in metastatic gastric cancer. In randomized phase 3 
ToGA trial patients were randomly assigned to receive trastuzumab plus CT (capecitabine 
plus cisplatin or fluorouracil plus cisplatin) or CT alone. The study revealed that median 
overall survival was 13.8 months in those assigned to trastuzumab plus CT as compared 
with 11.1 months in those received CT alone (HR: 0.74; 95% CI:0.60-0.91; P=0.046). The 
authors suggested that trastuzumab plus CT substantially improved OS in patients with 
high expression of HER-2 protein (immunohistochemistry 2+ and FISH + or 
immunohistochemistry 3+) compared with patients with low expression of HER-2 
(immunohistochemistry 0 or 1+ and FISH+). It was also reported that combining 
trastuzumab with CT did not cause additional toxic effect (Bang, Y.J., et al., 2010). It is 
currently not known whether the benefit achieved in metastatic gastric cancer will be 
translated to adjuvant setting. It was also shown that replacing cisplatin with oxaliplatin and 
fluorouracil with capecitabine is not inferior than the classical ECF (epirubicin, cisplatin, 
fluorouracil)(Okines, A.F., et al., 2009).  A study of capecitabine in combination with 
trastuzumab and oxaliplatin in patients with resectable gastric cancer, namely TOXAG 
(Trastuzumab, Oxaliplatin, and Xeloda for Adjuvant Gastric Cancer) was recently designed 
to evaluate the impact of trastuzumab in adjuvant and adjuvant strategy. 
Bevacizumab, recombinant humanized monoclonal antibody that targets vascular 
endothelial growth factor, was recently studied in combination with irinotecan and cisplatin 
in patients with metastatic gastric adenocarcinoma in a phase II multicenter study (Shah, 
M.A., et al., 2006). The study revealed that, time to disease progression improved by 75% in 
compared to historical controls. Rates of rare but important complications of bevacizumab, 
namely gastrointestinal perforation and hemorrhage, was also found similar to rates of 
several recent large advanced phase studies. The authors of this study concluded that 
bevacizumab could be added to CT safely and was active in the treatment of advanced 
gastric adenocarcinoma. A randomized phase III trial will assess the safety and efficacy of 
neoadjuvant and adjuvant CT including epirubicin, cisplatin and capecitabine with or 
without bevacizumab in patients with untreated resectable gastric or gastroesophageal 
junction cancer (MAGIC-B Study) (clinicaltrials.gov no: NCT00407186). Planning to have 
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1100 patients, the results of this study may clarify the role of bevacizumab in 
adjuvant/neoadjuvant setting. 
There are also adjuvant studies exploring the role of S-1, a newer oral fluoropyrimidine 
analog. 
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1. Introduction 
Advances in diagnosis and surgical techniques have improved the conditions of patients 
with gastric cancer.  Peritoneal dissemination, however, is still the most frequent cause of 
death, and the prognosis of patients with peritoneal metastasis of gastric cancer is extremely 
poor (Balfour, 1973; Hioki et al.,2010; Maruyama, 1987; Makino et al., 2010; M. Yamamoto et 
al., 2009). In patients with serosal invasion, about half develop peritoneal recurrence and die 
from the disease within the first 2 years of follow-up, even if curative resection is performed 
(Abe et al., 1995; Ikeguchi et al., 1994; Kaibara et al., 1987; Moriguchi et al., 1992; Ribero et 
al., 1998). Furthermore, it has been reported that the survival span of the patients with 
cytology-positive peritoneal lavage fluid and without the macroscopic peritoneal 
dissemination (CY+/P-) of gastric cancer was almost the same as that of patients with P+ 
(Boku, et al., 1990; Shimada et al., 2003), and the 5-year survival rate of patients with 
CY+/P- is only 2% (Bando et al., 1999). Accordingly, the treatment recommendations for 
gastric cancer in the event of positive cytology range from palliative chemotherapy to 
attempts at neo-adjuvant therapies followed by surgical resection. However, the results of 
published randomized clinical trials of adjuvant perioperative intra-peritoneal 
chemotherapy have not fully demonstrated any significant improvement in survival as 
compared with surgery alone, especially in the cases with P+ (Cunliffe & Sugarbaker, 1989; 
Cheong et al., 2007; Hagiwara et al., 1992; Ikeguchi et al., 2005; Kunisaki et al., 2002; Sauter 
et al., 1994). Therefore, a reliable and appropriate standard prophylactic regimen for 
peritoneal recurrence in patients with gastric cancer needs be established. 
Clinical and pathologic factors that have been found to correlate with the presence of 
positive cytology are usually at an advanced stage of the disease (Burke et al., 1998; Iitsuka 
et al., 1979; Koga et al., 1984; Ribeiro et al.,2006; Yawata et al.,1998). The most likely cause is 
the presence of intra-peritoneal free cancer cells from the serosal surface of the primary 
cancer and their implantation on the peritoneum. Furthermore, our previous study proved 
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that lymph node dissection opened the lymphatic channel and spread viable cancer cells 
into the peritoneal cavity (Marutsuka et al., 2003). This could explain the main reason for the 
peritoneal recurrence after curative surgery for patients with non serosa-invasive gastric 
cancer. 
Peritoneal dissemination is probably completed by the implantation of peritoneal free 
cancer cells exfoliated from serosa-invasive tumors. Consequently, it is very important to 
prevent peritoneal metastasis prior to the fixation and progression of free cancer cells to the 
peritoneum in patients with advanced gastric cancer. This is because the presence of intra-
peritoneal free cancer cells without macroscopic dissemination could possibly indicate a 
condition wherein the implantation of cancer cells on the intra-peritoneal wall has not yet 
occurred.  
Based on this assumption, we have been advocating the adoption of ‘extensive intra-
operative peritoneal lavage’ (EIPL) (Shimada et al., 2002; K. Yamamoto et al., 2005) as a 
reliable and practical intra-operative technique as an adjuvant therapy for preventing the 
implantation of cancer cells on the intra-peritoneal wall after a potentially curative resection 
combined with intra-peritoneal chemotherapy (EIPL-IPC). EIPL is very simple and can be 
performed anywhere and at anytime. It is a rather efficient method for reducing the number 
of intra-peritoneal free cancer cells to zero potentially, when the cancer cells are analyzed by 
a detection system using real-time reverse transcriptase-polymerase chain reaction (RT-
PCR), and intra-peritoneal chemotherapy subsequent to EIPL could be effective for 
eradicating the remaining cancer cells. We have confirmed the clinical effectiveness of EIPL 
by ultra-rapid quantitative RT-PCR protocol (Marutsuka et al., 2003). Very few intra-
peritoneal free cancer cells could be detected in the washing fluid after 6 to 8 washes.  
Finally, our recent prospective randomized controlled clinical trial clearly revealed that 
EIPL therapy significantly improved the 5-year survival rate of advanced gastric patients 
with intra-peritoneal free cancer cells (Kuramoto et al., 2009). 
In this manuscript, the risk factors on peritoneal recurrence from clinicopathological 
features of gastric carcinoma and the contribution of EIPL method to the remarkable 
improvement in the 5-year survival for patients with CY+/P- on clinical trials is reviewed, 
and the optimal treatment protocol for patients with gastric cancer is proposed. 
2. Clinicopathological features and risk factors on peritoneal recurrence for 
gastric carcinoma 
Results of specific preoperative studies, intraoperative findings, postoperative pathologic 
staging, clinical management, and follow-up data from 2117 patients underwent gastric 
resection with D2 lymph nodes dissection for primary gastric carcinoma were registered 
prospectively (Shimada S, et al.). Preoperative diagnosis was made on the basis of 
endoscopic, radiologic, and endoscopic ultrasonographic (EUS) (Kida et al., 1998) findings. 
Pathologic diagnosis and classifications were based on the Japanese Classification of Gastric 
Carcinoma by the Japanese Research Society for Gastric Cancer (Japanese Research Society 
for Gastric Cancer, 1999). 
The incidences of lymph node metastasis from tumors with mucosal (M), submucosal (SM), 
and advanced gastric cancer were 2.5%, 20.2%, and 71.2%, respectively. The detailed 
pathological analysis revealed that all M tumors with lymph node metastasis (n=14) had 
ulceration or ulceration scar (UL+) in the lesions even if the lesion was smaller than 1.5 cm 
in diameter. On the other hand, no M tumor without ulceration or ulceration scar (UL-) 
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(n=328) had any lymph node metastasis. In advanced gastric cancer, approximately 57% of 
the metastatic tumors had distant lymph nodes metastasis.  Serosal invasion was also 
popular in advanced gastric cancer; approximately 50% of the advanced tumors had serosal 
invasion. 
Fig 1 showed cancer-specific 5-year survival rates of gastric cancer according to the tumor 
depth.  Gastric resection with D2 lymph nodes dissection for primary gastric carcinoma 
yielded good prognosis in M and SM tumors; 98% and 95% of the cancer-specific 5-year 
survival rates, respectively.  There were no apparent prognostic factors in patients with M 
tumors. In patients with SM tumors, the cancer-specific 5-year survival of those with lymph 
node metastasis was significantly lower than that of those without such metastasis (77.6% vs 
98.2%; P < 0.001). An sharp decrease in survival was seen between patients with two 
positive nodes and those with three positive nodes, and the cancer-specific 5-year survival 
rate of patients with three or more metastatic lymph nodes was significantly lower than that 
of those with one or two nodes (P = 0.041). Multivariate analyses revealed that the 
involvement of three or more lymph nodes was the sole independent prognostic 
determinant (P = 0.016); the level of nodal metastasis was not an independent prognostic 
factor (P = 0.384). In advanced gastric cancer, serosal invasion was the strong prognostic 
factor as well as the factor of more than three lymph nodes metastasis.  These results suggest 
that gastric cancer patients with lymph nodes metastasis and serosal invasion should be 
given special weight of additional therapy after surgery (Fig. 1).  
 
 
Fig. 1. Cancer-specific 5-year survival rates of gastric cancer according to the tumor depth.  
M: mucosal tumor, SM: submucosal tumor, MP: tumor with muscularis proprial invasion, 
SS: tumor with subserosal invasion, SE: tumor with serosal invasion, SI: tumor invasion of 
adjacent structures (Shimada et al., 2003) 
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3. Real-time detection system for Intra-peritoneal free cancer cells 
An ultra-rapid quantitative RT-PCR protocol, which is a combined system of an ultra-rapid 
RT-PCR, using a fully automated mRNA extractor and a real-time one-step RT-PCR system 
with a hybridization probe format, has been established to diagnose intra-peritoneal cancer 
cells spread during a surgical operation (Marutsuka et al., 2003). This new method enabled 
us to obtain the results of RT-PCR within approximately 70 minutes after sampling.  
Furthermore, we carried out multiple-marker RT-PCR assays in a combination of 
carcinoembryonic antigen (CEA) and cytokeratin 20 (CK20) to eliminate false positive 
results and to improve specificity.  This assay system was able to detect at least 10 cancer 
cells in 1×107 of leukocytes, indicating comparable sensitivity to conventional nested-RT-
PCR. Accordingly, the accurate diagnosis of the spread of intra-peritoneal cancer cells was 
done during the actual operation (Fig. 2). 
 
 
Fig. 2. Sensitivity of ultra-rapid quantitative RT-PCR assay by LightCyclerTM using CEA (A) 
and CK20 (B) mRNA marker. Curves and lanes 1-5 were serially diluted 105 cells to 101 cells of 
WiDr colon carcinoma cell in 107 leukocytes from healthy volunteer, respectively; curve and 
lane 6: 107 leukocytes from healthy volunteer; curve and lane 7: no template. This assay system 
could detect at least 10 WiDr colon carcinoma cells in 107 leukocytes. The PCR products were 
analyzed by 2% agarose gel electrophresis, and they were matched to the expected sizes of 
CEA and CK20.  ‘Crossing points’ were used to establish an external standard curve for 
quantification.  Forty-five rounds of amplification were completed within 30min. (Marutsuka 
et al., 2003) 
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4. Mechanisms of peritoneal recurrence after operation for non-serosa-
invasive gastric cancer 
Even though curative surgery has been performed for patients with non- serosa-invasive 
gastric cancer, some patients die of peritoneal recurrence (Abe et al., 1995; Bozzetti et al., 
1986; Fink & Longmire, 1991; Shimada et al., 2001a; Yoo et al., 2000). As shown in Table 1, 
even in patients with early gastric cancer, three out of 420 died of peritoneal recurrence. 
 
 
Table 1. Lymph node metastasis and cancer death in early gastric carcinoma treated by D2 
gastrectomy 
Our investigations based on the intraoperative ultra-rapid RT-PCR system elucidated the 
cause (Marutsuka et al., 2003). Peritoneal lavage samples from 63 patients with non-serosa-
invasive gastric carcinoma were obtained at laparotomy and immediately after lymph node 
dissection.  To identify the free cancer cells in the samples, CEA and CK20 specific RT-PCR 
were performed using LightCyclerTM method in combination with an automated mRNA 
extractor. In the peritoneal lavage samples from non-serosa-invasive cases after lymph node 
dissection, a CEA mRNA product was detected in 15 of 63 patients (23.8%) (Fig. 3). This was 
not evident in the mucosal (M) tumors, but was identified in three (14.3%), five (33.3%), and 
seven (53.8%) patients with submucosal (SM), muscularis propria (MP), and subserosal (SS) 
tumor, respectively.  As regards CK20 mRNA, the product was identified in 14 of 63 
patients (22.2%).  Just like CEA mRNA, CK20 mRNA was not detected in the mucosal 
tumors, but was identified in three (14.3%), five (33.3%), and six patients (46.2%) with SM, 
MP, and SS tumor, respectively.  Both CEA mRNA and CK20 mRNA were detected in three 
(14.3%), four (26.7%), and six (46.2%) with SM, MP, and SS tumor, respectively.  In 
consequence, the number of free cancer cells, calculated by the standard curve for cancerous 
cells, were 3.5 ± 3.7 (mean ± SD), 12.1 ± 9.6, and 124.8 ± 224.0 cells/100ml in the lavage after 
lymph node dissection from SM, MP, and SS tumor, respectively.  
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PCR. Accordingly, the accurate diagnosis of the spread of intra-peritoneal cancer cells was 
done during the actual operation (Fig. 2). 
 
 
Fig. 2. Sensitivity of ultra-rapid quantitative RT-PCR assay by LightCyclerTM using CEA (A) 
and CK20 (B) mRNA marker. Curves and lanes 1-5 were serially diluted 105 cells to 101 cells of 
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lane 6: 107 leukocytes from healthy volunteer; curve and lane 7: no template. This assay system 
could detect at least 10 WiDr colon carcinoma cells in 107 leukocytes. The PCR products were 
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Establishment of the Standard Prophylactic Strategy for Peritoneal Recurrence 
and Proposal of the Optimal Therapeutic Protocol for Gastric Cancer 
 
317 
4. Mechanisms of peritoneal recurrence after operation for non-serosa-
invasive gastric cancer 
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This study using the intraoperative ultra-rapid RT-PCR system revealed that free cancer 
cells were found in 14.3% and 26.7% of the lavage fluid after lymph node dissection from 
patients with SM and MP tumors, respectively.  Statistical analysis demonstrated that lymph 
node metastasis was the independent predictor for the existence of intra-peritoneal free 
cancer cells after lymph node dissection.  
From our previous study on 1272 cases of gastric carcinoma, 1/257 cases (0.4%) of SM and 
6/136 cases (4.4%) of MP cases developed peritoneal metastasis after potentially curative 
operation (Shimada et al., 2001a, 2003). Among them, 86% of the patients had lymph node 
metastasis and/or lymphatic invasion.  Our results determined that lymph node dissection 
is the main factor for spreading viable free cancer cells into the peritoneal cavity.  Thus, it 
was proved that lymph node dissection opens the lymphatic channel and spreads viable 
cancer cells into the peritoneal cavity. 
 
 
Fig. 3. Representative results of ultra-rapid RT-PCR by LightCyclerTM in a patient with SM 
tumor of well-differentiated adenocarcinoma with lymph node metastasis and lymphatic 
invasion. Curve 1: WiDr colon cancer cells as positive control; curve 2: intraperitoneal 
lavage sample at laparotomy; curve 3: intraperitoneal lavage sample immediately after 
lymph nodes dissection; curve 4: no template as negative control. (Marutsuka et al., 2003) 
5. EIPL therapy 
To date, there are no definitive effective therapies for peritoneal carcinomatosis.  Therefore, 
attention has been paid to detecting peritoneal free cancer cells in patients with advanced 
gastric carcinoma without overt peritoneal metastasis, and attempts to prevent peritoneal 
metastasis (S. Fujimoto et al.,1999; T. Fujimoto et al., 2002; Hamazoe et al., 1994; Hayes et al., 
1999; Rosen et al, 1998; C.C. Wu et al., 1997, Yonemura et al., 1995; Yu et al., 1998).   
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The status of CY+/P- includes the condition where peritoneal implantation has not occurred 
yet. We have proposed that EIPL is a quite formidable method for reducing the number of 
cells to potentially zero, just like the so-called ‘limiting dilution’ approach. EIPL was 
performed in five cases of serosa-invasive (SE) gastric carcinoma with CY+/P-, and its 
efficacy was evaluated by the ultra-rapid quantitative RT-PCR protocol (Shimada et al., 
2002). Sequential washing of intra-peritoneal free cancer cells of 3.8 × 105 ± 1.4 × 105/100ml 
of lavage decreased the number to 2.8 ± 1.5 cells by 6 to 8 washes.  Free cancer cells were not 
detected in the washing fluid after that (Fig. 4). 
 
 
Fig. 4. Changes in numbers of intra-peritoneal free cancer cells in five gastric cancer patients 
with CY+ treated by EIPL therapy.  The numbers of free cancer cells in 100 ml of samples 
from the first to the 10th wash using each 1 litter of saline were quantitated by ultra-rapid 
RT-PCR.  The free cancer cells in the lavage fluids were serially diluted by 8 litters of saline 
and disappeared in washing fluids after the 8th wash. 
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On the other hand, 2.8 × 104 ± 4.5 × 104 of intra-peritoneal free cancer cells still remained in 
100ml of the lavage when not treated with EIPL. Our preliminary subset analysis based on 
24 consecutive patients with CY+/P- who underwent curative surgical treatment for 
advanced gastric cancer, and were followed up for 2 years or until death, has shown a 
statistically significant (P = 0.017) improvement of a two-year survival rate when treated 
with EIPL as compared with when not treated with EIPL (Shimada et al., 2002). 
6. Five-year survival rates of patients who had EIPL therapy through a 
prospective randomized clinical trial 
Following a pioneering study (Shimada et al., 2002; K. Yamamoto et al., 2005), we performed 
the EIPL therapy for advanced gastric cancer patients with CY+/P- in order to clearly clarify 
the distinct 5-year survival effects through a prospective randomized multicenter trial 
(Kuramoto et al., 2009). A total of 88 gastric cancer cases with CY+/P- from 1522 patients 
with advanced gastric cancer at multicenter were enrolled in this study, and were randomly 
allocated to three groups: surgery alone group, surgery plus intra-peritoneal chemotherapy 
(IPC) group, and surgery plus EIPL and IPC (EIPL-IPC) group. In EIPL-IPC group, 100mg of 
cisplatin (CDDP) was administered into the peritoneal cavity, after the EIPL treatment. 
Peritoneal lavage for the surgery alone group and the IPC group was done with 3 liters (1 
liter, three times) before the closure of the abdominal wall or intra-peritoneal chemotherapy, 
respectively. 
The overall five-year survival rate of the patients with EIPL-IPC was 43.8%, and this data 
was significantly higher than that of the IPC group (4.6%, P < 0.0001) and the surgery alone 
group (0 %, P < 0.0001) (Fig. 5). Among various recurrent patterns, the EIPL-IPC group had 
a significantly lower incidence of peritoneal recurrence than either of the other groups (P < 
0.0001).  Univariate and multivariate analyses clearly revealed that EIPL was the most 
significant impact factor.  
The results of the present prospective randomized multicenter study far exceeded our 
expectations and showed a remarkably much better prognosis than previous studies on 
gastric cancer patients with CY+/P-. For example, a study on the median survival time 
(MST) of 91 patients with CY+/P- who had potentially curative resection stated survival to 
be only 386 days (Kodera et al., 1999), and the 5-year overall survival rate has been 13% 
(Rosenberg et al., 2006). In this study, the surgery alone group as well as the IPC group also 
showed similar results to the reports just cited. Surprisingly, however, in the CY+/P- group 
the overall five-year survival rate and MST were 42.1% and 35 months, respectively, and 
showed remarkably significant (P < 0.0001) improvement of both survival and MST. The 
results appeared so convincing and promising to us as to serve as a solid basis for 
employing the EIPL-IPC therapy with a great degree of confidence and high expectations. 
7. Proposal of the optimal and practical therapeutic strategy for gastric 
cancer 
Based on the data presented in this review, the authors propose the following treatment 
protocol for gastric cancer (Fig. 6). Accurate diagnosis of mucosal or submucosal cancer is 
made macroscopically including an EUS examination. Mucosal and submucosal invasion is 
correctly diagnosed in 75 to 85% of patients using EUS. All mucosal lesions with UL- should 
be treated by endoscopic submucosal dissection (ESD). If histologic examination of the ESD 
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specimen reveals complete resection, the treatment is considered to be perfect and the 
patient only needs follow-up.  If histologic examination reveals an incomplete resection, 
laparoscopic local resection is required.  For a mucosal tumor with UL+, laparoscopic 
gastrectomy with D1 is indicated. All macroscopic SM and advanced cancer cancer (MP, SS, 
SE and SI) should be treated by gastrectomy with D2 (Shimada et al., 2001a). 
 
 
Fig. 5. The survival curves for 88 patients stratified according to the treatment. *By log-rank 
test. (Kuramoto et al., 2009) 
Although a Dutch report has described the high post-operative morbidity and hospital 
mortality after gastrectomy with D2 lymph node dissection (Bonenkamp et al., 1995), D2 
resections appear to be feasible and safe in Japanese (Japanese Research Society for Gastric 
Cancer, 1999; Kuramoto et al., 2009; Maruyama, 1987; Nakamura et al., 1992; Ohgaki et al., 
1999; Sano et al., 2004; Shimada et al., 2001b; C.W. Wu et al., 2008) and certain Western 
patients (Harrison et al., 1998; Lim et al., 2007). In our study, operative morbidity and 
hospital mortality was 1.5% (16 of 1051) and 0.5% (5 of 1051) respectively. Certain factors in 
the Dutch patients such as a more advanced tumor stage or larger physical build to the 
Japanese patients in this study might have influenced the high morbidity and mortality.  
The present study on patients with gastric cancer suggested that the potential benefits of D2 
operation outweigh the risk of increased postoperative morbidity and mortality.  Therefore, 
advanced gastric cancer should be treated by gastrectomy with D2, and D2+α may be 
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necessary for patients with apparent N2 and/or N3 lymph nodes metastasis. Complete 
extirpation of gastric cancer with a sufficient resection margin from the tumor and the 
removal of metastatic lymph nodes is the only treatment that offers hope of cure for patients 
with gastric cancer (Balfour, 1973; Harrison et al., 1998; Japanese Research Society for Gastric 
Cancer, 1999; Maruyama, 1987; Shimada et al., 2003; Zhang et al., 2010). However, as a 
matter of course, excessive gastrectomy and lymph node dissection have to be avoided for 
the adverse effects they have on a patient’s subsequent quality of life.  
From the viewpoint of prophylactic strategy against peritoneal recurrence, the findings 
presented in this paper should greatly transform the surgical treatment for gastric cancer, 
including non-serosa-involved tumors. The authors strongly advocate for the adoption of 
the new treatment protocol for gastric cancer as shown in Fig. 6.  
After the appropriate tumor resection and lymph node dissection, our novel EIPL regimen 
serves an extremely important role for gastric patients with high peritoneal recurrent risks 
such as serosal invasion and lymph node metastasis. The innovative EIPL method is very 
practical and the theoretical basis creates high expectation as to the effects of cyto-reduction, 
potentially to nil. Furthermore, the EIPL therapy is simple, very little time-consuming, 
inexpensive, it is not curtailed by place or time, and does not need any special techniques or 
devices in order to be applied.  In addition, even if a few cancer cells were to remain after 
EIPL therapy, these cells might find it difficult to survive and/or to disseminate due to the 
effects of IPC or postoperative systemic chemotherapy with S1 (Ishizoe et al., 2006; 
Shirasaka et al., 2000; Sugimachi et al., 1999) .  
Conventional cytological examination with Papanicolou staining (Papanicolaou, 1963) has 
been reported to lack sensitivity, and it is suggested that occult free cancer cells are present 
at the time of the operation in such cases. Therefore, improvements have been made by 
many investigators using immunological methods with selected monoclonal antibodies or 
real-time RT-PCR for the detection of free cancer cells in the peritoneal washes (Benevolo et 
al., 1998; Broll et al., 2001; Dicken et al., 2006; Kodera et al., 2002; Saito et al., 2007; P. Vogel et 
al., 1999; I. Vogel & Kalthoff, 2001). These methods have allowed the identification of 
cytology false-negative cases in gastric cancer. However, because these means are not 
generally available at the actual time of the operation, a cytological examination is 
commonly performed to detect the existence of free cancer cells in the peritoneal cavity. 
From these cautionary points of view, it is only prudent that the EIPL-IPC therapy would be 
employed for all patients with serosa-involved gastric cancer and regardless of CY+/P-. 
On the other hand, although curative surgery has been used for patients with non-serosa-
involved gastric cancer, some die of peritoneal recurrence. One of the reasons postulated for 
peritoneal dissemination in non-serosa-involved gastric cancer is that the lymph node 
dissection might open lymphatic channels and spread viable cancer cells to the peritoneal 
cavity (Fink & Longmire, 1991). We have demonstrated that free cancer cells were found in 
the lavage fluid after the lymph node dissection in 26.7% of patients with muscle-involved 
tumors, suggesting that the surgical operation itself causes the peritoneal dissemination of 
the these cancer cells (Marutsuka et al., 2003). Therefore, EIPL therapy is also strongly 
recommended for non-serosa-involved gastric carcinomas suspected of lymphatic invasion 
through surgery, or positive real-time RT-PCR for detection of free cancer cells in the 
peritoneal washes after D2 operation for non-serosa-involved tumor, including early gastric 
carcinoma (Fig. 6). 
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Fig. 6. A practical and optimal treatment protocol for gastric cancer. PR: peritoneal 
recurrence, M: mucosal tumor, SM: submucosal tumor, MP: tumor with muscularis proprial 
invasion, SS: tumor with subserosal invasion, SE: tumor with serosal invasion, SI: tumor 
invasion of adjacent structures, UL+: tumor with ulceration or ulceration scar, UL-: tumor 
without ulceration or ulceration scar, ESD: endoscopic submucosal dissection, D1 operation: 
gastrectomy with dissection of group 1 lymph node, D2 operation: gastrectomy with 
dissection of group 1 and 2 lymph node, N(+): positive lymph node metastasis through 
surgery, N(-): no evidence of lymph node metastasis, PCR: real-time reverse transcriptase-
polymerase chain reaction, EIPL: extensive intraoperative peritoneal lavage, IPC: intra-
peritoneal chemotherapy 
8. Conclusion 
EIPL therapy was developed as a prophylactic strategy for peritoneal recurrence, with the 
goal of improving the prognosis for patients with gastric cancer.  In the present article, the 
risk factors on peritoneal recurrence from clinicopathological features of gastric carcinoma 
and the therapy’s contribution to a remarkable improvement in the 5-year survival for 
gastric cancer patients with positive lavage cytology on prospective randomized controlled 
clinical trials was reviewed.  From the viewpoint of prophylactic strategy against peritoneal 
recurrence, we propose the optimal and practical treatment protocol for gastric cancer. 
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1. Introduction 
“Aprioristic passive attitude”: this is the mode that correctly defines the standard approach 
to gastric cancer patients presenting with hepatic metastases.  
This behaviour is deeply motivated by the aggressive biology of the disease that so often 
frustrates any therapeutic approach. In fact, at diagnosis liver metastases are often multiple 
and associated to other extra-hepatic metastatic sites [D’Angelica et al., 2004; Dicken et al., 
2005]. Furthermore, in the rare cases submitted to ablative treatments, hepatic and systemic 
recurrence has been experienced in the majority of cases. 
However, considering survival performances extrapolated from a cohort of 1452 patients 
submitted to hepatic resection for noncolorectal nonendocrine liver metastases [Adam et 
al.,2006], it was observed that metastases from gastric adenocarcinoma performed in an 
intermediate way, ranking 10th in a list of 18 primaries.  In fact, in selected cases an 
aggressive treatment can achieve unexpected results: 5-year survival rates from 10% to 40% 
have consistently been reported in surgical series considering patients with liver metastases 
as sole metastatic site.  
An aggressive attitude, however, doesn’t really penetrate into clinical practice and passivity 
still prevails, as depicted by an Italian survey reporting over 60% of patients not receiving 
specific treatments, including 30% of cases affected by 1 or 2 small metastases, and by 
therapeutic indication being influenced by patients’ determination [Tiberio et al., 2008]. This 
attitude is rather diffused if a recent review reported 436 surgically treated cases [Kerkar, 
2010] and a French survey recruited 101 patients from 41 centres [Chiche, 2005], numbers to 
be faced, for example, to more than 14700 resections for metastases from colo-rectal cancer 
enrolled in LiverMetSurvey as to December 2010.  
With this contribution we will attempt to promote a pragmatic approach to these patients, 
knowing that only a μετάνοια (change of mind) may lead to the recognition of cases that can 
benefit from a tailored treatment and thus to better results. This attitude seems particularly 
important in these days in which promising therapeutic improvements are announced by 
state-of-art multimodal treatments favouring local and systemic control of the disease. 
2. Clinical considerations 
The dimension of the phenomenon is difficult to assess. It is influenced by a number of 
factors such as the incidence of gastric cancer in different geographical areas, the 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
328 
immunohistochemical parameters. Journal of Surgical Oncology, Vol.95, No.2, pp. 
123-8 
Vogel, P., Rüschoff, J., Kümmel, S., Zirngibl, H., Hofstädter, F., Hohenberger, W., & Jauch, 
K.W. (1999). Immunocytology improves prognostic impact of peritoneal tumour 
cell detection compared to conventional cytology in gastric cancer. European Journal 
of Surgical Oncology, Vol.25, No.5, pp. 515-9 
Vogel, I., & Kalthoff, H. (2001). Disseminated tumor cells. Their detection and significance 
for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Archiv, 
Vol.439, No.2, pp. 109-17 
Wu, C.C., Chen, J.T., Chang, M.C., Ho, W.L., Chen, C.Y., Yeh, D.C., Liu, T.J., & P'eng, F.K. 
(1997). Optimal surgical strategy for potentially curable serosa-involved gastric 
carcinoma with intraperitoneal free cancer cells. Journal of the American College of 
Surgeons, Vol.184, No.6, pp. 611-7 
Wu, C.W., Chiou, J.M., Ko, F.S., Lo, S.S., Chen, J.H., Lui, W.Y., & Whang-Peng, J. (2008). 
Quality of life after curative gastrectomy for gastric cancer in a randomised 
controlled trial. British Journal of Cancer, Vol.98, No.1, pp. 54-9 
Yonemura, Y., Ninomiya, I., Kaji, M., Sugiyama, K., Fujimura, K., Sawa, T., Katayama, K., 
Tanaka, S., Hirono, Y., & Miwa, K. (1995). Prophylaxis with intraoperative 
chemohyperthermia against peritoneal recurrence of serosal invasion-positive 
gastric cancer. World Journal of Surgery, Vol.19, No.3, pp. 1-6 
Yawata, A., Adachi, M., Okuda, H., Naishiro, Y., Takamura, T., Hareyama, M., Takayama, 
S., Reed, J.C., & Imai, K. (1998). Prolonged cell survival enhances peritoneal 
dissemination of gastric cancer cells. Oncogene, Vol.16, No.20, pp. 2681-6 
Yu, W., Whang, I., Suh, I., Averbach, A., Chang, D., & Sugarbaker, P.H. (1998). Prospective 
randomized trial of early postoperative intraperitoneal chemotherapy as an 
adjuvant to resectable gastric cancer. Annals of Surgery, Vol.228, No.3, pp. 347-54 
Yoo, C.H., Noh, S.H., Shin, D.W., Choi, S.H., & Min, J.S. (2000). Recurrence following 
curative resection for gastric carcinoma. The British Journal of Surgery, Vol.87, No.2, 
pp. 236-42 
Yamamoto, K., Shimada, S., Hirota, M., Yagi, Y., Matsuda, M., & Baba, H. (2005). 
EIPL(extensive intraoperative peritoneal lavage) therapy significantly reduces 
peritoneal recurrence after pancreatectomy in patients with pancreatic cancer. 
International Journal of Oncology, Vol.27, No.5, pp. 1321-8 
Yamamoto, M., Matsuyama, A., Kameyama, T., Okamoto, M., Okazaki, J., Utsunomiya, T., 
Tsutsui, S., Fujiwara, M., & Ishida, T. (2009). Prognostic re-evaluation of peritoneal 
lavage cytology in Japanese patients with gastric carcinoma. Hepato-gastroenterology, 
Vol.56, No.89, pp. 261-5 
Zhang, H., Liu, C., Wu, D., Meng, Y., Song, R., Lu, P., & Wang, S. (2010). Does D3 surgery 
offer a better survival outcome compared to D1 surgery for gastric cancer? A result 
based on a hospital population of two decades as taking D2 surgery for reference. 
BMC Cancer, Vol.10, pp. No.6, 308 
16 
Hepatic Metastases from Gastric Carcinoma 
Guido Alberto Massimo Tiberio, Nazario Portolani 
and Stefano Maria Giulini 
University of Brescia 
Italy 
1. Introduction 
“Aprioristic passive attitude”: this is the mode that correctly defines the standard approach 
to gastric cancer patients presenting with hepatic metastases.  
This behaviour is deeply motivated by the aggressive biology of the disease that so often 
frustrates any therapeutic approach. In fact, at diagnosis liver metastases are often multiple 
and associated to other extra-hepatic metastatic sites [D’Angelica et al., 2004; Dicken et al., 
2005]. Furthermore, in the rare cases submitted to ablative treatments, hepatic and systemic 
recurrence has been experienced in the majority of cases. 
However, considering survival performances extrapolated from a cohort of 1452 patients 
submitted to hepatic resection for noncolorectal nonendocrine liver metastases [Adam et 
al.,2006], it was observed that metastases from gastric adenocarcinoma performed in an 
intermediate way, ranking 10th in a list of 18 primaries.  In fact, in selected cases an 
aggressive treatment can achieve unexpected results: 5-year survival rates from 10% to 40% 
have consistently been reported in surgical series considering patients with liver metastases 
as sole metastatic site.  
An aggressive attitude, however, doesn’t really penetrate into clinical practice and passivity 
still prevails, as depicted by an Italian survey reporting over 60% of patients not receiving 
specific treatments, including 30% of cases affected by 1 or 2 small metastases, and by 
therapeutic indication being influenced by patients’ determination [Tiberio et al., 2008]. This 
attitude is rather diffused if a recent review reported 436 surgically treated cases [Kerkar, 
2010] and a French survey recruited 101 patients from 41 centres [Chiche, 2005], numbers to 
be faced, for example, to more than 14700 resections for metastases from colo-rectal cancer 
enrolled in LiverMetSurvey as to December 2010.  
With this contribution we will attempt to promote a pragmatic approach to these patients, 
knowing that only a μετάνοια (change of mind) may lead to the recognition of cases that can 
benefit from a tailored treatment and thus to better results. This attitude seems particularly 
important in these days in which promising therapeutic improvements are announced by 
state-of-art multimodal treatments favouring local and systemic control of the disease. 
2. Clinical considerations 
The dimension of the phenomenon is difficult to assess. It is influenced by a number of 
factors such as the incidence of gastric cancer in different geographical areas, the 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
330 
characteristics and quality of different health-care systems, the deployment of effective 
mass-screening programs capable to detect -and cure- gastric malignancies in an early 
phase. It seems reasonable to assume that the incidence of hepatic metastases from gastric 
cancer during the course of the disease figures around 10%-20% in eastern countries like 
Japan and South Korea, rises to 30%-40% in Western Europe and Anglo-Saxon world were 
an increase of advanced stages at diagnosis is recorded despite a steady and significant 
reduction of the incidence of gastric carcinoma in the last 20 years [Fayçal et al., 2005] and 
lies unmeasured -but probably over 50%- in other less monitored countries. 
According to the presentation, hepatic metastases can be synchronous or metachronous. 
Synchronous metastases are detected during routine work-up of gastric primaries or -
unexpectedly- at surgical exploration, but in some cases their detection leads to diagnosis of 
gastric cancer. They must be differentiated from the direct infiltration of liver parenchyma 
originating from gastric cancer itself (T4). They can originate from unresectable gastric 
cancers but also from resectable primaries.  
Metachronous metastases are detected in up to 25-30% of patients submitted to curative 
gastrectomy. Eighty percent of them appear within the first 2 postoperative years, but it 
must be known that a wide consensus exists in considering synchronous those lesions 
diagnosed during the very first postoperative period (~ 6 months). 
At diagnosis metastases-related symptoms and signs are generally observed when hepatic 
metastases are discovered first and lead to the diagnosis of gastric cancer; in the other cases 
patients are asymptomatic or may display the signs and symptoms of gastric tumor. 
Clinical examination searches for epigastric or hypochondriac masses and hepatomegaly; at 
rectal or vaginal examination signs of peritoneal carcinosis are looked-for. 
When Tumor markers CA 19-9, CEA and CA 72-4 are simultaneously positive they are 
strongly suggestive of liver involvement [Marrelli et al., 2004]. 
At US and CT imaging metastases from gastric cancer display aspecific hypo-dense and 
hypo-vascularised patterns and can’t be distinguished from hepatic metastases originating 
from other gastro-enteric primaries.  
An adequate radiological report must enumerate their number, measures and location, the 
latter in reference to Couinaud’ segmentation. A good report allows the stadiation of hepatic 
disease according to the Japanese Gastric Cancer Association [10], a simple and practical 
classification, with direct therapeutic impact (table 1). In fact, H-3 hepatic involvement 
generally excludes ablative treatments, which are considered only for H-1 or H-2 cases. 
 
H-0 No liver metastases 
H-1 Liver metastases limited to one lobe of the liver 
H-2 Isolated diverse metastases in both lobes of the liver 
H-3 Multiple distributed metastases in both lobes of the liver 
Table 1. Classification of hepatic metastases from gastric cancer as proposed by the Japanese 
Gastric Cancer Association, 1998. 
3. Therapeutic approach 
3.1 Systemic chemotherapy 
At diagnosis liver metastases are often multiple and associated to other extra-hepatic 
metastatic sites such as peritoneal dissemination, extensive lymph-node and/or systemic 
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metastases. In these conditions nothing more than palliative or supportive treatments can be 
proposed, without appreciable long term results. Chemotherapy achieves median survival 
ranging from 7 to 15 months but long term survival remains anecdotal [Cocconi et al., 2003; 
Lee et al., 2007; Cao et al., 2009]. In particular, considering the few trials evaluating systemic 
chemotherapy in the subset of patients with liver-only metastatic involvement, 5-years 
survival rates do not reach 2% [Yoshida et al., 2004]. 
3.2 Surgical treatment 
Resection of liver metastases from gastric cancer is indicated in absence of extra-hepatic 
disease, if a complete ablation of the metastases can be achieved while preserving 
postoperative liver function [Ambiru et al, 2001; Okano et al., 2002]; it must also be 
associated to curative gastrectomy in case of synchronous lesions. In these conditions 
hepatectomy is a low-risk procedure, with negligible mortality and morbidity rates. 
The surgical literature shows that several clinical and pathological parameters correlate with 
survival; among these, staging factors of the primary tumor, metastases-related and surgery-
related variables have been reported more often than others (table 2).  
 
Author No. T N G H Ø metastasis Timing* Margin§ MST (months) 
No. 
survivors 
> 5 Years 
Ochiai ’94 21 √ √ - - n.a. n.a. n.a. 18 2 (19 %) 
Miyazaki ’97 21 - - - √ n.a. - √ n.a. 2 (9.5 %) 
Fujii ’01 10 - - - - √ √ n.a. 16 1 (10 %) 
Ambiru ’01 40 - - - - - √ - 12 6 (15 %) 
Imamura ’01 17 - √ √ - n.a √ √ 12 0 
Okano ’02 19 - - √ √ - √ n.a. 21 4 (21 %) 
Zacherl ’02 15 - - - √ - √ - 8.8 2 (13 %)^ 
Saiura ’02 10 - - - - - - n.a. 25 2 (20 %) 
Shirabe ’03 36 - ly - √ - - - n.a. 4 (11 %) 
Roh ’05  11 n.a. - - n.a. - - - 19 2 (18 %) 
Chiche ’05 101 - - - √ √ - √ 14,5 11 (10 %) 
Sakamoto ’07 37 √ - - √ √ - - 31 2 (5,4 %) 
Koga ’07 42 √ - - √ - - - 34 8 (19%) 
Tsujimoto ’10 17 √ ly n.a. - - - n.a. 34 5 (29%) 
MST: mean survival time Timing: synchronous vs.metachronous; § resection margin: + vs -; √ = 
prognostic factor; n.a.= not available; ly = lymphatic invasion; ^ = alive after 3 years. 
Table 2. Prognostic factors and survival from series of patients submitted to surgical 
treatment of hepatic metastases. 
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However, data concerning long-term survivors demonstrate that, if we exclude bi-lobar 
spread of metastases (H 3), none of the reported predictive factors -alone or in combination- 
can deprive a patient of the possibility of long-term survival after hepatic resection, raising 
concern about the clinical value of prognostic factors emerging from small and super-
selected populations submitted to liver resection. 
3.2.1 Results from unselected populations 
The correct approach to these particular patients can be extrapolated from a handful of key 
papers that addressed the topic analyzing unselected populations of gastric cancer patients 
presenting hepatic metastases as sole site of metastatic disease (table 3). From a cohort of 58 
patients, the Korean group of  Cheon and coll. did not extrapolate any primary-related or 
metastasis-related factor showing prognostic significance. On the very same line is the 
group of Makino and coll. from Japan, who studied 63 patients.  
Ueda and colleagues, again from Japan, studied a cohort of 73 patients presenting 
synchronous metastases. Their data show that factors influencing survival where the extent 
of hepatic involvement (H1-2 vs H3) and macroscopic peritoneal dissemination (P0 vs P1) 
detected at surgical exploration. When focusing on the subgroup of H1-2 and P0 patients, 
they showed that number (1 vs >1) and size of hepatic metastases and N status of gastric 
cancer (N0-1 vs N2-3) influenced survival. An Italian survey performed under the auspices 
of the Italian Research Group on Gastric Cancer [Tiberio et al., 2008] studied an unselected 
cohort of 73 patients presenting metachronous metastases after curative D ≥ 2 gastrectomy. 
It was found that the factors T, N and G of the gastric primary, when rated T3b-T4, N+ and 
G3, independently display a clear negative prognostic value with cumulative effect.  
These parameters may be helpful in order to appropriately select the therapeutic approach 
or, at least, to submit the cases to multidisciplinary evaluation, being aware that the 
prognosis of these patients is directly influenced by therapeutic choices. In fact, all the 4 
above mentioned studies strongly highlight that the main factor influencing long-term 
survival (p ranging from 0.01 to 0.001) is the therapeutic approach to the liver metastases, in 
particular when hepatectomy is performed. 
 
Author No Timing Prognostic factors 
Cheon 2008 58 Synchronous  + metachronous R0 resection of hepatic metastases 
    
Ueda 2009 72 Synchronous H; P; R0 Resection of hepatic metastases 
Tiberio 2008 73 Metachronous T; N; G of gastric primary; Resection of hepatic metastases 
Hwang 2009 73 Metachronous 
Stage of gastric primary 
Extrahepatic metastases; H 
Treatment of  hepatic metastases 
Table 3. Prognostic factors from series considering unselected populations. 
In the Italian study hepatectomy was associated to a five-fold increase in survival of the less 
favourable patients (>1 negative prognostic factor) and achieved a 5-year survival rate of 
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20%. Furthermore, Cheon and coll. and Ueda and coll. evidenced that the possibility to 
perform a radical operation (R0 vs R1) affects long-term survival and report overall 5-year 
survival rates of 20% and 60%, respectively. It is worth of note that in synchronous cases 
radical surgery was intended not only in regard to hepatic lesions, to be resected as 
prescribed by good surgical practice, but also in regard to gastric tumors, to be treated by 
standard curative D ≥ 2 gastrectomy (table 4). 
Data reported in table 2 and 4 show that surgical therapy offers interesting and sound 
results. On a more realistic level, we must however recognize that these patients, despite 
all efforts, generally die of cancer progression. Hepatic recurrence is observed in about 
70% of cases and in about half of them is associated to extra-hepatic relapse (table 5); if the 
literature and our experience do not permit an insight into the role of repeated 
hepatectomies in case of exclusive hepatic recurrence, this observation raises concern 
about the timing of treatment, in order to avoid superfluous operations. A simple time-
test can achieve an acceptable selection once a potential candidate to curative surgery is 
encountered. It can be easily suggested in case of metachronous lesions with favourable 
location but it can be contraindicated in case of critically located metastases and,  
in general, in case of synchronous metastases, especially if associated to symptomatic  
or resectable gastric primaries. The French school [Adam et al., 2006] strongly suggests a 
multidisciplinary approach to these patients and, in particular, favours a  
systemic chemotherapy, to be started at diagnosis whenever possible, in order to offer  
its advantages to the greatest number of patients and to effectively select cases for 
surgery.  
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20%. Furthermore, Cheon and coll. and Ueda and coll. evidenced that the possibility to 
perform a radical operation (R0 vs R1) affects long-term survival and report overall 5-year 
survival rates of 20% and 60%, respectively. It is worth of note that in synchronous cases 
radical surgery was intended not only in regard to hepatic lesions, to be resected as 
prescribed by good surgical practice, but also in regard to gastric tumors, to be treated by 
standard curative D ≥ 2 gastrectomy (table 4). 
Data reported in table 2 and 4 show that surgical therapy offers interesting and sound 
results. On a more realistic level, we must however recognize that these patients, despite 
all efforts, generally die of cancer progression. Hepatic recurrence is observed in about 
70% of cases and in about half of them is associated to extra-hepatic relapse (table 5); if the 
literature and our experience do not permit an insight into the role of repeated 
hepatectomies in case of exclusive hepatic recurrence, this observation raises concern 
about the timing of treatment, in order to avoid superfluous operations. A simple time-
test can achieve an acceptable selection once a potential candidate to curative surgery is 
encountered. It can be easily suggested in case of metachronous lesions with favourable 
location but it can be contraindicated in case of critically located metastases and,  
in general, in case of synchronous metastases, especially if associated to symptomatic  
or resectable gastric primaries. The French school [Adam et al., 2006] strongly suggests a 
multidisciplinary approach to these patients and, in particular, favours a  
systemic chemotherapy, to be started at diagnosis whenever possible, in order to offer  
its advantages to the greatest number of patients and to effectively select cases for 
surgery.  
 







No hepatic resection: 29.4%; 0%; 
0% 





 +  
Metachr. 




Hepatic resection: 82,3%; 46,4%; 
37.1% 
Ueda 
(2008) 72 Synchr. n.a. 
No hepatic resection: 36.4%; 0%; 
0% 
Hepatic resection ± HAIC: 80%; 
60%; 60% 
Tiberio 
(2008) 73 Metachr. 
Overall: 7  
BST: 5 BST: 22%; 2%; 0% 
Chemotherapy: 
12 
Chemotherapy: 45%; 6%; 0% 
Hepatic 
resection: 23 
Hepatic resection: 81%; 20%; 20% 
n.a. = not available; RFA = radio-frequency-ablation; HAIC = hepatic artery infusion chemotherapy; 
BST = best supportive treatment;  
Table 4. Survival from series considering unselected populations 
 
Gastric Carcinoma - Molecular Aspects and Current Advances 
 
334 
Author No. Hepatic recurrence (%) 
Overall 
recurrence (%) 
Miyazaki 1997 21 76.2 81 
Fujii 2001 10 50 80 
Ambiru 2001 40 72.5 77.5 
Ambiru 2001 40 72.5 77.5 
Okano 2002 19 63.2 73.7 
Okano 2002 19 63.2 73.7 
Saiura 2002 10 - 80 
Shirabe 2003 36 61.1 83.3 
Roh 2005  11 72.7 91 
Sakamoto 2007 37 62.2 86.5 
Koga 2007 42 50 66.7 
Cheon 2008 22 50 63.6 
Tiberio 2008 11 62.2 86.5 
Makino 2010 16 25 63.6 
Table 5. Recurrence after curative surgery. 
3.3 Multimodal treatment 
Multimodal treatments can further enhance survival rates, in particular if modern, state-
of-art chemotherapy protocols are employed. For example we signal that Ueda and coll. 
reported in the cited work an outstanding 75% 5-year survival rate in a subgroup  
of 8 patients submitted to radical surgery followed by hepatic artery infusion 
chemotherapy. 
Radio-frequency ablation is another front-line, state-of-art technique to be considered in 
designing the treatment strategy of hepatic metastases from gastric cancer. This ablative 
technique is employed either as alternative or in association to hepatectomy, following the 
guidelines for HCC or for metastases from colo-rectal cancer. It is a minimally invasive and 
low-cost procedure whose interest is particularly enhanced in case of poor general 
conditions contraindicating surgery, which is often the case in gastric cancer patients. Its 
exact role is yet to be defined, as the number of reported procedures is low, follow-up short, 
data can’t always be effectively extrapolated from the context and reports are not 
unanimous as far as survival results are concerned. However, one paper by Hwang et coll., 
considered 72 patients with metachronous metastases submitted to different treatments but 
not to hepatectomy (table 5). They showed that 15 patients without extrahepatic disease 
treated by RFA ± chemotherapy displayed a median survival of 22 months, with 3- and 5-
year survival rates of 50% and 40%, respectively, similar to those reported in the best 
surgical series. These data are coherent to those by Yamakado et al. which, however, suffer 
of short follow-up, and to those by Cheon et al.: in their experience a subgroup of 9 patients 
submitted to RFA compared favourably with 22 patients submitted to radical surgery, with 
a 4-year survival of 40% and 20%, respectively. Kim and collaborators appear less 
enthusiastic and report survival results superimposable to those of classic systemic 
chemotherapy alone. These data need further confirmation but highlight the interest of RFA 
in the management of these particular cases. 
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Author No. Timing MST (months) 1-; 3-; 5- year survival rates 
Yamakado 
(2005) 7 Methachronous 
RFA + HAIC: 
16.5 
RFA + HAIC: 85%; n.a; 
n.a. 
Cheon (2008) 9 Synch. + metach n.a. RFA: 57%; 40%; n.a. 
Hwang (2009) 73 Metachronous 
BST*: 3 BST*: 5%; 0%; 0% 
TACE*: 8 TACE*: 38%; 0%; 0% 
Chemoth.*: 15 Chemoth.*: 100%; 0%; 0% 
RFA*: 27 RFA*: 82%; 50%; 40% 
Kim (2009) 7 Metachronous RFA± Chemoth.: 10 RFA: 40%;14%; n.a. 
n.a. = not available; HAIC = hepatic artery infusion chemotherapy; BST = best supportive treatment; 
TACE = trans arterial catheter embolization; * = patients without extrahepatic metastases. 
Table 6. Radio-Frequency-Ablation (RFA) of hepatic metastases from gastric cancer. 
3. Conclusion 
Unexpected 5-year survival rates can be achieved in a subgroup of gastric cancer patients 
presenting hepatic metastases as sole metastatic site if an adequate treatment is selected. 
Simple clinical and biological characteristics of both the gastric primary and hepatic 
involvement display prognostic value which may be helpful in choosing therapeutic 
strategy, keeping in mind that the best results are achieved by aggressive treatments, which 
must be proposed whenever possible. 
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1. Introduction  
Gastric cancer is the second most frequent malignancy in the Western world [1]. The 
prognosis remains poor despite of advances in diagnostic techniques and therapeutic 
management: approximately 800.000 new cases und 620.000 cancer related deaths are 
reported worldwide per year [2]. More than 50% of gastric cancer patients and 
approximately 40% of esophageal cancer patients either die from a primary unresectable 
tumor or from tumor recurrence after radical treatment within five years [3]. The main  
reasons for this are the late onset of predominantly unspecific symptoms and the aggressive 
biological behavior [4]. Palliative chemotherapy, best supportive care and the 
interdisciplinary management of severe tumor-related complications (tumor bleeding, 
tumor perforation, complete obstruction, treatment-refractory pain) are well accepted 
treatment options whereas non-curative resections of the primary tumor as well as resection 
of secondary tumor lesions are controversially discussed [5]. However, there is growing 
evidence that non-curative tumor resections can prolong the remaining life time with 
acceptable perioperative morbidity [6-8]. Furthermore, the quality of life can be improved 
by reducing the incidence of severe tumor-related complications [9].  
2. General aspects of incurable gastric cancer 
Patients who do not undergo surgical or cytoreductive treatment die within three (stage 4) 
to six months (stage 3) [10,11].  
The only option for cure is radical surgical treatment, recently more and more in 
combination with neoadjuvant and adjuvant chemotherapy [12,13]. With advanced tumor 
stage survival of resected patients dramatically declines: at UICC stage 1 the 5-year-survival 
rate of patients with R0 resection is 95%, whereas at stage 2 it ranges from 35% to 65%, 
depending on the presence of positive lymph nodes and the number of dissected lymph 
nodes [14,15]. In the rare cases where curative resection is achieved, the 10-year-survival 
rate ranges from 3% for stage 3b  to 5% for stage 4 (according to UICC classification from 
2002)[16]. Following the standardized treatment for locally confined gastric cancer the main 
determining factor for survival is the extent of lymph node involvement although the 
impact of extended surgical lymph node removal is still under discussion [17].  
Unfortunately, the majority of patients with gastric cancer is diagnosed at an advanced stage 
of the disease and may not be suitable for treatment with curative intent [18]. But which 
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alternatives can be offered to those patients? Especially patients with an incurable stage of 
the disease have to face the fact that they will die from their tumor within short time. 
Furthermore, 50% of those patients will develop severe tumor related complications 
necessitating invasive endoscopic, radiological or surgical treatment [19]. There are two 
important aspects of individuality in incurable gastric cancer patients: the individuality of 
the patients and the individuality of the tumor. The decision as to whether aggressive 
palliative treatment should be used rather than best supportive care or no treatment at all at 
patients’ request depends on the personal expectation of the individual patient [20]. The 
reponse to that treatment on the other hand is crucially influenced by the molecular biology 
and the pathological behavior of the tumor [21,22]. Considering these circumstances, it 
becomes clear that the currently available tumor classification systems are limited with 
respect to the decision making process [3].  
In fact, palliative strategies are much less standardized than curative treatment. A multitude 
of protocols has been introduced to improve and prolong the remaining life span of 
palliatively treated patients [23]. Recently first steps towards molecular-based target-specific 
therapy using trastuzumab and bevacizumab have been undertaken. The importance of 
surgery for palliative treatment is controversially discussed for more than 40 years [6,7,9,24-
26]. Numerous authors reported about prolonged survival, improvement of quality of life 
and symptom relief and, therefore, supported palliative gastric resection [6,9,26]. Other 
investigators presented limited retrospective data and recommended gastric resection only 
in cases of otherwise not controllable complications, such as tumor bleeding or organ 
perforation [5,27]. 
Currently two basic palliative treatment strategies can be defined: a canonical palliative 
treatment strategy including palliative chemotherapy, best supportive care and invasive 
treatment for severe life-threatening tumor related complications versus cytoreductive 
(neoadjuvant) chemotherapy plus non-curative tumor resection. 
3. Canonical palliative treatment strategy 
The widely as beneficial accepted palliative chemotherapy and best supportive care is aimed 
to improve overall survival and to improve or at least to stabilize the quality of life [5]. Long 
term survival can be observed in few unusual cases but is not originally an aspired 
treatment outcome.  
Overall, it is generally accepted that patients with incurable gastric cancer who are treated 
with chemotherapy live longer than those who receive best supportive care only. Several 
studies indicate that patients who underwent chemotherapy have longer overall survival (11 
versus 4 months) and a longer time to progression (6-8 versus 2-3 months) as compared to 
those patients whose received best supportive care only [28].  
The variety of available chemotherapy protocols that have been published during the last 30 
years is very wide. Most chemotherapy protocols contain one or a combination of several of 
the following drugs: antimetabolites (5-Fluoruracil), platinum-containing analoga (cisplatin, 
oxaliplatin), topoisomerase-1-inhibitors (anthracyclins: epirubicin, doxorubicin), 
topoisomerase-2-inhibitors (irinothecan), tubulin depolymerisation inhibitors (taxans: 
paclitaxel, docetaxel) and mitomycin. All abovementioned agents are targeted to somehow 
disrupt the natural mechanisms of DNA synthesis or of the cell division process. Therefore, 
these agents manifest their effect not only on tumor cells but also on any other cells within 
the organism that undergo cell division to maintain the biological tissue and organ integrity. 
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The most frequently used agent is 5-fluoruracil and its oral analogon capecitabine. It has 
been described to elucidate an overall response of 20% when administered as a single agent 
treatment. Wagner and co-workers. compared 13 studies with a total of 1914 patients to 
evaluate the impact of a combination versus a single agent chemotherapy. Patients with a 
combination therapy had longer median survival (8.3 vs 6.7 months), longer progression 
free survival (5.6 vs 3.6 months) and a higher overall response rate (35% vs 18%). Based on 
these data, most oncologists in western countries do not treat their patients with a single-
agent protocol, whereas in Japan the use of S-1 as a single-agent therapy is widely utilized. 
Furthermore, it was shown in this study that a three-drug combination is better than a two-
drug combination in terms of survival as well as tumor response [10]. 
Clinical trials to study the effectiveness of the novel microtubule-dynamic-instability-
inhibiting agent eribulin are currently underway. 
But which patients are best siuted for palliative chemotherapy? Overall, the effectiveness of 
chemotherapy has to be weighed against chemotherapy-related toxicities and side effects. 
The most important factor to predict the benefit of palliative chemotherapy is to evaluate 
whether the patient is generally fit for this aggressive treatment. Hepatic, renal and 
carciopulmonary function should be taken into account. The toxicity increases with the 
number of chemotherapy agents which are administered in combination. To date, there is no 
evidence about preoperatively available clinical or pathohistological factors that could 
predict the response to chemotherapy. 
A first step towards a target specific chemotherapy might be the administration of 
trastuzumab, an inhibitor of the Her2/Neu-receptor. Van Cutsem and co-workers published 
the data from the ToGA study in 2009 with the main result that patients who were positive 
for the Her2/Neu receptor chemotherapy plus trastuzumab had a median survival of 13.8 as 
compared to a median survival of 11.1 months in patients who underwent chemotherapy 
only. Furthermore, the study group who was treated with the combination chemotherapy 
showed a higher overall tumor response rate (47% versus 35%), a higher complete response 
(5% versus 2%) and a longer time to progression (7.1 versus 5.6 months). This treatment has 
been shown to be effective in patients who are at least double positive for the receptor 
measured by the FISH test [29]. Trastuzumab was the first molecular target agent showing a 
survival benefit in patients with advanced gastric cancer. The next step towards target-
specific treatment might be the AVAGAST trial which investigates the benefit of the 
angiogenesis inhibitor bevacizumab plus chemotherapy versus chemotherapy alone [30]. 
Several studies investigating the survival benefit of further novel angiogenesis inhibitors, 
such as sorafinib, sunitinib, cediranib and axitinib are currently underway. The survival 
benefit of cetuximab – an inhibitor of the epidermal growth factor receptor – is currently 
investigated in a phase 3 trial. In summary, there is a growing selection of target specific 
agents that are thought to have an impact on the clinical course of advanced gastric cancer 
but to date only one agent (trastuzumab) has been approved for use in the clinical routine. 
The second column of the canonical palliative treatment strategy is the management of 
severe tumor related complications. Many authors suggest that patients who develop such 
complications should be treated most preferably by interventional procedures, such as 
endoscopy or radiological intervention. Only in those cases where interventional 
approaches are not feasible or where interventional treatment fails and the complication 
either relapses or persists, patients are considered for surgical treatment. Furthermore, this 
surgical treatment should be limited to the most restricted possible procedure whereas 
larger tumor resections should be reserved for rare individual cases. In particular, palliative 
resections should be avoided [5,27]. 
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The most frequently occurring complications are tumor bleeding, gastric obstruction and 
tumor perforation. Kang and co-workers analyzed data from 1856 patients with 
metastasized gastric cancer. Among these, there were 32 patients who had a tumor 
perforation during palliative chemotherapy. 17 patients underwent emergency surgery with 
a median survival of 5 months after the perforation  whereas 15 patients received antibiotics 
only and had a median survival of 1 month after the perforation [31]. These data show that 
survival in patients treated by surgery was longer as than that with non-surgical treatment 
strategies. Other studies demonstrated that patients who were treated with palliative 
resection had a lower perioperative mortality as compared to those who underwent simple 
closure of the perforation only [32]. 
Tumor bleeding is a frequently observed event in patients with unresectable gastric cancer. 
Some authors regard substitution of up to 2 units of red blood cells per week as acceptable 
with respect to tumor bleeding which can be treated by blood transfusion alone [33,34]. 
However, palliative chemotherapy administration might be limited by persistent bleeding 
which finally may affect overall survival. Other authors suggest treatment of those patients 
with short-course radiotherapy up to 30 Gy. Recently, Asakura and co-workers reported a 
response rate to radiotherapy of 73% [35]. The endoscopic approach provides the 
opportunity for active and direct hemostasis by local injection of epinephrine, clip 
application, fibrin application, argon plasma coagulation or stent implantation. In cases of 
persistent uncontrolled tumor bleeding, surgical treatment has been suggested as an last 
resort [27]. However, emergency surgery for tumor bleeding usually requires palliative 
resection and is associated with a high rate of perioperative mortality [35]. 
The symptoms of progressive tumor-related gastrointestinal obstruction range from 
dysphagia and nausea to manifest ileus. The endoscopic approach provides a multitude of 
procedures, such as stent implantation (or even in due course stent-in-stent implantation), 
argon plasma beam, laser therapy and percutaneous endoscopic assisted gastrostomy. A 
considerable number of patients receiving endoscopic treatment relapse with obstructive 
symptoms. Selected patients may undergo surgical treatment, especially those who develop 
manifest ileus or in cases of endoscopic treatment failure. Whereas patients with lower 
gastric cancer benefit from a gastrointestinal bypass with low perioperative mortality rates, 
patients with gastric cancer at the gastroesophageal junction usually require palliative 
resection associated with higher perioperative mortality rates. 
In summary, severe tumor-related complications frequently occur in patients with 
unresectable gastric cancer. They not only require invasive treatment in the majority of cases 
but also affect further palliative chemotherapy and, thus, affect overall survival and quality 
of life. 
4. Neoadjuvant chemotherapy plus non-curative surgery for incurable gastric 
cancer 
Whereas the canonical palliative treatment strategy can be regarded as the widely used 
standard, the combination of chemotherapy with cytoreductive non-curative resection is still 
under intensive debate.  
4.1 Intentions of primary non-curative resection 
One intention is to reduce the overall tumor mass by removing the primary tumor with a 
local R0 stage and by resecting secondary tumor mass. The reduction of secondary tumor 
growth includes liver metastases, positive lymph nodes and peritoneal carcinosis.  
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Several molecular considerations make this strategy sensible. Gross tumor formations are 
thought to be affected in a limited way by chemotherapy agents. Furthermore, it has been 
demonstrated that the primary tumor produces a local environment presumably via 
currently not fully understood molecular pathways that creates the precondition for the 
nidation of circulating tumor cells which subsequently can develop into distant metastases.  
The second intention is to reduce the incidence of tumor related complications. In other 
words, the potentially complications-producing tumor is removed before these 
complications occur. In fact, the natural course of gastric cancer growth is associated with a 
considerable number of severe tumor related complications. At least 50% of all patients with 
non-resected advanced gastric cancer will develop such complications within the remaining 
life time. These complications frequently require invasive treatment by endoscopic or 
radiological interventions and emergency surgery in a considerable number of cases. 
However, emergency procedures are associated with high mortality rates. Based on a 
retrospective analysis, we found that by primary non-curative gastric resection the incidence 
of severe tumor related complications decreased as compared to that in patients who did not 
undergo resection (data not published). 
Based on these intentions, primary non-curative resections are implemented to improve 
overall survival of palliative patients and to improve the quality of life within the remaining 
life time. 
4.2 Study results on non-curative gastric resection 
Gastric resections in patients with incurable gastric cancer have been reported for more than 
50 years now. The intention to perform such procedures as well as the criteria dedicated to 
define suitable patients have changed over that relatively long period. Furthermore, the 
allocation of patients to curative and non-curative strategies becomes increasingly complex: 
a considerable number of patients with an initially unresectable stage of gastric cancer 
respond to neoadjuvant chemotherapy and eventually become resectable. To date and for 
the understanding of this chapter it is important to distinguish two different categories of 
gastric resections with a postoperative non-R0-result: first the so-called palliative resection, 
which encompassed initially a collective term for patients who were resected with curative 
intention but had R1- or R2-situations postoperatively, as well as for those who were 
primarily resected with palliative intention either due to tumor-related complications or for 
potential improvement of overall survival; and secondly the term “non-curative gastric 
resection” which includes patients who have at least one non-curative factor but 
nevertheless undergo primary gastric resection as a part of the multimodal concept. 
Based on data of the last decades, the range of recommendations for palliative surgical 
treatment is wide. Some authors recommend to perform surgical treatment only in those 
cases where severe tumor related complications or symptoms are evident and interventional 
options have failed [27,36]. Other authors proposed that primary palliative resections should 
be performed whenever technically possible [9]. Palliative gastric resection is not a novel 
procedure. According to today´s benchmarks, the early beginnings of gastric surgery can be 
regarded as palliative procedures: the first documented gastric resections have been 
performed by Pean in 1879 and by Rygydier in 1880, both patients died within the 
perioperative period. The first successfully performed gastric resection traces back to 
Billroth (1881). The patient survived four months and died from local tumor recurrence. 
The first publication on larger series of palliative gastric resections was in 1958 by Lawrence 
and McNeer. Data of 1.623 patients who underwent surgery for gastric carcinoma from 1931 
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to 1955 were analyzed. It was demonstrated that palliative resections (141 cases) achieved 
remarkable symptom relief as well as it increased the survival time. Perioperative morbidity 
and mortality, however, were high [24]. 
Another frequently quoted paper was published in 1979: ReMine et al. reported about 206 
patients with non-curable gastric carcinoma who underwent surgical treatment. Palliative 
partial gastric resection was reported in 46 cases, while gastrectomy was performed in six 
cases. The other patients underwent gastroenteral bypass or no surgical treatment at all. 
The decision to extend the procedure from gastric resection to gastrectomy was due to 
additional proximal tumor infiltration. Although the perioperative mortality was 0% in 
the gastrectomy group, further survival was disappointing: five of the six patients died 
within nine months. Patients with palliative gastric resection showed significantly better 
survival: 20% of these patients lived more than two years. According to these findings, 


















Huang et al. [7] 2010 n=365 10.5 14-27% 0.5-6% 
Kunisaki et al. 
[8] 2008 n=164 9 15% 4% 
Lin et al. [6] 2008 n=183 20 No data No data 
Mizutani et al. 
[37] 2007 n=13 12 65% 0% 
Onate-Ocana et 
al. [38] 2007 n=71 12.4 32% 8.5% 
Lim et al. [39] 2007 n=63 13 No data No data 
Nazli et al.[40] 2007 n=29 10.4 35% 27% 
Saidi et al. [41] 2006 n=24 16.3 33% 9% 
Miner et al. [27] 2004 n=147 8.3 54% 6% 
Medina-Fr. et 
al. [42] 2004 n=40 13 26% 2.6% 
Hartgrink et al. 
[26] 2002 n=156 8.1 38% 12% 
Monson et al. 
[43] 1991 n=53 19 12% 8% 
Bozetti et al. [9] 1987 n=61 8 No data 11% 
Meijer et al. 
[44] 1983 n=26 9.5 No data 8% 
Table 1. Published data on palliative gastric resection from 1983 - 2010 
Over the last 20 years, several published series of palliative gastric resections showed 
significant improvement in symptom control, survival and quality of life [6,9,26,37]. In 
addition, several cases of long term survival following combined palliative treatment have 
been described. However, in the majority of the published data the definition of “palliative 
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intention” was not properly outlined. Frequently, curatively intended procedures with a 
postoperative R1-situation were included. In some publications, elective and emergency 
resections were not separated even though for emergency surgery there is a high rate of 
perioperative mortality. In several studies, the period of inclusion spans more than 20 years. 
An overview of the most important publications on palliative gastric resections is shown in 
Table 1. The median survival ranged from 8 to 20 months, whereas morbidity and mortality 
ranged from 12% to 65% and from 0% to 27%, respectively. In comparison, data from our 
hospital based on retrospectively analysed data from 48 patients with non-curable gastric 
cancer showed a median survival of 15 months with a morbidity of 32% and a mortality of 
4% (emergency gastrectomies excluded). Furthermore, long term survival was observed in 
three cases. 
Which patients are suitable for the non-curative gastric resection? The most pronounced 
benefit can be expected in cases with a limited number of tumor locations (2 tumor locations 
= primary tumor plus one more secondary tumor formation). Furthermore, younger 
patients seem to have a better survival following non-curative gastric resection. In a recently 
published study, Kunisaki and co-workers identified chemotherapy as an independent 
factor for longer survival in patients with no more than one “non-curative” factor. In our 
own study population, we found a significantly longer survival for younger patients (<50 
years) and for those who had no more than two tumor locations, furthermore the highest 
benefit was achieved in those patients who underwent chemotherapy according to the ECF 
scheme. 
Generally, at present, non-curative gastric resections should be performed preferentially in 
patients who can be included in a clinical trial investigating the clinical outcome of palliative 
surgery. Furthermore, non-curative resections should be part of a multimodal treatment 
strategy. The personal preferences of the individual patient should be taken into account in 
the decision-making process and every patient should be discussed in an interdisciplinary 
tumor conference. 
4.3 Surgical treatment for peritoneal carcinosis 
Peritoneal carcinosis from gastric cancer commonly indicates an advanced stage of the 
tumor disease and most frequently is associated with poor prognosis. The median survival 
time of patients with peritoneal carcinosis from gastric cancer is 3 months [45,46]. In 
comparison, for colorectal cancer it is 5 months and for ovarian cancer it is 12 – 23 months 
[47,48]. The degree of peritoneal involvement prior to cytoreductive resection is most 
frequently described by the peritoneal carcinosis index score (PCI) [49,50]. This index is a 
combination of peritoneal tumor size and the number and distribution of peritoneal tumors. 
There is a strong correlation between the PCI value and the prognosis. This has been 
demonstrated in patients with peritoneal carcinosis from colorectal cancer: patients with PCI 
up to 10 had 50% overall 5-year survival whereas for PCI 11-20, it was 20% and for PCI more 
than 20, there was no 5-year survival at all. The cytoreductive surgery in combination with 
intraperitoneal chemotherapy was first described by Sugarbaker in 1989. The surgical 
procedure may include parietal and visceral peritonectomy, resection of the liver capsule 
and the resection of adjacent organs located within the peritoneal cavity [51]. The surgical 
result is determined by the “completeness of cytoreduction score (CCR)” based on the 
macroscopic presentation to the surgeon at the end of the procedure [52]. Table 2 gives an 
overview on the details of PCI.  
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ranged from 12% to 65% and from 0% to 27%, respectively. In comparison, data from our 
hospital based on retrospectively analysed data from 48 patients with non-curable gastric 
cancer showed a median survival of 15 months with a morbidity of 32% and a mortality of 
4% (emergency gastrectomies excluded). Furthermore, long term survival was observed in 
three cases. 
Which patients are suitable for the non-curative gastric resection? The most pronounced 
benefit can be expected in cases with a limited number of tumor locations (2 tumor locations 
= primary tumor plus one more secondary tumor formation). Furthermore, younger 
patients seem to have a better survival following non-curative gastric resection. In a recently 
published study, Kunisaki and co-workers identified chemotherapy as an independent 
factor for longer survival in patients with no more than one “non-curative” factor. In our 
own study population, we found a significantly longer survival for younger patients (<50 
years) and for those who had no more than two tumor locations, furthermore the highest 
benefit was achieved in those patients who underwent chemotherapy according to the ECF 
scheme. 
Generally, at present, non-curative gastric resections should be performed preferentially in 
patients who can be included in a clinical trial investigating the clinical outcome of palliative 
surgery. Furthermore, non-curative resections should be part of a multimodal treatment 
strategy. The personal preferences of the individual patient should be taken into account in 
the decision-making process and every patient should be discussed in an interdisciplinary 
tumor conference. 
4.3 Surgical treatment for peritoneal carcinosis 
Peritoneal carcinosis from gastric cancer commonly indicates an advanced stage of the 
tumor disease and most frequently is associated with poor prognosis. The median survival 
time of patients with peritoneal carcinosis from gastric cancer is 3 months [45,46]. In 
comparison, for colorectal cancer it is 5 months and for ovarian cancer it is 12 – 23 months 
[47,48]. The degree of peritoneal involvement prior to cytoreductive resection is most 
frequently described by the peritoneal carcinosis index score (PCI) [49,50]. This index is a 
combination of peritoneal tumor size and the number and distribution of peritoneal tumors. 
There is a strong correlation between the PCI value and the prognosis. This has been 
demonstrated in patients with peritoneal carcinosis from colorectal cancer: patients with PCI 
up to 10 had 50% overall 5-year survival whereas for PCI 11-20, it was 20% and for PCI more 
than 20, there was no 5-year survival at all. The cytoreductive surgery in combination with 
intraperitoneal chemotherapy was first described by Sugarbaker in 1989. The surgical 
procedure may include parietal and visceral peritonectomy, resection of the liver capsule 
and the resection of adjacent organs located within the peritoneal cavity [51]. The surgical 
result is determined by the “completeness of cytoreduction score (CCR)” based on the 
macroscopic presentation to the surgeon at the end of the procedure [52]. Table 2 gives an 
overview on the details of PCI.  
 




the region Region 
Size of the largest regional 
lesion Score 
0 central no lesion detectable 0 
1 right cranial lesion size smaller than 5mm 1 
2 epigastric lesion size from 5 to 50mm 2 
3 left cranial lesion size larger than 50mm 3 
4 left side 
 
Calculation of the PCI-score: 
 
Every region is allocated to the score 0-3. 
Then all scores are added up. 
 
PCI can reach a maximum score of 36. 
5 left caudal 
6 pelvic 
7 right caudal 
8 right side 
9 upper jejunum 
10 lower jejunum 
11 upper ileum 
12 lower ileum 
Table 2. Peritoneal carcinosis index 
Table 3 shows the classification of the cytoreduction result according to the “completeness 
of cytoreduction score”.  
 
Size of residual tumor CCR value 
no residual tumor 0 
largest residual tumor smaller than 2.5mm 1 
largest residual tumor 2.5-25mm 2 
largest residual tumor larger than 25mm 3 
Table 3. Classification of the cytoreduction result according to the “completeness of the 
cytoreduction score” 
It is generally accepted that cytoreductive peritoneal resection should be performed in 
combination with intraperitoneal chemotherapy. Surgery only or surgery in combination 
with intravenous chemotherapy are not sufficient because some chemotherapy agents, such 
as 5-FU do not reach an appropriate concentration within the peritoneal cavity to kill cancer 
cells whereas other agents, such as taxans do not even cross the blood-peritoenal barrier 
because of their high molecular weight. For that purpose, three procedures depending on 
the date of administration are available: preoperative intraperitoneal plus systemic 
chemotherapy (NIPS), hyperthermic intraperitoneal chemotherapy (HIPEC) and early 
postoperative intraperitoneal chemotherapy (EPIC) [52].  
The best results from that combination therapy are achieved when the PCI is low, the CCR is 
0 or 1 and there are no free intraperitoneal cancer cells. The Peritoneal Surface Malignancy 
Group (PSMG) defined several criteria that indicate a high probability for achieving a CCR 0 
or 1 in patients with peritoneal carcinosis from colorectal cancer, these criteria are shown in 
Table 4. 
For cytoreductive surgery for peritoneal carcinosis from gastric cancer, the PCI should be 
limited to a maximum score of 15. 
Generally in cases of peritoneal carcinosis from gastric cancer, survival is worse than in 
other entities, such as ovarian cancer or colorectal cancer. For the combination of surgery 
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with HIPEC, overall median survival from 10 to 16 months and 5-year-survival of 7%-8% 
have been reported. For colorectal cancer, it was demonstrated that HIPEC has a better 
clinical outcome in terms of survival than EPIC [53]. Cheong and co-workers observed a 
median survival of 11 months following cytoreductive surgery combined with EPIC in 154 
patients with very advanced gastric cancer [52]. 
 
ECOG performance status 0-2* 
no evidence of extraabdominal tumor lesions 
up to 3 small, resectable parenchymal liver metastases 
no evidence of bilary obstruction 
no evidence of ureter obstruction 
no evidence of intestinal obstruction at more than 1 location 
small bowel involvement: no evidence of gross disease in the mesentery with 
several segmental locations of partial obstruction 
small volume disease in gastro-hepatic ligament 
*ECOG: Eastern Cooperative Oncology Group 
Table 4. Several criteria that indicate a high probability for achieving a CCR 0 or 1 in 
patients with peritoneal carcinosis from colorectal cancer, defined by the Peritoneal Surface 
Malignancy Group 
4.4 Surgical treatment of liver metastases from gastric cancer 
Generally, liver metastases from gastric cancer develop less frequently as compared to other 
gastrointestinal tumor entities, but in most cases they are unresectable due to general as well 
as hepatic non-curative factors. Whereas liver metastases develop in approximately 50% of 
all patients with colorectal carcinoma, the incidence of liver metastases from primary gastric 
cancer ranges from 5% to 9%. 
Liver resection for secondary tumor growth is performed mainly in cases of colorectal liver 
metastases with resection rates between 20% and 30% and a 5-year survival rate of 25% to 
58% [54,55]. In contrast, liver resection for hepatic metastasized gastric carcinoma is a rarely 
performed procedure: resection rates of liver metastases from gastric cancer range from 11% 
to 21% [56,57]. 
The majority of patients remain incurable due to several frequently occurring factors even if 
extended or multivisceral surgery had been performed. Those incurable factors include 
bilobar multinodular tumor spread, gross peritoneal dissemination, diffuse affection of 
distant lymph nodes or unresectable local recurrence. Especially bilobar tumor spread 
within the liver is more frequent in gastric cancer as compared to other gastrointestinal 
malignancies in spite of the same venous drainage via the portal vein which rises the 
question if the pathway follows the portal venuous flow or if liver metastases from gastric 
cancer are caused by free circulating tumor cells and, thus, have to be regarded as a 
generalized stage of the tumor disease. This distinct biological behavior may also reflect that 
molecular signalling and gene expression pattern are different from other gastrointestinal 
tumors. Even in cases of potentially resectable gastric liver metastases, many medical 
professionals are reluctant to consider these patients for radical surgical treatment. 
The first publication on the clinical outcome after liver resection for gastric cancer 
metastases was presented by Ochiai and co-workers: they described serosal perforation of 
the primary tumor (in cases of synchronous liver metastases) as well as lymphangiosis and 
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professionals are reluctant to consider these patients for radical surgical treatment. 
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venangiosis to be negative prognostic factors and reported a median survival time of 18 
months and an overall 5-year survival rate of 19% [56]. One of the first western publications 
with focus on resection of gastric liver metastases was presented in 2001 by Zacherl and co-
workers: the median survival of the 15 resected patients was 8.8 months while two of these 
patients survived more than three years [58]. In a recently published review, 19 studies were 
analysed to compare the survival following liver resection for hepatic metastasized gastric 
cancer. Median survival for all 436 patients was 17 months and 5 year survival was 26.5%. 
No prognostic factor was found to be statistically significant across all studies [59]. Table 5 
shows further studies on the topic of radical surgery for gastric liver metastases that have 
been published since 1994. At present, there are no data available on results from a 
prospectively conducted trial. Although the currently available study results indicate a 
significant improvement in terms of disease free and overall survival, all conclusions drawn 
from these studies are based on retrospectively performed analyses on small patient 
populations. Therefore, a prospective study should be performed to evaluate the impact of 
liver resection in patients with isolated liver metastases from gastric cancer. 
 









Ochiai et al. [56] 1994 n=21 18 19% 
Miyazaki et al. 
[60] 
1997 n=21 NA 9,5% 
Fujii et al. [61] 2001 n=10 16,3 10% 
Imamura et al. 
[62] 
2001 n=17 12 0% 
Ambiru et al. 
[63] 
2001 n=40 12 18% 
Zacherl et al. 
[58] 
2002 n=15 8,8 NA 
Saiura et al. [64] 2002 n=10 25 20% 
Okano et al. [57] 2002 n=19 21 34% 
Shirabe et al. 
[65] 
2003 n=36 NA 36% 
Sakamoto et al. 
[66] 
2003 n=22 11 38% 
Thelen et al. [67] 2006 n=26 9 10% 
Tsujimoto et al. 
[68] 
2010 n=17 34 31,5% 
Table 5. Studies on radical surgery for gastric liver metastases from 1994-2010 
5. The role of quality of life 
Health-related quality of life has become a major criterion in the decision-making process in 
patients with gastric cancer as well as other malignancies. In most recently randomized 
trials it is an important endpoint parameter [20]. The ultimate challenge in this field, 
however, is to measure quality of life. In fact, health-related quality of life is a complex 
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variable with a multi-dimensional structure [69]. Although a multitude of publications have 
been dedicated to this topic during the last two decades, a generally accepted and consistent 
definition does not exist. The essential tool for measurement of this variable are 
questionnaires. One of the major problems of interpretation of data related to quality of life 
is that uniform questionnaires are too unspecific and disease-related questionnaires are 
limited to small areas of clinical research. The questionnaires refer to four dimensions of 
patients’ perception: physical functions, the emotional experience, the social interactions 
and symptoms related to the disease itself as well as adverse effects of treatment [69]. The 
QLQ-30 is one of the most frequently used site-specific questionnaires in the field of cancer 
research. It can be further particularized by entity-specific questionnaire modules, such as 
the STO-22 for gastric cancer. Moreover, it has been observed that the baseline physical 
scores as well as role function and the global quality of life correlate with overall survival 
which makes several paramaters measured by QLQ-30 valuable in predicting clinical 
outcome [70].  
The impact of surgery on patients who underwent oesphagectomy for oesophageal cancer 
has been measured by using the QLQ-30 questionnaire. In the early postoperative course, all 
aspects of the quality of life except the emotional function decreased remarkably. Few 
scores, such as dysphagia were improved but were overshadowed by other symptoms, such 
as anorexia, nausea and diarrhoea. Overall, the deterioration of most key aspects resulted in 
reduced overall scores. Within the following nine months a gradual recovery of those 
symptoms was observed. 
Svedlund and co-workers compared the quality of life of patients with gastric cancer at the 
time of diagnosis with that of the general population: lower mood, reduced sexual interest, 
insomnia and poor appetite have been observed in tumor patients as compared to the 
normal population. Several studies indicated that weight loss as a significant parameter not 
only for the quality of life but for survival and chemotherapy response. Furthermore, it has 
been shown by other authors that the preservation of a gastric remnant as well as 
construction of stomach-like reservoirs resulted in improved quality of life [71,72].  
The course of quality of life in patients who undergo cytotoxic treatment mirrors the 
interplay of disease-related symptoms and treatment-associated toxicity. Glimelius and co-
workers compared the clinical outcomes including quality of life of incurable gastric cancer 
patients who underwent palliative chemotherapy plus best supportive care in comparison to 
those who received best supportive care only. Both groups showed similar levels of quality 
of life [73]. Bamias and co-workers showed that patients who underwent palliative 
chemotherapy according to the ECF scheme had reduced physical and role functioning after 
12 weeks whereas emotional functioning remained unaffected over that period. Within the 
posttreatment period, the global quality of life value improved in comparison to the baseline 
when the treatment had started. In addition to that, 6 years later it has been demonstrated 
that the ECF scheme is better tolerated than MCF (epirubicin exchanged with mitomycin) 
[74]. Furthermore, the comparison between irinothekan-based and docetaxel-based 
palliative chemotherapy resulted in similar effects on the quality of life: role function, 
emotional function, social function and sleep function improved 6 months after 
chemotherapy as compared to the baseline for both chemotherapy regimens but did not 
differ significantly from each other [75].  
Currently, there is only little known about the impact of adjuvant and neoadjuvant 
chemotherapy in patients with advanced gastric cancer. 
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venangiosis to be negative prognostic factors and reported a median survival time of 18 
months and an overall 5-year survival rate of 19% [56]. One of the first western publications 
with focus on resection of gastric liver metastases was presented in 2001 by Zacherl and co-
workers: the median survival of the 15 resected patients was 8.8 months while two of these 
patients survived more than three years [58]. In a recently published review, 19 studies were 
analysed to compare the survival following liver resection for hepatic metastasized gastric 
cancer. Median survival for all 436 patients was 17 months and 5 year survival was 26.5%. 
No prognostic factor was found to be statistically significant across all studies [59]. Table 5 
shows further studies on the topic of radical surgery for gastric liver metastases that have 
been published since 1994. At present, there are no data available on results from a 
prospectively conducted trial. Although the currently available study results indicate a 
significant improvement in terms of disease free and overall survival, all conclusions drawn 
from these studies are based on retrospectively performed analyses on small patient 
populations. Therefore, a prospective study should be performed to evaluate the impact of 
liver resection in patients with isolated liver metastases from gastric cancer. 
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6. Perspectives for the strategy of non-curative resection 
Due to the aggressive biological behavior of gastric cancer and the late onset of symptoms, 
50% have to be regarded as non-curable cases. The well accepted treatment options of 
palliative chemotherapy as well as best supportive care including the management of severe 
tumor related complications can be summarized as the so-called canonical palliative 
treatment strategy. 
Due to the lack of prospective randomized trials in this field, to date no recommendation for 
the value of palliative gastric resection can be given. Nevertheless, there are numerous 
references that indicate a survival benefit in selected cases. Therefore, the currently available 
study results show that the impact of non-curative gastric resection in combination with 
chemotherapy on survival as well as on the quality of life should be evaluated by 
conducting a prospective study. 
Multimodal treatment of peritoneal carcinosis including cytoreductive surgery is effective in 
cases of PCI up to 15 and if CCR 0-1 can be achieved.  
Liver resection or radiofrequency ablation can be performed in cases of limited liver 
involvement and if extrahepatic secondary tumor growth has been excluded. 
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Gastric cancer is one of the most common tumors worldwide. It has a heterogeneous 
milieu, where the genetic background, tumor immunology, oxidative stress, and 
microbial infections are key players in the multiple stages of tumorigenesis. These 
diverse factors are linked to the prognosis of the gastric cancer and the survival of 
gastric cancer patients. This book is appropriate for scientists and students in the 
field of oncology, gastroenterology, molecular biology, immunology, cell biology, 
biology, biochemistry, and pathology. This authoritative text carefully explains the 
fundamentals, providing a general overview of the principles followed by more 
detailed explanations of these recent topics efficiently. The topics presented herein 
contain the most recent knowledge in gastric cancer concerning the oncogenic 
signaling, genetic instability, the epigenetic aspect, molecular features and their 
clinical implications, miRNAs, integrin and E-cadherin, carbohydrate-associated-
transferases, free radicals, immune cell responses, mucins, Helicobacter-pylori,  
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